PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hochhaus, A; Kreil, S; Corbin, A; La Rosee, P; Lahaye, T; Berger, U; Cross, NCP; Linkesch, W; Druker, BJ; Hehlmann, R				Hochhaus, A; Kreil, S; Corbin, A; La Rosee, P; Lahaye, T; Berger, U; Cross, NCP; Linkesch, W; Druker, BJ; Hehlmann, R			Roots of clinical resistance to STI-571 cancer therapy	SCIENCE			English	Editorial Material									Univ Heidelberg, Fak Klin Med Mannheim, Med Klin 3, D-6800 Mannheim, Germany; Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97207 USA; Hammersmith Hosp, Imperial Coll Sch med, Dept Haematol, London, England; Karl Franzens Univ Graz, Med Klin, Hamatol Abt, Graz, Austria	Ruprecht Karls University Heidelberg; Oregon Health & Science University; Imperial College London; University of Graz	Hochhaus, A (corresponding author), Univ Heidelberg, Fak Klin Med Mannheim, Med Klin 3, D-6800 Mannheim, Germany.	hochhaus@uni-hd.de	Cross, Nicholas/B-4817-2009; D'Incalci, Maurizio/AAA-9021-2020	Cross, Nicholas/0000-0001-5481-2555; D'Incalci, Maurizio/0000-0001-8784-1360; GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X; Hochhaus, Andreas/0000-0003-0626-0834; Druker, Brian/0000-0001-8331-8206; La Rosee, Paul/0000-0002-6758-7809				Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; *GENB, U07563 GENB; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082	4	233	243	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2163	2163						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11569495				2022-12-28	WOS:000171139400002
J	Stead, ML; Fallowfield, L; Brown, JM; Selby, P				Stead, ML; Fallowfield, L; Brown, JM; Selby, P			Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							OUTCOMES; WOMEN		No & Yorkshire Clin Trials & Res Unit, Leeds LS2 9NG, W Yorkshire, England; Univ Sussex, Canc Res Campaign, Psychosocial Oncol Grp, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England	University of Leeds; University of Sussex; Saint James's University Hospital	Stead, ML (corresponding author), No & Yorkshire Clin Trials & Res Unit, Leeds LS2 9NG, W Yorkshire, England.			Fallowfield, Lesley/0000-0003-0577-4518; brown, julia/0000-0002-2719-7064				ANDERSEN BL, 1989, J CONSULT CLIN PSYCH, V57, P683, DOI 10.1037/0022-006X.57.6.683; CORNEY RH, 1993, BRIT J OBSTET GYNAEC, V100, P73, DOI 10.1111/j.1471-0528.1993.tb12955.x; CULL A, 1993, BRIT J CANCER, V68, P1216, DOI 10.1038/bjc.1993.507; Lamb M A, 1994, Cancer Pract, V2, P103; Strauss A., 1990, BASICS QUALITATIVE R	5	82	84	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 13	2001	323	7317					836	837		10.1136/bmj.323.7317.836	http://dx.doi.org/10.1136/bmj.323.7317.836			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597967	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000171650500025
J	Aoki, D; Huxley, A; Ressouche, E; Braithwaite, D; Flouquet, J; Brison, JP; Lhotel, E; Paulsen, C				Aoki, D; Huxley, A; Ressouche, E; Braithwaite, D; Flouquet, J; Brison, JP; Lhotel, E; Paulsen, C			Coexistence of superconductivity and ferromagnetism in URhGe	NATURE			English	Article							SPIN-TRIPLET SUPERCONDUCTOR; HEAT	The discovery(1) of superconductivity at high pressure (albeit over a restricted range) in the ferromagnetic material UGe2 raised the possibility that bulk superconductivity might be found in other ferromagnets. The exact symmetry of the paired state and the dominant mechanism responsible for the pairing, however, remain unidentified. Meanwhile, the conjecture that superconductivity could occur more generally in ferromagnets has been fuelled by the recent observation of a low-temperature transition that suggests an onset of superconductivity in high-quality crystals of the itinerant-ferromagnet ZrZn2 (ref. 2), although the thermodynamic signature of this transition could not be detected. Here we show that the ferromagnet URhGe is superconducting at ambient pressure. In this case, we rnd the thermodynamic signature of the transition-its form is consistent with a superconducting pairing of a spin-triplet type, although further testing with cleaner samples is needed to confirm this. The combination of superconductivity and ferromagnetism may thus be more common and consequently more important than hitherto realized.	CEA, Dept Rech Fondamentale Mat Condensee, SPSMS, F-38054 Grenoble 9, France; CNRS, Ctr Rech Tres Basses Temp, F-38042 Grenoble, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Huxley, A (corresponding author), CEA, Dept Rech Fondamentale Mat Condensee, SPSMS, F-38054 Grenoble 9, France.	huxley@cea.fr	Aoki, Dai/K-3673-2012; braithwaite, Daniel/V-1234-2019	Aoki, Dai/0000-0003-2334-8360; braithwaite, Daniel/0000-0002-9012-4255; Brison, Jean-Pascal/0000-0001-7077-6224				BRISON JP, 1994, J LOW TEMP PHYS, V95, P145, DOI 10.1007/BF00754931; BROHOLM C, 1990, PHYS REV LETT, V65, P2062, DOI 10.1103/PhysRevLett.65.2062; CAMPBELL AM, 1969, J PHYS PART C SOLID, V2, P1492, DOI 10.1088/0022-3719/2/8/318; DEBOER FR, 1990, PHYSICA B, V163, P175, DOI 10.1016/0921-4526(90)90160-V; Fomin IA, 2001, JETP LETT+, V74, P111, DOI 10.1134/1.1405897; Hagmusa IH, 2000, PHYSICA B, V281, P223, DOI 10.1016/S0921-4526(99)01190-4; HIRSCHFELD P, 1986, SOLID STATE COMMUN, V59, P111, DOI 10.1016/0038-1098(86)90190-0; Huxley A, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.144519; LEGGETT AJ, 1975, REV MOD PHYS, V47, P331, DOI 10.1103/RevModPhys.47.331; LONZARICH GG, 1985, J PHYS C SOLID STATE, V18, P4339, DOI 10.1088/0022-3719/18/22/017; LUKYANCHUK IA, 1986, JETP LETT+, V44, P233; Machida K, 2001, PHYS REV LETT, V86, P850, DOI 10.1103/PhysRevLett.86.850; MORIYA T, 1985, SPIN FLUCTUATIONS IT, pCH4; NishiZaki S, 1999, J LOW TEMP PHYS, V117, P1581, DOI 10.1023/A:1022551313401; Pfleiderer C, 2001, NATURE, V412, P58, DOI 10.1038/35083531; Saxena SS, 2000, NATURE, V406, P587, DOI 10.1038/35020500; Sechovsky V., 1998, HDB MAGNETIC MAT, P1; SHEIKIN I, IN PRESS PHYS REV B; Tateiwa N, 2001, J PHYS-CONDENS MAT, V13, pL17, DOI 10.1088/0953-8984/13/1/103; Tran VH, 1998, J MAGN MAGN MATER, V186, P81, DOI 10.1016/S0304-8853(98)00074-2	20	822	833	3	168	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 11	2001	413	6856					613	616		10.1038/35098048	http://dx.doi.org/10.1038/35098048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480WE	11595943				2022-12-28	WOS:000171485700043
J	Anand, SS; Yusuf, S; Jacobs, R; Davis, AD; Yi, QL; Gerstein, H; Montague, PA; Lonn, E				Anand, SS; Yusuf, S; Jacobs, R; Davis, AD; Yi, QL; Gerstein, H; Montague, PA; Lonn, E		SHARE-AP Investigators	Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP)	LANCET			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; ISCHEMIC-HEART-DISEASE; ETHNIC-GROUPS SHARE; MYOCARDIAL-INFARCTION; THICKNESS; MORTALITY; DESIGN; PLASMA	Background Little is known about the rates of cardiovascular disease (CVD), atherosclerosis, and their risk factors among Canada's Aboriginal people. To establish the relative prevalence of risk factors, atherosclerosis, and CVD, we undertook a population-based study among people of Aboriginal and European ancestry in Canada. Methods We randomly recruited 301 Aboriginal people from the Six Nations Reservation, and 326 people of European origin from Hamilton, Toronto, and Edmonton, Canada. Clinical CVD was defined by history or electrocardiographic findings, atherosclerosis was measured by B-mode carotid ultrasonography, and conventional and new CVD risk factors were measured using standardised methods. Findings Aboriginal people had significantly more carotid atherosclerosis (mean of the maximum intimal-medial thickness 0.82 (SD 0.20) mm vs 0.78 (0.20) mm, p = 0.027), and had a higher frequency of CVD (18.5% vs 7.6%, p = 0.00002) compared with Europeans. Aboriginal people had significantly higher rates of smoking, glucose intolerance, obesity, abdominal obesity, and substantially higher concentrations of fibrinogen, and plasminogen activator inhibitor-1. Aboriginal people had significantly higher rates of unemployment and a lower annual household income. For any given income level, Aboriginal people had higher rates of risk factors and CVD compared with the Europeans. Interpretation A significant proportion of Aboriginal people live in poverty which is associated with high rates of CVD and CVD risk factors. Improvement of the socioeconomic status of Aboriginal people might be a key to reduce CVD in this group.	McMaster Univ, Dept Med, Prevent Cardiol & Therapeut Res Program, Hamilton, ON L8L 2X2, Canada; Six Nations Hlth Serv, Ohsweken, ON, Canada	McMaster University	Anand, SS (corresponding author), McMaster Univ, Dept Med, Prevent Cardiol & Therapeut Res Program, Hamilton, ON L8L 2X2, Canada.		Gerstein, Hertzel C/B-1235-2013; Gerstein, Hertzel/ABB-8781-2020	Gerstein, Hertzel C/0000-0001-8072-2836; Gerstein, Hertzel/0000-0001-8072-2836; Yusuf, Salim/0000-0003-4776-5601				ALLAIN CC, 1974, CLIN CHEM, V20, P470; Anand S, 1999, Can J Cardiol, V15 Suppl G, p44G; Anand SS, 1998, CAN J CARDIOL, V14, P1349; Anand SS, 2000, LANCET, V356, P279, DOI 10.1016/S0140-6736(00)02502-2; Armitage P., 2001, STAT METHODS MED RES; BLACKBURN H, 1982, MINNESOTA CODE MANUA; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; CHOCKALINGHAM A, 2000, LANCET, V356, P347; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; ERIKSSON E, 1988, THROMB RES, V50, P91, DOI 10.1016/0049-3848(88)90177-6; FORTIN LJ, 1995, CLIN BIOCHEM, V28, P155, DOI 10.1016/0009-9120(94)00073-5; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Harris SB, 1997, DIABETES CARE, V20, P185, DOI 10.2337/diacare.20.2.185; HOSMER DW, 1989, APPL LOGISTIC REGRES; Lonn EM, 1996, AM J CARDIOL, V78, P914, DOI 10.1016/S0002-9149(96)00467-5; Lynch JW, 1997, SOC SCI MED, V44, P809, DOI 10.1016/S0277-9536(96)00191-8; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; Meigs JB, 2000, JAMA-J AM MED ASSOC, V283, P221, DOI 10.1001/jama.283.2.221; NEELEY WE, 1972, CLIN CHEM, V18, P509; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; *ROYAL COMM AB PEO, 1996, REP ROYAL COMM AB PE, V3; Scarabin PY, 1998, THROMB HAEMOSTASIS, V80, P749; Shah BR, 2000, ARCH INTERN MED, V160, P1862, DOI 10.1001/archinte.160.12.1862; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; *STAT CAN, 1996, 1996 CENS DIR; SYME SL, 1976, AM J EPIDEMIOL, V104, P1; Vartiainen E, 2000, INT J EPIDEMIOL, V29, P49, DOI 10.1093/ije/29.1.49; WARNICK GR, 1985, CLIN CHEM, V31, P217; Zatonski WA, 1998, BMJ-BRIT MED J, V316, P1047	29	225	234	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1147	1153		10.1016/S0140-6736(01)06255-9	http://dx.doi.org/10.1016/S0140-6736(01)06255-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597669				2022-12-28	WOS:000171399000012
J	Goodman, WG				Goodman, WG			Vascular calcification in chronic renal failure	LANCET			English	Editorial Material							MINERALIZATION-REGULATING PROTEINS; CALCIPHYLAXIS; ASSOCIATION; DISEASE; OSTEODYSTROPHY; DIALYSIS		Univ Calif Los Angeles, Sch Med, Dept Med, Div Nephrol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Goodman, WG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Nephrol, Los Angeles, CA 90024 USA.							Ahmed S, 2001, AM J KIDNEY DIS, V37, P1267, DOI 10.1053/ajkd.2001.24533; ANDROGUE H, 1983, J UROLOGY, V129, P362; CONN J, 1973, ANN SURG, V177, P206, DOI 10.1097/00000658-197302000-00015; FOX R, 1983, J UROLOGY, V129, P362, DOI 10.1016/S0022-5347(17)52098-4; GIPSTEIN RM, 1976, ARCH INTERN MED, V136, P1273, DOI 10.1001/archinte.136.11.1273; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Guerin AP, 2000, NEPHROL DIAL TRANSPL, V15, P1014, DOI 10.1093/ndt/15.7.1014; HUTCHISON AJ, 1994, AM J NEPHROL, V14, P19, DOI 10.1159/000168681; Llach F, 2001, NEPHROL DIAL TRANSPL, V16, P448, DOI 10.1093/ndt/16.3.448; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Marchais SJ, 1999, NEPHROL DIAL TRANSPL, V14, P2178, DOI 10.1093/ndt/14.9.2178; Mawad HW, 1999, CLIN NEPHROL, V52, P160; Mazhar AR, 2001, KIDNEY INT, V60, P324, DOI 10.1046/j.1523-1755.2001.00803.x; Ruggian JC, 1996, AM J KIDNEY DIS, V28, P409, DOI 10.1016/S0272-6386(96)90499-0; SALUSKY IB, 1994, KIDNEY INT, V45, P253, DOI 10.1038/ki.1994.31; SELYE H, 1962, ENDOCRINOLOGY, V71, P554, DOI 10.1210/endo-71-4-554; Shanahan CM, 1999, CIRCULATION, V100, P2168, DOI 10.1161/01.CIR.100.21.2168; Shanahan CM, 1998, CRIT REV EUKAR GENE, V8, P357, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.60; Shanahan CM, 2000, Z KARDIOL, V89, P63; Sherrard DJ, 1996, NEPHROL DIAL TRANSPL, V11, P29; Zacharias JM, 1999, PERITON DIALYSIS INT, V19, P248	21	56	57	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1115	1116		10.1016/S0140-6736(01)06299-7	http://dx.doi.org/10.1016/S0140-6736(01)06299-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597661				2022-12-28	WOS:000171399000004
J	Polyak, VJ; Asmerom, Y				Polyak, VJ; Asmerom, Y			Late Holocene climate and cultural changes in the southwestern United States	SCIENCE			English	Article							NEW-MEXICO; ARIZONA; SPELEOTHEM; HISTORY; RECORD; CAVE; PALEOCLIMATE; ENVIRONMENTS; STALAGMITES; VEGETATION	Columnar stalagmites in caves of the Guadalupe Mountains during the late Holocene record a 4000-year annually resolved climate history for the southwestern United States. Annual banding, hiatuses, and high-precision uranium-series dating show a present day-like climate from 4000 to 3000 years ago, following a drier middle Holocene. A distinctly wetter and cooler period from 3000 to 800 years ago was followed by a period of present day-like conditions, with the exception of a slightly wetter interval from 440 to 290 years before the present. The stalagmite record correlates well with the archaeological record of changes in cultural activities of indigenous people. Such climate change may help to explain evidence of dwelling abandonment and population redistribution.	Univ New Mexico, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA	University of New Mexico	Polyak, VJ (corresponding author), Univ New Mexico, Dept Earth & Planetary Sci, 200 Yale Blvd, Albuquerque, NM 87131 USA.							ANDERSON RS, 1993, QUATERNARY RES, V40, P351, DOI 10.1006/qres.1993.1088; Antevs E, 1955, AM ANTIQUITY, V20, P317, DOI 10.2307/277066; APPLEGARTH JS, 1979, US NATL PARK SERVICE, V4, P159; BAKER A, 1993, NATURE, V364, P518, DOI 10.1038/364518a0; Betancourt JL, 2001, PALAEOGEOGR PALAEOCL, V165, P71, DOI 10.1016/S0031-0182(00)00154-1; Brook GA, 1999, HOLOCENE, V9, P695, DOI 10.1191/095968399677907790; Buck BJ, 1999, J ARID ENVIRON, V43, P357, DOI 10.1006/jare.1999.0584; Cheng H, 2000, CHEM GEOL, V169, P17, DOI 10.1016/S0009-2541(99)00157-6; Cordell L. S., 1997, ARCHAEOLOGY SW; DAVIS OK, 1992, PALAEOGEOGR PALAEOCL, V92, P107, DOI 10.1016/0031-0182(92)90137-T; Denniston RF, 2000, QUATERNARY RES, V53, P196, DOI 10.1006/qres.1999.2111; DORALE JA, 1992, SCIENCE, V258, P1626, DOI 10.1126/science.258.5088.1626; EULER RC, 1979, SCIENCE, V205, P1089, DOI 10.1126/science.205.4411.1089; Genty D, 1996, J SEDIMENT RES, V66, P275; HALL SA, 1977, GEOL SOC AM BULL, V88, P1593, DOI 10.1130/0016-7606(1977)88<1593:LQSAPH>2.0.CO;2; HENDY CH, 1971, GEOCHIM COSMOCHIM AC, V35, P801, DOI 10.1016/0016-7037(71)90127-X; HILL CA, 1987, NEW MEXICO BUREAU MI, V117; HOLLIDAY VT, 1989, QUATERNARY RES, V31, P74, DOI 10.1016/0033-5894(89)90086-0; Krider PR, 1998, QUATERNARY RES, V50, P283, DOI 10.1006/qres.1998.1997; Lamb H.H., 1977, CLIMATIC HIST FUTURE; LUNDELIUS EL, 1979, US NATL PARK SERVICE, V4, P239; McFadden LD, 1997, GEOMORPHOLOGY, V19, P303, DOI 10.1016/S0169-555X(97)00017-2; MURRAY JW, 1954, J GEOL, V62, P481, DOI 10.1086/626192; Polyak VJ, 2001, GEOLOGY, V29, P643, DOI 10.1130/0091-7613(2001)029<0643:WACLHC>2.0.CO;2; RAILSBACK LB, 1994, J SEDIMENT RES A, V64, P147; SHOPOV YY, 1994, GEOLOGY, V22, P407, DOI 10.1130/0091-7613(1994)022<0407:LMISHR>2.3.CO;2; SMITH GI, 1983, LATE QUATERNARY ENV, V1, P190; STUART DE, 1996, PREHISTORIC NEW MEXI; Tagg MD, 1996, AM ANTIQUITY, V61, P311, DOI 10.2307/282428; Van Geel B, 1998, RADIOCARBON, V40, P535, DOI 10.1017/S0033822200018403; VANDEVENDER TR, 1994, QUATERNARY RES, V41, P99, DOI 10.1006/qres.1994.1011; Weng CY, 1999, PALAEOGEOGR PALAEOCL, V153, P179, DOI 10.1016/S0031-0182(99)00070-X; Wilkins DE, 1999, HOLOCENE, V9, P363, DOI 10.1191/095968399677728249	33	182	214	3	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					148	151		10.1126/science.1062771	http://dx.doi.org/10.1126/science.1062771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588259				2022-12-28	WOS:000171448800048
J	Ruegsegger, U; Leber, JH; Walter, P				Ruegsegger, U; Leber, JH; Walter, P			Block of HAC1 mRNA translation by long-range base pairing is released by cytoplasmic splicing upon induction of the unfolded protein response	CELL			English	Article							TRANSFER-RNA LIGASE; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEIN; TRANSCRIPTION FACTOR; C-ELEGANS; KINASE; YEAST; ER; INITIATION	Expression of the yeast transcription factor Hac1p, which controls the unfolded protein response, is regulated posttranscriptionally. Hac1p is only produced when an intron at the 3' end of its mRNA is removed by a nonconventional, regulated splicing reaction. We show that a previously unrecognized base-pairing interaction between the intron and the 5' untranslated region is required and sufficient to block mRNA translation. Unspliced HAC1 mRNA is stable, located in the cytosol, and is associated with polyribosomes, yet does not produce protein, indicating that the ribosomes engaged on the rnRNA are stalled. We show that the polysomal, cytoplasmic pool of HAC1 mRNA is a substrate for splicing, suggesting that the stalled ribosomes may resume translation after the intron is removed.	Univ Calif San Francisco, Dept Biochem & Biophys, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Walter, P (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	walter@cgl.ucsf.edu						Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Clark IE, 2000, CURR BIOL, V10, P1311, DOI 10.1016/S0960-9822(00)00754-5; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; JOHANSSON HE, 1994, NUCLEIC ACIDS RES, V22, P4591, DOI 10.1093/nar/22.22.4591; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; MORI K, 1993, CELL, V74, P743; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SPENA A, 1985, EMBO J, V4, P2153, DOI 10.1002/j.1460-2075.1985.tb03909.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, J CELL SCI, V113, P3697; VANDENHEUVEL JJ, 1990, YEAST, V6, P473, DOI 10.1002/yea.320060604; Vega Laso Maria R., 1993, Journal of Biological Chemistry, V268, P6453; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	33	224	234	1	21	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 5	2001	107	1					103	114		10.1016/S0092-8674(01)00505-0	http://dx.doi.org/10.1016/S0092-8674(01)00505-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595189	Bronze			2022-12-28	WOS:000171453100013
J	Stevens, RC; Yokoyama, S; Wilson, IA				Stevens, RC; Yokoyama, S; Wilson, IA			Global efforts in structural genomics	SCIENCE			English	Editorial Material							PROJECT	A worldwide initiative in structural genomics aims to capitalize on the recent successes of the genome projects. Substantial new investments in structural genomics in the past 2 years indicate the high level of support for these international efforts. Already, enormous progress has been made on high-throughput methodologies and technologies that will speed up macromolecular structure determinations. Recent international meetings have resulted in the formation of an International Structural Genomics Organization to formulate policy and foster cooperation between the public and private efforts.	Scripps Res Inst, Joint Ctr Struct Genom, La Jolla, CA 92037 USA; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan	Scripps Research Institute; RIKEN	Stevens, RC (corresponding author), Scripps Res Inst, Joint Ctr Struct Genom, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Yokoyama, Shigeyuki/N-6911-2015; Stevens, Raymond/K-7272-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Stevens, Raymond/0000-0002-4522-8725	NIGMS NIH HHS [P50 GM62411] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062411] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783; Kim SH, 1998, NAT STRUCT BIOL, V5, P643, DOI 10.1038/1334; Marshall E, 2001, SCIENCE, V292, P188; Montelione GT, 1999, NAT STRUCT BIOL, V6, P11, DOI 10.1038/4878; Stevens RC, 2001, SCIENCE, V293, P519, DOI 10.1126/science.293.5529.519; Terwilliger TC, 2000, NAT STRUCT BIOL, V7, P935, DOI 10.1038/80700; Vitkup D, 2001, NAT STRUCT BIOL, V8, P559, DOI 10.1038/88640	9	152	161	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					89	92		10.1126/science.1066011	http://dx.doi.org/10.1126/science.1066011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588249				2022-12-28	WOS:000171448800037
J	Wolff, J; Papathanasiou, AG; Kevrekidis, IG; Rotermund, HH; Ertl, G				Wolff, J; Papathanasiou, AG; Kevrekidis, IG; Rotermund, HH; Ertl, G			Spatiotemporal addressing of surface activity	SCIENCE			English	Article							PATTERN-FORMATION; COMPOSITE SURFACES; CATALYTIC REACTORS; CONTROLLING CHAOS; GLOBAL FEEDBACK; CO OXIDATION; SPIRAL WAVES; BOUNDARIES; SYSTEMS; PLATINUM	We have modified surface catalytic activity in real time and space by focusing an addressable laser beam to differentially heat a platinum (110) single-crystal surface. Ellipsomicroscopy imaging of local conditions (such as reactant and product local coverages) enabled us to close the loop between sensing and actuation (both spatiotemporally resolved). Pulses and fronts, the basic building blocks of patterns, could be formed, accelerated, modified, guided, and destroyed at will. Real-time image processing and feedback allow the design and implementation of new classes of nonlocal evolution rules.	Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA; Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany	Princeton University; Max Planck Society; Fritz Haber Institute of the Max Planck Society	Kevrekidis, IG (corresponding author), Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA.		Papathanasiou, Athanasios/C-3781-2016	Papathanasiou, Athanasios/0000-0002-8468-8126				Esch F, 1998, CATAL LETT, V52, P85, DOI 10.1023/A:1019015302467; GRAHAM MD, 1994, SCIENCE, V264, P80, DOI 10.1126/science.264.5155.80; GRAHAM MD, 1995, PHYS REV E, V52, P76, DOI 10.1103/PhysRevE.52.76; JAKUBITH S, 1990, PHYS REV LETT, V65, P3013, DOI 10.1103/PhysRevLett.65.3013; Kadar S, 1998, NATURE, V391, P770, DOI 10.1038/35814; Khinast JG, 2000, COMPUT CHEM ENG, V24, P139, DOI 10.1016/S0098-1354(00)00316-1; Kim M, 2001, SCIENCE, V292, P1357, DOI 10.1126/science.1059478; Kolodzejczyk M, 1997, APPL SURF SCI, V121, P480, DOI 10.1016/S0169-4332(97)00336-X; KUAN DY, 1983, CHEM ENG SCI, V38, P719, DOI 10.1016/0009-2509(83)80183-3; Lauterbach J, 1998, PHYSICA D, V123, P493, DOI 10.1016/S0167-2789(98)00145-6; Lin AL, 2000, PHYS REV LETT, V84, P4240, DOI 10.1103/PhysRevLett.84.4240; Lundqvist JA, 1998, P NATL ACAD SCI USA, V95, P10356, DOI 10.1073/pnas.95.18.10356; Matros YS, 1996, CAN J CHEM ENG, V74, P566, DOI 10.1002/cjce.5450740504; Matros YS, 1996, CATAL REV, V38, P1, DOI 10.1080/01614949608006453; MERTENS F, 1994, NATURE, V370, P124, DOI 10.1038/370124a0; Munuzuri AP, 1999, J AM CHEM SOC, V121, P8065, DOI 10.1021/ja9910457; OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196; Pappas GJ, 2000, IEEE T AUTOMAT CONTR, V45, P1144, DOI 10.1109/9.863598; PETROV V, 1993, NATURE, V361, P240, DOI 10.1038/361240a0; Rotermund H. H., 1997, Surface Science Reports, V29, P265, DOI 10.1016/S0167-5729(97)00012-5; ROTERMUND HH, 1995, SCIENCE, V270, P608, DOI 10.1126/science.270.5236.608; ROTERMUND HH, 1990, NATURE, V343, P355, DOI 10.1038/343355a0; SEMOWOGERERE D, 2000, B AM PHYS SOC, V45, P46; Shvartsman SY, 1999, PHYS REV LETT, V83, P2857, DOI 10.1103/PhysRevLett.83.2857; Sontag E.D., 1998, MATH CONTROL THEORY; Srinivasan R, 1997, AICHE J, V43, P3059, DOI 10.1002/aic.690431117; STEINBOCK O, 1993, NATURE, V366, P322, DOI 10.1038/366322a0; STEINBOCK O, 1992, PHYS REV LETT, V68, P248, DOI 10.1103/PhysRevLett.68.248; Vanag VK, 2000, NATURE, V406, P389, DOI 10.1038/35019038; Volkening S, 2001, J CHEM PHYS, V114, P6382, DOI 10.1063/1.1343836; Wong K, 1996, FARADAY DISCUSS, V105, P237, DOI 10.1039/fd9960500237; Yang MX, 1998, LANGMUIR, V14, P1458, DOI 10.1021/la970737a; Zykov VS, 1997, PHYS REV LETT, V78, P3398, DOI 10.1103/PhysRevLett.78.3398	34	113	114	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					134	137		10.1126/science.1063597	http://dx.doi.org/10.1126/science.1063597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588256				2022-12-28	WOS:000171448800044
J	Quill, TE; Arnold, RM; Platt, F				Quill, TE; Arnold, RM; Platt, F			"I wish things were different": Expressing wishes in response to loss, futility, and unrealistic hopes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EMPATHIC COMMUNICATION; PHYSICIANS; CARE		Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; Univ Colorado, Sch Med, Denver, CO 80205 USA	University of Rochester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Quill, TE (corresponding author), Univ Rochester, Med Ctr, 601 Elmwood Ave,Box 601, Rochester, NY 14642 USA.							ACKERMAN F, 1991, HASTINGS CENT REP, V21, P27, DOI 10.2307/3562998; BARRETTLENNARD GT, 1993, BRIT J MED PSYCHOL, V66, P3, DOI 10.1111/j.2044-8341.1993.tb01722.x; BRANCH WT, 1993, JAMA-J AM MED ASSOC, V269, P1667, DOI 10.1001/jama.269.13.1667; Byock I, 1997, DYING WELL PROSPECT; Coulehan JL, 2001, ANN INTERN MED, V135, P221, DOI 10.7326/0003-4819-135-3-200108070-00022; FOX RC, 1959, EXPT PERILOUS PHYSIC; GOOD MJD, 1990, CULT MED PSYCHIAT, V14, P59; Kohn L.T., 2000, TO ERR IS HUMAN BUIL; LAZARE A, 1989, OUTPATIENT PSYCHIAT, P157; Levinson W, 2000, JAMA-J AM MED ASSOC, V284, P1021, DOI 10.1001/jama.284.8.1021; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; NIGHTINGALE SD, 1991, J GEN INTERN MED, V6, P420, DOI 10.1007/BF02598163; PLATT FW, 1994, J GEN INTERN MED, V9, P222, DOI 10.1007/BF02600129; Quill T, 1996, MIDWIFE DYING PROCES; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; RIE MA, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3562997; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; [No title captured]; 1993, CONCISE OXFORD ENGLI	22	91	93	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					551	555		10.7326/0003-4819-135-7-200110020-00022	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00022			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	477EF	11578166				2022-12-28	WOS:000171269600017
J	Waugh, J; Johnson, A; Farkas, A				Waugh, J; Johnson, A; Farkas, A			Analysis of cord blood gas at delivery: questionnaire study of practice in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article									Royal Hallamshire Hosp, Dept Obstet & Gynaecol, Sheffield S10 2SF, S Yorkshire, England	University of Sheffield	Farkas, A (corresponding author), Royal Hallamshire Hosp, Dept Obstet & Gynaecol, Sheffield S10 2SF, S Yorkshire, England.							GELDABER GK, 1991, OBSTET GYNECOL, V78, P1103; MacLennan A, 1999, BMJ-BRIT MED J, V319, P1054, DOI 10.1136/bmj.319.7216.1054; *ROYAL COLL OBST G, 1999, SAF CHILDB MIN STAND, P22; WESTGATE J, 1994, BRIT J OBSTET GYNAEC, V101, P1054, DOI 10.1111/j.1471-0528.1994.tb13581.x	4	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					727	727		10.1136/bmj.323.7315.727	http://dx.doi.org/10.1136/bmj.323.7315.727			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HJ	11576980	Bronze, Green Published			2022-12-28	WOS:000171340700020
J	Dagotto, E				Dagotto, E			Superconductivity - The race to beat the cuprates	SCIENCE			English	Editorial Material							CU-O SYSTEM; DOPED C-60		Florida State Univ, Dept Phys, Tallahassee, FL 32306 USA; Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University	Dagotto, E (corresponding author), Florida State Univ, Dept Phys, Tallahassee, FL 32306 USA.							BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; Cote M, 1998, PHYS REV LETT, V81, P697, DOI 10.1103/PhysRevLett.81.697; DAGOTTO E, 1995, PHYS REV LETT, V74, P310, DOI 10.1103/PhysRevLett.74.310; DAGOTTO E, 1992, PHYS REV B, V45, P5744, DOI 10.1103/PhysRevB.45.5744; HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0; Nagata T, 1998, PHYS REV LETT, V81, P1090, DOI 10.1103/PhysRevLett.81.1090; NUNEZREGUEIRO M, 1993, SCIENCE, V262, P97, DOI 10.1126/science.262.5130.97; SCALETTAR RT, 1989, PHYS REV LETT, V62, P1407, DOI 10.1103/PhysRevLett.62.1407; SCHILLING A, 1993, NATURE, V363, P56, DOI 10.1038/363056a0; Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008; Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656; Schon JH, 2001, SCIENCE, V293, P2432, DOI 10.1126/science.1064773; Schon JH, 2001, SCIENCE, V293, P2430, DOI 10.1126/science.1064204; Uehara M, 1996, J PHYS SOC JPN, V65, P2764, DOI 10.1143/JPSJ.65.2764	14	30	31	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2410	2411		10.1126/science.1065711	http://dx.doi.org/10.1126/science.1065711			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577227				2022-12-28	WOS:000171237200036
J	Downing, PE; Jiang, YH; Shuman, M; Kanwisher, N				Downing, PE; Jiang, YH; Shuman, M; Kanwisher, N			A cortical area selective for visual processing of the human body	SCIENCE			English	Article							TEMPORAL CORTEX; PERCEPTION; REPRESENTATION; ACTIVATION; MOTION; PARTS	Despite extensive evidence for regions of human visual cortex that respond selectively to faces, few studies have considered the cortical representation of the appearance of the rest of the human body. We present a series of functional magnetic resonance imaging (fMRI) studies revealing substantial evidence for a distinct cortical region in humans that responds selectively to images of the human body, as compared with a wide range of control stimuli. This region was found in the lateral occipitotemporal cortex in all subjects tested and apparently reflects a specialized neural system for the visual perception of the human body.	Univ Wales, Ctr Cognit Neurosci, Sch Psychol, Bangor LL57 2AS, Gwynedd, Wales; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Nucl Magnet Resonance Imaging Ctr, Charlestown, MA 02129 USA	Bangor University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	Downing, PE (corresponding author), Univ Wales, Ctr Cognit Neurosci, Sch Psychol, Bangor LL57 2AS, Gwynedd, Wales.	p.downing@bangor.ac.uk		Downing, Paul/0000-0002-5046-2858				Amedi A, 2001, NAT NEUROSCI, V4, P324, DOI 10.1038/85201; Chao LL, 1999, NAT NEUROSCI, V2, P913, DOI 10.1038/13217; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Gauthier I, 2000, NAT NEUROSCI, V3, P191, DOI 10.1038/72140; Grill-Spector K, 2001, VISION RES, V41, P1409, DOI 10.1016/S0042-6989(01)00073-6; Grossman E, 2000, J COGNITIVE NEUROSCI, V12, P711, DOI 10.1162/089892900562417; Howard RJ, 1996, CURR BIOL, V6, P1015, DOI 10.1016/S0960-9822(02)00646-2; Jellema T, 2000, BRAIN COGNITION, V44, P280, DOI 10.1006/brcg.2000.1231; JOHANSSON G, 1973, PERCEPT PSYCHOPHYS, V14, P201, DOI 10.3758/BF03212378; Kanwisher N, 2000, NAT NEUROSCI, V3, P759, DOI 10.1038/77664; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kourtzi Z, 2000, J NEUROSCI, V20, P3310, DOI 10.1523/JNEUROSCI.20-09-03310.2000; Kourtzi Z, 2000, J COGNITIVE NEUROSCI, V12, P48, DOI 10.1162/08989290051137594; Le Clec'H G, 2000, NEUROIMAGE, V12, P381, DOI 10.1006/nimg.2000.0627; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; Puce A, 1996, J NEUROSCI, V16, P5205; Puce A, 1998, J NEUROSCI, V18, P2188; Rizzolatti G, 1997, CURR OPIN NEUROBIOL, V7, P562, DOI 10.1016/S0959-4388(97)80037-2; Shelton JR, 1998, NEUROCASE, V4, P339, DOI 10.1093/neucas/4.4.339; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; WACHSMUTH E, 1994, CEREB CORTEX, V4, P509, DOI 10.1093/cercor/4.5.509	21	1366	1380	11	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2470	2473		10.1126/science.1063414	http://dx.doi.org/10.1126/science.1063414			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577239				2022-12-28	WOS:000171237200052
J	Campos, H; Moye, LA; Glasser, SP; Stampfer, MJ; Sacks, FM				Campos, H; Moye, LA; Glasser, SP; Stampfer, MJ; Sacks, FM			Low-density lipoprotein size, pravastatin treatment, and coronary events	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE RISK; ARTERY DISEASE; MYOCARDIAL-INFARCTION; PLASMA TRIGLYCERIDE; PARTICLE DIAMETER; LDL SIZE; MEN; CHOLESTEROL; WOMEN; ASSOCIATION	Context Small low-density lipoprotein (LDL) particle size has been hypothesized to be a risk factor for coronary heart disease (CHD). Animal models link large LDL to atherosclerosis. However, the strong association between small LDL and other risk factors, particularly triglyceride levels, impedes determining whether LDL size independently predicts CHD in humans. Objective To examine whether LDL size is an independent predictor of recurrent coronary events in patients with known CHD, as opposed to a marker for other lipid abnormalities. Design and Setting Prospective, nested case-control study in the Cholesterol and Recurrent Events (CARE) trial, a randomized placebo-controlled trial of pravastatin conducted in 1989-1996. Participants Survivors of myocardial infarction with typical LDL concentrations (416 cases and 421 controls). Main Outcome Measure Subsequent myocardial infarction or coronary death during the 5-year follow-up, analyzed by quintile of LDL particle size and by treatment group. Results Overall, the mean LDL size was identical in cases and controls (25.6 nm). In patients in the placebo group, large LDL predicted coronary events in models adjusted only for age (relative risk [RR], 1.79; 95% confidence interval [CI], 1.01-3.17) and for age and lipid and nonlipid risk factors (RR, 4.00; 95% CI, 1.81-8.82), comparing those in the highest (mean, 26.6 nm) and lowest (mean, 24.5 nm) quintiles of LDL size. This increased risk was not present in those taking pravastatin (age-adjusted analysis: RR, 0.98; 95% CI, 0.47-2.04; P = .046 for interaction for a difference in the effect of LDL size on coronary events between the placebo and treatment groups; multivariable analysis: RR, 1.33; 95% CI, 0.52-3.38; P = .11 for interaction). Conclusions Large LDL size was an independent predictor of coronary events in a typical population with myocardial infarction, but the adverse effect was not present among patients who were treated with pravastatin. Identifying patients on the basis of LDL size may not be useful clinically, since effective treatment for elevated LDL cholesterol concentrations also effectively treats risk associated with large LDL.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Minnesota System; University of Minnesota Twin Cities	Campos, H (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave,Bldg 2,Room 353A, Boston, MA 02115 USA.		Glasser, Stephen P/S-5996-2019	Glasser, Stephen P/0000-0001-9620-6406				AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; Austin Melissa A., 1994, Current Opinion in Lipidology, V5, P395, DOI 10.1097/00041433-199412000-00002; Campos H, 1997, ARTERIOSCL THROM VAS, V17, P1074, DOI 10.1161/01.ATV.17.6.1074; CAMPOS H, 1995, ARTERIOSCL THROM VAS, V15, P1043, DOI 10.1161/01.ATV.15.8.1043; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; Campos H, 1997, J CLIN ENDOCR METAB, V82, P3955, DOI 10.1210/jc.82.12.3955; CHECOVICH WJ, 1988, BIOCHEMISTRY-US, V27, P1934, DOI 10.1021/bi00406a020; CORESH J, 1993, J LIPID RES, V34, P1687; Coresh J, 1996, JAMA-J AM MED ASSOC, V276, P914, DOI 10.1001/jama.276.11.914; CROUSE JR, 1985, J LIPID RES, V26, P566; DECKELBAUM RJ, 1984, ARTERIOSCLEROSIS, V4, P225, DOI 10.1161/01.ATV.4.3.225; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; Dreon DM, 1998, AM J CLIN NUTR, V67, P828, DOI 10.1093/ajcn/67.5.828; FRANCESCHINI G, 1994, ARTERIOSCLER THROMB, V14, P1569, DOI 10.1161/01.ATV.14.10.1569; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; Gray RS, 1997, ARTERIOSCL THROM VAS, V17, P2713, DOI 10.1161/01.ATV.17.11.2713; GRIFFIN BA, 1994, ATHEROSCLEROSIS, V106, P241, DOI 10.1016/0021-9150(94)90129-5; Grundy SM, 1997, CIRCULATION, V95, P1, DOI 10.1161/01.CIR.95.1.1; KRAUSS RM, 1982, J LIPID RES, V23, P97; Krauss Ronald M., 1994, Current Opinion in Lipidology, V5, P339, DOI 10.1097/00041433-199410000-00005; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; MANNING JM, 1994, LIPIDS, V29, P635, DOI 10.1007/BF02536098; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; Mykkanen L, 1999, ARTERIOSCL THROM VAS, V19, P2742, DOI 10.1161/01.ATV.19.11.2742; *NAT HEART LUNG BL, 1998, NIH PUBL NAT HEART L, P228; NIGON F, 1991, J LIPID RES, V32, P1741; Packard CJ, 1997, ARTERIOSCL THROM VAS, V17, P3542, DOI 10.1161/01.ATV.17.12.3542; Rudel LL, 1998, PROG LIPID RES, V37, P353, DOI 10.1016/S0163-7827(98)00015-0; Ruotolo G, 1998, ATHEROSCLEROSIS, V140, P65, DOI 10.1016/S0021-9150(98)00110-5; Sacks FM, 2000, CIRCULATION, V102, P1886, DOI 10.1161/01.CIR.102.16.1886; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sacks FM, 2000, CIRCULATION, V102, P1893, DOI 10.1161/01.CIR.102.16.1893; Shepherd J, 1996, LANCET, V348, P1339; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; STCLAIR RW, 1978, BIOCHIM BIOPHYS ACTA, V530, P279; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X; Wahi S, 1997, J Cardiovasc Risk, V4, P173, DOI 10.1097/00043798-199706000-00003	37	99	154	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1468	1474		10.1001/jama.286.12.1468	http://dx.doi.org/10.1001/jama.286.12.1468			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572739	Bronze			2022-12-28	WOS:000171188600024
J	Ahmad, K				Ahmad, K			Kid agencies withdraw staff from Afghanistan as refugees flee to the border	LANCET			English	Article													Ahmad, Khabir/I-6882-2019; Ahmad, Khabir/G-3903-2012	Ahmad, Khabir/0000-0002-1569-0628; Ahmad, Khabir/0000-0002-1569-0628					0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					943	943		10.1016/S0140-6736(01)06121-9	http://dx.doi.org/10.1016/S0140-6736(01)06121-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11584820				2022-12-28	WOS:000171135300006
J	Sacco, RL				Sacco, RL			Extracranial carotid stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIDISCIPLINARY CONSENSUS STATEMENT; TRANSIENT ISCHEMIC ATTACKS; HEALTH-CARE PROFESSIONALS; AD-HOC-COMMITTEE; STROKE COUNCIL; ENDARTERECTOMY; ARTERY; RISK; ATHEROSCLEROSIS; PREVENTION	A 64-year-old man with a history of smoking and hypercholesterolemia has a sudden, transient loss of vision in his left eye. He reports a prior episode during which he had difficulty speaking and mild weakness of the right hand. The results of an examination are normal except for a bruit in the left side of the neck. He is found to have stenosis of the left carotid artery of 60 to 79 percent on high-resolution carotid ultrasonography, confirmed by magnetic resonance angiography. How should he be treated?	Mailman Sch Publ Hlth, Dept Neurol, Div Epidemiol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Sergievsky Ctr, New York, NY USA; New York Presbyterian Hosp, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital	Sacco, RL (corresponding author), Neurol Inst, 710 W 168Th St, New York, NY 10032 USA.	rls1@columbia.edu	Sacco, Ralph/Y-9278-2019		NINDS NIH HHS [T32 NS 07153, R01 NS 29993, R01 NS 27517] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027517, R01NS029993, T32NS007153] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers CW, 2001, CHEST, V119, p300S, DOI 10.1378/chest.119.1_suppl.300S; Albers GW, 1999, STROKE, V30, P2502, DOI 10.1161/01.STR.30.11.2502; Alberts MJ, 2001, STROKE, V32, P325; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; Benavente O, 2001, NEW ENGL J MED, V345, P1084, DOI 10.1056/NEJMoa002994; Brown MM, 2001, LANCET, V357, P1729; CAPLAN LR, 1995, JAMA-J AM MED ASSOC, V274, P1383, DOI 10.1001/jama.274.17.1383; CROUSE JR, 1995, AM J CARDIOL, V75, P862; DIENER HC, 1991, STROKE, V22, P1229; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FISHER CM, 1965, J NEUROPATH EXP NEUR, V24, P455, DOI 10.1097/00005072-196507000-00007; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Goldstein LB, 1997, STROKE, V28, P889, DOI 10.1161/01.STR.28.5.889; Goldstein LB, 2001, STROKE, V32, P280, DOI 10.1161/01.STR.32.1.280; Goldstein LB, 1998, STROKE, V29, P750, DOI 10.1161/01.STR.29.4.750; Gorelick PB, 1999, JAMA-J AM MED ASSOC, V281, P1112, DOI 10.1001/jama.281.12.1112; Grubb RL, 1998, JAMA-J AM MED ASSOC, V280, P1055, DOI 10.1001/jama.280.12.1055; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; Henderson RD, 2000, STROKE, V31, P128, DOI 10.1161/01.STR.31.1.128; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; Johnston DCC, 2001, NEUROLOGY, V56, P1009, DOI 10.1212/WNL.56.8.1009; Kappelle IJ, 1999, STROKE, V30, P282, DOI 10.1161/01.STR.30.2.282; Karason K, 1999, INT J OBESITY, V23, P948, DOI 10.1038/sj.ijo.0801024; Kuntz KM, 1996, CIRCULATION, V94, P194; Lonn EM, 2001, CIRCULATION, V103, P919; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; Mohr JP, 1997, CEREBROVASC DIS, V7, P100; MOORE WS, 1995, CIRCULATION, V91, P566, DOI 10.1161/01.CIR.91.2.566; Naylor AR, 1998, J VASC SURG, V28, P326, DOI 10.1016/S0741-5214(98)70182-X; NICOLAIDES AN, 1995, INT ANGIOL, V14, P21; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; Rothwell PM, 2001, STROKE, V32, P327; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; Silvestrini M, 2000, JAMA-J AM MED ASSOC, V283, P2122, DOI 10.1001/jama.283.16.2122; STREIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P246, DOI 10.1001/archneur.1995.00540270034016; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TIMSIT SG, 1992, STROKE, V23, P486, DOI 10.1161/01.STR.23.4.486; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; Wolf PA, 1999, STROKE, V30, P1991, DOI 10.1161/01.STR.30.9.1991; Yusuf S, 2000, NEW ENGL J MED, V342, P145	44	64	65	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2001	345	15					1113	1118		10.1056/NEJMcp011227	http://dx.doi.org/10.1056/NEJMcp011227			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480QH	11596592				2022-12-28	WOS:000171473100007
J	Woloshin, S; Schwartz, LM; Tremmel, J; Welch, HG				Woloshin, S; Schwartz, LM; Tremmel, J; Welch, HG			Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?	LANCET			English	Article							JOURNALS; BENEFITS	Background Pharmaceutical companies spent US$1.8 billion on direct-to-consumer advertisements for prescription drugs in 1999. Our aim was to establish what messages are being communicated to the public by these advertisements. Methods We investigated the content of advertisements, which appeared in ten magazines in the USA. We examined seven issues of each of these published between July, 1998, and July, 1999. Findings 67 advertisements appeared a total of 211 times during our study. Of these, 133 (63%) were for drugs to ameliorate symptoms, 54 (26%) to treat disease, and 23 (11%) to prevent illness. In the 67 unique advertisements, promotional techniques used included emotional appeals (45, 67%) and encouragement of consumers to consider medical causes for their experiences (26, 39%). More advertisements described the benefit of medication with vague, qualitative terms (58, 87%), than with data (9, 13%). However, half the advertisements used data to describe side-effects, typically with lists of side-effects that generally occurred infrequently. None mentioned cost. Interpretation Provision of complete information about the benefit of prescription drugs in advertisements would serve the interests of physicians and the public.	Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA; Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH USA; Norris Cotton Canc Ctr, Lebanon, NH USA; Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA	VA Outcomes Group; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Schwartz, LM (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA.				NATIONAL CANCER INSTITUTE [R18CA091052] Funding Source: NIH RePORTER; NCI NIH HHS [CA9 1052-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM PHARM ASS, 1997, AM PHARM ASS PREV MA; Bell RA, 1999, J GEN INTERN MED, V14, P651, DOI 10.1046/j.1525-1497.1999.01049.x; Bell RA, 1999, J FAM PRACTICE, V48, P446; Bell RA, 2000, J FAM PRACTICE, V49, P1092; Charatan F, 2000, BRIT MED J, V321, P783, DOI 10.1136/bmj.321.7264.783; COHEN EP, 1988, NEW ENGL J MED, V318, P373, DOI 10.1056/NEJM198802113180608; Ferriman, 1999, BMJ, V319, P1208; *FOOD DRUGS ADM, 1985, FED REGISTER, V50, P36677; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; HERXHEIMER A, 1993, INT J HEALTH SERV, V23, P161, DOI 10.2190/1AK2-X8CX-QQ9E-F6ED; Hoffman JR, 1999, BRIT MED J, V318, P1301, DOI 10.1136/bmj.318.7194.1301; Hollon MF, 1999, JAMA-J AM MED ASSOC, V281, P382, DOI 10.1001/jama.281.4.382; HOMER A, 1999, JAMA-J AM MED ASSOC, V281, P380; Hueston WJ, 1997, ACAD MED, V72, P804, DOI 10.1097/00001888-199709000-00018; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; Jones M, 1999, J CLIN PHARM THER, V24, P451, DOI 10.1046/j.1365-2710.1999.00255.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEXCHIN J, 1994, CAN MED ASSOC J, V151, P47; Lipsky MS, 1997, J FAM PRACTICE, V45, P495; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; *OFF MED POL, 2000, ATT BEH ASS DIR CONS; Pines WL, 1999, FOOD DRUG LAW J, V54, P489; Stryer D, 1996, J GEN INTERN MED, V11, P575, DOI 10.1007/BF02599024; TIMMINS N, FINANCIAL TIMES 0720, P200; *US C, 1984, STAFF REP PRESCR DRU; Wilkes MS, 2000, HEALTH AFFAIR, V19, P110, DOI 10.1377/hlthaff.19.2.110; 1998, LANCET, V351, P921; 2001, NUTR FACTS BOX; 2001, DIRECT CONSUMER ADVE; 1998, MEDIAMARK RES MAGAZI; 1996, CONSUMER REPORTS, V61, P62	31	131	132	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1141	1146		10.1016/S0140-6736(01)06254-7	http://dx.doi.org/10.1016/S0140-6736(01)06254-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597668				2022-12-28	WOS:000171399000011
J	Wong, TY; Klein, R; Couper, DJ; Cooper, LS; Shahar, E; Hubbard, LD; Wofford, MR; Sharrett, AR				Wong, TY; Klein, R; Couper, DJ; Cooper, LS; Shahar, E; Hubbard, LD; Wofford, MR; Sharrett, AR			Retinal microvascular abnormalities and incident stroke: the atherosclerosis risk in communities study	LANCET			English	Article							JAPANESE PROVINCIAL CITY; BLOOD-PRESSURE; FOLLOW-UP; HYPERTENSION; RETINOPATHY; POPULATION; DISEASE; SHIBATA; COHORT	Background Retinal microvascular abnormalities reflect damage from hypertension and other vascular processes. We examined the relation of such abnormalities to incident stroke. Methods A cohort of 10 358 men and women (aged 51 to 72 years) living in four US communities underwent retinal photography and standard grading for retinal microvascular abnormalities. The calibres of all retinal arterioles and venules were measured after digital conversion of the photographs, and a summary arteriole-to-venule ratio (AVR) was calculated as an index of arteriolar narrowing (smaller AVR indicates greater narrowing). Cases of incident stroke admitted to hospital were identified and validated by case record reviews. Findings Over an average of 3.5 years, 110 participants had incident strokes. After adjustment for age, sex, race, 6-year mean arterial blood pressure, diabetes, and other stroke risk factors, most retinal microvascular characteristics were predictive of incident stroke, with adjusted relative risks of 2.58 (1.59-4.20) for any retinopathy, 3.11 (1.71-5.65) for microaneurysms, 3.08 (1.42-6.68) for soft exudates, 2.55 (1.27-5.14) for blot haemorrhages, 2.26 (1.00-5.12) for flame-shaped haemorrhages, and 1.60 (1.03-2.47) for arteriovenous nicking. The relative risk of stroke increased with decreasing AVR (p = 0.03). The associations were similar for ischaemic strokes specifically, and for strokes in individuals with hypertension, either with or without diabetes. Interpretation Retinal microvascular abnormalities are related to incident stroke. The findings support a microvascular role in the pathogenesis of stroke. They suggest that retinal photography may be useful for cerebrovascular-risk stratification in appropriate populations.	Univ Wisconsin, Dept Ophthalmol, Madison, WI 53705 USA; Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore 117548, Singapore; Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA; Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; NHLBI, Bethesda, MD 20892 USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA; Univ Mississippi, Med Ctr, Div Hypertens, Jackson, MS 39216 USA	University of Wisconsin System; University of Wisconsin Madison; National University of Singapore; Singapore National Eye Center; National University of Singapore; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Minnesota System; University of Minnesota Twin Cities; University of Mississippi; University of Mississippi Medical Center	Wong, TY (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,460 WARF, Madison, WI 53705 USA.	wong@epi.ophth.wisc.edu	Wong, Tien Yin/AAC-9724-2020	Wong, Tien Yin/0000-0002-8448-1264; Couper, David/0000-0002-4313-9235	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055018, N01HC055020, N01HC035126, N01HC055016, N01HC055015, N01HC055021, N01HC035125, N01HC055022] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55021, N01-HC-55018, N01-HC-55020, N01-HC-55016, N01-HC-35126, N01-HC-55022, N01-HC-55015, N01-HC-35125] Funding Source: Medline; PHS HHS [N01-C-55019] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AOKI N, 1975, JPN CIRC J, V39, P271, DOI 10.1253/jcj.39.271; DIMMITT SB, 1989, LANCET, V1, P1103; FUCHS FD, 1995, J HUM HYPERTENS, V9, P547; GARNER A, 1975, BRIT J OPHTHALMOL, V59, P3, DOI 10.1136/bjo.59.1.3; GOTO I, 1975, STROKE, V6, P263, DOI 10.1161/01.STR.6.3.263; Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0; Jackson R, 1996, J CLIN EPIDEMIOL, V49, P1441, DOI 10.1016/0895-4356(95)00047-X; *JOINT NAT COMM PR, 1997, NIH PUBL; KAGAN A, 1966, B WORLD HEALTH ORGAN, V34, P955; Kahn HA, 1989, STAT METHODS EPIDEMI; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P92, DOI 10.1001/archopht.1994.01090130102026; Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644; KORBER N, 1986, J NEUROL, V233, P30, DOI 10.1007/BF00313988; Lammie GA, 1997, STROKE, V28, P2222, DOI 10.1161/01.STR.28.11.2222; Leppala JM, 1999, STROKE, V30, P2535, DOI 10.1161/01.STR.30.12.2535; Nakayama T, 1997, STROKE, V28, P45, DOI 10.1161/01.STR.28.1.45; OKADA H, 1976, STROKE, V7, P599, DOI 10.1161/01.STR.7.6.599; PARR JC, 1974, AM J OPHTHALMOL, V77, P472, DOI 10.1016/0002-9394(74)90457-7; PARR JC, 1974, AM J OPHTHALMOL, V77, P478, DOI 10.1016/0002-9394(74)90458-9; Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736; SCHNEIDER R, 1993, STROKE, V24, P1874, DOI 10.1161/01.STR.24.12.1874; Shahar E, 1996, ANN EPIDEMIOL, V6, P498, DOI 10.1016/S1047-2797(96)00104-4; Sharrett AR, 1999, AM J EPIDEMIOL, V150, P263; SVARDSUDD K, 1978, ACTA MED SCAND, V204, P159; TANAKA H, 1985, STROKE, V16, P773, DOI 10.1161/01.STR.16.5.773; TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X	28	620	646	0	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1134	1140		10.1016/S0140-6736(01)06253-5	http://dx.doi.org/10.1016/S0140-6736(01)06253-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597667				2022-12-28	WOS:000171399000010
J	Brown, GE				Brown, GE			Surface science - How minerals react with water	SCIENCE			English	Editorial Material							X-RAY REFLECTIVITY; OBSERVED IN-SITU; OXIDE SURFACES; ALPHA-AL2O3(0001); INTERFACE; GEOCHEMISTRY		Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Brown, GE (corresponding author), Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA.	gordon@pangea.stanford.edu						Brown GE, 1999, CHEM REV, V99, P77, DOI 10.1021/cr980011z; CHENG L, IN PRESS PHYS REV LE; DAVIS JA, 1990, REV MINERAL, V23, P177; Davis KJ, 2000, SCIENCE, V290, P1134, DOI 10.1126/science.290.5494.1134; Eng PJ, 2000, SCIENCE, V288, P1029, DOI 10.1126/science.288.5468.1029; Eshleman VR, 1999, SCIENCE, V285, P531; Fenter P, 2000, J COLLOID INTERF SCI, V225, P154, DOI 10.1006/jcis.2000.6756; Fenter P, 2000, GEOCHIM COSMOCHIM AC, V64, P3663, DOI 10.1016/S0016-7037(00)00455-5; Fenter P, 2001, J PHYS CHEM B, V105, P8112, DOI 10.1021/jp0105600; Fenter P, 2000, GEOCHIM COSMOCHIM AC, V64, P1221, DOI 10.1016/S0016-7037(99)00403-2; Giordano L, 1998, PHYS REV LETT, V81, P1271, DOI 10.1103/PhysRevLett.81.1271; Hass KC, 1998, SCIENCE, V282, P265, DOI 10.1126/science.282.5387.265; HIEMSTRA T, 1996, J COLLOID INTERF SCI, V184, P660; Hochella M.F., 1990, REV MINERAL, V23; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; Hunter RJ., 1995, FDN COLLOID SCI, VI; Kelber JA, 2000, SURF SCI, V446, P76, DOI 10.1016/S0039-6028(99)01089-4; Liu P, 1998, SURF SCI, V412-13, P287, DOI 10.1016/S0039-6028(98)00444-0; Liu P, 1998, SURF SCI, V417, P53, DOI 10.1016/S0039-6028(98)00661-X; Myneni SCB, 1997, SCIENCE, V278, P1106, DOI 10.1126/science.278.5340.1106; Nugent MA, 1998, NATURE, V395, P588, DOI 10.1038/26951; O'Day PA, 1999, REV GEOPHYS, V37, P249, DOI 10.1029/1998RG900003; Renaud G, 1998, SURF SCI REP, V32, P1, DOI 10.1016/S0167-5729(98)00005-3; SCHIDEGGER AM, 1997, J COLLOID INTERF SCI, V186, P118; TEMPLETON AS, IN PRESS P NATL ACAD; VANCAPPELLEN P, 1993, GEOCHIM COSMOCHIM AC, V57, P3505, DOI 10.1016/0016-7037(93)90135-J; Wang XG, 2000, PHYS REV LETT, V84, P3650, DOI 10.1103/PhysRevLett.84.3650; WHITE AF, 1995, REV MINERAL, V31	28	180	184	4	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 5	2001	294	5540					67	+		10.1126/science.1063544	http://dx.doi.org/10.1126/science.1063544			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588241				2022-12-28	WOS:000171448800029
J	Gelinas, Y; Baldock, JA; Hedges, JI				Gelinas, Y; Baldock, JA; Hedges, JI			Organic carbon composition of marine sediments: Effect of oxygen exposure on oil generation potential	SCIENCE			English	Article							MATTER PRESERVATION; SELECTIVE PRESERVATION; MICROALGAE; PETROLEUM; KEROGEN; ORIGIN; C-13; ASSOCIATIONS; DEGRADATION; OXIDATION	Anaerobic sedimentary conditions have traditionally been linked to the generation of the source rocks for petroleum formation. However, the influence of sedimentary redox conditions on the composition of freshly deposited organic matter (OM) is not clear. We assessed the effect of in situ exposure time to oxic conditions on the composition of OM accumulating in different coastal and deep-sea sediments using solid-state C-13 nuclear magnetic resonance (NMR). C-13 NMR spectra were resolved into mixtures of mode[ components to distinguish between alkyl carbon present in protein and nonprotein structures. There is an inverse relation between the length of exposure to oxic conditions and the relative abundance of nonprotein alkyl (alkyl,) carbon, whose concentration is two orders of magnitude higher in coastal sediments with short exposure times than in deep-sea sediments with long exposure times. All alkyl(NP)-rich samples contain a physically separate polymethylene component similar in composition to algaenans and kerogens in type I oil shales. The duration of exposure to oxic conditions appears to directly influence the quality and oil generation potential of OM in marine shales.	Univ Washington, Sch Oceanog, Seattle, WA 98195 USA; CSIRO Land & Water, Glen Osmond, SA 5064, Australia	University of Washington; University of Washington Seattle; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Gelinas, Y (corresponding author), Concordia Univ, Dept Chem & Biochem, 1455 Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.		Gélinas, Yves/K-4019-2013; Baldock, Jeffrey A/G-1362-2010	Gélinas, Yves/0000-0001-5751-8378; Baldock, Jeffrey A/0000-0002-6428-8555				ATLAS RM, 1981, MICROBIOL REV, V45, P180, DOI 10.1128/MMBR.45.1.180-209.1981; BENNER R, 1984, APPL ENVIRON MICROB, V47, P98; BERNER RA, 1989, PALAEOGEOGR PALAEOCL, V75, P97, DOI DOI 10.1016/0031-0182(89)90186-7; Bock MJ, 2000, MAR GEOL, V163, P65, DOI 10.1016/S0025-3227(99)00105-X; COWIE GL, 1995, GEOCHIM COSMOCHIM AC, V59, P33, DOI 10.1016/0016-7037(94)00329-K; Dauwe B, 1999, LIMNOL OCEANOGR, V44, P1809, DOI 10.4319/lo.1999.44.7.1809; DELEEUW JW, 1993, ORGANIC GEOCHEMISTRY, pCH3; DEMAISON GJ, 1980, AAPG BULL, V64, P1179; DERENNE S, 1992, ORG GEOCHEM, V19, P345, DOI 10.1016/0146-6380(92)90004-H; Ganeshram RS, 1999, GEOCHIM COSMOCHIM AC, V63, P1723, DOI 10.1016/S0016-7037(99)00073-3; Gelin F, 1999, ORG GEOCHEM, V30, P147, DOI 10.1016/S0146-6380(98)00206-X; Gelin F, 1997, ORG GEOCHEM, V26, P659, DOI 10.1016/S0146-6380(97)00035-1; Gelinas Y, 2001, ORG GEOCHEM, V32, P677, DOI 10.1016/S0146-6380(01)00018-3; GOTH K, 1988, NATURE, V336, P759, DOI 10.1038/336759a0; Hartnett HE, 1998, NATURE, V391, P572, DOI 10.1038/35351; HATCHER PG, 1983, NATURE, V305, P498, DOI 10.1038/305498a0; HEDGES, 2001, NATURE, V409, P801; Hedges JI, 2000, ORG GEOCHEM, V31, P945, DOI 10.1016/S0146-6380(00)00096-6; Hedges JI, 1999, AM J SCI, V299, P529, DOI 10.2475/ajs.299.7-9.529; HEDGES JI, 1995, MAR CHEM, V49, P81, DOI 10.1016/0304-4203(95)00008-F; Henrichs S.M., 1993, ORG GEOCHEM, V11, P101; KEIL RG, 1994, NATURE, V370, P549, DOI 10.1038/370549a0; KEIL RG, 1994, NATURE, V369, P639, DOI 10.1038/369639a0; KINCHESH P, 1995, EUR J SOIL SCI, V46, P125, DOI 10.1111/j.1365-2389.1995.tb01819.x; Knicker H, 1996, ORG GEOCHEM, V24, P661, DOI 10.1016/0146-6380(96)00057-5; Luckge A, 1996, ORG GEOCHEM, V24, P437, DOI 10.1016/0146-6380(96)00045-9; Metzger P, 1991, PROGR CHEM ORGANIC N, V57, P1; Nelson PN, 1999, AUST J SOIL RES, V37, P289, DOI 10.1071/S98076; PHILP RP, 1976, NATURE, V262, P134, DOI 10.1038/262134a0; Salmon V, 2000, ORG GEOCHEM, V31, P463, DOI 10.1016/S0146-6380(00)00013-9; SIEGENTHALER U, 1993, NATURE, V365, P119, DOI 10.1038/365119a0; Smernik RJ, 2000, AUST J SOIL RES, V38, P665, DOI 10.1071/SR99115; TISSOT B, 1974, AAPG BULL, V58, P499; Wakeham SG, 1997, GEOCHIM COSMOCHIM AC, V61, P5363, DOI 10.1016/S0016-7037(97)00312-8; Wilson M. A., 1987, NMR TECHNIQUES APPL	35	65	69	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					145	148		10.1126/science.1062363	http://dx.doi.org/10.1126/science.1062363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588258				2022-12-28	WOS:000171448800047
J	Gabriel, JCP; Camerel, F; Lemaire, BJ; Desvaux, H; Davidson, P; Batail, P				Gabriel, JCP; Camerel, F; Lemaire, BJ; Desvaux, H; Davidson, P; Batail, P			Swollen liquid-crystalline lamellar phase based on extended solid-like sheets	NATURE			English	Article							SUSPENSIONS; MEMBRANES; DIAGRAM; SYSTEM	Ordering particles at the nanometre length scale is a challenging and active research area in materials science. Several approaches have so far been developed, ranging from the manipulation of individual particles(1,2) to the exploitation of self-assembly in colloids(3). Nanometre-scale ordering is well known to appear spontaneously when anisotropic organic moieties form liquid-crystalline phases; this behaviour is also observed for anisotropic mineral nanoparticles(4,5) resulting in the formation of nematic(4-7), smectic(8) and hexagonal(9,10) mesophases. Here we describe a lyotropic liquid-crystalline lamellar phase comprising an aqueous dispersion of planar solid-like sheets in which all the atoms involved in a layer are covalently bonded. The spacing of these phosphatoantimonate single layers can be increased 100-fold, resulting in one-dimensional structures whose periodicity can be tuned from 1.5 to 225 nanometres. These highly organized materials can be mechanically or magnetically aligned over large pH and temperature ranges, and this property can be used to measure residual dipolar couplings for the structure determination of biomolecules by liquid-state NMR. We also expect that our approach will result in the discovery of other classes of mineral lyotropic lamellar phases.	CNRS, FRE 2068, F-44322 Nantes 3, France; Univ Paris Sud, Phys Solides Lab, CNRS, UMR 8502, F-91405 Orsay, France; CEA Saclay, Serv Chim Mol, CNRS, URA 331, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Gabriel, JCP (corresponding author), CNRS, FRE 2068, 2 Rue Houssiniere,BP 32229, F-44322 Nantes 3, France.		Davidson, Patrick/Q-6691-2019; Davidson, Patrick/F-7874-2017; Gabriel, Jean-Christophe P/H-9959-2014	Davidson, Patrick/0000-0002-1363-6062; Davidson, Patrick/0000-0002-1363-6062; Gabriel, Jean-Christophe P/0000-0002-0194-683X; Lemaire, Bruno J./0000-0002-0227-0106				Blanco A, 2000, NATURE, V405, P437, DOI 10.1038/35013024; BOESECKE P, 1995, REV SCI INSTRUM, V66, P1636; Brown ABD, 1999, EUR PHYS J B, V11, P481, DOI 10.1007/s100510050959; DAVIDSON P, 1993, ADV MATER, V5, P665, DOI 10.1002/adma.19930050916; DERYAGUIN BV, 1941, ACTA PHYSICOCHIM USS, V14, P633; Desvaux H, 2001, ANGEW CHEM INT EDIT, V40, P373, DOI 10.1002/1521-3773(20010119)40:2<373::AID-ANIE373>3.0.CO;2-R; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Fang MM, 1999, CHEM MATER, V11, P1526, DOI 10.1021/cm981066k; Fraden S, 1995, NATO ADV SCI INST SE, V460, P113; Gabriel JCP, 1996, J PHYS CHEM-US, V100, P11139, DOI 10.1021/jp961088z; Gabriel JCP, 2000, ADV MATER, V12, P9, DOI 10.1002/(SICI)1521-4095(200001)12:1<9::AID-ADMA9>3.0.CO;2-6; JANIAK MJ, 1976, BIOCHEMISTRY-US, V15, P4575, DOI 10.1021/bi00666a005; KAJIWARA K, 1986, MAKROMOL CHEM, V187, P2883; Kaschak DM, 1998, J AM CHEM SOC, V120, P10887, DOI 10.1021/ja9818710; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; MAEDA Y, 1983, COLLOID SURFACE, V6, P1, DOI 10.1016/0166-6622(83)80001-8; Mourchid A, 1998, LANGMUIR, V14, P4718, DOI 10.1021/la980117p; NIKOOBAKHT B, 2000, J PHYS CHEM B, V104, P1346; PIFFARD Y, 1986, REV CHIM MINER, V23, P766; Poncharal P, 1999, SCIENCE, V283, P1513, DOI 10.1126/science.283.5407.1513; Ramirez BE, 1998, J AM CHEM SOC, V120, P9106, DOI 10.1021/ja982310b; SAFINYA CR, 1993, SCIENCE, V261, P588, DOI 10.1126/science.261.5121.588; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; Salditt T, 1999, PHYS REV E, V60, P7285, DOI 10.1103/PhysRevE.60.7285; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; TONER J, 1990, PHYS REV LETT, V64, P1741, DOI 10.1103/PhysRevLett.64.1741; van der Kooij FM, 2000, NATURE, V406, P868, DOI 10.1038/35022535; Verwey E.J., 1948, THEORY STABILITY LYO; Whittingham MS, 1982, INTERCALATION CHEM	29	228	230	1	134	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					504	508		10.1038/35097046	http://dx.doi.org/10.1038/35097046			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586355	Green Published			2022-12-28	WOS:000171340500042
J	Cohen, JD; Tong, F				Cohen, JD; Tong, F			Neuroscience - The face of controversy	SCIENCE			English	Editorial Material							INFEROTEMPORAL CORTEX; VISUAL-CORTEX; NEURONS; RECOGNITION; AREA; SYSTEMS		Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	Princeton University	Cohen, JD (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.	jdc@princeton.edu						ALLISON T, 1994, J NEUROPHYSIOL, V71, P821, DOI 10.1152/jn.1994.71.2.821; BODAMER J, 1947, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V118, P6, DOI 10.1007/BF00352849; CARAMAZZA A, 1986, BRAIN COGNITION, V5, P41, DOI 10.1016/0278-2626(86)90061-8; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Downing PE, 2001, SCIENCE, V293, P2470, DOI 10.1126/science.1063414; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; FARAH MJ, 1993, PSYCHOL REV, V100, P571, DOI 10.1037/0033-295X.100.4.571; FARAH MJ, 1995, NEUROPSYCHOLOGIA, V33, P661, DOI 10.1016/0028-3932(95)00002-K; FARAH MJ, 1991, J EXP PSYCHOL GEN, V120, P339, DOI 10.1037/0096-3445.120.4.339; Fodor J. A, 1983, MODULARITY MIND; Gauthier I, 2000, NAT NEUROSCI, V3, P191, DOI 10.1038/72140; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Hinton Geoffrey E, 1981, PARALLEL MODELS ASS; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; HUBEL DH, 1982, NATURE, V299, P515, DOI 10.1038/299515a0; Kanwisher N, 1999, NEUROREPORT, V10, P183, DOI 10.1097/00001756-199901180-00035; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KETTNER RE, 1988, J NEUROSCI, V8, P2938; MEADOWS JC, 1974, J NEUROL NEUROSUR PS, V37, P489, DOI 10.1136/jnnp.37.5.489; Moscovitch M, 1997, J COGNITIVE NEUROSCI, V9, P555, DOI 10.1162/jocn.1997.9.5.555; O'Reilly RC, 1999, COGN NEUROPSYCHOL, V16, P49, DOI 10.1080/026432999380979; PERRETT DI, 1991, EXP BRAIN RES, V86, P159; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PLAUT DC, 1995, J CLIN EXP NEUROPSYC, V17, P291, DOI 10.1080/01688639508405124; Plaut DC, 1996, PSYCHOL REV, V103, P56, DOI 10.1037/0033-295X.103.1.56; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, V1; Rumelhart DE, 1986, PARALLEL DISTRIBUTED; Tong F, 2000, COGNITIVE NEUROPSYCH, V17, P257, DOI 10.1080/026432900380607; YAMANE S, 1988, EXP BRAIN RES, V73, P209, DOI 10.1007/BF00279674	31	58	58	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2405	2407		10.1126/science.1066018	http://dx.doi.org/10.1126/science.1066018			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	476PD	11577224				2022-12-28	WOS:000171237200033
J	Farley, KA; Mukhopadhyay, S				Farley, KA; Mukhopadhyay, S			An extraterrestrial impact at the Permian-Triassic boundary?	SCIENCE			English	Editorial Material							EXTINCTION		CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology	Farley, KA (corresponding author), CALTECH, Div Geol & Planetary Sci, MS 170-25, Pasadena, CA 91125 USA.	farley@gps.caltech.edu	Isozaki, Yukio/A-1806-2009; Farley, Kenneth/AAE-7735-2020	Isozaki, Yukio/0000-0002-3596-581X; Farley, Kenneth/0000-0002-7846-7546				ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; ANDREWS JN, 1985, CHEM GEOL, V49, P339, DOI 10.1016/0009-2541(85)90166-4; Becker L, 2001, SCIENCE, V291, P1530, DOI 10.1126/science.1057243; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; HEYMANN D, 1996, GEOL SOC AM SPEC PAP, V307, P453; Mukhopadhyay S, 2001, GEOCHIM COSMOCHIM AC, V65, P653, DOI 10.1016/S0016-7037(00)00555-X; ROBL TL, 1993, ORG GEOCHEM, V20, P249, DOI 10.1016/0146-6380(93)90042-A	7	75	80	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2343	+						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577203				2022-12-28	WOS:000171237200001
J	Brott, LL; Naik, RR; Pikas, DJ; Kirkpatrick, SM; Tomlin, DW; Whitlock, PW; Clarson, SJ; Stone, MO				Brott, LL; Naik, RR; Pikas, DJ; Kirkpatrick, SM; Tomlin, DW; Whitlock, PW; Clarson, SJ; Stone, MO			Ultrafast holographic nanopatterning of biocatalytically formed silica	NATURE			English	Article								Diatoms are of interest to the materials research community because of their ability to create highly complex and intricate silica structures under physiological conditions: what these single-cell organisms accomplish so elegantly in nature requires extreme laboratory conditions to duplicate(1,2) -this is true for even the simplest of structures. Following the identification of polycationic peptides from the diatom Cylindrotheca fusiformis, simple silica nanospheres can now be synthesized in vitro from silanes at nearly neutral pH and at ambient temperatures and pressures(3,4). Here we describe a method for creating a hybrid organic/inorganic ordered nanostructure of silica spheres through the incorporation of a polycationic peptide (derived from the C. fusiformis silaffin-1 protein) into a polymer hologram created by two-photon-induced photopolymerization. When these peptide nanopatterned holographic structures are exposed to a silicic acid, an ordered array of silica nanospheres is deposited onto the clear polymer substrate. These structures exhibit a nearly fifty-fold increase in diffraction efficiency over a comparable polymer hologram without silica. This approach, combining the ease of processability of an organic polymer with the improved mechanical and optical properties of an inorganic material, could be of practical use for the fabrication of photonic devices.	USAF, Res Lab, Mat & Mfg Directorate, Wright Patterson AFB, OH 45433 USA; Univ Cincinnati, Dept Mat Sci & Engn, Cincinnati, OH 45221 USA	United States Department of Defense; United States Air Force; US Air Force Research Laboratory; University System of Ohio; University of Cincinnati	Stone, MO (corresponding author), USAF, Res Lab, Mat & Mfg Directorate, 3005 P St, Wright Patterson AFB, OH 45433 USA.							Belfield KD, 2000, J PHYS ORG CHEM, V13, P837, DOI 10.1002/1099-1395(200012)13:12<837::AID-POC315>3.0.CO;2-5; BROTT LL, 2001, POLYM PREPRINTS, V42, P675; BUNNING TJ, 1995, POLYMER, V36, P2699, DOI 10.1016/0032-3861(95)93646-4; Cha JN, 2000, NATURE, V403, P289, DOI 10.1038/35002038; Kirkpatrick SM, 1999, APPL PHYS A-MATER, V69, P461, DOI 10.1007/s003390051033; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2001, J BIOL CHEM, V276, P26066, DOI 10.1074/jbc.M102093200; Morse DE, 1999, TRENDS BIOTECHNOL, V17, P230, DOI 10.1016/S0167-7799(99)01309-8; Parkinson J, 1999, TRENDS BIOTECHNOL, V17, P190, DOI 10.1016/S0167-7799(99)01321-9; Wang C, 2000, CHEM MATER, V12, P3662, DOI 10.1021/cm990738j	10	209	226	2	77	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 20	2001	413	6853					291	293		10.1038/35095031	http://dx.doi.org/10.1038/35095031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565027				2022-12-28	WOS:000171040500034
J	Cascinelli, N; Belli, F; MacKie, RM; Santinami, M; Bufalino, R; Morabito, A				Cascinelli, N; Belli, F; MacKie, RM; Santinami, M; Bufalino, R; Morabito, A			Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial	LANCET			English	Article							IMMUNOTHERAPY; CHEMOTHERAPY	Background Less than half of patients with melanoma that has spread to local draining regional lymph nodes (stage III melanoma) live with no disease for 5 years or longer after surgery. We aimed to see whether interferon alpha-2a increased survival prospects in these patients. Methods 444 patients from 23 centres in the WHO Melanoma Programme had complete lymphadenectomy for pathologically proven regional nodal spread of melanoma and were randomly assigned to receive either 3 MU subcutaneously of recombinant interferon alpha-2a three times a week for 3 years, or to observation alone after surgery. Patients were stratified by centre, nodes with macroscopic or microscopic melanoma, number of affected nodes, and nodal metastatic spread. Treatment was continued for 3 years or until first sign of relapse. Findings 424 patients entered the study. 5-year disease-free survival of those who had surgery plus interferon alpha-2a was 27.5% (95% CI 21.7-33.6); for those who received surgery alone, survival was 28.4% (22.5-34.6) (p=0.50). Neither Kaplan-Meier cumulative survival rates, nor multivariate analysis of survival, showed a difference between those who had surgery and interferon alpha-2a (35%, 95% CI 29-42) and those who had surgery alone (37%, 31-44). Interpretation Patients with melanoma that has spread to the local draining regional lymph nodes tolerate well 3 MU of interferon alpha-2a given subcutaneously three times a week for 3 years, but this treatment does not improve either disease-free or overall survival.	Natl Canc Inst, I-20133 Milan, Italy; Natl Canc Inst, Dept Gen Surg, I-20133 Milan, Italy; Univ Glasgow, Dept Dermatol, Glasgow G12 8QQ, Lanark, Scotland; Dept Med Surg & Dent, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Glasgow	Cascinelli, N (corresponding author), Natl Canc Inst, Via G Venezian 1, I-20133 Milan, Italy.	who-melanoma@istitutotumori.mi.it	Belli, Filiberto/AAA-6209-2020; Santinami, Mario/I-3795-2017	Belli, Filiberto/0000-0003-3973-4979; Santinami, Mario/0000-0001-8436-4757				BALCH CM, 1981, ANN SURG, V193, P377, DOI 10.1097/00000658-198103000-00023; Caraceni A, 1998, CANCER, V83, P482, DOI 10.1002/(SICI)1097-0142(19980801)83:3<482::AID-CNCR17>3.0.CO;2-S; CASCINELLI N, 1994, LANCET, V343, P913, DOI 10.1016/S0140-6736(94)90030-2; CREAGAN ET, 1984, CANCER, V54, P2844, DOI 10.1002/1097-0142(19841215)54:12<2844::AID-CNCR2820541205>3.0.CO;2-Q; FISHER RI, 1981, SURG CLIN N AM, V61, P1267; Grob JJ, 1998, LANCET, V351, P1905, DOI 10.1016/S0140-6736(97)12445-X; KAISER LR, 1981, SURG CLIN N AM, V61, P1249; Kirkwood JM, 2000, J CLIN ONCOL, V18, P2444, DOI 10.1200/JCO.2000.18.12.2444; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Pehamberger H, 1998, J CLIN ONCOL, V16, P1425, DOI 10.1200/JCO.1998.16.4.1425; VERONESI U, 1982, NEW ENGL J MED, V307, P913, DOI 10.1056/NEJM198210073071503	11	175	178	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 15	2001	358	9285					866	869		10.1016/S0140-6736(01)06068-8	http://dx.doi.org/10.1016/S0140-6736(01)06068-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567700				2022-12-28	WOS:000171087000007
J	Warren, BL; Eid, A; Singer, P; Pillay, SS; Carl, P; Novak, I; Chalupa, P; Atherstone, A; Penzes, I; Kubler, A; Knaub, S; Keinecke, HO; Heinrichs, H; Schindel, F; Juers, M; Bone, RC; Opal, SM				Warren, BL; Eid, A; Singer, P; Pillay, SS; Carl, P; Novak, I; Chalupa, P; Atherstone, A; Penzes, I; Kubler, A; Knaub, S; Keinecke, HO; Heinrichs, H; Schindel, F; Juers, M; Bone, RC; Opal, SM		KyberSept Trial Study Grp	High-dose a randomized antithrombin III in severe sepsis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR PATHWAY INHIBITOR; CRITICALLY-ILL PATIENTS; MULTIPLE ORGAN FAILURE; TISSUE FACTOR PATHWAY; SEPTIC SHOCK; DOUBLE-BLIND; FACTOR VIIA; PROTEIN-C; MULTICENTER	Context Activation of the coagulation system and depletion of endogenous anticoagulants are frequently found in patients with severe sepsis and septic shock. Diffuse microthrombus formation may induce organ dysfunction and lead to excess mortality in septic shock. Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients. Objective To determine if high-dose antithrombin III (administered within 6 hours of onset) would provide a survival advantage in patients with severe Sepsis and septic shock. Design and Setting Double-blind, placebo-controlled, multicenter phase 3 clinical trial in patients with severe sepsis (the KyberSept Trial) was conducted from March 1997 through January 2000. Patients A total of 2314 adult patients were randomized into 2 equal groups of 1157 to receive either intravenous antithrombin III (30000 IU in total over 4 days) or a placebo (1% human albumin). Main Outcome Measure All-cause mortality 28 days after initiation of study medication. Results Overall mortality at 28 days in the antithrombin III treatment group was 38.9% vs 38.7% in the placebo group (P=.94). Secondary end points, including mortality at 56 and 90 days and survival time in the intensive care unit, did not differ between the antithrombin III and placebo groups. In the subgroup of patients who did not receive concomitant heparin during the 4-day treatment phase (n=698), the 28-day mortality was nonsignificantly lower in the antithrombin III group (37.8%) than in the placebo group (43.6%) (P=.08). This trend became significant after 90 days (n=686; 44.9% for antithrombin III group vs 52.5% for placebo group; P=.03). In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001). Conclusions High-dose antithrombin III therapy had no effect on 28-day all-cause mortality in adult patients with severe sepsis and septic shock when administered within 6 hours after the onset. High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin. There was some evidence to suggest a treatment benefit of antithrombin III in the subgroup of patients not receiving concomitant heparin.	Tygerberg Hosp, Dept Surg, Tygerberg, South Africa; Univ Stellenbosch, ZA-7505 Tygerberg, South Africa; Univ Oklahoma, Hlth Sci Ctr, Crit Care Div, Oklahoma City, OK USA; Rabin Med Ctr, Petah Tiqwa, Israel; Livingston Hosp, Dept Surg, Port Elizabeth, South Africa; Hvidovre Univ Hosp, DK-2650 Hvidovre, Denmark; Charles Univ Prague, Intens Care Unit, Plzen, Czech Republic; Clin Infect Dis, Brno, Czech Republic; Frere Hosp, Dept Surg, E London, South Africa; Semmelweis Univ, Dept Anaesthesiol & Intens Care, H-1085 Budapest, Hungary; Wroclaw Univ Med, Dept Anaesthesiol & Intens Therapy, Wroclaw, Poland; Aventis Behring, Marburg, Germany; Rush Presbyterian St Lukes Med Ctr, Crit Care Div, Chicago, IL USA; Brown Univ, Sch Med, Div Infect Dis, Providence, RI 02912 USA	Tygerberg Hospital; Stellenbosch University; University of Oklahoma System; University of Oklahoma Health Sciences Center; Rabin Medical Center; University of Copenhagen; Charles University Prague; Semmelweis University; Wroclaw Medical University; Rush University; Brown University	Opal, SM (corresponding author), Brown Univ, Mem Hosp Rhode Isl, Sch Med, Div Infect Dis, 111 Brewster St, Pawtucket, RI 02860 USA.	Steven_Opal@brown.edu	Chalupa, Pavel/J-2536-2014; Chalupa, Pavel/A-6081-2008	Chalupa, Pavel/0000-0001-8412-2176; Chalupa, Pavel/0000-0001-8412-2176				Baudo F, 1998, INTENS CARE MED, V24, P336, DOI 10.1007/s001340050576; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; Collett D., 1991, MODELLING BINARY DAT; CORRIGAN JJ, 1977, J PEDIATR-US, V91, P695, DOI 10.1016/S0022-3476(77)81017-2; Dickneite G, 1998, SEMIN THROMB HEMOST, V24, P61, DOI 10.1055/s-2007-995824; Eisele B, 1998, SEMIN THROMB HEMOST, V24, P71, DOI 10.1055/s-2007-995825; Eisele B, 1998, INTENS CARE MED, V24, P663, DOI 10.1007/s001340050642; FOURRIER F, 1992, CHEST, V101, P816, DOI 10.1378/chest.101.3.816; Fourrier F, 2000, CRIT CARE MED, V28, pS38, DOI 10.1097/00003246-200009001-00009; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; Gando S, 1996, THROMB HAEMOSTASIS, V75, P224; Gando S, 1998, CRIT CARE MED, V26, P2005, DOI 10.1097/00003246-199812000-00030; Giebler R, 1999, CRIT CARE MED, V27, P597, DOI 10.1097/00003246-199903000-00042; Hamamoto T, 1996, BLOOD COAGUL FIBRIN, V7, P470, DOI 10.1097/00001721-199606000-00007; Harada N, 1999, BLOOD, V93, P157, DOI 10.1182/blood.V93.1.157.401k08_157_164; Herson J., 1993, DRUG INF J, V27, DOI 10.1177/009286159302700317; Hinshaw LB, 1996, CRIT CARE MED, V24, P1072, DOI 10.1097/00003246-199606000-00031; Hoffmann JN, 2000, AM J PHYSIOL-CELL PH, V279, pC98, DOI 10.1152/ajpcell.2000.279.1.C98; HORIE S, 1990, THROMB RES, V59, P899; Ilias W, 2000, INTENS CARE MED, V26, P704, DOI 10.1007/s001340051236; Inthorn D, 1997, SHOCK, V8, P328, DOI 10.1097/00024382-199711000-00003; Jesty J, 1996, BLOOD, V87, P2301, DOI 10.1182/blood.V87.6.2301.bloodjournal8762301; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LeGall JR, 1996, JAMA-J AM MED ASSOC, V276, P802, DOI 10.1001/jama.276.10.802; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEGALL JR, 1995, JAMA-J AM MED ASSOC, V273, P644, DOI 10.1001/jama.273.8.644; LEITHAUSER B, 2000, INTENSIVE CARE ME SB, V26, P257; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; LORENTE JA, 1993, CHEST, V103, P1536, DOI 10.1378/chest.103.5.1536; Mammen EF, 2008, SEMIN THROMB HEMOST, V34, pA22, DOI 10.1055/s-2007-995819; MAMMEN EF, 1995, SEMIN HEMATOL     S2, V4, P2; Mesters RM, 1996, BLOOD, V88, P881, DOI 10.1182/blood.V88.3.881.881; MURANO G, 1980, THROMB RES, V18, P259, DOI 10.1016/0049-3848(80)90190-5; Opal SM, 1999, INFECT DIS CLIN N AM, V13, P285, DOI 10.1016/S0891-5520(05)70075-1; Opal SM, 2000, CRIT CARE MED, V28, pS34, DOI 10.1097/00003246-200009001-00008; Ostrovsky L, 1997, CIRCULATION, V96, P2302; PIXLEY RA, 1993, J CLIN INVEST, V91, P61, DOI 10.1172/JCI116201; POCOCK SJ, 1986, DRUG INFECT J, V20, P263; SCHIPPER HG, 1978, LANCET, V1, P854; Uchiba M, 1998, THROMB RES, V89, P233, DOI 10.1016/S0049-3848(98)00012-7; UCHIBA M, 1996, AM J PHYSIOL, V270, P921; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; VANDEVENTER SJH, 1996, BLOOD, V88, P2520; Vervloet MG, 1998, SEMIN THROMB HEMOST, V24, P33, DOI 10.1055/s-2007-995821; YAMAUCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1404, DOI 10.1016/0006-291X(89)91135-2	46	914	992	3	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2001	286	15					1869	1878		10.1001/jama.286.15.1869	http://dx.doi.org/10.1001/jama.286.15.1869			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	482UH	11597289	Bronze			2022-12-28	WOS:000171595300028
J	Wartofsky, L				Wartofsky, L			Update in endocrinology	ANNALS OF INTERNAL MEDICINE			English	Review							POSTMENOPAUSAL OSTEOPOROSIS; MYOCARDIAL-INFARCTION; CONTROLLED TRIAL; ALENDRONATE; WOMEN; THERAPY; FRACTURES; RISK; LEVOTHYROXINE		Washington Hosp Ctr, Dept Med, Washington, DC 20010 USA	MedStar Washington Hospital Center	Wartofsky, L (corresponding author), Washington Hosp Ctr, Dept Med, 110 Irving St NW, Washington, DC 20010 USA.							Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Danese ND, 2000, J CLIN ENDOCR METAB, V85, P2993, DOI 10.1210/jcem.85.9.6841; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Ganz DA, 2000, ANN INTERN MED, V132, P780, DOI 10.7326/0003-4819-132-10-200005160-00003; Grady D, 2000, ANN INTERN MED, V133, P999, DOI 10.7326/0003-4819-133-12-200012190-00016; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Kumeda Y, 2000, J CLIN ENDOCR METAB, V85, P4157, DOI 10.1210/jc.85.11.4157; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Mercuro G, 2000, J CLIN ENDOCR METAB, V85, P159, DOI 10.1210/jc.85.1.159; Mundy GR, 2000, ANN INTERN MED, V133, P828, DOI 10.7326/0003-4819-133-10-200011210-00016; O'Brien J, 2000, LANCET, V355, P1295; Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902; Ravn P, 1999, ANN INTERN MED, V131, P935, DOI 10.7326/0003-4819-131-12-199912210-00005; Robertson RP, 2000, NEW ENGL J MED, V343, P289, DOI 10.1056/NEJM200007273430409; Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109; WARTOFSKY L, 1995, ARCH INTERN MED, V155, P1130, DOI 10.1001/archinte.155.11.1130	18	2	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	1				601	609		10.7326/0003-4819-135-8_Part_1-200110160-00011	http://dx.doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481VY	11601932				2022-12-28	WOS:000171542200006
J	Ferreira, FL; Bota, DP; Bross, A; Melot, C; Vincent, JL				Ferreira, FL; Bota, DP; Bross, A; Melot, C; Vincent, JL			Serial evaluation of the SOFA score to predict outcome in critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNITS; MULTIPLE ORGAN FAILURE; ACUTE-PANCREATITIS; ACUTE PHYSIOLOGY; MULTICENTER; DYSFUNCTION/FAILURE; SEPSIS; MORTALITY; TRAUMA; APACHE	Context Evaluation of trends in organ dysfunction in critically ill patients may help predict outcome. Objective To determine the usefulness of repeated measurement the Sequential Organ Failure Assessment (SOFA) score for prediction of mortality in intensive care unit (ICU) patients. Design Prospective, observational cohort study conducted from April 1 to July 31, 1999. Setting A 31-bed medicosurgical ICU at a university hospital in Belgium. Patients Three hundred fifty-two consecutive patients (mean age, 59 years) admitted to the ICU for more than 24 hours for whom the SOFA score was calculated on admission and every 48 hours until discharge. Main Outcome Measures Initial SOFA score (0-24), Delta -SOFA scores (differences between subsequent scores), and the highest and mean SOFA scores obtained during the ICU stay and their correlations with mortality. Results The initial, highest, and mean SOFA scores correlated well with mortality. Initial and highest scores of more than 11 or mean scores of more than 5 corresponded to mortality of more than 80%. The predictive value of the mean score was independent of the length of ICU stay. In univariate analysis, mean and highest SOFA scores had the strongest correlation with mortality, followed by Delta-SOFA and initial SOFA scores. The area under the receiver operating characteristic curve was largest for highest scores (0.90; SE, 0.02; P<.001 vs initial score). When analyzing trends in the SOFA score during the first 96 hours, regardless of the initial score, the mortality rate was at least 50% when the score increased, 27% to 35% when it remained unchanged, and less than 27% when it decreased. Differences in mortality were better predicted in the first 48 hours than in the subsequent 48 hours. There was no significant difference in the length of stay among these groups. Except for initial scores of more than 11 (mortality rate >90%), a decreasing score during the first 48 hours was associated with a mortality rate of less than 6%, while an unchanged or increasing score was associated with a mortality rate of 37% when the initial score was 2 to 7 and 60% when the initial score was 8 to 11. Conclusions Sequential assessment of organ dysfunction during the first few days of ICU admission is a good indicator of prognosis. Both the mean and highest SOFA scores are particularly useful predictors of outcome. Independent of the initial score, an increase in SOFA score during the first 48 hours in the ICU predicts a mortality rate of at least 50%.	Free Univ Brussels, Erasme Univ Hosp, Dept Intens Care, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vincent, JL (corresponding author), Free Univ Brussels, Erasme Univ Hosp, Dept Intens Care, Route de Lennik 808, B-1070 Brussels, Belgium.			Vincent, Jean-Louis/0000-0001-6011-6951; MELOT, Christian/0000-0002-6172-0330				Antonelli M, 1999, INTENS CARE MED, V25, P389, DOI 10.1007/s001340050863; BION JF, 1988, INTENS CARE MED, V14, P167; Cryer HG, 1999, J TRAUMA, V46, P597, DOI 10.1097/00005373-199904000-00007; CULLEN DJ, 1994, CRIT CARE MED, V22, P1345; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; Di Filippo A, 1998, CHEMOTHERAPY, V44, P63, DOI 10.1159/000007092; Goldhill DR, 1998, CRIT CARE MED, V26, P1337, DOI 10.1097/00003246-199808000-00017; Hynninen M, 1999, J CRIT CARE, V14, P63, DOI 10.1016/S0883-9441(99)90015-1; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; LARVIN M, 1989, LANCET, V2, P201; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1988, CRIT CARE MED, V16, P470, DOI 10.1097/00003246-198805000-00002; Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; SAWYER RG, 1992, AM SURGEON, V58, P82; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; WAGNER DP, 1994, CRIT CARE MED, V22, P1359, DOI 10.1097/00003246-199409000-00004; ZWEIG MH, 1993, CLIN CHEM, V39, P561	21	1552	1629	1	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1754	1758		10.1001/jama.286.14.1754	http://dx.doi.org/10.1001/jama.286.14.1754			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480NC	11594901	Bronze			2022-12-28	WOS:000171466800026
J	Molnar, C; Lechleitner, M; Wetscher, G; Tilg, H				Molnar, C; Lechleitner, M; Wetscher, G; Tilg, H			A woman with vomiting and depression	LANCET			English	Editorial Material							PANCREATITIS		Univ Innsbruck Hosp, Dept Med, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Surg, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Tilg, H (corresponding author), Univ Innsbruck Hosp, Dept Med, A-6020 Innsbruck, Austria.							CAMUNAS M, 1996, REV ESP ENFERM DIG, V88, P672; Chen CH, 2001, GASTROINTEST ENDOSC, V53, P121, DOI 10.1067/mge.2001.111396; Chung Jun-Pyo, 1994, Journal of Korean Medical Science, V9, P351; Rubesin SE, 1997, BRIT J RADIOL, V70, P311, DOI 10.1259/bjr.70.831.9166060; Vix J, 1997, J CHIR-PARIS, V134, P73	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1154	1154		10.1016/S0140-6736(01)06257-2	http://dx.doi.org/10.1016/S0140-6736(01)06257-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597671				2022-12-28	WOS:000171399000014
J	de Caestecker, J				de Caestecker, J			ABC of the upper gastrointestinal tract - Oesophagus: Heartburn	BRITISH MEDICAL JOURNAL			English	Review									Glenfield Hosp NHS Trust, Leicester, Leics, England		de Caestecker, J (corresponding author), Glenfield Hosp NHS Trust, Leicester, Leics, England.			de Caestecker, John/0000-0001-5526-8176				Dent J, 1999, GUT, V44, pS1, DOI 10.1136/gut.44.2008.S1; LUNDELL L, 1998, GUIDELINES MANAGEMEN; *NAT I CLIN EXC, 2000, GUID US PROT PUMP IN	3	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					736	739		10.1136/bmj.323.7315.736	http://dx.doi.org/10.1136/bmj.323.7315.736			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HJ	11576983	Green Published			2022-12-28	WOS:000171340700023
J	Elkan, R; Kendrick, D; Dewey, M; Hewitt, M; Robinson, J; Blair, M; Williams, D; Brummell, K				Elkan, R; Kendrick, D; Dewey, M; Hewitt, M; Robinson, J; Blair, M; Williams, D; Brummell, K			Effectiveness of home based support for older people: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; ELDERLY PEOPLE; GENERAL-PRACTICE; COMMUNITY; VISITS; CARE; INTERVENTION; DISCHARGE; PROGRAM; SURVEILLANCE	Objective To evaluate the effectiveness of home visiting programmes that offer health promotion and preventive care to older people. Design Systematic review and meta-analysis of 15 studies of home visiting. Participants Older people living at home, including frail older people at risk of adverse outcomes. Outcome measures Mortality, admission to hospital, admission to institutional care, functional status, health status. Results Home visiting was associated with a significant reduction in mortality. The pooled odds ratio for eight studies that assessed mortality in members of the general elderly population Was 0.76 (95% confidence interval 0.64 to 0.89). Five studies of home visiting to frail older people who were at risk of adverse outcomes also showed a significant reduction in mortality (0.72; 0.54 to 0.97). Home visiting was associated with a significant reduction in admissions to long term institutional care in members of the general elderly population (0.65; 0.46 to 0.91). For three studies of home visiting to frail, "at risk" older people, the pooled odds ratio was 0.55 (0.35 to 0.88). Meta-analysis of six studies of home visiting to members of the general elderly population showed no significant reduction in admissions to hospital (odds ratio 0.95; 0.80 to 1.09). Three studies showed no significant effect on health (standardised effect size 0.06; -0.07 to 0.18). Four studies showed no effect on activities of daily living (0.05; -0.07 to 0.17). Conclusion Home visits to older people can reduce mortality and admission to long term institutional care.	Univ Nottingham, Queens Med Ctr, Sch Nursing, Postgrad Div, Nottingham NG7 2UH, England; Sch Community Hlth Sci, Div Gen Practice, Nottingham NG7 2RD, England; Univ Nottingham, Queens Med Ctr, Sch Community Hlth Sci, Trent Inst Hlth Serv Res, Nottingham NG7 2UH, England; Kingsmill Ctr, Evaluat Audit Ctr Res, Ashfield NG17 4JL, Notts, England; Northwick Pk & St Marks NHS Trust, Harrow HA1 3UJ, Middx, England	University of Nottingham; University of Nottingham; Imperial College London	Elkan, R (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Nursing, Postgrad Div, Nottingham NG7 2UH, England.	Ruth.Elkan@nottingham.ac.uk	Dewey, Michael E/E-2049-2010; Blair, Mitch/D-5612-2013	Dewey, Michael E/0000-0002-7522-3677; Blair, Mitch/0000-0001-7442-0188; Kendrick, Denise/0000-0003-3603-6542				ARCHBOLD PG, 1995, RES NURS HEALTH, V18, P3, DOI 10.1002/nur.4770180103; BALABAN DJ, 1988, J FAM PRACTICE, V26, P307; Barber J H, 1976, J R Coll Gen Pract, V26, P106; Brocklehurst J C, 1982, Health Visit, V55, P356; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; Coupland R, 1986, Health Visit, V59, P299; Cruse J, 1986, Health Visit, V59, P308; CURRIE G, 1974, BRIT MED J, V2, P108, DOI 10.1136/bmj.2.5910.108; DUNN RB, 1994, ARCH GERONTOL GERIAT, V18, P15, DOI 10.1016/0167-4943(94)90044-2; FABACHER D, 1994, J AM GERIATR SOC, V42, P630, DOI 10.1111/j.1532-5415.1994.tb06862.x; FLETCHER A, 2000, BMJ; HALL N, 1992, CAN J AGING, V11, P72, DOI 10.1017/S0714980800014537; HANSEN FR, 1992, AGE AGEING, V21, P445, DOI 10.1093/ageing/21.6.445; HEDGES LV, 1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; *HLTH VIS ASS BRIT, 1982, HLTH VIS HLTH AG; LUKER KA, 1982, EVALUATING HLTH VISI; MCEWAN RT, 1990, BRIT J GEN PRACT, V40, P94; MELIN AL, 1992, MED CARE, V30, P1004, DOI 10.1097/00005650-199211000-00004; OKTAY JS, 1990, AM J PUBLIC HEALTH, V80, P39, DOI 10.2105/AJPH.80.1.39; Orwin R.G., 1994, HDB RES SYNTHESIS; PATHY MSJ, 1992, LANCET, V340, P890, DOI 10.1016/0140-6736(92)93294-W; Petitti D, 1994, METAANALYSIS DECISIO; Phillips S, 1988, Health Visit, V61, P341; RAMSDELL JW, 1989, J AM GERIATR SOC, V37, P17, DOI 10.1111/j.1532-5415.1989.tb01563.x; REISCH JS, 1989, PEDIATRICS, V84, P815; RUBIN CD, 1992, J AM GERIATR SOC, V40, P989, DOI 10.1111/j.1532-5415.1992.tb04474.x; Sorensen K H, 1988, Compr Gerontol B, V2, P85; Stuck AE, 2000, ARCH INTERN MED, V160, P977, DOI 10.1001/archinte.160.7.977; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; SUTHERLAND S, 1999, CMND41921; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544; Tulloch A J, 1979, J R Coll Gen Pract, V29, P733; van Haastregt JCM, 2000, BMJ-BRIT MED J, V320, P754, DOI 10.1136/bmj.320.7237.754; VANROSSUM E, 1993, BMJ-BRIT MED J, V307, P27, DOI 10.1136/bmj.307.6895.27; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; WILLIAMS EI, 1992, J PUBLIC HEALTH MED, V14, P138; WILLIAMSON J, 1981, HLTH CARE ELDERLY; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	43	246	247	2	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 29	2001	323	7315					719	724B		10.1136/bmj.323.7315.719	http://dx.doi.org/10.1136/bmj.323.7315.719			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	478HJ	11576978	Bronze, Green Published			2022-12-28	WOS:000171340700017
J	Steinmetz, EJ; Conrad, NK; Brow, DA; Corden, JL				Steinmetz, EJ; Conrad, NK; Brow, DA; Corden, JL			RNA-binding protein Nrd1 directs poly(A)-independent 3 '-end formation of RNA polymerase II transcripts	NATURE			English	Article							C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; SPLICING ENDONUCLEASE; YEAST; GENE; SNRNA; SEN1; ACCUMULATION; EXPRESSION; DELETION	A eukaryotic chromosome contains many genes, each transcribed separately by RNA polymerase (pol) I, II or III. Transcription termination between genes prevents the formation of polycistronic RNAs and anti-sense RNAs, which are generally detrimental to the correct expression of genes. Terminating the transcription of protein-coding genes by pol II requires a group of proteins that also direct cleavage and polyadenylation of the messenger RNA in response to a specific sequence element, and are associated with the carboxyl-terminal domain of the largest subunit of pol II (refs 1-6). By contrast, the cis-acting elements and trans-acting factors that direct termination of non-polyadenylated transcripts made by pol II, including small nucleolar and small nuclear RNAs, are not known. Here we show that read-through transcription from yeast small nucleolar RNA and small nuclear RNA genes into adjacent genes is prevented by a cis-acting element that is recognized, in part, by the essential RNA-binding protein Nrd1. The RNA-binding protein Nab3, the putative RNA helicase Sen1, and the intact C-terminal domain of pol II are also required for efficient response to the element. The same proteins are required for maintaining normal levels of Nrd1 mRNA, indicating that these proteins may control elongation of a subset of mRNA transcripts.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University	Brow, DA (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA.	dabrow@facstaff.wisc.edu; jcorden@jhmi.edu						Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; Brachmann CB, 1998, YEAST, V14, P115; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Conrad NK, 2000, GENETICS, V154, P557; DEMARINI DJ, 1992, MOL CELL BIOL, V12, P2154, DOI 10.1128/MCB.12.5.2154; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; Fatica A, 2000, EMBO J, V19, P6218, DOI 10.1093/emboj/19.22.6218; Greger IH, 2000, P NATL ACAD SCI USA, V97, P8415, DOI 10.1073/pnas.140217697; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; LEE JM, 1991, GENE EXPRESSION, V1, P149; LESSER CF, 1993, GENETICS, V133, P851; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; Rasmussen TP, 1999, MOL CELL BIOL, V19, P5235; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Sacher M, 2000, EUR J CELL BIOL, V79, P71, DOI 10.1078/S0171-9335(04)70009-6; Seipelt RL, 1999, NUCLEIC ACIDS RES, V27, P587, DOI 10.1093/nar/27.2.587; Steinmetz EJ, 1998, P NATL ACAD SCI USA, V95, P6699, DOI 10.1073/pnas.95.12.6699; Steinmetz EJ, 1996, MOL CELL BIOL, V16, P6993, DOI 10.1128/mcb.16.12.6993; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Ursic D, 1997, NUCLEIC ACIDS RES, V25, P4778, DOI 10.1093/nar/25.23.4778; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; WEST ML, 1995, GENETICS, V140, P1223; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	27	278	284	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 20	2001	413	6853					327	331		10.1038/35095090	http://dx.doi.org/10.1038/35095090			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565036				2022-12-28	WOS:000171040500043
J	Lammert, E; Cleaver, O; Melton, D				Lammert, E; Cleaver, O; Melton, D			Induction of pancreatic differentiation by signals from blood vessels	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR ENDOTHELIUM; XENOPUS; GENE; EXPRESSION; LETHALITY; ENDODERM; FLT-1; FLK-1; PDX-1	Blood vessels supply developing organs with metabolic sustenance. Here, we demonstrate a role for blood vessels as a source of developmental signals during pancreatic organogenesis. In vitro experiments with embryonic mouse tissues demonstrate that blood vessel endothelium induces insulin expression in isolated endoderm. Removal of the dorsal aorta in Xenopus laevis embryos results in the failure of insulin expression in vivo. Furthermore, using transgenic mice, we show that ectopic vascularization in the posterior foregut leads to ectopic insulin expression and islet hyperplasia. These results indicate that vessels not only provide metabolic sustenance, but also provide inductive signals for organ development.	Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Melton, D (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Cleaver, Ondine/0000-0003-2454-6641				ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; BANTING FG, 1990, J LAB CLIN MED, V115, P254; Brekken RA, 1998, CANCER RES, V58, P1952; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Cleaver O, 1998, DEVELOPMENT, V125, P3905; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hirsch N, 1997, J NEUROBIOL, V32, P45, DOI 10.1002/(SICI)1097-4695(199701)32:1<45::AID-NEU5>3.3.CO;2-V; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kelly OG, 2000, DEV DYNAM, V218, P615, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1027>3.0.CO;2-8; Kim SK, 1997, DEVELOPMENT, V124, P4243; Lammert E, 2000, MECH DEVELOP, V94, P199, DOI 10.1016/S0925-4773(00)00317-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Offield MF, 1996, DEVELOPMENT, V122, P983; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; TEITELMAN G, 1987, DEV BIOL, V120, P425, DOI 10.1016/0012-1606(87)90246-6; Wells JM, 2000, DEVELOPMENT, V127, P1563; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002	22	793	837	4	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 19	2001	294	5542					564	567		10.1126/science.1064344	http://dx.doi.org/10.1126/science.1064344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	484NC	11577200				2022-12-28	WOS:000171695600038
J	Fonarow, GC				Fonarow, GC			Quality indicators for the management of heart failure in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							CONVERTING ENZYME-INHIBITORS; LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; CALCIUM-CHANNEL BLOCKER; RANDOMIZED-TRIAL; DOUBLE-BLIND; MORTALITY; MORBIDITY; THERAPY; CAPTOPRIL		Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Fonarow, GC (corresponding author), Univ Calif Los Angeles, Div Cardiol, 47-123 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	gfonarow@mednet.ucla.edu	Fonarow, Gregg C/D-5988-2014	Fonarow, Gregg C/0000-0002-3192-8093				*AM HEART ASS, 1997, HEART STROK STAT UPD; Blackshear JL, 1996, LANCET, V348, P633; CAS LD, 1995, CLIN CARDIOL, V18, P370, DOI 10.1002/clc.4960180704; Cohn JN, 1997, CIRCULATION, V96, P856, DOI 10.1161/01.cir.96.3.856; Doughty RN, 1997, EUR HEART J, V18, P560; ELKAYAM U, 1985, AM J CARDIOL, V56, P560, DOI 10.1016/0002-9149(85)91185-3; ELKAYAM U, 1990, CIRCULATION, V82, P1954, DOI 10.1161/01.CIR.82.6.1954; Gambassi G, 2000, ARCH INTERN MED, V160, P53, DOI 10.1001/archinte.160.1.53; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; Gheorghiade M, 1998, CIRCULATION, V97, P282, DOI 10.1161/01.CIR.97.3.282; GOLDSTEIN RE, 1991, CIRCULATION, V83, P52, DOI 10.1161/01.CIR.83.1.52; Grossman E, 1996, ANN INTERN MED, V125, P304, DOI 10.7326/0003-4819-125-4-199608150-00009; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; Hjalmarson A, 1999, LANCET, V353, P2001; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; KONSTAM MA, 1994, AHCPR PUBL; Kostis JB, 1997, AM HEART J, V133, P550, DOI 10.1016/S0002-8703(97)70150-9; Lechat P, 1999, LANCET, V353, P9; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; Levine TB, 2000, CIRCULATION, V101, P758, DOI 10.1161/01.CIR.101.7.758; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; PARKER M, 1996, NEW ENGL J MED, V334, P1349; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Philbin EF, 1998, ARCH INTERN MED, V158, P501, DOI 10.1001/archinte.158.5.501; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; RYMAN KS, 1986, AM J CARDIOL, V58, P583, DOI 10.1016/0002-9149(86)90280-8; Senni M, 1999, J AM COLL CARDIOL, V33, P164, DOI 10.1016/S0735-1097(98)00523-3; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; STEVENSON WG, 1993, CIRCULATION, V88, P2953, DOI 10.1161/01.CIR.88.6.2953; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; Thackray S, 2000, EUR J HEART FAIL, V2, P209, DOI 10.1016/S1388-9842(00)00080-5; Yusuf S, 2000, NEW ENGL J MED, V342, P145	40	15	15	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				694	702		10.7326/0003-4819-135-8_Part_2-200110161-00008	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481WA	11601952				2022-12-28	WOS:000171542400008
J	Higgins, J; Wilson, S; Bridge, P; Cooke, MW				Higgins, J; Wilson, S; Bridge, P; Cooke, MW			Communication difficulties during 999 ambulance calls: observational study	BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Dept Primary Care & Gen Practice, Emergency Med Res Grp, Birmingham B15 2TT, W Midlands, England; Univ Warwick, Sch Hlth & Social Studies, Ctr Primary Hlth Care Studies, Emergency Med Res Grp, Coventry CV4 7AL, W Midlands, England	University of Birmingham; University of Warwick	Wilson, S (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Emergency Med Res Grp, Birmingham B15 2TT, W Midlands, England.							Cooke MW, 1998, PREHOSPITAL IMMEDIAT, V2, P193; Marsden A K, 1995, Accid Emerg Nurs, V3, P177, DOI 10.1016/0965-2302(95)90002-0; MCNAUGHTON GW, 1997, PREHOSP IMMED CARE, V1, P71; *MOB PHON HLTH IND, 2000, NAT RAD PROT BOARD; NICHOLL J, 1996, PREHOSP IMMED CARE, V3, P71	5	14	14	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 6	2001	323	7316					781	782		10.1136/bmj.323.7316.781	http://dx.doi.org/10.1136/bmj.323.7316.781			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481LK	11588079	Green Published, Bronze			2022-12-28	WOS:000171520600028
J	Richards, JR				Richards, JR			Darwin the philosopher?	LANCET			English	Editorial Material									UCL, Ctr Bioeth & Philosophy Med, London N19 2UA, England	University of London; University College London	Richards, JR (corresponding author), UCL, Ctr Bioeth & Philosophy Med, London N19 2UA, England.	j.rr@chime.ucl.ac.uk						CHANDLER J, 2001, PHILOS MAG, V16, P11	1	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	2001	358	9288					1118	1118		10.1016/S0140-6736(01)06301-2	http://dx.doi.org/10.1016/S0140-6736(01)06301-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597663				2022-12-28	WOS:000171399000006
J	Nicewarner-Pena, SR; Freeman, RG; Reiss, BD; He, L; Pena, DJ; Walton, ID; Cromer, R; Keating, CD; Natan, MJ				Nicewarner-Pena, SR; Freeman, RG; Reiss, BD; He, L; Pena, DJ; Walton, ID; Cromer, R; Keating, CD; Natan, MJ			Submicrometer metallic barcodes	SCIENCE			English	Article							GOLD; MONOLAYERS; ARRAYS	We synthesized multimetal microrods intrinsically encoded with submicrometer stripes. Complex striping patterns are readily prepared by sequential electrochemical deposition of metal ions into templates with uniformly sized pores. The differential reflectivity of adjacent stripes enables identification of the striping patterns by conventional tight microscopy. This readout mechanism does not interfere with the use of fluorescence for detection of analytes bound to particles by affinity capture, as demonstrated by DNA and protein bioassays.	Penn State Univ, Dept Chem, Davey Lab 152, University Pk, PA 16802 USA; SurroMed Inc, Mt View, CA 94043 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Keating, CD (corresponding author), Penn State Univ, Dept Chem, Davey Lab 152, University Pk, PA 16802 USA.			Keating, Christine/0000-0001-6039-1961	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002228] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG02228] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALMAWLAWI D, 1994, J MATER RES, V9, P1014, DOI 10.1557/JMR.1994.1014; Battersby BJ, 2000, J AM CHEM SOC, V122, P2138, DOI 10.1021/ja993634i; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Dunbar SA, 2000, CLIN CHEM, V46, P1498; Grabar KC, 1997, ANAL CHEM, V69, P471, DOI 10.1021/ac9605962; Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228; Harder P, 1998, J PHYS CHEM B, V102, P426, DOI 10.1021/jp972635z; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; Henry MR, 1999, ANAL BIOCHEM, V276, P204, DOI 10.1006/abio.1999.4344; Hulteen JC, 1997, J MATER CHEM, V7, P1075, DOI 10.1039/a700027h; Inoue S., 1997, VIDEO MICROSCOPY; LIDE DR, 1990, CRC HDB CHEM PHYSICS; Martin BR, 1999, ADV MATER, V11, P1021, DOI 10.1002/(SICI)1521-4095(199908)11:12<1021::AID-ADMA1021>3.0.CO;2-S; Masuda H, 2001, ADV MATER, V13, P189, DOI 10.1002/1521-4095(200102)13:3<189::AID-ADMA189>3.0.CO;2-Z; Savas TA, 1996, J VAC SCI TECHNOL B, V14, P4167, DOI 10.1116/1.588613; SKOOG DA, 1992, FUNDAMENTALS ANAL CH, P42; Thurn-Albrecht T, 2000, SCIENCE, V290, P2126, DOI 10.1126/science.290.5499.2126; Ulman A., 1991, INTRO ULTRATHIN FILM; Walt DR, 2000, SCIENCE, V287, P451, DOI 10.1126/science.287.5452.451	21	1215	1318	8	287	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					137	141		10.1126/science.294.5540.137	http://dx.doi.org/10.1126/science.294.5540.137			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588257				2022-12-28	WOS:000171448800045
J	Bosch, X				Bosch, X			Vatican approves use of animal transplants 'to benefit humans'	NATURE			English	News Item																		1999, NATURE, V397, P281	1	2	2	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					445	445		10.1038/35097243	http://dx.doi.org/10.1038/35097243			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586318	Bronze			2022-12-28	WOS:000171340500012
J	Eschner, J; Raab, C; Schmidt-Kaler, F; Blatt, R				Eschner, J; Raab, C; Schmidt-Kaler, F; Blatt, R			Light interference from single atoms and their mirror images	NATURE			English	Article							INHIBITED SPONTANEOUS EMISSION; QUANTUM JUMPS; CAVITY; ION; PHOTONS	A single atom emitting single photons is a fundamental source of light. But the characteristics of this light depend strongly on the environment of the atom(1,2). For example, if an atom is placed between two mirrors, both the total rate and the spectral composition of the spontaneous emission can be modified. Such effects have been observed using various systems: molecules deposited on mirrors(3), dye molecules in an optical cavity(4), an atom beam traversing a two-mirror optical resonator(5-8), single atoms traversing a microwave cavity(9-11) and a single trapped electron(12). A related and equally fundamental phenomenon is the optical interaction between two atoms of the same kind when their separation is comparable to their emission wavelength. In this situation, light emitted by one atom may be reabsorbed by the other, leading to cooperative processes in the emission(13,14). Here we observe these phenomena with high visibility by using one or two single atom(s), a collimating lens and a mirror, and by recording the individual photons scattered by the atom(s). Our experiments highlight the intimate connection between one-atom and two-atom effects, and allow their continuous observation using the same apparatus.	Univ Innsbruck, Inst Expt Phys, A-6020 Innsbruck, Austria	University of Innsbruck	Eschner, J (corresponding author), Univ Innsbruck, Inst Expt Phys, Technikerstr 25, A-6020 Innsbruck, Austria.	juergen.eschner@uibk.ac.at	Eschner, Jürgen/N-1073-2013; Schmidt-Kaler, Ferdinand/E-2151-2017; Blatt, Rainer/H-9527-2014	Eschner, Jürgen/0000-0002-8393-7258; Schmidt-Kaler, Ferdinand/0000-0002-5697-2568				BERGQUIST JC, 1986, PHYS REV LETT, V57, P1699, DOI 10.1103/PhysRevLett.57.1699; DEMARTINI F, 1987, PHYS REV LETT, V59, P2955, DOI 10.1103/PhysRevLett.59.2955; DeVoe RG, 1996, PHYS REV LETT, V76, P2049, DOI 10.1103/PhysRevLett.76.2049; DICKE RH, 1954, PHYS REV, V93, P99, DOI 10.1103/PhysRev.93.99; DIEDRICH F, 1987, PHYS REV LETT, V58, P203, DOI 10.1103/PhysRevLett.58.203; Drexhage K. H., 1974, PROGR OPTICS, V12, P163, DOI DOI 10.1016/S0079-6638(08)70266-X; GABRIELSE G, 1985, PHYS REV LETT, V55, P67, DOI 10.1103/PhysRevLett.55.67; GOY P, 1983, PHYS REV LETT, V50, P1903, DOI 10.1103/PhysRevLett.50.1903; HEINZEN DJ, 1987, PHYS REV LETT, V58, P1320, DOI 10.1103/PhysRevLett.58.1320; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; HULET RG, 1985, PHYS REV LETT, V55, P2137, DOI 10.1103/PhysRevLett.55.2137; JHE W, 1987, PHYS REV LETT, V58, P666, DOI 10.1103/PhysRevLett.58.666; Loudon R., 1983, QUANTUM THEORY LIGHT; MILONNI PW, 1994, QUANTUM VACUUM, pCH6; MOERNER WE, 1995, AIP C P, V323, P467; NAGOURNEY W, 1986, PHYS REV LETT, V56, P2797, DOI 10.1103/PhysRevLett.56.2797; Pinkse PWH, 2000, NATURE, V404, P365, DOI 10.1038/35006006; PURCELL EM, 1946, PHYS REV, V69, P681; Raab C, 1998, APPL PHYS B-LASERS O, V67, P683, DOI 10.1007/s003400050566; Raab C, 2000, PHYS REV LETT, V85, P538, DOI 10.1103/PhysRevLett.85.538; Raab C, 1999, APPL PHYS B-LASERS O, V69, P253; REMPE G, 1987, PHYS REV LETT, V58, P353, DOI 10.1103/PhysRevLett.58.353; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; SAUTER T, 1986, PHYS REV LETT, V57, P1696, DOI 10.1103/PhysRevLett.57.1696; SCHUBERT M, 1995, PHYS REV A, V52, P2994, DOI 10.1103/PhysRevA.52.2994	25	199	199	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					495	498		10.1038/35097017	http://dx.doi.org/10.1038/35097017			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586352				2022-12-28	WOS:000171340500039
J	Park, HS; Himmelbach, A; Browning, KS; Hohn, T; Ryabova, LA				Park, HS; Himmelbach, A; Browning, KS; Hohn, T; Ryabova, LA			A plant viral "reinitiation" factor interacts with the host translational machinery	CELL			English	Article							CAULIFLOWER MOSAIC-VIRUS; OPEN READING FRAME; POLYCISTRONIC MESSENGER-RNA; FACTOR 3 EIF3; RIBOSOMAL-SUBUNIT; INITIATION-FACTORS; GENE-EXPRESSION; CROSS-LINKING; PROTEIN; YEAST	The cauliflower mosaic virus transactivator, TAV, controls translation reinitiation of major open reading frames on polycistronic RNA. We show here that TAV function depends on its association with polysomes and eukaryotic initiation factor eIF3 in vitro and in vivo. TAV physically interacts with eIF3 and the 60S ribosomal subunit. Two proteins mediating these interactions were identified: eIF3g and 60S ribosomal protein L24. Transient expression of eIF3g and L24 in plant protoplasts strongly affects TAV-mediated reinitiation activity. We demonstrate that TAV/eIF3/40S and eIF3/TAV160S ternary complexes form in vitro, and propose that TAV mediates efficient recruitment of eIF3 to polysomes, allowing translation of polycistronic mRNAs by reinitiation, overcoming the normal cell barriers to this process.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	Friedrich Miescher Institute for Biomedical Research; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Hohn, T (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	hohn@fmi.ch; iryabova@fmi.ch		Ryabova, Lyubov/0000-0003-1989-203X; Himmelbach, Axel/0000-0001-7338-0946				Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; BARONASLOWELL DM, 1990, MOL CELL BIOL, V10, P5235, DOI 10.1128/MCB.10.10.5235; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Cerritelli SM, 1998, NUCLEIC ACIDS RES, V26, P1834, DOI 10.1093/nar/26.7.1834; DETAPIA M, 1993, EMBO J, V12, P3305, DOI 10.1002/j.1460-2075.1993.tb06000.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DEZOETEN GA, 1989, VIROLOGY, V172, P213, DOI 10.1016/0042-6822(89)90123-2; Dominguez DI, 1998, J BIOL CHEM, V273, P3669, DOI 10.1074/jbc.273.6.3669; Dresios J, 2000, BIOCHEMISTRY-US, V39, P7236, DOI 10.1021/bi9925266; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; FUTTERER J, 1992, NUCLEIC ACIDS RES, V20, P3851, DOI 10.1093/nar/20.15.3851; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; FUTTERER J, 1990, POSTTRANSCRIPTIONAL, P347, DOI DOI 10.1007/978-3-642-75139-4_32; GIVORD L, 1984, EMBO J, V3, P1423, DOI 10.1002/j.1460-2075.1984.tb01987.x; GOWDA S, 1989, P NATL ACAD SCI USA, V86, P9203, DOI 10.1073/pnas.86.23.9203; HATAKEYAMA T, 1989, EUR J BIOCHEM, V185, P685, DOI 10.1111/j.1432-1033.1989.tb15166.x; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Herzog E, 2000, J VIROL, V74, P2073, DOI 10.1128/JVI.74.5.2073-2083.2000; HEUFLER C, 1988, BIOCHIM BIOPHYS ACTA, V951, P182, DOI 10.1016/0167-4781(88)90039-5; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; JACKSON AO, 1976, PLANT PHYSIOL, V57, P5, DOI 10.1104/pp.57.1.5; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Kobayashi K, 1998, MICROBIOL IMMUNOL, V42, P377, DOI 10.1111/j.1348-0421.1998.tb02298.x; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; Leh V, 2000, VIROLOGY, V266, P1, DOI 10.1006/viro.1999.0073; Lin L, 2001, J CELL BIOCHEM, V80, P483, DOI 10.1002/1097-4644(20010315)80:4<483::AID-JCB1002>3.0.CO;2-B; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; MARION MJ, 1987, BIOCHEM BIOPH RES CO, V149, P1077, DOI 10.1016/0006-291X(87)90518-3; MARTINEZIZQUIERDO JA, 1987, VIROLOGY, V160, P527, DOI 10.1016/0042-6822(87)90032-8; NAKAYASHIKI H, 1993, J GEN VIROL, V74, P2469, DOI 10.1099/0022-1317-74-11-2469; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; PEABODY DS, 1986, MOL CELL BIOL, V6, P2704, DOI 10.1128/MCB.6.7.2704; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Pooggin MM, 2000, J BIOL CHEM, V275, P17288, DOI 10.1074/jbc.M001143200; Pooggin MM, 1998, J VIROL, V72, P4157, DOI 10.1128/JVI.72.5.4157-4169.1998; RAMAIAH KVA, 1992, P NATL ACAD SCI USA, V89, P12063, DOI 10.1073/pnas.89.24.12063; ROTHNIE HM, 1994, ADV VIRUS RES, V44, P1, DOI 10.1016/S0065-3527(08)60327-9; Ryabova LA, 2000, GENE DEV, V14, P817; SchmidtPuchta W, 1997, NUCLEIC ACIDS RES, V25, P2854, DOI 10.1093/nar/25.14.2854; SCHOLTHOF HB, 1992, J VIROL, V66, P3131, DOI 10.1128/JVI.66.5.3131-3139.1992; Shepherd R J, 1976, Adv Virus Res, V20, P305, DOI 10.1016/S0065-3527(08)60508-4; SRIVASTAVA S, 1992, J MOL BIOL, V226, P301, DOI 10.1016/0022-2836(92)90946-H; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; UCHIUMI T, 1986, J BIOL CHEM, V261, P9663; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434	55	123	127	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 21	2001	106	6					723	733		10.1016/S0092-8674(01)00487-1	http://dx.doi.org/10.1016/S0092-8674(01)00487-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572778	Bronze			2022-12-28	WOS:000171213000009
J	Davidoff, F; DeAngelis, CD; Drazen, JM; Hoey, J; Hojgaard, L; Horton, R; Kotzin, S; Nicholls, MG; Nylenna, M; Overbeke, AJPM; Sox, HC; Van Der Weyden, MB; Wilkes, MS				Davidoff, F; DeAngelis, CD; Drazen, JM; Hoey, J; Hojgaard, L; Horton, R; Kotzin, S; Nicholls, MG; Nylenna, M; Overbeke, AJPM; Sox, HC; Van Der Weyden, MB; Wilkes, MS			Sponsorship, authorship, and accountability	LANCET			English	Editorial Material									Norwegian Med Assoc, Oslo, Norway				Højgaard, Liselotte/AAK-8329-2020					Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; HENDERSON L, 2000, CENTERWATCH, V7, P10; Kahn JO, 2000, JAMA-J AM MED ASSOC, V284, P2193, DOI 10.1001/jama.284.17.2193; KOWALCZYK L, 2000, BOSTON GLOBE    0728, pC4; MATHIEU MP, 1999, PAREXELS PHARM R D S; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238	6	139	146	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 15	2001	358	9285					854	856		10.1016/S0140-6736(01)06035-4	http://dx.doi.org/10.1016/S0140-6736(01)06035-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567695				2022-12-28	WOS:000171087000002
J	Silagy, CA; Stead, LF; Lancaster, T				Silagy, CA; Stead, LF; Lancaster, T			Use of systematic reviews in clinical practice guidelines: case study of smoking cessation	BRITISH MEDICAL JOURNAL			English	Article							BIOMEDICAL-RESEARCH; EVALUATING PAYBACK	Objective To examine the extent to which recommendations in the national guidelines for the cessation of smoking are based on evidence from systematic reviews of controlled trials. Design Retrospective analysis of recommendations for the national guidelines for the cessation of smoking. Materials National guidelines in clinical practice on smoking cessation published in English. Main outcome measures The type of evidence (systematic review of controlled trials, individual trials, other studies, expert opinion) used to support each recommendation. We also assessed whether a Cochrane systematic review was available and could have been used in formulating the recommendation. Results Four national smoking cessation guidelines (from Canada, New Zealand, the United Kingdom, and the United States) covering 105 recommendations were identified. An explicit evidence base for 100%, 89%, 68%, and 98% of recommendations, respectively, was detected, of which 60%, 56%, 59%, and 47% were based on systematic reviews of controlled studies. Cochrane systematic reviews could have been used to develop between 39% and 73% of recommendations but were actually used in 0% to 36% of recommendations. The UK guidelines had the highest proportion of recommendations based on Cochrane systematic reviews. Conclusions Use of systematic reviews in guidelines is a measure of the "payback" on investment in research synthesis. Systematic reviews commonly underpinned recommendations in guidelines on smoking cessation. The extent to which they were used varied by country and there was evidence of duplication of effort in some areas. Greater international collaboration in developing and maintaining an evidence base of systematic reviews can improve the efficiency of use of research resources.	Monash Med Ctr, Monash Inst Hlth Serv Res, Clayton, Vic 3168, Australia; Inst Hlth Sci, Dept Primary Hlth Care, Imperial Canc Res Fund Gen Practice Res Grp, Cochrane Tobacco Addict Grp, Oxford OX3 7LF, England	Monash University; University of Oxford	Silagy, CA (corresponding author), Monash Med Ctr, Monash Inst Hlth Serv Res, Clayton, Vic 3168, Australia.							Chalmers I, 2000, BRIT MED J, V321, P566, DOI 10.1136/bmj.321.7260.566; CHALMERS L, 1992, BRIT MED J, V340, P786; Cohen D, 1998, SMOKING CESSATION ME; FIORE MC, 1996, US DEP HHS PUBLICATI; FIORE MC, 2000, TREATING TOBACCO USE; Grant J, 2000, BRIT MED J, V321, P566; Grant J, 2000, BMJ-BRIT MED J, V320, P1107, DOI 10.1136/bmj.320.7242.1107; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; LANCASTER T, 2000, COCHRANE COLLABORATI; MCDONALD S, 2000, SYSTEMATIC REV CITED; *NAT HLTH COMM, 1999, GUID SMOK CESS LIT R; *NAT HLTH COMM, 1999, GUID SMOK CESS; Raw M, 1998, THORAX, V53, pS1, DOI 10.1136/thx.53.2008.S1; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; TAYLOR MC, 1994, CANADIAN GUIDE CLIN, P500; West R, 2000, THORAX, V55, P987, DOI 10.1136/thorax.55.12.987; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527	17	42	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 13	2001	323	7317					833	836		10.1136/bmj.323.7317.833	http://dx.doi.org/10.1136/bmj.323.7317.833			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597966	Bronze, Green Published			2022-12-28	WOS:000171650500024
J	Ikeda, SR				Ikeda, SR			Signal transduction - Calcium channels - Link locally, act globally	SCIENCE			English	Editorial Material							CA2+ CHANNELS; CREB PHOSPHORYLATION; HIPPOCAMPAL-NEURONS; CALMODULIN; INACTIVATION; SUPPORTS; NUCLEUS; DEPENDS		Guthrie Res Inst, Lab Mol Physiol, Sayre, PA 18840 USA		Ikeda, SR (corresponding author), Guthrie Res Inst, Lab Mol Physiol, Sayre, PA 18840 USA.		Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Ikeda, Stephen/0000-0002-4088-9508	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000430, ZIAAA000430] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BREHM P, 1978, SCIENCE, V202, P1203, DOI 10.1126/science.103199; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; HIMING LD, 1988, SCIENCE, V239, P57; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; Mermelstein PG, 2000, J NEUROSCI, V20, P266, DOI 10.1523/JNEUROSCI.20-01-00266.2000; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Tanabe M, 1998, J NEUROPHYSIOL, V80, P2268, DOI 10.1152/jn.1998.80.5.2268; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	19	13	15	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					318	319		10.1126/science.1066160	http://dx.doi.org/10.1126/science.1066160			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598289				2022-12-28	WOS:000171601400029
J	Lohmann, KJ; Cain, SD; Dodge, SA; Lohmann, CMF				Lohmann, KJ; Cain, SD; Dodge, SA; Lohmann, CMF			Regional magnetic fields as navigational markers for sea turtles	SCIENCE			English	Article							LONG-DISTANCE NAVIGATION; MECHANISMS	Young loggerhead sea turtles (Caretta caretta) from eastern Florida undertake a transoceanic migration in which they gradually circle the north Atlantic Ocean before returning to the North American coast. Here we report that hatchling loggerheads, when exposed to magnetic fields replicating those found in three widely separated oceanic regions, responded by swimming in directions that would, in each case, help keep turtles within the currents of the North Atlantic gyre and facilitate movement along the migratory pathway. These results imply that young loggerheads have a guidance system in which regional magnetic fields function as navigational markers and elicit changes in swimming direction at crucial geographic boundaries.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Lohmann, KJ (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.							Akesson S, 1996, TRENDS ECOL EVOL, V11, P398, DOI 10.1016/0169-5347(96)30040-2; BATSCHELET E, 1981, CIRCULAR STAT BIOL, P104; BEARMAN G, 1989, OCEAN CIRCULATION; BECK W, 1988, 19 C INT ORN, V2, P1955; Bolten AB, 1998, ECOL APPL, V8, P1; CARR A, 1986, BIOSCIENCE, V36, P92, DOI 10.2307/1310109; CARR A, 1987, Conservation Biology, V1, P103, DOI 10.1111/j.1523-1739.1987.tb00020.x; GOULD JL, 1982, NATURE, V296, P205, DOI 10.1038/296205a0; GOULD JL, 1985, MAGNETITE BIOMINERAL, P257; Hays GC, 1997, CAN J ZOOL, V75, P40, DOI 10.1139/z97-005; Jacobs JA, 1994, REVERSALS EARTHS MAG; KIRSCHVINK JL, 1992, BIOELECTROMAGNETICS, V13, P401, DOI 10.1002/bem.2250130507; Lohmann KJ, 1999, ETHOL ECOL EVOL, V11, P1, DOI 10.1080/08927014.1999.9522838; LOHMANN KJ, 1994, J EXP BIOL, V190, P1; Lohmann KJ, 1996, NATURE, V380, P59, DOI 10.1038/380059a0; LOHMANN KJ, 1994, J EXP BIOL, V194, P23; Lohmann KJ, 1998, J AVIAN BIOL, V29, P585, DOI 10.2307/3677179; LOHMANN KJ, BIOL CONSERVATION LO; MERRITT R, 1983, REV SCI INSTRUM, V54, P879, DOI 10.1063/1.1137480; Musick John A., 1997, P137; SALMON M, 1987, J EXP MAR BIOL ECOL, V109, P137, DOI 10.1016/0022-0981(87)90012-8; Schmitz W.J., 1996, WHOI9603; Skiles D.D., 1985, MAGNETITE BIOMINERAL, P43; SMITH FA, 1995, SCIENCE, V270, P2012, DOI 10.1126/science.270.5244.2012; Wehner R, 1998, J AVIAN BIOL, V29, P370, DOI 10.2307/3677156; WILTSCHKO R, 1995, MAGNETIC ORIENTATION, P177	26	188	202	6	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					364	366		10.1126/science.1064557	http://dx.doi.org/10.1126/science.1064557			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598298				2022-12-28	WOS:000171601400041
J	Sommeria, J				Sommeria, J			Unweaving the whirls	NATURE			English	Editorial Material									CNRS, Lab LEGI Coriolis, F-38000 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Sommeria, J (corresponding author), CNRS, Lab LEGI Coriolis, 21 Ave Martyrs, F-38000 Grenoble, France.							Frish U., 1995, LEGACY AN KOLMOGOROV; LESIEUR M, 2001, NEW TRENDS TURBULENC; Lesieur M., 1997, TURBULENCE FLUIDS; Shraiman BI, 2000, NATURE, V405, P639, DOI 10.1038/35015000	4	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 11	2001	413	6856					575	575		10.1038/35098189	http://dx.doi.org/10.1038/35098189			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480WE	11595926	Green Submitted, Bronze			2022-12-28	WOS:000171485700028
J	Campbell, SM; Hann, M; Hacker, J; Burns, C; Oliver, D; Thapar, A; Mead, N; Safran, DG; Roland, MO				Campbell, SM; Hann, M; Hacker, J; Burns, C; Oliver, D; Thapar, A; Mead, N; Safran, DG; Roland, MO			Identifying predictors of high quality care in English general practice: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; DIABETIC-PATIENTS; HEALTH-CARE; OF-CARE; MANAGEMENT; DISEASE; WELL	Objectives To assess variation in the quality of care in general practice and identify factors associated with high quality care. Design Observational study. Setting Stratified random sample of 60 general practices in six areas of England. Outcome measures Quality of management of chronic disease (angina, asthma in adults, and type 2 diabetes) and preventive care (rates of uptake for immunisation and cervical smear), access to care, continuity of care, and interpersonal care (general practice assessment survey). Multiple logistic regression with multilevel modelling was used to relate each of the outcome variables to practice size, routine booking interval for consultations, socioeconomic deprivation, and team climate. Results Quality of clinical care varied substantially, and access to care, continuity of care, and interpersonal care varied moderately. Scores for asthma, diabetes, and angina were 67%, 21%, and 17% higher in practices with 10 minute booking intervals for consultations compared with practices with five minute booking intervals. Diabetes care was better in larger practices and in practices where staff reported better team climate. Access to care was better in small practices. Preventive care was worse in practices located in socioeconomically deprived areas. Scores for satisfaction, continuity of care, and access to care were higher in practices where staff reported better team climate. Conclusions Longer consultation times are essential for providing high quality clinical care. Good teamworking is a key part of providing high quality care across a range of areas and may need specific support if quality of care is to be improved. Additional support is needed to provide preventive care to deprived populations. No single type of practice has a monopoly on high quality care: different types of practice may have different strengths.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ Manchester, Rusholme Hlth Ctr, Dept Gen Practice, Manchester M14 5NP, Lancs, England; Tufts Univ New England Med Ctr, Hlth Inst, Boston, MA 02111 USA	University of Manchester; University of Manchester; Tufts Medical Center	Campbell, SM (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	stephen.campbell@man.ac.uk		Campbell, Stephen/0000-0002-2328-4136				BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BAKER R, 1992, BRIT J GEN PRACT, V42, P415; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; Campbell JL, 2001, QUAL HEALTH CARE, V10, P90, DOI 10.1136/qhc.10.2.90; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; Campbell SM, 1999, QUAL HEALTH CARE, V8, P6, DOI 10.1136/qshc.8.1.6; Campbell SM, 2000, SOC SCI MED, V51, P1611, DOI 10.1016/S0277-9536(00)00057-5; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Collins S, 1998, Aust Fam Physician, V27, P907; Corwin P, 1997, NEW ZEAL MED J, V110, P253; *DEP HLTH, 1999, ORG MEM; *DEP HLTH, 2000, CMND4181L; *DEP HLTH, 2000, CMND4181I; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; DEPARTMENT OF HEALTH, 1999, SUPP DOCT PROT PAT C; Dunn NR, 1996, BRIT J GEN PRACT, V46, P401; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; Heath I., 1995, MYSTERY GEN PRACTICE; Howie J. G., 1997, 75 ROYAL COLL GEN PR; Howie JGR, 2000, FAM PRACT, V17, P455, DOI 10.1093/fampra/17.6.455; Kendall D, 1999, NEW ZEAL MED J, V112, P141; Khunti K, 1999, FAM PRACT, V16, P54, DOI 10.1093/fampra/16.1.54; Khunti K, 1999, FAM PRACT, V16, P489, DOI 10.1093/fampra/16.5.489; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; KOSECOFF J, 1987, MED CARE, V25, P196, DOI 10.1097/00005650-198703000-00003; Lathlean S, 1999, Aust Fam Physician, V28 Suppl 1, pS28; Leape LL, 2000, BMJ-BRIT MED J, V320, P725, DOI 10.1136/bmj.320.7237.725; Luck J, 2000, AM J MED, V108, P642, DOI 10.1016/S0002-9343(00)00363-6; MARSHALL M, IN PRESS ASSESSING Q; Norton PG, 1997, CAN FAM PHYSICIAN, V43, P1739; Poulton BC., 1999, J INTERPROF CARE, V13, P7, DOI [DOI 10.3109/13561829909025531, 10.3109/13561829909025531]; RABHESKETH S, 2000, STATA TECHNICAL B, V53, P4; RABHESKETH S, 2000, STATA TECHNICAL B, V53, P44; Ram P, 1998, FAM PRACT, V15, P354, DOI 10.1093/fampra/15.4.354; Ramsay J, 2000, FAM PRACT, V17, P372, DOI 10.1093/fampra/17.5.372; Roland M, 1999, BRIT J GEN PRACT, V49, P140; ROLAND M, 1998, QUALITY ASSESSMENT G; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Seddon ME, 2001, QUAL HEALTH CARE, V10, P152, DOI 10.1136/qhc.0100152..; Solomon DH, 2000, MED CARE, V38, P383, DOI 10.1097/00005650-200004000-00005; Van Drenth BB, 1998, BRIT J GEN PRACT, V48, P1054; Weingart SN, 2000, BRIT MED J, V320, P774, DOI 10.1136/bmj.320.7237.774	42	252	256	0	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 6	2001	323	7316					784	787		10.1136/bmj.323.7316.784	http://dx.doi.org/10.1136/bmj.323.7316.784			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481LK	11588082	Green Published, Bronze			2022-12-28	WOS:000171520600031
J	Dishy, V; Sofowora, GG; Xie, HG; Kim, RB; Byrne, DW; Stein, CM; Wood, AJJ				Dishy, V; Sofowora, GG; Xie, HG; Kim, RB; Byrne, DW; Stein, CM; Wood, AJJ			The effect of common polymorphisms of the beta(2)-adrenergic receptor on agonist-mediated vascular desensitization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-2-ADRENERGIC RECEPTOR; BLOOD-PRESSURE; HYPERTENSION; VASODILATION; GENOTYPES; ASTHMA	Background: With continuous exposure to beta (2)-adrenergic agonists, vascular tissue becomes desensitized to agonist-mediated vasodilatation. We studied the effects of two common polymorphisms of the beta (2)-adrenergic receptor, one at codon 16 and one at codon 27, on agonist-mediated vasodilatation and desensitization in the vascular bed. Methods: We studied 26 healthy subjects who were selected to represent three genotypes: 7 were homozygous for the alleles encoding Arg16 and GIn27, 8 were homozygous for the alleles encoding Gly16 and Gln27, and 11 were homozygous for the alleles encoding Gly16 and Glu27. Vascular responses were assessed by measuring changes in the diameter of a dorsal hand vein. A dose-response curve of the effect of the beta (2)-adrenergic-receptor agonist isoproterenol was constructed (dose range, 4 to 480 ng per minute). Desensitization was then induced by a 2-hour continuous infusion of isoproterenol, and venodilatation was measured 30, 60, 90, and 120 minutes after the start of the infusion. Results: Subjects who were homozygous for Arg16 had almost complete desensitization; venodilatation in response to isoproterenol in this group decreased from a mean (+/-SE) of 44+/-11 percent to 8+/-4 percent (P=0.006). In contrast, subjects who were homozygous for Gly16 did not have significant desensitization, irrespective of the amino acid encoded by codon 27. Subjects who were homozygous for Glu27 had higher maximal venodilatation in response to isoproterenol than those who were homozygous for Gln27 (86+/-13 percent vs. 54+/-8 percent, P=0.03). Conclusions: The Arg16 polymorphism of the beta (2)-adrenergic receptor is associated with enhanced agonist-mediated desensitization in the vasculature, and the Glu27 polymorphism is associated with increased agonist-mediated responsiveness. Therefore, polymorphisms of the beta (2)-adrenergic receptor are potentially important determinants of the vascular response to stress. (N Engl J Med 2001;345:1030-5.) Copyright (C) 2001 Massachusetts Medical Society.	Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Gen Clin Res Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Wood, AJJ (corresponding author), Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Rm 550,Med Res Bldg 1, Nashville, TN 37232 USA.		Kim, Richard/D-6971-2011; Sofowora, Gbemiga/E-4118-2011; Byrne, Daniel/GRE-6302-2022	Kim, Richard/0000-0001-8148-1632; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056251] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56251, HL-04012] Funding Source: Medline; NIGMS NIH HHS [GM-RR0095] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AELLIG WH, 1981, BRIT J CLIN PHARMACO, V11, P237, DOI 10.1111/j.1365-2125.1981.tb00527.x; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Chong LK, 2000, PHARMACOGENETICS, V10, P153, DOI 10.1097/00008571-200003000-00007; Cockcroft JR, 2000, HYPERTENSION, V36, P371, DOI 10.1161/01.HYP.36.3.371; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; FELDMAN RD, 1990, J CLIN INVEST, V85, P647, DOI 10.1172/JCI114487; Flier J, 1996, NEW ENGL J MED, V334, P580, DOI 10.1056/NEJM199602293340907; GOLDSTEIN DS, 1983, HYPERTENSION, V5, P86, DOI 10.1161/01.HYP.5.1.86; Gratze G, 1999, HYPERTENSION, V33, P1425, DOI 10.1161/01.HYP.33.6.1425; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; Hoit BD, 2000, AM HEART J, V139, P537, DOI 10.1016/S0002-8703(00)90099-1; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Landau R, 2000, ANESTHESIOLOGY, V93, pU212; LANG CC, 1995, NEW ENGL J MED, V333, P155, DOI 10.1056/NEJM199507203330304; NASLUND T, 1990, CLIN PHARMACOL THER, V48, P87, DOI 10.1038/clpt.1990.121; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Schobel HP, 1996, NEW ENGL J MED, V335, P1480, DOI 10.1056/NEJM199611143352002; STEIN CM, 1995, J CLIN INVEST, V96, P579, DOI 10.1172/JCI118070; Stein CM, 2001, PHARMACOGENETICS, V11, P95, DOI 10.1097/00008571-200103000-00001; STEIN M, 1993, CLIN PHARMACOL THER, V54, P187, DOI 10.1038/clpt.1993.130; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; VINCENT J, 1992, J CARDIOVASC PHARM, V19, P447, DOI 10.1097/00005344-199203000-00023; Xie HG, 1999, PHARMACOGENETICS, V9, P511	28	283	301	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1030	1035		10.1056/NEJMoa010819	http://dx.doi.org/10.1056/NEJMoa010819			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586955				2022-12-28	WOS:000171340400004
J	MacMahon, S; Neal, B; Tzourio, C; Rodgers, A; Woodward, M; Curler, J; Anderson, C; Chalmers, J; Ohkubo, T; Bousser, MG; Davis, S; Donnan, G; Hansson, L; Harrap, S; Lees, KR; Liu, L; Mancia, G; Omae, T; Reid, J; Sega, R; Terent, A; Warlow, C				MacMahon, S; Neal, B; Tzourio, C; Rodgers, A; Woodward, M; Curler, J; Anderson, C; Chalmers, J; Ohkubo, T; Bousser, MG; Davis, S; Donnan, G; Hansson, L; Harrap, S; Lees, KR; Liu, L; Mancia, G; Omae, T; Reid, J; Sega, R; Terent, A; Warlow, C		PROGRESS Collaborativ Grp	Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack	LANCET			English	Article							MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; RELIABLE ASSESSMENT; MAJOR MORBIDITY; RISK; MORTALITY; THERAPY; EVENTS	Background Blood pressure is a determinant of the risk of stroke among both hypertensive and non-hypertensive individuals with cerebrovascular disease. However, there is uncertainty about the efficacy and safety of blood-pressure-lowering treatments for many such patients. The perindopril protection against recurrent stroke study (PROGRESS) was designed to determine the effects of a blood-pressure-lowering regimen in hypertensive and non-hypertensive patients with a history of stroke or transient ischaemic attack. Methods 6105 individuals from 172 centres in Asia, Australasia, and Europe were randomly assigned active treatment (n = 3051) or placebo (n = 3054). Active treatment comprised a flexible regimen based on the angiotensin-converting-enzyme inhibitor perindopril (4 mg daily), with the addition of the diuretic indapamide at the discretion of treating physicians. The primary outcome was total stroke (fatal or non-fatal). Analysis was by intention to treat. Findings Over 4 years of follow up, active treatment reduced blood pressure by 9/4 mm Hg. 307 (10%) individuals assigned active treatment suffered a stroke, compared with 420 (14%) assigned placebo (relative risk reduction 28% [95% Cl 17-38], p < 0.0001). Active treatment also reduced the risk of total major vascular events (26% [16-34]). There were similar reductions in the risk of stroke in hypertensive and non-hypertensive subgroups (all p < 0.01). Combination therapy with perindopril plus indapamide reduced blood pressure by 12/5 mm Hg and stroke risk by 43% (30-54). Single-drug therapy reduced blood pressure by 5/3 mm Hg and produced no discernable reduction in the risk of stroke. Interpretation This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and nonhypertensive individuals with a history of stroke or transient ischaemic attack. Combination therapy with perindopril and indapamide produced larger blood pressure reductions and larger risk reductions than did single drug therapy with perindopril alone. Treatment with these two agents should now be considered routinely for patients with a history of stroke or transient ischaemic attack, irrespective of their blood pressure.	Univ Sydney, Inst Int Hlth, Progress Collaborat Grp, Sydney, NSW 2042, Australia	University of Sydney	MacMahon, S (corresponding author), Univ Sydney, Inst Int Hlth, Progress Collaborat Grp, POB 576, Sydney, NSW 2042, Australia.	progress@lih.usyd.edu.au	Lindley, Richard/B-8148-2013; Tzourio, christophe/L-6344-2019; Davis, Stephen M/L-5260-2013; Woodward, Mark/L-6817-2017; Tzourio, Christophe I/B-7459-2008; Simes, Robert John/P-1497-2014; Woodward, Mark/D-8492-2015; Tzourio, christophe/B-4015-2009	Lindley, Richard/0000-0002-0104-5679; Tzourio, christophe/0000-0002-6517-2984; Davis, Stephen M/0000-0003-0962-2300; Tzourio, christophe/0000-0002-6517-2984; Neal, Bruce/0000-0002-0490-7465				Algra A, 1999, J NEUROL NEUROSUR PS, V66, P255, DOI 10.1136/jnnp.66.2.255; ALTER M, 1994, STROKE, V25, P1605, DOI 10.1161/01.STR.25.8.1605; ALTER M, 1987, NEUROLOGY, V37, P503, DOI 10.1212/WNL.37.3.503; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1999, WORLD HLTH REPORT 19; Arakawa S, 1998, STROKE, V29, P1806, DOI 10.1161/01.STR.29.9.1806; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; Bosch J, 2000, J AM COLL CARDIOL, V35, p324A; BURN J, 1994, STROKE, V25, P333, DOI 10.1161/01.STR.25.2.333; Chalmers J, 1999, J HYPERTENS, V17, P151; Chalmers J, 1999, J HYPERTENS, V17, P1647; Chalmers J, 1996, J HYPERTENS, V14, pS41; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Gueyffier F, 1997, STROKE, V28, P2557, DOI 10.1161/01.STR.28.12.2557; Hankey GJ, 1999, LANCET, V354, P1457, DOI 10.1016/S0140-6736(99)04407-4; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; IRIE K, 1993, STROKE, V24, P1844, DOI 10.1161/01.STR.24.12.1844; LINDLEY RI, 1994, CEREBROVASC DIS, V4, P314, DOI 10.1159/000108501; LIU LS, 1995, CHINESE MED J-PEKING, V108, P710; MacMahon S, 1997, HYPERTENSION, V29, P537, DOI 10.1161/01.HYP.29.2.537; MacMahon S, 2001, LANCET, V357, P455, DOI 10.1016/S0140-6736(00)04017-4; Neal B, 2000, LANCET, V356, P1955; PEDERSEN TR, 1994, LANCET, V344, P1383; Qizilbash N, 1995, LANCET, V346, P1647; Rodgers A, 1998, LANCET, V352, P1801; Rodgers A, 1996, BRIT MED J, V313, P147, DOI 10.1136/bmj.313.7050.147; RODGERS A, 1997, NEUROL REV INT, V2, P12; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Yusuf S, 2000, NEW ENGL J MED, V342, P145	34	1575	1685	1	73	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	2001	358	9287					1033	1041		10.1016/S0140-6736(01)06178-5	http://dx.doi.org/10.1016/S0140-6736(01)06178-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589932				2022-12-28	WOS:000171393100007
J	Bailey, SM; Cornforth, MN; Kurimasa, A; Chen, DJ; Goodwin, EH				Bailey, SM; Cornforth, MN; Kurimasa, A; Chen, DJ; Goodwin, EH			Strand-specific postreplicative processing of mammalian telomeres	SCIENCE			English	Article							HUMAN-CHROMOSOMES; DNA; END; TRF2; FUSIONS; LENGTH	Telomeres are specialized nucleoprotein structures that stabilize the ends of linear eukaryotic chromosomes. In mammalian cells, abrogation of telomeric repeat binding factor TRF2 or DNA-dependent protein kinase (DNA-PK) activity causes end-to-end chromosomal fusion, thus establishing an essential role for these proteins in telomere function. Here we show that TRF2-mediated endcapping occurs after telomere replication. The postreplicative requirement for TRF2 and DNA-PKcs, the catalytic subunit of DNA-PK, is confined to only half of the telomeres, namely, those that were produced by leading-strand DNA synthesis. These results demonstrate a crucial difference in postrepticative processing of telomeres that is linked to their mode of replication.	Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87544 USA; Univ Texas, Med Branch, Dept Radiat Oncol, Galveston, TX 77550 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Cell & Mol Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; University of Texas System; University of Texas Medical Branch Galveston; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Goodwin, EH (corresponding author), Los Alamos Natl Lab, Biosci Div, POB 1663, Los Alamos, NM 87544 USA.				NATIONAL CANCER INSTITUTE [R01CA076260, R37CA050519, R01CA050519] Funding Source: NIH RePORTER; NCI NIH HHS [CA76260, CA50519] Funding Source: Medline; NIA NIH HHS [AG-917709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; BAILEY SM, 2001, DNA DAMAGE REPAIR, V3, pCH14; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; Cech TR, 2000, ANGEW CHEM INT EDIT, V39, P34, DOI 10.1002/(SICI)1521-3773(20000103)39:1<34::AID-ANIE34>3.0.CO;2-N; Cornforth MN, 2001, MUTAGENESIS, V16, P85, DOI 10.1093/mutage/16.1.85; GOODWIN EH, 1993, CYTOGENET CELL GENET, V63, P253; Goodwin EH, 1996, CHROMOSOMA, V104, P345, DOI 10.1007/BF00337223; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; MEYNE J, 1995, CHROMOSOME RES, V3, P375, DOI 10.1007/BF00710019; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	20	217	224	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2462	2465		10.1126/science.1062560	http://dx.doi.org/10.1126/science.1062560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577237	Green Published			2022-12-28	WOS:000171237200050
J	Freckleton, RP; Sutherland, WJ				Freckleton, RP; Sutherland, WJ			Hospital waiting-lists - Do power laws imply self-regulation?	NATURE			English	Article									Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Oxford; University of East Anglia	Freckleton, RP (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	robert.freckleton@zoology.oxford.ac.uk	Sutherland, William/B-1291-2013; Freckleton, Rob P/B-6455-2013	Sutherland, William/0000-0002-6498-0437; Freckleton, Robert/0000-0002-8338-864X				BULMER MG, 1975, BIOMETRICS, V31, P901, DOI 10.2307/2529815; Rothery P, 1998, INSECT POPULATIONS IN THEORY AND IN PRACTICE, P97; Smethurst DP, 2001, NATURE, V410, P652, DOI 10.1038/35070647; Sutherland W.J., 1996, INDIVIDUAL BEHAV POP	4	15	15	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 27	2001	413	6854					382	382		10.1038/35096646	http://dx.doi.org/10.1038/35096646			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574877				2022-12-28	WOS:000171188700043
J	Klein, T; Joumard, I; Blanchard, S; Marcus, J; Cubitt, R; Giamarchi, T; Le Doussal, P				Klein, T; Joumard, I; Blanchard, S; Marcus, J; Cubitt, R; Giamarchi, T; Le Doussal, P			A Bragg glass phase in the vortex lattice of a type II superconductor	NATURE			English	Article							MAGNETIC-FLUX LATTICE; TRANSITION; STABILITY; CRYSTALS; DIAGRAM	Although crystals are usually quite stable, they are sensitive to a disordered environment: even an infinitesimal amount of impurities can lead to the destruction of crystalline order(1). The resulting state of matter has been a long-standing puzzle. Until recently it was believed to be an amorphous state in which the crystal would break into 'crystallites'(2). But a different theory(3) predicts the existence of a novel phase of matter: the so-called Bragg glass, which is a glass and yet nearly as ordered as a perfect crystal. The 'lattice' of vortices that contain magnetic flux in type II superconductors provide a good system to investigate these ideas(4). Here we show that neutron-diffraction data of the vortex lattice provides unambiguous evidence for a weak, power-law decay of the crystalline order characteristic of a Bragg glass. The theory also predicts accurately the electrical transport properties of superconductors; it naturally explains the observed phase transitions(4-6) and the dramatic jumps in the critical current(7,8) associated with the melting of the Bragg glass. Moreover, the model explains experiments as diverse as X-ray scattering in disordered liquid crystals(9,10) and the conductivity of electronic crystals(11,12).	CNRS, Etud Proprietes Elect Solides Lab, F-38042 Grenoble 9, France; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France; Univ Paris 11, Phys Solides Lab, CNRS, UMR8502, F-91405 Orsay, France; Ecole Normale Super, CNRS, Phys Theor Lab, F-75231 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut Laue-Langevin (ILL); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Klein, T (corresponding author), CNRS, Etud Proprietes Elect Solides Lab, BP166, F-38042 Grenoble 9, France.	klein@polycnrs-gre.fr	Giamarchi, Thierry/B-5735-2008; cubitt, robert/B-9408-2008; JOUMARD, Isabelle/ABB-2327-2021	Giamarchi, Thierry/0000-0001-7409-5071; cubitt, robert/0000-0003-1778-3307; JOUMARD, Isabelle/0000-0003-1841-6058				Brandt EH, 1997, PHYS REV LETT, V78, P2208, DOI 10.1103/PhysRevLett.78.2208; Carpentier D, 1996, EUROPHYS LETT, V35, P379, DOI 10.1209/epl/i1996-00123-2; CHRISTEN DK, 1977, PHYS REV B, V15, P4506, DOI 10.1103/PhysRevB.15.4506; Crawford G. P., 1996, LIQUID CRYSTALS COMP; CUBITT R, 1993, NATURE, V365, P407, DOI 10.1038/365407a0; Deligiannis K, 1997, PHYS REV LETT, V79, P2121, DOI 10.1103/PhysRevLett.79.2121; Ertas D, 1996, PHYSICA C, V272, P79, DOI 10.1016/S0921-4534(96)00563-1; Fisher DS, 1997, PHYS REV LETT, V78, P1964, DOI 10.1103/PhysRevLett.78.1964; FISHER DS, 1991, PHYS REV B, V43, P130, DOI 10.1103/PhysRevB.43.130; FORGAN EM, 1990, NATURE, V343, P735, DOI 10.1038/343735a0; Fuchs DT, 1998, PHYS REV LETT, V81, P3944, DOI 10.1103/PhysRevLett.81.3944; Gammel PL, 1998, PHYS REV LETT, V80, P833, DOI 10.1103/PhysRevLett.80.833; Giamarchi T, 1997, PHYS REV B, V55, P6577, DOI 10.1103/PhysRevB.55.6577; GIAMARCHI T, 1995, PHYS REV B, V52, P1242, DOI 10.1103/PhysRevB.52.1242; Gingras MJP, 1996, PHYS REV B, V53, P15193, DOI 10.1103/PhysRevB.53.15193; Joumard I, 1999, PHYS REV LETT, V82, P4930, DOI 10.1103/PhysRevLett.82.4930; Kierfeld J, 1997, PHYS REV B, V55, P626, DOI 10.1103/PhysRevB.55.626; Kim P, 1999, PHYS REV B, V60, pR12589, DOI 10.1103/PhysRevB.60.R12589; LARKIN AI, 1970, ZH EKSP TEOR FIZ, V31, P784; Li CC, 2000, PHYS REV B, V61, P10905, DOI 10.1103/PhysRevB.61.10905; Marchevsky M, 2001, NATURE, V409, P591, DOI 10.1038/35054512; NATTERMANN T, 1990, PHYS REV LETT, V64, P2454, DOI 10.1103/PhysRevLett.64.2454; Paltiel Y, 2000, PHYS REV LETT, V85, P3712, DOI 10.1103/PhysRevLett.85.3712; Pardo F, 1998, NATURE, V396, P348, DOI 10.1038/24581; Perruchot F, 1998, PHYSICA B, V256, P587, DOI 10.1016/S0921-4526(98)00483-9; Saunders K, 2000, PHYS REV LETT, V85, P4309, DOI 10.1103/PhysRevLett.85.4309; Troyanovski AM, 1999, NATURE, V399, P665, DOI 10.1038/21385; van Otterlo A, 1998, PHYS REV LETT, V81, P1497, DOI 10.1103/PhysRevLett.81.1497; YARON U, 1995, NATURE, V376, P753, DOI 10.1038/376753a0; ZELDOV E, 1995, NATURE, V375, P373, DOI 10.1038/375373a0	30	150	151	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 27	2001	413	6854					404	406		10.1038/35096534	http://dx.doi.org/10.1038/35096534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574883	Green Submitted			2022-12-28	WOS:000171188700049
J	Aronow, WS				Aronow, WS			Approach to symptomatic coronary disease in the elderly: TIME to change?	LANCET			English	Editorial Material							CONGESTIVE-HEART-FAILURE; ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR EJECTION FRACTION; CONVERTING ENZYME-INHIBITORS; OLDER PATIENTS; THERAPY; WOMEN; CHOLESTEROL; ENALAPRIL; DIURETICS		Westchester Med Ctr, Dept Med, Div Cardiol, Valhalla, NY 10595 USA; Westchester Med Ctr, Dept Med, Div Geriatr, Valhalla, NY 10595 USA; New York Med Coll, Valhalla, NY 10595 USA	Westchester Medical Center; Westchester Medical Center; New York Medical College	Aronow, WS (corresponding author), Westchester Med Ctr, Dept Med, Div Cardiol, Valhalla, NY 10595 USA.							Aronow WS, 1997, AM J CARDIOL, V80, P207, DOI 10.1016/S0002-9149(97)00320-2; ARONOW WS, 1993, AM J CARDIOL, V71, P602, DOI 10.1016/0002-9149(93)90520-M; Aronow WS, 2001, J LAB CLIN MED, V137, P316, DOI 10.1067/mlc.2001.114106; ARONOW WS, IN PRESS AM J CARDIO; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1990, CIRCULATION, V81, P48; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Goldberg RJ, 1999, J AM COLL CARDIOL, V33, P1533, DOI 10.1016/S0735-1097(99)00040-6; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Hjalmarson A, 1999, LANCET, V353, P2001; Hochman JS, 1999, NEW ENGL J MED, V341, P625, DOI 10.1056/NEJM199908263410901; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hunt D, 2001, ANN INTERN MED, V134, P931, DOI 10.7326/0003-4819-134-10-200105150-00007; Lee PY, 2001, JAMA-J AM MED ASSOC, V286, P708, DOI 10.1001/jama.286.6.708; Lewis SJ, 1998, ANN INTERN MED, V129, P681, DOI 10.7326/0003-4819-129-9-199811010-00002; Miettinen TA, 1997, CIRCULATION, V96, P4211; Perry G, 1997, NEW ENGL J MED, V336, P525; Philbin EF, 2000, AM J MED, V109, P605, DOI 10.1016/S0002-9343(00)00601-X; SETARO JF, 1990, AM J CARDIOL, V66, P981, DOI 10.1016/0002-9149(90)90937-V; Thiemann DR, 2000, CIRCULATION, V101, P2239, DOI 10.1161/01.CIR.101.19.2239	21	25	29	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					945	946		10.1016/S0140-6736(01)06111-6	http://dx.doi.org/10.1016/S0140-6736(01)06111-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583742				2022-12-28	WOS:000171135300009
J	Saloojee, H; Violari, A				Saloojee, H; Violari, A			HIV infection in children	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; RANDOMIZED TRIAL; TRANSMISSION; ZIDOVUDINE		Univ Witwatersrand, Dept Paediat & Child Hlth, Div Community Paediat, ZA-2050 Johannesburg, South Africa; Chris Hani Baragwanath Hosp, Perinatal HIV Res Unit, Soweto, South Africa	University of Witwatersrand	Saloojee, H (corresponding author), Univ Witwatersrand, Dept Paediat & Child Hlth, Div Community Paediat, PO Wits, ZA-2050 Johannesburg, South Africa.	092sal@chiron.wits.ac.za	Saloojee, Haroon/J-5642-2019	Saloojee, Haroon/0000-0002-8298-7210				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; ANDIMAN WA, 1994, J PEDIATR-US, V124, P846, DOI 10.1016/S0022-3476(05)83169-5; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Boni J, 1997, AIDS, V11, pF47, DOI 10.1097/00002030-199706000-00001; Burns DN, 1999, CLIN INFECT DIS, V29, P328, DOI 10.1086/520210; CHURCH J, 2001, 8 C RETR OPP INF FEB; Coutsoudis A, 2001, AIDS, V15, P379, DOI 10.1097/00002030-200102160-00011; FARMER P, IN PRESS LANCET; Fawzi WW, 2000, J ACQ IMMUN DEF SYND, V23, P246; Gaillard P, 2001, AIDS, V15, P389, DOI 10.1097/00002030-200102160-00012; GRAY G, 2000, 13 INT AIDS C DURB S; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hunter S, 2000, CHILDREN BRINK EXECU; *JOINT UN PROGR AI, 2000, AIDS EP UPD DEC; Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401; Mandelbrot L, 2001, JAMA-J AM MED ASSOC, V285, P2083, DOI 10.1001/jama.285.16.2083; Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Nduati R, 2001, LANCET, V357, P1651, DOI 10.1016/S0140-6736(00)04820-0; OWOR M, 2000, 13 INT AIDS C DURB S; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P1; Porter K, 2001, BRIT MED J, V322, P1087, DOI 10.1136/bmj.322.7294.1087; *WHO, 1998, UNAIDS MOD 5 LAB REQ; WIKTOR SZ, 2000, 13 INT AIDS C DURB S	24	11	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 22	2001	323	7314					670	674		10.1136/bmj.323.7314.670	http://dx.doi.org/10.1136/bmj.323.7314.670			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	476LP	11566832	Green Published			2022-12-28	WOS:000171228800020
J	Katsanis, N; Ansley, SJ; Badano, JL; Eichers, ER; Lewis, RA; Hoskins, BE; Scambler, PJ; Davidson, WS; Beales, PL; Lupski, JR				Katsanis, N; Ansley, SJ; Badano, JL; Eichers, ER; Lewis, RA; Hoskins, BE; Scambler, PJ; Davidson, WS; Beales, PL; Lupski, JR			Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder	SCIENCE			English	Article							MICE LACKING GDNF; RETINITIS-PIGMENTOSA; HIRSCHSPRUNG DISEASE; GERMLINE MUTATIONS; CHROMOSOME 16Q; SYNDROME LOCUS; LINKAGE; FORM; RET; FAMILIES	Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder characterized by multiple clinical features that include pigmentary retinal dystrophy, polydactyly, obesity, developmental delay, and renal defects. BBS is considered an autosomal recessive disorder, and recent positional cloning efforts have identified two BBS genes (BBS2 and BBS6). We screened our cohort of 163 BBS families for, mutations in both BBS2 and BBS6 and report the presence of three mutant alleles in affected individuals in four pedigrees. In addition, we detected unaffected individuals in two pedigrees who carry two BBS2 mutations but not a BBS6 mutation. We therefore propose that BBS may not be a single-gene recessive disease but a complex trait requiring three mutant alleles to manifest the phenotype. This triallelic model of disease transmission may be important in the study of both Mendelian and multifactorial disorders.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; UCL, Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of London; University College London; Simon Fraser University	Lupski, JR (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	jlupski@bcm.tmc.edu	Scambler, Peter J/C-4998-2008; Scambler, Peter/AAZ-6026-2020; Beales, Philip L/C-7367-2009; Katsanis, Nicholas/E-1837-2012	Scambler, Peter J/0000-0002-1487-4628; Scambler, Peter/0000-0002-1487-4628; Katsanis, Nicholas/0000-0002-2480-0171; Badano, Jose/0000-0002-0706-8652	NEI NIH HHS [EY12666] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012666] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Angrist M, 1996, NAT GENET, V14, P341, DOI 10.1038/ng1196-341; Beales PL, 1997, J MED GENET, V34, P92, DOI 10.1136/jmg.34.2.92; Beales PL, 2001, AM J HUM GENET, V68, P606, DOI 10.1086/318794; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; CARMI R, 1995, HUM MOL GENET, V4, P9, DOI 10.1093/hmg/4.1.9; Floeth M, 1999, AM J HUM GENET, V65, P1530, DOI 10.1086/302672; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; GREEN JS, 1989, NEW ENGL J MED, V321, P1002, DOI 10.1056/NEJM198910123211503; HELWIG U, 1995, NAT GENET, V11, P60, DOI 10.1038/ng0995-60; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; Katsanis N, 1999, AM J HUM GENET, V65, P1672, DOI 10.1086/302684; Katsanis N, 2000, NAT GENET, V26, P67, DOI 10.1038/79201; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Morell R, 1997, HUM MOL GENET, V6, P659, DOI 10.1093/hmg/6.5.659; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Salomon R, 1996, NAT GENET, V14, P345, DOI 10.1038/ng1196-345; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116; Stone DL, 2000, NAT GENET, V25, P79, DOI 10.1038/75637; Todd JA, 1999, BIOESSAYS, V21, P164, DOI 10.1002/(SICI)1521-1878(199902)21:2<164::AID-BIES10>3.3.CO;2-W; Young TL, 1999, AM J HUM GENET, V64, P900, DOI 10.1086/302301	26	445	461	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2256	2259		10.1126/science.1063525	http://dx.doi.org/10.1126/science.1063525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567139				2022-12-28	WOS:000171139400044
J	Marquardt, T; Pfaff, SL				Marquardt, T; Pfaff, SL			Cracking the transcriptional code for cell specification in the neural tube	CELL			English	Review							OLIGODENDROCYTE DIFFERENTIATION; NEURONAL IDENTITY; MOTOR-NEURON; BHLH GENES; FATE; NEUROGENIN2; PROGENITORS; NKX2.2; ROLES; OLIG2	The bHLH repressor Olig2 participates in the transcriptional code governing cell fate specification in the ventral spinal cord. By temporally selective interactions with other transcription factors, Olig2 first directs motor neuron fate and later switches to promoting oligodendrocyte production.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Salk Institute	Pfaff, SL (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pfaff@salk.edu						Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Farah MH, 2000, DEVELOPMENT, V127, P693; Gowan K, 2001, NEURON, V31, P219, DOI 10.1016/S0896-6273(01)00367-1; Guillemot F, 1999, EXP CELL RES, V253, P357, DOI 10.1006/excr.1999.4717; Lillien L, 1998, CURR OPIN NEUROBIOL, V8, P37, DOI 10.1016/S0959-4388(98)80006-8; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Mizuguchi R, 2001, NEURON, V31, P757, DOI 10.1016/S0896-6273(01)00413-5; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Qi YC, 2001, DEVELOPMENT, V128, P2723; Scardigli R, 2001, NEURON, V31, P203, DOI 10.1016/S0896-6273(01)00358-0; Soula C, 2001, DEVELOPMENT, V128, P1369; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Vallstedt A, 2001, NEURON, V31, P743, DOI 10.1016/S0896-6273(01)00412-3; Zhou Q, 2001, NEURON, V31, P791, DOI 10.1016/S0896-6273(01)00414-7; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3	19	105	110	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 21	2001	106	6					651	654		10.1016/S0092-8674(01)00499-8	http://dx.doi.org/10.1016/S0092-8674(01)00499-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572771	Green Published, Bronze			2022-12-28	WOS:000171213000002
J	Rose, KD				Rose, KD			Evolution - The ancestry of whales	SCIENCE			English	Editorial Material							OSTEOLOGY; CETACEANS		Johns Hopkins Univ, Sch Med, Program Funct Anat & Evolut, Baltimore, MD 21205 USA	Johns Hopkins University	Rose, KD (corresponding author), Johns Hopkins Univ, Sch Med, Program Funct Anat & Evolut, Baltimore, MD 21205 USA.	kdrose@jhmi.edu						Colbert E.H., 1935, AM MUS NOVIT, V799, P1; COOMBS WP, 1977, NEUES JB GEOL PAL, P584; Erfurt Joerg, 2000, Hallesches Jahrbuch fuer Geowissenschaften Reihe B Geologie Palaeontologie Mineralogie Beiheft, V12, P57; Gatesy J, 1999, SYST BIOL, V48, P6, DOI 10.1080/106351599260409; Gingerich PD, 2001, SCIENCE, V293, P2239, DOI 10.1126/science.1063902; Luo Z., 1999, U MICHIGAN PAPERS PA, V31, P1; McKenna MC, 1997, CLASSIFICATION MAMMA; Milinkovitch MC, 1998, ADV VERT PALEOBIOL, P113; O'Leary MA, 1999, SYST BIOL, V48, P455, DOI 10.1080/106351599260102; ROSE KD, 1985, J PALEONTOL, V59, P1203; Scott W. B., 1940, Transactions of the American Philosophical Society Philadelphia, V28, P363, DOI 10.2307/1005504; Thewissen J.G.M., 1996, Courier Forschungsinstitut Senckenberg, V191, P1; Thewissen JGM, 2001, NATURE, V413, P277, DOI 10.1038/35095005; THEWISSEN JGM, 1990, ANAT HISTOL EMBRYOL, V19, P37, DOI 10.1111/j.1439-0264.1990.tb00876.x; Thewissen JGM, 1999, SYST BIOL, V48, P21, DOI 10.1080/106351599260418	15	8	10	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2216	2217		10.1126/science.1065305	http://dx.doi.org/10.1126/science.1065305			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567127				2022-12-28	WOS:000171139400030
J	Weimerskirch, H; Martin, J; Clerquin, Y; Alexandre, P; Jiraskova, S				Weimerskirch, H; Martin, J; Clerquin, Y; Alexandre, P; Jiraskova, S			Energy saving in flight formation - Pelicans flying in a 'V' can glide for extended periods using the other birds' air streams.	NATURE			English	Article							INDUCED DRAG		CNRS, Ctr Etud Biol Chize, F-79360 Villiers En Bois, France; Galatee Films, Peuple Migrateur Jacques Perrin, F-75017 Paris, France	Centre National de la Recherche Scientifique (CNRS)	Weimerskirch, H (corresponding author), CNRS, Ctr Etud Biol Chize, F-79360 Villiers En Bois, France.	henriw@cebc.cnrs.fr	Weimerskirch, Henri/K-7306-2019; Weimerskirch, Henri/F-5562-2013	Weimerskirch, Henri/0000-0002-0457-586X; Martin, Julien/0000-0002-7375-129X				BADGEROW JP, 1981, J THEOR BIOL, V93, P41, DOI 10.1016/0022-5193(81)90055-2; BADGEROW JP, 1988, AUK, V105, P749, DOI 10.1093/auk/105.4.749; CUTTS CJ, 1994, J EXP BIOL, V189, P251; GOULD LL, 1974, AUK, V91, P494; HAINSWORTH FR, 1988, J EXP BIOL, V135, P431; Hamilton WJ, 1967, ANIMAL ORIENTATION N, P57; HIGDON JJL, 1978, AM NAT, V112, P727, DOI 10.1086/283314; HUMMEL D, 1983, J THEOR BIOL, V104, P321, DOI 10.1016/0022-5193(83)90110-8; LISSAMAN PB, 1970, SCIENCE, V168, P1003, DOI 10.1126/science.168.3934.1003; OMALLEY JBE, 1982, CAN J ZOOL, V60, P1388, DOI 10.1139/z82-187; Weimerskirch H, 2000, P ROY SOC B-BIOL SCI, V267, P1869, DOI 10.1098/rspb.2000.1223	11	297	312	3	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 18	2001	413	6857					697	698		10.1038/35099670	http://dx.doi.org/10.1038/35099670			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482ZK	11607019				2022-12-28	WOS:000171608000031
J	Grossman, JM; MacLean, CH				Grossman, JM; MacLean, CH			Quality indicators for the management of osteoporosis in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MINERAL DENSITY; HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED TRIAL; FRACTURE INTERVENTION TRIAL; EARLY POSTMENOPAUSAL WOMEN; VITAMIN-D SUPPLEMENTATION; ESTROGEN PLUS PROGESTIN; POST-MENOPAUSAL WOMEN; BREAST-CANCER RISK; HIP FRACTURE		Univ Calif Los Angeles, Los Angeles, CA 90095 USA; RAND Corp, RAND Hlth, Santa Monica, CA 90406 USA	University of California System; University of California Los Angeles; RAND Corporation	Grossman, JM (corresponding author), Univ Calif Los Angeles, 1000 Vet Ave,Room 32-59, Los Angeles, CA 90095 USA.	jgrossman@mednet.ucla.edu						*AM ASS CLIN END, 2001, AM ASS CLIN END 2001; *AM ASS CLIN END, 1998, AM ASS CLIN END CLIN; Anderson FH, 1996, BONE, V18, P171, DOI 10.1016/8756-3282(95)00441-6; Bagur A, 1996, MEDICINA-BUENOS AIRE, V56, P247; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; Behre HM, 1997, J CLIN ENDOCR METAB, V82, P2386, DOI 10.1210/jc.82.8.2386; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BODY JJ, 1995, CLIN RHEUMATOL, V14, P18, DOI 10.1007/BF02210683; *CAN TASK FORC PRE, 1999, PHYS ACT COUNS; CANIGGIA A, 1984, Acta Vitaminologica et Enzymologica, V6, P117; Cardona JM, 1997, OSTEOPOROSIS INT, V7, P165, DOI 10.1007/BF01622285; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Chen JT, 1997, BONE, V20, P557, DOI 10.1016/S8756-3282(97)00054-9; CHESTNUT CH, 2001, AM J MED, V109, P267; CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026; CHRISTIANSEN C, 1981, LANCET, V1, P459; CUMMING RG, 1990, CALCIFIED TISSUE INT, V47, P194; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Davies KM, 1996, OSTEOPOROSIS INT, V6, P160, DOI 10.1007/BF01623941; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Eiken P, 1996, BONE, V19, pS191, DOI 10.1016/S8756-3282(96)00266-9; Ensrud KE, 1997, ARCH INTERN MED, V157, P2617, DOI 10.1001/archinte.157.22.2617; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; GALLAGHER JC, 1989, P SOC EXP BIOL MED, V191, P287; Gillespie WJ, 2000, COCHRANE DATABASE SY; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HARRISON JE, 1993, OSTEOPOROSIS INT, V3, P13, DOI 10.1007/BF01623171; Herd RJM, 1997, AM J MED, V103, P92, DOI 10.1016/S0002-9343(97)00019-3; Hochberg MC, 1996, ARTHRITIS RHEUM-US, V39, P1791; HOMIK J, 1998, COCHRANE LIB; HORSMAN A, 1983, NEW ENGL J MED, V309, P1405, DOI 10.1056/NEJM198312083092301; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUTCHINSON TA, 1979, LANCET, V2, P705; JACKSON JA, 1987, J CLIN ENDOCR METAB, V65, P53, DOI 10.1210/jcem-65-1-53; JAGLAL SB, 1993, AM J EPIDEMIOL, V138, P107, DOI 10.1093/oxfordjournals.aje.a116833; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; Jones G, 1996, OSTEOPOROSIS INT, V6, P233, DOI 10.1007/BF01622740; Josse R, 1996, CAN MED ASSOC J, V155, P1113; Kanis JA, 1997, OSTEOPOROSIS INT, V7, P390, DOI 10.1007/BF01623782; Karpf DB, 1997, JAMA-J AM MED ASSOC, V277, P1159; Kaufman JM, 1997, CLIN RHEUMATOL, V16, P343, DOI 10.1007/BF02242449; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOHRT WM, 1995, J BONE MINER RES, V10, P1303, DOI 10.1002/jbmr.5650100906; Komulainen M, 1997, OSTEOPOROSIS INT, V7, P126, DOI 10.1007/BF01623687; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1976, LANCET, V1, P1038; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LINDSAY R, 1992, OSTEOPOROSIS GUIDE D; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; Lyritis GP, 1997, CLIN RHEUMATOL, V16, P354, DOI 10.1007/BF02242451; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; MENCZEL J, 1994, CLIN ORTHOP RELAT R, P241; Montessori MLM, 1997, OSTEOPOROSIS INT, V7, P52, DOI 10.1007/BF01623461; MUNKJENSEN N, 1988, BRIT MED J, V296, P1150, DOI 10.1136/bmj.296.6630.1150; Murray TM, 1996, CAN MED ASSOC J, V155, P935; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; *NAT OST FDN, 2001, PHYS GUID PREV TREAT; National Osteoporosis Foundation, 1998, PHYS GUID PREV TREAT; NIELSEN SP, 1994, BRIT J OBSTET GYNAEC, V101, P319, DOI 10.1111/j.1471-0528.1994.tb13618.x; ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521; Orwoll ES, 1996, ANN INTERN MED, V124, P187, DOI 10.7326/0003-4819-124-2-199601150-00001; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PECK WA, 1993, AM J MED, V94, P646; PERIS P, 1995, BRIT J RHEUMATOL, V34, P936; PERIS P, 1996, CURR OPIN RHEUMATOL, P357; Preisinger E, 1996, BRIT J SPORT MED, V30, P209, DOI 10.1136/bjsm.30.3.209; PREISINGER E, 1995, AM J PHYS MED REHAB, V74, P120; Prior JC, 1996, CAN MED ASSOC J, V155, P940; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; Reid IR, 1996, ARCH INTERN MED, V156, P1173, DOI 10.1001/archinte.156.11.1173; REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002-9343(99)80310-6; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Shiraki M, 1996, ENDOCR J, V43, P211, DOI 10.1507/endocrj.43.211; Siminoski K, 1996, CAN MED ASSOC J, V155, P962; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P1966, DOI 10.1210/jc.84.6.1966; Storm T, 1996, J RHEUMATOL, V23, P1560; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; Tucci JR, 1996, AM J MED, V101, P488, DOI 10.1016/S0002-9343(96)00282-3; *US CONGR OFF TECH, 1994, OTABPH120 US CONGR O; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; 1984, NIH CONS STAT 2 4 AP, V5, P1; 1998, OSTEOPOROOS INT S4, V8, pS7; 1989, J R COLL PHYSICIANS, V23, P8	103	10	10	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				722	730		10.7326/0003-4819-135-8_Part_2-200110161-00011	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481WA	11601955				2022-12-28	WOS:000171542400011
J	Chander, R; Mervis, J				Chander, R; Mervis, J			The bottom line for US life scientists	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					395	395		10.1126/science.294.5541.395	http://dx.doi.org/10.1126/science.294.5541.395			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598303				2022-12-28	WOS:000171601400046
J	Maira, SM; Galetic, I; Brazil, DP; Kaech, S; Ingley, E; Thelen, M; Hemmings, BA				Maira, SM; Galetic, I; Brazil, DP; Kaech, S; Ingley, E; Thelen, M; Hemmings, BA			Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane	SCIENCE			English	Article							KINASE-B; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATASE INHIBITORS; MOLECULAR-CLONING; ACTIVATION; MECHANISM; INSULIN; TRANSLOCATION; LYMPHOMA	The PKB (protein kinase B, also called Akt) family of protein kinases plays a key role in insulin signaling, cellular survival, and transformation. PKB is activated by phosphorylation on residues threonine 308, by the protein kinase PDK1, and Serine 473, by a putative serine 473 kinase. Several protein binding partners for PKB have been identified. Here, we describe a protein partner for PKB alpha termed CTMP, or carboxyl-terminal modulator protein, that binds specifically to the carboxyl-terminal regulatory domain of PKB alpha at the plasma membrane. Binding of CTMP reduces the activity of PKB alpha by inhibiting phosphorylation on serine 473 and threonine 308. Moreover, CTMP expression reverts the phenotype of v-Akt-transformed cells examined under a number of criteria including cell morphology, growth rate, and in vivo tumorigenesis. These findings identify CTMP as a negative regulatory component of the pathway controlling PKB activity.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Inst Biomed Res, CH-6500 Bellinzona, Switzerland	Friedrich Miescher Institute for Biomedical Research; Universita della Svizzera Italiana	Hemmings, BA (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.		Ingley, Evan/C-2401-2013	Ingley, Evan/0000-0002-8112-9134; Brazil, Derek/0000-0003-1375-1076; Kaech Petrie, Stefanie/0000-0002-6246-6434				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; GALETIC I, UNPUB; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; MAIRA SM, UNPUB; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; POSNER BI, 1994, J BIOL CHEM, V269, P4596; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3	26	203	223	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					374	380		10.1126/science.1062030	http://dx.doi.org/10.1126/science.1062030			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598301				2022-12-28	WOS:000171601400044
J	Brooke, J; Rosenbaum, TF; Aeppli, G				Brooke, J; Rosenbaum, TF; Aeppli, G			Tunable quantum tunnelling of magnetic domain walls	NATURE			English	Article							DISORDERED MAGNET; CRYSTAL; ALLOY; NOISE	Perhaps the most anticipated, yet experimentally elusive, macroscopic quantum phenomenon(1) is spin tunnelling in a ferromagnet(2), which may be formulated in terms of domain wall tunnelling(3,4). One approach to identifying such a process is to focus on mesoscopic systems where the number of domain walls is finite and the motion of a single wall has measurable consequences. Research of this type includes magnetotransport measurements on thin ferromagnetic wires(5), and magnetization experiments on single particles(6,7), nanomagnet ensembles(8-10) and rare-earth multilayers(11). A second method is to investigate macroscopic disordered ferromagnets(12-15), whose dynamics are dominated by domain wall motion, and search the associated relaxation-time distribution functions for the signature of quantum effects. But whereas the classical, thermal processes that operate in these experiments are easily regulated via temperature, the quantum processes have so far not been tunable, making difficult a definitive interpretation of the results in terms of tunnelling. Here we describe a disordered magnetic system for which it is possible to adjust the quantum tunnelling probabilities. For this material, we can model both the classical, thermally activated response at high temperatures and the athermal, tunnelling behaviour at low temperatures within a unified framework, where the domain wall is described as a particle with a fixed mass. We show that it is possible to tune the quantum tunnelling processes by adjusting the 'mass' of this particle with an external magnetic field.	Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Phys, Chicago, IL 60637 USA; NEC Res Inst, Princeton, NJ 08540 USA	University of Chicago; University of Chicago; NEC Corporation	Rosenbaum, TF (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.	t-rosenbaum@uchicago.edu						ARNAUDAS JI, 1994, PHYS REV B, V50, P547, DOI 10.1103/PhysRevB.50.547; AWSCHALOM DD, 1992, PHYS REV LETT, V68, P3092, DOI 10.1103/PhysRevLett.68.3092; BARBARA B, 1994, J MAGN MAGN MATER, V129, P79, DOI 10.1016/0304-8853(94)90432-4; BARBARA B, 1993, PHYS SCRIPTA, VT49A, P268, DOI 10.1088/0031-8949/1993/T49A/047; Bitko D, 1996, PHYS REV LETT, V77, P940, DOI 10.1103/PhysRevLett.77.940; Braun HB, 1997, PHYS REV B, V56, P8129, DOI 10.1103/PhysRevB.56.8129; Brooke J, 1999, SCIENCE, V284, P779, DOI 10.1126/science.284.5415.779; CHUDNOVSKY EM, 1988, PHYS REV LETT, V60, P661, DOI 10.1103/PhysRevLett.60.661; COPPINGER F, 1995, PHYS REV LETT, V75, P3513, DOI 10.1103/PhysRevLett.75.3513; DEBYE P, 1929, POLAR MOLECULES, P91; DORING W, 1948, Z NATURFORSCH A, V3, P373, DOI 10.1515/zna-1948-0701; Friedman JR, 1996, PHYS REV LETT, V76, P3830, DOI 10.1103/PhysRevLett.76.3830; HANSEN PE, 1975, PHYS REV B, V12, P5315, DOI 10.1103/PhysRevB.12.5315; HONG K, 1996, J PHYS-CONDENS MAT, V8, P301; Kyriakidis J, 1998, PHYS REV B, V58, P5568, DOI 10.1103/PhysRevB.58.5568; LEGGETT AJ, 1987, REV MOD PHYS, V59, P1, DOI 10.1103/RevModPhys.59.1; Pugel E, 1997, APPL PHYS LETT, V71, P2205, DOI 10.1063/1.120443; Sachdev S., 1999, QUANTUM PHASE TRANSI, P39; STAMP PCE, 1992, INT J MOD PHYS B, V6, P1355, DOI 10.1142/S0217979292000670; TEJADA J, 1993, PHYS REV B, V47, P14977, DOI 10.1103/PhysRevB.47.14977; Thomas L, 1996, NATURE, V383, P145, DOI 10.1038/383145a0; UEHARA M, 1986, J PHYS-PARIS, V47, P235, DOI 10.1051/jphys:01986004702023500; VITALE S, 1994, J APPL PHYS, V76, P6332, DOI 10.1063/1.358257; Wernsdorfer W, 1997, PHYS REV LETT, V79, P4014, DOI 10.1103/PhysRevLett.79.4014	24	102	103	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 11	2001	413	6856					610	613		10.1038/35098037	http://dx.doi.org/10.1038/35098037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480WE	11595942	Green Accepted, Green Submitted			2022-12-28	WOS:000171485700042
J	Silliman, S; Blum, M				Silliman, S; Blum, M			Hemorrhagic transformation of a cerebral infarct	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Florida, Hlth Sci Ctr, Jacksonville, FL 32209 USA	State University System of Florida; University of Florida	Silliman, S (corresponding author), Univ Florida, Hlth Sci Ctr, Jacksonville, FL 32209 USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2001	345	15					1105	1105		10.1056/NEJMicm010043	http://dx.doi.org/10.1056/NEJMicm010043			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480QH	11596590				2022-12-28	WOS:000171473100005
J	Federman, AD; Adams, AS; Ross-Degnan, D; Soumerai, SB; Ayanian, JZ				Federman, AD; Adams, AS; Ross-Degnan, D; Soumerai, SB; Ayanian, JZ			Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BETA-BLOCKER USE; MYOCARDIAL-INFARCTION; PRESCRIPTION DRUGS; COST-EFFECTIVENESS; ADVERSE SELECTION; MEDIGAP INSURANCE; UNITED-STATES; COVERAGE; HEALTH; CHOLESTEROL	Context Cost-sharing in US prescription drug coverage plans for elderly persons varies widely. Evaluation of prescription drug use among elderly persons by type of health insurance could provide useful information for designing a Medicare drug program.. Objective To determine use of effective cardiovascular drugs among elderly per sons with coronary heart disease (CHD) by type of health insurance. Design, Setting, and Patients Cross-sectional evaluation of 1908 community-dwelling adults, aged 66 years or older, with a history of CHD or myocardial infarction from the 1997 Medicare Current Beneficiary Survey, a nationally representative sample of Medicare beneficiaries. Main Outcome Measures Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), beta -blockers, and nitrates, and out-of-pocket expenditures for prescription drugs, stratified by type of health insurance: Medicare without drug coverage (Medicare only or self-purchased supplemental insurance) or with drug coverage (Medicaid, other public program, Medigap, health maintenance organization, or employer-sponsored plan). Results Statin use ranged from 4.1% in Medicare patients with no drug coverage to 27.4% in patients with employer-sponsored drug coverage (P<.001). Less variation between these 2 types occurred for <beta>-blockers (20.7% vs 36.1%; P=.003) and nitrates (20.4% vs 38.0%; P=.005). In multivariate analyses, statin use remained significantly lower for patients with Medicare only (odds ratio [OR], 0.16; 95% confidence interval [CI], 0.05-0.49) and beta -blocker use was lower for Medicaid patients (OR, 0.55; 95% Cl, 0.34-0.88) vs those with employer-sponsored coverage. Nitrate use occurred less frequently in persons lacking drug coverage (patients with Medicare only, P=.049; patients with supplemental insurance without drug coverage, P=.03). Patients with Medicare only spent a much larger fraction of income on prescription compared with those with employer-sponsored drug coverage (7.9% vs; 1.7%; adjusted P<.001). Conclusion Elderly Medicare beneficiaries with CHD who lack drug coverage have disproportionately large drug expenditures and lower use rates of statins, a class of relatively expensive drugs that improve survival.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	ayanian@hcp.med.harvard.edu			DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE011001] Funding Source: NIH RePORTER; BHP HRSA HHS [5T32PE11001-13] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); BHP HRSA HHS		Adams AS, 2001, HEALTH AFFAIR, V20, P276, DOI 10.1377/hlthaff.20.1.276; Adams AS, 2001, ANNU REV PUBL HEALTH, V22, P49, DOI 10.1146/annurev.publhealth.22.1.49; Adler G S, 1994, Health Care Financ Rev, V15, P153; Alecxih L, 2001, HEALTH SERV RES, V35, P1365; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; BERK ML, 1990, HEALTH AFFAIR, V9, P146, DOI 10.1377/hlthaff.9.3.146; Blustein J, 2000, HEALTH AFFAIR, V19, P219, DOI 10.1377/hlthaff.19.2.219; BOWLIN SJ, 1993, J CLIN EPIDEMIOL, V46, P561, DOI 10.1016/0895-4356(93)90129-O; CASSIDY A, 2000, MEDICARE PLUS CHOICE; DAVIDSON BN, 1992, SOC SCI MED, V34, P1023, DOI 10.1016/0277-9536(92)90133-B; Davis M, 1999, HEALTH AFFAIR, V18, P231, DOI 10.1377/hlthaff.18.1.231; Ettner SL, 1997, J HEALTH ECON, V16, P543, DOI 10.1016/S0167-6296(97)00011-8; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Ganz DA, 2000, ANN INTERN MED, V132, P780, DOI 10.7326/0003-4819-132-10-200005160-00003; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GROSS D, 1999, STATE PHARM ASSISTAN; Harnick DJ, 1998, AM J CARDIOL, V81, P1416, DOI 10.1016/S0002-9149(98)00209-4; *HJ KAIS FAM FDN, 2000, HLTH POL ALT, V1; HJALMARSON A, 1988, AM J CARDIOL, V61, pB26; Hodgson TA, 1999, MED CARE, V37, P994, DOI 10.1097/00005650-199910000-00004; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; Jackevicius CA, 2000, J AM COLL CARDIOL, V35, p314A; JENSEN GA, 1992, GERONTOLOGIST, V32, P693, DOI 10.1093/geront/32.5.693; Johnson RE, 1997, HEALTH SERV RES, V32, P103; LONG SH, 1994, HEALTH AFFAIR, V13, P157, DOI 10.1377/hlthaff.13.2.157; Majumdar SR, 1999, J GEN INTERN MED, V14, P711, DOI 10.1046/j.1525-1497.1999.02229.x; McClellan M, 2000, HEALTH AFFAIR, V19, P26, DOI 10.1377/hlthaff.19.2.26; *MED EC CO INC, 1997, DRUG TOP RED BOOK; Miller M, 2000, ARCH INTERN MED, V160, P343, DOI 10.1001/archinte.160.3.343; MOELLER JF, 1991, HEALTH AFFAIR, V10, P210, DOI 10.1377/hlthaff.10.1.210; Pear R., 2001, NY TIMES B      1025, P1; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002-9149(00)00910-3; Phillips KA, 2000, JAMA-J AM MED ASSOC, V284, P2748, DOI 10.1001/jama.284.21.2748; Poisal JA, 2000, HEALTH AFFAIR, V19, P248, DOI 10.1377/hlthaff.19.2.248; Poisal JA, 2001, HEALTH AFFAIR, V20, P74, DOI 10.1377/hlthaff.20.2.74; Prosser LA, 2000, ANN INTERN MED, V132, P769, DOI 10.7326/0003-4819-132-10-200005160-00002; *RES TRIANGL I, 1997, PROF SOFTW SURV DAT; RICE T, 1991, HEALTH SERV RES, V26, P223; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schrott HG, 1997, JAMA-J AM MED ASSOC, V277, P1281, DOI 10.1001/jama.277.16.1281; Seddon ME, 2001, AM J MED, V111, P24, DOI 10.1016/S0002-9343(01)00741-0; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Stuart B, 1998, MED CARE, V36, P202, DOI 10.1097/00005650-199802000-00009; Stuart B, 1999, HEALTH AFFAIR, V18, P201, DOI 10.1377/hlthaff.18.2.201; STUART B, 2001, DESIGNING MED DRUG B; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; VISCOLI CM, 1993, ANN INTERN MED, V118, P99, DOI 10.7326/0003-4819-118-2-199301150-00004; Vistnes JP, 1997, INQUIRY-J HEALTH CAR, V34, P311; Wang TJ, 1998, ARCH INTERN MED, V158, P1901, DOI 10.1001/archinte.158.17.1901; WOLFE JR, 1991, J HEALTH ECON, V10, P433, DOI 10.1016/0167-6296(91)90024-H	57	134	136	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1732	1739		10.1001/jama.286.14.1732	http://dx.doi.org/10.1001/jama.286.14.1732			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	480NC	11594898	Bronze, Green Published			2022-12-28	WOS:000171466800023
J	Fiellin, DA; O'Connor, PG; Chawarski, M; Pakes, JP; Pantalon, MV; Schottenfeld, RS				Fiellin, DA; O'Connor, PG; Chawarski, M; Pakes, JP; Pantalon, MV; Schottenfeld, RS			Methadone maintenance in primary care - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NARCOTIC ADDICTION TREATMENT; DRUG-ABUSE TREATMENT; MEDICAL MAINTENANCE; FOLLOW-UP; GENERAL-PRACTITIONERS; OPIOID DEPENDENCE; PHARMACOTHERAPY; OUTCOMES; USERS	Context Methadone maintenance is an effective treatment for opioid dependence, yet its use is restricted to federally licensed narcotic treatment programs (NTPs). Office-based care of stabilized methadone maintenance patients is a promising alternative but no data are available from controlled trials regarding this type of program. Objective To determine the feasibility and efficacy of office-based methadone maintenance by primary care physicians vs in an NTP for stable opioid-dependent patients. Design Six-month, randomized controlled open clinical trial conducted February 1999-March 2000. Setting Offices of 6 primary care internists and an NTP. Patients Forty-seven opioid-dependent patients who had been receiving methadone maintenance therapy in an NTP without evidence of illicit drug use for 1 year and without significant untreated psychiatric comorbidity were randomized; 1 patient refused to participate after treatment assignment to NTP. Interventions Patients were randomly assigned to receive office-based methadone maintenance from primary care physicians, who received specialized training in the care of opioid-dependent patients (n =22), or usual care at an NTP (n =24). Main Outcome Measures Illicit drug use, clinical instability (persistent drug use), patient and clinician satisfaction, functional status, and use of health, legal, and social services, compared between the 2 groups. Results Eleven of 22 (50%; 95% confidence interval [CI], 29%-71%) patients in office-based care compared with 9 of 24 (38%; 95% Cl, 21%-57%) of NTP patients had a self-report or urine toxicology test result indicating illicit opiate use (P=39). Hair toxicology testing detected an additional 2 patients in each treatment group with evidence of illicit drug use, but this did not change the overall findings. Ongoing illicit drug use meeting criteria for clinical instability occurred in 4 of 22 (18%; 95% Cl, 7%-39%) patients in office-based care compared with 5 of 24 (21%; 95% Cl, 9%-41%) NTP patients (P=.82). Sixteen of the 22 (73%; 95% Cl, 54%-92%) office-based patients compared with 3 of the 24 (13%; 95% Cl, 0%-26%) NTP patients thought the quality of care was excellent (P=.001). There were no differences over time within or between groups in functional status or use of health, legal, or social services. Conclusions Our results support the feasibility and efficacy of transferring stable opioid-dependent patients receiving methadone maintenance to primary care physicians' offices for continuing treatment and suggest guidelines for identifying patients and clinical monitoring.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA USA	Yale University; Yale University; Harvard University; Harvard Medical School	Fiellin, DA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	david.fiellin@yale.edu		Fiellin, David/0000-0002-4006-010X	NATIONAL INSTITUTE ON DRUG ABUSE [K24DA000445, K12DA000167] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1998, JAMA, V280, P1936; Ball J.C., 2012, EFFECTIVENESS METHAD; Baumgartner WA, 1992, RECENT DEV THERAPEUT, P577; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; BOWDEN CL, 1976, AM J DRUG ALCOHOL AB, V3, P243, DOI 10.3109/00952997609077194; Brooner RK, 1997, ARCH GEN PSYCHIAT, V54, P71; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P177; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; COOPER JR, 1995, JAMA-J AM MED ASSOC, V273, P1619, DOI 10.1001/jama.273.20.1619; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; *ERLB ASS, 1988, STAT POW AN COMP PRO; FIELLIN D, 2001, METHADONE MED MAINTE; FIELLIN DA, 2001, DRUG ALCOHOL DEPEN S, V63, P47; GREENWOOD J, 1992, BRIT J ADDICT, V87, P567; HARTEL DM, 1995, AM J PUBLIC HEALTH, V85, P83, DOI 10.2105/AJPH.85.1.83; Hubbard RL, 1997, PSYCHOL ADDICT BEHAV, V11, P261, DOI 10.1037/0893-164X.11.4.261; Lewis DC, 1999, J ADDICT DIS, V18, P5, DOI 10.1300/J069v18n02_02; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; METZGER DS, 1993, J ACQ IMMUN DEF SYND, V6, P1049; Metzger DS, 1999, PUBLIC HEALTH, V113, P97; Moatti JP, 1998, ADDICTION, V93, P1567, DOI 10.1046/j.1360-0443.1998.9310156714.x; NOVICK DM, 1988, JAMA-J AM MED ASSOC, V259, P3299, DOI 10.1001/jama.259.22.3299; NOVICK DM, 1994, J GEN INTERN MED, V9, P127, DOI 10.1007/BF02600025; O'Connor PG, 1998, AM J MED, V105, P100, DOI 10.1016/S0002-9343(98)00194-6; O'Connor PG, 2000, ANN INTERN MED, V133, P40, DOI 10.7326/0003-4819-133-1-200007040-00008; *OFF NAT DRUG CONT, 1999, POL PAP OP AG TREATM; PARRINO MW, 1998, J MAINTENANCE ADDICT, V1, P71; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reese TV, 2001, NEW ENGL J MED, V344, P530; Rettig RA., 1995, FEDERAL REGULATION M; Salsitz EA, 2000, MT SINAI J MED, V67, P388; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; Schwartz RP, 1999, AM J ADDICTION, V8, P293; Sees KL, 2000, JAMA-J AM MED ASSOC, V283, P1303, DOI 10.1001/jama.283.10.1303; Senay Edward C., 1993, Journal of Addictive Diseases, V12, P59, DOI 10.1300/J069v12n04_05; *US DEP HHS, 1993, STAT METH TREATM GUI, V1; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Warner EA, 1997, MED CLIN N AM, V81, P909, DOI 10.1016/S0025-7125(05)70555-1; Weinrich M, 2000, JAMA-J AM MED ASSOC, V283, P1343, DOI 10.1001/jama.283.10.1343; Zanis DA, 1997, DRUG ALCOHOL DEPEN, V49, P25, DOI 10.1016/S0376-8716(97)00135-X; 2001, FED REG, V66, P4076	41	114	115	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1724	1731		10.1001/jama.286.14.1724	http://dx.doi.org/10.1001/jama.286.14.1724			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	480NC	11594897	Bronze			2022-12-28	WOS:000171466800022
J	Ford, N				Ford, N			Tackling female genital cutting in Somalia	LANCET			English	Article									Med Sans Frontieres, London EC1R 5DJ, England	Doctors Without Borders	Ford, N (corresponding author), Med Sans Frontieres, 123-132 Clerkenwell Rd, London EC1R 5DJ, England.							ANNAIM A, 1999, INTENTIONS CONSEQUEN; *MSF, 1999, FEM GEN CUTT POL PAP; World Health Organization, 1998, FEMALE GENITAL MUTIL	3	8	8	1	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1179	1179		10.1016/S0140-6736(01)06263-8	http://dx.doi.org/10.1016/S0140-6736(01)06263-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597697				2022-12-28	WOS:000171399000039
J	Pearson, PN; Ditchfield, PW; Singano, J; Harcourt-Brown, KG; Nicholas, CJ; Olsson, RK; Shackleton, NJ; Hall, MA				Pearson, PN; Ditchfield, PW; Singano, J; Harcourt-Brown, KG; Nicholas, CJ; Olsson, RK; Shackleton, NJ; Hall, MA			Warm tropical sea surface temperatures in the Late Cretaceous and Eocene epochs	NATURE			English	Article							ATMOSPHERIC CARBON-DIOXIDE; GLOBAL CLIMATE; MIDDLE EOCENE; OCEAN; OXYGEN; DIAGENESIS; EVOLUTION; ISOTOPES; RECORD; CO2	Climate models with increased levels of carbon dioxide predict that global warming causes heating in the tropics, but investigations of ancient climates based on palaeodata have generally indicated cool tropical temperatures during supposed greenhouse episodes. For example, in the Late Cretaceous and Eocene epochs there is abundant geological evidence for warm, mostly ice-free poles, but tropical sea surface temperatures are generally estimated to be only 15-23 degreesC, based on oxygen isotope palaeothermometry of surface-dwelling planktonic foraminifer shells. Here we question the validity of most such data on the grounds of poor preservation and diagenetic alteration. We present new data from exceptionally well preserved foraminifer shells extracted from impermeable clay-rich sediments, which indicate that for the intervals studied, tropical sea surface temperatures were at least 28-32 degreesC. These warm temperatures are more in line with our understanding of the geographical distributions of temperature-sensitive fossil organisms and the results of climate models with increased CO2 levels.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Tanzania Petr Dev Corp, Dar Es Salaam, Tanzania; Univ Dublin Trinity Coll, Dept Geol, Dublin 2, Ireland; Rutgers State Univ, Dept Geol Sci, Piscataway, NJ 08855 USA; Univ Cambridge, Dept Earth Sci, Godwin Lab, Cambridge CB2 3SA, England	University of Bristol; Trinity College Dublin; Rutgers State University New Brunswick; University of Cambridge	Pearson, PN (corresponding author), Univ Bristol, Dept Earth Sci, Queens Rd, Bristol BS8 1RJ, Avon, England.	paul.pearson@bristol.ac.uk	Pearson, Paul N/B-2276-2009	Pearson, Paul N/0000-0003-4628-9818				ADAMS CG, 1990, PALAEOGEOGR PALAEOCL, V77, P289; Andreasson FP, 1998, PALEOCEANOGRAPHY, V13, P183, DOI 10.1029/98PA00120; BARRON EJ, 1995, EFFECTS PAST GLOBAL, P108; Barron EJ, 1987, PALEOCEANOGRAPHY, V2, P729, DOI 10.1029/PA002i006p00729; Bice KL, 2000, PALAEOGEOGR PALAEOCL, V161, P295, DOI 10.1016/S0031-0182(00)00072-9; Blow W.H., 1962, FUNDAMENTALS MIDTERT, P61; Blow WH, 1979, CAINOZOIC GLOBIGERIN, V1, pxv+752; Boersma A, 1987, PALEOCEANOGRAPHY, V2, P287, DOI 10.1029/PA002i003p00287; BRALOWER TJ, 1995, PALEOCEANOGRAPHY, V10, P841, DOI 10.1029/95PA01143; Bush ABG, 1997, PALEOCEANOGRAPHY, V12, P495, DOI 10.1029/97PA00721; Coxall HK, 2000, GEOLOGY, V28, P87, DOI 10.1130/0091-7613(2000)028<0087:HDAAEL>2.3.CO;2; Crowley TJ, 2001, SCIENCE, V292, P870, DOI 10.1126/science.1061664; Crowley TJ, 2000, WARM CLIMATES EARTH, P50, DOI DOI 10.1017/CBO9780511564512.004; DHONDT S, 1995, PALEOCEANOGRAPHY, V10, P123, DOI 10.1029/94PA02671; DHondt S, 1996, SCIENCE, V271, P1838, DOI 10.1126/science.271.5257.1838; EMILIANI C, 1954, AM J SCI, V252, P149, DOI 10.2475/ajs.252.3.149; EREZ J, 1983, GEOCHIM COSMOCHIM AC, V47, P1025, DOI 10.1016/0016-7037(83)90232-6; GRAHAM A, 1994, AM J BOT, V81, P301, DOI 10.2307/2445456; Hemleben C., 1989, MODERN PLANKTONIC FO, DOI [DOI 10.1016/S0016-6995(89)80108-1, DOI 10.1007/978-1-4612-3544-6_2]; Horrell MA, 1990, PALEOCEANOGRAPHY, V5, P339, DOI 10.1029/PA005i003p00339; Huber M, 2000, PALEOCEANOGRAPHY, V15, P443, DOI 10.1029/1999PA000455; Kent PE, 1971, 6 NAT ENV RES COUNC; KILLINGLEY JS, 1983, NATURE, V301, P594, DOI 10.1038/301594a0; KOLODNY Y, 1988, PALAEOGEOGR PALAEOCL, V64, P59, DOI 10.1016/0031-0182(88)90142-3; MANABE S, 1985, J GEOPHYS RES-OCEANS, V90, P1689, DOI 10.1029/JC090iC06p11689; Markwick PJ, 1998, PALAEOGEOGR PALAEOCL, V137, P205, DOI 10.1016/S0031-0182(97)00108-9; Norris RD, 1998, GEOLOGY, V26, P823, DOI 10.1130/0091-7613(1998)026<0823:LLSSTF>2.3.CO;2; Pearson PN, 2000, NATURE, V406, P695, DOI 10.1038/35021000; PEARSON PN, 1993, J FORAMIN RES, V23, P123, DOI 10.2113/gsjfr.23.2.123; RAMANATHAN V, 1991, NATURE, V351, P27, DOI 10.1038/351027a0; Retallack GJ, 2001, NATURE, V411, P287, DOI 10.1038/35077041; RIND D, 1991, J GEOPHYS RES-ATMOS, V96, P7437, DOI 10.1029/91JD00009; Rind D, 1998, J GEOPHYS RES-ATMOS, V103, P5943, DOI 10.1029/97JD03649; SAVIN SM, 1977, ANNU REV EARTH PL SC, V5, P319, DOI 10.1146/annurev.ea.05.050177.001535; SCHLUTER T, 1997, GEOLOGY E AFRICA, V239; SCHRAG DP, 1995, GEOCHIM COSMOCHIM AC, V59, P2265, DOI 10.1016/0016-7037(95)00105-9; Schrag DP, 1999, CHEM GEOL, V161, P215, DOI 10.1016/S0009-2541(99)00088-1; SHACKLETON N, 1981, J GEOL SOC LONDON, V138, P153, DOI 10.1144/gsjgs.138.2.0153; SHACKLETON NJ, 1984, FOSSILS CLIMATE, P27; Sloan LC, 1996, PALAEOGEOGR PALAEOCL, V119, P275, DOI 10.1016/0031-0182(95)00012-7; Spero HJ, 1997, NATURE, V390, P497, DOI 10.1038/37333; UREY HC, 1947, J CHEM SOC, P562, DOI 10.1039/jr9470000562; Veizer J, 2000, NATURE, V408, P698, DOI 10.1038/35047044; Wade BS, 2001, GEOL SOC SPEC PUBL, V183, P273, DOI 10.1144/GSL.SP.2001.183.01.13; Waliser DE, 1996, B AM METEOROL SOC, V77, P357; Wilson PA, 2001, NATURE, V412, P425, DOI 10.1038/35086553; Wilson PA, 1998, NATURE, V392, P889, DOI 10.1038/31865; Wilson PA, 1996, GEOLOGY, V24, P555, DOI 10.1130/0091-7613(1996)024<0555:ESSTFT>2.3.CO;2; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412; ZACHOS JC, 1994, PALEOCEANOGRAPHY, V9, P353, DOI 10.1029/93PA03266	50	492	509	3	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 4	2001	413	6855					481	487		10.1038/35097000	http://dx.doi.org/10.1038/35097000			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586350				2022-12-28	WOS:000171340500037
J	Vergis, EN; Hayden, MK; Chow, JW; Snydman, DR; Zervos, MJ; Linden, PK; Wagener, MM; Schmitt, B; Muder, RR				Vergis, EN; Hayden, MK; Chow, JW; Snydman, DR; Zervos, MJ; Linden, PK; Wagener, MM; Schmitt, B; Muder, RR			Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia - A prospective multicenter study	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-STREAM INFECTIONS; FAECIUM BACTEREMIA; RISK-FACTORS; CLINICAL-FEATURES; SURGICAL PATIENTS; FAECALIS; LEVEL; ENDOCARDITIS; GENTAMICIN; GENE	Background: Enterococcus species are major nosocomial pathogens and are exhibiting vancomycin resistance with increasing frequency. Previous studies have not resolved whether vancomycin resistance Is an independent risk factor for death in patients with invasive disease due to Enterococcus species or whether antibiotic therapy alters the outcome of enterococcal bacteremia. Objective: To determine whether vancomycin resistance is an independent predictor of death in patients with enterococcal bacteremia and whether appropriate antimicrobial therapy influences outcome. Design: Prospective observational study. Setting: Four academic medical centers and a community hospital. Patients: All patients with enterococcal bacteremia. Measurements: Demographic characteristics; underlying disease; Acute Physiology and Chronic Health Evaluation (APACHE) II scores; antibiotic therapy, immunosuppression, and procedures before onset; and antibiotic therapy during the ensuing 6 weeks. The major end point was 14-day survival. Results: Of 398 episodes, 60% were caused by E. faecalis and 37% were caused by E. faecium. Thirty-seven percent of isolates exhibited resistance or Intermediate susceptibility to vancomycin. Twenty-two percent of E. faecium isolates showed reduced susceptibility to quinupristin-dalfopristin. Previous vancomycin use (odds ratio [OR], 5.82 [95% Cl, 3.20 to 10.58]; P < 0.001), previous corticosteroid use (OR, 2.43 [Cl, 1.22 to 4.86]; P = 0.01), and total APACHE II score (OR, 1.06 per unit change [Cl, 1.02 to 1.10 per unit change]; P = 0.003) were associated with vancomycin-resistant enterococcal bacteremia. The mortality rate was 19% at 14 days. Hematologic malignancy (OR, 3.83 [Cl, 1.56 to 9.39]; P = 0.003), vancomycin resistance (OR, 2.10 [Cl, 1.14 to 3.88]; P = 0.02), and APACHE II score (OR, 1.10 per unit change [Cl, 1.05 to 1.14 per unit change]; P < 0.001) were associated with 14-day mortality. Among patients with monomicrobial enterococcal bacteremia, receipt of effective antimicrobial therapy within 48 hours independently predicted survival (OR for death, 0.21 [Cl, 0.06 to 0.80]; P = 0.02). Conclusions: vancomycin resistance is an independent predictor of death from enterococcal bacteremia. Early, effective antimicrobial therapy is associated with a significant improvement in survival.	Univ Pittsburgh, Med Ctr, Vet Affairs Med Ctr, Pittsburgh, PA USA; Rush Presbyterian St Lukes Med Ctr, Rush Med Coll, Chicago, IL 60612 USA; Wayne State Univ, Sch Med, Detroit, MI USA; John D Dingell Vet Affairs Med Ctr, Detroit, MI USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Rush University; Wayne State University; Beaumont Health; Tufts University; Tufts Medical Center	Muder, RR (corresponding author), Vet Affairs Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.		Snydman, David R/O-3889-2014; Chow, Joseph W/W-4164-2017	Snydman, David R/0000-0003-0119-3978; Chow, Joseph W/0000-0002-5934-5877; Hayden, Mary/0000-0002-4603-8501				[Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P1; BARRALL DT, 1985, ARCH SURG-CHICAGO, V120, P57; Beezhold DW, 1997, CLIN INFECT DIS, V24, P704, DOI 10.1093/clind/24.4.704; BRISSONNOEL A, 1990, ANTIMICROB AGENTS CH, V34, P924, DOI 10.1128/AAC.34.5.924; BRYAN CS, 1985, SURG GYNECOL OBSTET, V160, P557; Chow JW, 1997, CLIN INFECT DIS, V24, P90, DOI 10.1093/clinids/24.1.90; Chow JW, 1997, ANTIMICROB AGENTS CH, V41, P511, DOI 10.1128/AAC.41.3.511; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Dever LL, 1996, MICROB DRUG RESIST, V2, P407, DOI 10.1089/mdr.1996.2.407; DOUGHERTY SH, 1983, ARCH SURG-CHICAGO, V118, P232; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; DUTKAMALEN S, 1995, J CLIN MICROBIOL, V33, P24, DOI 10.1128/JCM.33.1.24-27.1995; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; FACKLAM RR, 1989, J CLIN MICROBIOL, V27, P731, DOI 10.1128/JCM.27.4.731-734.1989; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; Free Laurie, 1996, P150; GARRISON RN, 1982, ANN SURG, V196, P43, DOI 10.1097/00000658-198207000-00010; GRANINGER W, 1992, CLIN INFECT DIS, V15, P49, DOI 10.1093/clinids/15.1.49; GRAY J, 1994, J HOSP INFECT, V27, P179, DOI 10.1016/0195-6701(94)90125-2; GULLBERG RM, 1989, REV INFECT DIS, V11, P74; HILF M, 1989, AM J MED, V87, P540, DOI 10.1016/S0002-9343(89)80611-4; HOFFMANN SA, 1987, ANN INTERN MED, V106, P757, DOI 10.7326/0003-4819-106-5-757; HOGE CW, 1991, REV INFECT DIS, V13, P600; HUYCKE MM, 1991, ANTIMICROB AGENTS CH, V35, P1626, DOI 10.1128/AAC.35.8.1626; Kao SJ, 2000, ANTIMICROB AGENTS CH, V44, P2876, DOI 10.1128/AAC.44.10.2876-2879.2000; KORVICK JA, 1992, ANTIMICROB AGENTS CH, V36, P2639, DOI 10.1128/AAC.36.12.2639; Lai KK, 1996, ARCH INTERN MED, V156, P2579, DOI 10.1001/archinte.156.22.2579; Lautenbach E, 1999, INFECT CONT HOSP EP, V20, P318, DOI 10.1086/501624; Leclercq R, 1997, CLIN INFECT DIS, V24, P545, DOI 10.1093/clind/24.4.545; Linden PK, 1997, J ANTIMICROB CHEMOTH, V39, P145, DOI 10.1093/jac/39.suppl_1.145; Linden PK, 1996, CLIN INFECT DIS, V22, P663, DOI 10.1093/clinids/22.4.663; Lucas GM, 1998, CLIN INFECT DIS, V26, P1127, DOI 10.1086/520311; MAKI DG, 1988, MEDICINE, V67, P248, DOI 10.1097/00005792-198807000-00005; MALONE DA, 1986, AM J MED, V81, P601, DOI 10.1016/0002-9343(86)90544-9; National Committee for Clinical Laboratory Standards, 1999, PERF STAND ANT SUSC; Noskin GA, 1999, ANTIMICROB AGENTS CH, V43, P2059, DOI 10.1128/AAC.43.8.2059; NOSKIN GA, 1995, CLIN INFECT DIS, V20, P296, DOI 10.1093/clinids/20.2.296; RIMAILHO A, 1988, CRIT CARE MED, V16, P126, DOI 10.1097/00003246-198802000-00006; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P1588, DOI 10.1128/AAC.33.9.1588; SHAY DK, 1995, J INFECT DIS, V172, P993, DOI 10.1093/infdis/172.4.993; SHLAES DM, 1981, ARCH INTERN MED, V141, P578, DOI 10.1001/archinte.141.5.578; SPERA RV, 1992, JAMA-J AM MED ASSOC, V268, P2563, DOI 10.1001/jama.268.18.2563; Stosor V, 1998, ARCH INTERN MED, V158, P522, DOI 10.1001/archinte.158.5.522; Stroud L, 1996, INFECT CONT HOSP EP, V17, P576; Tornieporth NG, 1996, CLIN INFECT DIS, V23, P767, DOI 10.1093/clinids/23.4.767; Tsai SF, 1998, ANTIMICROB AGENTS CH, V42, P1229, DOI 10.1128/AAC.42.5.1229; You I, 2000, DIAGN MICR INFEC DIS, V36, P37, DOI 10.1016/S0732-8893(99)00104-2	48	241	248	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					484	492		10.7326/0003-4819-135-7-200110020-00007	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	477EF	11578151				2022-12-28	WOS:000171269600002
J	von Hippel, FN				von Hippel, FN			Energy - Plutonium and reprocessing of spent nuclear fuel	SCIENCE			English	Editorial Material									Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA	Princeton University	von Hippel, FN (corresponding author), Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA.							BUNN M, 2001, INTERIM STORAGE SPEN; Hibbs M, 2001, B ATOM SCI, V57, P63; HIBBS M, B AT SCI, V25, P5; LLOYD WR, 1994, UCRLID115199 LAWR LI; Macfarlane A, 2001, B ATOM SCI, V57, P53; Mark J. Carson, 1993, SCI GLOBAL SECURITY, V4, P111, DOI DOI 10.1080/08929889308426394; National Science and Technology Council, 1996, NUCL WAST TECHN SEP, P3; *OECD NUCL EN AG I, 2000, UR 1999 RES PROD DEM; Perkovich George, 1999, INDIAS NUCL BOMB, p[28, 55]; *PLANN COMM GOV FR, 2000, EC FOR STUD NUCL OPT; U.S. Department of Energy Office of Scientific and Technical Information, 1997, NONPR ARMS CONTR ASS, P37; *US AT EN COMM, 1974, WASH1535 US AT EN CO; *US DEP EN, 1999, YMP0106 US DEP EN; *WHIT HOUS, 2001, NAT EN POL, P5; WILLRICH M, 1974, NUCL THEFT; 2001, NUKERN MARKET REPORT; 1996, NUCL WASTES TECHNOLO, P117	17	33	33	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2397	2398		10.1126/science.1064667	http://dx.doi.org/10.1126/science.1064667			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	476PD	11577221				2022-12-28	WOS:000171237200028
J	Dalton, R				Dalton, R			Swift move to collect fallout data	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					335	335		10.1038/35096704	http://dx.doi.org/10.1038/35096704			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574836	Bronze			2022-12-28	WOS:000171188700004
J	Kawabata, H; Ueno, T				Kawabata, H; Ueno, T			Screening recommendation for women taking tamoxifen	LANCET			English	Letter							BREAST-CANCER; ADJUVANT TAMOXIFEN; ENDOMETRIUM		JR Tokyo Gen Hosp, Dept Surg, Tokyo 1510053, Japan		Kawabata, H (corresponding author), JR Tokyo Gen Hosp, Dept Surg, Tokyo 1510053, Japan.							Barakat RR, 2000, J CLIN ONCOL, V18, P3459, DOI 10.1200/JCO.2000.18.20.3459; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gerber B, 2000, J CLIN ONCOL, V18, P3464, DOI 10.1200/JCO.2000.18.20.3464; Katase K, 1998, CANCER, V82, P1698, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1698::AID-CNCR16>3.3.CO;2-K; *ONC COMM, 2001, NIPPON SANFUJINNKA G, V53, P788	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					1018	1018		10.1016/S0140-6736(01)06150-5	http://dx.doi.org/10.1016/S0140-6736(01)06150-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11593503				2022-12-28	WOS:000171135300059
J	McCarthy, M				McCarthy, M			USA talks of war after more than 5000 killed in terrorist attacks	LANCET			English	Article																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					939	939		10.1016/S0140-6736(01)06116-5	http://dx.doi.org/10.1016/S0140-6736(01)06116-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11584816				2022-12-28	WOS:000171135300002
J	Sharp, D				Sharp, D			Health economics without tears	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Sharp, D (corresponding author), Lancet, London WC1X 8RR, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					950	950		10.1016/S0140-6736(01)06115-3	http://dx.doi.org/10.1016/S0140-6736(01)06115-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583746				2022-12-28	WOS:000171135300013
J	Knight, EL; Avorn, J				Knight, EL; Avorn, J			Quality indicators for appropriate medication use in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							CONVERTING ENZYME-INHIBITOR; OVERACTIVE BLADDER; HEART-FAILURE; RISK-FACTORS; HYPOGLYCEMIA; HYPERTENSION; INTERVENTION; OUTPATIENTS; THERAPY; DRUGS		Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Avorn, J (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, 221 Londwood Ave, Boston, MA 02115 USA.							Abrams P, 1998, BRIT J UROL, V81, P801; *ABT ASS, 1998, EV DRUG US REV DEM P; Appell RA, 1997, UROLOGY, V50, P90, DOI 10.1016/S0090-4295(97)00599-2; ASPLUND K, 1983, DIABETOLOGIA, V24, P412; AVORN J, 2001, GERIATRIC MED; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; Black HR, 1997, ARCH INTERN MED, V157, P2413; Chiquette E, 1998, ARCH INTERN MED, V158, P1641, DOI 10.1001/archinte.158.15.1641; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; EISENDRATH SJ, 1987, AM J PSYCHIAT, V144, P1062; FERNER RE, 1988, BRIT MED J, V296, P949, DOI 10.1136/bmj.296.6627.949; GOETZ DW, 1989, J ALLERGY CLIN IMMUN, V84, P316, DOI 10.1016/0091-6749(89)90414-4; GONZALEZFERNANDEZ RA, 1990, AM J CARDIOL, V65, P1384, DOI 10.1016/0002-9149(90)91332-Z; GOODYER LI, 1995, BRIT J CLIN PRACT, V49, P173; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; HIRSH J, 1995, AM J CARDIOL, V75, pB39, DOI 10.1016/0002-9149(95)80009-H; Hirsh J, 1998, CHEST, V114, p445S, DOI 10.1378/chest.114.5_Supplement.445S; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Kalra PA, 1999, BMJ-BRIT MED J, V318, P234; Knight EL, 1999, AM HEART J, V138, P849, DOI 10.1016/S0002-8703(99)70009-8; Koenig K L, 1994, Acad Emerg Med, V1, P544; LOWE CJ, 1995, BRIT MED J, V310, P1229, DOI 10.1136/bmj.310.6989.1229; MACDONALD JB, 1977, BRIT MED J, V2, P483, DOI 10.1136/bmj.2.6085.483; MacDowall P, 1998, LANCET, V352, P13, DOI 10.1016/S0140-6736(97)11060-1; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MONANE M, 1993, ARCH INTERN MED, V153, P633, DOI 10.1001/archinte.153.5.633; Monane M, 1998, JAMA-J AM MED ASSOC, V280, P1249, DOI 10.1001/jama.280.14.1249; PAICE BJ, 1985, ADVERSE DRUG REACT T, V4, P23; POTAMIANOS G, 1982, BRIT J PSYCHIAT, V140, P470, DOI 10.1192/bjp.140.5.470; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Reardon LC, 1998, ARCH INTERN MED, V158, P26, DOI 10.1001/archinte.158.1.26; Rich MW, 1996, AM J MED, V101, P270, DOI 10.1016/S0002-9343(96)00172-6; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; Sands L, 1997, AM J GERIAT PSYCHIAT, V5, P156; SELTZER HS, 1972, DIABETES, V21, P955, DOI 10.2337/diab.21.9.955; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; 1991, JAMA, V165, P3255	45	93	94	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				703	710		10.7326/0003-4819-135-8_Part_2-200110161-00009	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481WA	11601953				2022-12-28	WOS:000171542400009
J	Webster, JR				Webster, JR			How and why we should move our geriatric cheese	ANNALS OF INTERNAL MEDICINE			English	Article									Buehler Ctr Aging, Chicago, IL 60611 USA		Webster, JR (corresponding author), Buehler Ctr Aging, 750 N Lake Shore Dr,Suite 601, Chicago, IL 60611 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				641	642		10.7326/0003-4819-135-8_Part_2-200110161-00001	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00001			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481WA	11601945				2022-12-28	WOS:000171542400001
J	Bibby, TS; Nield, J; Partensky, F; Barber, J				Bibby, TS; Nield, J; Partensky, F; Barber, J			Oxyphotobacteria - Antenna ring around photosystem I	NATURE			English	Article							MARINE PROKARYOTE; PROCHLOROCOCCUS; LIGHT; PROCHLOROPHYTE		Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, London SW7 2AY, England; CNRS, Observ Oceanol Roscoff, F-29682 Roscoff, France; Univ Paris 06, Biol Stn, F-29682 Roscoff, France	Imperial College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Bibby, TS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, London SW7 2AY, England.	j.barber@ic.ac.uk	Partensky, Frédéric/B-9194-2018; Partensky, Frédéric/AAH-1170-2021; Bibby, Thomas/C-9159-2014; Nield, Jon/C-5892-2013	Partensky, Frédéric/0000-0003-1274-4050; Partensky, Frédéric/0000-0003-1274-4050; Nield, Jon/0000-0001-9983-0239; Bibby, Thomas/0000-0003-1743-473X				Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; CHISHOLM SW, 1992, ARCH MICROBIOL, V157, P297, DOI 10.1007/BF00245165; Garczarek L, 2000, P NATL ACAD SCI USA, V97, P4098, DOI 10.1073/pnas.070040897; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; LEWIN RA, 1976, NATURE, V261, P697, DOI 10.1038/261697b0; MOORE LR, 1995, MAR ECOL PROG SER, V116, P259, DOI 10.3354/meps116259; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	10	81	92	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 11	2001	413	6856					590	590		10.1038/35098153	http://dx.doi.org/10.1038/35098153			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480WE	11595938	Bronze			2022-12-28	WOS:000171485700038
J	Dupuis, J				Dupuis, J			Endothelin-receptor antagonists in pulmonary hypertension	LANCET			English	Editorial Material							ETB-RECEPTOR; CIRCULATION		Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Montreal, PQ H1T 1C8, Canada	Universite de Montreal; Universite de Montreal	Dupuis, J (corresponding author), Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.		Dupuis, Jocelyn/B-3898-2009; Dupuis, Jocelyn/C-6613-2013	Dupuis, Jocelyn/0000-0002-3193-1014				Battistini B, 1998, PULM PHARMACOL THER, V11, P97, DOI 10.1006/pupt.1998.0154; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; Dupuis J, 2000, PULM PHARMACOL THER, V13, P135, DOI 10.1006/pupt.2000.0242; Dupuis J, 1996, CIRCULATION, V94, P1578, DOI 10.1161/01.CIR.94.7.1578; Gratton JP, 1997, HYPERTENSION, V30, P1204, DOI 10.1161/01.HYP.30.5.1204; Jasmin JF, 2001, CIRCULATION, V103, P314; OKADA M, 1995, CIRCULATION, V92, P114, DOI 10.1161/01.CIR.92.1.114; SATO K, 1995, AM J PHYSIOL-LUNG C, V269, pL668, DOI 10.1152/ajplung.1995.269.5.L668; Sutsch G, 1998, CIRCULATION, V98, P2262, DOI 10.1161/01.CIR.98.21.2262; Williamson DJ, 2000, CIRCULATION, V102, P411	10	31	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1113	1114		10.1016/S0140-6736(01)06298-5	http://dx.doi.org/10.1016/S0140-6736(01)06298-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597660				2022-12-28	WOS:000171399000003
J	de Lemos, JA; Morrow, DA; Bentley, JH; Omland, T; Sabatine, MS; McCabe, CH; Hall, C; Cannon, CP; Braunwald, E				de Lemos, JA; Morrow, DA; Bentley, JH; Omland, T; Sabatine, MS; McCabe, CH; Hall, C; Cannon, CP; Braunwald, E			The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR FUNCTION; INCREASED PLASMA-LEVELS; UNSTABLE ANGINA; HEART-FAILURE; ATRIAL; ANGIOPLASTY; SECRETION; STRATIFICATION; ENOXAPARIN	Background: Brain (B-type) natriuretic peptide is a neurohormone synthesized predominantly in ventricular myocardium. Although the circulating level of this neurohormone has been shown to provide independent prognostic information in patients with transmural myocardial infarction, few data are available for patients with acute coronary syndromes in the absence of ST-segment elevation. Methods: We measured B-type natriuretic peptide in plasma specimens obtained a mean (+/-SD) of 40+/-20 hours after the onset of ischemic symptoms in 2525 patients from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction 16 study. Results: The base-line level of B-type natriuretic peptide was correlated with the risk of death, heart failure, and myocardial infarction at 30 days and 10 months. The unadjusted rate of death increased in a stepwise fashion among patients in increasing quartiles of base-line B-type natriuretic peptide levels (P<0.001). This association remained significant in subgroups of patients who had myocardial infarction with ST-segment elevation (P=0.02), patients who had myocardial infarction without ST-segment elevation (P<0.001), and patients who had unstable angina (P<0.001). After adjustment for independent predictors of the long-term risk of death, the odds ratios for death at 10 months in the second, third, and fourth quartiles of B-type natriuretic peptide were 3.8 (95 percent confidence interval, 1.1 to 13.3), 4.0 (95 percent confidence interval, 1.2 to 13.7), and 5.8 (95 percent confidence interval, 1.7 to 19.7). The level of B-type natriuretic peptide was also associated with the risk of new or recurrent myocardial infarction (P=0.01) and new or worsening heart failure (P<0.001) at 10 months. Conclusions: A single measurement of B-type natriuretic peptide, obtained in the first few days after the onset of ischemic symptoms, provides predictive information for use in risk stratification across the spectrum of acute coronary syndromes. Cardiac neurohormonal activation may be a unifying feature among patients at high risk for death after acute coronary syndromes. (N Engl J Med 2001;345:1014-21.) Copyright (C) 2001 Massachusetts Medical Society.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Nottingham Clin Res Grp, Nottingham, England; Univ Oslo, Natl Hosp, Internal Med Res Inst, Oslo, Norway	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Oslo; National Hospital Norway	de Lemos, JA (corresponding author), Univ Texas, SW Med Ctr, Donald W Reynolds Cardiovasc Clin Res Ctr, 5323 Harry Hines Blvd,Rm CS7-142, Dallas, TX 75390 USA.		Sabatine, Marc/AAJ-6751-2020; Cannon, Christopher P/AAY-7644-2020; de Lemos, James/ABD-6669-2021	Sabatine, Marc/0000-0002-0691-3359; Cannon, Christopher P/0000-0003-4596-2791; 				Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; ARAKAWA N, 1994, CARDIOLOGY, V85, P334, DOI 10.1159/000176706; Arakawa N, 1996, J AM COLL CARDIOL, V27, P1656, DOI 10.1016/0735-1097(96)00067-8; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Cannon CP, 2000, CIRCULATION, V102, P149, DOI 10.1161/01.CIR.102.2.149; Cheng V, 2001, J AM COLL CARDIOL, V37, P386, DOI 10.1016/S0735-1097(00)01157-8; Dao Q, 2001, J AM COLL CARDIOL, V37, P379, DOI 10.1016/S0735-1097(00)01156-6; Darbar D, 1996, AM J CARDIOL, V78, P284, DOI 10.1016/S0002-9149(96)00278-0; HAMA N, 1995, CIRCULATION, V92, P1558, DOI 10.1161/01.CIR.92.6.1558; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; HORIO T, 1993, AM HEART J, V126, P293, DOI 10.1016/0002-8703(93)91042-D; Kikuta K, 1996, AM HEART J, V132, P101, DOI 10.1016/S0002-8703(96)90396-8; Kyriakides ZS, 2000, CLIN CARDIOL, V23, P285, DOI 10.1002/clc.4960230412; MARUMOTO K, 1995, CLIN SCI, V88, P551, DOI 10.1042/cs0880551; MORITA E, 1993, CIRCULATION, V88, P82, DOI 10.1161/01.CIR.88.1.82; Morrow DA, 2000, J AM COLL CARDIOL, V36, P1812, DOI 10.1016/S0735-1097(00)00942-6; MOTWANI JG, 1993, LANCET, V341, P1109, DOI 10.1016/0140-6736(93)93126-L; Nagaya N, 1998, AM HEART J, V135, P21, DOI 10.1016/S0002-8703(98)70338-2; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232; Richards AM, 1998, CIRCULATION, V97, P1921, DOI 10.1161/01.CIR.97.19.1921; Richards AM, 1999, HEART, V81, P114, DOI 10.1136/hrt.81.2.114; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Stein B, 1998, AM HEART J, V135, P914, DOI 10.1016/S0002-8703(98)70054-7; Talwar S, 2000, HEART, V84, P421, DOI 10.1136/heart.84.4.421; Talwar S, 2000, EUR HEART J, V21, P1514, DOI 10.1053/euhj.1999.2045; Tateishi J, 2000, CLIN CARDIOL, V23, P776, DOI 10.1002/clc.4960231016; Wiese S, 2000, CIRCULATION, V102, P3074; YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195; YOSHIMURA M, 1993, CIRCULATION, V87, P464, DOI 10.1161/01.CIR.87.2.464	30	1008	1057	1	15	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1014	1021		10.1056/NEJMoa011053	http://dx.doi.org/10.1056/NEJMoa011053			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586953	Bronze			2022-12-28	WOS:000171340400002
J	Mitrovic, VF; Sigmund, EE; Eschrig, M; Bachman, HN; Halperin, WP; Reyes, AP; Kuhns, P; Moulton, WG				Mitrovic, VF; Sigmund, EE; Eschrig, M; Bachman, HN; Halperin, WP; Reyes, AP; Kuhns, P; Moulton, WG			Spatially resolved electronic structure inside and outside the vortex cores of a high-temperature superconductor	NATURE			English	Article							SPIN-LATTICE RELAXATION; MIXED-STATE; YBA2CU3O7; NMR; DENSITY; LINES	Puzzling aspects of high-transition-temperature (high-T-c) superconductors include the prevalence of magnetism in the normal state and the persistence of superconductivity in high magnetic fields. Superconductivity and magnetism generally are thought to be incompatible, based on what is known about conventional superconductors. Recent results(1), however, indicate that antiferromagnetism can appear in the superconducting state of a high-T-c superconductor in the presence of an applied magnetic field. Magnetic fields penetrate a superconductor in the form of quantized flux lines, each of which represents a vortex of supercurrents. Superconductivity is suppressed in the core of the vortex and it has been suggested that antiferromagnetism might develop there(2). Here we report the results of a high-field nuclear-magnetic-resonance (NMR) imaging experiment(3-5) in which we spatially resolve the electronic structure of near-optimally doped YBa2Cu3O7-delta inside and outside vortex cores. Outside the cores, we rnd strong antiferromagnetic fluctuations, whereas inside we detect electronic states that are rather different from those found in conventional superconductors.	Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; Natl High Magnet Field Lab, Tallahassee, FL 32310 USA	Northwestern University; United States Department of Energy (DOE); Argonne National Laboratory; State University System of Florida; Florida State University	Halperin, WP (corresponding author), Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA.		Mitrovic, Vesna F/GWU-8281-2022; Eschrig, Matthias/B-4786-2009; Sigmund, Eric/E-1981-2013	Sigmund, Eric/0000-0001-6783-3611; Eschrig, Matthias/0000-0003-4954-5549				Arovas DP, 1997, PHYS REV LETT, V79, P2871, DOI 10.1103/PhysRevLett.79.2871; Brandt EH, 1997, PHYS REV LETT, V78, P2208, DOI 10.1103/PhysRevLett.78.2208; Curro NJ, 2000, PHYS REV B, V62, P3473, DOI 10.1103/PhysRevB.62.3473; Franz M, 1998, PHYS REV LETT, V80, P4763, DOI 10.1103/PhysRevLett.80.4763; HESS HF, 1989, PHYS REV LETT, V62, P214, DOI 10.1103/PhysRevLett.62.214; Lake B, 2001, SCIENCE, V291, P1759, DOI 10.1126/science.1056986; LESUEUR J, 1992, PHYSICA C, V191, P325, DOI 10.1016/0921-4534(92)90926-4; MAGGIOAPRILE I, 1995, PHYS REV LETT, V75, P2754, DOI 10.1103/PhysRevLett.75.2754; Mitrovic VF, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.024520; Morr DK, 2000, PHYS REV B, V61, pR882, DOI 10.1103/PhysRevB.61.R882; Pan SH, 2000, PHYS REV LETT, V85, P1536, DOI 10.1103/PhysRevLett.85.1536; Reyes AP, 1997, PHYS REV B, V55, P14737, DOI 10.1103/PhysRevB.55.R14737; Takigawa M, 1999, PHYS REV LETT, V83, P3057, DOI 10.1103/PhysRevLett.83.3057; VOLOVIK GE, 1993, JETP LETT+, V58, P469; Wortis R, 2000, PHYS REV B, V61, P12342, DOI 10.1103/PhysRevB.61.12342; Wu CJ, 2000, PHYS REV B, V62, P14427, DOI 10.1103/PhysRevB.62.14427	16	166	167	1	31	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					501	504		10.1038/35097039	http://dx.doi.org/10.1038/35097039			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586354				2022-12-28	WOS:000171340500041
J	Parkhill, J; Wren, BW; Thomson, NR; Titball, RW; Holden, MTG; Prentice, MB; Sebaihia, M; James, KD; Churcher, C; Mungall, KL; Baker, S; Basham, D; Bentley, SD; Brooks, K; Cerdeno-Tarraga, AM; Chillingworth, T; Cronin, A; Davies, RM; Davis, P; Dougan, G; Feltwell, T; Hamlin, N; Holroyd, S; Jagels, K; Karlyshev, AV; Leather, S; Moule, S; Oyston, PCF; Quail, M; Rutherford, K; Simmonds, M; Skelton, J; Stevens, K; Whitehead, S; Barrell, BG				Parkhill, J; Wren, BW; Thomson, NR; Titball, RW; Holden, MTG; Prentice, MB; Sebaihia, M; James, KD; Churcher, C; Mungall, KL; Baker, S; Basham, D; Bentley, SD; Brooks, K; Cerdeno-Tarraga, AM; Chillingworth, T; Cronin, A; Davies, RM; Davis, P; Dougan, G; Feltwell, T; Hamlin, N; Holroyd, S; Jagels, K; Karlyshev, AV; Leather, S; Moule, S; Oyston, PCF; Quail, M; Rutherford, K; Simmonds, M; Skelton, J; Stevens, K; Whitehead, S; Barrell, BG			Genome sequence of Yersinia pestis, the causative agent of plague	NATURE			English	Article							DNA-SEQUENCE; PSEUDOTUBERCULOSIS; ENTEROCOLITICA; VIRULENCE; IDENTIFICATION; INVASION; PLASMID; LOCUS; CELLS; SHOWS	The Gram-negative bacterium Yersinia pestis is the causative agent of the systemic invasive infectious disease classically referred to as plague(1), and has been responsible for three human pandemics: the Justinian plague (sixth to eighth centuries), the Black Death (fourteenth to nineteenth centuries) and modern plague (nineteenth century to the present day). The recent identification of strains resistant to multiple drugs(2) and the potential use of Y. pestis as an agent of biological warfare mean that plague still poses a threat to human health. Here we report the complete genome sequence of Y. pestis strain CO92, consisting of a 4.65-megabase (Mb) chromosome and three plasmids of 96.2 kilobases (kb), 70.3 kb and 9.6 kb. The genome is unusually rich in insertion sequences and displays anomalies in GC base-composition bias, indicating frequent intragenomic recombination. Many genes seem to have been acquired from other bacteria and viruses (including adhesins, secretion systems and insecticidal toxins). The genome contains around 150 pseudogenes, many of which are remnants of a redundant enteropathogenic lifestyle. The evidence of ongoing genome fluidity, expansion and decay suggests Y. pestis is a pathogen that has undergone large-scale genetic flux and provides a unique insight into the ways in which new and highly virulent pathogens evolve.	Sanger Ctr, Cambridge CB10 1SA, England; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Chem & Biol Sci, Salisbury SP4 0JQ, Wilts, England; St Bartholomews & Royal London Sch Med & Dent, Dept Med Microbiol, London EC1A 7BE, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ctr Mol Microbiol & Infect, London SW7 2AZ, England	Wellcome Trust Sanger Institute; University of London; London School of Hygiene & Tropical Medicine; University of London; Queen Mary University London; Imperial College London	Parkhill, J (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.		Rutherford, Kim/Y-7995-2018; Holden, Matthew TG/K-6449-2014; Quail, michael/ABE-6131-2020; Prentice, Michael/AAE-7246-2019; Parkhill, Julian/G-4703-2011; Karlyshev, Andrey/D-2797-2011; Sebaihia, Mohammed/AAF-6589-2019; Thomson, Nicholas/P-5988-2014	Rutherford, Kim/0000-0001-6277-726X; Holden, Matthew TG/0000-0002-4958-2166; Prentice, Michael/0000-0003-1117-2388; Parkhill, Julian/0000-0002-7069-5958; Karlyshev, Andrey/0000-0003-3124-019X; Sebaihia, Mohammed/0000-0002-3324-3346; Baker, Stephen/0000-0003-1308-5755; Davis, Paul/0000-0001-5545-0824; Thomson, Nicholas/0000-0002-4432-8505; Davies, Robert/0000-0002-9983-1378; Cerdeno-Tarraga, Ana M./0000-0001-6635-3237				Achtman M, 1999, P NATL ACAD SCI USA, V96, P14043, DOI 10.1073/pnas.96.24.14043; Buchrieser C, 1999, INFECT IMMUN, V67, P4851, DOI 10.1128/IAI.67.9.4851-4861.1999; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cowan C, 2000, INFECT IMMUN, V68, P4523, DOI 10.1128/IAI.68.8.4523-4530.2000; Darwin AJ, 1999, MOL MICROBIOL, V32, P51, DOI 10.1046/j.1365-2958.1999.01324.x; DOLL JM, 1994, AM J TROP MED HYG, V51, P109, DOI 10.4269/ajtmh.1994.51.109; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; Guiyoule A, 1997, J CLIN MICROBIOL, V35, P2826, DOI 10.1128/JCM.35.11.2826-2833.1997; Haller JC, 2000, MOL MICROBIOL, V36, P1436, DOI 10.1046/j.1365-2958.2000.01964.x; Henderson IR, 1999, MOL MICROBIOL, V33, P919, DOI 10.1046/j.1365-2958.1999.01555.x; Hinnebusch J, 2000, INT J MED MICROBIOL, V290, P483, DOI 10.1016/S1438-4221(00)80070-3; Lerm M, 2000, FEMS MICROBIOL LETT, V188, P1; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; McDonough KA, 1997, J BACTERIOL, V179, P2081, DOI 10.1128/jb.179.6.2081-2085.1997; Mecsas J, 2001, INFECT IMMUN, V69, P2779, DOI 10.1128/IAI.67.5.2779-2787.2001; Nesper J, 2001, INFECT IMMUN, V69, P435, DOI 10.1128/IAI.69.1.435-445.2001; Odaert M, 1996, J CLIN MICROBIOL, V34, P2231, DOI 10.1128/JCM.34.9.2231-2235.1996; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; PIERSON DE, 1994, J BACTERIOL, V176, P4043, DOI 10.1128/JB.176.13.4043-4051.1994; Prentice MB, 2001, J BACTERIOL, V183, P2586, DOI 10.1128/JB.183.8.2586-2594.2001; Sebbane F, 2001, INFECT IMMUN, V69, P170, DOI 10.1128/IAI.69.1.170-176.2001; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; Skurnik M, 2000, MOL MICROBIOL, V37, P316, DOI 10.1046/j.1365-2958.2000.01993.x; TOROSIAN SD, 1996, 96 GEN M AM SOC MICR, P191; Townsend SM, 2001, INFECT IMMUN, V69, P2894, DOI 10.1128/IAI.69.5.2894-2901.2001; WACHTEL MR, 1995, INFECT IMMUN, V63, P2541, DOI 10.1128/IAI.63.7.2541-2548.1995; Wang P, 1997, P NATL ACAD SCI USA, V94, P6977, DOI 10.1073/pnas.94.13.6977; Waterfield NR, 2001, TRENDS MICROBIOL, V9, P185, DOI 10.1016/S0966-842X(01)01978-3; Young GM, 2000, INFECT IMMUN, V68, P4323, DOI 10.1128/IAI.68.7.4323-4326.2000	30	934	2060	4	145	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					523	527		10.1038/35097083	http://dx.doi.org/10.1038/35097083			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586360	Green Accepted, hybrid			2022-12-28	WOS:000171340500047
J	Schwetz, BA				Schwetz, BA			Hypercalcemia of malignancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	4	4	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1569	1569		10.1001/jama.286.13.1569-b	http://dx.doi.org/10.1001/jama.286.13.1569-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585463				2022-12-28	WOS:000171340600005
J	Brodsky, RA; Sensenbrenner, LL; Smith, BD; Dorr, D; Seaman, PJ; Lee, SM; Karp, JE; Brodsky, I; Jones, RJ				Brodsky, RA; Sensenbrenner, LL; Smith, BD; Dorr, D; Seaman, PJ; Lee, SM; Karp, JE; Brodsky, I; Jones, RJ			Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; TERM-FOLLOW-UP; ANTITHYMOCYTE GLOBULIN; ANTILYMPHOCYTE GLOBULIN; IMMUNOSUPPRESSIVE TREATMENT; CYCLOSPORINE	Background: severe aplastic anemia is a life-threatening bone marrow failure disorder. High-dose cyclophosphamide therapy followed by allogeneic bone marrow transplantation cures the disease. However, it requires a suitable donor and carries the risk for graft-versus-host disease. A small pilot study demonstrated that high-dose cyclophosphamide therapy without bone marrow transplantation leads to durable, treatment-free complete remission. Objective: To confirm the safety and efficacy of high-dose cyclophosphamide therapy alone in patients with severe aplastic anemia. Design: Uncontrolled clinical trial. Setting: Three tertiary care hospitals. Patients: 19 patients with untreated severe aplastic anemia. Intervention: Cyclophosphamide, 50 mg/kg of body weight per day for 4 consecutive days. Measurements: Probability of response and overall survival were measured. Complete remission was defined as normal blood count for age and sex. Partial remission was defined as independence from transfusion and an absolute neutrophil count greater than 0.5 x 10(9) cells/L without growth factor support. Nonresponders were patients who remained transfusion dependent or died. Relapse was defined as no longer meeting criteria for partial or complete remission. Results: The median time to an absolute neutrophil count of 0.5 x 109 cells/L was 49 days. The probability of survival was 84% (95% Cl, 59% to 95%) at 24 months. The probability of achieving treatment-free remission was 73% (Cl, 51% to 91%) at 24 months, and the probability of achieving complete remission was 65% (Cl, 39% to 89%) at 50 months. No responding patients have had relapse or have developed secondary clonal disorders. Conclusions: High-dose cyclophosphamide therapy without bone marrow transplantation produces durable treatment-free remission in severe aplastic anemia. This approach deserves further study in patients with severe aplastic anemia who are not suitable candidates for allogeneic bone marrow transplantation.	Johns Hopkins Oncol Ctr, Baltimore, MD USA; Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Med Coll Penn & Hahnemann Univ, Philadelphia, PA USA	Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; Drexel University	Brodsky, RA (corresponding author), Johns Hopkins Oncol Ctr, Bunting Blaustein Canc Res Bldg,Room 242,1650 Orl, Baltimore, MD USA.	rbrodsky@jhmi.edu			NCI NIH HHS [CA70970] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacigalupo A, 2000, SEMIN HEMATOL, V37, P69, DOI 10.1016/S0037-1963(00)90031-3; Bacigalupo A, 2000, BLOOD, V95, P1931, DOI 10.1182/blood.V95.6.1931; Brodsky RA, 1996, BLOOD, V87, P491, DOI 10.1182/blood.V87.2.491.bloodjournal872491; Brodsky RA, 2001, TRANSPLANTATION, V71, P482, DOI 10.1097/00007890-200102150-00025; Brodsky RA, 1998, ANN INTERN MED, V129, P1031, DOI 10.7326/0003-4819-129-12-199812150-00007; CAMITTA BM, 1979, BLOOD, V53, P504; Deeg HJ, 1998, BLOOD, V91, P3637; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; Doney K, 1997, ANN INTERN MED, V126, P107, DOI 10.7326/0003-4819-126-2-199701150-00003; Frickhofen N, 2000, SEMIN HEMATOL, V37, P56, DOI 10.1053/shem.2000.0370056; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; Nakao S, 1997, BLOOD, V89, P3691, DOI 10.1182/blood.V89.10.3691.3691_3691_3699; Ohara A, 1997, BLOOD, V90, P1009, DOI 10.1182/blood.V90.3.1009.1009_1009_1013; Passweg JR, 1997, BLOOD, V90, P858; ROSENFELD SJ, 1995, BLOOD, V85, P3058, DOI 10.1182/blood.V85.11.3058.bloodjournal85113058; Rosenfeld SJ, 1997, BLOOD, V90, P1929; SCHREIBER B, 1985, DIAGN MICR INFEC DIS, V3, P1, DOI 10.1016/0732-8893(85)90060-4; SCHREZENMEIER H, 1993, BRIT J HAEMATOL, V85, P371, DOI 10.1111/j.1365-2141.1993.tb03181.x; Sobocinski K A, 1994, J Hematother, V3, P95, DOI 10.1089/scd.1.1994.3.95; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; Storb R, 1997, BLOOD, V89, P3890, DOI 10.1182/blood.V89.10.3890.3890_3890_3890; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; Tichelli A, 1998, BRIT J HAEMATOL, V100, P393, DOI 10.1046/j.1365-2141.1998.00578.x; Tisdale JF, 2000, LANCET, V356, P1554, DOI 10.1016/S0140-6736(00)03126-3; Young NS, 1999, JAMA-J AM MED ASSOC, V282, P271, DOI 10.1001/jama.282.3.271; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501	26	78	89	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					477	483		10.7326/0003-4819-135-7-200110020-00006	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	477EF	11578150				2022-12-28	WOS:000171269600001
J	Taguchi, A; Sharma, N; Saleem, RM; Sessler, DI; Carpenter, RL; Seyedsadr, M; Kurz, A				Taguchi, A; Sharma, N; Saleem, RM; Sessler, DI; Carpenter, RL; Seyedsadr, M; Kurz, A			Selective postoperative inhibition of gastrointestinal opioid receptors.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL NALOXONE; CONTROLLED TRIAL; MORPHINE; ILEUS; CONSTIPATION; MOTILITY; METHYLNALTREXONE; ANALGESIA; COLON	Background: Postoperative recovery of gastrointestinal function and resumption of oral intake are critical determinants of the length of hospital stay. Although opioids are effective treatments for postoperative pain, they contribute to the delayed recovery of gastrointestinal function. Methods: We studied the effects of ADL 8-2698, an investigational opioid antagonist with limited oral absorption that does not readily cross the blood-brain barrier, on postoperative gastrointestinal function and the length of hospitalization. We randomly assigned 79 patients - including 1 whose surgery was canceled - to receive one capsule containing 1 mg or 6 mg of ADL 8-2698 or an identical-appearing placebo capsule two hours before major abdominal surgery and then twice daily until the first bowel movement or until discharge from the hospital. Data were analyzed for 26 patients in each of the three groups; all received opioids for postoperative pain relief. Observers who were unaware of the group assignments evaluated the outcomes. Results: Fifteen patients underwent partial colectomy and 63 underwent total abdominal hysterectomy. Patients given 6 mg of ADL 8-2698 had significantly faster recovery of gastrointestinal function than those given placebo. The median time to the first passage of flatus decreased from 70 to 49 hours (P=0.03), the median time to the first bowel movement decreased from 111 to 70 hours (P=0.01), and the median time until patients were ready for discharge decreased from 91 to 68 hours (P=0.03). Effects in the group that received 1 mg of ADL 8-2698 were less pronounced. Conclusions: Selective inhibition of gastrointestinal opioid receptors by an antagonist with limited oral absorption that does not readily cross the blood-brain barrier speeds recovery of bowel function and shortens the duration of hospitalization. (N Engl J Med 2001;345:935-40.) Copyright (C) 2001 Massachusetts Medical Society.	Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA; Univ Louisville, Dept Anesthesiol, Louisville, KY 40292 USA; Univ Louisville, Outcomes Res Inst, Louisville, KY 40292 USA; Univ Vienna, Dept Anesthesia & Gen Intens Care, Vienna, Austria; Adolor, Exton, PA USA	Washington University (WUSTL); University of Louisville; University of Louisville; University of Vienna	Kurz, A (corresponding author), Washington Univ, Dept Anesthesiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	kurza@mnotes.wustl.edu	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077; Kurz, Andrea/0000-0001-5887-3099	NIGMS NIH HHS [GM 58273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058273] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKENHEAD A R, 1984, Anesthesiology (Hagerstown), V61, pA381, DOI 10.1097/00000542-198409001-00381; Barr WH, 2000, CLIN PHARMACOL THER, V67, P91; Bungard TJ, 1999, PHARMACOTHERAPY, V19, P416, DOI 10.1592/phco.19.6.416.31040; Cali RL, 2000, DIS COLON RECTUM, V43, P163, DOI 10.1007/BF02236975; Cox DR., 1970, ANAL BINARY DATA; CULPEPPERMORGAN JA, 1992, CLIN PHARMACOL THER, V52, P90, DOI 10.1038/clpt.1992.106; FERRAZ AAB, 1995, DIGEST DIS SCI, V40, P1417, DOI 10.1007/BF02285185; FRANTZIDES CT, 1992, AM J SURG, V163, P144, DOI 10.1016/0002-9610(92)90267-U; Gan TJ, 1997, ANESTHESIOLOGY, V87, P1075, DOI 10.1097/00000542-199711000-00011; Gibbons JD, 1992, NONPARAMETRIC STAT I; Holte K, 2000, BRIT J SURG, V87, P1480, DOI 10.1046/j.1365-2168.2000.01595.x; Joshi GP, 1999, ANESTHESIOLOGY, V90, P1007, DOI 10.1097/00000542-199904000-00013; Liu SS, 2001, CLIN PHARMACOL THER, V69, P66, DOI 10.1067/mcp.2001.112680; LIVINGSTON EH, 1990, DIGEST DIS SCI, V35, P121, DOI 10.1007/BF01537233; Meissner W, 2000, PAIN, V84, P105, DOI 10.1016/S0304-3959(99)00185-2; Resnick J, 1997, AM J GASTROENTEROL, V92, P934; SAS Institute, 1999, SAS STAT US GUID VER; SCHANG JC, 1986, LIFE SCI, V38, P671, DOI 10.1016/0024-3205(86)90580-1; Sykes NP, 1996, PALLIATIVE MED, V10, P135, DOI 10.1177/026921639601000208; Thorn SE, 1996, ACTA ANAESTH SCAND, V40, P177, DOI 10.1111/j.1399-6576.1996.tb04417.x; WATTWIL M, 1989, ACTA CHIR SCAND, P140; WOODS JH, 1978, SURGERY, V84, P527; Woods MS, 2000, PERSPECT COLON RECTA, V12, P57; Yuan CS, 2000, JAMA-J AM MED ASSOC, V283, P367, DOI 10.1001/jama.283.3.367; Yuan CS, 1996, CLIN PHARMACOL THER, V59, P469, DOI 10.1016/S0009-9236(96)90117-4; ZIMMERMAN DM, 1994, J MED CHEM, V37, P2262, DOI 10.1021/jm00041a003	26	214	248	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2001	345	13					935	940		10.1056/NEJMoa010564	http://dx.doi.org/10.1056/NEJMoa010564			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475NF	11575284				2022-12-28	WOS:000171170000001
J	Mickisch, GHJ; Garin, A; van Poppel, H; de Prijck, L; Sylvester, R				Mickisch, GHJ; Garin, A; van Poppel, H; de Prijck, L; Sylvester, R		European Org Res Treatment Canc EO	Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial	LANCET			English	Article							CYTOREDUCTIVE SURGERY; INTERLEUKIN-2; THERAPY	Background Surgery is the main treatment for localised renal cell carcinoma, but use of radical nephrectomy for metastatic disease is highly controversial. We aimed to establish whether radical nephrectomy done before interferon-alfa-based immunotherapy improved time to progression and overall survival (primary endpoints) compared with interferon alfa alone. Methods We included 85 patients from June, 1995, to July, 1998: two (one per group) were ineligible. 42 of the 83 participants were randomly assigned combined treatment (study group) and 43 immunotherapy alone (controls). All patients had metastatic renal-cell carcinoma that had been histologically confirmed and was progressive at entry. In study patients, surgery was done within 4 weeks of randomisation, and immunotherapy (5x10(6) IU/m(2) subcutaneously three times per week) started 2-4 weeks later. In controls, immunotherapy was started within 1 working day of randomisation. Follow-up visits were monthly. All analyses were by intention to treat. Findings 40 (53%) of 75 patients received at least 16 weeks of interferon-alfa treatment, which was also the median duration of treatment. Time to progression (5 vs 3 months, hazard ratio 0.60, 95% CI 0.36-0.97) and median duration of survival were significantly better in study patients than in controls (17 vs 7 months, 0.54, 0.31-0.94). Five patients responded completely to combined treatment, and one to interferon alfa alone. Dose modification was necessary in 32% of patients, most commonly because of non-haematological side-effects. Interpretation Radical nephrectomy before interferon-based immunotherapy might substantially delay time to progression and improve survival of patients with metastatic renal cell carcinoma who present with good performance status.	Erasmus Univ, Dept Urol, NL-3015 GD Rotterdam, Netherlands; Acad Hosp Rotterdam Dijkzigt, Dept Urol, NL-3015 GD Rotterdam, Netherlands; Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia; UZ Gasthuisberg, Louvain, Belgium; EORTC Data Ctr, Brussels, Belgium	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Russian Academy of Medical Sciences; KU Leuven; University Hospital Leuven; European Organisation for Research & Treatment of Cancer	Mickisch, GHJ (corresponding author), Erasmus Univ, Dept Urol, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.				NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER; NCI NIH HHS [2U10 CA11488-28, 2U10 CA11488-25, 5U10 CA11488-24, 5U10 CA11488-30, 5U10 CA11488-29, 5U10 CA11488-27, 5U10 CA11488-26] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT RT, 1995, J UROLOGY, V154, P32, DOI 10.1016/S0022-5347(01)67217-3; Fallick ML, 1997, J UROLOGY, V158, P1691, DOI 10.1016/S0022-5347(01)64097-7; FLANIGAN RC, 2000, J UROL S4, V163, P685; Joffe JK, 1996, BRIT J UROL, V77, P638, DOI 10.1046/j.1464-410X.1996.09573.x; Mickisch GH, 1999, UROL INT, V63, P16, DOI 10.1159/000030413; MICKISCH GH, 1998, EUR UROL UPDATE SER, V7, P115; Motzer RJ, 2000, J CLIN ONCOL, V18, P1928, DOI 10.1200/JCO.2000.18.9.1928; OCONNELL JR, 1996, SEMIN ONCOL, V23, P17; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; SCHELTEMA JMW, 1997, EUR UROL UPDATE SERI, V6, P27; TANEJA SS, 1995, UROLOGY, V45, P911, DOI 10.1016/S0090-4295(99)80108-3; Tigrani VS, 2000, UROLOGY, V55, P36, DOI 10.1016/S0090-4295(99)00395-7; Van Poppel H, 1996, Acta Urol Belg, V64, P11; Wagner JR, 1999, J UROLOGY, V162, P43, DOI 10.1097/00005392-199907000-00011; Walther MM, 1999, UROLOGY, V53, P496, DOI 10.1016/S0090-4295(98)00562-7; Walther MM, 1997, J UROLOGY, V158, P1675, DOI 10.1016/S0022-5347(01)64091-6	16	1035	1065	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					966	970		10.1016/S0140-6736(01)06103-7	http://dx.doi.org/10.1016/S0140-6736(01)06103-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583750				2022-12-28	WOS:000171135300017
J	Pfisterer, M; Bertel, O; Erne, P; Goy, JJ; Kuster, G; Rickenbacher, P; Schindler, C; Schonenberger, R; Allemann, U; Amann, W; Angehrn, W; Estlinbaum, W; Moccetti, T; Ricou, F; Buser, P; Osswald, S; Zerkowski, HR; Brett, W; Knutti, U; Kaiser, C; Vuillomenet, A; Yoon, S; Eberli, F; Schlapfer, H; Rothlisberger, C; Hess, N; Dubach, P; Sixt, S; Allemann, U; Gradel, C; Eeckhout, E; Kloter, U; Moccetti, D; Friesewinkel, O; Genoni, M; Naegeli, B; Amann, W; Kiowski, W; Botschi, M; Turina, M; Bader, F; Dreifuss, P; Forrer-Christ, U; Hagmann, A; Osterwalder, R; Mughal, F; Schob, L; Burckhardt, D; Follath, F; Rutishauser, W; Schindler, C; Grize, L; Schonenberger, R; Mark, D				Pfisterer, M; Bertel, O; Erne, P; Goy, JJ; Kuster, G; Rickenbacher, P; Schindler, C; Schonenberger, R; Allemann, U; Amann, W; Angehrn, W; Estlinbaum, W; Moccetti, T; Ricou, F; Buser, P; Osswald, S; Zerkowski, HR; Brett, W; Knutti, U; Kaiser, C; Vuillomenet, A; Yoon, S; Eberli, F; Schlapfer, H; Rothlisberger, C; Hess, N; Dubach, P; Sixt, S; Allemann, U; Gradel, C; Eeckhout, E; Kloter, U; Moccetti, D; Friesewinkel, O; Genoni, M; Naegeli, B; Amann, W; Kiowski, W; Botschi, M; Turina, M; Bader, F; Dreifuss, P; Forrer-Christ, U; Hagmann, A; Osterwalder, R; Mughal, F; Schob, L; Burckhardt, D; Follath, F; Rutishauser, W; Schindler, C; Grize, L; Schonenberger, R; Mark, D		TIME Investigators	Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial	LANCET			English	Article							QUALITY-OF-LIFE; 3-YEAR FOLLOW-UP; MYOCARDIAL-INFARCTION; BYPASS-SURGERY; ANGIOPLASTY; ANGINA; REVASCULARIZATION; SURVIVAL; OUTCOMES; AGE	Background Since previous randomised treatment trials in coronary disease have focused on patients younger than 75 years of age, their findings might not apply to the elderly population in whom the cardiac risk profile, risk of intervention, and comorbidities are increased. We aimed to assess quality of life and outcome of elderly patients with coronary disease after medical or revascularisation therapy. Methods In this randomised, prospective, multicentre trial, we enrolled patients aged 75 years or older with chronic angina of at least Canadian Cardiac Society class II despite at least two antianginal drugs. Patients were randomly assigned coronary angiography and revascularlsation or optimised medical therapy. The primary endpoint was quality of life after 6 months, as assessed by questionnaire and the presence of major adverse cardiac events (death, non-fatal myocardial infarction, or hospital admission for acute coronary syndrome with or without the need for revascularlsation). Analysis was by Intention to treat. Findings 150 patients were assigned medical therapy and 155 invasive therapy. Two protocol violators in each group were not included In the analysis. After 6 months, angina severity decreased and measures of quality of life increased in both treatment groups; however, these improvements were significantly greater after revascularisation. Major adverse cardiac events occurred in 72 (49%) of patients in the medical group and 29 (19%) in the invasive group (p<0.0001). Interpretation Patients aged 75 years or older with angina despite standard drug therapy benefit more from revascularlsation than from optimised medical therapy in terms of symptom relief and quality of life. Therefore, these patients should be offered invasive assessment despite their high risk profile followed by revascularisation If feasible.	Univ Basel Hosp, Div Cardiol, CH-4031 Basel, Switzerland; Univ Hosp Bern, CH-3010 Bern, Switzerland; Regionalspital Biel, Biel, Switzerland; Kantonsspital Bruderholz, Bruderholz, Switzerland; Kantonsspital Chur, Chur, Switzerland; Clara Hosp, Basel, Switzerland; Univ Lausanne Hosp, Lausanne, Switzerland; Kantonsspital Liestal, Liestal, Switzerland; Cardioctr Lugano, Lugano, Switzerland; Kantonsspital St Gallen, St Gallen, Switzerland; Triemli Hosp, Zurich, Switzerland; Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Univ Basel Hosp, Inst Social & Prevent Med, CH-4031 Basel, Switzerland; Kantonsspital Solothurn, Solothurn, Switzerland; Duke Univ, Durham, NC USA	University of Basel; University of Bern; University Hospital of Bern; Kantonsspital Baselland; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Kantonsspital Baselland; Triemli Hospital; University of Zurich; University Zurich Hospital; University of Basel; Duke University	Pfisterer, M (corresponding author), Univ Basel Hosp, Div Cardiol, CH-4031 Basel, Switzerland.	pfisterer@email.ch	Schindler, Christian/D-3472-2015; Kaiser, Christoph/AAA-9284-2022; Osswald, Stefan/A-6904-2018; Kuster, Gabriela M/AAB-5478-2022	Osswald, Stefan/0000-0002-9240-6731; Kuster, Gabriela M/0000-0002-8209-4631				ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; Alexander KP, 2000, J AM COLL CARDIOL, V35, P731, DOI 10.1016/S0735-1097(99)00606-3; [Anonymous], 1982, Lancet, V2, P1173; Batchelor WB, 2000, J AM COLL CARDIOL, V36, P723, DOI 10.1016/S0735-1097(00)00777-4; Blumenthal RS, 2000, J AM COLL CARDIOL, V36, P668, DOI 10.1016/S0735-1097(00)00791-9; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; Chamberlain DA, 1997, LANCET, V350, P461; FLETCHER A, 1988, LANCET, V2, P4; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; Hochman JS, 1999, NEW ENGL J MED, V341, P625, DOI 10.1056/NEJM199908263410901; Kolh P, 2001, EUR HEART J, V22, P1235, DOI 10.1053/euhj.2000.2443; Lee PY, 2001, JAMA-J AM MED ASSOC, V286, P708, DOI 10.1001/jama.286.6.708; Lefevre T, 1998, AM J CARDIOL, V82, P17, DOI 10.1016/S0002-9149(98)00236-7; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; MULLANY CJ, 1990, CIRCULATION, V82, P229; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEDUZZI P, 1992, CIRCULATION, V86, P121; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; Pitt B, 1999, NEW ENGL J MED, V341, P70, DOI 10.1056/NEJM199907083410202; Pocock SJ, 1996, CIRCULATION, V94, P135, DOI 10.1161/01.CIR.94.2.135; Pocock SJ, 2000, J AM COLL CARDIOL, V35, P907, DOI 10.1016/S0735-1097(99)00637-3; RIHAL CS, 1999, EVIDENCE BASED CARDI, P368; Rose G, 1982, CARDIOVASCULAR SURVE; *SEN SPEC COMM AG, 1991, AG AM TRENDS PROJ 19; SPENCER G, 1989, CURRENT POPULATI P25, V1018; STRAUSS WE, 1995, CIRCULATION, V92, P1710, DOI 10.1161/01.CIR.92.7.1710; Thompson RC, 1996, J AM COLL CARDIOL, V27, P8, DOI 10.1016/0735-1097(95)00436-X; *TIME INV, 2001, HEART DRUG, V1, P144; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; WEINTRAUB WS, 1995, CIRCULATION, V92, P2831, DOI 10.1161/01.CIR.92.10.2831; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	32	310	326	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 22	2001	358	9286					951	957						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583747				2022-12-28	WOS:000171135300014
J	Burghes, AHM; Vaessin, HEF; de la Chapelle, A				Burghes, AHM; Vaessin, HEF; de la Chapelle, A			Genetics - The land between Mendelian and multifactorial inheritance	SCIENCE			English	Editorial Material							BARDET-BIEDL-SYNDROME; SUSCEPTIBILITY; MUTATIONS; GENES		Ohio State Univ, Dept Mol & Cellular Biol, Columbus, OH 43210 USA; Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Neurobiotech Ctr, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Burghes, AHM (corresponding author), Ohio State Univ, Dept Mol & Cellular Biol, Columbus, OH 43210 USA.	burgh-es.1@osu.edu; vaessin.1@osu.edu; delachapelle-1@medctr.osu.edu		Burghes, Arthur/0000-0001-9031-1555				Alifragis P, 1997, P NATL ACAD SCI USA, V94, P13099, DOI 10.1073/pnas.94.24.13099; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Katsanis N, 2000, NAT GENET, V26, P67, DOI 10.1038/79201; McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465; Mykytyn K, 2001, NAT GENET, V28, P188, DOI 10.1038/88925; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; SCHRONS H, 1992, GENETICS, V132, P481; Sheffield VC, 2001, CURR OPIN GENET DEV, V11, P317, DOI 10.1016/S0959-437X(00)00196-9; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116; Stone DL, 2000, NAT GENET, V25, P79, DOI 10.1038/75637; Todd JA, 2001, NATURE, V411, P537, DOI 10.1038/35079223; Weatherall DJ, 2001, NAT REV GENET, V2, P245, DOI 10.1038/35066048	16	54	54	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2213	2214		10.1126/science.1065930	http://dx.doi.org/10.1126/science.1065930			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567125				2022-12-28	WOS:000171139400028
J	Deshpande, G; Swanhart, L; Chiang, P; Schedl, P				Deshpande, G; Swanhart, L; Chiang, P; Schedl, P			Hedgehog signaling in germ cell migration	CELL			English	Article							GONADAL MESODERM; CUBITUS-INTERRUPTUS; GENE-EXPRESSION; FAT-BODY; DROSOPHILA-MELANOGASTER; TRANSDUCING HEDGEHOG; MEMBRANE-PROTEIN; RECEPTOR COMPLEX; EMBRYONIC GONAD; NANOS	The primitive gonad of the Drosophila embryo is formed from two cell types, the somatic gonad precursor cells (SGPs) and the germ cells, which originate at distant sites. To reach the SGPs the germ cells must undergo a complex series of cell movements. While there is evidence that attractive and repulsive signals guide germ cell migration through the embryo, the molecular identity of these instructive molecules has remained elusive. Here, we present evidence suggesting that hedgehog (hh) may serve as such an attractive guidance cue. Misexpression of hh in the soma induces germ cells to migrate to inappropriate locations. Conversely, cell-autonomous components of the hh pathway appear to be required in the germline for proper germ cell migration.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Deshpande, G (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Alcedo J, 1997, BIOL CHEM, V378, P583; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Azpiazu N, 1996, GENE DEV, V10, P3183, DOI 10.1101/gad.10.24.3183; Boyle M, 1997, DEVELOPMENT, V124, P971; BOYLE M, 1995, DEVELOPMENT, V121, P1815; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broihier HT, 1998, DEVELOPMENT, V125, P655; BROOKMAN JJ, 1992, DEVELOPMENT, V116, P1185; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, DEVELOPMENT, V125, P4943; CHOU TB, 1992, GENETICS, V131, P643; Chuang PT, 2000, CURR OPIN GENET DEV, V10, P515, DOI 10.1016/S0959-437X(00)00121-0; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; DESHPANDE G, 1995, MOL CELL BIOL, V15, P4430; Deshpande G, 1999, CELL, V99, P271, DOI 10.1016/S0092-8674(00)81658-X; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Forbes A, 1998, DEVELOPMENT, V125, P679; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Howard K, 1998, NATURE, V396, P406, DOI 10.1038/24714; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; JAGLARZ MK, 1995, DEVELOPMENT, V121, P3495; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Kalderon D, 2000, CELL, V103, P371, DOI 10.1016/S0092-8674(00)00129-X; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; Kuwabara PE, 2000, GENE DEV, V14, P1933; LANE ME, 1995, MECH DEVELOP, V49, P191, DOI 10.1016/0925-4773(94)00317-G; Luer K, 1997, DEVELOPMENT, V124, P2681; Methot N, 2001, DEVELOPMENT, V128, P733; Moore LA, 1998, DEVELOPMENT, V125, P837; Moore LA, 1998, DEVELOPMENT, V125, P667; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Ramirez-Weber FA, 2000, MOL CELL, V6, P479, DOI 10.1016/S1097-2765(00)00046-0; Riechmann V, 1998, DEVELOPMENT, V125, P713; Sam S, 1996, MECH DEVELOP, V60, P197, DOI 10.1016/S0925-4773(96)00615-6; Seydoux G, 1999, DEVELOPMENT, V126, P3275; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; St Johnston Daniel, 1993, P325; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; Strigini M, 1997, DEVELOPMENT, V124, P4697; Struhl G, 1997, DEVELOPMENT, V124, P2155; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Van Doren M, 1998, NATURE, V396, P466, DOI 10.1038/24871; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wang QT, 2000, DEVELOPMENT, V127, P3131; WARRIOR R, 1994, DEV BIOL, V166, P180, DOI 10.1006/dbio.1994.1306; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0; Zhang N, 1996, GENETICS, V143, P1231	58	67	70	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 21	2001	106	6					759	769		10.1016/S0092-8674(01)00488-3	http://dx.doi.org/10.1016/S0092-8674(01)00488-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572781	Bronze			2022-12-28	WOS:000171213000012
J	Johnson, ES; Gupta, AA				Johnson, ES; Gupta, AA			An E3-like factor that promotes SUMO conjugation to the yeast septins	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; UBIQUITIN; PROTEIN; COMPLEX; ENZYME; HOMOLOG; GENE; ACTIVATION; COMPONENT; PATHWAY	Covalent attachment of the ubiquitin-related protein SUMO to other proteins participates in many processes including signal transduction, transcriptional regulation, and growth control. We report the characterization of Siz1 as an E3-like factor in the SUMO pathway. Siz1 is required for SUMO attachment to the S. cerevisiae septins in vivo and strongly stimulates septin sumoylation in vitro. Siz1 and the related protein Siz2 promote SUMO conjugation to different substrates at different stages of the cell cycle and, together, are required for most SUMO conjugation in yeast. Siz1, Siz2, and the PIAS (protein inhibitor of activated STAT) proteins form a conserved family defined by an unusual RING-related motif. Our results suggest that this family functions by promoting SUMO conjugation to specific substrates.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA	Jefferson University	Johnson, ES (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062268] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62268] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Betting J, 1996, J BIOL CHEM, V271, P25790, DOI 10.1074/jbc.271.42.25790; BUSCHMANN T, 2001, IN PRESS J BIOL CHEM; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson EW, 1997, J BACK MUSCULOSKELET, V9, P3, DOI 10.3233/BMR-1997-9102; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; PRINGLE J R, 1991, P565; Rosenblum JS, 1998, J CELL BIOL, V143, P887, DOI 10.1083/jcb.143.4.887; SAMPSON DA, 2001, J BIOL CHEM, V19, P19; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Sherman F., 1986, METHODS YEAST GENETI; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Smith J.A., 2000, CURRENT PROTOCOLS MO; Strunnikov AV, 2001, GENETICS, V158, P95; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; TATHAM MH, 2001, IN PRESS J BIOL CHEM; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; WHITE HD, 1993, BIOCHEMISTRY-US, V32, P9859, DOI 10.1021/bi00088a042; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	46	517	540	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 21	2001	106	6					735	744		10.1016/S0092-8674(01)00491-3	http://dx.doi.org/10.1016/S0092-8674(01)00491-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572779	Bronze			2022-12-28	WOS:000171213000010
J	Villeneuve, AM; Hillers, KJ				Villeneuve, AM; Hillers, KJ			Whence meiosis?	CELL			English	Review							MEIOTIC RECOMBINATION; YEAST; SYNAPSIS; PATHWAY	Sexual reproduction predominates among eukaryotic organisms on our planet. While debate continues over why this should be so, burgeoning genomic and functional information now allows us to begin to think reasonably about some of the events that may have occurred to make sex possible in the first place.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Villeneuve, AM (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.							Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; Grelon M, 2001, EMBO J, V20, P589, DOI 10.1093/emboj/20.3.589; Hartung F, 2001, GENE, V271, P81, DOI 10.1016/S0378-1119(01)00496-6; HAWLEY RS, 1980, GENETICS, V94, P625; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; McKim KS, 1998, SCIENCE, V279, P876, DOI 10.1126/science.279.5352.876; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; Novak JE, 2001, GENETICS, V158, P1013; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pochart P, 1997, J BIOL CHEM, V272, P30345, DOI 10.1074/jbc.272.48.30345; Riddle D. L, 1997, C ELEGANS, P47; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Thompson DA, 1999, GENETICS, V153, P621; Zalevsky J, 1999, GENETICS, V153, P1271; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619	20	189	196	0	22	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 21	2001	106	6					647	650		10.1016/S0092-8674(01)00500-1	http://dx.doi.org/10.1016/S0092-8674(01)00500-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572770	Bronze			2022-12-28	WOS:000171213000001
J	Matsumoto, K; Yoshitomi, H; Rossant, J; Zaret, KS				Matsumoto, K; Yoshitomi, H; Rossant, J; Zaret, KS			Liver organogenesis promoted by endothelial cells prior to vascular function	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; ANGIOGENESIS INHIBITOR; TIE2 RECEPTOR; ANGIOPOIETIN-1; VASCULOGENESIS; ANTAGONIST; HGF/NK4; LIGAND; FLK-1	The embryonic role of endothelial cells and nascent vessels in promoting organogenesis, prior to vascular function, is unclear. We find that early endothelial cells in mouse embryos surround newly specified hepatic endoderm and delimit the mesenchymal domain into which the Liver bud grows. In flk-1 mutant embryos, which lack endothelial cells, hepatic specification occurs, but liver morphogenesis fails prior to mesenchyme invasion. We developed an embryo tissue explant system that permits liver bud vasculogenesis and show that in the absence of endothelial cells, or when the latter are inhibited, there is a selective defect in hepatic outgrowth. We conclude that vasculogenic endothelial cells and nascent vessels are critical for the earliest stages of organogenesis, prior to blood vessel function.	Fox Chase Canc Ctr, Program Cell & Dev Biol, Philadelphia, PA 19111 USA; Osaka Univ, Grad Sch Med, Course Adv Med, Div Mol Regenerat Med, Osaka 5650871, Japan; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5T 1K5, Canada	Fox Chase Cancer Center; Osaka University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Zaret, KS (corresponding author), Fox Chase Canc Ctr, Program Cell & Dev Biol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	zaret@fccc.edu	Yoshitomi, Hideyuki/AAN-8812-2020; Matsumoto, Kunio/D-8441-2015	Yoshitomi, Hideyuki/0000-0003-2911-8056; Matsumoto, Kunio/0000-0002-6532-4482	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036477, R01GM036477] Funding Source: NIH RePORTER; NCI NIH HHS [CA06297] Funding Source: Medline; NIGMS NIH HHS [GM36477] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbera JPM, 2000, DEVELOPMENT, V127, P2433; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; KINGSBURY JW, 1956, ANAT RECORD, V124, P165, DOI 10.1002/ar.1091240204; Kuba K, 2000, CANCER RES, V60, P6737; LEDOUARIN NM, 1975, MED BIOL, V53, P427; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; OELRICHS RB, 1993, ONCOGENE, V8, P11; Ohmichi H, 1998, DEVELOPMENT, V125, P1315; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PAUL J, 1969, CELL TISSUE KINET, V2, P283, DOI 10.1111/j.1365-2184.1969.tb00238.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROSS MA, IN PRESS HEPATOLOGY; Rossi JM, 2001, GENE DEV, V15, P1998, DOI 10.1101/gad.904601; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHERER GK, 1975, DEV BIOL, V46, P281, DOI 10.1016/0012-1606(75)90105-0; SHERER GK, 1991, DEV VASCULAR SYSTEM, V14, P37; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takebayashi-Suzuki K, 2000, DEVELOPMENT, V127, P3523; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; WIDMANN JJ, 1975, AM J PATHOL, V80, P349; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YAMANE A, 1994, ONCOGENE, V9, P2683	31	611	646	4	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 19	2001	294	5542					559	563		10.1126/science.1063889	http://dx.doi.org/10.1126/science.1063889			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	484NC	11577199				2022-12-28	WOS:000171695600037
J	Yusuf, S; Gerstein, H; Hoogwerf, B; Pogue, J; Bosch, J; Wolffenbuttel, BHR; Zinman, B				Yusuf, S; Gerstein, H; Hoogwerf, B; Pogue, J; Bosch, J; Wolffenbuttel, BHR; Zinman, B		HOPE Study Investigators	Ramipril and the development of diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSULIN SENSITIVITY; GLUCOSE-TRANSPORT; ACE-INHIBITION; CAPTOPRIL; THERAPY; MUSCLE	Context Type 2 diabetes is a growing clinical and public health problem. Preventive efforts related to lifestyle modification are not always successful; therefore, alternative prevention strategies need to be studied. Objective To investigate the effectiveness of ramipril, an angiotensin-converting-enzyme inhibitor, in preventing diabetes among high-risk persons. Design, Setting, and Participants The randomized, controlled Heart Outcomes Prevention Evaluation trial of 5720 patients older than 55 years without known diabetes but with vascular disease who were followed up for a mean of 4.5 years. The study included 267 hospitals in 19 countries and was conducted between 1994 and 1999. Intervention Patients were randomly assigned to receive ramipril, up to 10 mg/d (n = 2837), or placebo (n = 2883). Main Outcome Measure Diagnosis of diabetes determined from self-report at follow-up visits every 6 months, compared between the 2 groups. Results one hundred and two individuals (3.6%) in the ramipril group developed diabetes compared with 155 (5.4%) in the placebo group (relative risk [RR], 0.66; 95% confidence interval [CI], 0.51-0.85, P<.001). Similar results were noted when different diagnostic criteria were used; in the ramipril group, the RR for diagnosis of diabetes and hemoglobin A(1c) greater than 110% was 0.60 (95% Cl, 0.43-0.85), for initiation of glucose-lowering therapy, 0.56 (95% CI, 0.41-0.77), and for both, 0.51 (95% CI, 0.34-0.76). These effects were also consistently seen in several subgroups examined. Conclusions Ramipril is associated with lower rates of new diagnosis of diabetes in high-risk individuals. Because these results have important clinical and public health implications, this hypothesis requires prospective confirmation.	McMaster Univ, Hamilton, ON, Canada; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Clin Maastricht, Maastricht, Netherlands; Toronto Hosp, Toronto, ON M5T 2S8, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	McMaster University; Cleveland Clinic Foundation; Maastricht University; Maastricht University Medical Centre (MUMC); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Yusuf, S (corresponding author), Hamilton Gen Hosp, Canadian Cardiovasc Collaborat Project Off, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca	Wolffenbuttel, Bruce/A-8419-2011; Zinman, Bernard/E-7266-2013; Gerstein, Hertzel/ABB-8781-2020; Gerstein, Hertzel C/B-1235-2013; Bosch, Jacqueline/AAP-6910-2021	Wolffenbuttel, Bruce/0000-0001-9262-6921; Gerstein, Hertzel/0000-0001-8072-2836; Gerstein, Hertzel C/0000-0001-8072-2836; Bosch, Jacqueline/0000-0001-6292-4207; Yusuf, Salim/0000-0003-4776-5601				Baron AD, 1999, AM J CARDIOL, V84, p25J; Carlsson PO, 1998, DIABETOLOGIA, V41, P127, DOI 10.1007/s001250050880; FERRANNINI E, 1994, J CARDIOVASC PHARM, V24, pS61; Fogari R, 1998, BRIT J CLIN PHARMACO, V46, P467, DOI 10.1046/j.1365-2125.1998.00811.x; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; *HEART OUTC PREV E, 2000, LANCET, V255, P253; Henriksen EJ, 1999, AM J PHYSIOL-REG I, V277, pR332, DOI 10.1152/ajpregu.1999.277.1.R332; HENRIKSEN EJ, 1995, METABOLISM, V44, P267, DOI 10.1016/0026-0495(95)90276-7; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Lonn E., 2000, Canadian Journal of Cardiology, V16, p233F; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; PEDERSEN TR, 1994, LANCET, V344, P1383; Ray NF, 1998, DIABETES CARE, V21, P296; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Stearne MR, 1998, BRIT MED J, V317, P713; TORLONE E, 1991, DIABETOLOGIA, V34, P119, DOI 10.1007/BF00500383; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; VUORINENMARKKOLA H, 1995, METABOLISM, V44, P85, DOI 10.1016/0026-0495(95)90293-7; Yusuf S, 2000, NEW ENGL J MED, V342, P145	19	390	412	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2001	286	15					1882	1885		10.1001/jama.286.15.1882	http://dx.doi.org/10.1001/jama.286.15.1882			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	482UH	11597291	Bronze			2022-12-28	WOS:000171595300030
J	Marshall, E				Marshall, E			After the prize - For winners, a new life of opportunity - and perils	SCIENCE			English	News Item																			0	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					293	+		10.1126/science.294.5541.293	http://dx.doi.org/10.1126/science.294.5541.293			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598284				2022-12-28	WOS:000171601400013
J	Wang, YQ; Hu, YM; Meng, J; Li, C				Wang, YQ; Hu, YM; Meng, J; Li, C			An ossified Meckel's cartilage in two cretaceous mammals and origin of the mammalian middle ear	SCIENCE			English	Article							EVOLUTION; MORGANUCODON	An ossified Meckel's cartilage has been recovered from two early Cretaceous mammals from China. This element is similar to Meckel's cartilage in prenatal and some postnatal extant mammals and indicates the relationship of Meckel's cartilage with the middle ear in early mammals, The evidence shows that brain expansion may not be the initial factor that caused the separation of postdentary bones from the dentary as middle ear ossicles during mammalian evolution. The failure of the dentary to seize reduced postdentary elements during ontogeny of early mammals is postulated as an alternative mechanism for the separation. Modifications of both feeding and hearing apparatuses in early mammals may have led to the development of the definitive mammalian middle ear.	Chinese Acad Sci, IVPP, Beijing 100044, Peoples R China; Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; CUNY City Coll, New York, NY 10016 USA; CUNY, Grad Sch, Biol Program Ecol Evolutionary Biol & Behav, New York, NY 10016 USA	Chinese Academy of Sciences; American Museum of Natural History (AMNH); City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System	Wang, YQ (corresponding author), Chinese Acad Sci, IVPP, POB 643, Beijing 100044, Peoples R China.	wang.yuanqing@pa.ivpp.ac.cn; jmeng@amnh.org						ALLIN EF, 1992, EVOLUTIONARY BIOLOGY OF HEARING, P587; ALLIN EF, 1975, J MORPHOL, V147, P403, DOI 10.1002/jmor.1051470404; BARGHUSEN HR, 1970, SCIENCE, V168, P573, DOI 10.1126/science.168.3931.573; CLARK CT, 1993, J MORPHOL, V215, P119, DOI 10.1002/jmor.1052150203; CROMPTON A. W., 1963, PROC ZOOL SOC LONDON, V140, P697; CROMPTON AW, 1985, ZOOL J LINN SOC-LOND, V85, P99, DOI 10.1111/j.1096-3642.1985.tb01500.x; Crompton AW, 1993, MAMMAL PHYLOGENY, V1, P30, DOI DOI 10.1007/978-1-4613-9249-1; Gambaryan Petr P., 1995, Acta Palaeontologica Polonica, V40, P45; Gaupp EWT, 1913, REICHERTSCHE THEORIE; Goodrich ES., 1930, STUDIES STRUCTURE DE, DOI [DOI 10.5962/BHL.TITLE.82144, 10.5962/bhl.title.82144]; HOPSON JA, 1966, AM ZOOL, V6, P437; Hu YM, 1997, NATURE, V390, P137, DOI 10.1038/36505; Jenkins F.A. Jr, 1988, Journal of Vertebrate Paleontology, V8, P1; Ji Q, 1999, NATURE, V398, P326; KERMACK KA, 1981, ZOOL J LINN SOC-LOND, V71, P1, DOI 10.1111/j.1096-3642.1981.tb01127.x; KERMACK KA, 1973, ZOOL J LINN SOC-LOND, V53, P87, DOI 10.1111/j.1096-3642.1973.tb00786.x; Kielan-Jaworowska Z, 1998, ACTA PALAEONTOL POL, V43, P413; KUHN HJ, 1971, ABH SENCKENB NAT, V28, P1; KUHN HJ, 1987, MORPHOGENESIS MAMMAL, P1; Li J-L, 2000, CHINESE SCI BULL, V45, P2545; LUO ZX, 1994, J VERTEBR PALEONTOL, V14, P341, DOI 10.1080/02724634.1994.10011564; Luo ZX, 2001, SCIENCE, V292, P1535, DOI 10.1126/science.1058476; MAIER W, 1990, NETH J ZOOL, V40, P55, DOI 10.1163/156854289X00183; McKenna MC, 1997, CLASSIFICATION MAMMA; Owen R., 1871, MONOGRAPH FOSSIL MAM; ROUGIER GW, 1966, AM MUS NOVIT, P1; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; Rowe Timothy, 1996, Memoirs of the California Academy of Sciences, V20, P71; Sanchez-Villagra Marcelo R., 1997, Journal of Mammalian Evolution, V4, P119, DOI 10.1023/A:1027318213347; SIMPSON G. G., 1928, CATALOGUE MESOZOIC M; Wang Xiaolin, 1998, Vertebrata Palasiatica, V36, P81; Zeller U., 1987, Mammalia Depicta, P17; ZELLER U, 1993, MAMMAL PHYLOGENY, P95	33	105	122	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					357	361		10.1126/science.1063830	http://dx.doi.org/10.1126/science.1063830			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598297				2022-12-28	WOS:000171601400039
J	Kapp, C				Kapp, C			Funding squeeze forces UNHCR cutbacks	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1177	1177		10.1016/S0140-6736(01)06261-4	http://dx.doi.org/10.1016/S0140-6736(01)06261-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597695				2022-12-28	WOS:000171399000037
J	Mansley, EC; McKenna, MT				Mansley, EC; McKenna, MT			Importance of perspective in economic analyses of cancer screening decisions	LANCET			English	Article							RECOMMENDATIONS; KNOWLEDGE; BREAST	As the fifth, and final, report in this Lancet series on health economics, we discuss how economic analyses in public health, with cancer screening as the example, differ depending on the perspective taken. We identify nine different, but related, decision makers at various levels, from the individual patient to society as a whole, and discuss how their different viewpoints affect their ultimate decisions. Central to our discussion Is the identification of seven distinct components of perspective, each potentially important in the screening decision. In many fields of healthcare, decisions about the use of resources, such as time, wealth, or energy, are made by weighing up the positive and negative consequences of the alternatives under consideration and are thus based on an economic analysis of the situation (although sometimes this process is subconscious). For simplicity, we restrict our report to the effect of perspective on cancer screening decisions and show how the costs (negative consequences) and benefits (positive consequences) vary depending on the decision maker.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Mansley, EC (corresponding author), Merck & Co Inc, Outcomes Res & Management, POB 4,WP39-160, West Point, PA 19486 USA.	edward_mansley@merck.com						*AG HEALTHC RES QU, 2000, AHRQ RES ACTIVITIES, V239, P5; *AG HEALTHC RES QU, 2000, AHRQ RES ACTIVITIES, V239, P4; [Anonymous], 1996, COST EFFECTIVENESS H; Breslow RA, 1997, PREV MED, V26, P170, DOI 10.1006/pmed.1996.0136; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P162; Drummond MF, 1997, METHODS EC EVALUATIO, P52; Dugan E, 2000, J AM GERIATR SOC, V48, P413, DOI 10.1111/j.1532-5415.2000.tb04699.x; ELMORE JG, 1998, NEW ENGL J MED, V338, P1145; Farnham P. G., 1996, PREVENTION EFFECTIVE, P12; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; Fowler FJ, 2000, JAMA-J AM MED ASSOC, V283, P3217, DOI 10.1001/jama.283.24.3217; Gold MR, 1996, COST EFFECTIVENESS H; Hurley J, 2000, HANDB ECON, V17, P55; Lee MR, 1999, EXPERT SYST APPL, V17, P315, DOI 10.1016/S0957-4174(99)00043-3; MANSLEY EC, 1997, NBCCEDP DIAGNOSIS TR; May DS, 1998, AM J ROENTGENOL, V170, P97, DOI 10.2214/ajr.170.1.9423608; Meltzer MI, 2001, LANCET, V358, P993, DOI 10.1016/S0140-6736(01)06107-4; *NIH, 1997, NIH CONS DEV C BREAS; O'Dell KJ, 1999, J FAM PRACTICE, V48, P682; Ries L, 2000, SEER CANC STAT REV 1; Torrance GW., 1996, COST EFFECTIVENESS H, P54; Torrance GW, 1996, COST EFFECTIVENESS H, P276; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Woloshin S, 1999, NEW ENGL J MED, V340, P884, DOI 10.1056/NEJM199903183401112	25	8	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	2001	358	9288					1169	1173		10.1016/S0140-6736(01)06258-4	http://dx.doi.org/10.1016/S0140-6736(01)06258-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	479HM	11597692				2022-12-28	WOS:000171399000034
J	Garrus, JE; von Schwedler, UK; Pornillos, OW; Morham, SG; Zavitz, KH; Wang, HE; Wettstein, DA; Stray, KM; Cote, M; Rich, RL; Myszka, DG; Sundquist, WI				Garrus, JE; von Schwedler, UK; Pornillos, OW; Morham, SG; Zavitz, KH; Wang, HE; Wettstein, DA; Stray, KM; Cote, M; Rich, RL; Myszka, DG; Sundquist, WI			Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; PLASMA-MEMBRANE PROTEINS; GAG PROTEINS; UBIQUITIN LIGASE; MATRIX PROTEIN; LIFE-CYCLE; WW DOMAINS; RELEASE; YEAST; MOTIF	Like other enveloped viruses, HIV-1 uses cellular machinery to bud from infected cells. We now show that Tsg101 protein, which functions in vacuolar protein sorting (Vps), is required for HIV-1 budding. The UEV domain of Tsg101 binds to an essential tetrapeptide (PTAP) motif within the p6 domain of the structural Gag protein and also to ubiquitin. Depletion of cellular Tsg101 by small interfering RNA arrests HIV-1 budding at a late stage, and budding is rescued by reintroduction of Tsg101. Dominant negative mutant Vps4 proteins that inhibit vacuolar protein sorting also arrest HIV-1 and MLV budding. These observations suggest that retroviruses bud by appropriating cellular machinery normally used in the Vps pathway to form multivesicular bodies.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Ctr Biomol Interact Anal, Salt Lake City, UT 84132 USA; Myriad Genet, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Myriad Genetics, Inc	Sundquist, WI (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.				NIGMS NIH HHS [P32 GM07464] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; BARTEL PL, 1997, YEAST 2 HYBRID SCREE; Berthoud VM, 2000, METHODS, V20, P180, DOI 10.1006/meth.1999.0935; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Craven RC, 1999, J VIROL, V73, P3359, DOI 10.1128/JVI.73.4.3359-3365.1999; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Harty RN, 1999, J VIROL, V73, P2921, DOI 10.1128/JVI.73.4.2921-2929.1999; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; James P, 1996, GENETICS, V144, P1425; Jayakar HR, 2000, J VIROL, V74, P9818, DOI 10.1128/JVI.74.21.9818-9827.2000; JENKINS Y, 2001, IN PRESS J VIROL; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Komada M, 2001, BIOCHEM BIOPH RES CO, V281, P1065, DOI 10.1006/bbrc.2001.4441; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li Y, 1999, MOL CELL BIOL, V19, P3588; Losko S, 2001, MOL BIOL CELL, V12, P1047, DOI 10.1091/mbc.12.4.1047; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ott DE, 2000, VIROLOGY, V278, P111, DOI 10.1006/viro.2000.0648; Owen DJ, 2000, CURR OPIN CELL BIOL, V12, P467, DOI 10.1016/S0955-0674(00)00118-6; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; Ponting CP, 1997, J MOL MED-JMM, V75, P467; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Puffer BA, 1997, J VIROL, V71, P6541, DOI 10.1128/JVI.71.9.6541-6546.1997; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vogt VM, 2000, P NATL ACAD SCI USA, V97, P12945, DOI 10.1073/pnas.97.24.12945; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700; Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000; Zhong Q, 1998, CANCER RES, V58, P2699	59	1104	1161	0	35	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 5	2001	107	1					55	65		10.1016/S0092-8674(01)00506-2	http://dx.doi.org/10.1016/S0092-8674(01)00506-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595185	Bronze			2022-12-28	WOS:000171453100009
J	Shope, JT; Molnar, LJ; Elliott, MB; Waller, PF				Shope, JT; Molnar, LJ; Elliott, MB; Waller, PF			Graduated driver licensing in Michigan - Early impact on motor vehicle crashes among 16-year-old drivers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Public-Health-Association	NOV 15-16, 2000	BOSTON, MASSACHUSETTS	Amer Public Hlth Assoc			PASSENGERS; PROGRAM; SYSTEM; RISK	Context Graduated driver licensing (GDL) programs are being adopted in many states to address the high rate of motor vehicle fatalities among teens by requiring teenaged drivers to gain experience and maturity under conditions of relatively low crash risk before gaining full driving privileges. Objective To evaluate the early impact of Michigan's GDL program on traffic crashes among 16-year-old drivers. Design, Setting, and Subjects Analysis of Michigan motor vehicle crash data from 1996 (before GDL program implementation) vs 1998 and 1999 (after GDL program implementation) for 16-year-olds, adjusting for trends among persons 25 years or older. Intervention Michigan's GDL program, instituted April 1, 1997, for teens younger than 18 years entering the driver license system, includes 3 licensure levels, each with driving restrictions and requirements to progress to the next level. Requirements include extended, supervised practice in the learning level, 2-phase driver education, and night driving restrictions in the intermediate level. Main Outcome Measures Rates in 1996 vs 1998 and 1999 for all police-reported crashes; for fatal injury, nonfatal injury, and fatal/nonfatal injury combined crashes; for day, evening, and night crashes; for single-vehicle and multivehicle crashes; and for alcohol-related crashes. Results Overall, the rate of 16-year-old drivers (per 1000 population) involved in crashes declined from 154 in 1996 to 111 in 1999 (relative risk [RR], 0.72; 95% confidence interval [CI], 0.71-0.73). After adjusting for populationwide trends, the overall crash risk for 16-year-olds was significantly reduced in 1999 from 1996 by 25% (adjusted RR, 0.75; 95% CI, 0.74-0.77). There were also significant reductions for nonfatal injury and combined fatal and nonfatal crashes; for day, evening, and night crashes; and for single-vehicle and multivehicle crashes. Fatal crashes declined from 1996 to 1999, but not significantly (RR, 0.74; 95% CI, 0.49-1.14), and alcohol-related crashes continued at a low rate (RR, 1.01; 95% CI, 0.80-1.29). Conclusions Analysis of the first 2 full calendar years following Michigan's GDL program implementation indicates substantial crash reductions among 16-year-olds. Future research is necessary to determine if these reductions are maintained and if other jurisdictions achieve similar results.	Univ Michigan, Transportat Res Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania; Pennsylvania Medicine	Shope, JT (corresponding author), Univ Michigan, Transportat Res Inst, 2901 Baxter Rd, Ann Arbor, MI 48109 USA.							Begg DJ, 2000, J SAFETY RES, V31, P211, DOI 10.1016/S0022-4375(00)00038-4; Beirness D.J., 1997, STUDY PROFILE HIGH R; BOASE P, 1998, GRADUATED LICENSING; BOUCHARD J, 2000, P 15 INT C ALC DRUGS; *CDCP, 1997, WOND DAT PROGR; Chen LH, 2000, JAMA-J AM MED ASSOC, V283, P1578, DOI 10.1001/jama.283.12.1578; Doherty ST, 1998, ACCIDENT ANAL PREV, V30, P45, DOI 10.1016/S0001-4575(97)00060-2; Foss RD, 2000, JAMA-J AM MED ASSOC, V283, P1617, DOI 10.1001/jama.283.12.1617; FOSS RD, 2000, PRELIMINARY EVALUATI; *INS I HIGHW SAF, 2000, US LIC SYST YOUNG DR; *INS I HIGHW SAF, 2000, FAT FACTS TEEN; *INS I HIGHW SAF, 2000, BEG TEEN DRIV; *INS I HIGHW SAF, 2000, GRAD DRIV LIC QUEST; Jonah B. A, 1987, ALCOHOL DRUGS DRIV, V3, P13; Langley JD, 1996, ACCIDENT ANAL PREV, V28, P139, DOI 10.1016/0001-4575(95)00040-2; MAYHEW DR, 1999, IMPACT GRADUATED DRI; National Highway Traffic Safety Administration, 1999, TRAFF SAF FACTS 1999; National Highway Traffic Safety Administration, 1998, SAV TEEN LIV CAS GRA; National Safety Council, 1989, MAN CLASS MOT VEH TR; Ohio Department of Public Safety, 2001, EV OH GRAD DRIV LIC; Ulmer RG, 2000, ACCIDENT ANAL PREV, V32, P527, DOI 10.1016/S0001-4575(99)00074-3; *US CENS BUR, 2001, POP EST PROGR; Waller PE, 2000, J SAFETY RES, V31, P9, DOI 10.1016/S0022-4375(99)00025-0; WALLER PF, 1977, J TRAFFIC SAFETY ED, V25, P7; WALLER PF, 1973, WHO WHEN ACC RISK CA; WILLIAMS AF, 1998, GRAD LIC BLUEPR N AM; 2001, FARS WEB BAS ENCY	27	81	81	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1593	1598		10.1001/jama.286.13.1593	http://dx.doi.org/10.1001/jama.286.13.1593			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	478HH	11585482	Bronze			2022-12-28	WOS:000171340600026
J	Sanchez, AM; Schreiber, GB; Bethel, J; McCurdy, PR; Glynn, SA; Williams, AE; Gilcher, R				Sanchez, AM; Schreiber, GB; Bethel, J; McCurdy, PR; Glynn, SA; Williams, AE; Gilcher, R		Retrovirus Epidemiology Donor Stud	Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B ANTIGEN; HEREDITARY HEMOCHROMATOSIS; UNITED-STATES; TRANSFUSION; EXCLUSION; ANTIBODY; IMPACT	Context Despite changes in eligibility policies, practical barriers limit blood donations from individuals with hemochromatosis. Increased knowledge of hemochromatosis donor characteristics may help foster further changes that will promote more donations. Objectives To estimate the prevalence of donors diagnosed as having hemochromatosis and to compare rates of unreported deferrable risks for transfusion-transmissible viral infections (TTVIs), positive screening test results for TTVIs, and donation patterns between hemochromatosis patient donors and donors reporting no medical conditions necessitating phlebotomy (non-health-related donors). Design An anonymous mail survey conducted in 1998 as part of the ongoing Retrovirus Epidemiology Donor Study. Setting and Participants Among a stratified probability sample of 92581 blood donors from 8 geographically diverse US blood centers, 52650 (57%) responded. Main Outcome Measures Prevalence of hemochromatosis among blood donors; prevalence of unreported deferrable risks and positive screening test results for TTVIs among hemochromatosis patient donors vs non-health-related donors. Results One hundred ninety-seven respondents (0.4%) identified themselves as hemochromatosis patients and 50079 (95.1%) as non-health-related donors. An estimated 0.8% of all donations were from hemochromatosis patients, 45.8% of whom reported that they had donated blood to treat their illness. The proportion of repeat donors was higher in hemochromatosis patients than in non-health-related donors (83.5% vs 76.5%; P = .03). Among repeat donors, 68.7% of hemochromatosis patients reported donating at least 3 times in the past year compared with 49.1% of non-health-related donors (P<.001). The prevalence of unreported deferrable risks for TTVIs was similar in hemochromatosis patients (2.0%) and non-health-related donors (3.1%) as was the overall prevalence of positive screening test results (1.3% of hemochromatosis patients vs 1.6% of non-health-related donors). Conclusions Although significant numbers of hemochromatosis patients reported donating blood for therapeutic reasons, our findings suggest that this population does not present a greater risk to blood safety than other donors.	WESTAT Corp, Rockville, MD 20850 USA; Amer Red Cross, Jerome H Holland Lab, Rockville, MD USA; NHLBI, Bethesda, MD 20892 USA; Oklahoma Blood Inst, Sylvan N Goldman Ctr, Oklahoma City, OK USA	Westat; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sanchez, AM (corresponding author), WESTAT Corp, WB 266,1650 Res Blvd, Rockville, MD 20850 USA.				NHLBI NIH HHS [N01-HB-97079, N01-HB-97081, N01-HB-97082, N01-HB-97078, N01-HB-97077, N01-HB-47114, N01-HB-97080] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097078, N01HB097082, N01HB097081, N01HB097080, N01HB097077, N01HB047114, N01HB097079] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1980, ANN INTERN MED, V92, P539, DOI 10.7326/0003-4819-92-4-539; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; Bartolotta A, 1999, POLYM ENG SCI, V39, P549, DOI 10.1002/pen.11445; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; Bothwell TH, 1998, SEMIN HEMATOL, V35, P55; CHERUBIN CE, 1971, TRANSFUSION, V11, P25, DOI 10.1111/j.1537-2995.1971.tb04370.x; Conry-Cantilena C, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P564; *CTR BIOL EV RES, 2001, GUID IND VAR BLOOD C; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; *CYT SOFTW CO, 1999, STATXACT 4 SOFTW PRO; DOMEN RE, 1995, TRANSFUS MED REV, V9, P53, DOI 10.1016/S0887-7963(05)80030-6; Eastlund T, 1998, TRANSFUSION, V38, P874, DOI 10.1046/j.1537-2995.1998.38998409009.x; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Glynn SA, 2000, JAMA-J AM MED ASSOC, V284, P229, DOI 10.1001/jama.284.2.229; GRINDON AJ, 1993, JAMA-J AM MED ASSOC, V270, P880; Jeffrey G, 1999, TRANSFUSION, V39, P549, DOI 10.1046/j.1537-2995.1999.39060549.x; JOHNSON ES, 1994, TRANSFUSION, V34, P769, DOI 10.1046/j.1537-2995.1994.34994378277.x; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; Levstik M, 1998, CAN J GASTROENTEROL, V12, P61, DOI 10.1155/1998/590428; McCullough J, 2000, TRANSFUSION, V40, P143; McDonnell SM, 1999, TRANSFUSION, V39, P651, DOI 10.1046/j.1537-2995.1999.39060651.x; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; Mitka M, 2001, JAMA-J AM MED ASSOC, V285, P1694, DOI 10.1001/jama.285.13.1694; Munsterman KA, 1998, TRANSFUSION, V38, P45, DOI 10.1046/j.1537-2995.1998.38198141497.x; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; PILIAVIN JA, 1990, TRANSFUSION, V30, P444, DOI 10.1046/j.1537-2995.1990.30590296381.x; Powell LW, 1996, GASTROENTEROLOGY, V110, P1304, DOI 10.1053/gast.1996.v110.agast961304; Sacher RA, 1999, TRANSFUSION, V39, P551, DOI 10.1046/j.1537-2995.1999.39060551.x; Seeff L B, 1988, Transfus Med Rev, V2, P204, DOI 10.1016/S0887-7963(88)70046-2; SZMUNESS W, 1973, J INFECT DIS, V127, P17, DOI 10.1093/infdis/127.1.17; Tan L, 1999, TRANSFUSION, V39, P1018, DOI 10.1046/j.1537-2995.1999.39091018.x; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; Walker EM, 1998, ANN CLIN LAB SCI, V28, P300; *WEST INC, 1994, WESVAR SAS PROC; Williams AE, 1997, JAMA-J AM MED ASSOC, V277, P967, DOI 10.1001/jama.277.12.967; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x; 1997, P 146 ANN M HOUS DEL	39	22	22	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1475	1481		10.1001/jama.286.12.1475	http://dx.doi.org/10.1001/jama.286.12.1475			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572740	Bronze			2022-12-28	WOS:000171188600025
J	Parving, HH; Lehnert, H; Brochner-Mortensen, J; Gomis, R; Andersen, S; Arner, P				Parving, HH; Lehnert, H; Brochner-Mortensen, J; Gomis, R; Andersen, S; Arner, P		Irbesartan Patients Type 2 Diabete	The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONVERTING ENZYME-INHIBITION; RANDOMIZED TRIAL; KIDNEY-FUNCTION; RENAL-DISEASE; MICROALBUMINURIA; PROGRESSION; CAPTOPRIL; MELLITUS; ALBUMINURIA; PROTEINURIA	Background Microalbuminuria and hypertension are risk factors for diabetic nephropathy. Blockade of the renin angiotensin system slows the progression to diabetic nephropathy in patients with type 1 diabetes, but similar data are lacking for hypertensive patients with type 2 diabetes. We evaluated the renoprotective effect of the angiotensin-II receptor antagonist irbesartan in hypertensive patients with type 2 diabetes and microalbuminuria. Methods A total of 590 hypertensive patients with type 2 diabetes and microalbuminuria were enrolled in this multinational, randomized, double-blind, placebo-controlled study of irbesartan, at a dose of either 150 mg daily or 300 mg daily, and were followed for two years. The primary outcome was the time to the onset of diabetic nephropathy, defined by persistent albuminuria in overnight specimens, with a urinary albumin excretion rate that was greater than 200 mug per minute and at least 30 percent higher than the base-line level. Results The base-line characteristics in the three groups were similar. Ten of the 194 patients in the 300-mg group (5.2 percent) and 19 of the 195 patients in the 150-mg group (9.7 percent) reached the primary end point, as compared with 30 of the 201 patients in the placebo group ( 14.9 percent) ( hazard ratios, 0.30 [95 percent confidence interval, 0.14 to 0.61; P< 0.001] and 0.61 [95 percent confidence interval, 0.34 to 1.08; P= 0.08] for the two irbesartan groups, respectively). The average blood pressure during the course of the study was 144/83 mm Hg in the placebo group, 143/83 mm Hg in the 150-mg group, and 141/ 83 mm Hg in the 300-mg group ( P= 0.004 for the comparison of systolic blood pressure between the placebo group and the combined irbesartan groups). Serious adverse events were less frequent among the patients treated with irbesartan ( P= 0.02). Conclusions Irbesartan is renoprotective independently of its blood-pressure lowering effect in patients with type 2 diabetes and microalbuminuria. (N Engl J Med 2001; 345: 870-8.) Copyright (C) 2001 Massachusetts Medical Society.	Steno Diabet Ctr, Copenhagen, Denmark; Univ Magdeburg, Sch Med, Dept Endocrinol & Metab, D-39106 Magdeburg, Germany; Aalborg Hosp, Dept Clin Physiol, Aalborg, Denmark; Univ Barcelona, Dept Endocrinol, Barcelona, Spain; Huddinge Hosp, Dept Med, S-14186 Huddinge, Sweden	Steno Diabetes Center; Otto von Guericke University; Aalborg University; Aalborg University Hospital; University of Barcelona	Parving, HH (corresponding author), Steno Diabet Ctr, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark.		Avramopoulos, Iraklis/AAQ-3210-2021; Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Arner, Peter/0000-0002-6208-6220; Andersen, Steen/0000-0002-1987-1661				Agardh CD, 1996, J HUM HYPERTENS, V10, P185; BAKRIS GL, 1996, KIDNEY INT, V50, P17641; Chan JCN, 2000, KIDNEY INT, V57, P590, DOI 10.1046/j.1523-1755.2000.t01-1-00879.x; Chaturvedi N, 2001, ANN INTERN MED, V134, P370, DOI 10.7326/0003-4819-134-5-200103060-00009; Christensen PK, 2000, KIDNEY INT, V58, P1719, DOI 10.1046/j.1523-1755.2000.00333.x; COX DR, 1972, J R STAT SOC B, V34, P187; De Jong PE, 1999, LANCET, V354, P352, DOI 10.1016/S0140-6736(99)90122-8; Estacio RO, 2000, DIABETES CARE, V23, pB54; Gaede P, 1999, LANCET, V353, P617, DOI 10.1016/S0140-6736(98)07368-1; Gerstein HC, 2000, LANCET, V355, P253; GOLDSTEIN DE, 1986, CLIN CHEM, V32, P64; Hofmann W, 1989, LAB MED, V13, P470; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LACOURCIERE Y, 1993, HYPERTENSION, V21, P786, DOI 10.1161/01.HYP.21.6.786; LEBOVITZ HE, 1994, KIDNEY INT, V45, pS150; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mathiesen ER, 1999, BRIT MED J, V319, P24, DOI 10.1136/bmj.319.7201.24; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; Nelson RG, 1996, NEW ENGL J MED, V335, P1636, DOI 10.1056/NEJM199611283352203; Parving HH, 1996, NEW ENGL J MED, V335, P1682, DOI 10.1056/NEJM199611283352212; Parving HH., 2000, KIDNEY, V6, P1731; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; REMUZZI G, 1990, KIDNEY INT, V38, P384, DOI 10.1038/ki.1990.217; ROSSING P, 1994, DIABETOLOGIA, V37, P511, DOI 10.1007/s001250050140; ROSSING P, 1994, DIABETOLOGIA, V37, P708, DOI 10.1007/s001250050168; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; SEELIG HP, 1969, Z KLIN CHEM KLIN BIO, V7, P581; Stearne MR, 1998, BRIT MED J, V317, P713; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; TREVISAN R, 1995, AM J HYPERTENS, V8, P876, DOI 10.1016/0895-7061(95)00162-I; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275	33	2336	2478	1	99	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2001	345	12					870	878		10.1056/NEJMoa011489	http://dx.doi.org/10.1056/NEJMoa011489			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	473JW	11565519				2022-12-28	WOS:000171039600003
J	Lightman, A				Lightman, A			In the name of love? By defining ideas precisely, as science does, fiction would deny its readers freedom of interpretation.	NATURE			English	Editorial Material									MIT, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lightman, A (corresponding author), MIT, Cambridge, MA 02139 USA.								0	0	0	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 18	2001	413	6857					681	681		10.1038/35099636	http://dx.doi.org/10.1038/35099636			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482ZK	11607007				2022-12-28	WOS:000171608000021
J	Worlock, DR				Worlock, DR			The best and worst of times - What winners will emerge from the battles over access to scholarly data?	NATURE			English	Editorial Material									Elect Publishing Serv Ltd, London EC19 4SX, England		Worlock, DR (corresponding author), Elect Publishing Serv Ltd, 26 Rosebery Ave, London EC19 4SX, England.								0	1	1	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 18	2001	413	6857					671	671		10.1038/35099599	http://dx.doi.org/10.1038/35099599			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482ZK	11606995				2022-12-28	WOS:000171608000019
J	Mahal, LK; Charter, NW; Angata, K; Fukuda, M; Koshland, DE; Bertozzi, CR				Mahal, LK; Charter, NW; Angata, K; Fukuda, M; Koshland, DE; Bertozzi, CR			A small-molecule modulator of poly-alpha 2,8-sialic acid expression on cultured neurons and tumor cells	SCIENCE			English	Article							ADHESION MOLECULE; POLYSIALIC ACID; 2 POLYSIALYLTRANSFERASES; SIALIC ACIDS; STX; SURFACE; PST; POLYSIALYLATION; PLASTICITY; PATTERN	Poly-alpha2,8-sialic acid (PSA) has been implicated in numerous normal and pathological processes, including development, neuronal plasticity, and tumor metastasis. We report that cell surface PSA expression can be reversibly inhibited by a small molecule, N-butanoylmannosamine (ManBut). Inhibition occurs through a metabolic mechanism in which ManBut is converted to unnatural sialic acid derivatives that effectively act as chain terminators during cellular PSA biosynthesis. N-Propanoylmannosamine (ManProp), which differs from ManBut by a single methylene group, did not inhibit PSA biosynthesis. Modulation of PSA expression by chemical means has a rote complementary to genetic and biochemical approaches in the study of complex PSA-mediated events.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Sanford Burnham Prebys Medical Discovery Institute	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.		Angata, Kiyohiko/M-2749-2018; Mahal, Lara/GRY-7287-2022	Angata, Kiyohiko/0000-0001-5561-1368; Mahal, Lara/0000-0003-4791-8524	NCI NIH HHS [CA33895] Funding Source: Medline; NIDDK NIH HHS [DK09765] Funding Source: Medline; NIGMS NIH HHS [GM58867-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM058867, R01GM058867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820; BERTOZZI CR, 1995, CHEM BIOL, V2, P703, DOI 10.1016/1074-5521(95)90096-9; Chappell MD, 1997, TETRAHEDRON, V53, P11109, DOI 10.1016/S0040-4020(97)00370-0; Charter NW, 2000, GLYCOBIOLOGY, V10, P1049, DOI 10.1093/glycob/10.10.1049; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Fukuda M, 1996, CANCER RES, V56, P2237; Hildebrandt H, 1998, CANCER RES, V58, P779; JORGENSEN OS, 1995, NEUROCHEM RES, V20, P533, DOI 10.1007/BF01694535; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; Liu TM, 2000, J BIOL CHEM, V275, P32832, DOI 10.1074/jbc.C000573200; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PROBSTMEIER R, 1994, J NEUROSCI RES, V37, P324, DOI 10.1002/jnr.490370305; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Schumacher U, 1996, HISTOCHEM CELL BIOL, V106, P599; SZELE FG, 1994, NEUROSCIENCE, V60, P133, DOI 10.1016/0306-4522(94)90209-7; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Yarema KJ, 1998, J BIOL CHEM, V273, P31168, DOI 10.1074/jbc.273.47.31168	26	90	91	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					380	382		10.1126/science.1062192	http://dx.doi.org/10.1126/science.1062192			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598302				2022-12-28	WOS:000171601400045
J	Ali, NY; Lo, TYS; Auvache, VL; White, PD				Ali, NY; Lo, TYS; Auvache, VL; White, PD			Bad press for doctors: 21 year survey of three national newspapers	BRITISH MEDICAL JOURNAL			English	Article									Univ London Queen Mary Coll, St Bartholomews & Royal London Sch Med & Dent, London EC1A 7BE, England	University of London; Queen Mary University London	White, PD (corresponding author), Univ London Queen Mary Coll, St Bartholomews & Royal London Sch Med & Dent, London EC1A 7BE, England.			White, Peter/0000-0002-8193-5355				Davies HTO, 1999, J EVAL CLIN PRACT, V5, P335, DOI 10.1046/j.1365-2753.1999.00200.x; Ferriman A, 2001, BRIT MED J, V322, P694, DOI 10.1136/bmj.322.7288.694; Goodman, 2000, BMJ, V320, P1414, DOI 10.1136/bmj.320.7246.1414; KEEP P, 2000, HOSP DOCTOR     0217, P42; Lupton D, 1998, SOC SCI MED, V46, P947, DOI 10.1016/S0277-9536(97)10013-2	5	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 6	2001	323	7316					782	783		10.1136/bmj.323.7316.782	http://dx.doi.org/10.1136/bmj.323.7316.782			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481LK	11588080	Green Published, Bronze			2022-12-28	WOS:000171520600029
J	Lewis, SJ; Egger, M; Sylvester, PA; Thomas, S				Lewis, SJ; Egger, M; Sylvester, PA; Thomas, S			Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials	BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVE RANDOMIZED TRIAL; ELECTIVE COLORECTAL SURGERY; POSTOPERATIVE ORAL INTAKE; ELEMENTAL DIET; MALNUTRITION; ANASTOMOSES; NUTRITION; QUALITY; RESECTION; EFFICACY	Objective To determine whether a period of starvation (nil by mouth) after gastrointestinal surgery is beneficial in terms of specific outcomes. Design Systematic review and meta-analysis of randomised controlled trials comparing any type of enteral feeding started within 24 hours after surgery with nil by mouth management in elective gastrointestinal surgery. Three electronic databases (PubMed, Embase, and the Cochrane controlled trials register) were searched, reference lists checked, and letters requesting details of unpublished trials and data sent to pharmaceutical companies and authors of previous trials. Main outcome measures Anastomotic dehiscence, infection of any type, wound infection, pneumonia, intra-abdominal abscess, length of hospital stay, and mortality. Results Eleven studies with 837 patients met the inclusion criteria. In six studies patients in the intervention group were fed directly into the small bowel and in five studies patients were fed orally. Early feeding reduced the risk of any type of infection (relative risk 0.72, 95% confidence interval 0.54 to 0.98, P = 0.036) and the mean length of stay in hospital (number of days reduced by 0.84, 0.36 to 1.33, P=0.001). Risk reductions were also seen for anastomotic dehiscence (0.53, 0.26 to 1.08, P=0.080), wound infection, pneumonia, intra-abdominal abscess, and mortality, but these failed to reach significance (P > 0.10). The risk of vomiting was increased among patients fed early (1.27, 1.01 to 1.61, P = 0.046). Conclusions There seems to be no clear advantage to keeping patients nil by mouth after elective gastrointestinal resection. Early feeding may be of benefit An adequately powered trial is required to confirm or refute the benefits seen in small trials.	Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; Bristol Royal Infirm & Gen Hosp, Dept Surg, Bristol BS2 8HW, Avon, England; Univ Bristol, Dept Maxillofacial Surg, Bristol BS1 2LY, Avon, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Bristol; Bristol Royal Infirmary; University of Bristol	Lewis, SJ (corresponding author), Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England.							BeierHolgersen R, 1996, GUT, V39, P833, DOI 10.1136/gut.39.6.833; BINDEROW SR, 1994, DIS COLON RECTUM, V37, P584, DOI 10.1007/BF02050994; Carr CS, 1996, BRIT MED J, V312, P869, DOI 10.1136/bmj.312.7035.869; CATCHPOLE BN, 1989, AUST NZ J SURG, V59, P199, DOI 10.1111/j.1445-2197.1989.tb01502.x; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GOODLAD RA, 1983, VIRCHOWS ARCH B, V43, P55, DOI 10.1007/BF02932943; Hartsell PA, 1997, ARCH SURG-CHICAGO, V132, P518; Heslin MJ, 1997, ANN SURG, V226, P567, DOI 10.1097/00000658-199710000-00016; HILL GL, 1977, LANCET, V1, P689; HOOVER HC, 1980, AM J SURG, V139, P153, DOI 10.1016/0002-9610(80)90245-7; IRVIN TT, 1973, BRIT J SURG, V60, P461, DOI 10.1002/bjs.1800600612; IRVIN TT, 1974, ANN SURG, V180, P765, DOI 10.1097/00000658-197411000-00010; Lennard-Jones J E, 1992, POSITIVE APPROACH NU; MCCARTER MD, 1996, J GASTROINTEST SURG, V1, P278; MCWHIRTER JP, 1994, BRIT MED J, V308, P945, DOI 10.1136/bmj.308.6934.945; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOSS G, 1981, JPEN-PARENTER ENTER, V5, P215, DOI 10.1177/0148607181005003215; MOSS G, 1980, JPEN-PARENTER ENTER, V4, P535, DOI 10.1177/0148607180004006535; Ortiz H, 1996, INT J COLORECTAL DIS, V11, P119, DOI 10.1007/s003840050032; REISSMAN P, 1995, ANN SURG, V222, P73, DOI 10.1097/00000658-199507000-00012; RYAN JA, 1981, AM SURGEON, V47, P393; SAGAR S, 1979, BMJ-BRIT MED J, V1, P293, DOI 10.1136/bmj.1.6159.293; Schilder JM, 1997, GYNECOL ONCOL, V67, P235, DOI 10.1006/gyno.1997.4860; SCHROEDER D, 1991, JPEN-PARENTER ENTER, V15, P376, DOI 10.1177/0148607191015004376; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Stewart BT, 1998, AUST NZ J SURG, V68, P125, DOI 10.1111/j.1445-2197.1998.tb04721.x; Thornton FJ, 1997, SURG CLIN N AM, V77, P549, DOI 10.1016/S0039-6109(05)70568-5; UDEN P, 1988, AM J SURG, V156, P381, DOI 10.1016/S0002-9610(88)80192-2; WARD MWN, 1982, BRIT J SURG, V69, P308, DOI 10.1002/bjs.1800690604; Watters JM, 1997, ANN SURG, V226, P369, DOI 10.1097/00000658-199709000-00016; Wheeler JMD, 1999, ANN ROY COLL SURG, V81, P105; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; Windsor ACJ, 1998, GUT, V42, P431, DOI 10.1136/gut.42.3.431	37	449	499	0	23	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 6	2001	323	7316					773	776		10.1136/bmj.323.7316.773	http://dx.doi.org/10.1136/bmj.323.7316.773			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481LK	11588077	Green Published, Bronze			2022-12-28	WOS:000171520600024
J	Reid, G; Flonta, ML				Reid, G; Flonta, ML			Physiology - Cold current in thermoreceptive neurons	NATURE			English	Article							MENTHOL; RAT		Univ Bucharest, Fac Biol, Dept Anim Physiol & Biophys, Bucharest 76201, Romania	University of Bucharest	Reid, G (corresponding author), Univ Bucharest, Fac Biol, Dept Anim Physiol & Biophys, Splaiul Independentei 91-95, Bucharest 76201, Romania.							Gee MD, 1999, NEUROSCIENCE, V90, P509, DOI 10.1016/S0306-4522(98)00454-0; HENSEL H, 1951, ACTA PHYSIOL SCAND, V24, P27, DOI 10.1111/j.1748-1716.1951.tb00824.x; HENSEL H, 1974, PFLUG ARCH EUR J PHY, V352, P87, DOI 10.1007/BF01061953; Hensel H, 1981, THERMORECEPTION TEMP; KENSHALO DR, 1977, J NEUROPHYSIOL, V40, P319, DOI 10.1152/jn.1977.40.2.319; LEEM JW, 1993, J NEUROPHYSIOL, V69, P1684, DOI 10.1152/jn.1993.69.5.1684; Okazawa M, 2000, NEUROREPORT, V11, P2151, DOI 10.1097/00001756-200007140-00018; PIERAU FK, 1974, BRAIN RES, V73, P156, DOI 10.1016/0006-8993(74)91015-4; Reid G, 2001, J NEUROSCI METH, V111, P1, DOI 10.1016/S0165-0270(01)00416-2; Reid G, 2001, NEUROSCI LETT, V297, P171, DOI 10.1016/S0304-3940(00)01694-3; SCHAFER K, 1986, J GEN PHYSIOL, V88, P757, DOI 10.1085/jgp.88.6.757; Suto K, 1999, NEUROSCIENCE, V92, P1131, DOI 10.1016/S0306-4522(99)00063-9	12	129	138	0	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					480	480		10.1038/35097164	http://dx.doi.org/10.1038/35097164			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586349				2022-12-28	WOS:000171340500036
J	McDermott, MM; Greenland, P; Liu, K; Guralnik, JM; Criqui, MH; Dolan, NC; Chan, CL; Celic, L; Pearce, WH; Schneider, JR; Sharma, L; Clark, E; Gibson, D; Martin, GJ				McDermott, MM; Greenland, P; Liu, K; Guralnik, JM; Criqui, MH; Dolan, NC; Chan, CL; Celic, L; Pearce, WH; Schneider, JR; Sharma, L; Clark, E; Gibson, D; Martin, GJ			Leg symptoms in peripheral arterial disease - Associated clinical characteristics and functional impairment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY FUNCTION; INTERMITTENT CLAUDICATION; CARDIOVASCULAR HEALTH; PHYSICAL-DISABILITY; WOMENS HEALTH; 6-MINUTE WALK; ACCELEROMETER; PREDICTOR; MORTALITY; CRITERIA	Context Persons with lower-extremity peripheral arterial disease (PAD) are often asymptomatic or have leg symptoms other than intermittent claudication (IC). Objective To identify clinical characteristics and functional limitations associated with a broad range of leg symptoms identified among patients with PAD. Design, Setting, and Participants Cross-sectional study of 460 men and women with PAD and 130 without PAD, who were identified consecutively, conducted between October 1998 and January 2000 at 3 Chicago-area medical centers. Main Outcome Measures Ankle-brachial index score of less than 0.90; scores from 6-minute walk, accelerometer-measured physical activity over 7 days, repeated chair raises, standing balance (full tandem stand), 4-m walking velocity, San Diego claudication questionnaire, Geriatric Depression Score Short-Form, and the Walking Impairment Questionnaire. Results All groups with PAD had poorer functioning than participants without PAD. The following values are for patients without IC vs those with IC. Participants in the group with leg pain on exertion and rest (n=88) had a higher (poorer) score for neuropathy (5.6 vs 3.5; P<.001), prevalence of diabetes mellitus (48.9% vs 26.7%; P<.001), and spinal stenosis (20.8% vs 7.2%; P=.002). The atypical exertional leg pain/carry on group (exertional leg pain other than IC associated with walking through leg pain [n=41]) and the atypical exertional leg pain/stop group (exertional leg pain other than IC that causes one to stop walking [n=90]) had better functioning than the IC group. The group without exertional leg pain/inactive (no exertional leg pain in individual who walks less than or equal to6 blocks per week [n=28]) and the leg pain on exertion and rest group had poorer functioning than those with IC. Adjusting for age, sex, race, and comorbidities and compared with IC, participants with atypical exertional leg pain/carry on achieved a greater distance on the 6-minute walk (404.3 vs 328.5 m; P<.001) and were less likely to stop during the 6-minute walk (6.8% vs 36%; P=.002). The group with pain on exertion and rest had a slower time for completing 5 chair raises (13.5 vs 11.9 seconds; P=.009), completed the tandem stand less frequently (37.5% vs 60.0%; P=.004), and had a slower 4-m walking velocity (0.80 vs 0.90 m/s; P<.001). Conclusions There is a wide range of leg symptoms in persons with PAD beyond that of classic IC. Comorbid disease may contribute to these symptoms in PAD. Functional impairments are found in every PAD symptom group, and the degree of functional limitation varies depending on the type of leg symptom.	Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Surg, Chicago, IL 60611 USA; Evanston Northwestern Hosp, Dept Surg, Div Vasc Surg, Evanston, IL USA; Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA; Catholic Hlth Partners, Dept Surg, Div Vasc Surg, Chicago, IL USA	Northwestern University; Northwestern University; Northwestern University; NorthShore University Health System; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	McDermott, MM (corresponding author), 675 N St Clair,Suite 18-200, Chicago, IL 60611 USA.		Greenland, Philip/ABD-5528-2021	Sharma, Leena/0000-0002-5571-1622	NCRR NIH HHS [RR-00048] Funding Source: Medline; PHS HHS [R01-58099] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; BERNSTEIN EF, 1982, SURG CLIN N AM, V62, P473; BIRKE JA, 1986, LEPROSY REV, V57, P261; Criqui M H, 1996, Vasc Med, V1, P65; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; Feinglass J, 2000, J VASC SURG, V31, P93, DOI 10.1016/S0741-5214(00)70071-1; FRIED LP, 1994, J CLIN EPIDEMIOL, V47, P747, DOI 10.1016/0895-4356(94)90172-4; Fried LP, 1999, J CLIN EPIDEMIOL, V52, P27, DOI 10.1016/S0895-4356(98)00124-3; Gardner AW, 1998, ANGIOLOGY, V49, P327, DOI 10.1177/000331979804900501; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Guralnik JM, 1995, NIH PUBLICATION, V95-4009; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HIATT WR, 1995, CIRCULATION, V91, P1472, DOI 10.1161/01.CIR.91.5.1472; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; McDermott MM, 1998, J AM GERIATR SOC, V46, P1355, DOI 10.1111/j.1532-5415.1998.tb06001.x; McDermott MM, 2000, J VASC SURG, V32, P1164, DOI 10.1067/mva.2000.108640; McDermott MM, 1999, ARCH INTERN MED, V159, P387; McDermott MM, 2000, CIRCULATION, V101, P1007, DOI 10.1161/01.CIR.101.9.1007; McDermott MM, 2001, J AM GERIATR SOC, V49, P747, DOI 10.1046/j.1532-5415.2001.49151.x; McDermott MM, 2001, J GEN INTERN MED, V16, P384, DOI 10.1046/j.1525-1497.2001.016006384.x; McDermott MM, 2000, ANGIOLOGY, V51, P91, DOI 10.1177/000331970005100201; MCKENNA M, 1991, ATHEROSCLEROSIS, V87, P119, DOI 10.1016/0021-9150(91)90014-T; MILLER DJ, 1994, MED SCI SPORT EXER, V26, P376; Montgomery PS, 1998, J AM GERIATR SOC, V46, P706, DOI 10.1111/j.1532-5415.1998.tb03804.x; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OGREN M, 1995, BMJ-BRIT MED J, V310, P1294, DOI 10.1136/bmj.310.6990.1294; OLIN JW, 1998, AM J MED CONTINUING, P10; OLMOS PR, 1995, AM J MED SCI, V309, P76, DOI 10.1097/00000441-199502000-00004; Regensteiner JG, 1990, J VASC MED BIOL, V2, P142; Richardson M T, 1995, J Cardiopulm Rehabil, V15, P107, DOI 10.1097/00008483-199503000-00003; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Swan PD, 1997, BRIT J SPORT MED, V31, P235, DOI 10.1136/bjsm.31.3.235; Weitz JI, 1996, CIRCULATION, V94, P3026, DOI 10.1161/01.CIR.94.11.3026; [No title captured]	37	562	574	2	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1599	1606						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585483				2022-12-28	WOS:000171340600027
J	Vandenbroucke, JP; de Craen, AJM				Vandenbroucke, JP; de Craen, AJM			Alternative medicine: A "mirror image" for scientific reasoning in conventional medicine	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED-TRIALS; CLINICAL-TRIALS; VASOVAGAL SYNCOPE; HOMEOPATHY; METAANALYSIS; PACEMAKER; INDUSTRY	A reflection on the scientific behavior of adherents of conventional medicine toward one form of alternative medicine-homeopathy-teaches us that physicians do reject seemingly solid evidence because it is not compatible with theory. Further reflection, however, shows that physicians do the same within conventional medical science: Sometimes they discard a theory because of new facts, but at other times they cling to a theory despite the facts. This essay highlights the seeming contradiction and discusses whether it still permits the building of rational medical science. We propose that rational science Is compatible with physicians' behavior, provided that physicians acknowledge the subjective element in the evaluation of science, as exemplified in the crossword analogy by the philosopher Haack. This type of thinking fits very well with the Bayesian approach to decision making that has been advocated for decades in clinical medicine. It does not lead to complete and uncontrollable subjectivity because discernment between rivaling explanations is still possible through argument and counterargument.	Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Vandenbroucke, JP (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, Bldg 1,POB 9600, NL-2300 RC Leiden, Netherlands.	vdbroucke@mail.medfac.leidenuniv.nl	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Boissel JP, 1996, CRITICAL LIT REV EFF; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; BROWNER WS, 1987, JAMA-J AM MED ASSOC, V257, P2459, DOI 10.1001/jama.257.18.2459; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; CORNFIELD J, 1976, AM J EPIDEMIOL, V104, P408, DOI 10.1093/oxfordjournals.aje.a112313; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; el-Bedawi K M, 1994, Clin Auton Res, V4, P41; Ernst E, 1996, ARCH INTERN MED, V156, P2162, DOI 10.1001/archinte.156.19.2162; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Gould SJ, 2000, SCIENCE, V287, P253, DOI 10.1126/science.287.5451.253; Haack S., 1998, MANIFESTO PASSIONATE; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; Langman MJS, 1997, LANCET, V350, P825, DOI 10.1016/S0140-6736(05)62025-9; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; OBRIEN E, 1980, LANCET, V2, P1356; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; SKRABANEK P, 1986, LANCET, V1, P960; Sterne J, 2001, SYSTEMATIC REV HLTH; Sutton R, 2000, CIRCULATION, V102, P294; Vandenbroucke JP, 1998, LANCET, V352, P2001, DOI 10.1016/S0140-6736(98)10208-8; Vandenbroucke JP, 1997, LANCET, V350, P824, DOI 10.1016/S0140-6736(97)22038-6; Vincent JL, 1998, LANCET, V351, P922; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6; WIERSMA TJ, 1988, KENNIS METHODE, V12, P295; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	31	57	58	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					507	513		10.7326/0003-4819-135-7-200110020-00010	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	477EF	11578154				2022-12-28	WOS:000171269600005
J	Ito, T; Sawaishi, Y; Ito, Y; Sugawara, A				Ito, T; Sawaishi, Y; Ito, Y; Sugawara, A			Severe pulmonary hypertension in an infant with achondroplasia	LANCET			English	Editorial Material									Nakadori Gen Hosp, Dept Pediat, Akita 0108577, Japan; Nakadori Gen Hosp, Dept Neurol Surg, Akita 0108577, Japan; Akita Univ, Sch Med, Dept Pediat, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Neurol Surg, Akita 0108543, Japan	Akita University; Akita University	Ito, T (corresponding author), Nakadori Gen Hosp, Dept Pediat, 3-15 Misono Cho,Minami Dori, Akita 0108577, Japan.							GUNTHARD J, 1995, CLIN GENET, V48, P35; HECHT JT, 1990, J CHILD NEUROL, V5, P84, DOI 10.1177/088307389000500203; Hunter AGW, 1998, J MED GENET, V35, P705, DOI 10.1136/jmg.35.9.705; PAUH RM, 1984, J PEDIATR, V104, P342; REID CS, 1987, J PEDIATR-US, V110, P522, DOI 10.1016/S0022-3476(87)80542-5	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 29	2001	358	9287					1062	1062		10.1016/S0140-6736(01)06184-0	http://dx.doi.org/10.1016/S0140-6736(01)06184-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589938				2022-12-28	WOS:000171393100013
J	Korevaar, JC; Jansen, MAM; Dekker, FW; Jager, KJ; Boeschoten, EW; Krediet, RT; Bossuyt, PMM				Korevaar, JC; Jansen, MAM; Dekker, FW; Jager, KJ; Boeschoten, EW; Krediet, RT; Bossuyt, PMM		Netherlands Cooperative Study Adeq	When to initiate dialysis: effect of proposed US guidelines on survival	LANCET			English	Article							RESIDUAL RENAL-FUNCTION; PERITONEAL-DIALYSIS; CONTROLLED TRIALS; DISEASE; STAGE; PROGRESSION; PREDICTORS; PROTEIN; THERAPY	Background Recent guidelines from the US National Kidney Foundation Dialysis Outcomes Quality Initiative recommend an earlier start of dialysis treatment than has been common practice. Their implementation would have a substantial effect on patients' daily lives and would increase costs. The guidelines are largely opinion-based, because evidence is still lacking. Methods As part of a prospective multicentre study in the Netherlands, we included, between January, 1997, and May, 1999, all new patients with end-stage renal disease, for whom data were available on residual renal function 0-4 weeks before the start of dialysis. We recorded date of death or censoring until August, 2000. Findings 94 (37%) of 253 patients started dialysis treatment later than recommended by the US guideline. There was an increased mortality risk for these patients compared with those who started dialysis on time, although it was not significant (adjusted hazard ratio 1.66 [95% Cl 0.95-2-89]). The adjusted difference in estimated survival time after 3 years on dialysis treatment was 2.5 months (1.1-4.0) in favour of timely starters. Conversely, the average delay in dialysis initiation for late starters, the extra time free of dialysis, was at least 4.1 months. Interpretation Although we observed a gain in survival time with a timely start of dialysis, it is probably a reflection of initiating dialysis earlier in the disease. We question the benefit of putting this guideline into daily practice, given the current clinical evidence and the effects it would have on patients and dialysis resources.	Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dianet Dialysis Ctr, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Nephrol, NL-1100 DD Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Korevaar, JC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, POB 22660, NL-1100 DD Amsterdam, Netherlands.		Bossuyt, Patrick M/AAR-1183-2021; Bossuyt, Patrick M./B-4557-2016; Jager, Kitty J/C-3887-2008; Dekker, Friedo W/B-6452-2011; Krediet, Raymond/GLT-2390-2022; Krediet, Raymond/AAP-3291-2021	Bossuyt, Patrick M/0000-0003-4427-0128; Bossuyt, Patrick M./0000-0003-4427-0128; Dekker, Friedo W/0000-0002-2433-2494; Krediet, Raymond/0000-0002-9851-8507; 				Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; BERGSTROM J, 1993, KIDNEY INT, V44, P1048, DOI 10.1038/ki.1993.347; Bergstrom J, 1998, PERITON DIALYSIS INT, V18, P467; BONOMINI V, 1985, KIDNEY INT, V28, P57; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Davies SJ, 1998, NEPHROL DIAL TRANSPL, V13, P962, DOI 10.1093/ndt/13.4.962; Fink JC, 1999, AM J KIDNEY DIS, V34, P694, DOI 10.1016/S0272-6386(99)70395-1; Gokal R, 2000, PERITON DIALYSIS INT, V20, P386; HAKIM RM, 1995, J AM SOC NEPHROL, V6, P1319; Hunsicker LG, 1997, KIDNEY INT, V51, P1908, DOI 10.1038/ki.1997.260; Ifudu O, 1998, AM J NEPHROL, V18, P193, DOI 10.1159/000013336; Jacobs C, 2000, NEPHROL DIAL TRANSPL, V15, P305, DOI 10.1093/ndt/15.3.305; KHAN IH, 1993, LANCET, V341, P415, DOI 10.1016/0140-6736(93)93003-J; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; *NAT KIDN FDN, 1997, AM J KIDNEY DIS S, V30, pS1; National Kidney Foundation, 1997, AM J KIDNEY DIS, V30, pS67; Obrador GT, 1999, KIDNEY INT, V56, P2227, DOI 10.1046/j.1523-1755.1999.00779.x; Samuelsson O, 1998, J AM SOC NEPHROL, V9, P1482; TATTERSALL J, 1995, AM J NEPHROL, V15, P283, DOI 10.1159/000168850; Tonelli M., 1998, Journal of the American Society of Nephrology, V9, p80A; Van Biesen W, 1999, PERITON DIALYSIS INT, V19, pS273; WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27	22	158	165	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 29	2001	358	9287					1046	1050		10.1016/S0140-6736(01)06180-3	http://dx.doi.org/10.1016/S0140-6736(01)06180-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589934				2022-12-28	WOS:000171393100009
J	Montmerle, T				Montmerle, T			Astronomy - A stellar merry-go-round	SCIENCE			English	Editorial Material							X-RAY-EMISSION; STARS		CEA, Ctr Etud Saclay, Serv Astrophys, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Montmerle, T (corresponding author), CEA, Ctr Etud Saclay, Serv Astrophys, F-91191 Gif Sur Yvette, France.							Babcock H. W., 1947, PASP, V59, P112; BABCOCK HW, 1947, ASTROPHYS J, V105, P105, DOI 10.1086/144887; Babel J, 1997, ASTRON ASTROPHYS, V323, P121; Babel J, 1997, ASTROPHYS J, V485, pL29, DOI 10.1086/310806; DONATI JF, IN PRESS MON NOT R A; HAVNES O, 1984, ASTRON ASTROPHYS, V138, P421; SHORE SN, 1987, ASTRON J, V94, P731, DOI 10.1086/114511; SHORE SN, 1990, ASTROPHYS J, V365, P665, DOI 10.1086/169520; SMITH MA, IN PRESS ASTRON ASTR; TRIGILIO C, UNPUB	10	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2409	2410		10.1126/science.1065304	http://dx.doi.org/10.1126/science.1065304			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577226				2022-12-28	WOS:000171237200035
J	Shim, SH; Duffy, TS; Shen, GY				Shim, SH; Duffy, TS; Shen, GY			Stability and structure of MgSiO3 perovskite to 2300-kilometer depth in Earth's mantle	SCIENCE			English	Article							V-T EQUATION; HIGH-PRESSURE; (MG,FE)SIO3 PEROVSKITE; PHASE-TRANSITION; STATE; TEMPERATURE; DISSOCIATION; STISHOVITE; SILICA	Unexplained features have been observed seismically near the middle (similar to 1700-kilometer depth) and bottom of the Earth's tower mantle, and these could have important implications for the dynamics and evolution of the planet. (Mg,Fe)SiO3 perovskite is expected to be the dominant mineral in the deep mantle, but experimental results are discrepant regarding its stability and structure. Here we report in situ x-ray diffraction observations of (Mg,Fe)SiO3 perovskite at conditions (50 to 106 gigapascals, 1600 to 2400 kelvin) close to a mantle geotherm from three different starting materials, (Mg0.9Fe0.1)SiO enstatite, MgSiO3 glass, and an MgO+SiO2 mixture. Our results confirm the stability of (Mg,Fe)SiO3 perovskite to at least 2300-kitometer depth in the mantle. However, diffraction patterns above 83 gigapascals and 1700 kelvin (1900-kilometer depth) cannot presently rule out a possible transformation from Pbnm perovskite to one of three other possible perovskite structures with space group P2(1)/m, Pmmn, or P4(2)/nmc.	Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Univ Chicago, CARS, Chicago, IL 60637 USA	Princeton University; University of Chicago	Shim, SH (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.		Shen, Guoyin/D-6527-2011; Duffy, Thomas S/C-9140-2017	Shen, Guoyin/0000-0001-5146-1147; Duffy, Thomas S/0000-0002-5357-1259; Shim, Sang-Heon/0000-0001-5203-6038				Andrault D, 1998, SCIENCE, V282, P720, DOI 10.1126/science.282.5389.720; Andrault D, 2001, J GEOPHYS RES-SOL EA, V106, P2079, DOI 10.1029/2000JB900362; BROWN JM, 1981, GEOPHYS J ROY ASTRON, V66, P576; Dubrovinsky LS, 1997, NATURE, V388, P362, DOI 10.1038/41066; Dubrovinsky LS, 2001, CHEM PHYS LETT, V333, P264, DOI 10.1016/S0009-2614(00)01147-7; DUBROVINSKY LS, 1999, SCIENCE         0813; FINGER LW, 1981, APPL PHYS LETT, V39, P892, DOI 10.1063/1.92597; Fiquet G, 2000, GEOPHYS RES LETT, V27, P21, DOI 10.1029/1999GL008397; Fiquet G, 1998, PHYS EARTH PLANET IN, V105, P21, DOI 10.1016/S0031-9201(97)00077-0; GLAZER AM, 1972, ACTA CRYSTALLOGR B, VB 28, P3384, DOI 10.1107/S0567740872007976; HEMLEY RJ, 1994, SILICA PHYSICAL BEHA, P41; HOLMES NC, 1989, J APPL PHYS, V66, P2962, DOI 10.1063/1.344177; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; KIEFER B, 2000, EOS, V81, pS55; KINGMA KJ, 1995, NATURE, V374, P243, DOI 10.1038/374243a0; KNITTLE E, 1987, SCIENCE, V235, P668, DOI 10.1126/science.235.4789.668; LARSON AC, 1988, 86748 LAUR LOS AL NA; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; MEADE C, 1995, SCIENCE, V268, P1743, DOI 10.1126/science.268.5218.1743; Saxena SK, 1998, EUR J MINERAL, V10, P1275; Saxena SK, 1996, SCIENCE, V274, P1357, DOI 10.1126/science.274.5291.1357; Serghiou G, 1998, SCIENCE, V280, P2093, DOI 10.1126/science.280.5372.2093; SERGHIOU G, 1999, SCIENCE         0813; Shen GY, 2001, REV SCI INSTRUM, V72, P1273, DOI 10.1063/1.1343867; Shim SH, 2000, J GEOPHYS RES-SOL EA, V105, P25955, DOI 10.1029/2000JB900183; Sidorin I, 1999, SCIENCE, V286, P1326, DOI 10.1126/science.286.5443.1326; Speziale S, 2001, J GEOPHYS RES-SOL EA, V106, P515, DOI 10.1029/2000JB900318; Teter DM, 1998, PHYS REV LETT, V80, P2145, DOI 10.1103/PhysRevLett.80.2145; van der Hilst RD, 1999, SCIENCE, V283, P1885, DOI 10.1126/science.283.5409.1885; Woodward PM, 1997, ACTA CRYSTALLOGR B, V53, P32, DOI 10.1107/S0108768196010713	30	79	87	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2437	2440		10.1126/science.1061235	http://dx.doi.org/10.1126/science.1061235			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577232				2022-12-28	WOS:000171237200042
J	Jimba, M; Wakai, S				Jimba, M; Wakai, S			Is Gandhi's philosophy of non-violence dead in Nepal?	LANCET			English	Letter									Univ Tokyo, Dept Int Community Hlth, Tokyo, Japan; Sch & Community Hlth Project Off, Lalitpur, Nepal	University of Tokyo	Wakai, S (corresponding author), Univ Tokyo, Dept Int Community Hlth, Tokyo, Japan.		Jimba, Masamine/AAF-5630-2020					ADAMS V, 1998, DOCTORS DEMOCRACY HL, P3; BHATTARAI D, 2000, DISASTER REV 1998 19; MAHARJAN PN, 2000, DOMESTIC CONFLICT CR, P163; Noji Eric K, 1997, PUBLIC HLTH CONSEQUE, P7; UPADHYAYA KP, 2001, NEPAL HUMAN RIGHTS Y, P82	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					1017	1018		10.1016/S0140-6736(01)06148-7	http://dx.doi.org/10.1016/S0140-6736(01)06148-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11586993				2022-12-28	WOS:000171135300057
J	Miller, V; Savage, M				Miller, V; Savage, M			Changes in seismic anisotropy after volcanic eruptions: Evidence from Mount Ruapehu	SCIENCE			English	Article							SHEAR-WAVE POLARIZATIONS; NEW-ZEALAND; EARTHQUAKE PREDICTION; SOUTHERN-CALIFORNIA; QUANTITATIVE MEASUREMENTS; STRESS; DEFORMATION; TRANSITION; NETWORK; ROCK	The eruptions of andesite volcanoes are explosively catastrophic and notoriously difficult to predict. Yet changes in shear waveforms observed after an eruption of Mount Ruapehu, New Zealand, suggest that forces generated by such volcanoes are powerful and dynamic enough to locally overprint the regional stress regime, which suggests a new method of monitoring volcanoes for future eruptions. These results show a change in shear-wave polarization with time and are interpreted as being due to a localized stress regime caused by the volcano, with a release in pressure after the eruption.	Victoria Univ Wellington, Inst Geophys, Wellington, New Zealand	Victoria University Wellington	Savage, M (corresponding author), Victoria Univ Wellington, Inst Geophys, Wellington, New Zealand.		Savage, Martha K/F-1857-2011; Miller, Victoria/O-9063-2014	Savage, Martha K/0000-0002-2080-0676; Miller, Victoria/0000-0003-1962-9223				ASTER RC, 1990, J GEOPHYS RES-SOLID, V95, P12449, DOI 10.1029/JB095iB08p12449; ASTER RC, 1991, J GEOPHYS RES-SOLID, V96, P6415, DOI 10.1029/91JB00294; Audoine E, 2000, J GEOPHYS RES-SOL EA, V105, P8013, DOI 10.1029/1999JB900444; Bianco F, 1999, PHYS CHEM EARTH PT A, V24, P977, DOI 10.1016/S1464-1895(99)00145-3; CRAMPIN S, 1994, GEOPHYS J INT, V118, P428, DOI 10.1111/j.1365-246X.1994.tb03974.x; Crampin S, 1998, T ROY SOC EDIN-EARTH, V89, P121, DOI 10.1017/S0263593300007057; Crampin S, 1999, GEOPHYS J INT, V138, pF1, DOI 10.1046/j.1365-246x.1999.00891.x; CRAMPIN S, 1991, J GEOPHYS RES-SOLID, V96, P6403, DOI 10.1029/90JB02453; Crampin S., 1989, SCI DRILLING, V1, P21; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; FOURNIER RO, 1991, GEOPHYS RES LETT, V18, P955, DOI 10.1029/91GL00966; HACKETT RW, 1985, THESIS VICTORIA U WE; HROUDA F, 1993, PHYS EARTH PLANET IN, V77, P251, DOI 10.1016/0031-9201(93)90102-F; Hurst AW, 1998, B VOLCANOL, V60, P1, DOI 10.1007/s004450050212; LATTER JH, 1981, J VOLCANOL GEOTH RES, V10, P125, DOI 10.1016/0377-0273(81)90059-7; LAY T, 1995, MODERN GLOBAL SEISMO, pCH2; MILLER VL, 2000, THESIS VICTORIA U WE; Nairn IA, 1998, J VOLCANOL GEOTH RES, V86, P19, DOI 10.1016/S0377-0273(98)00085-7; NAIRN IA, 1981, NEW ZEAL J GEOL GEOP, V24, P585, DOI 10.1080/00288306.1981.10421534; Nakagawa M, 1999, B VOLCANOL, V61, P15, DOI 10.1007/s004450050259; NUTTLI OW, 1962, B SEISMOL SOC AM, V51, P237; Pacheco JF, 1999, J S AM EARTH SCI, V12, P567, DOI 10.1016/S0895-9811(99)00040-1; PARSONS T, 1991, SCIENCE, V253, P1399, DOI 10.1126/science.253.5026.1399; PEACOCK S, 1988, J GEOPHYS RES-SOLID, V93, P3339, DOI 10.1029/JB093iB04p03339; Saltzer RL, 2000, GEOPHYS J INT, V141, P374, DOI 10.1046/j.1365-246x.2000.00088.x; SAVAGE MK, 1990, J GEOPHYS RES-SOLID, V95, P11165, DOI 10.1029/JB095iB07p11165; SAVAGE MK, 1989, TECTONOPHYSICS, V165, P279, DOI 10.1016/0040-1951(89)90053-X; Sherburn S, 1999, J VOLCANOL GEOTH RES, V88, P255, DOI 10.1016/S0377-0273(99)00014-1; SILVER PG, 1991, J GEOPHYS RES-SOL EA, V96, P16429, DOI 10.1029/91JB00899; TAPLEY WC, 1992, SAC2000 COMMAND REFE; Zatsepin SV, 1997, GEOPHYS J INT, V129, P477, DOI 10.1111/j.1365-246X.1997.tb04488.x	31	83	86	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2231	2233		10.1126/science.1063463	http://dx.doi.org/10.1126/science.1063463			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567133				2022-12-28	WOS:000171139400036
J	Richardson, JE; Pennington, RT; Pennington, TD; Hollingsworth, PM				Richardson, JE; Pennington, RT; Pennington, TD; Hollingsworth, PM			Rapid diversification of a species-rich genus of neotropical rain forest trees	SCIENCE			English	Article							RIBOSOMAL DNA; SEQUENCES; CHLOROPLAST; DIVERGENCE; PHYLOGENY; DIVERSITY; FABACEAE; REGIONS	Species richness in the tropics has been attributed to the gradual accumulation of species over a long geological period in stable equatorial climates or, conversely, to speciation in response to late Tertiary geological events and unstable Pleistocene climates. DNA sequence data are consistent with recent diversification in Inga, a species-rich neotropical tree genus. We estimate that speciation was concentrated in the past 10 million years, with many species arising as recently as 2 million years ago. This coincides with the more recent major uplifts of the Andes, the bridging of the Isthmus of Panama, and Quaternary glacial cycles. Inga may be representative of other species-rich neotropical genera with rapid growth and reproduction, which contribute substantially to species numbers in the world's most diverse flora.	Royal Bot Garden Edinburgh, Edinburgh EH3 5LR, Midlothian, Scotland; Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA; Royal Bot Gardens, Richmond TW9 3AB, Surrey, England	University of California System; University of California Santa Cruz; Royal Botanic Gardens, Kew	Pennington, RT (corresponding author), Royal Bot Garden Edinburgh, 20A Inverleith Row, Edinburgh EH3 5LR, Midlothian, Scotland.	t.pennington@rbge.org.uk	Richardson, James-Edward/L-2768-2016	Richardson, James-Edward/0000-0001-9014-4865; Hollingsworth, Peter/0000-0003-0602-0654; Pennington, Toby/0000-0002-8196-288X				Baldwin BG, 1998, P NATL ACAD SCI USA, V95, P9402, DOI 10.1073/pnas.95.16.9402; Burnham RJ, 1999, ANN MO BOT GARD, V86, P546, DOI 10.2307/2666185; BUSH MB, 1994, J BIOGEOGR, V21, P5, DOI 10.2307/2845600; Coates Anthony G., 1996, P21; Comes HP, 1999, SYST ASSOC SPEC VOL, V57, P171; De Oliveira AA, 1999, BIODIVERS CONSERV, V8, P1219, DOI 10.1023/A:1008908615271; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Gentry A., 1989, TROPICAL FORESTS BOT, P113; GENTRY AH, 1982, ANN MO BOT GARD, V69, P557, DOI 10.2307/2399084; Haffer J., 1982, P6; Kass E, 1997, PLANT SYST EVOL, V208, P139, DOI 10.1007/BF00985439; KOPTUR S, 1984, EVOLUTION, V38, P1130, DOI 10.2307/2408445; LI WH, 1987, J MOL EVOL, V25, P330, DOI 10.1007/BF02603118; Mes THM, 1996, BOT ACTA, V109, P477, DOI 10.1111/j.1438-8677.1996.tb00601.x; Moritz C, 2000, ANNU REV ECOL SYST, V31, P533, DOI 10.1146/annurev.ecolsys.31.1.533; Pennington RT, 1996, SYST BIOL, V45, P496, DOI 10.2307/2413527; Pennington T.D., 1997, GENUS INGA BOT; PENNINGTON TD, 1998, GENUS INGA UTILIZATI, P159; Pennington TD, 1998, GENUS INGA UTILIZATI; RAMBAUT A, 2000, TREEEDIT VERSION 1 0; Richardson JE, 2001, TAXON, V50, P405, DOI 10.2307/1223889; Sanderson MJ, 1997, MOL BIOL EVOL, V14, P1218, DOI 10.1093/oxfordjournals.molbev.a025731; SANG T, 1994, AM J BOT, V81, P1494, DOI 10.2307/2445322; SANG T, 1995, SYST BOT, V20, P55, DOI 10.2307/2419632; Stebbins G. L., 1974, EVOLUTION SPECIES LE; SUH YB, 1993, AM J BOT, V80, P1042, DOI 10.2307/2445752; Swofford D.L., 1998, PAUP 4 0B2 PHYLOGENE; Thomas WW, 1999, BIODIVERS CONSERV, V8, P1007, DOI 10.1023/A:1008857429787; VALENCIA R, 1994, BIODIVERS CONSERV, V3, P21, DOI 10.1007/BF00115330; Vargas P, 1999, AM J BOT, V86, P724, DOI 10.2307/2656582; WENDEL JF, 1995, MOL PHYLOGENET EVOL, V4, P298, DOI 10.1006/mpev.1995.1027; WHITEMORE TC, 1987, BIOGEOGRAPHY QUATERN; WHITEMORE TC, 1998, INTRO TROPICAL RAINF; Wojciechowski MF, 1999, SYST BOT, V24, P409, DOI 10.2307/2419698; WOLFE KH, 1987, P NATL ACAD SCI USA, V84, P9054, DOI 10.1073/pnas.84.24.9054; ZURAWSKI G, 1984, GENETICS, V106, P735	36	585	608	3	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2242	2245		10.1126/science.1061421	http://dx.doi.org/10.1126/science.1061421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567135				2022-12-28	WOS:000171139400040
J	Pitot, HC				Pitot, HC			Pathways of progression in hepatocarcinogenesis	LANCET			English	Editorial Material							GENETIC MODEL; CANCER		Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Pitot, HC (corresponding author), Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA.	pitot@oncology.wisc.edu						Ames BN, 1998, TOXICOL LETT, V103, P5, DOI 10.1016/S0378-4274(98)00282-3; BOVERI T, 1914, FRAGE ENSTEBHUNG MAL; BUHLER H, 1982, GASTROENTEROLOGY, V82, P775; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GAREWAL HS, 1991, HEMATOL ONCOL CLIN N, V5, P69, DOI 10.1016/S0889-8588(18)30454-4; HALPERN MT, 1993, JNCI-J NATL CANCER I, V85, P457, DOI 10.1093/jnci/85.6.457; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Miyaki M, 1999, CANCER RES, V59, P4506; MOORE MA, 1987, CARCINOGENESIS, V8, P483, DOI 10.1093/carcin/8.3.483; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; Pitot H, 2001, CHEM CARCINOGENESIS, P241; Sargent LM, 1997, CANCER RES, V57, P3451; Simile MM, 1996, CARCINOGENESIS, V17, P1533, DOI 10.1093/carcin/17.7.1533; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719	15	21	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 15	2001	358	9285					859	860		10.1016/S0140-6736(01)06038-X	http://dx.doi.org/10.1016/S0140-6736(01)06038-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567698				2022-12-28	WOS:000171087000005
J	MacLehose, L; Brand, H; Camaroni, I; Fulop, N; Gill, ON; Reintjes, R; Schaefer, O; McKee, M; Weinberg, J				MacLehose, L; Brand, H; Camaroni, I; Fulop, N; Gill, ON; Reintjes, R; Schaefer, O; McKee, M; Weinberg, J			Communicable disease outbreaks involving more than one country: systems approach to evaluating the response	BRITISH MEDICAL JOURNAL			English	Article							SURVEILLANCE; ENGLAND		Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; PHLS, Ctr Communicable Dis Surveillance, Cardiff CF4 3QX, S Glam, Wales; Inst Publ Hlth N Rhine Westfalia, Munster, Germany; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	Public Health England; University of London; London School of Hygiene & Tropical Medicine	Weinberg, J (corresponding author), City Univ London, London EC1 0HV, England.		Mckee, Martin/E-6673-2018; McKee, Marc D/E-2187-2011; Brand, Helmut/F-6368-2013	Mckee, Martin/0000-0002-0121-9683; McKee, Marc D/0000-0001-8349-965X; Brand, Helmut/0000-0002-2755-0673; Weinberg, Julius/0000-0001-5973-359X; Fulop, Naomi/0000-0001-5306-6140				[Anonymous], 1997, Commun Dis Rep CDR Wkly, V7, P36; Burgess R., 1982, FIELD RES SOURCEBOOK; CHECKLAND P, 1994, AM BEHAV SCI, V38, P75, DOI 10.1177/0002764294038001007; DESENCLOS JC, 1993, LANCET, V341, P1003, DOI 10.1016/0140-6736(93)91084-Y; FISHER I, 1994, PHLS MICROBIOL DIGES, V9, P107; Giesecke J, 1998, LANCET, V352, P1308, DOI 10.1016/S0140-6736(98)00042-7; Joseph C, 1996, EUR J EPIDEMIOL, V12, P215, DOI 10.1007/BF00145408; Killalea D, 1996, BMJ-BRIT MED J, V313, P1105, DOI 10.1136/bmj.313.7065.1105; Lavanchy D, 1998, Euro Surveill, V3, P23; Mounts AW, 1999, J INFECT DIS, V180, P505, DOI 10.1086/314903; *NAT ADV COMM MICR, 1998, J FOOD PROTECT, V61, P1246; SAMUELSSON S, 1999, THESIS U SO DENMARK; Sorensen H T, 1995, Int J Risk Saf Med, V7, P179, DOI 10.3233/JRS-1995-7303; Threlfall EJ, 1998, EPIDEMIOL INFECT, V121, P289, DOI 10.1017/S0950268898001149; Van Steenbergen J.E., 1999, Euro Surveill, V4, P18; VANLOOCK F, 1997, EUROSURVEILLANCE JUN; Wheeler JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/bmj.318.7190.1046; Yin R.K., 1994, CASE STUDY RES; 1996, COMMUN DIS REP CDR W, V6, P355	19	19	19	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 13	2001	323	7317					861	863		10.1136/bmj.323.7317.861	http://dx.doi.org/10.1136/bmj.323.7317.861			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597974	Green Accepted, Green Published			2022-12-28	WOS:000171650500036
J	Venters, GA				Venters, GA			New variant Creutzfeldt-Jakob disease: the epidemic that never was	BRITISH MEDICAL JOURNAL			English	Article							TRANSMISSION; BSE; CJD		Lanarkshire Hlth Board, Hamilton ML3 OTA, Scotland		Venters, GA (corresponding author), Lanarkshire Hlth Board, Hamilton ML3 OTA, Scotland.							Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Brown P, 2001, BRIT MED J, V322, P841, DOI 10.1136/bmj.322.7290.841; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; CHIN JE, 2000, CONTROL COMMUNICABLE, P183; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Cornell J, 1998, Commun Dis Public Health, V1, P28; Creutzfeldt HG, 1920, Z GESAMTE NEUROL PSY, V57, P1, DOI 10.1007/BF02866081; GARCIA R, 1967, ACTA NEUROPATHOLO S3, V3, P145; JAKOB H, 1967, ACTA NEUROPATHOLO S3, V3, P148; KIRSCHBAUM WR, 1968, J CREUTZFELDT DIS; Lantos PL, 1997, LANCET, V350, P187, DOI 10.1016/S0140-6736(05)62355-0; LINDENBAUM S, 1979, KURW SORCERY DIS DAN; NISSL F, 1921, HISTOL HISTOPATH, V6, P1; Patterson W J, 1999, Commun Dis Public Health, V2, P5; Scott MR, 1999, P NATL ACAD SCI USA, V96, P15137, DOI 10.1073/pnas.96.26.15137; Skrabanek P, 1989, FOLLIES FALLACIES ME, P30; Will RG, 2000, ANN NEUROL, V47, P575; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	19	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 13	2001	323	7317					858	861		10.1136/bmj.323.7317.858	http://dx.doi.org/10.1136/bmj.323.7317.858			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597973	Green Published			2022-12-28	WOS:000171650500035
J	Vidale, JE				Vidale, JE			Geophysics - Peeling back the layers in Earth's mantle	SCIENCE			English	Editorial Material							DISCONTINUITY; TRANSITION		Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Vidale, JE (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.		Vidale, John/H-4965-2011	Vidale, John/0000-0002-3658-818X				BENZ HM, 1993, NATURE, V365, P147, DOI 10.1038/365147a0; Chaljub E, 1997, GEOPHYS RES LETT, V24, P2613, DOI 10.1029/97GL52693; Deuss A, 2001, SCIENCE, V294, P354, DOI 10.1126/science.1063524; Flanagan MP, 1998, J GEOPHYS RES-SOL EA, V103, P2673, DOI 10.1029/97JB03212; ITA J, 1992, J GEOPHYS RES-SOL EA, V97, P6849, DOI 10.1029/92JB00068; JONES LE, 1992, J GEOPHYS RES-SOL EA, V97, P8765, DOI 10.1029/92JB00887; JORDAN TH, 1988, J PETROL, P11, DOI DOI 10.1093/PETROLOGY/SPECIAL_VOLUME.1.11; REVENAUGH J, 1991, J GEOPHYS RES-SOL EA, V96, P19763, DOI 10.1029/91JB01486; SHEARER PM, 1990, NATURE, V344, P121, DOI 10.1038/344121a0; Stixrude L, 1997, J GEOPHYS RES-SOL EA, V102, P14835, DOI 10.1029/97JB00550; TACKLEY PJ, 1993, NATURE, V361, P699, DOI 10.1038/361699a0; VIDALE JE, 1992, NATURE, V356, P678, DOI 10.1038/356678a0	12	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					313	313		10.1126/science.1065715	http://dx.doi.org/10.1126/science.1065715			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598286				2022-12-28	WOS:000171601400026
J	Baker, DW; Sudano, JJ; Albert, JM; Borawski, EA; Dor, A				Baker, DW; Sudano, JJ; Albert, JM; Borawski, EA; Dor, A			Lack of health insurance and decline in overall health in late middle age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL-CARE; MORTALITY; COVERAGE; TERMINATION; SKEPTICISM; OUTCOMES; ABILITY; ADULTS; COHORT	Background: The number of adults in their 50s and 60s in the United States who do not have health insurance is increasing. This group may be particularly vulnerable to the ill effects of being uninsured. Methods: We conducted a prospective cohort study using files from the Health and Retirement Study, a national survey of adults who were 51 to 61 years old in 1992. We determined the risks of a major decline in overall health and of the development of new physical difficulties between 1992 and 1996 for participants who were continuously uninsured (uninsured in 1992 and in 1994), those who were intermittently uninsured (uninsured either in 1992 or in 1994), and those who were continuously insured. We used logistic regression to determine the independent effects of being uninsured on health outcomes after adjustment for base-line sociodemographic factors, preexisting medical conditions, and types of health-related behavior such as smoking and alcohol use. Results: We analyzed data for 7577 participants. The 717 continuously uninsured participants and the 825 intermittently uninsured participants were more likely than the 6035 continuously insured participants to have a major decline in overall health between 1992 and 1996 (21.6 percent, 16.1 percent, and 8.3 percent of the three groups, respectively; P<0.001 for both comparisons). According to a multivariate analysis, the adjusted relative risk of a major decline in overall health was 1.63 (95 percent confidence interval, 1.26 to 2.08) for continuously uninsured participants and 1.41 (95 percent confidence interval, 1.11 to 1.78) for intermittently uninsured participants, as compared with continuously insured participants. A new difficulty in walking or climbing stairs was also more likely to develop in the continuously or intermittently uninsured participants than in the continuously insured participants (28.8 percent, 26.4 percent, and 17.1 percent of the three groups, respectively; P<0.001 for both comparisons). The adjusted relative risk of such a new physical difficulty was 1.23 (95 percent confidence interval, 1.02 to 1.47) for the continuously uninsured participants and 1.26 (95 percent confidence interval, 1.01 to 1.54) for the intermittently uninsured participants. Conclusions: The lack of health insurance is associated with an increased risk of a decline in overall health among adults 51 to 61 years old. (N Engl J Med 2001;345:1106-12.) Copyright (C) 2001 Massachusetts Medical Society.	Metrohlth Med Ctr, Ctr Hlth Care Res & Policy, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Econ, Cleveland, OH 44106 USA	MetroHealth System; Case Western Reserve University; Case Western Reserve University	Baker, DW (corresponding author), Metrohlth Med Ctr, Ctr Hlth Care Res & Policy, 2500 Metrohlth Dr,Rammelkamp 221, Cleveland, OH 44109 USA.		Borawski, Elaine/R-9959-2019; Albert, Jeffrey/P-7273-2019	Borawski, Elaine/0000-0001-7629-6889; Albert, Jeffrey/0000-0003-2245-1745	AHRQ HHS [R01 HS10283-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010283] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM COLL PHYS AM S, 2000, NO HLTH INS ITS ENOU; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; Baker DW, 1997, MED CARE, V35, P1, DOI 10.1097/00005650-199701000-00001; BERK ML, 1995, HEALTH AFFAIR, V14, P139, DOI 10.1377/hlthaff.14.3.139; BURSTIN HR, 1999, INQUIRY, V35, P389; Clark DO, 1998, AM J EPIDEMIOL, V148, P63, DOI 10.1093/oxfordjournals.aje.a009561; Cunningham PJ, 1998, JAMA-J AM MED ASSOC, V280, P921, DOI 10.1001/jama.280.10.921; FIHN SD, 1988, J GEN INTERN MED, V3, P356, DOI 10.1007/BF02595794; FILLENBAUM GG, 1993, 20 ITEM WORD LIST TE; Fiscella K, 1998, MED CARE, V36, P180, DOI 10.1097/00005650-199802000-00007; Fiscella K, 1999, MED CARE, V37, P409, DOI 10.1097/00005650-199904000-00010; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; Heeringa S.G., 1995, TECHNICAL DESCRIPTIO; JENSEN GA, 1992, MED CARE, V30, P598, DOI 10.1097/00005650-199207000-00003; Jensen GA, 1998, MED CARE, V36, P107, DOI 10.1097/00005650-199802000-00001; Korn EL., 1999, ANAL HLTH SURVEYS; LOPREST P, 1997, UNINSURED OLDER ADUL; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391; RHOADES J, 2000, AHRQ PUBLICATION; ROWLAND D, 1998, FUTURE US HEALTHCARE, P25; Schoen C, 2000, HEALTH SERV RES, V35, P187; Shea DG, 2001, HEALTH AFFAIR, V20, P219, DOI 10.1377/hlthaff.20.1.219; Sloan FA, 1998, MED CARE, V36, P110, DOI 10.1097/00005650-199802000-00002; SORLIE PD, 1994, ARCH INTERN MED, V154, P2409, DOI 10.1001/archinte.154.21.2409; VERBRUGGE LM, 1989, MILBANK Q, V67, P450, DOI 10.2307/3350223; Weissman JS., 1994, FALLING SAFETY NET I; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	31	186	187	3	21	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2001	345	15					1106	1112		10.1056/NEJMsa002887	http://dx.doi.org/10.1056/NEJMsa002887			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	480QH	11596591				2022-12-28	WOS:000171473100006
J	Herbert, RD; Maher, CG; Moseley, AM; Sherrington, C				Herbert, RD; Maher, CG; Moseley, AM; Sherrington, C			Regular review - Effective physiotherapy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; PULMONARY REHABILITATION; SYSTEMATIC REVIEWS; RISK-FACTORS; EXERCISE; THERAPY; STROKE; INTENSITY; PEOPLE; REDUCE		Univ Sydney, Sch Physiotherapy, Lidcombe, NSW 1825, Australia; Prince Wales Med Res Inst, St Pauls, NSW 2031, Australia; Univ Sydney, Rehabil Studies Unit, Ryde, NSW 1680, Australia	University of Sydney; Prince Wales Medical Research Institute; University of Sydney	Herbert, RD (corresponding author), Univ Sydney, Sch Physiotherapy, POB 170, Lidcombe, NSW 1825, Australia.	R.Herbert@cchs.usyd.edu.au	Sherrington, Catherine/S-9196-2019; Maher, Christopher/AAC-6267-2019	Sherrington, Catherine/0000-0001-8934-4368; Maher, Christopher/0000-0002-1628-7857; Herbert, Rob/0000-0003-4188-9195				ANNANE D, 2001, COCHRANE DATABASE SY; Bo K, 2000, ACTA OBSTET GYN SCAN, V79, P598, DOI 10.1034/j.1600-0412.2000.079007598.x; Cambach W, 1999, ARCH PHYS MED REHAB, V80, P103, DOI 10.1016/S0003-9993(99)90316-7; *CLIN STAND ADV GR, 1994, CLIN STAND ADV GROUP; *CTR EV BAS PHYS, 2001, PEDR PHYS EV DAT; Dromerick AW, 2000, STROKE, V31, P2984, DOI 10.1161/01.STR.31.12.2984; Feine JS, 1997, PAIN, V71, P5, DOI 10.1016/S0304-3959(96)03287-3; FURLAN AD, 2000, COCHRANE DATABASE SY; Gardner MM, 2000, BRIT J SPORT MED, V34, P7, DOI 10.1136/bjsm.34.1.7; Gardner MM, 2001, AGE AGEING, V30, P77, DOI 10.1093/ageing/30.1.77; Gillespie LD, 2001, COCHRANE DATABASE SY; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; HAGEN KB, 2001, COCHRANE DATABASE SY; Hannestad YS, 2000, J CLIN EPIDEMIOL, V53, P1150, DOI 10.1016/S0895-4356(00)00232-8; HAYSMITH EJC, 2001, COCHRANE DATABASE SY; HERBISON P, 2001, COCHRANE DATABASE SY; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Moffett JK, 1999, BRIT MED J, V319, P279, DOI 10.1136/bmj.319.7205.279; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; Olsen MF, 1997, BRIT J SURG, V84, P1535, DOI 10.1002/bjs.1800841111; Patman S, 2001, AUST J PHYSIOTHER, V47, P7, DOI 10.1016/S0004-9514(14)60294-4; *STROK UN TRIAL CO, 2001, COCHR DAT SYST REV; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Van Baar ME, 1999, ARTHRITIS RHEUM-US, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9; VANDENENDE CHM, 2001, COCHRANE DATABASE SY; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Waddell G, 1997, BRIT J GEN PRACT, V47, P647	31	16	16	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 6	2001	323	7316					788	790		10.1136/bmj.323.7316.788	http://dx.doi.org/10.1136/bmj.323.7316.788			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481LK	11588084	Green Published			2022-12-28	WOS:000171520600032
J	Friedberg, EC; Fischhaber, PL; Kisker, C				Friedberg, EC; Fischhaber, PL; Kisker, C			Error-prone DNA polymerases: Novel structures and the benefits of infidelity	CELL			English	Review							CRYSTAL-STRUCTURE; Y-FAMILY; REPLICATION; BYPASS; ETA	Studies on several recently discovered error-prone DNA polymerases reveal novel structures that may explain the low fidelity of this general class of enzymes, a number of which are involved in the replicative bypass (translesion synthesis) of base damage in DNA.	Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA; SUNY Stony Brook, Dept Pharmacol Sci, Ctr Struct Biol, Stony Brook, NY 11794 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA.	errol.friedberg@utsouthwestern.edu	Kisker, Caroline/T-1724-2019	Kisker, Caroline/0000-0002-0216-6026				Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Gerlach VL, 2000, COLD SPRING HARB SYM, V65, P41, DOI 10.1101/sqb.2000.65.41; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Masutani C, 2000, COLD SPRING HARB SYM, V65, P71, DOI 10.1101/sqb.2000.65.71; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Prakash S, 2000, COLD SPRING HARB SYM, V65, P51, DOI 10.1101/sqb.2000.65.51; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; WANG Z, 2001, DNA REP, V486, P59; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	17	103	112	2	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 5	2001	107	1					9	12		10.1016/S0092-8674(01)00509-8	http://dx.doi.org/10.1016/S0092-8674(01)00509-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595180	Bronze			2022-12-28	WOS:000171453100004
J	Schueler, MG; Higgins, AW; Rudd, MK; Gustashaw, K; Willard, HF				Schueler, MG; Higgins, AW; Rudd, MK; Gustashaw, K; Willard, HF			Genomic and genetic definition of a functional human centromere	SCIENCE			English	Article							ALPHA-SATELLITE DNA; HUMAN X-CHROMOSOME; SEQUENCE-ANALYSIS; EVOLUTION; INACTIVATION; ISOCHROMOSOMES; RECOMBINATION; ORGANIZATION; HYPOTHESIS; PRIMATES	The definition of centromeres of human chromosomes requires a complete genomic understanding of these regions. Toward this end, we report integration of physical mapping, genetic, and functional approaches, together with sequencing of selected regions, to define the centromere of the human X chromosome and to explore the evolution of sequences responsible for chromosome segregation. The transitional region between expressed sequences on the short arm of the X and the chromosome-specific alpha satellite array DXZ1 spans about 450 kilobases and is satellite-rich. At the junction between this satellite region and canonical DXZ1 repeats, diverged repeat units provide direct evidence of unequal crossover as the homogenizing force of these arrays. Results from deletion analysis of mitotically stable chromosome rearrangements and from a human artificial chromosome assay demonstrate that DXZ1 DNA is sufficient for centromere function. Evolutionary studies indicate that, white alpha satellite DNA present throughout the pericentromeric region of the X chromosome appears to be a descendant of an ancestral primate centromere, the current functional centromere based on DXZ1 sequences is the product of the much more recent concerted evolution of this satellite DNA.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; University Hospitals of Cleveland	Willard, HF (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.	willard@uhri.org			NHGRI NIH HHS [HG00107] Funding Source: Medline; NICHD NIH HHS [HD07518, HD32111] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD032111] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alexandrov I, 2001, CHROMOSOMA, V110, P253, DOI 10.1007/s004120100146; ALEXANDROV IA, 1993, NUCLEIC ACIDS RES, V21, P2209; Bailey JA, 2000, P NATL ACAD SCI USA, V97, P6634, DOI 10.1073/pnas.97.12.6634; Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; Choo KHA, 2000, TRENDS CELL BIOL, V10, P182, DOI 10.1016/S0962-8924(00)01739-6; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; Darlington CD, 1939, J GENET, V37, P341, DOI 10.1007/BF02982733; DONEHOWER L, 1979, J MOL BIOL, V134, P805, DOI 10.1016/0022-2836(79)90487-X; DURFY SJ, 1989, GENOMICS, V5, P810, DOI 10.1016/0888-7543(89)90123-7; Ebersole TA, 2000, HUM MOL GENET, V9, P1623, DOI 10.1093/hmg/9.11.1623; Goldberg IG, 1996, MOL CELL BIOL, V16, P5156; GREIG GM, 1993, HUM MOL GENET, V2, P1611; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Henikoff S, 2001, SCIENCE, V293, P1098, DOI 10.1126/science.1062939; Higgins AW, 1999, CHROMOSOMA, V108, P256, DOI 10.1007/s004120050376; Horvath JE, 2000, HUM MOL GENET, V9, P113, DOI 10.1093/hmg/9.1.113; Horvath JE, 2000, GENOME RES, V10, P839, DOI 10.1101/gr.10.6.839; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laurent AM, 1997, GENOMICS, V46, P127, DOI 10.1006/geno.1997.4987; Laurent AM, 1999, CHROMOSOME RES, V7, P305, DOI 10.1023/A:1009283015738; Lee C, 2000, CHROMOSOMA, V109, P381, DOI 10.1007/s004120000095; Mahtani MM, 1998, GENOME RES, V8, P100, DOI 10.1101/gr.8.2.100; MILLER AP, 1995, HUM MOL GENET, V4, P731, DOI 10.1093/hmg/4.4.731; Montefalcone G, 1999, GENOME RES, V9, P1184, DOI 10.1101/gr.9.12.1184; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; OHNO S, 1973, NATURE, V244, P259, DOI 10.1038/244259a0; Puechberty J, 1999, GENOMICS, V56, P274, DOI 10.1006/geno.1999.5742; ROSENBERG H, 1978, SCIENCE, V200, P394, DOI 10.1126/science.205944; Schueler MG, 2000, GENOMICS, V66, P104, DOI 10.1006/geno.2000.6180; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; SMITH GP, 1976, SCIENCE, V191, P528, DOI 10.1126/science.1251186; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; Sullivan BA, 2001, NAT REV GENET, V2, P584, DOI 10.1038/35084512; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Ventura M, 2001, GENOME RES, V11, P595, DOI 10.1101/gr.152101; Warburton PE, 2001, TRENDS GENET, V17, P243, DOI 10.1016/S0168-9525(01)02283-1; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; Warburton PE, 1996, HUMAN GENOME EVOLUTI, P121; WAYE JS, 1985, NUCLEIC ACIDS RES, V13, P2731, DOI 10.1093/nar/13.8.2731; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; Willard HF, 1998, CURR OPIN GENET DEV, V8, P219, DOI 10.1016/S0959-437X(98)80144-5; Wolff DJ, 1996, AM J HUM GENET, V58, P154	43	360	375	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					109	115		10.1126/science.1065042	http://dx.doi.org/10.1126/science.1065042			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588252				2022-12-28	WOS:000171448800040
J	Chen, GY; Tseng, GC				Chen, GY; Tseng, GC			Mucinous cystadenoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Tao Yuan Gen Hosp, Tao Yuan, Taiwan		Chen, GY (corresponding author), Tao Yuan Gen Hosp, Tao Yuan, Taiwan.								0	5	5	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1041	1041		10.1056/NEJMicm960402	http://dx.doi.org/10.1056/NEJMicm960402			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586957				2022-12-28	WOS:000171340400006
J	Harvey, J				Harvey, J			The natural economy	NATURE			English	Article									NIOO NAW, Netherlands Institute of Ecology, Ctr Terr Ecol, Dept Multitroph Interact, NL-6666 ZG Heteren, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Harvey, J (corresponding author), NIOO NAW, Netherlands Institute of Ecology, Ctr Terr Ecol, Dept Multitroph Interact, POB 40, NL-6666 ZG Heteren, Netherlands.		Harvey, Jeffrey A/B-7439-2008	Harvey, Jeffrey A/0000-0002-4227-7935				BASKIN Y, 1997, WORK NATURE; Jones C. G., 1995, LINKING SPECIES ECOS; LEVIN SA, 1999, FRAGILE DOMINION COR; Maurer BA, 1999, UNTANGLING ECOLOGICA; Pimm SL, 1991, BALANCE NATURE ECOLO	5	6	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					463	463		10.1038/35097209	http://dx.doi.org/10.1038/35097209			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586335	Bronze			2022-12-28	WOS:000171340500024
J	Hugosson, HW; Jansson, U; Johansson, B; Eriksson, O				Hugosson, HW; Jansson, U; Johansson, B; Eriksson, O			Restricting dislocation movement in transition metal carbides by phase stability tuning	SCIENCE			English	Article							BAND-STRUCTURE; HARDNESS; CARBON; SUPERLATTICES; DEPOSITION; TI	A mechanism to enhance hardness in multilayer coatings is proposed. Using the technologically important hard transition metal carbides as prototypes, although the principle is transferable also to other systems, we demonstrate, from first-principles calculations, that by suitable alloying the energy difference between several competing structures in the transition meta[ carbides is small or tunable. This creates multiphase/polytypic compounds with a random or controllable layer stacking sequence, systems in which the propagation of dislocations can be strongly suppressed by a large number of interfaces between structures with different glide systems, accordingly allowing the possibility of a greatly enhanced hardness. With modern thin-film technologies, it should therefore be possible to deposit such materials that will express multilayer characteristics with only minor changes in the chemical constitution of the material, which is in contrast to conventional superlattices.	Uppsala Univ, Dept Phys, Condensed Matter Theory Grp, S-75121 Uppsala, Sweden; Uppsala Univ, Angstrom Lab, Dept Chem Mat, S-75121 Uppsala, Sweden; Royal Inst Technol, Dept Mat Sci & Engn, S-10044 Stockholm, Sweden	Uppsala University; Uppsala University; Royal Institute of Technology	Hugosson, HW (corresponding author), Uppsala Univ, Dept Phys, Condensed Matter Theory Grp, Box 530, S-75121 Uppsala, Sweden.	hakan.hugosson@fysik.uu.se	Hugosson, Håkan/D-3358-2014; Hugosson, Håkan/GXZ-6101-2022; Eriksson, Olle/E-3265-2014	Hugosson, Håkan/0000-0001-8748-3890; Eriksson, Olle/0000-0001-5111-1374				Barnett S, 1998, PHYS WORLD, V11, P45; Boxman RL, 2000, SURF COAT TECH, V125, P257, DOI 10.1016/S0257-8972(99)00570-8; Goldschmidt HJ., 1967, INTERSTITIAL ALLOYS, P88, DOI [10.1007/978-1-4899-5880-8, DOI 10.1007/978-1-4899-5880-8]; HELMERSSON U, 1987, J APPL PHYS, V62, P481, DOI 10.1063/1.339770; Hugosson HW, 1999, J APPL PHYS, V86, P3758, DOI 10.1063/1.371284; Hultman L, 1999, Z METALLKD, V90, P803; Jhi SH, 1999, NATURE, V399, P132, DOI 10.1038/20148; JOHANSSON LI, 1995, SURF SCI REP, V21, P179; Kelly A., 1986, STRONG SOLIDS; KNOTEK O, 1990, THIN SOLID FILMS, V193, P557, DOI 10.1016/S0040-6090(05)80065-3; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558; LIU AY, 1988, PHYS REV B, V38, P9483, DOI 10.1103/PhysRevB.38.9483; Lu J, 2000, THIN SOLID FILMS, V370, P203, DOI 10.1016/S0040-6090(00)00750-1; Maerky C, 1996, MAT SCI ENG A-STRUCT, V209, P329, DOI 10.1016/0921-5093(95)10152-7; Norin L, 1998, APPL PHYS LETT, V73, P2754, DOI 10.1063/1.122580; PRICE DL, 1989, PHYS REV B, V39, P4945, DOI 10.1103/PhysRevB.39.4945; REDINGER J, 1985, J PHYS CHEM SOLIDS, V46, P383, DOI 10.1016/0022-3697(85)90183-0; SCHWARZ K, 1987, CRC CR REV SOL STATE, V13, P211, DOI 10.1080/10408438708242178; Toth L., 1971, TRANSITION METAL CAR; VELIKANOVA TY, 1988, SOV POWDER METALL+, V27, P891; Wills JM, 2000, LECT NOTES PHYS, V535, P148	22	90	91	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2434	2437		10.1126/science.1060512	http://dx.doi.org/10.1126/science.1060512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577231				2022-12-28	WOS:000171237200041
J	Barbeau, K; Rue, EL; Bruland, KW; Butler, A				Barbeau, K; Rue, EL; Bruland, KW; Butler, A			Photochemical cycling of iron in the surface ocean mediated by microbial iron(III)-binding ligands	NATURE			English	Article							EQUATORIAL PACIFIC-OCEAN; CATHODIC STRIPPING VOLTAMMETRY; MARINE-BACTERIA; SIDEROPHORE PRODUCTION; PHYTOPLANKTON BLOOM; COMPLEXATION; CHEMISTRY; SEAWATER; FERTILIZATION; CYANOBACTERIA	Iron is a limiting nutrient for primary production in large areas of the oceans(1-4). Dissolved iron(III) in the upper oceans occurs almost entirely in the form of complexes with strong organic ligands(5-7) presumed to be of biological origin(8,9). Although the importance of organic ligands to aquatic iron cycling is becoming clear, the mechanism by which they are involved in this process remains uncertain. Here we report observations of photochemical reactions involving Fe(III) bound to siderophores-high-affinity iron(III) ligands produced by bacteria to facilitate iron acquisition(10-12). We show that photolysis of Fe(III)-siderophore complexes leads to the formation of lower-affinity Fe(III) ligands and the reduction of Fe(III), increasing the availability of siderophore-bound iron for uptake by planktonic assemblages. These photochemical reactions are mediated by the alpha -hydroxy acid moiety, a group which has generally been found to be present in the marine siderophores that have been characterized(13-15). We suggest that Fe(III)-binding ligands can enhance the photolytic production of reactive iron species in the euphotic zone and so influence iron availability in aquatic systems.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Univ Calif Santa Cruz, Inst Marine Sci, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Cruz	Butler, A (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.		Butler, Alison/D-5094-2015	Butler, Alison/0000-0002-3525-7864; Barbeau, Katherine/0000-0002-2132-7219				Albrecht-Gary AM, 1998, MET IONS BIOL SYST, V35, P239; Archer DE, 2000, GLOBAL BIOGEOCHEM CY, V14, P269, DOI 10.1029/1999GB900053; Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; DONAT JR, 1988, ANAL CHEM, V60, P240, DOI 10.1021/ac00154a011; Emmenegger L, 1998, ENVIRON SCI TECHNOL, V32, P2990, DOI 10.1021/es980207g; FAUST BC, 1993, ENVIRON SCI TECHNOL, V27, P2517, DOI 10.1021/es00048a032; GLEDHILL M, 1994, MAR CHEM, V47, P41, DOI 10.1016/0304-4203(94)90012-4; Granger J, 1999, LIMNOL OCEANOGR, V44, P541, DOI 10.4319/lo.1999.44.3.0541; HAYGOOD MG, 1993, LIMNOL OCEANOGR, V38, P1091, DOI 10.4319/lo.1993.38.5.1091; HUDSON RJM, 1989, LIMNOL OCEANOGR, V34, P1113, DOI 10.4319/lo.1989.34.6.1113; Hutchins DA, 1999, NATURE, V400, P858, DOI 10.1038/23680; Hutchins DA, 1998, NATURE, V393, P561, DOI 10.1038/31203; Johnson KS, 1997, MAR CHEM, V57, P137, DOI 10.1016/S0304-4203(97)00043-1; JOHNSON KS, 1994, MAR CHEM, V46, P319, DOI 10.1016/0304-4203(94)90029-9; LEWIS BL, 1995, MAR CHEM, V50, P179, DOI 10.1016/0304-4203(95)00034-O; MACRELLIS HM, IN PRESS MAR CHEM; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; Martinez JS, 2000, SCIENCE, V287, P1245, DOI 10.1126/science.287.5456.1245; OSULLIVAN DW, 1991, LIMNOL OCEANOGR, V36, P1727, DOI 10.4319/lo.1991.36.8.1727; REID RT, 1993, NATURE, V366, P455, DOI 10.1038/366455a0; RUE EL, 1995, MAR CHEM, V50, P117, DOI 10.1016/0304-4203(95)00031-L; Rue EL, 1997, LIMNOL OCEANOGR, V42, P901, DOI 10.4319/lo.1997.42.5.0901; TRICK CG, 1989, CURR MICROBIOL, V18, P375, DOI 10.1007/BF01571131; WAITE TD, 1995, MAR CHEM, V50, P79, DOI 10.1016/0304-4203(95)00028-P; WELLS ML, 1991, NATURE, V353, P248, DOI 10.1038/353248a0; WILHELM SW, 1994, LIMNOL OCEANOGR, V39, P1979, DOI 10.4319/lo.1994.39.8.1979; WU JF, 1995, MAR CHEM, V50, P159, DOI 10.1016/0304-4203(95)00033-N; ZUO YG, 1992, ENVIRON SCI TECHNOL, V26, P1014, DOI 10.1021/es00029a022	30	389	401	5	188	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					409	413		10.1038/35096545	http://dx.doi.org/10.1038/35096545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574885				2022-12-28	WOS:000171188700051
J	Edwards, RG				Edwards, RG			IVF and the history of stem cells - Embryo stem cells are poised to fulfil their considerable historical potential.	NATURE			English	Editorial Material							IN-VITRO				Edwards, RG (corresponding author), Duck End Farm,Dry Drayton, Cambridge CB3 8DB, England.							Biggers J D, 2000, Reprod Biomed Online, V1, P74; COLE R, 1967, DEV BIOL, V13, P285; Edwards R G, 1978, Ups J Med Sci Suppl, V22, P39; EDWARDS RG, 1965, LANCET, V2, P926; EDWARDS RG, 1980, BRIT J OBSTET GYNAEC, V87, P737, DOI 10.1111/j.1471-0528.1980.tb04610.x; EDWARDS RG, 1969, NATURE, V221, P632, DOI 10.1038/221632a0; EDWARDS RG, 1992, FETAL TISSUE TRANSPL; EDWARDS RG, 2001, REPROD BIOMED ONLINE, V3; Edwards RG, 1980, CONCEPTION HUMAN FEM; EDWARDS RG, 1982, HUMAN CONCEPTION IN, P371; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FISHEL SB, 1984, SCIENCE, V223, P816, DOI 10.1126/science.6546453; GARDNER RL, 1968, NATURE, V220, P596, DOI 10.1038/220596a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLLANDS P, 1988, BRIT J HAEMATOL, V69, P437, DOI 10.1111/j.1365-2141.1988.tb02394.x; HOLLANDS P, 1987, DEVELOPMENT, V99, P69; Maximow A, 1925, CONTRIB EMBRYOL, V16, P49; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; *ROYAL SOC, 2000, STEM CELL RES THER C; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; STEPTOE PC, 1980, BRIT J OBSTET GYNAEC, V87, P757, DOI 10.1111/j.1471-0528.1980.tb04611.x; STEPTOE PC, 1971, NATURE, V229, P132, DOI 10.1038/229132a0; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; 2001, NATURE, V413, P242	25	27	27	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 27	2001	413	6854					349	351		10.1038/35096649	http://dx.doi.org/10.1038/35096649			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574850				2022-12-28	WOS:000171188700016
J	Marescaux, J; Leroy, J; Gagner, M; Rubino, F; Mutter, D; Vix, M; Butner, SE; Smith, MK				Marescaux, J; Leroy, J; Gagner, M; Rubino, F; Mutter, D; Vix, M; Butner, SE; Smith, MK			Transatlantic robot-assisted telesurgery	NATURE			English	Article									Univ Strasbourg, IRCAD European Inst Telesurg, F-6700 Strasbourg, France; Mt Sinai Med Ctr, Dept Laparoscop Surg, New York, NY 10029 USA; Mt Sinai Med Ctr, IRCAD European Inst Telesurg, New York, NY 10029 USA; Univ Calif Santa Barbara, Dept Elect & Comp Engn, Santa Barbara, CA 93106 USA	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of California System; University of California Santa Barbara	Marescaux, J (corresponding author), Univ Strasbourg, IRCAD European Inst Telesurg, 1 Pl Hop, F-6700 Strasbourg, France.	jacques.marescaux@ircad.u-strasbg.fr						Broderick TJ, 2001, TELEMED J E-HEALTH, V7, P47, DOI 10.1089/153056201300093912; BUCKINGHAM RA, 1995, BRIT MED J, V311, P1479, DOI 10.1136/bmj.311.7018.1479; Cheah W K, 2000, Surg Endosc, V14, P1085; Cubano M, 1999, SURG ENDOSC-ULTRAS, V13, P673, DOI 10.1007/s004649901071; Fabrizio MD, 2000, J ENDOUROL, V14, P133, DOI 10.1089/end.2000.14.133; Haluck RS, 2000, ARCH SURG-CHICAGO, V135, P786, DOI 10.1001/archsurg.135.7.786; Janetschek G, 1998, J UROLOGY, V160, P1413, DOI 10.1016/S0022-5347(01)62552-7; Lee BR, 1998, WORLD J UROL, V16, P367, DOI 10.1007/s003450050082; Link RE, 2001, UROL CLIN N AM, V28, P177, DOI 10.1016/S0094-0143(01)80020-3; Mack MJ, 2001, JAMA-J AM MED ASSOC, V285, P568, DOI 10.1001/jama.285.5.568; Micali S, 2000, J ENDOUROL, V14, P493, DOI 10.1089/end.2000.14.493; Rosser JC, 1999, J AM COLL SURGEONS, V189, P397, DOI 10.1016/S1072-7515(99)00185-4; Satava RM, 1998, PROTOCOLS GEN SURG, P141; Satava RM, 1999, ARCH SURG-CHICAGO, V134, P1197, DOI 10.1001/archsurg.134.11.1197	14	551	605	4	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 27	2001	413	6854					379	380		10.1038/35096636	http://dx.doi.org/10.1038/35096636			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574874				2022-12-28	WOS:000171188700040
J	Wei, DS; Mei, YA; Bagal, A; Kao, JPY; Thompson, SM; Tang, CM				Wei, DS; Mei, YA; Bagal, A; Kao, JPY; Thompson, SM; Tang, CM			Compartmentalized and binary behavior of terminal dendrites in hippocampal pyramidal neurons	SCIENCE			English	Article							CELLS; SPINES	The dendritic arbor of pyramidal neurons is not a monolithic structure. We show here that the excitability of terminal apical, dendrites differs from that of the apical trunk. in response to fluorescence-guided focal photolysis of caged glutamate, individual terminal apical dendrites generated cadmium-sensitive all-or-none responses that were subthreshold for somatic action potentials. Calcium transients produced by all-or-none responses were not restricted to the sites of photolysis, but occurred throughout individual distal dendritic compartments, indicating that electrogenesis is mediated primarily by voltage-gated calcium channels. Compartmentalized and binary behavior of parallel-connected terminal dendrites can greatly expand the computational power of a single neuron.	Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Tang, CM (corresponding author), Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA.		Thompson, Scott M/K-8921-2015	Kao, Joseph/0000-0002-8875-2180				BANNISTER NJ, 1995, J COMP NEUROL, V360, P150, DOI 10.1002/cne.903600111; GAHWILER BH, 1991, CULTURING NERVE CELL, P379; Golding NL, 1999, J NEUROSCI, V19, P8789, DOI 10.1523/JNEUROSCI.19-20-08789.1999; Hausser M, 2000, SCIENCE, V290, P739, DOI 10.1126/science.290.5492.739; HESTRIN S, 1990, COLD SH Q B, V55, P87; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; MACCAFERRI G, 1993, J NEUROPHYSIOL, V69, P2129, DOI 10.1152/jn.1993.69.6.2129; Magee J. C., 1999, DENDRITES, P139; MCALLISTER AK, 2000, BIOLISTIC TRANSFECTI; Mel B. W., 1999, DENDRITES, P271; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; RHODES PA, 1999, CEREBRAL CORTEX, V13, pCH3; Rossi FM, 1997, J BIOL CHEM, V272, P32933, DOI 10.1074/jbc.272.52.32933; Schiller J, 2000, NATURE, V404, P285, DOI 10.1038/35005094; Segev I, 2000, SCIENCE, V290, P744, DOI 10.1126/science.290.5492.744; Segev I, 1998, TRENDS NEUROSCI, V21, P453, DOI 10.1016/S0166-2236(98)01327-7; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; TANG CM, IN PRESS CURR PROTOC; TROMMALD M, 1995, J COMP NEUROL, V353, P260, DOI 10.1002/cne.903530208; YLINEN A, 1995, J NEUROSCI, V15, P30; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	21	156	160	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2272	2275		10.1126/science.1061198	http://dx.doi.org/10.1126/science.1061198			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567143				2022-12-28	WOS:000171139400049
J	Louis, ED				Louis, ED			Essential tremor.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; QUANTITATIVE-ANALYSIS; PARKINSONS-DISEASE; PRIMIDONE; PROPRANOLOL; PLACEBO; EFFICACY; TRIAL	A 66-year-old woman presents with tremor of the hands. She first noticed a mild tremor six years earlier, but the tremor has been worsening for the past two years. It occurs when she is using her hands, interfering with some activities of daily living. For example, she can no longer eat soup without spilling, put in her contact lenses, or apply lipstick. A writer, she is no longer able to write in longhand or type her manuscripts and must dictate them. The tremor causes a great deal of embarrassment in social situations. How should this patient be evaluated and treated?	Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA; Columbia Univ, Dept Neurol, New York, NY USA	Columbia University; Columbia University	Louis, ED (corresponding author), Neurol Inst, Unit 198, 710 W 168th St, New York, NY 10032 USA.				NINDS NIH HHS [R01 NS39422] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039422] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAIN PG, 1994, BRAIN, V117, P805, DOI 10.1093/brain/117.4.805; BIARY N, 1995, NEUROLOGY, V45, P1523, DOI 10.1212/WNL.45.8.1523; CLEEVES L, 1988, J NEUROL NEUROSUR PS, V51, P379, DOI 10.1136/jnnp.51.3.379; CURRAN T, 1993, CLIN NEUROPHARMACOL, V16, P460, DOI 10.1097/00002826-199310000-00011; DIETRICHSON P, 1981, J NEUROL NEUROSUR PS, V44, P677, DOI 10.1136/jnnp.44.8.677; FINDLEY LJ, 1985, J NEUROL NEUROSUR PS, V48, P911, DOI 10.1136/jnnp.48.9.911; GORMAN WP, 1986, J NEUROL NEUROSUR PS, V49, P64, DOI 10.1136/jnnp.49.1.64; HUBER SJ, 1988, NEUROLOGY, V38, P241, DOI 10.1212/WNL.38.2.241; Jankovic J, 1996, MOVEMENT DISORD, V11, P250, DOI 10.1002/mds.870110306; JEFFERSON D, 1979, J NEUROL NEUROSUR PS, V42, P904, DOI 10.1136/jnnp.42.10.904; KOLLER WC, 1989, CLIN NEUROPHARMACOL, V12, P293, DOI 10.1097/00002826-198908000-00006; KOLLER WC, 1989, NEUROLOGY, V39, P1587, DOI 10.1212/WNL.39.12.1587; KOLLER WC, 1986, NEUROLOGY, V36, P121; Louis ED, 1997, NEUROLOGY, V48, P376, DOI 10.1212/WNL.48.2.376; Louis ED, 2000, ARCH NEUROL-CHICAGO, V57, P1194, DOI 10.1001/archneur.57.8.1194; Louis ED, 2001, ANN NEUROL, V49, P761, DOI 10.1002/ana.1022; Louis ED, 1998, ARCH NEUROL-CHICAGO, V55, P1553, DOI 10.1001/archneur.55.12.1553; Louis ED, 1999, ARCH NEUROL-CHICAGO, V56, P807, DOI 10.1001/archneur.56.7.807; MALLY J, 1995, J NEUROL SCI, V132, P129, DOI 10.1016/0022-510X(95)00128-O; Ondo W, 2000, MOVEMENT DISORD, V15, P678, DOI 10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0; SASSO E, 1990, CLIN NEUROPHARMACOL, V13, P67, DOI 10.1097/00002826-199002000-00007; SASSO E, 1988, NEUROLOGY, V38, P808, DOI 10.1212/WNL.38.5.808; Scheinberg IH., 1984, WILSONS DIS; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; THOMPSON C, 1984, CLIN NEUROPHARMACOL, V7, P83, DOI 10.1097/00002826-198403000-00004; TOLOSA ES, 1975, NEUROLOGY, V25, P1041, DOI 10.1212/WNL.25.11.1041; TOPAKTAS S, 1987, EUR NEUROL, V27, P114, DOI 10.1159/000116142; WALSHE JM, 1992, J NEUROL NEUROSUR PS, V55, P692, DOI 10.1136/jnnp.55.8.692	28	141	150	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2001	345	12					887	891		10.1056/NEJMcp010928	http://dx.doi.org/10.1056/NEJMcp010928			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	473JW	11565522				2022-12-28	WOS:000171039600006
J	Taggart, DP; D'Amico, R; Altman, DG				Taggart, DP; D'Amico, R; Altman, DG			Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries	LANCET			English	Article							ANGIOGRAPHIC FOLLOW-UP; BYPASS GRAFT-SURGERY; CORONARY-BYPASS; CARDIAC-SURGERY; 10-YEAR; DISEASE	Background Coronary artery bypass grafting (CABG) is the commonest major operation in most developed countries. A single internal mammary artery (IMA) graft has proven survival benefits, but the additional survival advantage of a second graft is unknown. We systematically reviewed published studies of bilateral versus single IMA grafts in CABG to assess any differences in survival. Methods We identified from Medline all studies in which single and bilateral IMA grafts were compared. We included studies in which at least 100 patients in each group had been followed up for at least 4 years. We assessed study quality on the basis of patient selection, comparability of intervention groups (especially for age, sex, ventricular function, and diabetes status), outcome assessment, and completeness of follow-up. Our primary outcome was survival. Estimates of treatment effect (single versus bilateral) expressed as hazard ratios were pooled across studies. Findings None of the studies was a randomised trial, but nine cohort studies met our inclusion criteria. Seven studies yielded survival data for meta-analysis, and included 15 962 patients: 11269 single and 4693 bilateral IMA grafts. The bilateral group had significantly better survival than the single group (hazard ratio for death 0.81; 95% Cl 0.70-0.94). Exclusion of methodologically weak studies improved survival rates with bilateral IMA grafts. Interpretation Because no study was a randomised trial, our results are more uncertain than is indicated by the 95% CI. Nevertheless, bilateral IMA grafts seem to give better survival rates than single grafts.	John Radcliffe Hosp, Oxford Heart Ctr, Oxford OX3 9DU, England; Imperial Canc Res Fund, NHS Ctr Stat Med, Inst Hlth Sci, Oxford, England; Ctr Evaluat Effectiveness Hlth Care, Modena, Italy; Italian Cochrane Ctr, Milan, Italy	University of Oxford; University of Oxford	Taggart, DP (corresponding author), John Radcliffe Hosp, Oxford Heart Ctr, Oxford OX3 9DU, England.	david.taggart@orh.nhs.uk	D'Amico, Roberto/I-8106-2014	D'Amico, Roberto/0000-0002-3211-6687				BERREKLOUW E, 1995, ANN THORAC SURG, V59, P1456, DOI 10.1016/0003-4975(95)00183-L; Buxton BF, 2000, EUR J CARDIO-THORAC, V18, P255, DOI 10.1016/S1010-7940(00)00527-3; Buxton BF, 1998, CIRCULATION, V98, pII1; Calafiore AM, 2000, J THORAC CARDIOV SUR, V120, P990, DOI 10.1067/mtc.2000.110249; Cameron A, 1996, NEW ENGL J MED, V334, P216, DOI 10.1056/NEJM199601253340402; Detre KM, 2000, NEW ENGL J MED, V342, P989, DOI 10.1056/NEJM200004063421401; DEWAR LRS, 1995, CIRCULATION, V92, P8, DOI 10.1161/01.CIR.92.9.8; Dion R, 2000, EUR J CARDIO-THORAC, V17, P407, DOI 10.1016/S1010-7940(00)00370-5; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Eagle KA, 1999, CIRCULATION, V100, P1464, DOI 10.1161/01.CIR.100.13.1464; Farinas JM, 1999, ANN THORAC SURG, V67, P466, DOI 10.1016/S0003-4975(98)01196-5; FitzGibbon GM, 1996, J AM COLL CARDIOL, V28, P616, DOI 10.1016/0735-1097(96)00206-9; Gurevitch J, 2000, ANN THORAC SURG, V69, P841, DOI 10.1016/S0003-4975(99)01407-1; Horton R, 1996, LANCET, V347, P984, DOI 10.1016/S0140-6736(96)90137-3; JOHNSON WD, 1989, ANN THORAC SURG, V48, P19, DOI 10.1016/0003-4975(89)90170-7; KAUL TK, 1995, J CARDIOVASC SURG, V36, P303; KEOGH BE, 2001, SOC CARDIOTHORACIC S; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Lytle BW, 1999, J THORAC CARDIOV SUR, V117, P855, DOI 10.1016/S0022-5223(99)70365-X; MORRIS JJ, 1990, CIRCULATION, V82, P214; MOSES LE, 1995, MED CARE S, V33, pS8; NAUNHEIM KS, 1992, ANN THORAC SURG, V53, P716, DOI 10.1016/0003-4975(92)90346-6; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Pick AW, 1997, ANN THORAC SURG, V64, P599, DOI 10.1016/S0003-4975(97)00620-6; Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x; Schmidt SE, 1997, ANN THORAC SURG, V64, P9, DOI 10.1016/S0003-4975(97)00473-6; Sergeant P, 1997, EUR J CARDIO-THORAC, V12, P1, DOI 10.1016/S1010-7940(97)00134-6; Sergeant P, 1998, EUR J CARDIO-THORAC, V14, P480, DOI 10.1016/S1010-7940(98)00214-0; Taggart DP, 2000, J THORAC CARDIOV SUR, V120, P651, DOI 10.1067/mtc.2000.106325; Taggart DP, 2000, EUR J CARDIO-THORAC, V18, P31, DOI 10.1016/S1010-7940(00)00438-3; Verhelst R, 1996, Cardiovasc Surg, V4, P212, DOI 10.1016/0967-2109(96)82318-0; WEINTRAUB WS, 1994, AM J CARDIOL, V73, P103, DOI 10.1016/0002-9149(94)90198-8; Wells GA, 2000, 3 S SYST REV BAS OXF; Wendler O, 2000, CIRCULATION, V102, P79; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	35	577	607	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 15	2001	358	9285					870	875		10.1016/S0140-6736(01)06069-X	http://dx.doi.org/10.1016/S0140-6736(01)06069-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567701				2022-12-28	WOS:000171087000008
J	Nishiizumi, K; Caffee, IW				Nishiizumi, K; Caffee, IW			Beryllium-10 from the Sun	SCIENCE			English	Article								Beryltium-10 (Be-10) in excess of that expected from in situ cosmic ray spallation reactions is present in lunar surface soil 78481; its presence was revealed with a sequential leaching technique. This excess Be-10, representing only 0.7 to 1.1% of the total Be-10 inventory, is associated with surface layers (<1 micrometer) of the mineral grains composing 78481. This excess Be-10 and its association with surficial layers corresponds to (1.9<plus/minus>0.8) x 10(8) atoms per square centimeter, requiring a Be-10 implantation rate of (2.9 +/-1.2) x 10(-6) atoms per square centimeter per second on the surface of the Moon. The most likely site for the production of this excess Be-10 is the Sun's atmosphere. The Be-10 is entrained into the solar wind and transported to the lunar surface.	Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Lawrence Livermore Natl Lab, Geosci & Environm Technol Div, Livermore, CA 94550 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Nishiizumi, K (corresponding author), Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA.							BEGEMANN F, 1972, P LUNAR PLANET SCI C, V3, P1693; DAVIS JC, 1990, NUCL INSTRUM METH B, V52, P269, DOI 10.1016/0168-583X(90)90419-U; FIREMAN EL, 1977, P LUNAR PLANET SCI C, V8, P3749; HUA XM, 1989, ASTROPHYS J, V341, P516, DOI 10.1086/167513; Jull AJT, 1995, EARTH PLANET SC LETT, V136, P693, DOI 10.1016/0012-821X(95)00163-7; Jull AJT, 2000, NUCL INSTRUM METH B, V172, P867, DOI 10.1016/S0168-583X(00)00232-9; LANGEVIN Y, 1982, J GEOPHYS RES, V87, P6681, DOI 10.1029/JB087iB08p06681; MORRIS RV, 1983, PUBLICATION JOHNSON, V67; Murphy R. J., 1984, Advances in Space Research, V4, P127, DOI 10.1016/0273-1177(84)90171-6; RAMATY R, 1990, ASTROPHYS J SUPPL S, V73, P199, DOI 10.1086/191452; RANCITELLI LA, 1974, P LUNAR PLANET SCI C, V5, P2185; Ziegler JF., 1985, TREATISE HEAVY ION S	12	26	26	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					352	354		10.1126/science.1062545	http://dx.doi.org/10.1126/science.1062545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598295				2022-12-28	WOS:000171601400037
J	Keane, J; Gershon, S; Wise, RP; Mirabile-Levens, E; Kasznica, J; Schwieterman, WD; Siegel, JN; Braun, MM				Keane, J; Gershon, S; Wise, RP; Mirabile-Levens, E; Kasznica, J; Schwieterman, WD; Siegel, JN; Braun, MM			Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; CELL-DEATH; APOPTOSIS; INFECTION; MACROPHAGES; GAMMA; MICE; TNF	Background: Infliximab is a humanized antibody against tumor necrosis factor (alpha) (TNF-(alpha)) that is used in the treatment of Crohn's disease and rheumatoid arthritis. Approximately 147,000 patients throughout the world have received infliximab. Excess TNF-(alpha) in association with tuberculosis may cause weight loss and night sweats, yet in animal models it has a protective role in the host response to tuberculosis. There is no direct evidence of a protective role of TNF-(alpha) in patients with tuberculosis. Methods: We analyzed all reports of tuberculosis after infliximab therapy that had been received as of May 29, 2001, through the MedWatch spontaneous reporting system of the Food and Drug Administration. Results: There were 70 reported cases of tuberculosis after treatment with infliximab for a median of 12 weeks. In 48 patients, tuberculosis developed after three or fewer infusions. Forty of the patients had extrapulmonary disease (17 had disseminated disease, 11 lymph-node disease, 4 peritoneal disease, 2 pleural disease, and 1 each meningeal, enteric, paravertebral, bone, genital, and bladder disease). The diagnosis was confirmed by a biopsy in 33 patients. Of the 70 reports, 64 were from countries with a low incidence of tuberculosis. The reported frequency of tuberculosis in association with infliximab therapy was much higher than the reported frequency of other opportunistic infections associated with this drug. In addition, the rate of reported cases of tuberculosis among patients treated with infliximab was higher than the available background rates. Conclusions: Active tuberculosis may develop soon after the initiation of treatment with infliximab. Before prescribing the drug, physicians should screen patients for latent tuberculosis infection or disease. (N Engl J Med 2001;345:1098-104.) Copyright (C) 2001 Massachusetts Medical Society.	Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; US FDA, Ctr Biol Evaluat & Res, Off Biostat & Epidemiol, Div Epidemiol, Rockville, MD 20857 USA; US FDA, Off Therapeut Res & Review, Rockville, MD 20857 USA	Boston University; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Keane, J (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Dept Med, 80 E Concord St,R-304, Boston, MA 02118 USA.		Keane, Joseph/AAX-6658-2021	Keane, Joseph/0000-0001-5313-385X	NHLBI NIH HHS [HL-03964] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Britton WJ, 1998, INFECT IMMUN, V66, P2122, DOI 10.1128/IAI.66.5.2122-2127.1998; *CDCP, 2000, REP TUB US 1999, P24; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; CREE IA, 1987, J CLIN PATHOL, V40, P1314, DOI 10.1136/jcp.40.11.1314; de Jong R, 1998, SCIENCE, V280, P1435; Fayyazi A, 2000, J PATHOL, V191, P417, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH664&gt;3.0.CO;2-R; FISCHKOFF S, 2001, ADV TARG THER M NASS; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; Fratazzi C, 1997, J IMMUNOL, V158, P4320; Garcia I, 1997, EUR J IMMUNOL, V27, P3182, DOI 10.1002/eji.1830271215; Keane J, 1997, INFECT IMMUN, V65, P298, DOI 10.1128/IAI.65.1.298-304.1997; Keane J, 2000, J IMMUNOL, V164, P2016, DOI 10.4049/jimmunol.164.4.2016; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; Kim HA, 1998, CLIN EXP RHEUMATOL, V16, P9; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; Kornbluth A, 1998, Inflamm Bowel Dis, V4, P328, DOI 10.1002/ibd.3780040415; LIEBERMAN P, 1972, J ALLERGY CLIN IMMUN, V49, P329, DOI 10.1016/0091-6749(72)90131-5; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Mohan VP, 2001, INFECT IMMUN, V69, P1847, DOI 10.1128/IAI.69.3.1847-1855.2001; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Pryhuber GS, 2000, AM J RESP CELL MOL, V22, P150, DOI 10.1165/ajrcmb.22.2.3783; RIEDER HL, 1990, AM REV RESPIR DIS, V141, P347, DOI 10.1164/ajrccm/141.2.347; ROOK GAW, 1987, IMMUNOLOGY, V62, P229; Scallon B, 2000, ARTHRITIS RHEUM, V43, pS226; SCHATZ M, 1976, ANN INTERN MED, V84, P261, DOI 10.7326/0003-4819-84-3-261; Schuna AA, 2000, AM J HEALTH-SYST PH, V57, P225, DOI 10.1093/ajhp/57.3.225; Senaldi G, 1996, J IMMUNOL, V157, P5022; STEAD WW, 1967, AM REV RESPIR DIS, V95, P729; SUTHERLAND I, 1982, TUBERCLE, V63, P255, DOI 10.1016/S0041-3879(82)80013-5; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TRAMONTANA JM, 1995, MOL MED, V1, P384, DOI 10.1007/BF03401576; Turner J, 2001, IMMUNOLOGY, V102, P248, DOI 10.1046/j.1365-2567.2001.01161.x; *WHO, 1999, GLOB TUB CONTR WHO R; WOLFE F, IN PRESS ARTHRITIS R; Wood AJJ, 2000, NEW ENGL J MED, V342, P1824, DOI 10.1056/NEJM200006153422410; 1999, MED LETT DRUGS THER, V41, P19; 2000, AM J RESP CRIT CAR S, V161, pS221; 2001, N ENGL J MED, V344, P1099	40	2744	2834	3	151	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2001	345	15					1098	1104		10.1056/NEJMoa011110	http://dx.doi.org/10.1056/NEJMoa011110			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480QH	11596589				2022-12-28	WOS:000171473100004
J	Sargent, DJ; Goldberg, RM; Jacobson, SD; Macdonald, JS; Labianca, R; Haller, DG; Shepherd, LE; Seitz, JF; Francini, G				Sargent, DJ; Goldberg, RM; Jacobson, SD; Macdonald, JS; Labianca, R; Haller, DG; Shepherd, LE; Seitz, JF; Francini, G			A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVANCED COLORECTAL-CANCER; BREAST-CANCER; THERAPEUTIC RESPONSE; RANDOMIZED TRIAL; AGE; OLDER; TOXICITY; 5-FLUOROURACIL; FLUOROURACIL; LEVAMISOLE	Background: Adjuvant chemotherapy is standard treatment for patients with resected colon cancer who are at high risk for recurrence, but the efficacy and toxicity of such treatment in patients more than 70 years of age are controversial. Methods: We performed a pooled analysis, based on the intention to treat, of individual patient data from seven phase 3 randomized trials (involving 3351 patients) in which the effects of postoperative fluorouracil plus leucovorin (five trials) or fluorouracil plus levamisole (two trials) were compared with the effects of surgery alone in patients with stage II or III colon cancer. The patients were grouped into four age categories of equal size, and analyses were repeated with 10-year age ranges (less than or equal to 50, 51 to 60, 61 to 70, and >70 years), with the same conclusions. The toxic effects measured in all trials were nausea or vomiting, diarrhea, stomatitis, and leukopenia. Patients in the fluorouracil-plus-leucovorin and fluorouracil-plus-levamisole groups were combined for the efficacy analysis but kept separate for toxicity analyses. Results: Adjuvant treatment had a significant positive effect on both overall survival and time to tumor recurrence (P<0.001 for each, with hazard ratios of death and recurrence of 0.76 [95 percent confidence interval, 0.68 to 0.85] and 0.68 [95 percent confidence interval, 0.60 to 0.76], respectively). The five-year overall survival was 71 percent for those who received adjuvant therapy, as compared with 64 percent for those untreated. No significant interaction was observed between age and the efficacy of treatment. The incidence of toxic effects was not increased among the elderly (age >70 years), except for leukopenia in one study. Conclusions: Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects. (N Engl J Med 2001;345:1091-7.) Copyright (C) Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; St Vincent Comprehens Canc Ctr, New York, NY USA; Osped Riuniti Bergamo, I-24100 Bergamo, Italy; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Queens Univ, Natl Canc Inst Canada, Kingston, ON, Canada; Univ Mediterranean, Marseille, France; Univ Siena, I-53100 Siena, Italy	Mayo Clinic; Saint Vincents Hospital Manhattan; Ospedali Riuniti di Bergamo; University of Pennsylvania; Queens University - Canada; Canadian Cancer Trials Group; UDICE-French Research Universities; Aix-Marseille Universite; University of Siena	Sargent, DJ (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.		Goldberg, Richard/O-1871-2017; Cusi, Maria Grazia/H-6309-2019; Labianca, Roberto/N-1847-2016; Goldberg, Richard M/M-1311-2013	Goldberg, Richard/0000-0003-3713-6895; Cusi, Maria Grazia/0000-0001-8869-8164; Labianca, Roberto/0000-0001-7149-822X; Sargent, Daniel/0000-0002-2684-4741	NATIONAL CANCER INSTITUTE [U10CA025224] Funding Source: NIH RePORTER; NCI NIH HHS [CA 25224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aschele, 1995, Cancer Control, V2, P36; Balducci L, 1997, CANCER, V80, P1317, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1317::AID-CNCR18>3.3.CO;2-I; Balducci L, 1992, Oncology (Williston Park), V6, P62; BEGG CB, 1983, CANCER, V52, P1986, DOI 10.1002/1097-0142(19831201)52:11<1986::AID-CNCR2820521103>3.0.CO;2-7; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; Brower M, 1993, P AM SOC CLIN ONCOL, V12, P195; CAMPBELL PR, 1996, POPULATION PROJECTIO, P86; Cascinu S, 1996, AM J CLIN ONCOL-CANC, V19, P371, DOI 10.1097/00000421-199608000-00010; Chiara S, 1998, CANCER CHEMOTH PHARM, V42, P336, DOI 10.1007/s002800050826; CHRISTMAN K, 1992, JAMA-J AM MED ASSOC, V268, P57, DOI 10.1001/jama.268.1.57; COOPER GS, 1995, CANCER, V75, P775, DOI 10.1002/1097-0142(19950201)75:3<775::AID-CNCR2820750305>3.0.CO;2-D; COVA D, 1998, COMPREHENSIVE GERIAT, P429; COX DR, 1972, J R STAT SOC B, V34, P187; *EARL BREAST CANC, 1992, LANCET, V339, P1; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; Extermann M, 1997, CLIN GERIATR MED, V13, P227; FENTIMAN IS, 1990, LANCET, V335, P1020, DOI 10.1016/0140-6736(90)91075-L; FRANCINI G, 1994, GASTROENTEROLOGY, V106, P899, DOI 10.1016/0016-5085(94)90748-X; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; Furner SE, 1997, GERIATRIC MED, P37; GELMAN RS, 1984, J CLIN ONCOL, V2, P1404, DOI 10.1200/JCO.1984.2.12.1404; GOODWIN JS, 1993, CANCER-AM CANCER SOC, V72, P594, DOI 10.1002/1097-0142(19930715)72:2<594::AID-CNCR2820720243>3.0.CO;2-#; GOODWIN JS, 1988, ARCH INTERN MED, V148, P2258, DOI 10.1001/archinte.148.10.2258; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Gray RG, 2000, LANCET, V355, P1588; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GUTHEIL J, 1996, CHEMOTHERAPY SOURCE, P317; GUTHRIE TH, 1990, J CLIN ONCOL, V8, P342, DOI 10.1200/JCO.1990.8.2.342; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; KANE RL, 1999, ESSENTIALS CLIN GERI, P19; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LABIANCA R, 1995, LANCET, V345, P939; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; Mahoney T, 2000, ARCH SURG-CHICAGO, V135, P182, DOI 10.1001/archsurg.135.2.182; Mamounas E, 1999, J CLIN ONCOL, V17, P1349, DOI 10.1200/JCO.1999.17.5.1349; MANTEL N, 1959, J NATL CANCER I, V22, P719; MILANO G, 1992, J CLIN ONCOL, V10, P1171, DOI 10.1200/JCO.1992.10.7.1171; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MONFARDINI S, 1995, CANCER, V76, P333, DOI 10.1002/1097-0142(19950715)76:2<333::AID-CNCR2820760226>3.0.CO;2-I; MOR V, 1985, J AM GERIATR SOC, V33, P585, DOI 10.1111/j.1532-5415.1985.tb06313.x; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; PETERSON B, 1994, CONTROL CLIN TRIALS, V15, P326; PETERSON BA, 1982, CANCER TREAT REP, V66, P889; Popescu RA, 1999, J CLIN ONCOL, V17, P2412, DOI 10.1200/JCO.1999.17.8.2412; Ries LAG .M.K.C, 2001, SEER CANC STAT REV 1; SAMET J, 1986, JAMA-J AM MED ASSOC, V255, P3385, DOI 10.1001/jama.255.24.3385; STEIN BN, 1995, CANCER-AM CANCER SOC, V75, P11, DOI 10.1002/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N; STEINBERG J, 1992, EUR J CANCER, V28A, P1817, DOI 10.1016/0959-8049(92)90011-P; STERNBERG CN, 1989, CANCER, V64, P2448, DOI 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7; SUNDARARAJAN V, 1999, PROG P AM SOC CLIN O, V18, pA413; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; Vestal RE, 1997, CANCER, V80, P1302, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1302::AID-CNCR16>3.0.CO;2-B; WALSH SJ, 1989, SEMIN ONCOL, V16, P66; WINAWER SJ, 1984, ADV INTERNAL MED, V30, P471; WINDLE R, 1987, BRIT J SURG, V74, P569, DOI 10.1002/bjs.1800740707; Zalcberg J, 1998, EUR J CANCER, V34, P1871, DOI 10.1016/S0959-8049(98)00259-7	58	670	685	1	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2001	345	15					1091	1097		10.1056/NEJMoa010957	http://dx.doi.org/10.1056/NEJMoa010957			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480QH	11596588				2022-12-28	WOS:000171473100003
J	Riedler, J; Braun-Fahrlander, C; Eder, W; Schreuer, M; Waser, M; Maisch, S; Carr, D; Schierl, R; Nowak, D; von Mutius, E				Riedler, J; Braun-Fahrlander, C; Eder, W; Schreuer, M; Waser, M; Maisch, S; Carr, D; Schierl, R; Nowak, D; von Mutius, E		ALEX Study Team	Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey	LANCET			English	Article							HAY-FEVER; AUSTRIAN CHILDREN; IGE PRODUCTION; CHILDHOOD; SENSITIZATION; PREVALENCE; ATOPY; RISK; STIMULATION; CHALLENGE	Background A farming environment protects against development of asthma, hay fever, and atopic sensitisation in children. We aimed to establish whether increased exposure to microbial compounds has to occur early in life to affect maturation of the immune system and thereby reduces risk for development of allergic diseases. Methods We did a cross-sectional survey in rural areas of Austria, Germany, and Switzerland. 2618 (75%) of 3504 parents of 6-13-year-old children completed a standardised questionnaire on asthma, hay fever, and atopic eczema. Children from farming families, and a random sample of non-farmers' children, who gave consent for blood samples to be obtained for measurements of specific serum IgE antibodies to common allergens were invited to participate (n = 901). Findings Exposure of children younger than 1 year, compared with those aged 1-5 years, to stables and consumption of farm milk was associated with lower frequencies of asthma (1% [3/218] vs 11% [15/138]), hay fever (3% [7] vs 13% [18]), and atopic sensitisation (12% [27] vs 29% [40]). Protection against development of asthma was independent from effect on atopic sensitisation. Continual long-term exposure to stables until age 5 years was associated with the lowest frequencies of asthma (0.8% [1/122]), hay fever (0.8% [1]), and atopic sensitisation (8.2% [10]). Interpretation Long-term and early-life exposure to stables and farm milk induces a strong protective effect against development of asthma, hay fever, and atopic sensitisation.	Childrens Hosp, A-5020 Salzburg, Austria; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; Salzburg Univ, Dept Sociol, A-5020 Salzburg, Austria; Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; Univ Munich, Inst Occupat & Environm Med, Munich, Germany	University of Basel; Salzburg University; University of Munich; University of Munich	Riedler, J (corresponding author), Childrens Hosp, Muellner Hauptstr 48, A-5020 Salzburg, Austria.		riedler, josef/AAQ-4666-2020					Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; Kilewein G, 1994, LEITFADEN MILCHKUNDE, P83; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Klinman DM, 1999, VACCINE, V17, P19, DOI 10.1016/S0264-410X(98)00151-0; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P153; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632, DOI 10.1164/ajrccm.150.6.7952626; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Riedler J, 1998, EUR RESPIR J, V11, P355, DOI 10.1183/09031936.98.11020355; Sudo N, 1997, J IMMUNOL, V159, P1739; SUHREN G, 1986, MILCHWISSENSCHAFT, V41, P156; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230	24	1064	1094	0	148	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1129	1133		10.1016/S0140-6736(01)06252-3	http://dx.doi.org/10.1016/S0140-6736(01)06252-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597666				2022-12-28	WOS:000171399000009
J	LaRiviere, FJ; Wolfson, AD; Uhlenbeck, OC				LaRiviere, FJ; Wolfson, AD; Uhlenbeck, OC			Uniform binding of aminoacyl-tRNAs to elongation factor Tu by thermodynamic compensation	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASES; INDIRECT READOUT; TERNARY COMPLEX; EF-TU; GTP; ASSOCIATION; DISCRIMINATION; AFFINITIES; PROTEINS; ACIDS	Elongation factor Tu (EF-Tu) binds all elongator aminoacyl-transfer RNAs (aa-tRNAs) for delivery to the ribosome during protein synthesis. Here, we show that EF-Tu binds misacylated tRNAs over a much wider range of affinities than it binds the corresponding correctly acylated tRNAs, suggesting that the protein exhibits considerable specificity for both the amino acid side chain and the tRNA body. The thermodynamic contributions of the amino acid and the tRNA body to the overall binding affinity are independent of each other and compensate for one another when the tRNAs are correctly acylated. Because certain misacylated tRNAs bind EF-Tu significantly more strongly or weakly than cognate aa-tRNAs, EF-Tu may contribute to translational accuracy.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Uhlenbeck, OC (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.				NIGMS NIH HHS [GM-37552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bareket-Samish A, 1998, J MOL BIOL, V277, P1071, DOI 10.1006/jmbi.1998.1638; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; BRUCE AG, 1982, BIOCHEMISTRY-US, V21, P855, DOI 10.1021/bi00534a007; CHAPEVILLE F, 1962, P NATL ACAD SCI USA, V48, P1086, DOI 10.1073/pnas.48.6.1086; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; JAKUBOWSKI H, 1988, J THEOR BIOL, V133, P363, DOI 10.1016/S0022-5193(88)80327-8; JANIAK F, 1990, BIOCHEMISTRY-US, V29, P4268, DOI 10.1021/bi00470a002; KNOWLTON RG, 1980, J MOL BIOL, V139, P721, DOI 10.1016/0022-2836(80)90057-1; Leonard DA, 1998, NAT STRUCT BIOL, V5, P877, DOI 10.1038/2316; Liu JCH, 1998, RNA, V4, P639, DOI 10.1017/S1355838298980013; LOUIE A, 1985, BIOCHEMISTRY-US, V24, P6433, DOI 10.1021/bi00344a019; LOUIE A, 1984, J BIOL CHEM, V259, P5010; Martin AM, 1999, NAT STRUCT BIOL, V6, P269; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; NAZARENKO IA, 1994, EMBO J, V13, P2464, DOI 10.1002/j.1460-2075.1994.tb06531.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nissen P, 1999, STRUCTURE, V7, P143, DOI 10.1016/S0969-2126(99)80021-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, NATURE, V321, P2163; OTT G, 1990, BIOCHIM BIOPHYS ACTA, V1050, P222, DOI 10.1016/0167-4781(90)90170-7; Pleiss JA, 2001, J MOL BIOL, V308, P895, DOI 10.1006/jmbi.2001.4612; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; SHERMAN JM, 1992, NUCLEIC ACIDS RES, V20, P2847, DOI 10.1093/nar/20.11.2847; STANZEL M, 1994, EUR J BIOCHEM, V219, P435, DOI 10.1111/j.1432-1033.1994.tb19956.x; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; YARUS M, 1972, NATURE-NEW BIOL, V239, P106, DOI 10.1038/newbio239106a0	31	260	267	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					165	168		10.1126/science.1064242	http://dx.doi.org/10.1126/science.1064242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588263				2022-12-28	WOS:000171448800053
J	Zavialov, AV; Buckingham, RH; Ehrenberg, M				Zavialov, AV; Buckingham, RH; Ehrenberg, M			A posttermination ribosomal complex is the guanine nucleotide exchange factor for peptide release factor RF3	CELL			English	Article							ELONGATION-FACTOR TU; ESCHERICHIA-COLI; TRANSLATION TERMINATION; POLYPEPTIDE-SYNTHESIS; MESSENGER-RNA; FACTOR RF-3; BINDING; ERF3; INITIATION; MECHANISM	The mechanism by which peptide release factor RF3 recycles RF1 and RF2 has been clarified and incorporated in a complete scheme for translation termination. Free RF3 is in vivo stably bound to GDP, and ribosomes in complex with RF1 or RF2 act as guanine nucleotide exchange factors (GEF). Hydrolysis of peptldyl-tRNA by RF1 or RF2 allows GTP binding to RF3 on the ribosome. This induces an RF3 conformation with high affinity for ribosomes and leads to rapid dissociation of RF1 or RF2. Dissociation of RF3 from the ribosome requires GTP hydrolysis. Our data suggest that RF3 and its eukaryotic counterpart, eRF3, have mechanistic principles in common.	Uppsala Univ, BMC, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Inst Biol Physicochim, CNRS, UPR 9073, F-75005 Paris, France	Uppsala University; Centre National de la Recherche Scientifique (CNRS)	Zavialov, AV (corresponding author), Uppsala Univ, BMC, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.		Zavialov, Anton V./C-7664-2015	Zavialov, Anton V./0000-0001-6191-5931; Zavialov, Andrey/0000-0001-6420-0368; Buckingham, Richard/0000-0002-8567-4500				ADAMSKI FM, 1994, J MOL BIOL, V238, P302, DOI 10.1006/jmbi.1994.1293; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CM, 1994, J BIOL CHEM, V269, P33164; BRUNEL C, 1993, BIOCHIMIE, V75, P1167, DOI 10.1016/0300-9084(93)90016-L; Ehrenberg M, 1990, RIBOSOMES PROTEIN SY, P101; Freistroffer DV, 2000, P NATL ACAD SCI USA, V97, P2046, DOI 10.1073/pnas.030541097; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Frolova L, 1996, RNA, V2, P334; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; GOLDSTEIN JL, 1970, P NATL ACAD SCI USA, V67, P537, DOI 10.1073/pnas.67.2.537; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; Grentzmann G, 1998, RNA, V4, P973, DOI 10.1017/S1355838298971576; Holst-Hansen P, 1997, BIOCHIMIE, V79, P725, DOI 10.1016/S0300-9084(97)86930-1; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; Merkulova TI, 1999, FEBS LETT, V443, P41, DOI 10.1016/S0014-5793(98)01669-X; MIKUNI O, 1994, P NATL ACAD SCI USA, V91, P5798, DOI 10.1073/pnas.91.13.5798; MILMAN G, 1969, P NATL ACAD SCI USA, V63, P183, DOI 10.1073/pnas.63.1.183; Mortensen KK, 1995, EUR J BIOCHEM, V234, P732, DOI 10.1111/j.1432-1033.1995.732_a.x; Nakamura Y, 2000, CELL, V101, P349, DOI 10.1016/S0092-8674(00)80845-4; Nakamura Y, 1996, CELL, V87, P147, DOI 10.1016/S0092-8674(00)81331-8; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; Pel HJ, 1998, RNA, V4, P47; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; RUUSALA T, 1982, EMBO J, V1, P741, DOI 10.1002/j.1460-2075.1982.tb01240.x; RUUSALA T, 1982, EMBO J, V1, P75, DOI 10.1002/j.1460-2075.1982.tb01127.x; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; SOFFIENTINI A, 1994, PROTEIN EXPRES PURIF, V5, P118, DOI 10.1006/prep.1994.1018; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Tomsic J, 2000, EMBO J, V19, P2127, DOI 10.1093/emboj/19.9.2127; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	39	161	170	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 5	2001	107	1					115	124		10.1016/S0092-8674(01)00508-6	http://dx.doi.org/10.1016/S0092-8674(01)00508-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595190	Bronze			2022-12-28	WOS:000171453100014
J	Marcil, I; Stern, RS				Marcil, I; Stern, RS			Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study	LANCET			English	Article							SEVERE PSORIASIS; TRANSPLANT RECIPIENTS; RISK; CYCLOSPORINE; CARCINOMA; PHOTOCHEMOTHERAPY; THERAPY	Background Immunosuppressive treatments have been associated with an increased risk of skin cancer, especially in patients who have had organ transplants. We aimed to assess the risk of skin cancer in patients taking the ciclosporin who had been exposed to psoralen and ultraviolet-A light (PUVA) and other treatments for severe psoriasis. Methods We did a nested cohort crossover study of 28 participants in the PUVA follow-up study who were on ciclosporin to compare the frequency of squamous-cell carcinoma before and after first use of ciclosporin. We also analysed the entire PUVA study cohort (1380) to assess the relation between use of this drug and frequency of squamous-cell carcinoma. Findings In the 5 years before first use, six of 28 (21%) ciclosporin users developed a total of 20 squamous cell cancers. After ciclosporin use (average follow-up 6 years), 13 (46%) developed a total of 169 squamous-cell carcinomas. In the nested cohort, after adjustment for amount of exposure to PUVA and methotrexate, incidence of tumours was seven times higher after first ciclosporin use than in the previous 5 years (incidence rate ratio 6.9 [95% CI 4.3-11]). Multivariate, analysis of the entire cohort showed that risk of squamous-cell carcinoma after any use of ciclosporin is close to that recorded for at least 200 PUVA treatments (3.1 [2.6-3.7] and 2.8 [2.6-3.2], respectively). Interpretation The risk of squamous cell cancer of the skin is increased by ciclosporin in patients with psoriasis who have been exposed to PUVA. Such risks should be balanced against the effectiveness of the drug and possible newer immunosuppressive agents.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Stern, RS (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, 330 Brookline Ave, Boston, MA 02215 USA.	rstern@caregroup.harvard.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR002246, N01AR042214] Funding Source: NIH RePORTER; NIAMS NIH HHS [N01-AR-0-2246, N01-AR-4-2214] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abrams JR, 2000, J EXP MED, V192, P681, DOI 10.1084/jem.192.5.681; Bavinck JNB, 1996, TRANSPLANTATION, V61, P715, DOI 10.1097/00007890-199603150-00008; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; Cribier B, 1999, DERMATOLOGY, V199, P208, DOI 10.1159/000018276; Grundmann-Kollmann M, 2000, J AM ACAD DERMATOL, V42, P835, DOI 10.1067/mjd.2000.104890; HENSELER T, 1987, J AM ACAD DERMATOL, V16, P108, DOI 10.1016/S0190-9622(87)70010-3; Ho VC, 1999, BRIT J DERMATOL, V141, P283; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Jensen P, 1999, J AM ACAD DERMATOL, V40, P177, DOI 10.1016/S0190-9622(99)70185-4; Koo J, 1998, BRIT J DERMATOL, V139, P88; LINDELOF B, 1991, LANCET, V338, P91, DOI 10.1016/0140-6736(91)90083-2; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1046/j.1365-2133.2000.03703.x; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; Nabel GJ, 1999, NATURE, V397, P471, DOI 10.1038/17207; Owen CM, 2000, CLIN EXP DERMATOL, V25, P195, DOI 10.1046/j.1365-2230.2000.00612.x; Ramsay HM, 2000, AM J KIDNEY DIS, V36, P167, DOI 10.1053/ajkd.2000.8290; SCOTTO J, 1983, PUBLICATION NIH; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; Stern RS, 1998, JNCI-J NATL CANCER I, V90, P1278, DOI 10.1093/jnci/90.17.1278; STERN RS, 1994, CANCER-AM CANCER SOC, V73, P2759, DOI 10.1002/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C; STERN RS, 1979, NEW ENGL J MED, V300, P809, DOI 10.1056/NEJM197904123001501; VandeKerkhof PCM, 1997, BRIT J DERMATOL, V136, P275, DOI 10.1046/j.1365-2133.1997.d01-1187.x	22	164	169	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	2001	358	9287					1042	1045		10.1016/S0140-6736(01)06179-7	http://dx.doi.org/10.1016/S0140-6736(01)06179-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589933				2022-12-28	WOS:000171393100008
J	Klein, G; Klein, E				Klein, G; Klein, E			Bridge or ravine?	NATURE			English	Article									Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Klein, G (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.								0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					365	365						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574864				2022-12-28	WOS:000171188700032
J	Zhu, RX; Hoffman, KA; Potts, R; Deng, CL; Pan, YX; Guo, B; Shi, CD; Guo, ZT; Yuan, BY; Hou, YM; Huang, WW				Zhu, RX; Hoffman, KA; Potts, R; Deng, CL; Pan, YX; Guo, B; Shi, CD; Guo, ZT; Yuan, BY; Hou, YM; Huang, WW			Earliest presence of humans in northeast Asia	NATURE			English	Article							MAGNETIC-SUSCEPTIBILITY; BASIN; CHINA; HOMO	The timing of the earliest habitation and oldest stone technologies in different regions of the world remains a contentious topic in the study of human evolution(1-4). Here we contribute to this debate with detailed magnetostratigraphic results on two exposed parallel sections of lacustrine sediments at Xiaochangliang in the Nihewan Basin, north China; these results place stringent controls on the age of Palaeolithic stone artifacts that were originally reported over two decades ago(5). Our palaeomagnetic findings indicate that the artifact layer resides in a reverse polarity magnetozone bounded by the Olduvai and Jaramillo subchrons. Coupled with an estimated rate of sedimentation, these findings constrain the layer's age to roughly 1.36 million years ago. This result represents the age of the oldest known stone assemblage comprising recognizable types of Palaeolithic tool in east Asia, and the earliest definite occupation in this region as far north as 40 degrees N.	Chinese Acad Sci, Inst Geol & Geophys, Beijing 100101, Peoples R China; Calif Polytech State Univ San Luis Obispo, Dept Phys, San Luis Obispo, CA 93410 USA; Smithsonian Inst, Natl Museum Nat Hist, Human Origins Program, Washington, DC 20560 USA; Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China	Chinese Academy of Sciences; Institute of Geology & Geophysics, CAS; California State University System; California Polytechnic State University San Luis Obispo; Smithsonian Institution; Smithsonian National Museum of Natural History; Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	Zhu, RX (corresponding author), Chinese Acad Sci, Inst Geol & Geophys, Beijing 100101, Peoples R China.		Huang, WW/GXH-0977-2022; Deng, Chenglong/B-8871-2009; Zhu, Rixiang/F-2126-2018; huang, wen/GXW-0661-2022; Deng, Chenglong/B-8881-2009; Pan, Yongxin/B-4302-2008; Guo, Zhengtang/B-6854-2008	Deng, Chenglong/0000-0003-1848-3170; Zhu, Rixiang/0000-0002-4985-925X; Pan, Yongxin/0000-0002-4227-3061; Guo, Zhengtang/0000-0003-2259-9715				Ambrose SH, 2001, SCIENCE, V291, P1748, DOI 10.1126/science.1059487; AN ZH, 1989, QUATERNARY RES, V32, P213, DOI 10.1016/0033-5894(89)90077-X; Barbour G.B., 1925, B GEOLOGICAL SOC CHI, V4, P53; Berggren W. A., 1995, GEOCHRONOLOGY TIME S, P129, DOI DOI 10.2110/PEC.95.04.0129; CHEN C, IN PRESS ACTA ANTHR; Chen IM, 1999, INT J ROBOT RES, V18, P225; DAY R, 1977, PHYS EARTH PLANET IN, V13, P260, DOI 10.1016/0031-9201(77)90108-X; Gabunia L, 2000, SCIENCE, V288, P1019, DOI 10.1126/science.288.5468.1019; Hou YM, 2000, SCIENCE, V287, P1622, DOI 10.1126/science.287.5458.1622; Huang Weiwen, 1985, Acta Anthropologica Sinica, V4, P301; HUANG WP, 1995, NATURE, V378, P275; HUANG WP, 1991, WUSHAN HOMINID SITE, P105; JELINEK V, 1978, STUD GEOPHYS GEOD, V22, P50, DOI 10.1007/BF01613632; JIA LP, 1980, QUAT SINICA, V5, P12; Keates SG, 2000, BAR INT SERIES, V863, P107; Li YX, 1999, ACTA ANTHR SINICA, V18, P241; LIU TS, 1999, QUAT SCI, V4, P289; Morwood MJ, 1998, NATURE, V392, P173, DOI 10.1038/32401; PEI WZ, 1980, QUAT SINICA, V5, P11; Qiu Z.X., 2000, QUATERNARY SCI, V20, P142; ROCHETTE P, 1992, REV GEOPHYS, V30, P209, DOI 10.1029/92RG00733; Rutherford S, 2000, NATURE, V408, P72, DOI 10.1038/35040533; SCHICK K, 1991, J HUM EVOL, V21, P13, DOI 10.1016/0047-2484(91)90033-R; Tang Yingjun, 1995, Vertebrata Palasiatica, V33, P74; Teilhard de Chardin P., 1930, ANN PALEONTOL, V19, P1; Wei Q., 1997, EVIDENCE EVOLUTION E, P193; Wei Qi, 1985, Acta Anthropologica Sinica, V4, P223; You Y.Z., 1980, QUATERNARIA SINICA, V5, P1	28	164	261	4	57	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					413	417		10.1038/35096551	http://dx.doi.org/10.1038/35096551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574886				2022-12-28	WOS:000171188700052
J	Schneider, EC; Cleary, PD; Zaslavsky, AM; Epstein, AM				Schneider, EC; Cleary, PD; Zaslavsky, AM; Epstein, AM			Racial disparity in influenza vaccination - Does managed care narrow the gap between African Americans and whites?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; REVASCULARIZATION PROCEDURES; PREVENTIVE SERVICES; POPULATION; MORTALITY; OUTCOMES; ACCESS; RACE	Context Substantial racial disparities exist in use of some health services. Whether managed care could reduce racial disparities in the use of preventive services is not known. Objective To determine whether the magnitude of racial disparity in influenza vaccination is smaller among managed care enrollees than among those with fee-for-service insurance. Design, Setting, and Participants The 1996 Medicare Current Beneficiary Survey of a US cohort of 13674 African American and white Medicare beneficiaries with managed care and fee-for-service insurance. Main Outcome Measures Percentage of respondents (adjusted for sociodemographic characteristics, clinical comorbid conditions, and care-seeking attitudes) who received influenza vaccination and magnitude of racial disparity in influenza vaccination, compared among those with managed care and fee-for-service insurance. Results Eight percent of the beneficiaries were African American and 11% were enrolled in managed care. Overall, 65.8% received influenza vaccination. Whites were substantially more likely to be vaccinated than African Americans (67.7% vs 46.1%; absolute disparity, 21.6%; 95% confidence interval [CI], 18.2%-25.0%). Managed care enrollees were more likely than those with fee-for-service insurance to receive influenza vaccination (71.2% vs 65.4%; difference, 5.8%; 95% Cl, 3.6%-8.3%). The adjusted racial disparity in fee-for-service was 24.9% (95% CI, 19.6%-30.1%) and in managed care was 18.6% (95% CI, 9.8%-27.4%). These adjusted racial disparities were both statistically significant, but the absolute percentage point difference in racial disparity between the 2 insurance groups (6.3%; 95% CI, -4.6% to 17.2%) was not. Conclusion Managed care is associated with higher rates of influenza vaccination for both whites and African Americans, but racial disparity in vaccination is not reduced in managed care. Our results suggest that additional efforts are needed to adequately address this disparity.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Schneider, EC (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,4th Floor, Boston, MA 02115 USA.		Cleary, Paul/AAF-7048-2019	Schneider, Eric/0000-0002-1132-5084	AHRQ HHS [HS09473-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Brandeis GH, 1998, ALZ DIS ASSOC DIS, V12, P140, DOI 10.1097/00002093-199809000-00004; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; Cogswell ME, 1997, HEALTH AFFAIR, V16, P219, DOI 10.1377/hlthaff.16.6.219; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; Fiscella K, 1998, MED CARE, V36, P180, DOI 10.1097/00005650-199802000-00007; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; *GEN ACC OFF, 1999, MED MAN CAR PLANS MA, P1; Gene J, 1992, Fam Pract Res J, V12, P61; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; *HJ KAIS FAM FDN, 1999, RAC ETH MED CAR SURV, P1; Kiefe CI, 2001, JAMA-J AM MED ASSOC, V285, P2871, DOI 10.1001/jama.285.22.2871; MERKEL PA, 1994, J GEN INTERN MED, V9, P679, DOI 10.1007/BF02599008; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; Nichol KL, 1996, J GEN INTERN MED, V11, P673, DOI 10.1007/BF02600158; OCONNELL J, 1998, SAMPLING ESTIMATION; OHMIT SE, 1995, AM J PREV MED, V11, P271, DOI 10.1016/S0749-3797(18)30457-4; Oleske DM, 1998, HEALTH SERV RES, V33, P55; PEARSON DC, 1994, PUBLIC HEALTH REP, V109, P571; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; Phillips KA, 2000, HEALTH AFFAIR, V19, P102, DOI 10.1377/hlthaff.19.1.102; Reschovsky JD, 1999, INQUIRY-J HEALTH CAR, V36, P390; Roetzheim RG, 1999, J NATL CANCER I, V91, P1409, DOI 10.1093/jnci/91.16.1409; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; SHEA S, 1991, AM J EPIDEMIOL, V133, P489, DOI 10.1093/oxfordjournals.aje.a115916; STEIN AD, 1995, AM J EPIDEMIOL, V141, P1097, DOI 10.1093/oxfordjournals.aje.a117375; Tu HT, 1999, INQUIRY-J HEALTH CAR, V36, P400; Williams SJ, 1997, J COMMUN HEALTH, V22, P417, DOI 10.1023/A:1025176531596; Wood D, 1998, JAMA-J AM MED ASSOC, V279, P29, DOI 10.1001/jama.279.1.29; 1995, MMWR MORB MORTAL WKL, V44, P744; 1995, MMWR MORB MORTAL WKL, V44, P24; 1999, MMWR MORB MORTAL WKL, V48, P886; 1997, MMWR MORB MORTAL WKL, V46, P919; 1998, MMWR MORB MORTAL WKL, V47, P956; 1998, MMWR MORB MORTAL WKL, V47, P797; 1994, MMWR MORB MORTAL WKL, V43, P771; 1997, MMWR MORB MORTAL WKL, V46, P974	40	176	176	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1455	1460		10.1001/jama.286.12.1455	http://dx.doi.org/10.1001/jama.286.12.1455			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	475UX	11572737	Bronze			2022-12-28	WOS:000171188600022
J	McCarthy, M				McCarthy, M			Attacks provide first major test of USA's national antiterrorist medical response plans	LANCET			English	Article																			0	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					941	941		10.1016/S0140-6736(01)06119-0	http://dx.doi.org/10.1016/S0140-6736(01)06119-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11584818	Bronze			2022-12-28	WOS:000171135300004
J	Bruneau, BG; Nemer, G; Schmitt, JP; Charron, F; Robitaille, L; Caron, S; Conner, DA; Gessler, M; Nemer, M; Seidman, CE; Seidman, JG				Bruneau, BG; Nemer, G; Schmitt, JP; Charron, F; Robitaille, L; Caron, S; Conner, DA; Gessler, M; Nemer, M; Seidman, CE; Seidman, JG			A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease	CELL			English	Article							ULNAR-MAMMARY SYNDROME; CARDIAC CONDUCTION; MICE LACKING; CONNEXIN40-DEFICIENT MICE; GENE FAMILY; HEART; EXPRESSION; MUTATIONS; MOUSE; NKX2-5	Heterozygous Tbx5(del/+) mice were generated to study the mechanisms by which TBX5 haploinsufficiency causes cardiac and forelimb abnormalities seen in Holt-Oram syndrome. Tbx5 deficiency in homozygous mice (Tbx5(del/del)) decreased expression of multiple genes and caused severe hypoplasia of posterior domains in the developing heart. Surprisingly, Tbx5 haploinsufficiency also markedly decreased atrial natriuretic factor (ANF) and connexin 40 (cx40) transcription, implicating these as Tbx5 target genes and providing a mechanism by which 50% reduction of T-box transcription factors cause disease. Direct and cooperative transactivation of the ANF and cx40 promoters by Tbx5 and the homeodomain transcription factor Nkx2-5 was also demonstrated. These studies provide one potential explanation for Holt-Oram syndrome conduction system defects, suggest mechanisms for intrafamilial phenotypic variability, and account for related cardiac malformations caused by other transcription factor mutations.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Inst Rech Clin Montreal, Lab Dev & Differenciat Cardiaques, Montreal, PQ H2W 1R7, Canada; Univ Wurzburg, Biozentrum, D-97074 Wurzburg, Germany; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Wurzburg; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital	Nemer, M (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.		Nemer, Georges/H-7801-2014; Nemer, Georges/ABB-5117-2020; Charron, Frederic/O-8017-2019; Schmitt, Joachim/GQP-7068-2022	Nemer, Georges/0000-0003-2157-5279; Charron, Frederic/0000-0003-3483-8672; Gessler, Manfred/0000-0002-7915-6045; Bruneau, Benoit/0000-0002-0804-7597	NCRR NIH HHS [S10 RR14792] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014792] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; Basson CT, 1999, P NATL ACAD SCI USA, V96, P2919, DOI 10.1073/pnas.96.6.2919; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Bevilacqua LM, 2000, J INTERV CARD ELECTR, V4, P459, DOI 10.1023/A:1009800328836; Bruneau BG, 1999, DEV BIOL, V211, P100, DOI 10.1006/dbio.1999.9298; Bruneau BG, 2000, DEV BIOL, V217, P266, DOI 10.1006/dbio.1999.9548; Bruneau BG, 2001, MOL CELL BIOL, V21, P1730, DOI 10.1128/MCB.21.5.1730-1736.2001; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Erives A, 2000, DEV BIOL, V225, P169, DOI 10.1006/dbio.2000.9815; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; Hagendorff A, 1999, CIRCULATION, V99, P1508, DOI 10.1161/01.CIR.99.11.1508; He ML, 1999, P NATL ACAD SCI USA, V96, P10212, DOI 10.1073/pnas.96.18.10212; HENDRICKSON BA, 1995, J EXP MED, V182, P1905, DOI 10.1084/jem.182.6.1905; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Horb ME, 1999, DEVELOPMENT, V126, P1739; Kirchhoff S, 2000, CIRC RES, V87, P399; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; KISPERT A, 1993, EMBO J, V12, P4898, DOI 10.1002/j.1460-2075.1993.tb06179.x; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Li QY, 1997, NAT GENET, V15, P21; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MARRIOTT HJL, 1983, PRACTICAL ELECTROCAR; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; NewburyEcob RA, 1996, J MED GENET, V33, P300, DOI 10.1136/jmg.33.4.300; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Seul KH, 1997, GENOMICS, V46, P120, DOI 10.1006/geno.1997.5025; Simon AM, 1998, CURR BIOL, V8, P295, DOI 10.1016/S0960-9822(98)70113-7; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Tada M, 2001, DEV GROWTH DIFFER, V43, P1	45	758	786	1	42	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 21	2001	106	6					709	721		10.1016/S0092-8674(01)00493-7	http://dx.doi.org/10.1016/S0092-8674(01)00493-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572777	Bronze			2022-12-28	WOS:000171213000008
J	Gorden, J; Usher, BW				Gorden, J; Usher, BW			Massive arteriovenous malformation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Vanderbilt Univ, Nashville, TN 37212 USA; Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Gorden, J (corresponding author), Vanderbilt Univ, Nashville, TN 37212 USA.			Gorden, Jed/0000-0003-0683-9547					0	1	1	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2001	345	12					886	886		10.1056/NEJMicm960493	http://dx.doi.org/10.1056/NEJMicm960493			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	473JW	11565521				2022-12-28	WOS:000171039600005
J	Goldman, P				Goldman, P			Herbal medicines today and the roots of modern pharmacology	ANNALS OF INTERNAL MEDICINE			English	Article							PROPHYLACTIC TREATMENT; EPIDEMIOLOGIC RESEARCH; UNITED-STATES; EFFICACY; MIGRAINE; FEVERFEW; HYPERFORIN; DIGOXIN; SAFETY	The transformation of digitalis from a folk medicine, foxglove, to a modem drug, digoxin, illustrates principles of modern pharmacology that have helped make drugs safer and more effective. Digitalis was improved because its preparation was standardized, first by bioassay and then by chemical methods; however, few of today's herbs are standardized by methods that can ensure a consistent product and, hence, consistent safety and efficacy profiles. Many herbs have been evaluated in randomized, controlled trials, and several-St. John's wort and ginkgo, for example-are apparently effective. Yet, many trials of herbs have limited value because of poor design, small samples, and, above all, use of products of uncertain composition and consistency. The uncertain composition of many herbal products raises questions about their safety as does evidence indicating that herbs may have harmful interactions with prescription drugs. Such adverse effects of herbs are probably underreported. Meanwhile, systematic studies, such as those identifying adverse reactions to drugs, are hindered because herbal preparations are not standardized-one: brand of St. John's wort, for example, will differ chemically from another-and, unlike for prescription drugs, there are no databases linking herb consumption to later medical problems. Since herbal medicines are regulated as dietary supplements, they are not subject to the premarketing regulatory clearance required for drugs. The burden of proof, is on the U.S. Food and Drug Administration to show a dietary supplement is unsafe, unlike for drugs, which cannot be approved until the manufacturer has demonstrated safety and effectiveness.	Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Boston, MA 02215 USA; Harvard Univ, Sch Med, Harvard Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health	Goldman, P (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, 330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000607] Funding Source: NIH RePORTER; NCCIH NIH HHS [1 RO1 AT00607-01] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Ackermann RT, 2001, ARCH INTERN MED, V161, P813, DOI 10.1001/archinte.161.6.813; Awang D. V. C., 1998, Journal of Herbs, Spices & Medicinal Plants, V5, P95, DOI 10.1300/J044v05n04_11; BEAN WB, 1968, SIR W OSLER APHORISM, P105; Berthold HK, 1998, JAMA-J AM MED ASSOC, V279, P1900, DOI 10.1001/jama.279.23.1900; Blumenthal M, 2000, HERBAL MED EXPANDED; Capasso L, 1998, LANCET, V352, P1864, DOI 10.1016/S0140-6736(05)79939-6; Chatterjee SS, 1998, LIFE SCI, V63, P499, DOI 10.1016/S0024-3205(98)00299-9; Committee on Toxicology, 1997, REP COMM SECR GEN, P1; De Smet P. A. G. M., 1993, ADVERSE EFFECTS HERB, VII; De Smet P. A. G. M., 1992, ADVERSE EFFECTS HERB, VI; DeFeudis FV, 1998, GINKGO BILOBA EXTRAC, P7; DeSmet P., 1997, ADVERSE EFFECTS HERB, V3, P99; DESMET PAG, 1999, ESSENTIALS COMPLEMEN, P108; DeWeerdt CJ, 1996, PHYTOMEDICINE, V3, P225, DOI 10.1016/S0944-7113(96)80057-2; Edmunds CW, 1907, J AMER MED ASSOC, V48, P1744; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; Foster DF, 2000, J AM GERIATR SOC, V48, P1560, DOI 10.1111/j.1532-5415.2000.tb03864.x; Gold H, 1941, J PHARMACOL EXP THER, V73, P212; GOLDMAN P, 1981, NEW ENGL J MED, V304, P983; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; ISRAELSEN LD, 1998, Q REV NATURAL MED, P251; Jick H, 1998, LANCET, V352, P1767, DOI 10.1016/S0140-6736(98)04350-5; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; Kessler DA, 2000, NEW ENGL J MED, V342, P1742, DOI 10.1056/NEJM200006083422309; Ko RJ, 1998, NEW ENGL J MED, V339, P847, DOI 10.1056/NEJM199809173391214; Laakmann G, 1998, PHYTOMEDICINE, V5, P435, DOI 10.1016/S0944-7113(98)80039-1; Lawson LD, 1998, JAMA-J AM MED ASSOC, V280, P1568, DOI 10.1001/jama.280.18.1568; Linde K., 2000, STJOHNS WORT DEPRESS; LINDENBAUM J, 1971, NEW ENGL J MED, V285, P1344, DOI 10.1056/NEJM197112092852403; Love L, 1998, J TOXICOL-CLIN TOXIC, V36, P263, DOI 10.3109/15563659809028953; Matthews HB, 1999, ENVIRON HEALTH PERSP, V107, P773, DOI 10.2307/3454572; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; Okada M, 1999, LANCET, V354, P1732, DOI 10.1016/S0140-6736(05)76721-0; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Palevitch D, 1997, PHYTOTHER RES, V11, P508, DOI 10.1002/(SICI)1099-1573(199711)11:7<508::AID-PTR153>3.3.CO;2-8; Perry G, 1997, NEW ENGL J MED, V336, P525; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Rodriguez LAG, 1997, PHARMACOTHERAPY, V17, P721; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; SCHWARZ A. JOHN, 1934, AMER JOUR PHARM, V106, P196; Slifman NR, 1998, NEW ENGL J MED, V339, P806, DOI 10.1056/NEJM199809173391204; SRINIVASAN VS, 1998, PHARMACOPEIAL FORUM, V24, P6623; Stevinson C, 2000, ANN INTERN MED, V133, P420, DOI 10.7326/0003-4819-133-6-200009190-00009; Temin P., 1980, TAKING YOUR MED DRUG; Vogler BK, 1998, CEPHALALGIA, V18, P704, DOI 10.1046/j.1468-2982.1998.1810704.x; WALLER PC, 1985, BRIT MED J, V291, P1128, DOI 10.1136/bmj.291.6502.1128; WITHERING W, 1785, ACCOUNT FOXGLOVE SOM, P2; Yue QY, 2000, LANCET, V355, P576, DOI 10.1016/S0140-6736(05)73227-X; 1906, JAMA, V46, P1027; 1995, CONSUMER REPORTS, V60, P698	51	132	138	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	1				594	600		10.7326/0003-4819-135-8_Part_1-200110160-00010	http://dx.doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481VY	11601931				2022-12-28	WOS:000171542200005
J	Wenger, NS; Rosenfeld, K				Wenger, NS; Rosenfeld, K			Quality indicators for end-of-life care in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							NURSING-HOME RESIDENTS; ADVANCE DIRECTIVES; RESUSCITATION PREFERENCES; SUSTAINING TREATMENT; DYING PATIENTS; ILL; PHYSICIANS; DISCUSSIONS; MANAGEMENT; INSIGHTS		Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Health Care Syst, Los Angeles, CA USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Wenger, NS (corresponding author), Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90095 USA.	nwenger@mednet.ucla.edu						ADAMOWSKI K, 1994, CAN MED ASSOC J, V150, P326; *AM MED ASS, 1991, COD MED ETH REP AMA; [Anonymous], 1992, ANN INTERN MED, V117, P947; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; *APS, 1997, APS B, V7, P1; BLACKHALL LJ, 1989, J GEN INTERN MED, V4, P399, DOI 10.1007/BF02599689; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; CAMPBELL ML, 1998, AACN CRITICAL CARE P, P61; Canadian Palliative Care Association, 1995, PALL CAR CONS STAND; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DENNIS C, 1998, VACCOS COMMISSION QU; Desbiens NA, 1998, PAIN, V75, P237, DOI 10.1016/S0304-3959(97)00225-X; DRANE JF, 1984, JAMA-J AM MED ASSOC, V252, P925, DOI 10.1001/jama.252.7.925; Ehman JW, 1999, ARCH INTERN MED, V159, P1803, DOI 10.1001/archinte.159.15.1803; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Faber-Langendoen K, 2000, ANN INTERN MED, V133, P886, DOI 10.7326/0003-4819-133-11-200012050-00013; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; Field MJ, 1997, APPROACHING DEATH IM; Fischer GS, 1998, J GEN INTERN MED, V13, P447, DOI 10.1046/j.1525-1497.1998.00133.x; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; Goodman MD, 1998, CRIT CARE MED, V26, P701, DOI 10.1097/00003246-199804000-00018; Gregory J J, 1995, N J Med, V92, P438; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; *HAST CTR, 1987, GUID TERM LIF SUST T; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; KEAY TJ, 1994, J AM GERIATR SOC, V42, P853, DOI 10.1111/j.1532-5415.1994.tb06557.x; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LANKEN PN, 1991, AM REV RESPIR DIS, V144, P726, DOI 10.1164/ajrccm/144.3_Pt_1.726; Levin JR, 1999, J AM GERIATR SOC, V47, P82, DOI 10.1111/j.1532-5415.1999.tb01905.x; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LUCHINS DJ, 1993, J AM GERIATR SOC, V41, P25; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; MOWER WR, 1993, ARCH INTERN MED, V153, P375, DOI 10.1001/archinte.153.3.375; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; ROBINSON L, 1994, BRIT J GEN PRACT, V44, P461; SCHNEIDERMAN L, 1995, WRONG MED; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Sulmasy DP, 1996, J MED ETHICS, V22, P344, DOI 10.1136/jme.22.6.344; SULMASY DP, 1992, JAMA-J AM MED ASSOC, V267, P682; SWARTZ RD, 1993, J AM SOC NEPHROL, V3, P1623; Taylor RM, 1996, NEUROLOGY, V46, P870; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TENO JM, 1994, HASTINGS CENT REP, V24, pS32, DOI 10.2307/3563482; Tolle SW, 2000, WESTERN J MED, V172, P374, DOI 10.1136/ewjm.172.6.374; *U CAL, 1998, TERM WEAN MECH VENT; UHLMANN RF, 1989, WESTERN J MED, V150, P705; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; Wenger N. S., 1997, JGIM, V12, P105; Wenger N. S., 1994, Journal of the American Geriatrics Society, V42, pSA67; Wenger NS, 2000, J AM GERIATR SOC, V48, pS44, DOI 10.1111/j.1532-5415.2000.tb03140.x; Wenger NS, 1996, J CLIN ETHIC, V7, P48; Wenger NS, 2001, JAMA-J AM MED ASSOC, V285, P2880, DOI 10.1001/jama.285.22.2880; 1983, PRESIDENTS COMM STUD; 1996, JAMA, V274, P474; 1995, J AM GERIATR SOC, V43, P577	64	54	54	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				677	685		10.7326/0003-4819-135-8_Part_2-200110161-00006	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601950				2022-12-28	WOS:000171542400006
J	Nemec, P; Altmann, J; Marhold, S; Burda, H; Oelschlager, HHA				Nemec, P; Altmann, J; Marhold, S; Burda, H; Oelschlager, HHA			Neuroanatomy of magnetoreception: The superior colliculus involved in magnetic orientation in a mammal	SCIENCE			English	Article							VISUAL-SYSTEM; C-FOS; COMPASS; ARCHITECTURE; RESPONSES; BOBOLINK; CELLS	The neural substrate subserving magnetic orientation is largely unknown in vertebrates and unstudied in mammals, We combined a behavioral test for magnetic compass orientation in mole rats and immunocytochemical visualization of the transcription factor c-Fos as a marker of neuronal activity. We found that the superior colliculus of the Zambian mote rat (Cryptomys anselli) contains neurons that are responsive to magnetic stimuli. These neurons are directionally selective and organized within a discrete sublayer. Our results constitute evidence for the involvement of a specific mammalian brain structure in magnetoreception.	Charles Univ, Dept Zool, CZ-12844 Prague, Czech Republic; Univ Frankfurt, Dept Anat 3, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Zool, D-60323 Frankfurt, Germany; Univ Essen Gesamthsch, Dept Gen Zool, D-45117 Essen, Germany	Charles University Prague; Goethe University Frankfurt; Goethe University Frankfurt; University of Duisburg Essen	Nemec, P (corresponding author), Charles Univ, Dept Zool, CZ-12844 Prague, Czech Republic.		Nemec, Pavel/K-1163-2012	Nemec, Pavel/0000-0003-0277-0239				BEASON RC, 1987, NEUROSCI LETT, V80, P229, DOI 10.1016/0304-3940(87)90659-8; BURDA H, 1990, EXPERIENTIA, V46, P528, DOI 10.1007/BF01954256; Chevalier G, 2000, J COMP NEUROL, V419, P137, DOI 10.1002/(SICI)1096-9861(20000403)419:2<137::AID-CNE1>3.0.CO;2-6; DEAN P, 1989, TRENDS NEUROSCI, V12, P137, DOI 10.1016/0166-2236(89)90052-0; DEMAINE C, 1985, NEUROSCI LETT, V62, P119, DOI 10.1016/0304-3940(85)90294-0; DRAGUNOW M, 1989, J NEUROSCI METH, V29, P261, DOI 10.1016/0165-0270(89)90150-7; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Huerta M.F., 1984, P687; HUERTA MF, 1984, TRENDS NEUROSCI, V7, P286, DOI 10.1016/S0166-2236(84)80197-6; ILLING RB, 1992, P NATL ACAD SCI USA, V89, P10900, DOI 10.1073/pnas.89.22.10900; Illing RB, 1996, PROG BRAIN RES, V112, P17; Lohmann KJ, 2000, TRENDS NEUROSCI, V23, P153, DOI 10.1016/S0166-2236(99)01542-8; Marhold S, 1997, NATURWISSENSCHAFTEN, V84, P421, DOI 10.1007/s001140050422; Morgan Marcyliena., 1991, PRAGMATICS, V1, P421; Oelschlager HHA, 2000, BRAIN BEHAV EVOLUT, V55, P209, DOI 10.1159/000006653; SEMM P, 1990, BRAIN RES BULL, V25, P735, DOI 10.1016/0361-9230(90)90051-Z; SEMM P, 1986, J COMP PHYSIOL A, V159, P619, DOI 10.1007/BF00612035; SEMM P, 1984, J COMP PHYSIOL, V155, P283, DOI 10.1007/BF00610581; SEMM P, 1980, NATURE, V288, P607, DOI 10.1038/288607a0; SPARKS DL, 1988, BRAIN BEHAV EVOLUT, V31, P49, DOI 10.1159/000116575; Stein BE, 1998, EXP BRAIN RES, V123, P124, DOI 10.1007/s002210050553; Stein BE., 1993, MERGING SENSES; Walker MM, 1997, NATURE, V390, P371, DOI 10.1038/37057; Wiltschko R., 1995, TIEROSYCHOL	24	93	100	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					366	368		10.1126/science.1063351	http://dx.doi.org/10.1126/science.1063351			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598299				2022-12-28	WOS:000171601400042
J	Flum, DR; Morris, A; Koepsell, T; Dellinger, EP				Flum, DR; Morris, A; Koepsell, T; Dellinger, EP			Has misdiagnosis of appendicitis decreased over time? A population-based analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPUTED-TOMOGRAPHY; NEGATIVE APPENDECTOMY; DIAGNOSIS; IMPACT; CT	Context Misdiagnosis of presumed appendicitis is an adverse outcome that leads to unnecessary surgery. Computed tomography, ultrasonography, and laparoscopy have been suggested for use in patients with equivocal signs of appendicitis to decrease unnecessary surgery. Objective To determine if frequency of misdiagnosis preceding appendectomy has decreased with increased availability of computed tomography, ultrasonography, and laparoscopy. Design, Setting, and Patients Retrospective, population-based cohort study of data from a Washington State hospital discharge database for 85790 residents assigned International Classification of Diseases, Ninth Revision procedure codes for appendectomy, and United States Census Bureau data for 1987-1998. Main Outcome Measure Population-based age- and sex-standardized incidence of appendectomy with acute appendicitis (perforated or not) or with a normal appendix. Results Among 63707 nonincidental appendectomy patients, 84.5% had appendicitis (25.8% with perforation) and 15.5% had no associated diagnosis of appendicitis. After adjusting for age and sex, the population-based incidence of unnecessary appendectomy and of appendicitis with perforation did not change significantly over time. Among women of reproductive age, the population-based incidence of misdiagnosis increased 1% per year (P =.005). The incidence of misdiagnosis increased 8% yearly in patients older than 65 years (P<.001) but did not change significantly in children younger than 5 years (P =.17). The proportion of patients undergoing laparoscopic appendectomy who were misdiagnosed was significantly higher than that of open appendectomy patients (19.6% vs 15.5%; P<.001). Conclusion Contrary to expectation, the frequency of misdiagnosis leading to unnecessary appendectomy has not changed with the introduction of computed tomography, ultrasonography, and laparoscopy, nor has the frequency of perforation decreased. These data suggest that on a population level, diagnosis of appendicitis has not improved with the availability of advanced diagnostic testing.	Univ Washington, Hlth Sci Ctr H220, Robert Wood Johnson Clin Scholars Program, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol & Hlth Serv, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Flum, DR (corresponding author), Univ Washington, Hlth Sci Ctr H220, Robert Wood Johnson Clin Scholars Program, Dept Surg, Box 357183, Seattle, WA 98195 USA.	daveflum@u.washington.edu	Flum, David/GPX-7976-2022	Morris, Arden/0000-0001-5795-2940				ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; Balthazar EJ, 1998, AM J GASTROENTEROL, V93, P768; Barrat C, 1999, SURG LAPAROSC ENDOSC, V9, P27, DOI 10.1097/00019509-199901000-00005; Birnbaum BA, 2000, RADIOLOGY, V215, P337, DOI 10.1148/radiology.215.2.r00ma24337; Borgstein PJ, 1997, SURG ENDOSC-ULTRAS, V11, P923, DOI 10.1007/s004649900488; DETMER DE, 1981, JAMA-J AM MED ASSOC, V246, P1318, DOI 10.1001/jama.246.12.1318; Firilas AM, 1999, AM SURGEON, V65, P769; Franke C, 1999, WORLD J SURG, V23, P141, DOI 10.1007/PL00013165; Grunewald B, 1993, J R Coll Surg Edinb, V38, P158; JADALLAH FA, 1994, EUR J SURG, V160, P41; Korner H, 1998, BRIT J SURG, V85, P341; Korner H, 1997, WORLD J SURG, V21, P313, DOI 10.1007/s002689900235; Pittman-Waller VA, 2000, AM SURGEON, V66, P548; Rao PM, 1999, ANN SURG, V229, P344, DOI 10.1097/00000658-199903000-00007; Rao PM, 1997, J COMPUT ASSIST TOMO, V21, P686, DOI 10.1097/00004728-199709000-00002; Rao PM, 1998, NEW ENGL J MED, V338, P141, DOI 10.1056/NEJM199801153380301; STRINGEL G, 1987, AM J SURG, V154, P631, DOI 10.1016/0002-9610(87)90231-5; Styrud J, 1999, DIGEST SURG, V16, P39, DOI 10.1159/000018692; Velanovich V, 1998, AM SURGEON, V64, P7; Weyant MJ, 2000, SURGERY, V128, P145, DOI 10.1067/msy.2000.107422; Wong SW, 1999, AUST NZ J SURG, V69, P31, DOI 10.1046/j.1440-1622.1999.01482.x	21	326	337	2	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1748	1753		10.1001/jama.286.14.1748	http://dx.doi.org/10.1001/jama.286.14.1748			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480NC	11594900	Bronze			2022-12-28	WOS:000171466800025
J	Wilcox, AJ; Baird, DD; Dunson, D; McChesney, R; Weinberg, CR				Wilcox, AJ; Baird, DD; Dunson, D; McChesney, R; Weinberg, CR			Natural limits of pregnancy testing in relation to the expected menstrual period	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN CHORIONIC-GONADOTROPIN; URINE; SERUM; CYCLE	Context Pregnancy test kits routinely recommend testing "as early as the first day of the missed period." However, a pregnancy cannot be detected before the blastocyst implants. Due to natural variability in the timing of ovulation, implantation does not necessarily occur before the expected onset of next menses. Objective To estimate the maximum screening sensitivity of pregnancy tests when used on the first day of the expected period, taking into account the natural variability of ovulation and implantation. Design and Setting Community-based prospective cohort study conducted in North Carolina between 1982 and 1986. Participants Two hundred twenty-one healthy women 21 to 42 years of age who were planning to conceive. Main Outcome Measures Day of implantation, defined by the serial assay of first morning urine samples using an extremely sensitive immunoradiometric assay for human chorionic gonadotropin (hCG), relative to the first day of the missed period, defined as the day on which women expected their next menses to begin, based on self-reported usual cycle length. Results Data were available for 136 clinical pregnancies conceived during the study, 14 (10%) of which had not yet implanted by the first day of the missed period. The highest possible screening sensitivity for an hCG-based pregnancy test therefore is estimated to be 90% (95% confidence interval [CI], 84%-94%) on the first day of the missed period. By 1 week after the first day of the missed period, the highest possible screening sensitivity is estimated to be 97% (95% Cl, 94%-99%). Conclusions In this study, using an extremely sensitive assay for hCG, 10% of clinical pregnancies were undetectable on the first day of missed menses. fn practice, an even larger percentage of clinical pregnancies may be undetected by current test kits on this day, given their reported assay properties and other practical limitations.	NIEHS, Epidemiol Branch, Durham, NC USA; NIEHS, Biostat Branch, Durham, NC USA; Columbia Univ Barnard Coll, Dept Biol Sci, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Columbia University	Wilcox, AJ (corresponding author), NIEHS, Epidemiol Branch, MD A3-05, Res Triangle Pk, NC 27709 USA.		Wilcox, Allen J/C-7723-2019; Baird, Donna D/D-5214-2017	Wilcox, Allen J/0000-0002-3376-1311; Baird, Donna D/0000-0002-5544-2653; Weinberg, Clarice/0000-0002-7713-8556	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES049003, Z01ES044003, ZIAES044003, Z01ES049003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALFTHAN H, 1993, SCAND J CLIN LAB INV, V53, P105, DOI 10.3109/00365519309086911; ARMSTRONG EG, 1984, J CLIN ENDOCR METAB, V59, P867, DOI 10.1210/jcem-59-5-867; Bastian LA, 1998, ARCH FAM MED, V7, P465, DOI 10.1001/archfami.7.5.465; CHARD T, 1992, HUM REPROD, V7, P701, DOI 10.1093/oxfordjournals.humrep.a137722; COLE LA, 1993, AM J OBSTET GYNECOL, V168, P1580, DOI 10.1016/S0002-9378(11)90802-3; Harlow SD, 2000, J CLIN EPIDEMIOL, V53, P722, DOI 10.1016/S0895-4356(99)00202-4; Ikomi A, 1998, BRIT J OBSTET GYNAEC, V105, P462, DOI 10.1111/j.1471-0528.1998.tb10135.x; LENTON EA, 1984, BRIT J OBSTET GYNAEC, V91, P681, DOI 10.1111/j.1471-0528.1984.tb04830.x; LIPSITZ R, 2000, SCI AM, V283, P110; MISHALANI SH, 1994, CLIN CHEM, V40, P1944; Shew ML, 2000, AM J PUBLIC HEALTH, V90, P974, DOI 10.2105/AJPH.90.6.974; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Wilcox AJ, 1999, NEW ENGL J MED, V340, P1796, DOI 10.1056/NEJM199906103402304; Wilcox AJ, 2000, BRIT MED J, V321, P1259, DOI 10.1136/bmj.321.7271.1259	14	62	62	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1759	1761		10.1001/jama.286.14.1759	http://dx.doi.org/10.1001/jama.286.14.1759			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480NC	11594902	Bronze			2022-12-28	WOS:000171466800027
J	Mitra, M; Chang, B; James, T				Mitra, M; Chang, B; James, T			Exacerbation of angina associated with latanoprost	BRITISH MEDICAL JOURNAL			English	Article																		Lai J, 1996, AM J PHYSIOL-HEART C, V271, pH2197, DOI 10.1152/ajpheart.1996.271.6.H2197; Linden C, 1999, DRUG AGING, V14, P387, DOI 10.2165/00002512-199914050-00006; SELWYN AP, 1994, HARRISONS PRINCIPLES, P1077; Watson PG, 1998, OPHTHALMOLOGY, V105, P82, DOI 10.1016/S0161-6420(98)91372-0	4	13	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 6	2001	323	7316					783	783		10.1136/bmj.323.7316.783	http://dx.doi.org/10.1136/bmj.323.7316.783			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481LK	11588081	Bronze, Green Published			2022-12-28	WOS:000171520600030
J	Baker, D; Sali, A				Baker, D; Sali, A			Protein structure prediction and structural genomics	SCIENCE			English	Editorial Material							PROTEASES; DATABASE; BINDING; TOOL	Genome sequencing projects are producing linear amino acid sequences, but full understanding of the biological role of these proteins will require knowledge of their structure and function. Although experimental structure determination methods are providing high-resolution structure information about a subset of the proteins, computational structure prediction methods will provide valuable information for the large fraction of sequences whose structures will not be determined experimentally. The first class of protein structure prediction methods, including threading and comparative modeling, rely on detectable similarity spanning most of the modeled sequence and at least one known structure. The second class of methods, de novo or ab initio methods, predict the structure from sequence alone, without relying on similarity at the fold level between the modeled sequence and any of the known structures. In this Viewpoint, we begin by describing the essential features of the methods, the accuracy of the models, and their application to the prediction and understanding of protein function, both for single proteins and on the scale of whole genomes. We then discuss the important role that protein structure prediction methods play in the growing worldwide effort in structural genomics.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Rockefeller Univ, Pels Family Ctr Biochem & Struct Biol, Lab Mol Biophys, New York, NY 10021 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Rockefeller University	Baker, D (corresponding author), Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA.	dabaker@u.washington.edu; sail@rockefeller.edu	Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217	NIGMS NIH HHS [GM 54762] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054762, R29GM054762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aloy P, 2001, J MOL BIOL, V311, P395, DOI 10.1006/jmbi.2001.4870; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; Bonneau R, 2001, ANNU REV BIOPH BIOM, V30, P173, DOI 10.1146/annurev.biophys.30.1.173; Bonneau R, 2001, J STRUCT BIOL, V134, P186, DOI 10.1006/jsbi.2000.4370; BONNEAU R, IN PRESS PROTEINS ST; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Brenner SE, 2000, NAT STRUCT BIOL, V7, P967, DOI 10.1038/80747; BROWNE WJ, 1969, J MOL BIOL, V42, P65, DOI 10.1016/0022-2836(69)90487-2; Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Fischer D, 1997, P NATL ACAD SCI USA, V94, P11929, DOI 10.1073/pnas.94.22.11929; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Gonzalez C, 2000, P NATL ACAD SCI USA, V97, P11221, DOI 10.1073/pnas.210301097; GREER J, 1981, J MOL BIOL, V153, P1027, DOI 10.1016/0022-2836(81)90465-4; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; HAVEL TF, 1991, J MOL BIOL, V217, P1, DOI 10.1016/0022-2836(91)90603-4; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Jones DT, 1997, PROTEINS, P185; Koehl Patrice, 1999, Nature Structural Biology, V6, P108, DOI 10.1038/5794; Kolinski A, 2001, PROTEINS, V44, P133, DOI 10.1002/prot.1080; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; MARTIRENOM MA, IN PRESS STRUCTURE; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Ortiz AR, 1999, PROTEINS, P177; Pillardy A, 2001, P NATL ACAD SCI USA, V98, P2329, DOI 10.1073/pnas.041609598; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sali Andrej, 1998, Nature Structural Biology, V5, P1029, DOI 10.1038/4136; SAMUDRALA R, 1999, PROTEINS, V3, P197; Sanchez R, 2000, NUCLEIC ACIDS RES, V28, P250, DOI 10.1093/nar/28.1.250; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; Sanchez R, 2000, NAT STRUCT BIOL, V7, P986, DOI 10.1038/80776; Simons KT, 2001, J MOL BIOL, V306, P1191, DOI 10.1006/jmbi.2000.4459; SPAHN CMT, IN PRESS CELL; Torda AE, 1997, CURR OPIN STRUC BIOL, V7, P200, DOI 10.1016/S0959-440X(97)80026-7; Vitkup D, 2001, NAT STRUCT BIOL, V8, P559, DOI 10.1038/88640; Wallace AC, 1997, PROTEIN SCI, V6, P2308; Xu LZ, 1996, J BIOL CHEM, V271, P24711; Zhang BH, 1999, PROTEIN SCI, V8, P1104, DOI 10.1110/ps.8.5.1104	41	1164	1306	8	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 5	2001	294	5540					93	96		10.1126/science.1065659	http://dx.doi.org/10.1126/science.1065659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588250				2022-12-28	WOS:000171448800038
J	Hilleren, P; McCarthy, T; Rosbash, M; Parker, R; Jensen, TH				Hilleren, P; McCarthy, T; Rosbash, M; Parker, R; Jensen, TH			Quality control of mRNA 3 '-end processing is linked to the nuclear exosome	NATURE			English	Article							MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; RIBOSOMAL-RNA; EXPORT; YEAST; POLYADENYLATION; MUTATIONS; TURNOVER; PATHWAY	An emerging theme in messenger RNA metabolism is the coupling of nuclear pre-mRNA processing events, which contributes to mRNA quality control(1). Most eukaryotic mRNAs acquire a poly(A) tail during 3'-end processing within the nucleus, and this is coupled to efficient export of mRNAs to the cytoplasm(2,3). In the yeast Saccharomyces cerevisiae, a common consequence of defective nuclear export of mRNA is the hyperadenylation of nascent transcripts(4,5), which are sequestered at or near their sites of transcription(5). This implies that polyadenylation and nuclear export are coupled in a step that involves the release of mRNA from transcription site foci. Here we demonstrate that transcripts which fail to acquire a poly(A) tail are also retained at or near transcription sites. Surprisingly, this retention mechanism requires the protein Rrp6p and the nuclear exosome, a large complex of exonucleolytic enzymes(6,7). In exosome mutants, hypo- as well as hyperadenylated mRNAs are released and translated. These observations suggest that the exosome contributes to a checkpoint that monitors proper 3'-end formation of mRNA.	Univ Arizona, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Brandeis Univ, Howard Hughes Med Inst, Dept Biol, Waltham, MA 02454 USA	Howard Hughes Medical Institute; University of Arizona; Brandeis University; Howard Hughes Medical Institute	Hilleren, P (corresponding author), Univ Arizona, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.		Jensen, Torben H/G-2954-2017					Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Amrani N, 1996, MOL GEN GENET, V252, P552, DOI 10.1007/BF02172401; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Briggs MW, 1998, J BIOL CHEM, V273, P13255, DOI 10.1074/jbc.273.21.13255; Burkard KTD, 2000, MOL CELL BIOL, V20, P604, DOI 10.1128/MCB.20.2.604-616.2000; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Hilleren P, 2001, RNA, V7, P753, DOI 10.1017/S1355838201010147; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; MANDART E, 1995, MOL CELL BIOL, V15, P6979; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; Vainberg IE, 2000, MOL CELL BIOL, V20, P3996, DOI 10.1128/MCB.20.11.3996-4005.2000; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000	18	284	288	0	24	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					538	542		10.1038/35097110	http://dx.doi.org/10.1038/35097110			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586364				2022-12-28	WOS:000171340500051
J	Goldie, SJ; Levin, AR				Goldie, SJ; Levin, AR			Genomics in medicine and public health: Role of cost-effectiveness analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review									Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Brown Univ, Providence, RI 02912 USA	Harvard University; Harvard T.H. Chan School of Public Health; Brown University	Goldie, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.			Levin, April/0000-0003-4192-4720				BROWN ML, 1995, J NATL CANCER I, V87, P1131, DOI 10.1093/jnci/87.15.1131; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; Emery J, 2001, LANCET, V358, P56, DOI 10.1016/S0140-6736(00)05257-0; Gold MR, 1996, COST EFFECTIVENESS H; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213; Motulsky AG, 1999, LANCET, V354, pSI35; Veenstra DL, 2000, AAPS PHARMSCI, V2, part. no.; Weinstein MC, 2001, ANN INTERN MED, V134, P440, DOI 10.7326/0003-4819-134-6-200103200-00008	8	4	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1637	1638		10.1001/jama.286.13.1637	http://dx.doi.org/10.1001/jama.286.13.1637			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585493	hybrid			2022-12-28	WOS:000171340600036
J	Williams, SV; Fihn, SD; Gibbons, RJ				Williams, SV; Fihn, SD; Gibbons, RJ			Guidelines for the management of patients with chronic stable angina: Diagnosis and risk stratification	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; BUNDLE-BRANCH-BLOCK; AMERICAN-HEART-ASSOCIATION; MEDICALLY TREATED PATIENTS; INCREMENTAL PROGNOSTIC VALUE; LEFT-VENTRICULAR FUNCTION; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; HIGH-DOSE DIPYRIDAMOLE	Patients with suspected chronic stable angina can be evaluated in three stages. In stage one, the clinician uses information from the history, physical examination, laboratory tests for diabetes and hyperlipidemia, and resting electrocardiography to estimate the patient's probability of coronary artery disease (CAD). In stage two, additional testing for patients with a low probability of CAD focuses on diagnosing noncoronary causes of chest pain. Patients with a high probability of CAD have stress tests to assess their risk from CAD, and patients with an intermediate probability of CAD have stress tests to estimate the probability of CAD and assess their risk from CAD. Most patients with new-onset angina can start stress testing with exercise electrocardiography. The initial stress test should be a stress imaging procedure for patients with rest ST-segment depression greater than 1 mm, complete left bundle-branch block, ventricular paced rhythm, preexcitation syndrome, or previous revascularization with percutaneous coronary angioplasty or coronary artery bypass grafting. Patients who cannot exercise can have an imaging procedure with stress induced by pharmacologic agents. In stage three, patients with a predicted average annual cardiac mortality rate between 1% and 3% should have a stress Imaging study or coronary angiography with left ventriculography. Those with a known left ventricular dysfunction should have cardiac catheterization. Patients with CAD who have an estimated annual mortality rate greater than 3% should have cardiac catheterization to determine whether their anatomy is suitable for revascularization. Patients with an estimated annual mortality rate less than 1% can begin to receive medical therapy.	VA Puget Sound Hlth Care Syst, Seattle, WA USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Washington, Seattle, WA 98195 USA; Mayo Med Ctr, Rochester, MN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Pennsylvania; University of Washington; University of Washington Seattle; Mayo Clinic	Williams, SV (corresponding author), 1220 Blockley Hall,423 Guadrian Dr, Philadelphia, PA 19104 USA.	sankey@wharton.upenn.edu	Fihn, Stephan/ABA-1040-2020					AFRIDI I, 1994, AM HEART J, V127, P1510, DOI 10.1016/0002-8703(94)90378-6; *AG HLTH CAR POL R, 1994, UNST ANG DIAGN MAN; ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; Alexander KP, 1998, J AM COLL CARDIOL, V32, P1657, DOI 10.1016/S0735-1097(98)00451-3; *AM COLL CARD AM H, 2000, ACC AHA ACP ASIM POC; BAROLSKY SM, 1979, CIRCULATION, V60, P1021, DOI 10.1161/01.CIR.60.5.1021; BELESLIN BD, 1994, CIRCULATION, V90, P1168, DOI 10.1161/01.CIR.90.3.1168; Bonow RO, 1997, J NUCL CARDIOL, V4, pS172, DOI 10.1016/S1071-3581(97)90098-2; Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; BORGESNETO S, 1988, J AM COLL CARDIOL, V11, P962, DOI 10.1016/S0735-1097(98)90052-3; Boyne TS, 1997, AM J CARDIOL, V79, P270, DOI 10.1016/S0002-9149(96)00746-1; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; BROWN KA, 1990, AM J CARDIOL, V65, P160, DOI 10.1016/0002-9149(90)90078-F; BRUNELLI C, 1989, EUR HEART J, V10, P292, DOI 10.1093/oxfordjournals.eurheartj.a059486; BUROW RD, 1979, J NUCL MED, V20, P771; Califf RM, 1996, J AM COLL CARDIOL, V27, P1007, DOI 10.1016/0735-1097(96)87733-3; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Cecil MP, 1996, J CLIN EPIDEMIOL, V49, P735, DOI 10.1016/0895-4356(96)00014-5; CHAE SC, 1993, J AM COLL CARDIOL, V21, P1305, DOI 10.1016/0735-1097(93)90301-G; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; Chatterjee K, 1998, PRIMARY CARDIOLOGY, P234; Cheitlin MD, 1997, CIRCULATION, V95, P1686; Christian TF, 1997, AM J CARDIOL, V79, P1295, DOI 10.1016/S0002-9149(97)00108-2; CHRISTIAN TF, 1994, ANN INTERN MED, V121, P825, DOI 10.7326/0003-4819-121-11-199412010-00001; COLETTA C, 1995, J AM COLL CARDIOL, V26, P887, DOI 10.1016/0735-1097(95)00272-5; CONNOLLY DC, 1984, MAYO CLIN PROC, V59, P247, DOI 10.1016/S0025-6196(12)61257-9; COYNE EP, 1991, J AM COLL CARDIOL, V17, P1289, DOI 10.1016/S0735-1097(10)80137-8; DAGIANTI A, 1995, J AM COLL CARDIOL, V26, P18, DOI 10.1016/0735-1097(95)00121-F; DelCampo J, 1996, ANN NONINVAS ELECTRO, V1, P430; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; DEVRIES S, 1995, AM J CARDIOL, V75, P973, DOI 10.1016/S0002-9149(99)80706-1; Douglas PS, 1997, CIRCULATION, V95, P299; EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645; FISCH C, 1992, HEART DIS TXB CARDIO, P145; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; Froelicher VF, 1998, ANN INTERN MED, V128, P965, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00001; Garber AM, 1999, ANN INTERN MED, V130, P719, DOI 10.7326/0003-4819-130-9-199905040-00003; GARCIA E, 1981, J NUCL MED, V22, P309; Geleijnse ML, 1996, J AM COLL CARDIOL, V28, P447, DOI 10.1016/0735-1097(96)00149-0; GERSH BJ, 1989, CIRCULATION, V79, P46; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; Gibbons RJ, 1999, CIRCULATION, V99, P2829, DOI 10.1161/01.CIR.99.21.2829; Gibbons RJ, 1997, CIRCULATION, V96, P345; Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3; GIBBONS RJ, 1990, ANN INTERN MED, V112, P743, DOI 10.7326/0003-4819-112-10-743; GIBSON RS, 1983, CONTROVERSIES CORONA, P1; Gil VM, 1998, J NUCL CARDIOL, V5, P414, DOI 10.1016/S1071-3581(98)90147-7; GOHLKE H, 1983, CIRCULATION, V68, P979, DOI 10.1161/01.CIR.68.5.979; GOLDMAN L, 1982, CIRCULATION, V66, P945, DOI 10.1161/01.CIR.66.5.945; Gomez MA, 1996, J AM COLL CARDIOL, V28, P25, DOI 10.1016/0735-1097(96)00093-9; GUPTA NC, 1992, J AM COLL CARDIOL, V19, P248, DOI 10.1016/0735-1097(92)90474-2; Hachamovitch R, 1998, CIRCULATION, V97, P535; Hachamovitch R, 1996, CIRCULATION, V93, P905, DOI 10.1161/01.CIR.93.5.905; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; Heller GV, 1997, AM HEART J, V134, P105, DOI 10.1016/S0002-8703(97)70113-3; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; HUNG J, 1984, J AM COLL CARDIOL, V4, P8, DOI 10.1016/S0735-1097(84)80312-5; ILSLEY C, 1982, BRIT HEART J, V48, P161; ISKANDRIAN AS, 1985, AM HEART J, V110, P135, DOI 10.1016/0002-8703(85)90527-7; ISKANDRIAN AS, 1988, AM J CARDIOL, V61, P269, DOI 10.1016/0002-9149(88)90929-0; JANOWITZ WR, 1991, AM J CARDIOL, V68, P1, DOI 10.1016/0002-9149(91)90700-U; JOHNSON LW, 1989, CATHETER CARDIO DIAG, V17, P5, DOI 10.1002/ccd.1810170103; KAMAI AM, 1994, J NUCL CARDIOL, V1, P254, DOI 10.1007/BF02940339; KAMARAN M, 1995, AM J CARDIOL, V76, P887, DOI 10.1016/S0002-9149(99)80255-0; KASSER IS, 1969, CIRCULATION, V39, P759, DOI 10.1161/01.CIR.39.6.759; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; KAUL S, 1988, CIRCULATION, V77, P745, DOI 10.1161/01.CIR.77.4.745; KAUL S, 1986, J AM COLL CARDIOL, V7, P527, DOI 10.1016/S0735-1097(86)80462-4; KAUL S, 1995, AM J CARDIOL, V75, pD18; KENNEDY JW, 1982, CIRCULATION, V66, P16; KETTUNEN R, 1991, AM J CARDIOL, V68, P575, DOI 10.1016/0002-9149(91)90346-M; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; KNOCHEL JP, 1961, AM J MED, V30, P299, DOI 10.1016/0002-9343(61)90101-2; KRIVOKAPICH J, 1993, AM J CARDIOL, V71, P646, DOI 10.1016/0002-9149(93)91004-2; Kuntz KM, 1999, ANN INTERN MED, V130, P709, DOI 10.7326/0003-4819-130-9-199905040-00002; KURITA A, 1991, CLIN CARDIOL, V14, P886, DOI 10.1002/clc.4960141106; LACROIX AZ, 1990, CIRCULATION, V81, P437, DOI 10.1161/01.CIR.81.2.437; LADENHEIM ML, 1986, J AM COLL CARDIOL, V7, P464, DOI 10.1016/S0735-1097(86)80454-5; LADENHEIM ML, 1987, AM J CARDIOL, V59, P270, DOI 10.1016/0002-9149(87)90798-3; LEPPO JA, 1989, J NUCL MED, V30, P281; Leppo JA, 1996, J NUCL CARDIOL, V3, pS22, DOI 10.1016/S1071-3581(96)90204-4; LEVINE HJ, 1980, AM HEART J, V100, P108, DOI 10.1016/0002-8703(80)90286-0; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; LINHART JW, 1974, CIRCULATION, V50, P1173, DOI 10.1161/01.CIR.50.6.1173; LUWAERT RJ, 1988, EUR HEART J, V9, P418, DOI 10.1093/oxfordjournals.eurheartj.a062519; MACHECOURT J, 1994, J AM COLL CARDIOL, V23, P1096, DOI 10.1016/0735-1097(94)90597-5; MAHMARIAN JJ, 1995, J AM COLL CARDIOL, V25, P1333, DOI 10.1016/0735-1097(95)00016-W; Marcovitz PA, 1996, AM J CARDIOL, V78, P404, DOI 10.1016/S0002-9149(96)00327-X; Marcovitz PA, 1997, PROG CARDIOVASC DIS, V39, P533, DOI 10.1016/S0033-0620(97)80012-6; MARIE PY, 1995, J AM COLL CARDIOL, V26, P879, DOI 10.1016/0735-1097(95)00243-9; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MARTINEZCARO D, 1984, EUR HEART J, V5, P63, DOI 10.1093/eurheartj/5.suppl_E.63; Mattera JA, 1998, J NUCL CARDIOL, V5, P498, DOI 10.1016/S1071-3581(98)90181-7; MAZEIKA PK, 1993, AM J CARDIOL, V71, P33, DOI 10.1016/0002-9149(93)90706-I; McCully RB, 1998, J AM COLL CARDIOL, V31, P144, DOI 10.1016/S0735-1097(97)00427-0; MILLIKEN JA, 1990, AM J CARDIOL, V65, P946, DOI 10.1016/0002-9149(90)91450-K; MOCK MB, 1982, CIRCULATION, V66, P562, DOI 10.1161/01.CIR.66.3.562; MORISE AP, 1995, AM HEART J, V130, P741, DOI 10.1016/0002-8703(95)90072-1; MORROW K, 1993, ANN INTERN MED, V118, P689, DOI 10.7326/0003-4819-118-9-199305010-00005; MYERS J, 1990, CIRCULATION, V82, P1839, DOI 10.1161/01.CIR.82.5.1839; NALLAMOTHU N, 1995, J AM COLL CARDIOL, V25, P830, DOI 10.1016/0735-1097(94)00471-2; Nallamothu N, 1997, J NUCL CARDIOL, V4, P487, DOI 10.1016/S1071-3581(97)90006-4; *NAT CTR HLTH STAT, 1984, VIT STAT US 1979, V2; NGUYEN T, 1990, J AM COLL CARDIOL, V16, P1375, DOI 10.1016/0735-1097(90)90379-4; Nigam A, 1998, J NUCL MED, V39, P579; NISHIMURA S, 1992, J AM COLL CARDIOL, V20, P265, DOI 10.1016/0735-1097(92)90090-A; O'Rourke RA, 2000, J AM COLL CARDIOL, V36, P326, DOI 10.1016/S0735-1097(00)00831-7; OGILBY JD, 1992, CIRCULATION, V86, P887, DOI 10.1161/01.CIR.86.3.887; OKADA RD, 1980, AM J CARDIOL, V45, P1211, DOI 10.1016/0002-9149(80)90480-4; OKEEFE JH, 1989, AM J MED, V86, P658, DOI 10.1016/0002-9343(89)90439-7; PARODI O, 1991, J AM COLL CARDIOL, V18, P1439, DOI 10.1016/0735-1097(91)90672-V; PATEL R, 1995, NUCL MED COMMUN, V16, P137, DOI 10.1097/00006231-199516030-00004; Polanczyk CA, 1998, AM J CARDIOL, V81, P288, DOI 10.1016/S0002-9149(97)00897-7; POLLOCK SG, 1992, CIRCULATION, V85, P237, DOI 10.1161/01.CIR.85.1.237; PRYOR DB, 1991, AM J MED, V90, P553; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; PRYOR DB, 1990, CIRCULATION, V82, P302, DOI 10.1161/01.CIR.82.1.302; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RIHAL CS, 1995, AM J CARDIOL, V75, P220, DOI 10.1016/0002-9149(95)80023-L; RINGQVIST I, 1983, J CLIN INVEST, V71, P1854, DOI 10.1172/JCI110941; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; Roger VL, 1997, CIRCULATION, V95, P405; ROZANSKI A, 1983, NEW ENGL J MED, V309, P518, DOI 10.1056/NEJM198309013090902; Santana-Boado C, 1998, J NUCL MED, V39, P751; SAWADA SG, 1990, AM HEART J, V120, P49, DOI 10.1016/0002-8703(90)90159-U; SCHWARTZ RS, 1993, CIRCULATION, V87, P165, DOI 10.1161/01.CIR.87.1.165; SEVERI S, 1994, CIRCULATION, V89, P1160, DOI 10.1161/01.CIR.89.3.1160; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; Shaw LJ, 1999, J GEN INTERN MED, V14, P1, DOI 10.1046/j.1525-1497.1999.00273.x; SIMARI RD, 1991, AM J CARDIOL, V67, P573, DOI 10.1016/0002-9149(91)90894-Q; SKETCH MH, 1981, AM J CARDIOL, V48, P655, DOI 10.1016/0002-9149(81)90143-0; SKETCH MH, 1975, AM J CARDIOL, V36, P169, DOI 10.1016/0002-9149(75)90521-4; SOX HC, 1990, AM J MED, V89, P7, DOI 10.1016/0002-9343(90)90090-Z; SRIDHARA BS, 1993, AM J CARDIOL, V72, P1015, DOI 10.1016/0002-9149(93)90855-7; STRATMANN HG, 1994, CIRCULATION, V89, P615, DOI 10.1161/01.CIR.89.2.615; STRATMANN HG, 1994, AM J CARDIOL, V73, P647, DOI 10.1016/0002-9149(94)90927-X; STUART RJ, 1980, CHEST, V77, P94, DOI 10.1378/chest.77.1.94; VASILOMANOLAKIS EC, 1985, GERIATRICS, V40, P47; VERANI MS, 1993, CURR PROB CARDIOLOGY, V18, P483; VERANI MS, 1978, J NUCL MED, V19, P773; VERANI MS, 1993, NUCLEAR CARDIOLOGY S, P216; WACKERS FJT, 1985, SEMIN NUCL MED, V15, P46, DOI 10.1016/S0001-2998(85)80043-X; Wagdy HM, 1998, CIRCULATION, V97, P1563, DOI 10.1161/01.CIR.97.16.1563; WATSON DD, 1981, J NUCL MED, V22, P577; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; Wenger NK, 1993, CARDIOVASCULAR HLTH, P67; WHINNERY JE, 1977, AM HEART J, V94, P316, DOI 10.1016/S0002-8703(77)80474-2; WHINNERY JE, 1977, CHEST, V71, P335, DOI 10.1378/chest.71.3.335; Williams MJ, 1996, J AM COLL CARDIOL, V27, P132, DOI 10.1016/0735-1097(95)00393-2; WONG ND, 1995, CIRCULATION, V92, P632, DOI 10.1161/01.CIR.92.3.632; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; ZARET BL, 1995, CIRCULATION, V91, P313, DOI 10.1161/01.CIR.91.2.313; ZARET BL, 1992, HEART DISEASE TXB CA, P276	159	39	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					530	547		10.7326/0003-4819-135-7-200110020-00014	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00014			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	477EF	11578158				2022-12-28	WOS:000171269600009
J	Blue, L; Lang, E; McMurray, JJV; Davie, AP; McDonagh, TA; Murdoch, DR; Petrie, MC; Connolly, E; Norrie, J; Round, CE; Ford, I; Morrison, CE				Blue, L; Lang, E; McMurray, JJV; Davie, AP; McDonagh, TA; Murdoch, DR; Petrie, MC; Connolly, E; Norrie, J; Round, CE; Ford, I; Morrison, CE			Randomised controlled trial of specialist nurse intervention in heart failure	BRITISH MEDICAL JOURNAL			English	Article							MULTIDISCIPLINARY INTERVENTION; HOSPITALIZATION	Objectives To determine whether specialist nurse intervention improves outcome in patients with chronic heart failure. Design Randomised controlled trial. Setting Acute medical admissions unit in a teaching hospital. Participants 165 patients admitted with heart failure due to left ventricular systolic dysfunction. The intervention started before discharge and continued thereafter with home visits for up to 1 year. Main outcome measures Time to first event analysis of death from all causes or readmission to hospital with worsening heart failure. Results 31 patients (37%) in the intervention group died or were readmitted with heart failure compared with 45 (53%) in the usual care group (hazard ratio= 0.61, 95% confidence interval 0.33 to 0.96). Compared with usual care, patients in the intervention group had fewer readmissions for any reason (86 v 114, P=0.018), fewer admissions for heart failure (19 v 45, P<0.001) and spent fewer days in hospital for heart failure (mean 3.43 v 7.46 days, P=0.0051). Conclusions Specially trained nurses can improve the outcome of patients admitted to hospital with heart failure.	Western Infirm & Associated Hosp, Dept Cardiol, Glasgow G12 6NT, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland; Greater Glasgow Hlth Board, Glasgow G3 8YT, Lanark, Scotland	University of Glasgow	McMurray, JJV (corresponding author), Western Infirm & Associated Hosp, Dept Cardiol, Dumbarton Rd, Glasgow G12 6NT, Lanark, Scotland.		mcmurray, John/B-2467-2013; Lang, Eddy/AAS-2080-2020; Ford, Ian/ABE-6145-2020	mcmurray, John/0000-0002-6317-3975; 				Ashton CM, 1999, J GEN INTERN MED, V14, P138, DOI 10.1046/j.1525-1497.1999.00300.x; Chin MH, 1997, AM J PUBLIC HEALTH, V87, P643, DOI 10.2105/AJPH.87.4.643; Cline CMJ, 1998, HEART, V80, P442, DOI 10.1136/hrt.80.5.442; McMurray JJ, 2000, HEART, V83, P596, DOI 10.1136/heart.83.5.596; McMurray JJV, 1998, HEART, V80, P430, DOI 10.1136/hrt.80.5.430; Packer M, 1999, CIRCULATION, V100, P2312, DOI 10.1161/01.CIR.100.23.2312; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Stewart S, 1999, LANCET, V354, P1077, DOI 10.1016/S0140-6736(99)03428-5; Stewart S, 2001, EUR J HEART FAIL, V3, P315, DOI 10.1016/S1388-9842(00)00141-0; Stewart S, 2001, IMPROVING OUTCOMES C	10	327	336	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					715	718		10.1136/bmj.323.7315.715	http://dx.doi.org/10.1136/bmj.323.7315.715			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HJ	11576977	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000171340700016
J	Griekspoor, A; Collins, S				Griekspoor, A; Collins, S			Raising standards in emergency relief: how useful are Sphere minimum standards for humanitarian assistance?	BRITISH MEDICAL JOURNAL			English	Article									Med Sans Frontieres, Amsterdam, Netherlands; Valid Int Oleuffynon, Llanidloes SY18 6PJ, Powys, Wales	Doctors Without Borders	Griekspoor, A (corresponding author), 148 Impasse Saugy, F-01210 Ornex, France.							BRIGGS SM, 1999, HUMANITARIAN CRISES, P69; BUZARD N, 1998, RELIEF REHABILITATIO, V12, P13; COLLINS S, 1999, EVALUATION SERIES MS, V9; *DAN MIN FOR AFF, 1999, REP EV DAN HUM ASS S, V7, P42; Gostelow L, 1999, DISASTERS, V23, P316, DOI 10.1111/1467-7717.00121; Harrel-Bond B., 1986, IMPOSING AID EMERGEN; KEEN D, 1999, FIELD EXCHANGE, V6, P6; *MED FRONT, 1995, NUTR GUID; *REL REH NETW, 1996, 16 RRN OV DEV I; 1998, SPHER PROJ C REP LON; 2000, SPHERE PROJECT HUMAN	11	36	36	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					740	742		10.1136/bmj.323.7315.740	http://dx.doi.org/10.1136/bmj.323.7315.740			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HJ	11576984	Green Published			2022-12-28	WOS:000171340700024
J	Clutton-Brock, TH; Russell, AF; Sharpe, LL; Brotherton, PNM; McIlrath, GM; White, S; Cameron, EZ				Clutton-Brock, TH; Russell, AF; Sharpe, LL; Brotherton, PNM; McIlrath, GM; White, S; Cameron, EZ			Effects of helpers on juvenile development and survival in meerkats	SCIENCE			English	Article							COOPERATIVE MONGOOSE; FOOD ALLOCATION; GROUP-SIZE; BEHAVIOR; DYNAMICS	Although breeding success is known to increase with group size in several cooperative mammals, the mechanisms underlying these relationships are uncertain. We show that in wild groups of cooperative meerkats, Suricata suricatta, reductions in the ratio of helpers to pups depress the daily weight gain and growth of pups and the daily weight gain of helpers. Increases in the daily weight gain of pups are associated with heavier weights at independence and at 1 year of age, as well as with improved foraging success as juveniles and higher survival rates through the first year of life. These results suggest that the effects of helpers on the fitness of pups extend beyond weaning and that helpers may gain direct as well as indirect benefits by feeding pups.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Stellenbosch, Dept Zool, ZA-7602 Matieland, South Africa; Univ Pretoria, Mammal Res Inst, ZA-0002 Pretoria, South Africa	University of Cambridge; Stellenbosch University; University of Pretoria	Clutton-Brock, TH (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	thcb@hermes.cam.ac.uk	Cameron, Elissa/B-8053-2014; Cameron, Elissa Z/E-4280-2010	Cameron, Elissa/0000-0002-9243-0547; 				Brotherton PNM, 2001, BEHAV ECOL, V12, P590, DOI 10.1093/beheco/12.5.590; Brown J.L., 1987, HELPING COMMUNAL BRE; Clutton-Brock TH, 1998, P ROY SOC B-BIOL SCI, V265, P185, DOI 10.1098/rspb.1998.0281; Clutton-Brock TH, 2000, P ROY SOC B-BIOL SCI, V267, P301, DOI 10.1098/rspb.2000.1000; Clutton-Brock TH, 2001, SCIENCE, V291, P478, DOI 10.1126/science.291.5503.478; Clutton-Brock TH, 2001, ANIM BEHAV, V61, P705, DOI 10.1006/anbe.2000.1631; Clutton-Brock TH, 1999, J ANIM ECOL, V68, P672, DOI 10.1046/j.1365-2656.1999.00317.x; Clutton-Brock TH, 1999, SCIENCE, V284, P1640, DOI 10.1126/science.284.5420.1640; CLUTTONBROCK TH, 1982, NATURE, V300, P178, DOI 10.1038/300178a0; Cockburn A, 1998, ANNU REV ECOL SYST, V29, P141, DOI 10.1146/annurev.ecolsys.29.1.141; Courchamp F, 1999, P ROY SOC B-BIOL SCI, V266, P557, DOI 10.1098/rspb.1999.0672; Courchamp F, 2000, ANIM CONSERV, V3, P277, DOI 10.1017/S1367943000001001; CREEL S, IN PRESS AFRICAN WIL; GRIFFIN AS, 1999, THESIS U EDINBURGH; JENNIONS MD, 1994, TRENDS ECOL EVOL, V9, P89, DOI 10.1016/0169-5347(94)90202-X; *LAW AGR TRUST ROT, 1998, GENSTAT 5 4 1; Lindstrom J, 1999, TRENDS ECOL EVOL, V14, P343, DOI 10.1016/S0169-5347(99)01639-0; MALCOLM JR, 1982, BEHAV ECOL SOCIOBIOL, V10, P1, DOI 10.1007/BF00296390; Manser MB, 2000, BEHAV ECOL SOCIOBIOL, V48, P429, DOI 10.1007/s002650000248; Moehlman P.D., 1989, P143; ROOD JP, 1990, ANIM BEHAV, V39, P566, DOI 10.1016/S0003-3472(05)80423-3; Solomon N. G., 1997, COOPERATIVE BREEDING; VANSCHAIK CP, 1983, BEHAVIOUR, V87, P120, DOI 10.1163/156853983X00147; Woodroffe R, 2000, J ZOOL, V250, P113, DOI 10.1017/S0952836900001102	24	168	169	1	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2446	2449		10.1126/science.1061274	http://dx.doi.org/10.1126/science.1061274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577235				2022-12-28	WOS:000171237200045
J	Sanvitto, D; Pulizzi, F; Shields, AJ; Christianen, PCM; Holmes, SN; Simmons, MY; Ritchie, DA; Maan, JC; Pepper, M				Sanvitto, D; Pulizzi, F; Shields, AJ; Christianen, PCM; Holmes, SN; Simmons, MY; Ritchie, DA; Maan, JC; Pepper, M			Observation of charge transport by negatively charged excitons	SCIENCE			English	Article							EXCESS ELECTRONS; TRIONS; SPECTROSCOPY; GAS	We report transport of electron-hole complexes in semiconductor quantum wells under applied electric fields. Negatively charged excitons (X-), created by laser excitation of a high electron mobility transistor, are observed to drift upon applying a voltage between the source and drain. In contrast, neutral excitons do not drift under similar conditions. The X- mobility is found to be as high as 6.5 x 10(4) cm(2) V-1 s(-1). The results demonstrate that X- exists as a free particle in the best-quality samples and suggest that light emission from opto-electronic devices can be manipulated through exciton drift under applied electric fields.	Toshiba Res Europe Ltd, Cambridge Res Lab, Cambridge CB4 0WE, England; Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; Catholic Univ Nijmegen, High Field Magnet Lab, NL-6525 ED Nijmegen, Netherlands	Toshiba Corporation; University of Cambridge; University of Cambridge; Radboud University Nijmegen	Shields, AJ (corresponding author), Toshiba Res Europe Ltd, Cambridge Res Lab, 260 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0WE, England.	andrew.shields@crl.toshiba.co.uk	Maan, Jan Cornelis/D-4952-2012; Christianen, Peter CM/E-1627-2012; Ritchie, David/K-2206-2014; Simmons, Michelle Yvonne/B-2755-2010; Sanvitto, Daniele/B-5785-2013	Ritchie, David/0000-0002-9844-8350; Simmons, Michelle Yvonne/0000-0002-6422-5888; Holmes, Stuart/0000-0002-3221-5124; Sanvitto, Daniele/0000-0002-3831-8829				BETHE HA, 1957, QUANTUM MECH ONE 2 E, P154; Ciulin V, 2000, PHYS REV B, V62, P16310, DOI 10.1103/PhysRevB.62.R16310; Esser A, 2000, PHYS REV B, V62, P8232, DOI 10.1103/PhysRevB.62.8232; Eytan G, 1998, PHYS REV LETT, V81, P1666, DOI 10.1103/PhysRevLett.81.1666; Finkelstein G, 1996, PHYS REV B, V53, P12593, DOI 10.1103/PhysRevB.53.12593; FINKELSTEIN G, 1995, PHYS REV LETT, V74, P976, DOI 10.1103/PhysRevLett.74.976; KHENG K, 1993, PHYS REV LETT, V71, P1752, DOI 10.1103/PhysRevLett.71.1752; LAMPERT MA, 1958, PHYS REV LETT, V1, P450, DOI 10.1103/PhysRevLett.1.450; Pulizzi F, 2001, PHYSICA B, V298, P397, DOI 10.1016/S0921-4526(01)00349-0; Ron A, 1996, SOLID STATE COMMUN, V97, P741, DOI 10.1016/0038-1098(95)00758-X; Sanvitto D, 2000, PHYS REV B, V62, pR13294, DOI 10.1103/PhysRevB.62.R13294; Shields AJ, 1995, ADV PHYS, V44, P47, DOI 10.1080/00018739500101496; SHIELDS AJ, 1995, PHYS REV B, V51, P18049, DOI 10.1103/PhysRevB.51.18049; Stebe B, 1997, PHYS REV B, V56, P12454, DOI 10.1103/PhysRevB.56.12454; STEBE B, 1989, SUPERLATTICE MICROST, V5, P545, DOI 10.1016/0749-6036(89)90382-0	15	75	75	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 26	2001	294	5543					837	839		10.1126/science.1064847	http://dx.doi.org/10.1126/science.1064847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	487AP	11577201				2022-12-28	WOS:000171851800042
J	FitzGerald, M				FitzGerald, M			Extracts from "Clinical Evidence" - Acute asthma	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NEAR-FATAL ASTHMA; NEBULIZED SALBUTAMOL; MECHANICAL VENTILATION; INTERMITTENT ALBUTEROL; IPRATROPIUM BROMIDE; ACUTE EXACERBATIONS; DOUBLE-BLIND; RISK-FACTORS; EMERGENCY; THERAPY		Vancouver Gen Hosp, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1L8, Canada	University of British Columbia	FitzGerald, M (corresponding author), Vancouver Gen Hosp, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1L8, Canada.	markf@interchange.ubc.ca						Bartter T, 1996, CHEST, V110, P1589, DOI 10.1378/chest.110.6.1589; Behbehani NA, 1999, CHEST, V115, P1627; Bradding P, 1999, EUR RESPIR J, V13, P290, DOI 10.1034/j.1399-3003.1999.13b12.x; CATES C, IN PRESS BMJ; CATES C, 2001, CLIN EVIDENCE, P1011; CATES CJ, 2000, COCHRANE DATABASE SY; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHEONG B, 1988, BRIT MED J, V297, P448, DOI 10.1136/bmj.297.6646.448; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; DUFF AL, 1992, PEDIATR CLIN N AM, V39, P1277; EDMONDS ML, 2000, COCHRANE DATABASE SY; Emerman CL, 1999, CHEST, V115, P919, DOI 10.1378/chest.115.4.919; FITZGERALD JM, 1999, EVID BASED MED, V4, P138; FITZGERALD JM, 2000, EVIDENCE BASED ASTHM, P233; GIBSON PG, 2000, COCHRANE DATABASE SY; Henderson SO, 1999, ANN EMERG MED, V33, P141, DOI 10.1016/S0196-0644(99)70386-0; HIGGINS B, 1986, THORAX, V41, P464, DOI 10.1136/thx.41.6.464; Kass JE, 1999, CHEST, V116, P296, DOI 10.1378/chest.116.2.296; Kaur B, 1998, BRIT MED J, V316, P118; Keenan SP, 1998, CRIT CARE CLIN, V14, P359, DOI 10.1016/S0749-0704(05)70005-1; Khine H, 1996, ACAD EMERG MED, V3, P1019, DOI 10.1111/j.1553-2712.1996.tb03346.x; Lam K N, 1992, Singapore Med J, V33, P460; LAWFORD P, 1978, BRIT MED J, V1, P84, DOI 10.1136/bmj.1.6105.84; Levy ML, 1996, THORAX, V51, P1087, DOI 10.1136/thx.51.11.1087; LIM T K, 1989, SMJ Singapore Medical Journal, V30, P334; LIN RY, 1993, ANN EMERG MED, V22, P1847, DOI 10.1016/S0196-0644(05)80412-3; MANSEL JK, 1990, AM J MED, V89, P42, DOI 10.1016/0002-9343(90)90096-V; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P310, DOI 10.1164/ajrccm.151.2.7842183; MENITOVE SM, 1983, AM J MED, V74, P898, DOI 10.1016/0002-9343(83)91082-3; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; NAHUM A, 2000, EVIDENCE BASED ASTHM, P245; Nannini LJ, 2000, AM J MED, V108, P193, DOI 10.1016/S0002-9343(99)00463-5; NOUIRA S, 1999, CLIN INTENSIVE CARE, V10, P227; ODRISCOLL BR, 1993, LANCET, V341, P324, DOI 10.1016/0140-6736(93)90134-3; REISNER C, 1995, ANN ALLERG ASTHMA IM, V75, P41; Rodrigo CJ, 2000, AM J RESP CRIT CARE, V161, P1862; Rodrigo G, 1999, AM J MED, V107, P363, DOI 10.1016/S0002-9343(99)00243-0; ROWE BH, 1992, AM J EMERG MED, V10, P301, DOI 10.1016/0735-6757(92)90007-K; Rowe BH, 2000, COCHRANE DATABASE SY; RUDNITSKY GS, 1993, ANN EMERG MED, V22, P1842, DOI 10.1016/S0196-0644(05)80411-1; SALMERON S, 1994, AM J RESP CRIT CARE, V149, P1466, DOI 10.1164/ajrccm.149.6.8004299; Shrestha M, 1996, CHEST, V110, P42, DOI 10.1378/chest.110.1.42; Turner MO, 1998, AM J RESP CRIT CARE, V157, P1804, DOI 10.1164/ajrccm.157.6.9708092; WILLIAMS TJ, 1992, AM REV RESPIR DIS, V146, P607, DOI 10.1164/ajrccm/146.3.607; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T	46	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 13	2001	323	7317					841	845		10.1136/bmj.323.7317.841	http://dx.doi.org/10.1136/bmj.323.7317.841			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597969	Green Published			2022-12-28	WOS:000171650500030
J	Heine, A; DeSantis, G; Luz, JG; Mitchell, M; Wong, CH; Wilson, IA				Heine, A; DeSantis, G; Luz, JG; Mitchell, M; Wong, CH; Wilson, IA			Observation of covalent intermediates in an enzyme mechanism at atomic resolution	SCIENCE			English	Article							FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; CRYSTAL-STRUCTURE; MUSCLE ALDOLASE; DEOXYRIBOSE-5-PHOSPHATE ALDOLASE; BINDING; CONDENSATION; ANTIBODIES; CATALYST; CLEAVAGE; ANGSTROM	In classical enzymology, intermediates and transition states in a catalytic mechanism are usually inferred from a series of biochemical experiments. Here, we derive an enzyme mechanism from true atomic-resolution x-ray structures of reaction intermediates. Two ultra-high resolution structures of wild-type and mutant D-2-deoxyribose-5-phosphate (DRP) aldolase complexes with DRP at 1.05 and 1.10 angstroms unambiguously identify the postulated covalent carbinolamine and Schiff base intermediates in the aldolase mechanism. In combination with site-directed mutagenesis and H-1 nuclear magnetic resonance, we can now propose how the heretofore elusive C-2 proton abstraction step and the overall stereochemical course are accomplished. A proton relay system appears to activate a conserved active-site water that functions as the critical mediator for proton transfer.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Wong, CH (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044154, R01GM044154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard J, 2001, P NATL ACAD SCI USA, V98, P3679, DOI 10.1073/pnas.071380898; Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; BARBAS CF, 1990, J AM CHEM SOC, V112, P2013, DOI 10.1021/ja00161a064; BARBAS CF, 1989, THESIS TEXAS A M U C; Blom N, 1997, NAT STRUCT BIOL, V4, P36, DOI 10.1038/nsb0197-36; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN LR, 1992, J AM CHEM SOC, V114, P741, DOI 10.1021/ja00028a050; Choi KH, 1999, BIOCHEMISTRY-US, V38, P12655, DOI 10.1021/bi9828371; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; COPLEY RR, 1994, J MOL BIOL, V242, P321; Dalby A, 1999, PROTEIN SCI, V8, P291; DeSantis G, 1998, J AM CHEM SOC, V120, P8582, DOI 10.1021/ja980072e; Fong S, 2000, CHEM BIOL, V7, P873, DOI 10.1016/S1074-5521(00)00035-1; GREEN MM, 1974, J ORG CHEM, V39, P2166, DOI 10.1021/jo00929a006; HEINE A, UNPUB; HOFFEE P, 1974, ARCH BIOCHEM BIOPHYS, V164, P736, DOI 10.1016/0003-9861(74)90087-3; Jia J, 1997, PROTEIN SCI, V6, P119; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karlstrom A, 2000, P NATL ACAD SCI USA, V97, P3878, DOI 10.1073/pnas.97.8.3878; Kim H, 1998, BIOCHEMISTRY-US, V37, P4388, DOI 10.1021/bi972233h; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNAN G, 1991, EUR J BIOCHEM, V195, P343, DOI 10.1111/j.1432-1033.1991.tb15712.x; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LITTLECHILD JA, 1993, TRENDS BIOCHEM SCI, V18, P36, DOI 10.1016/0968-0004(93)90048-R; Machajewski TD, 2000, ANGEW CHEM INT EDIT, V39, P1352, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1352::AID-ANIE1352>3.0.CO;2-J; MELOCHE HP, 1973, SCIENCE, V181, P350, DOI 10.1126/science.181.4097.350; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; Morris AJ, 1996, PROTEIN ENG, V9, P61, DOI 10.1093/protein/9.1.61; NICHOLAS PC, 1988, BIOCHEM SOC T, V16, P752, DOI 10.1042/bst0160752; NICHOLAS PC, 1988, BIOCHEM SOC T, V76, P752; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRICER WE, 1960, J BIOL CHEM, V5, P1292; ROSE IA, 1967, ARCH BIOCHEM BIOPHYS, V118, P758, DOI 10.1016/0003-9861(67)90414-6; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SHERIFF S, 1993, IMMUNOMETHODS, V3, P191; SILVESTRI M, IN PRESS TOPICS STER; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; VALENTINHANSEN P, 1982, EUR J BIOCHEM, V125, P561, DOI 10.1111/j.1432-1033.1982.tb06719.x; Verlinde CLMJ, 1999, J MOL MODEL, V5, P37, DOI 10.1007/s008940050103; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; WESTHEIMER FH, 1995, TETRAHEDRON, V51, P3, DOI 10.1016/0040-4020(94)00865-R; Wymer N, 2001, STRUCTURE, V9, P1, DOI 10.1016/S0969-2126(00)00555-4; Zhong GF, 1999, ANGEW CHEM INT EDIT, V38, P3738, DOI 10.1002/(SICI)1521-3773(19991216)38:24<3738::AID-ANIE3738>3.0.CO;2-2; Zhong GF, 1998, ANGEW CHEM INT EDIT, V37, P2481, DOI 10.1002/(SICI)1521-3773(19981002)37:18<2481::AID-ANIE2481>3.0.CO;2-T	47	252	258	4	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					369	374		10.1126/science.1063601	http://dx.doi.org/10.1126/science.1063601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598300				2022-12-28	WOS:000171601400043
J	Seibel, BA; Walsh, PJ				Seibel, BA; Walsh, PJ			Carbon cycle - Potential, impacts of CO2 injection on deep-sea biota	SCIENCE			English	Editorial Material							ANIMALS; METABOLISM; DEPTH; ADAPTATIONS; HABITAT; FISHES; LIFE		Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Div Marine Biol & Fisheries, NIEHS,Marine & Freshwater Biomed Sci Ctr, Miami, FL 33149 USA	Monterey Bay Aquarium Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Miami	Seibel, BA (corresponding author), Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA.							ARP AJ, 1985, PHYSIOL ZOOL, V58, P38, DOI 10.1086/physzool.58.1.30161218; AUERBACH D, 1996, OCEAN STORAGE CARBON, P41; BARRY JJA, UNPUB; Brewer P. G., 2000, OCEANOGRAPHY, V13, P84, DOI [DOI 10.5670/OCEANOG.2000.38, 10.5670/oceanog.2000.38]; CHILDRESS JJ, 1995, TRENDS ECOL EVOL, V10, P30, DOI 10.1016/S0169-5347(00)88957-0; Childress JJ, 1998, J EXP BIOL, V201, P1223; Drange H, 2001, GEOPHYS RES LETT, V28, P2637, DOI 10.1029/2000GL012609; Gage J. D., 1991, DEEP SEA BIOL NATURA; GIBBS A, 1990, MAR BIOL, V106, P315, DOI 10.1007/BF01344307; Goffredi SK, 2001, MAR BIOL, V138, P259, DOI 10.1007/s002270000462; Guppy M, 1999, BIOL REV, V74, P1, DOI 10.1017/S0006323198005258; Haedrich RL, 1996, J FISH BIOL, V49, P40, DOI 10.1111/j.1095-8649.1996.tb06066.x; HEISLER N, 1989, CAN J ZOOL, V67, P2923, DOI 10.1139/z89-415; HENRY RP, 1990, J CRUSTACEAN BIOL, V10, P413, DOI 10.2307/1548331; Hunt JC, 2000, MAR BIOL, V136, P543, DOI 10.1007/s002270050714; Kerr RA, 2001, SCIENCE, V292, P1978, DOI 10.1126/science.292.5524.1978; Kochevar RE, 1996, MAR BIOL, V125, P375, DOI 10.1007/BF00346318; MARCHETTI C, 1977, CLIMATIC CHANGE, V1, P59, DOI 10.1007/BF00162777; MICKEL TJ, 1978, BIOL BULL, V154, P138, DOI 10.2307/1540779; Morgan IJ, 2001, GLOBAL CHANGE BIOL, V7, P345, DOI 10.1046/j.1365-2486.2001.00424.x; NOBLE RW, 1986, BIOCHIM BIOPHYS ACTA, V870, P552, DOI 10.1016/0167-4838(86)90265-7; Reipschloger A., 1996, OCEAN STORAGE CARBON, P57; Seibel BA, 1997, BIOL BULL, V192, P262, DOI 10.2307/1542720; SMITH KL, 1982, MAR BIOL, V68, P287, DOI 10.1007/BF00409595; Somero G.N., 1985, P454; Tamburri MN, 2000, MAR CHEM, V72, P95, DOI 10.1016/S0304-4203(00)00075-X; WALSH PJ, 1989, CAN J ZOOL, V67, P2994, DOI 10.1139/z89-422; White D., 2012, PHYSL BIOCH PROKARYO	28	154	163	6	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					319	320		10.1126/science.1065301	http://dx.doi.org/10.1126/science.1065301			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598290				2022-12-28	WOS:000171601400030
J	Mazurek, GH; LoBue, PA; Daley, CL; Bernardo, J; Lardizabal, AA; Bishai, WR; Iademarco, MF; Rothel, JS				Mazurek, GH; LoBue, PA; Daley, CL; Bernardo, J; Lardizabal, AA; Bishai, WR; Iademarco, MF; Rothel, JS			Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BOVINE TUBERCULOSIS; ACTIVE TUBERCULOSIS; ENZYME-IMMUNOASSAY; HIGH-RISK; CATTLE; RESPONSES; VACCINATION; BCG; SPECIFICITY; PROTECTION	Context Identifying persons with. latent tuberculosis infection (LTBI) is crucial to the goal of TB elimination. A whole-blood interferon gamma (IFN-gamma) assay, the Quanti-FERON-TB test, is a promising in vitro diagnostic test for LTBI that has potential advantages over the tuberculin skin test (TST). Objectives To compare the IFN-gamma assay with the TST and to identify factors associated with discordance between the tests. Design and Setting. Prospective comparison study conducted at 5 university-affiliated sites in the United States between March 1, 1998 and June 30, 1999. Participants A total of 1226 adults (mean age, 39 years) with varying risks of Mycobacterium tuberculosis infection or documented or suspected active TB, all of whom underwent both the IFN-gamma assay and the TST. Main Outcome Measure Level of agreement between the IFN-gamma assay and the TST. Results Three hundred ninety participants (31.8%) had a positive TST result and 349 (28.5%) had a positive IFN-gamma assay result. Overall agreement between the IFN-gamma assay and the TST was 83.1% (kappa =0.60). Multivariate analysis revealed that the odds of having a positive TST result but negative IFN-gamma assay result were 7 times higher for BCG-vaccinated persons compared with unvaccinated persons. The IFN-gamma assay provided evidence that among unvaccinated persons with a positive TST result but negative IFN-gamma assay result, 21.2% were responding to mycobacteria other than M tuberculosis. Conclusions For all study participants, as well as for those being screened for LTBI, the IFN-gamma assay was comparable with the TST in its ability to detect LTBI, was less affected by BCG vaccination, discriminated responses due to nontuberculous mycobacteria, and avoided variability and subjectivity associated with placing and reading the TST.	Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Dept Med, Div Pulm & Crit Care, Atlanta, GA USA; Univ Calif San Diego, Div Pulm & Crit Care, La Jolla, CA 92093 USA; Univ Calif San Francisco, Div Pulm & Crit Care, San Francisco, CA 94143 USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02215 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Natl TB Ctr, Newark, NJ 07103 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; CSL Ltd, Biosci Div, Parkville, Vic, Australia	Centers for Disease Control & Prevention - USA; Emory University; University of California System; University of California San Diego; University of California System; University of California San Francisco; Boston University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Johns Hopkins University; CSL	Mazurek, GH (corresponding author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd,Mailstop E10, Atlanta, GA 30333 USA.		Daley, Charles L./AAC-3231-2021	Bernardo, John/0000-0002-3922-0559				*ADV COUNC EL TUB, 1995, MMWR-MORBID MORTAL W, V44, P19; ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BEARMAN JE, 1964, AM REV RESPIR DIS, V90, P913; BUDDLE BM, 1995, RES VET SCI, V59, P10, DOI 10.1016/0034-5288(95)90023-3; BUDDLE BM, 1995, VACCINE, V13, P1123, DOI 10.1016/0264-410X(94)00055-R; Chaisson RE, 1996, J ACQ IMMUN DEF SYND, V11, P455, DOI 10.1097/00042560-199604150-00005; CHAPARAS SD, 1984, MYCOBACTERIA SOURCE, P195; Converse PJ, 1997, J INFECT DIS, V176, P144, DOI 10.1086/514016; Desem N, 1998, CLIN DIAGN LAB IMMUN, V5, P531, DOI 10.1128/CDLI.5.4.531-536.1998; Dlugovitzky D, 1999, SCAND J IMMUNOL, V49, P210, DOI 10.1046/j.1365-3083.1999.00492.x; DOMINGO M, 1995, TUBERCULOSIS WILDLIF, P304; DONDO A, 1996, MED VET PREVENTIVA, V13, P14; EDWARDS PHYLLIS, 1960, AMER REV RESPIRATORY DIS, V81, P1; Ellner JJ, 1997, J INFECT DIS, V176, P1351, DOI 10.1086/514132; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; *I MED, 2000, END NEGL EL TUB US; Johnson PDR, 1999, CLIN DIAGN LAB IMMUN, V6, P934, DOI 10.1128/CDLI.6.6.934-937.1999; JUDSON FN, 1974, AM REV RESPIR DIS, V109, P544; Kimura M, 1999, J INFECT DIS, V179, P1297, DOI 10.1086/314707; MENZIES R, 1992, AM REV RESPIR DIS, V145, P621, DOI 10.1164/ajrccm/145.3.621; Monaghan M, 1997, IRISH VET J, V50, P229; MONAGHAN M, 1995, TUBERCULOSIS WILDLIF, P319; NARDELL EA, 1993, TUBERCULOSIS COMPREH, P103; NEILL SD, 1994, VET REC, V135, P134, DOI 10.1136/vr.135.6.134; Pottumarthy S, 1999, J CLIN MICROBIOL, V37, P3229, DOI 10.1128/JCM.37.10.3229-3232.1999; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; ROONEY JJ, 1976, AM J MED, V60, P517, DOI 10.1016/0002-9343(76)90718-X; ROTHEL JS, 1990, AUST VET J, V67, P134, DOI 10.1111/j.1751-0813.1990.tb07730.x; Ryan T., 2000, Surveillance (Wellington), V27, P8; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SNIDER DE, 1985, JAMA-J AM MED ASSOC, V253, P3438, DOI 10.1001/jama.253.23.3438; Sodhi A, 1997, CLIN INFECT DIS, V25, P617, DOI 10.1086/513769; Streeton JA, 1998, INT J TUBERC LUNG D, V2, P443; Swaminathan S, 1999, CLIN INFECT DIS, V28, P1290, DOI 10.1086/514794; Villarino ME, 1999, JAMA-J AM MED ASSOC, V281, P169, DOI 10.1001/jama.281.2.169; von Reyn CF, 1998, J INFECT DIS, V177, P730, DOI 10.1086/514225; Wedlock DN, 1999, INFECT IMMUN, V67, P2172, DOI 10.1128/IAI.67.5.2172-2177.1999; *WHO, 1999, WHOCDSCPCTB99259; Wood PR, 2001, TUBERCULOSIS, V81, P147, DOI 10.1054/tube.2000.0272; WOOD PR, 1991, AUST VET J, V68, P286, DOI 10.1111/j.1751-0813.1991.tb03254.x; WOOD PR, 1992, VET MICROBIOL, V31, P71, DOI 10.1016/0378-1135(92)90142-G; 2000, AMJ RESP CRIT CARE M, V161, P1376	46	261	273	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1740	1747		10.1001/jama.286.14.1740	http://dx.doi.org/10.1001/jama.286.14.1740			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480NC	11594899	Bronze			2022-12-28	WOS:000171466800024
J	Hamilton, BA; Frankel, WN				Hamilton, BA; Frankel, WN			Of mice and genome sequence	CELL			English	Review							ESCHERICHIA-COLI; MODEL	Availability of the mouse genome sequence will have a major impact on the study of vertebrate evolution, mammalian biology, and animal models of human disease. Resources to explore genome biology in mice will maximize the effect of this watershed event.	Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University of California System; University of California San Diego; Jackson Laboratory	Hamilton, BA (corresponding author), Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.	bah@ucsd.edu; wnf@jax.org		Hamilton, Bruce/0000-0001-5599-9139	NIMH NIH HHS [R01 MH059207] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059207] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Boeke JD, 1997, RETROVIRUSES; Engle SJ, 1996, HUM MOL GENET, V5, P1607, DOI 10.1093/hmg/5.10.1607; Festing M. F. W., 1996, GENETIC VARIANTS STR; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; Hirschhorn JN, 2000, P NATL ACAD SCI USA, V97, P12164, DOI 10.1073/pnas.210394597; Janne PA, 1998, J CLIN INVEST, V101, P2042, DOI 10.1172/JCI2414; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; Mills AA, 2001, TRENDS GENET, V17, P331, DOI 10.1016/S0168-9525(01)02321-6; RUSSELL LB, 1992, MUTAT RES, V296, P107, DOI 10.1016/0165-1110(92)90035-8; Sherr CJ, 2001, CELL, V106, P531, DOI 10.1016/S0092-8674(01)00486-X; STOYE J, 2001, IN PRESS CURR BIOL; TURNER G, 2001, CURR BIOL, V123, P123; WU CL, 1993, NAT GENET, V3, P235, DOI 10.1038/ng0393-235; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859	19	26	26	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 5	2001	107	1					13	16		10.1016/S0092-8674(01)00514-1	http://dx.doi.org/10.1016/S0092-8674(01)00514-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595181	Bronze			2022-12-28	WOS:000171453100005
J	Lai, CSL; Fisher, SE; Hurst, JA; Vargha-Khadem, F; Monaco, AP				Lai, CSL; Fisher, SE; Hurst, JA; Vargha-Khadem, F; Monaco, AP			A forkhead-domain gene is mutated in a severe speech and language disorder	NATURE			English	Article							TRANSCRIPTION FACTORS; CLEFT-PALATE; HEAD; FAMILY; LOCALIZATION; MUTATIONS; GLAUCOMA; MODEL; FOXC1; FKHL7	Individuals affected with developmental disorders of speech and language have substantial difficulty acquiring expressive and/or receptive language in the absence of any profound sensory or neurological impairment and despite adequate intelligence and opportunity(1). Although studies of twins consistently indicate that a significant genetic component is involved(1-3), most families segregating speech and language deficits show complex patterns of inheritance, and a gene that predisposes individuals to such disorders has not been identified. We have studied a unique three-generation pedigree, KE, in which a severe speech and language disorder is transmitted as an autosomal-dominant monogenic trait(4). Our previous work mapped the locus responsible, SPCH1, to a 5.6-cM interval of region 7q31 on chromosome 7 (ref. 5). We also identified an unrelated individual, CS, in whom speech and language impairment is associated with a chromosomal translocation involving the SPCH1 interval(6). Here we show that the gene FOXP2, which encodes a putative transcription factor containing a polyglutamine tract and a forkhead DNA-binding domain, is directly disrupted by the translocation breakpoint in CS. In addition, we identify a point mutation in affected members of the KE family that alters an invariant amino-acid residue in the forkhead domain. Our findings suggest that FOXP2 is involved in the developmental process that culminates in speech and language.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Oxford Radcliffe Hosp, Dept Clin Genet, Oxford OX3 7LJ, England; Inst Child Hlth, Dev Cognit Neurosci Unit, London WC1N 2AP, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of London; University College London	Monaco, AP (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.		Vargha-Khadem, Faraneh/C-2558-2008; Fisher, Simon E./E-9130-2012; Monaco, Anthony P/A-4495-2010	Fisher, Simon E./0000-0002-3132-1996; Monaco, Anthony P/0000-0001-7480-3197; vargha-khadem, faraneh/0000-0003-4890-8379				Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; BISHOP DVM, 1995, DEV MED CHILD NEUROL, V37, P56; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Clifton-Bligh RJ, 1998, NAT GENET, V19, P399, DOI 10.1038/1294; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Dale PS, 1998, NAT NEUROSCI, V1, P324, DOI 10.1038/1142; De Felice M, 1998, NAT GENET, V19, P395, DOI 10.1038/1289; Fang JM, 2000, AM J HUM GENET, V67, P1382, DOI 10.1086/316915; Fisher SE, 1998, NAT GENET, V18, P168, DOI 10.1038/ng0298-168; GOPNIK M, 1991, COGNITION, V39, P1, DOI 10.1016/0010-0277(91)90058-C; Kaestner KH, 2000, GENE DEV, V14, P142; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Lai CSL, 2000, AM J HUM GENET, V67, P357, DOI 10.1086/303011; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lehmann OJ, 2000, AM J HUM GENET, V67, P1129; LI C, 1993, P NATL ACAD SCI USA, V90, P11583, DOI 10.1073/pnas.90.24.11583; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Nishimura DY, 2001, AM J HUM GENET, V68, P364, DOI 10.1086/318183; Semina EV, 2001, HUM MOL GENET, V10, P231, DOI 10.1093/hmg/10.3.231; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Smith RS, 2000, HUM MOL GENET, V9, P1021, DOI 10.1093/hmg/9.7.1021; Tomblin JB, 1998, J SPEECH LANG HEAR R, V41, P188, DOI 10.1044/jslhr.4101.188; Vargha-Khadem F, 1998, P NATL ACAD SCI USA, V95, P12695, DOI 10.1073/pnas.95.21.12695; VARGHAKHADEM F, 1995, P NATL ACAD SCI USA, V92, P930, DOI 10.1073/pnas.92.3.930; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; [No title captured]	30	1296	1342	2	221	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					519	523		10.1038/35097076	http://dx.doi.org/10.1038/35097076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586359	Green Published			2022-12-28	WOS:000171340500046
J	Falkenburger, BH; Barstow, KL; Mintz, IM				Falkenburger, BH; Barstow, KL; Mintz, IM			Dendrodendritic inhibition through reversal of dopamine transport	SCIENCE			English	Article							RAT SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA; DENDRITIC RELEASE; PARS RETICULATA; IN-VITRO; NEURONS; SLICES; ELECTROPHYSIOLOGY; STIMULATION; CHANNELS	Synapses in the central nervous system are usually defined by presynaptic exocytotic release sites and postsynaptic differentiations. We report here a demonstration of dendrodendritic inhibition that does not engage a conventional synapse. Using amperometric and patch-clamp recordings in rat brain slices of the substantia nigra, we found that blockade of the dopamine transporter abolished the dendritic release of dopamine and the resulting self-inhibition. These findings demonstrate that dendrodendritic autoinhibition entails the carrier-mediated release of dopamine rather than conventional exocytosis. This suggests that some widely used antidepressants that inhibit the dopamine transporter may benefit patients in the early stages of Parkinson's disease.	Boston Univ, Med Ctr, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA	Boston University	Mintz, IM (corresponding author), Boston Univ, Med Ctr, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA.	imintz@bu.edu		Falkenburger, Bjoern/0000-0002-2387-526X	PHS HHS [R01-3445] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARANEDA R, 1989, J NEUROCHEM, V52, P962, DOI 10.1111/j.1471-4159.1989.tb02548.x; BARSTOW KL, 2001, THESIS BOSTON U SCH; Bjorklund A., 1984, HDB CHEM NEUROANAT 1, V2, P55; BUDA M, 1981, EUR J PHARMACOL, V73, P61, DOI 10.1016/0014-2999(81)90145-X; CHERAMY A, 1981, NATURE, V16, P415; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLLINGRIDGE GL, 1979, J PHYSIOL-LONDON, V290, pP44; DRAY A, 1976, BRAIN RES, V113, P45, DOI 10.1016/0006-8993(76)90005-6; Elverfors A, 1997, SYNAPSE, V26, P359, DOI 10.1002/(SICI)1098-2396(199708)26:4<359::AID-SYN4>3.0.CO;2-5; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; GEFFEN LB, 1976, NATURE, V260, P258, DOI 10.1038/260258a0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; GROVES PM, 1975, SCIENCE, V190, P522, DOI 10.1126/science.242074; HAUSSER M, 1995, NEURON, V15, P637, DOI 10.1016/0896-6273(95)90152-3; Hoffman AF, 1998, J PHARMACOL EXP THER, V287, P487; Hoffman AF, 1999, J PHARMACOL EXP THER, V289, P455; Iribe Y, 1999, J NEUROPHYSIOL, V82, P925, DOI 10.1152/jn.1999.82.2.925; Jaffe EH, 1998, J NEUROSCI, V18, P3548; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; Lai CT, 1997, BIOCHEM PHARMACOL, V53, P363, DOI 10.1016/S0006-2952(96)00731-9; LLINAS R, 1984, BRAIN RES, V294, P127, DOI 10.1016/0006-8993(84)91316-7; Lozano AM, 1998, CURR OPIN NEUROBIOL, V8, P783, DOI 10.1016/S0959-4388(98)80122-0; MINTZ I, 1986, BRAIN RES, V376, P406, DOI 10.1016/0006-8993(86)90209-X; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; PUCAK ML, 1995, CRIT REV NEUROBIOL, V9, P67; Rice ME, 1997, J NEUROPHYSIOL, V77, P853, DOI 10.1152/jn.1997.77.2.853; ROSALES MG, 1994, BRAIN RES, V645, P335, DOI 10.1016/0006-8993(94)91669-1; ROTHMAN RB, 1993, SYNAPSE, V14, P34, DOI 10.1002/syn.890140106; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; SHARIF NA, 1992, NEUROCHEM INT, V21, P69, DOI 10.1016/0197-0186(92)90068-3; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; WASSEF M, 1981, NEUROSCIENCE, V6, P2125, DOI 10.1016/0306-4522(81)90003-8; YUNG WH, 1991, J PHYSIOL-LONDON, V436, P643, DOI 10.1113/jphysiol.1991.sp018571	34	163	165	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2465	2470		10.1126/science.1060645	http://dx.doi.org/10.1126/science.1060645			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577238				2022-12-28	WOS:000171237200051
J	Garcia-Pichel, F; Pringault, O				Garcia-Pichel, F; Pringault, O			Microbiology - Cyanobacteria track water in desert soils	NATURE			English	Article							CHEMOTAXIS; MIGRATIONS		Arizona State Univ, Dept Microbiol, Tempe, AZ 85287 USA; Univ Bordeaux 1, Lab Oceanog Biol, CNRS, UMR EPOC 5805, F-33120 Arcachon, France	Arizona State University; Arizona State University-Tempe; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite de Bordeaux	Garcia-Pichel, F (corresponding author), Arizona State Univ, Dept Microbiol, Tempe, AZ 85287 USA.	ferran@asu.edu	Pringault, Olivier/P-2495-2019; Pringault, Olivier/A-7399-2008	Pringault, Olivier/0000-0003-2363-8376; Pringault, Olivier/0000-0003-2363-8376				Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; BEBOUT BM, 1995, APPL ENVIRON MICROB, V61, P4215, DOI 10.1128/AEM.61.12.4215-4222.1995; BELNAP J, 1993, GREAT BASIN NAT, V53, P40; Garcia-Pichel F, 2001, APPL ENVIRON MICROB, V67, P1902, DOI 10.1128/AEM.67.4.1902-1910.2001; GarciaPichel F, 1996, J PHYCOL, V32, P774, DOI 10.1111/j.0022-3646.1996.00774.x; GARCIAPICHEL F, 1994, APPL ENVIRON MICROB, V60, P1500, DOI 10.1128/AEM.60.5.1500-1511.1994; LI CY, 1988, P NATL ACAD SCI USA, V85, P9451, DOI 10.1073/pnas.85.24.9451; MALIN G, 1985, J GEN MICROBIOL, V131, P2643; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; Wilkinson PC, 1997, AUTOIMMUNITY, V26, P55, DOI 10.3109/08916939709009550	10	147	155	3	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 27	2001	413	6854					380	381		10.1038/35096640	http://dx.doi.org/10.1038/35096640			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574875				2022-12-28	WOS:000171188700041
J	Jarvis, MJ				Jarvis, MJ			Atmospheric science - Bridging the atmospheric divide	SCIENCE			English	Editorial Material							MESOSPHERE; THERMOSPHERE; MESOPAUSE		British Antarctic Survey, Cambridge CB3 0ET, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Jarvis, MJ (corresponding author), British Antarctic Survey, Cambridge CB3 0ET, England.							Arnold NF, 1998, ANN GEOPHYS-ATM HYDR, V16, P69, DOI 10.1007/s00585-997-0069-3; GADSDEN M, 1990, J ATMOS TERR PHYS, V52, P247, DOI 10.1016/0021-9169(90)90091-Z; Gardner CS, 1999, J GEOPHYS RES-ATMOS, V104, P11903, DOI 10.1029/1999JD900105; Gardner CS, 2001, GEOPHYS RES LETT, V28, P1199, DOI 10.1029/2000GL012622; Huaman MM, 1999, GEOPHYS RES LETT, V26, P1529, DOI 10.1029/1999GL900294; Lawrence AR, 2001, GEOPHYS RES LETT, V28, P203, DOI 10.1029/2000GL000116; Lubken FJ, 2000, GEOPHYS RES LETT, V27, P3603, DOI 10.1029/2000GL011893; Lubken FJ, 1999, GEOPHYS RES LETT, V26, P3581, DOI 10.1029/1999GL010719; PANCHEVA D, IN PRESS J ATMOS SOL; ROBLE RG, 1989, GEOPHYS RES LETT, V16, P1441, DOI 10.1029/GL016i012p01441; Siskind DE, 2000, GEOPHYS RES LETT, V27, P329, DOI 10.1029/1999GL010940; Taylor MJ, 1997, ADV SPACE RES-SERIES, V19, P667, DOI 10.1016/S0273-1177(97)00161-0	12	5	7	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2218	2219		10.1126/science.1064467	http://dx.doi.org/10.1126/science.1064467			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567129				2022-12-28	WOS:000171139400032
J	Kazlauskas, R				Kazlauskas, R			Modeling - A tool for experimentalists	SCIENCE			English	Article							ENANTIOSELECTIVITY; LIPASE		McGill Univ, Dept Chem, Montreal, PQ H3A 2K6, Canada	McGill University	Kazlauskas, R (corresponding author), McGill Univ, Dept Chem, 801 Sherbrooke St W, Montreal, PQ H3A 2K6, Canada.			Kazlauskas, Romas/0000-0002-3570-2411				AERTS J, 1995, J COMPUT CHEM, V16, P914, DOI 10.1002/jcc.540160708; EKSTEROWICZ JE, 1993, CHEM REV, V93, P2439, DOI 10.1021/cr00023a006; Gascoyne DG, 2001, J ORG CHEM, V66, P3041, DOI 10.1021/jo005681v; Haeffner F, 1998, BIOPHYS J, V74, P1251, DOI 10.1016/S0006-3495(98)77839-7; HORSMAN G, UNPUB; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; Leach A., 1996, MOL MODELING PRINCIP; Li QS, 2001, BBA-PROTEIN STRUCT M, V1545, P114, DOI 10.1016/S0167-4838(00)00268-5; Monard G, 1999, ACCOUNTS CHEM RES, V32, P904, DOI 10.1021/ar970218z; RHODES G, 2000, CRYSTALLOGRAPHY MADE, P146; Schulz T, 2000, PROTEIN SCI, V9, P1053, DOI 10.1110/ps.9.6.1053; Zheng YJ, 2001, P NATL ACAD SCI USA, V98, P432, DOI 10.1073/pnas.021547498	13	12	13	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2277	+		10.1126/science.293.5538.2277	http://dx.doi.org/10.1126/science.293.5538.2277			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567144				2022-12-28	WOS:000171139400050
J	Milan, M; Weihe, U; Perez, L; Cohen, SM				Milan, M; Weihe, U; Perez, L; Cohen, SM			The LRR proteins Capricious and Tartan mediate cell interactions during DV boundary formation in the Drosophila wing	CELL			English	Article							LIM-HOMEODOMAIN ACTIVITY; APICAL ECTODERMAL RIDGE; VENTRAL CELLS; EPH RECEPTORS; DORSOVENTRAL COMPARTMENTALIZATION; LINEAGE RESTRICTION; GRADIENT FORMATION; ADHESION MOLECULE; GENE-EXPRESSION; RADICAL FRINGE	Mechanisms to segregate cell populations play important roles in tissue patterning during animal development. Rhombomeres and compartments in the ectoderm and imaginal discs of Drosophila are examples in which initially homogenous populations of cells come to be separated by boundaries of lineage restriction. Boundary formation depends in part on signaling between the distinctly specified cell populations that comprise compartments and in part on formation of affinity boundaries that prevent intermingling of these cell populations. Here, we present evidence that two transmembrane proteins with leucine-rich repeats, known as Capricious and Tartan, contribute to formation of the affinity boundary between dorsal and ventral compartments during Drosophila wing development.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Cohen, SM (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	cohen@embl-heidelberg.de	Milan, Marco/H-1450-2015; Cohen, Stephen M/G-9930-2011; Perez, Lidia/F-7695-2016	Milan, Marco/0000-0002-7111-6444; Cohen, Stephen M/0000-0003-2858-9163; Perez, Lidia/0000-0002-8821-1202				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; Blair SS, 1997, DEVELOPMENT, V124, P4053; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; Cho KO, 2000, CELL, V103, P331, DOI 10.1016/S0092-8674(00)00124-0; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; Dahmann C, 1999, TRENDS GENET, V15, P320, DOI 10.1016/S0168-9525(99)01774-6; Dahmann C, 2000, CELL, V100, P411, DOI 10.1016/S0092-8674(00)80677-7; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; Fernandez-Funez P, 1998, EMBO J, V17, P6846, DOI 10.1093/emboj/17.23.6846; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Martin-Blanco E, 2000, P NATL ACAD SCI USA, V97, P7888, DOI 10.1073/pnas.97.14.7888; MEADOWS LA, 1994, J CELL SCI, V107, P321; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Micchelli CA, 1999, NATURE, V401, P473, DOI 10.1038/46779; Milan M, 1999, MOL CELL, V4, P267, DOI 10.1016/S1097-2765(00)80374-3; Milan M, 1998, GENE DEV, V12, P2912, DOI 10.1101/gad.12.18.2912; Milan M, 1999, MOL CELL, V4, P1073, DOI 10.1016/S1097-2765(00)80235-X; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; Morcillo P, 1997, GENE DEV, V11, P2729, DOI 10.1101/gad.11.20.2729; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Raghavan S, 1997, NEURON, V18, P873, DOI 10.1016/S0896-6273(00)80327-X; Raich WB, 1999, CURR BIOL, V9, P1139, DOI 10.1016/S0960-9822(00)80015-9; Ramirez-Weber FA, 2000, MOL CELL, V6, P479, DOI 10.1016/S1097-2765(00)00046-0; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; Rauskolb C, 1999, NATURE, V401, P476, DOI 10.1038/46786; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Salzberg A, 1997, GENETICS, V147, P1723; Shishido E, 1998, SCIENCE, V280, P2118, DOI 10.1126/science.280.5372.2118; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; van Meyel DJ, 1999, MOL CELL, V4, P259, DOI 10.1016/S1097-2765(00)80373-1; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; ZECCA M, 1995, DEVELOPMENT, V121, P2265	58	106	107	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 21	2001	106	6					785	794		10.1016/S0092-8674(01)00489-5	http://dx.doi.org/10.1016/S0092-8674(01)00489-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572783	Bronze			2022-12-28	WOS:000171213000014
J	Salama, AD; Levy, JB; Lightstone, L; Pusey, CD				Salama, AD; Levy, JB; Lightstone, L; Pusey, CD			Goodpasture's disease	LANCET			English	Editorial Material							MEMBRANE		Hammersmith Hosp, Imperial Coll Sch Med, Div Med, Renal Sect, London W12 0NN, England	Imperial College London	Salama, AD (corresponding author), Brigham & Womens Hosp, Lab Immunogenet & Transplantat, 75 Francis St, Boston, MA 02115 USA.		Lightstone, Liz/M-4331-2014; Salama, Alan/B-5183-2010	Lightstone, Liz/0000-0002-4603-4076; 				DUNCAN DA, 1965, ANN INTERN MED, V62, P920, DOI 10.7326/0003-4819-62-5-920; Fisher M, 1997, KIDNEY INT, V51, P222, DOI 10.1038/ki.1997.27; Goodpasture EW, 1919, AM J MED SCI, V158, P863, DOI 10.1097/00000441-191911000-00012; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; Levy JB, 1996, AM J KIDNEY DIS, V27, P573, DOI 10.1016/S0272-6386(96)90169-9; Levy JB, 2001, ANN INTERN MED, V134, P1033, DOI 10.7326/0003-4819-134-11-200106050-00009; Long E R, 1965, Biogr Mem Natl Acad Sci, V38, P111; SALAMA AD, IN PRESS J AM SOC NE; SCHEER RL, 1964, ANN INTERN MED, V60, P1009, DOI 10.7326/0003-4819-60-6-1009; STANTON M. C., 1958, AUSTRALASEAN ANN MED, V7, P132; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; WILSON CB, 1973, KIDNEY INT, V3, P74, DOI 10.1038/ki.1973.14	12	109	119	2	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 15	2001	358	9285					917	920		10.1016/S0140-6736(01)06077-9	http://dx.doi.org/10.1016/S0140-6736(01)06077-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567730				2022-12-28	WOS:000171087000031
J	Attaran, A; Gillespie-White, L				Attaran, A; Gillespie-White, L			Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMBINATION THERAPY; LAMIVUDINE; STAVUDINE; ZIDOVUDINE; NEVIRAPINE; EFFICACY; REGIMEN; SAFETY; INDIVIDUALS; DIDANOSINE	Public attention and debate recently have focused on access to treatment of acquired immunodeficiency syndrome (AIDS) in poor, severely affected countries, such as those in Africa. Whether patents on antiretroviral drugs In Africa are impeding access to lifesaving treatment for the 25 million Africans with human immunodeficiency virus infection is unknown. We studied the patent statuses of 15 antiretroviral drugs in 53 African countries. Using a survey method, we found that these antiretroviral drugs are patented in few African countries (median, 3; mode, 0) and that in countries where antiretroviral drug patents exist, generally only a small subset of antiretroviral drugs are patented (median and mode, 4). The observed scarcity of patents cannot be simply explained by a lack of patent laws because most African countries have offered patent protection for pharmaceuticals for many years. Furthermore, in this particular case, geographic patent coverage does not appear to correlate with antiretroviral treatment access in Africa, suggesting that patents and patent law are not a major barrier to treatment access in and of themselves. We conclude that a variety of de facto barriers are more responsible for impeding access to antiretroviral treatment, including but not limited to the poverty of African countries, the high cost of antiretroviral treatment, national regulatory requirements for medicines, tariffs and sales taxes, and, above all, a lack of sufficient international financial aid to fund anti-retroviral treatment. We consider these findings in light of policies for enhancing antiretroviral treatment access in poor countries.	Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA; Int Intellectual Property Inst, Washington, DC USA	Harvard University; Harvard University	Attaran, A (corresponding author), Harvard Univ, Ctr Int Dev, 79 JFK St, Cambridge, MA 02138 USA.	amir_attaran@harvard.edu						[Anonymous], PATENT POLICY PROPOS; Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; ATTARAN A, 1999, MED SANS FRONT WHO W; ATTARAN A, 1999, HLTH HUM RIGHTS, V4, P28; BALA K, 2001, HLTH ACTION INT  APR; Bale H., 1998, J INT ECON LAW, V1, P637, DOI DOI 10.1093/JIEL/1.4.637; BALE HE, 2001, CONSUMPTION TRADE OF; BOULET P, 2000, DRUG PATENTS FRENCHS; BOULET P, 2000, PATENT PROTECTION ME; *CA DEP TRANSP, 1999, EST COST VFAR FREEW; CORREA C, 2001, INTELLECTUAL PROPERT; CORREA C, 2001, INTEGRATING PUBLIC H; *DEP HLTH HUM SERV, 2001, GUID US ANT AG HIV I; Eron JJ, 2000, AIDS, V14, P1601, DOI 10.1097/00002030-200007280-00016; Ford S., 2000, AM U INT L REV, V15, P941; Gartland M, 2001, ANTIVIR THER, V6, P127; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; JOHNSON V, 2001, 8 C RETR OPP INF FEB; *JOINT UN PROGR HI, 2000, PAT SIT HIV AIDS REL; Laing RO, 2000, INT J TUBERC LUNG D, V4, pS194; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; McKee RL, 2001, PEOPLE EYE STORIES D, V1st; *PAN I, 2001, OUR MEANS COST TREAT; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Raffi F, 2000, ANTIVIR THER, V5, P267; Rockstroh JK, 2000, AIDS, V14, P1181, DOI 10.1097/00002030-200006160-00015; Shalit P, 2001, AIDS, V15, P804, DOI 10.1097/00002030-200104130-00020; Squires KE, 2000, AIDS, V14, P1591, DOI 10.1097/00002030-200007280-00015; Stephenson J, 2001, JAMA-J AM MED ASSOC, V286, P405, DOI 10.1001/jama.286.4.405; SWAMS RL, 2001, NY TIMES        0308, pA1; *WHO, 2001, WHO INT CONS M HIV A; 1883, PAR CONVENTION PROTE; 2000, MANUAL HANDLING APPL; 2000, FED REG, V65, P30521; 2001, TOP HIV MED, V9, P14; 2001, AGREEMENT TRADE RELA	36	105	106	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2001	286	15					1886	1892		10.1001/jama.286.15.1886	http://dx.doi.org/10.1001/jama.286.15.1886			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	482UH	11597292				2022-12-28	WOS:000171595300031
J	Fihn, SD; Williams, SV; Daley, J; Gibbons, RJ				Fihn, SD; Williams, SV; Daley, J; Gibbons, RJ			Guidelines for the management of patients with chronic stable angina: Treatment	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; TOTAL ISCHEMIC BURDEN; ASSOCIATION TASK-FORCE; PATIENTS RECEIVING PROPRANOLOL; ESTROGEN REPLACEMENT THERAPY; ACC/AHA/ACP-ASIM GUIDELINES; RANDOMIZED CONTROLLED-TRIAL; BETA-ADRENERGIC-BLOCKADE; INTERNAL-MAMMARY-ARTERY	The dual alms of treating patients with chronic stable angina are 1) to reduce morbidity and mortality and 2) to eliminate angina with minimal adverse effects and allow the patient to return to normal activities. In the absence of contraindications, is-blockers are recommended as initial therapy. All beta -blockers seem to be equally effective. If the patient has serious contraindications to beta -blockers, unacceptable side effects, or persistent angina, calcium antagonists should be administered. Long-acting dihydropyridine and nondihydropyridine agents are generally as effective as beta -blockers in relieving angina. Long-acting nitrates are considered third-line therapy because a nitrate-free interval is required to avoid developing tolerance. All long-acting nitrates seem to be equally effective. Patients with angina should take 75 to 325 mg of aspirin daily unless they have contraindications. Such risk factors as, smoking, elevated low-density lipoprotein cholesterol level, diabetes, and hypertension should be treated appropriately. Coronary revascularization has not been shown to improve survival for most patients with chronic angina but may be required to control symptoms. However, coronary artery bypass grafting (CABG) is often indicated for symptomatic patients with left-main disease, three-vessel disease, or two-vessel disease including proximal stenosis of the left anterior descending coronary artery; it improves their survival. Percutaneous transluminal coronary angioplasty is an alternative to CABG for patients with normal left ventricular function and favorable angiographic features. Coronary artery bypass grafting is initially more effective in relieving angina than medical therapy, but the two procedures yield similar results after 5 to 10 years. Eighty percent of patients who undergo CABG remain angina-free 5 years after surgery. In low-risk patients, percutaneous transluminal coronary angioplasty seems to control angina better than medical therapy, but recurrent angina and repeated procedures are more likely than with CABG. Patient education is an important component of. management. Long-term follow-up should be individualized to ascertain clinical stability at regular intervals and to reassess prognosis when warranted.	VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA; Massachusetts Gen Hosp, Partners Hlth Care Syst, Boston, MA 02114 USA; Univ Penn, Philadelphia, PA 19104 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Harvard University; Massachusetts General Hospital; Partners Healthcare System; University of Pennsylvania; Mayo Clinic	Fihn, SD (corresponding author), VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, 152,1660 S Columbian Way, Seattle, WA 98108 USA.		Fihn, Stephan/ABA-1040-2020					ABRAMS J, 1987, DRUGS, V34, P391, DOI 10.2165/00003495-198734030-00005; ABRAMS J, 1983, AM J MED, V74, P85, DOI 10.1016/0002-9343(83)90858-6; ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; AHUJA RC, 1993, INT J CARDIOL, V41, P191, DOI 10.1016/0167-5273(93)90115-W; AKHRAS F, 1991, LANCET, V338, P1036, DOI 10.1016/0140-6736(91)91900-F; AKHRAS F, 1989, INT J CARDIOL, V24, P191, DOI 10.1016/0167-5273(89)90304-5; Alderman E, 1997, CIRCULATION, V96, P1761, DOI 10.1161/01.CIR.96.6.1761; Alderman EL, 1996, NEW ENGL J MED, V335, P217; ALDERMAN EL, 1993, J AM COLL CARDIOL, V22, P1141, DOI 10.1016/0735-1097(93)90429-5; Alderman EL, 2000, J AM COLL CARDIOL, V35, P1122; Alderman M, 1997, J HYPERTENS, V15, P105; Alderman MH, 1997, LANCET, V349, P594, DOI 10.1016/S0140-6736(96)08359-6; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANKIER SI, 1989, J INT MED RES, V17, P172, DOI 10.1177/030006058901700210; [Anonymous], 1976, JAMA, V235, P825; [Anonymous], 1993, ARCH INTERN MED, V153, P154, DOI DOI 10.1001/archinte.1993.00410020010002; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; ANTMAN E, 1980, NEW ENGL J MED, V302, P1269, DOI 10.1056/NEJM198006053022301; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; BASSAN MM, 1983, CHEST, V83, P233, DOI 10.1378/chest.83.2.233; BASSAN MM, 1983, CIRCULATION, V68, P568, DOI 10.1161/01.CIR.68.3.568; Betriu A, 1999, J AM COLL CARDIOL, V34, P1498, DOI 10.1016/S0735-1097(99)00366-6; BREMNER AD, 1993, J HUM HYPERTENS, V7, P79; BURR ML, 1989, LANCET, V2, P757; BUTLER WJ, 1985, AM J EPIDEMIOL, V121, P541; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Campeau L, 1997, NEW ENGL J MED, V336, P153; CANNISTRA LB, 1992, AM J CARDIOL, V69, P1274, DOI 10.1016/0002-9149(92)91220-X; CARNEY RM, 1987, AM J CARDIOL, V60, P1273, DOI 10.1016/0002-9149(87)90607-2; Chamberlain DA, 1997, LANCET, V350, P461; Cheitlin MD, 1999, J AM COLL CARDIOL, V33, P273, DOI 10.1016/S0735-1097(98)00656-1; CHESEBRO JH, 1984, NEW ENGL J MED, V310, P209, DOI 10.1056/NEJM198401263100401; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cutler Jeffrey A., 1995, P253; Dargie HJ, 1996, EUR HEART J, V17, P104; DEANFIELD JE, 1994, J AM COLL CARDIOL, V24, P1460, DOI 10.1016/0735-1097(94)90140-6; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; deVries RJM, 1996, INT J CARDIOL, V57, P143, DOI 10.1016/S0167-5273(96)02806-9; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DURYEE R, 1992, HEART LUNG, V21, P217; ELKAYAM U, 1990, CIRCULATION, V82, P1954, DOI 10.1161/01.CIR.82.6.1954; EMANUELSSON H, 1989, EUR J CLIN PHARMACOL, V36, P561, DOI 10.1007/BF00637736; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FISHMAN WH, 1991, AM J CARDIOL, V67, P665; FOALE RA, 1993, EUR HEART J, V14, P1369, DOI 10.1093/eurheartj/14.10.1369; FROELICHER V, 1984, JAMA-J AM MED ASSOC, V252, P1291, DOI 10.1001/jama.252.10.1291; FUNG HL, 1994, CARDIOVASC DRUG THER, V8, P489, DOI 10.1007/BF00877927; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GAVAGHAN TP, 1991, CIRCULATION, V83, P1526, DOI 10.1161/01.CIR.83.5.1526; GENEST J, 1991, AM J CARDIOL, V67, P1039, DOI 10.1016/0002-9149(91)90862-F; Genest J, 1992, CURR OPIN LIPIDOL, V3, P295; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gerstein HC, 2000, LANCET, V355, P253; GETZ GS, 1993, ARTERIOSCLER THROMB, V13, P459, DOI 10.1161/01.ATV.13.3.459; Gibbons RJ, 1999, CIRCULATION, V99, P2829, DOI 10.1161/01.CIR.99.21.2829; Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3; Gibson RS, 1996, AM J HYPERTENS, V9, pS172, DOI 10.1016/S0895-7061(96)00386-X; GLASSER SP, 1995, AM J CARDIOL, V75, pE68, DOI 10.1016/S0002-9149(99)80451-2; GOLDMAN S, 1991, CIRCULATION, V84, P520, DOI 10.1161/01.CIR.84.2.520; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Gould AL, 1998, CIRCULATION, V97, P946; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grines CL, 1999, NEW ENGL J MED, V341, P1949, DOI 10.1056/NEJM199912233412601; Grodstein F, 2001, ANN INTERN MED, V135, P1, DOI 10.7326/0003-4819-135-1-200107030-00003; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hambrecht R, 1993, J AM COLL CARDIOL, V22, P468, DOI 10.1016/0735-1097(93)90051-2; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HaufZachariou U, 1997, EUR J CLIN PHARMACOL, V52, P95, DOI 10.1007/s002280050256; Held C, 1997, CIRCULATION, V95, P2380, DOI 10.1161/01.CIR.95.10.2380; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; HILL JA, 1982, AM J CARDIOL, V49, P431, DOI 10.1016/0002-9149(82)90521-5; HIRSH J, 1995, CHEST, V108, pS247, DOI 10.1378/chest.108.4_Supplement.247S; HJERMANN I, 1981, LANCET, V2, P1303; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jeppesen J, 1998, CIRCULATION, V97, P1029, DOI 10.1161/01.CIR.97.11.1029; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; KASKI JC, 1985, AM HEART J, V110, P238, DOI 10.1016/0002-8703(85)90493-4; KAWANISHI DT, 1992, J AM COLL CARDIOL, V19, P409, DOI 10.1016/0735-1097(92)90499-D; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; Kingsbury K, 1998, CAN J CARDIOL, V14, p22A; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; Kostner G. M., 1992, CURR OPIN LIPIDOL, V3, P279; KREPP HP, 1991, CARDIOLOGY, V79, P14, DOI 10.1159/000174919; LACOSTE LL, 1994, AM J CARDIOL, V73, P1058; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; Larson CO, 1996, INT J QUAL HEALTH C, V8, P447, DOI 10.1093/intqhc/8.5.447; LEHMANN G, 1993, EUR HEART J, V14, P1531, DOI 10.1093/eurheartj/14.11.1531; Levin ME, 1998, DIABETES CARE, V21, P1; LEWIS BS, 1993, PREV MED, V22, P110, DOI 10.1006/pmed.1993.1008; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; LYTLE BW, 1993, J THORAC CARDIOV SUR, V105, P605; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANOLIO TA, 1993, CIRCULATION, V88, P2163, DOI 10.1161/01.CIR.88.5.2163; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MAY GA, 1984, PHYS THER, V64, P1361, DOI 10.1093/ptj/64.9.1361; MCBRIDE PE, 1992, MED CLIN N AM, V76, P333, DOI 10.1016/S0025-7125(16)30356-X; MCLENACHAN JM, 1992, J CARDIOVASC PHARM, V20, P311, DOI 10.1097/00005344-199208000-00018; MCTAVISH D, 1990, DRUGS, V40, P238, DOI 10.2165/00003495-199040020-00006; Meade TW, 1998, LANCET, V351, P233; MELANDRI G, 1993, CIRCULATION, V88, P2517, DOI 10.1161/01.CIR.88.6.2517; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; MEYER TE, 1993, CARDIOVASC DRUG THER, V7, P909, DOI 10.1007/BF00877726; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Moore S M, 1997, J Cardiovasc Nurs, V12, P59; Moser M, 1996, J AM COLL CARDIOL, V27, P1214, DOI 10.1016/0735-1097(95)00606-0; NARAHARA KA, 1990, AM J CARDIOL, V65, P577, DOI 10.1016/0002-9149(90)91033-3; OCALLAGHAN WG, 1984, EUR HEART J, V5, P649, DOI 10.1093/oxfordjournals.eurheartj.a061721; OCKENE JK, 1994, HEALTH PSYCHOL, V13, P278, DOI 10.1037/0278-6133.13.3.278; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; OLDRIDGE NB, 1989, MED SCI SPORT EXER, V21, P308; OLDRIDGE NB, 1980, AM HEART J, V100, P755, DOI 10.1016/0002-8703(80)90244-6; ONeill C, 1996, J EPIDEMIOL COMMUN H, V50, P538, DOI 10.1136/jech.50.5.538; OPIE LH, 1995, CIRCULATION, V92, P1068, DOI 10.1161/01.CIR.92.5.1068; ORNISH D, 1983, JAMA-J AM MED ASSOC, V249, P54, DOI 10.1001/jama.249.1.54; PARAMESHWAR J, 1993, INT J CARDIOL, V40, P135, DOI 10.1016/0167-5273(93)90276-M; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PASSAMANI E, 1985, NEW ENGL J MED, V312, P1665, DOI 10.1056/NEJM198506273122603; PEDERSEN TR, 1994, LANCET, V344, P1383; PEPINE CJ, 1981, AM HEART J, V101, P719, DOI 10.1016/0002-8703(81)90606-2; PEPINE CJ, 1994, CIRCULATION, V90, P762, DOI 10.1161/01.CIR.90.2.762; Plach S, 1996, HEART LUNG, V25, P367, DOI 10.1016/S0147-9563(96)80078-1; PRIDA XE, 1987, AM J CARDIOL, V59, P1084, DOI 10.1016/0002-9149(87)90853-8; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PYORALA K, 1994, ATHEROSCLEROSIS, V110, P121, DOI 10.1016/0021-9150(94)90200-3; Raftery EB, 1996, EUR HEART J, V17, P30, DOI 10.1093/eurheartj/17.suppl_B.30; Rehnqvist N, 1995, Cardiologia, V40, P301; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; Ronnevik PK, 1995, EUR HEART J, V16, P1535, DOI 10.1093/oxfordjournals.eurheartj.a060774; ROSE G, 1982, J EPIDEMIOL COMMUN H, V36, P102, DOI 10.1136/jech.36.2.102; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAVI P, 1994, J PHARMACOL EXP THER, V269, P772; Savonitto S, 1996, J AM COLL CARDIOL, V27, P311, DOI 10.1016/0735-1097(95)00489-0; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SCHNEIDER W, 1988, EUR HEART J, V9, P149, DOI 10.1093/oxfordjournals.eurheartj.a062468; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SCHWARTZ CJ, 1992, DIABETES CARE, V15, P1156, DOI 10.2337/diacare.15.9.1156; SEBRECHTS CP, 1986, AM HEART J, V112, P1217, DOI 10.1016/0002-8703(86)90351-0; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SILBER S, 1990, EUR J CLIN PHARMACOL, V38, pS35, DOI 10.1007/BF01417564; SINGH BN, 1992, AM J CARDIOL, V69, pD68; SINGH BN, 1991, AM J CARDIOL, V68, P306, DOI 10.1016/0002-9149(91)90824-5; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SMITH SC, 1995, J AM COLL CARDIOL, V26, P292, DOI 10.1016/0735-1097(95)90846-G; STAMLER J, 1989, HYPERTENSION S1, V13, P12; STAMLER J, 1987, CARDIOLOGY, P1; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STEFFENSEN R, 1993, INT J CARDIOL, V40, P143, DOI 10.1016/0167-5273(93)90277-N; Stone GW, 1999, CIRCULATION, V99, P1548, DOI 10.1161/01.CIR.99.12.1548; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; THADANI U, 1991, CIRCULATION, V84, P2398, DOI 10.1161/01.CIR.84.6.2398; TILMANT PY, 1983, AM J CARDIOL, V52, P230, DOI 10.1016/0002-9149(83)90113-3; TIRLAPUR VG, 1984, AM J CARDIOL, V53, P487, DOI 10.1016/0002-9149(84)90018-3; TODD IC, 1992, BRIT HEART J, V68, P560; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *US DEP HHS, 1989, RED HLTH CONS SMOK 2; *US DEP HHS, 1990, HLTH BEN SMOK CES RE; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; VANCAMP SP, 1986, JAMA-J AM MED ASSOC, V256, P1160, DOI 10.1001/jama.256.9.1160; VANDENBOS AA, 1993, CIRCULATION, V88, P2058, DOI 10.1161/01.CIR.88.5.2058; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; VONARNIM T, 1995, J AM COLL CARDIOL, V25, P231, DOI 10.1016/0735-1097(94)00345-Q; WASSERTHEILSMOLLER S, 1992, AM J HYPERTENS, V5, P37, DOI 10.1093/ajh/5.1.37; WAYSBORT J, 1991, CARDIOLOGY, V79, P19, DOI 10.1159/000174920; Weaver WD, 2000, LANCET, V355, P2199, DOI 10.1016/S0140-6736(00)02403-X; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; Williams SV, 2001, ANN INTERN MED, V135, P530, DOI 10.7326/0003-4819-135-7-200110020-00014; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; 1991, LANCET, V337, P459; 1992, CIRCULATION, V86, P121, DOI DOI 10.1161/01.CIR.86.1.121	191	39	40	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	1				616	632		10.7326/0003-4819-135-8_Part_1-200110160-00014	http://dx.doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00014			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481VY	11601935				2022-12-28	WOS:000171542200009
J	Reynolds, T				Reynolds, T			Disease prediction models aim to guide medical decision making	ANNALS OF INTERNAL MEDICINE			English	News Item																			0	11	11	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	1				637	640		10.7326/0003-4819-135-8_Part_1-200110160-00023	http://dx.doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00023			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481VY	11601944				2022-12-28	WOS:000171542200015
J	Olsen, O; Middleton, P; Ezzo, J; Gotzsche, P; Hadhazy, V; Herxheimer, A; Kleijnen, J; McIntosh, H				Olsen, O; Middleton, P; Ezzo, J; Gotzsche, P; Hadhazy, V; Herxheimer, A; Kleijnen, J; McIntosh, H			Quality of Cochrane reviews: assessment of sample from 1998	BRITISH MEDICAL JOURNAL			English	Article							SYSTEMATIC REVIEWS; TRIALS; METAANALYSES; BIAS; METHODOLOGY; ARTICLES	Objective To assess the quality of Cochrane reviews. Design Ten methodologists affiliated with the Cochrane Collaboration independently examined, in a semistructured way, the quality of reviews first published in 1998. Each review was assessed by two people; if one of them noted any major problems, they agreed on a common assessment. Predominant types of problem were categorised. Setting Cyberspace collaboration coordinated from the Nordic Cochrane Centre. Studies All 53 reviews first published in issue 4 of the Cochrane Library in 1998. Main outcome measure Proportion of reviews with various types of major problem. Results No problems or only minor ones were found in most reviews. Major problems were identified in 15 reviews (29%). The evidence did not fully support the conclusion in nine reviews (17%), the conduct or reporting was unsatisfactory in 12 reviews (23%), and stylistic problems were identified in 12 reviews (23%). The problematic conclusions all gave too favourable a picture of the experimental intervention. Conclusions Cochrane reviews have previously been shown to be of higher quality and less biased on average than other systematic reviews, but improvement is always possible. The Cochrane Collaboration has taken steps to improve editorial processes and the quality of its reviews. Meanwhile, the Cochrane Library remains a key source of evidence about the effects of healthcare interventions. Its users should interpret reviews cautiously, particularly those with conclusions favouring experimental interventions and those with many typographical errors.	Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2100 Copenhagen O, Denmark; Flinders Med Ctr, Australasian Cochrane Ctr, Dept Gen Practice, Adelaide, SA 5042, Australia; Univ Maryland, Sch Med, Cochrane Complementary Med Field, Complementary & Alternat Program, Baltimore, MD USA; UK Cochrane Ctr, NHS R&D Programme, Oxford OX2 7LG, England; Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England	Rigshospitalet; Flinders Medical Centre; University System of Maryland; University of Maryland Baltimore; Cochrane Centre; University of York - UK	Olsen, O (corresponding author), Rigshosp, Nord Cochrane Ctr, Dept 7112, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.							ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Clarke M, 2001, COCHRANE REV HDB; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; MOHER D, 1999, PEER REV HLTH SCI, P146; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; Mulrow CD, 1994, COCHRANE LIB; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SHEA B, 1999, 7 COCHR C ROM 5 9 OC, pA39; SHEA B, 1999, 7 COCHR C ROM 5 9 OC, pA40; STERN JM, 1997, BRIT MED J, V315, P645; TRAMER MR, 1997, BRIT MED J, V315, P6335; YUSUF S, 1987, STAT MED, V6, P217, DOI 10.1002/sim.4780060302	19	111	114	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 13	2001	323	7317					829	832		10.1136/bmj.323.7317.829	http://dx.doi.org/10.1136/bmj.323.7317.829			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597965	Bronze, Green Published			2022-12-28	WOS:000171650500023
J	Abbott, A				Abbott, A			Last-minute floods sink research	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					443	443		10.1038/35097231	http://dx.doi.org/10.1038/35097231			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586314	Bronze			2022-12-28	WOS:000171340500008
J	Ferguson, NM; Donnelly, CA; Anderson, RM				Ferguson, NM; Donnelly, CA; Anderson, RM			Transmission intensity and impact of control policies on the foot and mouth epidemic in Great Britain	NATURE			English	Article							DISEASE; SPREAD	The foot and mouth disease (FMD) epidemic in British livestock remains an ongoing cause for concern, with new cases still arising in previously unaffected areas. Epidemiological analyses(1-3) have been vital in delivering scientific advice to government on effective control measures. Using disease, culling and census data on all livestock farms in Great Britain, we analysed the risk factors determining the spatiotemporal evolution of the epidemic and of the impact of control policies on FMD incidence. Here we show that the species mix, animal numbers and the number of distinct land parcels in a farm are central to explaining regional variation in transmission intensity. We use the parameter estimates thus obtained in a dynamical model of disease spread to show that extended culling programmes were essential for controlling the epidemic to the extent achieved, but demonstrate that the epidemic could have been substantially reduced in scale had the most efficient control measures been rigorously applied earlier.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England	Imperial College London	Ferguson, NM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, St Mary Campus,Norfolk Pl, London W2 1PG, England.	neil.ferguson@ic.ac.uk	Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093; Donnelly, Christl/0000-0002-0195-2463; Anderson, Roy/0000-0002-9528-3175				ANDERSON R M, 1991; [Anonymous], 2001, NATURE, V411, P977; Barber CB, 1996, ACM T MATH SOFTWARE, V22, P469, DOI 10.1145/235815.235821; Donaldson AI, 2001, VET REC, V148, P602, DOI 10.1136/vr.148.19.602; Ferguson NM, 2001, SCIENCE, V292, P1155, DOI 10.1126/science.1061020; HIGHFIELD R, 2001, TELEGRAPH       0702; HMSO (Her Majesty's Stationery Office), 1968, NORTHUMBERLAND REPOR; Kao RR, 2001, VET REC, V148, P746, DOI 10.1136/vr.148.24.746; MCCOLL KA, 1995, AUST VET J, V72, P286, DOI 10.1111/j.1751-0813.1995.tb03556.x; *UK MIN AGR FISH F, 2001, JUN 2000 AGR HORT CE; Woolhouse M, 2001, NATURE, V411, P258, DOI 10.1038/35077149; 2001, VET REC, V148, P550; 2001, GUARDIAN UNLIMI 0320	13	319	322	3	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 4	2001	413	6855					542	548		10.1038/35097116	http://dx.doi.org/10.1038/35097116			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586365				2022-12-28	WOS:000171340500052
J	Guinn, DA; Atkinson, MW; Sullivan, L; Lee, M; MacGregor, S; Parilla, BV; Davies, J; Hanlon-Lundberg, K; Simpson, L; Stone, J; Wing, D; Ogasawara, K; Muraskas, J				Guinn, DA; Atkinson, MW; Sullivan, L; Lee, M; MacGregor, S; Parilla, BV; Davies, J; Hanlon-Lundberg, K; Simpson, L; Stone, J; Wing, D; Ogasawara, K; Muraskas, J			Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; CEREBRAL-PALSY; INTRAVENTRICULAR HEMORRHAGE; PREMATURE-INFANTS; ULTRASOUND; BRAIN; DEXAMETHASONE; EXPOSURE; CHILDREN; SIZE	Context The practice of administering weekly courses of antenatal corticosteroids to pregnant women at risk of preterm delivery is widespread, but no randomized trial has established the efficacy or safety of this practice. Objectives To evaluate the efficacy of weekly administration of antenatal corticosteroids compared with a single course in reducing the incidence of neonatal morbidity and to evaluate potential complications of weekly treatment. Design and Setting Randomized, double-blind, placebo-controlled intention-to-treat trial conducted in 13 academic centers in the United States from February 1996 through April 2000. Participants A total of 502 pregnant women between 24 and 32 completed weeks' gestation who were at high risk of preterm delivery. Intervention All patients received a complete single course of antenatal corticosteroids (either betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses, or dexamethasone, 6 mg intramuscularly repeated every 12 hours for 4 doses). Participants who had not delivered 1 week after receipt of the single course were randomly assigned to receive either betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses every week until 34 weeks' gestation or delivery, whichever came first (n=256), or a similarly administered placebo (n=246). Main Outcome Measure Composite neonatal morbidity (including severe respiratory distress syndrome, bronchopulmonary dysplasia, severe intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis, or perinatal death). Results Composite morbidity occurred in 22.5% of the weekly-course group vs 28.0% of the single-course group (unadjusted relative risk, 0.80; 95% confidence interval, 0.59-1.10). Neither group assignment nor the number of treatment courses was associated with a reduction in composite morbidity. Conclusions Weekly courses of antenatal corticosteroids did not reduce composite neonatal morbidity compared with a single course of treatment. Weekly courses of antenatal corticosteroids should not be routinely prescribed for women at risk of preterm delivery.	Denver Hlth Med Ctr, Denver, CO 80204 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Washington, Seattle, WA 98195 USA; Boston Univ, Boston, MA 02215 USA; Columbia Univ, New York, NY USA; NYU, New York, NY USA; Mt Sinai Med Ctr, New York, NY 10029 USA; Northwestern Univ, Evanston Hosp, Evanston, IL 60201 USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ So Calif, Los Angeles, CA USA; Kapi Olani Med Ctr Women & Children, Honolulu, HI USA; Loyola Univ, Maywood, IL 60153 USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; Boston University; Columbia University; New York University; Icahn School of Medicine at Mount Sinai; NorthShore University Health System; Northwestern University; Northwestern University; University of Michigan System; University of Michigan; University of Southern California; Loyola University Chicago	Guinn, DA (corresponding author), Denver Hlth Med Ctr, 777 Bannock St,MC 0660, Denver, CO 80204 USA.	dguinn@dhha.org		Guinn, Debra/0000-0003-0489-098X	NCRR NIH HHS [M01 RR00069] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BELL M, 1978, ANN SURG, V1, P325; BOHN MC, 1982, J NEUROSCI, V2, P1292; Brocklehurst P, 1999, BRIT J OBSTET GYNAEC, V106, P977, DOI 10.1111/j.1471-0528.1999.tb08440.x; CARLOS RQ, 1992, TERATOLOGY, V46, P45, DOI 10.1002/tera.1420460108; Chess PR, 1997, PEDIATR RADIOL, V27, P305, DOI 10.1007/s002470050134; Cooker LA, 1999, ADV PERIT D, V15, P17; DEFRANCE B, 2001, EVID BASED OBSTET GY, V3, P109; Doyle LW, 2000, J PAEDIATR CHILD H, V36, P7, DOI 10.1046/j.1440-1754.2000.00452.x; Dunlop S A, 1997, J Matern Fetal Med, V6, P309; Esplin M. S., 2000, American Journal of Obstetrics and Gynecology, V182, pS24; French NP, 1999, AM J OBSTET GYNECOL, V180, P114, DOI 10.1016/S0002-9378(99)70160-2; FRENCH NP, 1998, PEDIATR RES, V43, P214; GILSTRAP LC, 1995, JAMA-J AM MED ASSOC, V273, P413, DOI 10.1001/jama.1995.03520290065031; HACK M, 1991, NEW ENGL J MED, V325, P231, DOI 10.1056/NEJM199107253250403; Hagan R, 1997, PEDIATR RES, V41, P405; HOWARD E, 1968, EXP NEUROL, V22, P661, DOI 10.1016/0014-4886(68)90155-6; MACARTHUR BA, 1982, PEDIATRICS, V70, P99; MARTIN R, 1992, NEONATAL PERINATAL M, V2, P811; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PLANER P, 1996, AM J OBSTET GYNECOL, V174, pA467; ROTH SC, 1993, DEV MED CHILD NEUROL, V35, P755; Skinner AM, 1997, AM J PERINAT, V14, P539, DOI 10.1055/s-2007-994330; SMOLDERSDEHAAS H, 1990, PEDIATRICS, V86, P65; STEWART J, 1997, AM J OBSTET GYNECOL, V176, P676; UNO H, 1994, HORM BEHAV, V28, P336, DOI 10.1006/hbeh.1994.1030; Vohr B, 1999, SEMIN PERINATOL, V23, P212, DOI 10.1016/S0146-0005(99)80065-2; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417; Yoon BH, 2000, AM J OBSTET GYNECOL, V182, P675, DOI 10.1067/mob.2000.104207	28	192	206	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1581	1587		10.1001/jama.286.13.1581	http://dx.doi.org/10.1001/jama.286.13.1581			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585480				2022-12-28	WOS:000171340600024
J	Adinolfi, M; Sherlock, J				Adinolfi, M; Sherlock, J			Prenatal detection of chromosome disorders by QF-PCR	LANCET			English	Editorial Material							POLYMERASE-CHAIN-REACTION; RAPID DETECTION; DOWNS-SYNDROME; ANEUPLOIDIES; DIAGNOSIS		UCL, Galton Lab, London NW1 2HE, England; UCL, Dept Obstet & Gynaecol, London NW1 2HE, England	University of London; University College London; University of London; University College London	Adinolfi, M (corresponding author), UCL, Galton Lab, London NW1 2HE, England.	matteo@galton.ucl.ac.uk		Sherlock, Jon/0000-0001-5475-2361				Adinolfi M, 1997, PRENATAL DIAG, V17, P1299; ADINOLFI M, 2000, COMMUNITY GENET, V3, P50; Cirigliano V, 1999, PRENATAL DIAG, V19, P1099, DOI 10.1002/(SICI)1097-0223(199912)19:12<1099::AID-PD709>3.0.CO;2-2; CIRIGLIANO V, IN PRESS ANN HUM GEN; Levett LJ, 2001, ULTRASOUND OBST GYN, V17, P115, DOI 10.1046/j.1469-0705.2001.00340.x; MANSFIELD ES, 1993, HUM MOL GENET, V2, P43, DOI 10.1093/hmg/2.1.43; Pertl B, 1997, AM J OBSTET GYNECOL, V177, P899, DOI 10.1016/S0002-9378(97)70292-8; PERTL B, 1994, LANCET, V343, P1197, DOI 10.1016/S0140-6736(94)92404-X; Schmidt W, 2000, MOL HUM REPROD, V6, P855, DOI 10.1093/molehr/6.9.855; Sherlock J, 1998, ANN HUM GENET, V62, P9; SUTHERLAND GR, 1994, NEW ENGL J MED, V331, P191, DOI 10.1056/NEJM199407213310310; Verma L, 1998, LANCET, V352, P9, DOI 10.1016/S0140-6736(97)11090-X	12	25	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	2001	358	9287					1030	1031		10.1016/S0140-6736(01)06229-8	http://dx.doi.org/10.1016/S0140-6736(01)06229-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589930				2022-12-28	WOS:000171393100005
J	Jellinek, EH				Jellinek, EH			Thomas Bowdler: censor, philanthropist, and doctor	LANCET			English	Review								A recent biography of the physician William Osler credits him with having generated a verb, to "oslerize", as a synonym for euthanasia. Actually, Osler had been mocking his own impending senescent uselessness at the time of his move from Baltimore to Oxford. That neologism did not last. Two earlier doctors who did make it to the dictionaries in a verbally eponymous way were F A Mesmer and Thomas Bowdler, and Bowdler, at least, would not have liked the recognition. The first use of the verb to "bowdlerise" seems to have been in 1836, with a reference to "names in the writings of the apostles which modern ultrachristians would probably have Bowdler-ized". However, Bowdler is better remembered for his cleaning up of the plays of Shakespeare.			Jellinek, EH (corresponding author), 14 Moray Pl, Edinburgh EH3 6DT, Midlothian, Scotland.							BLAIR JSG, 1987, HIST MED ST ANDREWS; BOWDLER T, 1788, LETT WRITTEN HOLLAND; BOWDLER T, 1815, SHORT LIFE CHARACTER; BOWDLER T, 1825, ANN BIOGRAPHY OBITUA, V10, P191; BOWDLER T, 1824, FAMILY SHAKSPEARE; BOWDLER T, 1823, SELECTED CHAPTERS OL; BOWDLER T, 1836, GIBBONS HIST DECLINE; Jackson MacD. P., 1986, CAMBRIDGE COMPANION, P163; KITCHIN L, 1959, 3 TRIAL EXPT BIOGRAP; SHAKESPEARE W, 1921, COMPLETE WORKS CAMBR; Swinburne Algernon Charles, 1894, STUDIES PROSE POETRY; 1822, BRIT CRITIC, V17, P372; 1821, EDINB REV        OCT, P52	13	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 29	2001	358	9287					1091	1094		10.1016/S0140-6736(01)06187-6	http://dx.doi.org/10.1016/S0140-6736(01)06187-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11594316				2022-12-28	WOS:000171393100031
J	Julsgaard, B; Kozhekin, A; Polzik, ES				Julsgaard, B; Kozhekin, A; Polzik, ES			Experimental long-lived entanglement of two macroscopic objects	NATURE			English	Article							CONTINUOUS VARIABLE SYSTEMS; QUANTUM TELEPORTATION; REALIZATION; CRITERION; STATE; LIGHT	Entanglement is considered to be one of the most profound features of quantum mechanics(1,2). An entangled state of a system consisting of two subsystems cannot be described as a product of the quantum states of the two subsystems(3-6). In this sense, the entangled system is considered inseparable and nonlocal. It is generally believed that entanglement is usually manifest in systems consisting of a small number of microscopic particles. Here we demonstrate experimentally the entanglement of two macroscopic objects, each consisting of a caesium gas sample containing about 10(12) atoms. Entanglement is generated via interaction of the samples with a pulse of light, which performs a non-local Bell measurement on the collective spins of the samples(7). The entangled spin-state can be maintained for 0.5 milliseconds. Besides being of fundamental interest, we expect the robust and long-lived entanglement of material objects demonstrated here to be useful in quantum information processing, including teleportation(8-10) of quantum states of matter and quantum memory.	Aarhus Univ, Inst Phys & Astron, DK-8000 Aarhus, Denmark	Aarhus University	Polzik, ES (corresponding author), Aarhus Univ, Inst Phys & Astron, DK-8000 Aarhus, Denmark.		Polzik, Eugene/M-4724-2014	Polzik, Eugene/0000-0001-9859-6591				ASPECT A, 1982, PHYS REV LETT, V49, P1804, DOI 10.1103/PhysRevLett.49.1804; Ban M, 1999, J OPT B-QUANTUM S O, V1, pL9, DOI 10.1088/1464-4266/1/6/101; Bell J. S., 1988, SPEAKABLE UNSPEAKABL; Boschi D, 1998, PHYS REV LETT, V80, P1121, DOI 10.1103/PhysRevLett.80.1121; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Braunstein SL, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.042302; Duan LM, 2000, PHYS REV LETT, V84, P2722, DOI 10.1103/PhysRevLett.84.2722; Duan LM, 2000, PHYS REV LETT, V85, P5643, DOI 10.1103/PhysRevLett.85.5643; Einstein A, 1935, PHYS REV, V47, P0777, DOI 10.1103/PhysRev.47.777; Furusawa A, 1998, SCIENCE, V282, P706, DOI 10.1126/science.282.5389.706; Hald J, 1999, PHYS REV LETT, V83, P1319, DOI 10.1103/PhysRevLett.83.1319; KITAGAWA M, 1993, PHYS REV A, V47, P5138, DOI 10.1103/PhysRevA.47.5138; KUPRIYANOV DV, 1992, QUANTUM OPT, V4, P55, DOI 10.1088/0954-8998/4/1/006; Kuzmich A, 2000, PHYS REV LETT, V85, P1594, DOI 10.1103/PhysRevLett.85.1594; Kuzmich A, 2000, PHYS REV LETT, V85, P5639, DOI 10.1103/PhysRevLett.85.5639; Mattle K, 1996, PHYS REV LETT, V76, P4656, DOI 10.1103/PhysRevLett.76.4656; OU ZY, 1992, PHYS REV LETT, V68, P3663, DOI 10.1103/PhysRevLett.68.3663; Rauschenbeutel A, 2000, SCIENCE, V288, P2024, DOI 10.1126/science.288.5473.2024; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Simon R, 2000, PHYS REV LETT, V84, P2726, DOI 10.1103/PhysRevLett.84.2726; TOGERSON JR, 1995, PHYS LETT A, V204, P323	22	915	936	4	66	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					400	403		10.1038/35096524	http://dx.doi.org/10.1038/35096524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574882	Green Submitted			2022-12-28	WOS:000171188700048
J	Thompson, PM; Ollason, JC				Thompson, PM; Ollason, JC			Lagged effects of ocean climate change on fulmar population dynamics	NATURE			English	Article							NORTH-ATLANTIC; CONSEQUENCES; VARIABILITY; GLACIALIS; FISHERIES; SURVIVAL; ORKNEY; TRENDS	Environmental variation reflected by the North Atlantic Oscillation affects breeding and survival in terrestrial vertebrates(1,2), and climate change is predicted to have an impact on population dynamics by influencing food quality or availability(3). The North Atlantic Oscillation also affects the abundance of marine fish and zooplankton(4,5), but it is unclear whether this filters up trophic levels to long-lived marine top predators. Here we show by analysis of data from a 50-year study of the fulmar that two different indices of ocean climate variation may have lagged effects on population dynamics in this procellariiform seabird.	Univ Aberdeen, Dept Zool, Lighthouse Field Stn, Cromarty IV11 8YJ, Ross Shire, Scotland; Univ Aberdeen, Dept Zool, Culterty Field Stn, Ellon AB41 6AA, Aberdeen, Scotland	University of Aberdeen; University of Aberdeen	Thompson, PM (corresponding author), Univ Aberdeen, Dept Zool, Lighthouse Field Stn, Cromarty IV11 8YJ, Ross Shire, Scotland.		Thompson, Paul Michael/AGR-6267-2022; Thompson, Paul M/B-6742-2009	Thompson, Paul Michael/0000-0001-6195-3284; Thompson, Paul M/0000-0001-6195-3284				Bradley JS, 2000, J ANIM ECOL, V69, P639, DOI 10.1046/j.1365-2656.2000.00422.x; Briffa KR, 1998, NATURE, V393, P450, DOI 10.1038/30943; BROWN RGB, 1970, IBIS, V112, P44, DOI 10.1111/j.1474-919X.1970.tb00074.x; COOPER CF, 1983, SCIENCE, V219, P969, DOI 10.1126/science.219.4587.969; DUNNET GM, 1991, IBIS, V133, P24, DOI 10.1111/j.1474-919X.1991.tb07665.x; DUNNET GM, 1979, IBIS, V121, P293, DOI 10.1111/j.1474-919X.1979.tb06846.x; DUNNET GM, 1961, BIRD STUDY, V8, P119; FISHER J, 1952, FULMAR; Furness RW, 1996, ECOLOGY, V77, P1181, DOI 10.2307/2265587; Gaillard JM, 1998, TRENDS ECOL EVOL, V13, P58, DOI 10.1016/S0169-5347(97)01237-8; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Kitaysky AS, 2000, J ANIM ECOL, V69, P248, DOI 10.1046/j.1365-2656.2000.00392.x; Lloyd C, 1991, STATUS SEABIRDS BRIT; Milner JM, 1999, J ANIM ECOL, V68, P1235, DOI 10.1046/j.1365-2656.1999.00366.x; Mougin JL, 1997, IBIS, V139, P40, DOI 10.1111/j.1474-919X.1997.tb04502.x; O'Brien CM, 2000, NATURE, V404, P142, DOI 10.1038/35004654; Ollason J.C., 1988, P263; OLLASON JC, 1980, J FIELD ORNITHOL, V51, P39; Phillips RA, 1999, MAR BIOL, V135, P159, DOI 10.1007/s002270050613; Planque B, 1998, ICES J MAR SCI, V55, P644, DOI 10.1006/jmsc.1998.0390; Pomeroy PP, 2000, J ZOOL, V250, P1; Post E, 1999, NATURE, V401, P905, DOI 10.1038/44814; Post E, 1999, ECOLOGY, V80, P1322, DOI 10.1890/0012-9658(1999)080[1322:CVPPAN]2.0.CO;2; Saether BE, 2000, SCIENCE, V287, P854, DOI 10.1126/science.287.5454.854; SALOMONS.F, 1965, AUK, V82, P327, DOI 10.2307/4083117; Wilby RL, 1997, WEATHER, V52, P266, DOI [10.1002/j.1477-8696.1997.tb06323.x, DOI 10.1002/J.1477-8696.1997.TB06323.X]; Wynne-Edwards V. C., 1962, pUnpaginated	27	188	191	0	83	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					417	420		10.1038/35096558	http://dx.doi.org/10.1038/35096558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574887				2022-12-28	WOS:000171188700053
J	Vulliamy, T; Marrone, A; Goldman, F; Dearlove, A; Bessler, M; Mason, PJ; Dokal, I				Vulliamy, T; Marrone, A; Goldman, F; Dearlove, A; Bessler, M; Mason, PJ; Dokal, I			The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita	NATURE			English	Article							MICE; CELLS	Dyskeratosis congenita is a progressive bone-marrow failure syndrome that is characterized by abnormal skin pigmentation, leukoplakia and nail dystrophy(1,2). X-linked, autosomal recessive and autosomal dominant inheritance have been found in different pedigrees. The X-linked form of the disease is due to mutations in the gene DKC1 in band 2, sub-band 8 of the long arm of the X chromosome (ref. 3). The affected protein, dyskerin, is a nucleolar protein that is found associated with the H/ACA class of small nucleolar RNAs and is involved in pseudo-uridylation of specific residues of ribosomal RNA(4). Dyskerin is also associated with telomerase RNA (hTR)(5), which contains a H/ACA consensus sequence(6,7). Here we map the gene responsible for dyskeratosis congenita in a large pedigree with autosomal dominant inheritance. Affected members of this family have an 821-base-pair deletion on chromosome 3q that removes the 3' 74 bases of hTR. Mutations in hTR were found in two other families with autosomal dominant dyskeratosis congenita.	Hammersmith Hosp, Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Haematol,Div Invest Sci, London W12 0NN, England; Univ Iowa Hosp & Clin, Dept Pediat, Iowa City, IA 52242 USA; MRC UK, HGMP Resource Ctr, Cambridge CB10 1SB, England; Washington Univ, Sch Med, Div Hematol, St Louis, MO 63110 USA	Imperial College London; University of Iowa; Washington University (WUSTL)	Mason, PJ (corresponding author), Hammersmith Hosp, Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Haematol,Div Invest Sci, Ducane Rd, London W12 0NN, England.		Mason, Philip J/B-1087-2008	Dokal, Inderjeet/0000-0003-4462-4782				Alter BP, 2000, J PEDIATR-US, V136, P275, DOI 10.1067/mpd.2000.104285; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bachand F, 2001, MOL CELL BIOL, V21, P1888, DOI 10.1128/MCB.21.5.1888-1897.2001; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Dokal I, 2000, BRIT J HAEMATOL, V110, P768, DOI 10.1046/j.1365-2141.2000.02109.x; DRACHTMAN RA, 1992, AM J PEDIAT HEMATOL, V14, P297; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Marciniak RA, 2000, TRENDS GENET, V16, P193, DOI 10.1016/S0168-9525(00)01984-3; Martin-Rivera L, 2001, J BIOL CHEM, V276, P5856, DOI 10.1074/jbc.M008419200; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Prescott JC, 1999, CURR OPIN GENET DEV, V9, P368, DOI 10.1016/S0959-437X(99)80055-0; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Sambrook J., 2002, MOL CLONING LAB MANU; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Vulliamy TJ, 2001, BLOOD CELL MOL DIS, V27, P353, DOI 10.1006/bcmd.2001.0389; Vulliamy TJ, 1997, BLOOD, V90, P2213	29	707	736	1	31	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					432	435		10.1038/35096585	http://dx.doi.org/10.1038/35096585			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574891				2022-12-28	WOS:000171188700057
J	Hopayian, K				Hopayian, K			The need for caution in interpreting high quality systematic reviews	BRITISH MEDICAL JOURNAL			English	Article							EPIDURAL STEROID INJECTIONS; LOW-BACK-PAIN; MEDICAL LITERATURE; USERS GUIDES; METAANALYSIS; SCIATICA; MORPHINE; ARTICLE; CONCLUSIONS; ACUPUNCTURE		Seahills, Aldeburgh IP15 5PL, England		Hopayian, K (corresponding author), Seahills, Leiston Rd, Aldeburgh IP15 5PL, England.		Hopayian, Kevork/L-1359-2019					Beliveau P, 1971, Rheumatol Phys Med, V11, P40, DOI 10.1093/rheumatology/11.1.40; BENZON H, 1986, PAIN, V224, P277; Carette S, 1997, NEW ENGL J MED, V336, P1634, DOI 10.1056/NEJM199706053362303; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CUCKLER JM, 1985, J BONE JOINT SURG AM, V67A, P63, DOI 10.2106/00004623-198567010-00009; DALLAS TL, 1987, ANESTHESIOLOGY, V67, P408, DOI 10.1097/00000542-198709000-00021; Furlan A D, 2001, Spine (Phila Pa 1976), V26, pE155, DOI 10.1097/00007632-200104010-00018; GLYNN C, 1988, PAIN, V34, P123, DOI 10.1016/0304-3959(88)90157-1; Gotzsche PC, 2000, BRIT MED J, V321, P585, DOI 10.1136/bmj.321.7261.585; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Hopayian K, 1999, BRIT J GEN PRACT, V49, P57; Jadad AR, 1997, CAN MED ASSOC J, V156, P1411; Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; KEPES ER, 1985, PAIN, V22, P33, DOI 10.1016/0304-3959(85)90146-0; Koes BW, 1995, PAIN, V63, P279, DOI 10.1016/0304-3959(95)00124-7; Lindbaek M, 1999, BRIT MED J, V318, P873, DOI 10.1136/bmj.318.7187.873b; MESSERLI F, 1985, LANCET, P767; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; NELEMANS P, 2001, COCHRANE DATABASE SY; *NHS CTR REV DISS, 2001, UND SYST REV RES EFF; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; Petticrew M, 1997, BRIT MED J, V315, P665, DOI 10.1136/bmj.315.7109.665; Prins JM, 1996, LANCET, V348, P199, DOI 10.1016/S0140-6736(05)66148-X; Richardson W S, 1995, ACP J Club, V123, pA12; ROCCO AG, 1989, PAIN, V36, P297, DOI 10.1016/0304-3959(89)90088-2; RUTA D, 1994, PAIN, V19, P1187; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; SNOEK W, 1977, ACTA ORTHOP SCAND, V48, P635, DOI 10.3109/17453677708994810; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; WATTS RW, 1995, ANAESTH INTENS CARE, V23, P564, DOI 10.1177/0310057X9502300506	32	43	43	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					681	684		10.1136/bmj.323.7314.681	http://dx.doi.org/10.1136/bmj.323.7314.681			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	476LP	11566835	Green Published			2022-12-28	WOS:000171228800025
J	MacKenzie, K; Millar, A; Wilson, JA; Sellars, C; Deary, IJ				MacKenzie, K; Millar, A; Wilson, JA; Sellars, C; Deary, IJ			Is voice therapy an effective treatment for dysphonia? A randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							FUNCTIONAL DYSPHONIA; PERSONALITY; DISORDER; STILL		Glasgow Royal Infirm, Dept Otorhinolaryngol Head & Neck Surg, Glasgow G31 2ER, Lanark, Scotland; Glasgow Royal Infirm, Dept Speech & Language Therapy, Glasgow G31 2ER, Lanark, Scotland; Univ Newcastle Upon Tyne, Dept Otorhinolaryngol Head & Neck Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Univ Edinburgh, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland	University of Glasgow; University of Glasgow; Newcastle University - UK; University of Edinburgh	MacKenzie, K (corresponding author), Glasgow Royal Infirm, Dept Otorhinolaryngol Head & Neck Surg, Glasgow G31 2ER, Lanark, Scotland.		Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X; wilson, janet/0000-0002-6416-5870				ARONSON A, 1996, J SPEECH HEAR DISORD, V31, P115; CARDING PN, 1992, EUR J DISORDER COMM, V27, P137; Deary IJ, 1997, BRIT J HEALTH PSYCH, V2, P333, DOI 10.1111/j.2044-8287.1997.tb00547.x; Dunnet CP, 1997, EUR J DISORDER COMM, V32, P333; ELIAS A, 1989, BRIT J DISORD COMMUN, V24, P61; Fairbanks G, 1960, VOICE ARTICULATION D; GERRITSMA EJ, 1991, FOLIA PHONIATR, V43, P13, DOI 10.1159/000266096; HOUSE A, 1987, J PSYCHOSOM RES, V31, P483, DOI 10.1016/0022-3999(87)90006-7; HOUSE AO, 1988, J PSYCHOSOM RES, V32, P311, DOI 10.1016/0022-3999(88)90073-6; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; MATAS M, 1991, CAN J PSYCHIAT, V36, P363, DOI 10.1177/070674379103600509; Scott S, 1997, CLIN OTOLARYNGOL, V22, P37, DOI 10.1046/j.1365-2273.1997.00855.x; Scott S, 1997, PSYCHOL HEALTH MED, V2, P169; White A, 1997, EUR J DISORDER COMM, V32, P307; Wilson DK., 1987, VOICE PROBLEMS CHILD; WILSON JA, 1995, BRIT MED J, V311, P1039, DOI 10.1136/bmj.311.7012.1039; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	18	89	93	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					658	661		10.1136/bmj.323.7314.658	http://dx.doi.org/10.1136/bmj.323.7314.658			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	476LP	11566828	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000171228800015
J	Peterson, EJ; Woods, ML; Dmowski, SA; Derimanov, G; Jordan, MS; Wu, JN; Myung, PS; Liu, QH; Pribila, JT; Freedman, BD; Shimizu, Y; Koretzky, GA				Peterson, EJ; Woods, ML; Dmowski, SA; Derimanov, G; Jordan, MS; Wu, JN; Myung, PS; Liu, QH; Pribila, JT; Freedman, BD; Shimizu, Y; Koretzky, GA			Coupling of the TCR to integrin activation by SLAP-130/Fyb	SCIENCE			English	Article							T-CELL RECEPTOR; ADAPTER PROTEIN SLP-76; LYMPHOCYTE MIGRATION; TYROSINE KINASES; ADHESION; MICE; LFA-1; SUBSTRATE; CLONING; ZAP-70	SLAP-130/Fyb (SLP-76-associated phosphoprotein or Fyn-binding protein; also known as Fyb/Slap) is a hematopoietic-specific adapter, which associates with and modulates function of SH2-containing leukocyte phosphoprotein of 76 kilodaltons (SLP-76). T cells from mice lacking SLAP-130/Fyb show markedly impaired proliferation following CD3 engagement. In addition, the T cell receptor (TCR) in SLAP-130/Fyb mutant cells fails to enhance integrin-dependent adhesion. Although TCR-induced actin polymerization is normal, TCR-stimulated clustering of the integrin LFA-1 is defective in SLAP-130/Fyb-deficient cells. These data indicate that SLAP-130/Fyb is important for coupling TCR-mediated actin cytoskeletal rearrangement with activation of integrin function, and for T cells to respond fully to activating signals.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Minnesota, Sch Med, Ctr Canc, Ctr Immunol,Dept Pathol & Lab Med, Minneapolis, MN 55455 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Minnesota System; University of Minnesota Twin Cities	Koretzky, GA (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	koretzky@mail.med.upenn.edu	Koretzky, Gary/AAU-5381-2021; Peterson, Erik/M-9365-2013	Shimizu, Yoji/0000-0001-9760-0288	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060921] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI060921] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Epler JA, 2000, J IMMUNOL, V165, P4941, DOI 10.4049/jimmunol.165.9.4941; Freedman BD, 1999, J EXP MED, V190, P943, DOI 10.1084/jem.190.7.943; GENG L, IN PRESS NATL ACAD S; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hunter AJ, 2000, J IMMUNOL, V164, P1143, DOI 10.4049/jimmunol.164.3.1143; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; PETERSON ET, UNPUB; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Reichert P, 2001, J IMMUNOL, V166, P4278, DOI 10.4049/jimmunol.166.7.4278; Samelson LE, 1999, PROG BIOPHYS MOL BIO, V71, P393, DOI 10.1016/S0079-6107(98)00050-9; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; Schmits R, 1996, J EXP MED, V183, P1415, DOI 10.1084/jem.183.4.1415; Stewart MP, 1996, J IMMUNOL, V156, P1810; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; VAN SG, 1990, J IMMUNOL, V144, P4579; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zell T, 1999, IMMUNOL RES, V20, P127; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	28	259	273	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2263	2265		10.1126/science.1063486	http://dx.doi.org/10.1126/science.1063486			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567141				2022-12-28	WOS:000171139400046
J	Saha, S; Bardelli, A; Buckhaults, P; Velculescu, VE; Rago, C; St Croix, B; Romans, KE; Choti, MA; Lengauer, C; Kinzler, KW; Vogelstein, B				Saha, S; Bardelli, A; Buckhaults, P; Velculescu, VE; Rago, C; St Croix, B; Romans, KE; Choti, MA; Lengauer, C; Kinzler, KW; Vogelstein, B			A phosphatase associated with metastasis of colorectal cancer	SCIENCE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; PROTEIN-TYROSINE PHOSPHATASES; TUMOR-SUPPRESSOR GENES; PROSTATE-CANCER; AMPLIFICATION; TRANSCRIPTOMES; PRENYLATION; EXPRESSION; BREAST	To gain insights into the molecular basis for metastasis, we compared the global gene expression profile of metastatic colorectal cancer with that of primary cancers, benign colorectal tumors, and normal colorectal epithelium. Among the genes identified, the PRL-3 protein tyrosine phosphatase gene was of particular interest. It was expressed at high levels in each of 18 cancer metastases studied but at lower levels in nonmetastatic tumors and normal colorectal epithelium. In 3 of 12 metastases examined, multiple copies of the PRL-3 gene were found within a small amplicon located at chromosome 8q24.3. These data suggest that the PRL-3 gene is important for colorectal cancer metastasis and provide a new therapeutic target for these intractable lesions.	Johns Hopkins Med Inst, Howard Hughes Med Inst, Ctr Oncol, Dept Surg, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Program Cellular & Mol Med, Baltimore, MD 21231 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Kinzler, KW (corresponding author), Johns Hopkins Med Inst, Howard Hughes Med Inst, Ctr Oncol, Dept Surg, Baltimore, MD 21231 USA.	kinzlke@jhmi.edu; vogelbe@welch.jhu.edu	Velculescu, Victor/ABF-4846-2020; BARDELLI, Alberto/J-9721-2018	Velculescu, Victor/0000-0003-1195-438X; BARDELLI, Alberto/0000-0003-1647-5070	NATIONAL CANCER INSTITUTE [R37CA043460, R01CA057345, P50CA062924, R01CA043460, R37CA057345] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345, CA43460, CA 62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alers JC, 1997, LAB INVEST, V77, P437; BRODEUR GM, 1998, GENETIC BASIS HUMAN, V1, P161; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; El Gedaily A, 2001, PROSTATE, V46, P184; Fidler I J, 2001, Surg Oncol Clin N Am, V10, P257; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Heiskanen MA, 2000, CANCER RES, V60, P799; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Paredes-Zaglul A, 1998, CLIN CANCER RES, V4, P879; Pegram M D, 2000, Cancer Treat Res, V103, P57; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weiss L, 2000, CANCER METAST REV, V19, P193, DOI 10.1023/A:1010646304844; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	24	548	618	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 9	2001	294	5545					1343	1346		10.1126/science.1065817	http://dx.doi.org/10.1126/science.1065817			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11598267				2022-12-28	WOS:000172130200050
J	Agrawal, AA				Agrawal, AA			Ecology - Phenotypic plasticity in the interactions and evolution of species	SCIENCE			English	Review							TETRACYCLINE-RESISTANCE OPERON; ADAPTIVE PLASTICITY; INDUCIBLE DEFENSES; PREDATOR; BEHAVIOR; PLANTS; SELECTION; MUTUALISM; SIZE; AVAILABILITY	When individuals of two species interact, they can adjust their phenotypes in response to their respective partner, be they antagonists or mutualists. The reciprocal phenotypic change between individuals of interacting species can reflect an evolutionary response to spatial and temporal variation in species interactions and ecologically result in the structuring of food chains. The evolution of adaptive phenotypic plasticity has led to the success of organisms in novel habitats, and potentially contributes to genetic differentiation and speciation. Taken together, phenotypic responses in species interactions represent modifications that can lead to reciprocal change in ecological time, altered community patterns, and expanded evolutionary potential of species.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada	University of Toronto	Agrawal, AA (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.	agrawal@botany.utoronto.ca	Langerhans, R. Brian/A-7205-2009; Agrawal, Anurag A/Y-2497-2019; Vazquez-Dominguez, Guillermo GVD/L-7818-2014	Agrawal, Anurag A/0000-0003-0095-1220; 				ADLER FR, 1994, AM NAT, V144, P813, DOI 10.1086/285708; Agrawal AA, 1999, NATURE, V401, P60, DOI 10.1038/43425; Agrawal AA, 2000, ENTOMOL EXP APPL, V96, P39, DOI 10.1023/A:1004073411100; Agrawal AA, 1999, ECOLOGY, V80, P518, DOI 10.1890/0012-9658(1999)080[0518:IOPAAI]2.0.CO;2; Agrawal AA, 1998, OIKOS, V83, P227, DOI 10.2307/3546834; Agrawal AA, 1998, SCIENCE, V279, P1201, DOI 10.1126/science.279.5354.1201; Axen AH, 1998, BEHAV ECOL, V9, P109, DOI 10.1093/beheco/9.2.109; Barth M, 1997, ANIM BEHAV, V53, P25, DOI 10.1006/anbe.1996.0275; Beckerman AP, 1997, P NATL ACAD SCI USA, V94, P10735, DOI 10.1073/pnas.94.20.10735; BOLTER CJ, 1995, J INSECT PHYSIOL, V41, P1071, DOI 10.1016/0022-1910(95)00073-4; BROADWAY RM, 1995, J INSECT PHYSIOL, V41, P107, DOI 10.1016/0022-1910(94)00101-L; CHORNESKY EA, 1983, BIOL BULL, V165, P569, DOI 10.2307/1541466; De Moraes CM, 1998, NATURE, V393, P570, DOI 10.1038/31219; Denison RF, 2000, AM NAT, V156, P567, DOI 10.1086/316994; DENNO RF, 1992, ECOLOGY, V73, P1323, DOI 10.2307/1940679; DeWitt TJ, 1998, TRENDS ECOL EVOL, V13, P77, DOI 10.1016/S0169-5347(97)01274-3; Doebeli M, 1998, P NATL ACAD SCI USA, V95, P8676, DOI 10.1073/pnas.95.15.8676; Donohue K, 1998, MATERNAL EFFECTS AS ADAPTATIONS, P137; Drukker B, 2000, PHYSIOL ENTOMOL, V25, P260, DOI 10.1046/j.1365-3032.2000.00190.x; Dudley SA, 1996, AM NAT, V147, P445, DOI 10.1086/285860; Dukas R, 2000, P NATL ACAD SCI USA, V97, P2637, DOI 10.1073/pnas.050461497; FEDER JL, 1994, P NATL ACAD SCI USA, V91, P7990, DOI 10.1073/pnas.91.17.7990; Felton GW, 1999, CURR BIOL, V9, P317, DOI 10.1016/S0960-9822(99)80140-7; Fox CW, 1997, AM NAT, V149, P149, DOI 10.1086/285983; Fox CW, 2000, ECOLOGY, V81, P3, DOI 10.2307/177128; Gage DJ, 2000, CURR OPIN MICROBIOL, V3, P613, DOI 10.1016/S1369-5274(00)00149-1; Giraud A, 2001, SCIENCE, V291, P2606, DOI 10.1126/science.1056421; Grandbastien MA, 1998, TRENDS PLANT SCI, V3, P181, DOI 10.1016/S1360-1385(98)01232-1; GREEN J, 1967, J ZOOL, V151, P181; GREENE E, 1989, SCIENCE, V243, P643, DOI 10.1126/science.243.4891.643; HARVELL CD, 1990, P NATL ACAD SCI USA, V87, P508, DOI 10.1073/pnas.87.2.508; Harvey JA, 2000, NATURE, V406, P183, DOI 10.1038/35018074; HAUKIOJA E, 1991, ANNU REV ENTOMOL, V36, P25, DOI 10.1146/annurev.en.36.010191.000325; HAUKIOJA E, 1975, REP KEVO SUBARCTIC R, V12, P1; Hazel WN, 1996, BIOL J LINN SOC, V57, P81, DOI 10.1006/bijl.1995.9993; Irwin RE, 1998, OECOLOGIA, V116, P519, DOI 10.1007/s004420050617; Karban R, 1997, ECOLOGY, V78, P603, DOI 10.1890/0012-9658(1997)078[0603:TPAHPC]2.0.CO;2; Karban R., 1997, INDUCED RESPONSES HE, DOI 10.7208/chicago/9780226424972.001.0001; Kessler A, 2001, SCIENCE, V291, P2141, DOI 10.1126/science.291.5511.2141; Kidwell MG, 2001, EVOLUTION, V55, P1, DOI 10.1111/j.0014-3820.2001.tb01268.x; KOUKI J, 1993, FUNCT ECOL, V7, P21, DOI 10.2307/2389863; Ladio AH, 1999, OECOLOGIA, V120, P235, DOI 10.1007/s004420050853; Lamarck Jean-Baptiste, 1984, ZOOLOGICAL PHILOS EX; LEIMAR O, 1993, ANIM BEHAV, V46, P1177, DOI 10.1006/anbe.1993.1307; Leimar O, 1997, P ROY SOC B-BIOL SCI, V264, P1209, DOI 10.1098/rspb.1997.0167; LENSKI RE, 1994, MOL ECOL, V3, P127, DOI 10.1111/j.1365-294X.1994.tb00113.x; Leonard GH, 1999, ECOLOGY, V80, P1; LIVELY CM, 1986, EVOLUTION, V40, P232, DOI 10.1111/j.1558-5646.1986.tb00466.x; Losey JE, 1998, ECOLOGY, V79, P2143, DOI 10.2307/176717; Losos JB, 2000, EVOLUTION, V54, P301, DOI 10.1111/j.0014-3820.2000.tb00032.x; Losos JB, 1997, NATURE, V387, P70, DOI 10.1038/387070a0; Mittelbach GC, 1999, EVOL ECOL RES, V1, P111; MOORE J, 1995, BIOSCIENCE, V45, P89, DOI 10.2307/1312610; Mousseau T.A., 1998, MATERNAL EFFECTS ADA; NGUYEN TNM, 1989, MOL BIOL EVOL, V6, P213; PELLMYR O, 1994, NATURE, V372, P257, DOI 10.1038/372257a0; Pfennig DW, 2000, EVOLUTION, V54, P1738; PROKOPY RJ, 1982, SCIENCE, V218, P76, DOI 10.1126/science.218.4567.76; Radman M, 1999, NATURE, V401, P866, DOI 10.1038/44738; Raimondi PT, 2000, OIKOS, V91, P353, DOI 10.1034/j.1600-0706.2000.910215.x; Reimer O, 1996, OIKOS, V75, P383, DOI 10.2307/3545878; RISCH SJ, 1981, NATURE, V291, P149, DOI 10.1038/291149a0; Robinson BW, 1999, OIKOS, V85, P582, DOI 10.2307/3546709; Schmitt J, 1999, AM NAT, V154, pS43, DOI 10.1086/303282; SCRIBER JM, 1989, OECOLOGIA, V81, P186, DOI 10.1007/BF00379804; SEELEY RH, 1986, P NATL ACAD SCI USA, V83, P6897, DOI 10.1073/pnas.83.18.6897; Shine R, 1999, OECOLOGIA, V119, P1, DOI 10.1007/s004420050754; SMITH LD, 1994, SCIENCE, V264, P710, DOI 10.1126/science.264.5159.710; Snyder MJ, 1996, J COMP PHYSIOL A, V179, P255, DOI 10.1007/BF00222792; STIMSON J, 1990, MAR BIOL, V106, P211, DOI 10.1007/BF01314802; THOMPSON JN, 1988, ANNU REV ECOL SYST, V19, P65, DOI 10.1146/annurev.es.19.110188.000433; Thompson JN, 1999, HERBIVORES: BETWEEN PLANTS AND PREDATORS, P7; TOLIRIAN R, 1999, ECOLOGY EVOLUTION IN; TOLLRIAN R, COMMUNICATION; Trussell GC, 2000, P NATL ACAD SCI USA, V97, P2123, DOI 10.1073/pnas.040423397; Van Buskirk J, 2000, ECOLOGY, V81, P3009, DOI 10.1890/0012-9658(2000)081[3009:PIPPIL]2.0.CO;2; van Kleunen M, 2000, EVOLUTION, V54, P1947, DOI 10.1111/j.0014-3820.2000.tb01239.x; Vet Louise E.M., 1995, P65; Wagner D, 1997, ECOL ENTOMOL, V22, P352, DOI 10.1046/j.1365-2311.1997.00077.x; WARKENTIN KM, 1995, P NATL ACAD SCI USA, V92, P3507, DOI 10.1073/pnas.92.8.3507; WASHBURN JO, 1988, SCIENCE, V240, P1193, DOI 10.1126/science.3131877; Weisser WW, 1999, P ROY SOC B-BIOL SCI, V266, P1175, DOI 10.1098/rspb.1999.0760; WESTEBERHARD MJ, 1989, ANNU REV ECOL SYST, V20, P249, DOI 10.1146/annurev.es.20.110189.001341; Young TP, 1998, OECOLOGIA, V115, P508, DOI 10.1007/s004420050548	84	1076	1135	16	778	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 12	2001	294	5541					321	326		10.1126/science.1060701	http://dx.doi.org/10.1126/science.1060701			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598291				2022-12-28	WOS:000171601400031
J	Choudhry, S; Brennan, TA				Choudhry, S; Brennan, TA			Collective bargaining by physicians - Labor law, antitrust law, and organized medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Toronto, Fac Law, Toronto, ON M5S 1A1, Canada; Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5S 1A1, Canada; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	University of Toronto; University of Toronto; Harvard University; Harvard T.H. Chan School of Public Health	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St,Clin 3 PBB, Boston, MA 02115 USA.			Choudhry, Sujit/0000-0002-6543-6644				ALBERT T, 2001, AMA BOARD STUDY COUR; *AM COLL MED EUR F, 2001, CHART MED PROF; *BNA HLTH LAW, 2000, BNA HLTH LAW REP, V9, P171; Budrys G., 1997, DOCTORS JOIN UNIONS; *C RIV ASS, 2000, COMM AM MED ASS SPON; *C RIV ASS, 2000, NAT COSTS PHYS ANT W; DEBAKEY M, 1999, WALL STREET J   0707, P22; DEIS JJ, 1999, HOUS L REV, V36, P951; *DEP JUST FED TRAD, 1996, STAT ENF POL PHYS NE; Ginsburg J, 2001, ANN INTERN MED, V134, P787, DOI 10.7326/0003-4819-136-9-200205070-00023; GREENE J, 2001, AM MED NEWS     0521, P16; Hellinger FJ, 2001, JAMA-J AM MED ASSOC, V286, P83, DOI 10.1001/jama.286.1.83; Hsia DC, 2001, ANN INTERN MED, V134, P780, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00015; Kletke PR, 1996, JAMA-J AM MED ASSOC, V276, P555, DOI 10.1001/jama.276.7.555; Phan C, 1999, J LEGAL MED, V20, P115, DOI 10.1080/01947649909511082; ROMANO M, 2001, MOD HEALTHCARE, V31, P12; ROMANO M, 2001, MOD HEALTHCARE, V31, P14; Yacht AC, 2000, NEW ENGL J MED, V342, P429, DOI 10.1056/NEJM200002103420613	18	8	9	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2001	345	15					1141	1144		10.1056/NEJM200110113451522	http://dx.doi.org/10.1056/NEJM200110113451522			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480QH	11596605				2022-12-28	WOS:000171473100025
J	Levy-Leblond, JM				Levy-Leblond, JM			Science's fiction - Scientists deal with the facts. But they wouldn't get anywhere without dreaming up stories first.	NATURE			English	Editorial Material									Univ Nice, Dept Phys, F-06108 Nice, France; Univ Nice, Dept Philosophy, F-06108 Nice, France	UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur	Levy-Leblond, JM (corresponding author), Univ Nice, Dept Phys, Parc Valrose, F-06108 Nice, France.		Lévy-Leblond, Jean-Marc/AAK-4755-2021						0	4	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 11	2001	413	6856					573	573		10.1038/35098186	http://dx.doi.org/10.1038/35098186			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480WE	11595925	Bronze			2022-12-28	WOS:000171485700027
J	Horton, R				Horton, R			Public health: a neglected counterterrorist measure	LANCET			English	Editorial Material							AFGHANISTAN; SANCTIONS		Lancet, London WC1X 8RR, England		Horton, R (corresponding author), Lancet, London WC1X 8RR, England.							Ahmad K, 2000, LANCET, V356, P839; Ahmad K, 1999, LANCET, V354, P1536, DOI 10.1016/S0140-6736(05)76575-2; Ahmad K, 2001, LANCET, V357, P207, DOI 10.1016/S0140-6736(05)71314-3; Borovik Artyom, 1990, HIDDEN WAR; BUMILLER E, 2001, NY TIMES        0926, P1; Horton R, 1999, LANCET, V353, P2223, DOI 10.1016/S0140-6736(99)06043-2; MacQueen G, 2001, LANCET, V357, P1460, DOI 10.1016/S0140-6736(00)04668-7; Pillar P., 2001, TERRORISM US FOREIGN; Rowland M, 2001, T ROY SOC TROP MED H, V95, P125, DOI 10.1016/S0035-9203(01)90132-4; Singh M, 2000, PEDIATRICS, V105, P160, DOI 10.1542/peds.105.1.160; *UNDP, 2001, HUM DEV REP 2001; World Health Organization, 2000, WORLD HLTH REP 2000; 2001, LANCET, V358, P937	13	21	21	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1112	1113		10.1016/S0140-6736(01)06297-3	http://dx.doi.org/10.1016/S0140-6736(01)06297-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597659				2022-12-28	WOS:000171399000002
J	Singleton, MR; Scaife, S; Wigley, DB				Singleton, MR; Scaife, S; Wigley, DB			Structural analysis of DNA replication fork reversal by RecG	CELL			English	Article							SINGLE-STRANDED-DNA; CRYSTAL-STRUCTURE; HOLLIDAY JUNCTION; BRANCH MIGRATION; PCRA HELICASE; PROTEIN; RECOMBINATION; MECHANISM; RUVA; TRANSLOCATION	The stalling of DNA replication forks that occurs as a consequence of encountering DNA damage is a critical problem for cells. RecG protein is involved in the processing of stalled replication forks, and acts by reversing the fork past the damage to create a four-way junction that allows template switching and lesion bypass. We have determined the crystal structure of RecG bound to a DNA substrate that mimics a stalled replication fork. The structure not only reveals the elegant mechanism used by the protein to recognize junctions but has also trapped the protein in the initial stage of fork reversal. We propose a mechanism for how forks are processed by RecG to facilitate replication fork restart. In addition, this structure suggests that the mechanism and function of the two largest helicase superfamilies are distinct.	Imperial Canc Res Fund, Clare Hall Labs, Potters Bar EN6 3LD, Herts, England		Wigley, DB (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Blanche Lane, Potters Bar EN6 3LD, Herts, England.	d.wigley@icrf.icnet.uk		Singleton, Martin/0000-0001-5716-7715				Ariyoshi M, 2000, P NATL ACAD SCI USA, V97, P8257, DOI 10.1073/pnas.140212997; ASAI T, 1993, EMBO J, V12, P3287, DOI 10.1002/j.1460-2075.1993.tb05998.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DELTITO BJD, 1995, J BACTERIOL, V177, P7086, DOI 10.1128/jb.177.24.7086-7091.1995; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; Dudas KC, 2001, MOL CELL BIOL, V21, P2706, DOI 10.1128/MCB.21.8.2706-2715.2001; Frei C, 2000, J CELL SCI, V113, P2641; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HONG XK, 1995, EMBO J, V14, P2385, DOI 10.1002/j.1460-2075.1995.tb07233.x; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kornberg A., 1992, DNA REPLICATION; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; Mahdi AA, 1997, NUCLEIC ACIDS RES, V25, P3875, DOI 10.1093/nar/25.19.3875; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; MOSIG G, 1987, ANNU REV GENET, V21, P347, DOI 10.1146/annurev.ge.21.120187.002023; Neuwald AF, 1999, GENOME RES, V9, P27; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Roe SM, 1998, MOL CELL, V2, P361, DOI 10.1016/S1097-2765(00)80280-4; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Skalka A., 1974, MECH RECOMBINATION, P421, DOI [10.1007/978-1-4684-2133-0_37, DOI 10.1007/978-1-4684-2133-0_37]; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Story RM, 2001, P NATL ACAD SCI USA, V98, P1465, DOI 10.1073/pnas.98.4.1465; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Vincent SD, 1996, J MOL BIOL, V264, P713, DOI 10.1006/jmbi.1996.0671; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	61	233	246	3	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 5	2001	107	1					79	89		10.1016/S0092-8674(01)00501-3	http://dx.doi.org/10.1016/S0092-8674(01)00501-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595187	Bronze			2022-12-28	WOS:000171453100011
J	Martin, S; Wolf-Eichbaum, D; Duinkerken, G; Scherbaum, WA; Kolb, H; Noordzij, JG; Roep, BO				Martin, S; Wolf-Eichbaum, D; Duinkerken, G; Scherbaum, WA; Kolb, H; Noordzij, JG; Roep, BO			Brief report - Development of type 1 diabetes despite severe hereditary B-cell deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; TYROSINE KINASE; BONE-MARROW; GENE REARRANGEMENTS; T-CELLS; MICE; AUTOANTIBODIES; LYMPHOCYTES; INITIATION; REACTIVITY		Univ Dusseldorf, German Diabet Res Inst, German Diabet Ctr, D-40225 Dusseldorf, Germany; Childrens Hosp, Hosp Minden, Minden, Germany; Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands	Deutsches Diabetes-Zentrum (DDZ); Heinrich Heine University Dusseldorf; Ruhr University Bochum; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam	Martin, S (corresponding author), Univ Dusseldorf, German Diabet Res Inst, German Diabet Ctr, Hennekamp 65, D-40225 Dusseldorf, Germany.		Roep, Bart/AAD-7609-2021	Noordzij, Jeroen/0000-0002-0076-8568				Archelos JJ, 2000, ANN NEUROL, V47, P694, DOI 10.1002/1531-8249(200006)47:6<694::AID-ANA2>3.0.CO;2-W; BRADLEY LAD, 1994, HUM MOL GENET, V3, P79, DOI 10.1093/hmg/3.1.79; Gottlieb PA, 1998, ANNU REV MED, V49, P391; JIN H, 1995, HUM MOL GENET, V4, P693, DOI 10.1093/hmg/4.4.693; LAMPETER EF, 1993, LANCET, V341, P1243, DOI 10.1016/0140-6736(93)91148-F; MANDRUPPOULSEN T, 1985, LANCET, V1, P599; NAKANO K, 1988, DIABETES, V37, P520, DOI 10.2337/diabetes.37.5.520; Noble JA, 1996, AM J HUM GENET, V59, P1134; Nomura K, 2000, BLOOD, V96, P610; Noorchashm H, 1999, J IMMUNOL, V163, P743; Noorchashm H, 1997, DIABETES, V46, P941, DOI 10.2337/diabetes.46.6.941; Noordzij JG, 2000, BLOOD, V96, P203, DOI 10.1182/blood.V96.1.203.013k33_203_209; OELTJEN JC, 1995, MAMM GENOME, V6, P334, DOI 10.1007/BF00364796; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; Peakman M, 1999, J CLIN INVEST, V104, P1449, DOI 10.1172/JCI7936; PETERSEN JS, 1994, DIABETES, V43, P1291, DOI 10.2337/diabetes.43.11.1291; Petersen LD, 1996, J AUTOIMMUN, V9, P731; Reijonen H, 2000, DIABETES, V49, P1621, DOI 10.2337/diabetes.49.10.1621; ROEP BO, 1995, DIABETES, V44, P278, DOI 10.2337/diabetes.44.3.278; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U; Roll U, 2000, DIABETOLOGIA, V43, P598, DOI 10.1007/s001250051349; Schloot NC, 1999, J AUTOIMMUN, V12, P289, DOI 10.1006/jaut.1999.0280; Seissler J, 1999, HORM METAB RES, V31, P657, DOI 10.1055/s-2007-978816; Serreze DV, 1998, J IMMUNOL, V161, P3912; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; Szczepanski T, 1999, BLOOD, V93, P4079, DOI 10.1182/blood.V93.12.4079.412k42_4079_4085; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592; Van Lochem EG, 1997, LEUKEMIA, V11, P2208, DOI 10.1038/sj.leu.2400862; VETRIE D, 1993, NATURE, V364, P362, DOI 10.1038/364362a0; Vihinen M, 1998, NUCLEIC ACIDS RES, V26, P242, DOI 10.1093/nar/26.1.242; WICKER LS, 1988, J EXP MED, V167, P1801, DOI 10.1084/jem.167.6.1801	32	198	202	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1036	1040		10.1056/NEJMoa010465	http://dx.doi.org/10.1056/NEJMoa010465			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586956	Bronze			2022-12-28	WOS:000171340400005
J	Lendon, C; Craddock, N				Lendon, C; Craddock, N			Is LBP-1c/CP2/LSF a disease-modifying gene for Alzheimer's disease?	LANCET			English	Editorial Material							CHROMOSOME-12; LOCUS; HETEROGENEITY		Univ Birmingham, Queen Elizabeth Psychiat Hosp, Dept Psychiat, Div Neurosci, Birmingham B15 2QZ, W Midlands, England	University of Birmingham	Lendon, C (corresponding author), Univ Birmingham, Queen Elizabeth Psychiat Hosp, Dept Psychiat, Div Neurosci, Birmingham B15 2QZ, W Midlands, England.							Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Craddock N, 1998, LANCET, V352, P1720, DOI 10.1016/S0140-6736(98)00075-0; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Lambert JC, 2000, HUM MOL GENET, V9, P2275, DOI 10.1093/oxfordjournals.hmg.a018918; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; Martin ES, 1998, JAMA-J AM MED ASSOC, V279, P433, DOI 10.1001/jama.279.6.433; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; Rogaeva E, 1998, JAMA-J AM MED ASSOC, V280, P614, DOI 10.1001/jama.280.7.614; Schellenberg G D, 2000, Curr Psychiatry Rep, V2, P158, DOI 10.1007/s11920-000-0061-z; Scott WK, 2000, AM J HUM GENET, V66, P922, DOI 10.1086/302828; Taylor AE, 2001, J MED GENET, V38, P232, DOI 10.1136/jmg.38.4.232; Wu WS, 1998, JAMA-J AM MED ASSOC, V280, P619, DOI 10.1001/jama.280.7.619	12	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 29	2001	358	9287					1029	1030		10.1016/S0140-6736(01)06228-6	http://dx.doi.org/10.1016/S0140-6736(01)06228-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589929				2022-12-28	WOS:000171393100004
J	Chiappe, LM; Salgado, L; Coria, RA				Chiappe, LM; Salgado, L; Coria, RA			Embryonic skulls of titanosaur sauropod dinosaurs	SCIENCE			English	Article								Little is known about the cranial anatomy of the taxonomically diverse and geographically widespread titanosaurs, a paucity that has hindered inferences about the genealogical history and evolutionary development of the latest sauropod dinosaurs. Newly discovered fossil eggs containing embryonic remains from the Late Cretaceous of Argentina provide the first articulated skulls of titanosaur dinosaurs. The nearly complete fetal skulls shed light on the evolution of some of the most notable cranial features of sauropod dinosaurs, including the retraction of the external nares, the forward rotation of the braincase, and the abbreviation of the infraorbital region.	Nat Hist Museum Los Angeles, Dept Vertebrate Paleontol, Los Angeles, CA 90007 USA; Univ Nacl Comahue, Museo Geol & Paleontol, RA-8300 Neuquen, Argentina; Museo Carmen Funes, RA-8318 Plaza Huincul, Neuquen, Argentina	Universidad Nacional del Comahue	Chiappe, LM (corresponding author), Nat Hist Museum Los Angeles, Dept Vertebrate Paleontol, 900 Exposit Blvd, Los Angeles, CA 90007 USA.	lchiappe@nhm.org		Chiappe, Luis/0000-0001-9661-0601				Calvo Jorge O., 1994, Gaia, V10, P183; Chiappe L. M., 2001, WALKING EGGS; Chiappe L.M., 2000, 1 INT S DIN EGGS BAB, P23; Chiappe LM, 1998, NATURE, V396, P258, DOI 10.1038/24370; Coria RA, 1999, AMEGHINIANA, V36, P98; Dingus Lowell, 2000, American Museum Novitates, V3290, P1, DOI 10.1206/0003-0082(2000)290<0001:SAMFCF>2.0.CO;2; JACOBS LL, 1993, PALAEONTOLOGY, V36, P523; McIntosh J.S., 1990, P345; MCINTOSH JS, 1997, ENCY DINOSAURS, P664; Powell JE., 1986, THESIS U NACL TUCUMA; Rogers KC, 2001, NATURE, V412, P530, DOI 10.1038/35087566; Salgado Leonardo, 1997, Ameghiniana, V34, P33; Shubin Neil H., 1994, P249; Upchurch P, 1999, J VERTEBR PALEONTOL, V19, P106, DOI 10.1080/02724634.1999.10011127; Wilson JA, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011115	15	103	111	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2444	2446		10.1126/science.1063723	http://dx.doi.org/10.1126/science.1063723			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577234				2022-12-28	WOS:000171237200044
J	Isozaki, Y				Isozaki, Y			An extraterrestrial impact at the Permian-Triassic boundary?	SCIENCE			English	Editorial Material									Univ Tokyo, Dept Earth Sci & Astron, Tokyo 1538902, Japan	University of Tokyo	Isozaki, Y (corresponding author), Univ Tokyo, Dept Earth Sci & Astron, Tokyo 1538902, Japan.		Isozaki, Yukio/A-1806-2009	Isozaki, Yukio/0000-0002-3596-581X				Becker L, 2001, SCIENCE, V291, P1530, DOI 10.1126/science.1057243; Isozaki Y, 1997, SCIENCE, V276, P235, DOI 10.1126/science.276.5310.235; Kakuwa Y, 1996, PALAEOGEOGR PALAEOCL, V121, P35, DOI 10.1016/0031-0182(95)00070-4; Kuwahara K., 1991, Journal of the Geological Society of Japan, V97, P1005	4	35	35	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2343	2343						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11579934				2022-12-28	WOS:000171237200002
J	Shekelle, PG; Ortiz, E; Rhodes, S; Morton, SC; Eccles, MP; Grimshaw, JM; Woolf, SH				Shekelle, PG; Ortiz, E; Rhodes, S; Morton, SC; Eccles, MP; Grimshaw, JM; Woolf, SH			Validity of the agency for healthcare research and quality clinical practice guidelines - How quickly do guidelines become outdated?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Practice guidelines need to be up-to-date to be useful to clinicians. No published methods are available for assessing whether existing practice guidelines are still valid, nor does any empirical information exist regarding how often such assessments need to be made. Objectives To assess the current validity of 17 clinical practice guidelines published by the US Agency for Healthcare Research and Quality (AHRQ) that are still in circulation, and to use this information to estimate how quickly guidelines become obsolete. Design, Setting, and Participants We developed criteria for defining when a guideline needs updating, mailed surveys to members of the original AHRQ guideline panels (n = 170; response rate, 71%), and searched the literature for evidence through March 2000 (n = 6994 titles yielding 173 articles plus 159 new guidelines on the same topics). Main Outcome Measures Identification of new evidence calling for a major, minor, or no update of the 17 guidelines; survival analysis of the rate at which guidelines became outdated. Results For 7 guidelines, new evidence and expert judgment indicated that a major update is required; 6 were found to be in need of a minor update; 3 were judged as still valid; and for 1 guideline, we could reach no conclusion. Survival analysis indicated that about half the guidelines were outdated in 5.8 years (95% confidence interval [CI], 5.0-6.6 years). The point at which no more than 90% of the guidelines were still valid was 3.6 years (95% CI, 2.6-4.6 years). Conclusions More than three quarters of the AHRQ guidelines need updating. As a general rule, guidelines should be reassessed for validity every 3 years.	RAND Corp, Hlth Div, So Calif Evidence Based Pratice Ctr, Santa Monica, CA 90401 USA; Greater Los Angeles Vet Affairs Hlth Care Syst, Los Angeles, CA USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; San Diego Vet Affairs Hlth Care Syst, San Diego, CA USA; Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland; Virginia Commonwealth Univ, Dept Family Practice, Richmond, VA USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California San Diego; Newcastle University - UK; University of Aberdeen; Virginia Commonwealth University	Shekelle, PG (corresponding author), RAND Corp, Hlth Div, So Calif Evidence Based Pratice Ctr, 1700 Main St,POB 2138, Santa Monica, CA 90401 USA.		Eccles, Martin P/AAD-4029-2020; Grimshaw, Jeremy/D-8726-2013	Grimshaw, Jeremy/0000-0001-8015-8243	PHS HHS [290-97-0001] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Field MJ., 1992, GUIDELINES CLIN PRAC; FIORE MC, 2000, TREATING TOBACCO USE; Mathsoft, 1998, S PLUS 2000 PROF REL; Shekelle P, 2001, BMJ-BRIT MED J, V323, P155, DOI 10.1136/bmj.323.7305.155; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; [No title captured]	6	392	425	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1461	1467		10.1001/jama.286.12.1461	http://dx.doi.org/10.1001/jama.286.12.1461			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572738	Bronze			2022-12-28	WOS:000171188600023
J	Bhandari, S; Eris, J				Bhandari, S; Eris, J			Premature osteonecrosis and sirolimus treatment in renal transplantation	BRITISH MEDICAL JOURNAL			English	Letter																		ADAMS J, 1999, J AM SOC NEPHROL, V752, pA3803; Han D, 1998, TRANSPLANT P, V30, P3034, DOI 10.1016/S0041-1345(98)00918-X; HRICIK DE, 1999, J AM SOC NEPHROL, V758, pA3835; Kubo T, 1998, TRANSPLANT P, V30, P3039, DOI 10.1016/S0041-1345(98)00920-8	4	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					665	665		10.1136/bmj.323.7314.665	http://dx.doi.org/10.1136/bmj.323.7314.665			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	476LP	11566830	Green Published, Bronze			2022-12-28	WOS:000171228800018
J	Macfarlane, GJ; McBeth, J; Silman, AJ				Macfarlane, GJ; McBeth, J; Silman, AJ			Widespread body pain and mortality: prospective population based study	BRITISH MEDICAL JOURNAL			English	Article							LOW-BACK-PAIN; GENERAL-POPULATION; FIBROMYALGIA SYNDROME; PREVALENCE; CANCER	Objective To determine whether there is excess mortality in groups of people who report widespread body pain, and if so to establish the nature and extent of any excess. Design Prospective follow up study over eight years. Mortality rate ratios were adjusted for age group, sex, and study location. Setting North west England. Participants 6569 people who took part in two pain surveys during 1991-2. Main outcome measures Pain status at baseline and subsequent mortality. Results 1005 (15%) participants had widespread pain, 3176 (48%) had regional pain, and 2388 (36%) had no pain. During follow up mortality was higher in people with regional pain (mortality rate ratio 1.21, 95% confidence interval 1.01 to 1.44) and widespread pain (1.31, 1.05 to 1.65) than in those who reported no pain. The excess mortality among people with regional and widespread pain was almost entirely related to deaths from cancer (1.55 (1.09 to 2.19) for regional pain and 2.07 (1.37 to 3.13) for widespread pain). The excess cancer mortality remained after exclusion of people in whom cancer had been diagnosed before the original survey and after adjustment for potential confounding factors. There were also more deaths from causes other than disease (for example, accidents, suicide, violence) among people with widespread pain (5.21, 0.94 to 28.78). Conclusion There is an intriguing association between the report of widespread pain and subsequent death from cancer in the medium and long term. This may have implications for the long term follow up of patients with "unexplained widespread pain symptoms, such as those with fibromyalgia.	Univ Manchester, Sch Med, Unit Chron Dis Epidemiol, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Med, Arthrit Res Campaign Epidemiol Unit, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester	Macfarlane, GJ (corresponding author), Univ Manchester, Sch Med, Unit Chron Dis Epidemiol, Manchester M13 9PT, Lancs, England.		McBeth, John/AAG-1954-2019; Macfarlane, Gary J/I-9521-2014	Macfarlane, Gary J/0000-0003-2322-3314; McBeth, John/0000-0001-7047-2183				Andersson HI, 1996, SCAND J RHEUMATOL, V25, P146, DOI 10.3109/03009749609080005; BOISSETPIORO MH, 1995, ARTHRITIS RHEUM, V38, P235, DOI 10.1002/art.1780380212; COX T, 1982, SOC SCI MED, V16, P381, DOI 10.1016/0277-9536(82)90048-X; CROFT P, 1993, J RHEUMATOL, V20, P710; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; HAWLEY DJ, 1988, J RHEUMATOL, V15, P1551; Hunt IM, 1999, RHEUMATOLOGY, V38, P275, DOI 10.1093/rheumatology/38.3.275; International Association for the Study of Pain, 1986, PAIN S, V3, P1; McBeth J, 2001, RHEUMATOLOGY, V40, P95, DOI 10.1093/rheumatology/40.1.95; McBeth J, 2001, ARTHRITIS RHEUM, V44, P940, DOI 10.1002/1529-0131(200104)44:4<940::AID-ANR151>3.0.CO;2-S; MCBETH J, IN PRESS J RHEUMATOL; *OFF NAT STAT, 1998, SER DH1, V31; PAPAGEORGIOU AC, 1995, SPINE, V20, P1889, DOI 10.1097/00007632-199509000-00009; PAPAGEORGIOUS AC, 1997, SPINE, V22, P137; SHEKELLE RB, 1981, PSYCHOSOM MED, V43, P117, DOI 10.1097/00006842-198104000-00003; Spiegel D, 1998, ANN NY ACAD SCI, V840, P674, DOI 10.1111/j.1749-6632.1998.tb09606.x; Spiegel D, 1996, BRIT J PSYCHIAT, V168, P109, DOI 10.1192/S0007125000298486; WALSH K, 1992, J EPIDEMIOL COMMUN H, V46, P227, DOI 10.1136/jech.46.3.227; White KP, 1999, J RHEUMATOL, V26, P1570; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203	21	149	150	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					662	664B		10.1136/bmj.323.7314.662	http://dx.doi.org/10.1136/bmj.323.7314.662			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	476LP	11566829	Green Published, Bronze			2022-12-28	WOS:000171228800016
J	Robinson, A; Thompson, DG; Wilkin, D; Roberts, C				Robinson, A; Thompson, DG; Wilkin, D; Roberts, C		NW Gastrointestinal Res Grp	Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial	LANCET			English	Article							INFLAMMATORY-BOWEL-DISEASE; OUTPATIENT CLINICS; ASTHMA; MINIMIZATION; INFORMATION; EDUCATION; VIEW; CARE; NEED	Background Ulcerative colitis is managed mainly in secondary care by regular outpatient reviews done by specialist clinicians. Alternatives would be to discharge patients to primary care or to provide open-access clinics, but neither of these options reduce patients' dependency on doctors or allow patients' involvement in disease management. We did a randomised controlled trial to assess an alternative to traditional outpatient care. Methods We randomly assigned 203 patients with ulcerative colitis who were undergoing hospital follow-up to receive patient-centred self-management training and follow-up on request (intervention group), or normal treatment and follow-up (control group). The main outcome was the interval between relapse and treatment, and secondary outcomes were rates of primary and secondary care consultation, quality of life, and acceptability to patients. Analysis was by intention to treat. Findings Intervention patients had relapses treated within a mean of 14.8 h (SID 19.1) compared with 49.6 h (65.1) in controls (difference 34.8 h [95% CI 16.4-60.2]). Furthermore, intervention patients compared with controls made significantly fewer visits to hospital (0.9 vs 2.9 per patient per year, difference 2.0 [1.6-2.7]) and to the primary-care physician (0.3 vs 0.9 per patient per year, difference 0.6 [0.2-1.1], p<0.006). Only two patients in the intervention group preferred traditional management. Health-related quality-of-life, scores were unchanged in both groups. Interpretation Self-management of ulcerative colitis accelerates treatment provision and reduces doctor visits, and does not increase morbidity. This approach could be used in long-term management of many other chronic diseases to improve health-service provision and use, and to reduce costs.	Univ Manchester, Hope Hosp, Sect Gastrointestinal Sci, Salford M6 8HD, Lancs, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England	University of Manchester; University of Manchester	Robinson, A (corresponding author), Univ Manchester, Hope Hosp, Sect Gastrointestinal Sci, Clin Sci Bldg, Salford M6 8HD, Lancs, England.							ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; ARMSTRONG D, 1992, J PUBLIC HEALTH MED, V14, P173; Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; *BRIT SOC GASTR, 1996, GUID GASTR INFL BOW; Burkey Y, 1997, FAM PRACT, V14, P29, DOI 10.1093/fampra/14.1.29; Coulter A, 1997, J Health Serv Res Policy, V2, P112; DELAMATER AM, 1990, DIABETES CARE, V13, P492, DOI 10.2337/diacare.13.5.492; *DEP HLTH, 1997, NEW NHS MOD DEP EX S, P5; *DEP HLTH, 1999, SAV LIV OUR HLTH NAT; Entwistle VA, 1996, INT J QUAL HEALTH C, V8, P425; Golin CE, 1996, DIABETES CARE, V19, P1153, DOI 10.2337/diacare.19.10.1153; *GOV STAT SERV, 1995, OUTP WARD ATT ENGL F; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; KOTSES H, 1995, J ALLERGY CLIN IMMUN, V95, P529, DOI 10.1016/S0091-6749(95)70315-2; Lahdensuo A, 1996, BRIT MED J, V312, P748; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LEITCH AG, 1990, RESP MED, V84, P119, DOI 10.1016/S0954-6111(08)80013-3; Mansfield JC, 1997, J ROY COLL PHYS LOND, V31, P184; MOODY GA, 1993, J ROY SOC MED, V86, P26; PROBERT CSJ, 1993, J ROY SOC MED, V86, P271; RAZ I, 1988, DIABETES CARE, V11, P67, DOI 10.2337/diacare.11.1.67; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; Shaw C D, 1981, Health Trends, V13, P107; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; Treasure T, 1998, BRIT MED J, V317, P362; Williams JG, 2000, BRIT MED J, V320, P544, DOI 10.1136/bmj.320.7234.544; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5; [No title captured]	29	151	154	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					976	981		10.1016/S0140-6736(01)06105-0	http://dx.doi.org/10.1016/S0140-6736(01)06105-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583752				2022-12-28	WOS:000171135300019
J	Jeong, H; Chang, AM; Melloch, MR				Jeong, H; Chang, AM; Melloch, MR			The Kondo effect in an artificial quantum dot molecule	SCIENCE			English	Article							COULOMB-BLOCKADE; SPECTROSCOPY; TRANSPORT; BARRIER	Double quantum dots provide an ideal model system for studying interactions between localized impurity spins. We report on the transport properties of a series-coupled double quantum dot as electrons are added one by one onto the dots. When the many-body molecular states are formed, we observe a splitting of the Kondo resonance peak in the differential conductance. This splitting reflects the energy difference between the bonding and antibonding states formed by the coherent superposition of the Kondo states of each dot. The occurrence of the Kondo resonance and its magnetic field dependence agree with a simple interpretation of the spin status of a double quantum dot.	Purdue Univ, Dept Phys, W Lafayette, IN 47907 USA; Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chang, AM (corresponding author), Purdue Univ, Dept Phys, W Lafayette, IN 47907 USA.	yingshe@physics.purdue.edu						Aguado R, 2000, PHYS REV LETT, V85, P1946, DOI 10.1103/PhysRevLett.85.1946; ANDERSON PW, 1961, PHYS REV, V124, P41, DOI 10.1103/PhysRev.124.41; Aono T, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.125327; Blick RH, 1998, PHYS REV LETT, V80, P4032, DOI 10.1103/PhysRevLett.80.4032; Busser CA, 2000, PHYS REV B, V62, P9907, DOI 10.1103/PhysRevB.62.9907; Cronenwett SM, 1998, SCIENCE, V281, P540, DOI 10.1126/science.281.5376.540; Georges A, 1999, PHYS REV LETT, V82, P3508, DOI 10.1103/PhysRevLett.82.3508; GLAZMAN LI, 1988, JETP LETT+, V47, P452; Golden JM, 1996, PHYS REV B, V53, P3893, DOI 10.1103/PhysRevB.53.3893; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Izumida W, 2000, PHYS REV B, V62, P10260, DOI 10.1103/PhysRevB.62.10260; JAYAPRAKASH C, 1981, PHYS REV LETT, V47, P737, DOI 10.1103/PhysRevLett.47.737; Ji Y, 2000, SCIENCE, V290, P779, DOI 10.1126/science.290.5492.779; JONES BA, 1987, PHYS REV LETT, V58, P843, DOI 10.1103/PhysRevLett.58.843; JONES BA, 1988, PHYS REV LETT, V61, P125, DOI 10.1103/PhysRevLett.61.125; KASUYA T, 1956, PROG THEOR PHYS, V16, P45, DOI 10.1143/PTP.16.45; KONDO J, 1964, PROG THEOR PHYS, V32, P37, DOI 10.1143/PTP.32.37; Livermore C, 1996, SCIENCE, V274, P1332, DOI 10.1126/science.274.5291.1332; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Matveev KA, 1996, PHYS REV B, V53, P1034, DOI 10.1103/PhysRevB.53.1034; NG TK, 1988, PHYS REV LETT, V61, P1768, DOI 10.1103/PhysRevLett.61.1768; Nygard J, 2000, NATURE, V408, P342, DOI 10.1038/35042545; Oosterkamp TH, 1998, NATURE, V395, P873, DOI 10.1038/27617; RUDERMAN MA, 1954, PHYS REV, V96, P99, DOI 10.1103/PhysRev.96.99; Sasaki S, 2000, NATURE, V405, P764, DOI 10.1038/35015509; Schmid J, 1998, PHYSICA B, V256, P182, DOI 10.1016/S0921-4526(98)00533-X; van der Wiel WG, 2000, SCIENCE, V289, P2105, DOI 10.1126/science.289.5487.2105; WAUGH FR, 1995, PHYS REV LETT, V75, P705, DOI 10.1103/PhysRevLett.75.705; YOSIDA K, 1957, PHYS REV, V106, P893, DOI 10.1103/PhysRev.106.893	29	256	265	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2221	2223		10.1126/science.1063182	http://dx.doi.org/10.1126/science.1063182			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567130				2022-12-28	WOS:000171139400033
J	Williams, JA; Su, HS; Bernards, A; Field, J; Sehgal, A				Williams, JA; Su, HS; Bernards, A; Field, J; Sehgal, A			A circadian output in Drosophila mediated by neurofibromatosis-1 and Ras/MAPK	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; PATHWAY; CLOCK; RAS; SEVENLESS; RHYTHMS; SON; PHOSPHORYLATION; MELANOGASTER; GENES	Output from the circadian clock controls rhythmic behavior through poorly understood mechanisms. In Drosophila, null mutations of the neurofibromatosis-1 (Nf1) gene produce abnormalities of circadian rhythms in locomotor activity. Mutant flies show normal oscillations of the clock genes period (per) and timeless (tim) and of their corresponding proteins, but altered oscillations and levels of a clock-controlled reporter. Mitogen-activated protein kinase (MAPK) activity is increased in Nf1 mutants, and the circadian phenotype is rescued by loss-of-function mutations in the Ras/MAPK pathway. Thus, Nf1 signals through Ras/MAPK in Drosophila. Immunohistochemical staining revealed a circadian oscillation of phospho-MAPK in the vicinity of nerve terminals containing pigment-dispersing factor (PDF), a secreted output from clock cells, suggesting a coupling of PDF to Ras/MAPK signaling.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Harvard University; Massachusetts General Hospital	Sehgal, A (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.							Akashi M, 2000, GENE DEV, V14, P645; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Guo HF, 2000, NATURE, V403, P895, DOI 10.1038/35002593; Harada Y, 2000, J BIOL CHEM, V275, P37078, DOI 10.1074/jbc.M004706200; Helfrich-Forster C, 2000, J NEUROSCI, V20, P3339, DOI 10.1523/JNEUROSCI.20-09-03339.2000; HICKMAN L, UNPUB; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Huang AM, 2000, GENETICS, V156, P1219; Ko GYP, 2001, NEURON, V29, P255, DOI 10.1016/S0896-6273(01)00195-7; Krishnan B, 2001, NATURE, V411, P313, DOI 10.1038/35077094; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; MAJORCAK J, 1997, MOL CELL BIOL, V17, P5915; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; VISCKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183; Williams JA, 2001, ANNU REV PHYSIOL, V63, P729, DOI 10.1146/annurev.physiol.63.1.729; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	26	168	174	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2251	2256		10.1126/science.1063097	http://dx.doi.org/10.1126/science.1063097			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567138				2022-12-28	WOS:000171139400043
J	Wybenga-Groot, LE; Baskin, B; Ong, SH; Tong, JF; Pawson, T; Sicheri, F				Wybenga-Groot, LE; Baskin, B; Ong, SH; Tong, JF; Pawson, T; Sicheri, F			Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region	CELL			English	Article							INTERNAL TANDEM DUPLICATION; TGF-BETA RECEPTOR; CRYSTAL-STRUCTURE; C-KIT; FLT3 GENE; DOMAIN; PHOSPHORYLATION; LIGANDS; ACTIVATION; COMPLEX	The Eph receptor tyrosine kinase family is regulated by autophosphorylation within the juxtamembrane region and the kinase activation segment. We have solved the X-ray crystal structure to 1.9 Angstrom resolution of an autoinhibited, unphosphorylated form of EphB2 comprised of the juxtamembrane region and the kinase domain. The structure, supported by mutagenesis data, reveals that the juxtamembrane segment adopts a helical conformation that distorts the small lobe of the kinase domain, and blocks the activation segment from attaining an activated conformation. Phosphorylation of conserved juxtamembrane tyrosines would relieve this autoinhibition by disturbing the association of the juxtamembrane segment with the kinase domain, while liberating phosphotyrosine sites for binding SH2 domains of target proteins. We propose that the autoinhibitory mechanism employed by EphB2 is a more general device through which receptor tyrosine kinases are controlled.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca; sicheri@mshri.on.ca	Pawson, Tony J/E-4578-2013; Sicheri, Frank/F-8856-2013					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANDERSSON LC, 1998, JAPN J CANC RES, V89, P1; [Anonymous], 1997, Cell, V90, P403; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Connor RJ, 1995, ONCOGENE, V11, P2429; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Hollander E, 1997, CNS SPECTRUMS, V2, P16, DOI DOI 10.1017/S1092852900011068; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalo MS, 1999, BIOCHEMISTRY-US, V38, P14396, DOI 10.1021/bi991628t; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nakao M, 1996, LEUKEMIA, V10, P1911; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Tsujimura T, 1996, BLOOD, V87, P273; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	55	259	265	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 21	2001	106	6					745	757		10.1016/S0092-8674(01)00496-2	http://dx.doi.org/10.1016/S0092-8674(01)00496-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572780	Bronze			2022-12-28	WOS:000171213000011
J	Lewis, EJ; Hunsicker, LG; Clarke, WR; Berl, T; Pohl, MA; Lewis, JB; Ritz, E; Atkins, RC; Rohde, R; Raz, I				Lewis, EJ; Hunsicker, LG; Clarke, WR; Berl, T; Pohl, MA; Lewis, JB; Ritz, E; Atkins, RC; Rohde, R; Raz, I		Collaborative Study Grp	Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONVERTING ENZYME-INHIBITION; II ANTAGONIST; DYSFUNCTION; EPROSARTAN; TRIAL	Background It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression of nephropathy in patients with type 2 diabetes independently of its capacity to lower the systemic blood pressure. Methods We randomly assigned 1715 hypertensive patients with nephropathy due to type 2 diabetes to treatment with irbesartan ( 300 mg daily), amlodipine (10 mg daily), or placebo. The target blood pressure was 135/85 mm Hg or less in all groups. We compared the groups with regard to the time to the primary composite end point of a doubling of the base-line rum creatinine concentration, the development of endstage renal disease, or death from any cause. We also compared them with regard to the time to a secondary cardiovascular composite end point. Results The mean duration of follow-up was 2.6 years. Treatment with irbesartan was associated with a risk of the primary composite end point that was 20 percent lower than that in the placebo group ( P= 0.02) and 23 percent lower than that in the amlodipine group ( P= 0.006). The risk of a doubling of the serum concentration was 33 percent lower in the irbesartan group than in the placebo group ( P= 0.003) and 37 percent lower in the irbesartan group than in the amlodipine group ( P<0.001). Treatment with irbesartan was associated with a relative risk of end-stage renal disease that was 23 percent lower than that in both other groups ( P= 0.07 for both comparisons). These differences were not explained by differences in the blood pressures that were achieved. The serum creatinine concentration increased 24 percent more slowly in the irbesartan group than in the placebo group ( P= 0.008) and 21 percent more slowly than in the amlodipine group (P=0.02). There were no significant differences in the rates of death from any cause or in the cardiovascular composite end point. Conclusions The angiotensin-II receptor blocker irbesartan is effective in protecting against the of nephropathy due to type 2 diabetes. This protection is independent of the reduction in blood pressure it causes. (N Engl J Med 2001; 345: 851-60.) Copyright (C) 2001 Massachusetts Medical Society.	Rush Presbyterian St Lukes Med Ctr, Dept Med, Chicago, IL 60612 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA; Univ Colorado, Sch Med, Dept Internal Med, Denver, CO USA; Cleveland Clin Fdn, Dept Med, Cleveland, OH 44195 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Heidelberg Univ, Dept Med, Heidelberg, Germany; Monash Med Ctr, Dept Nephrol, Melbourne, Vic, Australia; Hadassah Univ, Dept Med, Jerusalem, Israel	Rush University; University of Iowa; University of Iowa; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Cleveland Clinic Foundation; Vanderbilt University; Ruprecht Karls University Heidelberg; Monash University; Hebrew University of Jerusalem; Hadassah University Medical Center	Lewis, EJ (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Med, 1650 W Harrison,Suite 515 RA, Chicago, IL 60612 USA.		ALMEIDA, FERNANDO/S-1880-2019	ALMEIDA, FERNANDO/0000-0002-9404-9707; Keymeulen, Bart/0000-0002-8671-4527				Abbate M, 1998, J AM SOC NEPHROL, V9, P1213; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; KON V, 1993, KIDNEY INT, V44, P545, DOI 10.1038/ki.1993.279; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEE ET, 1992, STATISTICAL METHODS, P250; LEE ET, 1992, STAT METHODS SURVIVA, P67; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Neal B, 2000, LANCET, V356, P1955; Osei SY, 2000, HYPERTENSION, V36, P122, DOI 10.1161/01.HYP.36.1.122; Price DA, 1997, HYPERTENSION, V30, P240, DOI 10.1161/01.HYP.30.2.240; Price DA, 1999, J AM SOC NEPHROL, V10, P2382; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Rodby RA, 2000, NEPHROL DIAL TRANSPL, V15, P487, DOI 10.1093/ndt/15.4.487; Ruggenenti P, 1999, KIDNEY INT, V55, P984, DOI 10.1046/j.1523-1755.1999.055003984.x; Ruggenenti P, 2000, AM J KIDNEY DIS, V35, P1155, DOI 10.1016/S0272-6386(00)70054-0; Stearne MR, 1998, BRIT MED J, V317, P713; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; *US REN DAT SYST, 1999, ANN DAT REP, P25; WOLF G, 1992, AM J PATHOL, V140, P95; WOOLSON RF, 1987, STAT METHODS ANAL BI, P227; Yusuf S, 2000, NEW ENGL J MED, V342, P145; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521	26	4178	4389	3	159	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2001	345	12					851	860		10.1056/NEJMoa011303	http://dx.doi.org/10.1056/NEJMoa011303			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	473JW	11565517	Green Submitted			2022-12-28	WOS:000171039600001
J	Pardoll, DM				Pardoll, DM			Immunology - Stress, NK receptors, and immune surveillance	SCIENCE			English	Editorial Material							NKG2D RECEPTOR; CELLS; ACTIVATION; EXPRESSION; GENES		Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA	Johns Hopkins University	Pardoll, DM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.	dmpardol@jhmi.edu						ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; Bakker ABH, 2000, HUM IMMUNOL, V61, P18, DOI 10.1016/S0198-8859(99)00160-3; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Cerwenka A, 2001, P NATL ACAD SCI USA, V98, P11521, DOI 10.1073/pnas.201238598; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Holtmeier V, 2001, J INVEST DERMATOL, V116, P275, DOI 10.1046/j.1523-1747.2001.01250.x; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730	14	48	56	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 19	2001	294	5542					534	536		10.1126/science.1066284	http://dx.doi.org/10.1126/science.1066284			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	484NC	11567108				2022-12-28	WOS:000171695600032
J	Schiermeier, Q				Schiermeier, Q			Bid to end EU's transgenic impasse	NATURE			English	News Item																		2001, NATURE, V409, P967	1	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 18	2001	413	6857					661	661		10.1038/35099712	http://dx.doi.org/10.1038/35099712			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482ZK	11606987	Bronze			2022-12-28	WOS:000171608000012
J	Raedle, J; Trojan, J; Brieger, A; Weber, N; Schafer, D; Plotz, G; Staib-Sebler, E; Kriener, S; Lorenz, M; Zeuzem, S				Raedle, J; Trojan, J; Brieger, A; Weber, N; Schafer, D; Plotz, G; Staib-Sebler, E; Kriener, S; Lorenz, M; Zeuzem, S			Bethesda guidelines: Relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer	ANNALS OF INTERNAL MEDICINE			English	Article							MISMATCH REPAIR GENES; REPLICATION ERRORS; GERMLINE MUTATIONS; DNA METHYLATION; HMLH1 PROMOTER; COLON-CANCER; HYPERMETHYLATION; TUMORS; HMSH2; EPIGENETICS	Background: Microsatellite instability is a hallmark of mismatch repair deficiency in hereditary nonpolyposis colorectal cancer and results from mutations in the mismatch repair genes MLH1 or MSH2 or from gene inactivation associated with DNA methylation. The Bethesda guidelines were established to identify patients with colorectal cancer who should be tested for microsatellite instability. Objective: To assess the Bethesda guidelines for detection, of microsatellite instability and to determine the role of MLH1 promoter methylation in colorectal cancer. Design: Prospective cohort study. Setting: Tertiary care referral center in Frankfurt, Germany. Patients: 125 consecutive patients with colorectal cancer. Measurements, Patients were assessed according to the Bethesda guidelines, and tumor specimens were analyzed for micro-satellite instability. Patients with microsatellite Instability were tested for MLH1 promoter methylation and MLH1 and MSH2 germline mutations. Results: Microsatellite instability was detected in 17 of 58 patients who fulfilled and 5 of 67 patients who did not fulfill criteria of the Bethesda guidelines. In I I of 17 patients with microsatellite instability who fulfilled Bethesda guidelines, an MLH1 (n = 3), MSH2 (n = 7), or combined MLH1 and MSH2 (n = 1) mutation was found. Among the patients with microsatellite instability who did not fulfill Bethesda guidelines, no mutations were observed; MLH1 promoter methylation was observed in 6 of 11 patients with an MLH1 or MSH2 mutation and 5 of 11 patients without an MLH1 or MSH2 mutation. Conclusions: The Bethesda guidelines are useful for selecting patients for microsatellite instability testing. MLH1 and MSH2 testing should be recommended in all patients with colorectal cancer and microsatellite instability who fulfill at least one Bethesda criterion. MLH1 promoter methylation may accompany rather than initiate carcinogenesis in patients with colorectal cancer who have mismatch repair gene defects.	Goethe Univ Frankfurt, Dept Internal Med 2, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Human Genet, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Gen & Vasc Surg, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Pathol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt	Raedle, J (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Raedle@em.uni-frankfurt.de	Zeuzem, Stefan/AAE-7435-2019	Plotz, Guido/0000-0001-5314-9739				AALTONEN LA, 1994, CANCER RES, V54, P1645; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Basik M, 1997, GENE CHROMOSOME CANC, V18, P19, DOI 10.1002/(SICI)1098-2264(199701)18:1<19::AID-GCC3>3.0.CO;2-4; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bocker T, 1997, CANCER RES, V57, P4739; Boland CR, 1998, CANCER RES, V58, P5248; Brieger A, 1999, CLIN CHEM, V45, P1564; Canzian F, 1996, CANCER RES, V56, P3331; CAWKWELL L, 1995, GASTROENTEROLOGY, V109, P465, DOI 10.1016/0016-5085(95)90334-8; Cravo ML, 1999, CANCER, V85, P779, DOI 10.1002/(SICI)1097-0142(19990215)85:4<779::AID-CNCR4>3.0.CO;2-C; Cunningham JM, 1998, CANCER RES, V58, P3455; Dietmaier W, 1997, CANCER RES, V57, P4749; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; Fleisher AS, 1999, CANCER RES, V59, P1090; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; *INT COLL GROUP HE, 2001, MUT DAT PATH MUT MSH; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5; Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kane MF, 1997, CANCER RES, V57, P808; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOLODNER RD, 1995, CANCER RES, V55, P242; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Lamberti C, 1999, GUT, V44, P839, DOI 10.1136/gut.44.6.839; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; Lynch HT, 1998, NEW ENGL J MED, V338, P1537, DOI 10.1056/NEJM199805213382109; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Oda S, 1997, NUCLEIC ACIDS RES, V25, P3415, DOI 10.1093/nar/25.17.3415; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Raedle J, 1999, MODERN PATHOL, V12, P485; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Sambrook J, 1989, MOL CLONING LAB MANU, V2; Syngal S, 1999, JAMA-J AM MED ASSOC, V282, P247, DOI 10.1001/jama.282.3.247; Syngal S, 2000, J MED GENET, V37, P641, DOI 10.1136/jmg.37.9.641; Terdiman JP, 2001, GASTROENTEROLOGY, V120, P21, DOI 10.1053/gast.2001.20874; Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Wang Q, 1999, HUM GENET, V105, P79, DOI 10.1007/s004390051067; Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804	48	58	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	1				566	576		10.7326/0003-4819-135-8_Part_1-200110160-00007	http://dx.doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481VY	11601928				2022-12-28	WOS:000171542200002
J	Shekelle, PG; MacLean, CH; Morton, SC; Wenger, NS				Shekelle, PG; MacLean, CH; Morton, SC; Wenger, NS			Assessing Care of Vulnerable Elders: Methods for developing quality indicators	ANNALS OF INTERNAL MEDICINE			English	Article							VALIDITY; CRITERIA; UNDERUSE; TRIALS		RAND Corp, Santa Monica, CA 90407 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Rand Stat Grp, San Francisco, CA USA; RAND Hlth, Santa Monica, CA USA; RAND Stat Grp, Santa Monica, CA USA	RAND Corporation; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; RAND Corporation	Shekelle, PG (corresponding author), RAND Corp, 1700 Main St,Box 2138, Santa Monica, CA 90407 USA.	shekelle@rand.org						*AG HLTH CAR POL R, 1999, CONQUEST 1 1 COMP NE; *AM MED ASS DEP PR, 1998, DIR CLIN PRACT GUID; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Brook RH, 1994, CLIN PRACTICE GUIDEL; CALIFF RM, 1986, CIRCULATION, V74, P1191, DOI 10.1161/01.CIR.74.6.1191; *FAULKN GRAYS HEAL, 1992, MED OUTC GUID SOURC; GOURLAY SG, 2000, CLONIDINE SMOKING CE; Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706; *JOINT COMM ACCR H, 1997, NAT LIB HEALTHC IND; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; PALMER RH, 1994, DEMPAQ PROJECT DEV E; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022; Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607; *US I MED COMM EV, 1985, ASS MED TECHN; *US NAT COMM QUAL, 1997, HEDIS 3 0 HLTH PLAN; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002; 1999, NATL GUIDELINE CLEAR	21	151	152	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				647	652		10.7326/0003-4819-135-8_Part_2-200110161-00003	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481WA	11601947				2022-12-28	WOS:000171542400003
J	Humphries, MJ; Mould, AP				Humphries, MJ; Mould, AP			Structure - An anthropomorphic integrin	SCIENCE			English	Editorial Material							LIGAND-BINDING REGION; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; A-DOMAIN; RECOGNITION; RECEPTOR; SITES; MODEL		Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Humphries, MJ (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.			Humphries, Martin/0000-0002-4331-6967				CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; Chen LL, 1998, BIOCHEMISTRY-US, V37, P8743, DOI 10.1021/bi980311a; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	15	13	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					316	317		10.1126/science.1066240	http://dx.doi.org/10.1126/science.1066240			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598288				2022-12-28	WOS:000171601400028
J	Zuraw, B				Zuraw, B			Bradykinin in protection against left-ventricular hypertrophy	LANCET			English	Editorial Material							ANGIOTENSIN-CONVERTING-ENZYME; B-2 KININ RECEPTOR; INSERTION/DELETION POLYMORPHISM; INHIBITOR; GENE		Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zuraw, B (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.	zuraw@scripps.edu		Zuraw, Bruce/0000-0003-0640-6768				Benzing T, 1999, CIRCULATION, V99, P2034, DOI 10.1161/01.CIR.99.15.2034; Dell'Italia LJ, 1999, CIRCULATION, V100, P2305, DOI 10.1161/01.CIR.100.23.2305; Emanueli C, 1999, CIRCULATION, V100, P2359, DOI 10.1161/01.CIR.100.23.2359; Gainer JV, 1998, NEW ENGL J MED, V339, P1285, DOI 10.1056/NEJM199810293391804; LINZ W, 1995, PHARMACOL REV, V47, P25; Lorell BH, 2000, CIRCULATION, V102, P470; Lung CC, 1997, J ALLERGY CLIN IMMUN, V99, P134, DOI 10.1016/S0091-6749(97)81054-8; Marcic BM, 2000, J PHARMACOL EXP THER, V294, P605; Murphey LJ, 2000, CIRCULATION, V102, P829; Myerson SG, 2001, CIRCULATION, V103, P226; Prasad A, 2000, J AM COLL CARDIOL, V36, P1467, DOI 10.1016/S0735-1097(00)00892-5; Silva JA, 2000, FASEB J, V14, P1858; Wang JG, 2000, EUR J PHARMACOL, V410, P289, DOI 10.1016/S0014-2999(00)00822-0; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759	14	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	2001	358	9288					1116	1118		10.1016/S0140-6736(01)06300-0	http://dx.doi.org/10.1016/S0140-6736(01)06300-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597662				2022-12-28	WOS:000171399000005
J	Kawakami, RK; Kato, Y; Hanson, M; Malajovich, I; Stephens, JM; Johnston-Halperin, E; Salis, G; Gossard, AC; Awschalom, DD				Kawakami, RK; Kato, Y; Hanson, M; Malajovich, I; Stephens, JM; Johnston-Halperin, E; Salis, G; Gossard, AC; Awschalom, DD			Ferromagnetic imprinting of nuclear spins in semiconductors	SCIENCE			English	Article							HETEROSTRUCTURE; GAAS	We examine how a ferromagnetic layer affects the coherent electron spin dynamics in a neighboring gallium arsenide semiconductor. Uttrafast optical pump-probe measurements reveal that the spin dynamics are unexpectedly dominated by hyperpolarized nuclear spins that align along the ferromagnet's magnetization. We find evidence that photoexcited carriers acquire spin-polarization from the ferromagnet, and dynamically polarize these nuclear spins. The resulting hyperfine fields are as high as 9000 gauss in small external fields (less than 1000 gauss), enabling ferromagnetic control of local electron spin coherence.	Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Awschalom, DD (corresponding author), Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA.		Johnston-Halperin, Ezekiel/AAM-2564-2021; Johnston-Halperin, Ezekiel/B-5902-2012; Salis, Gian/B-5651-2018; Kato, Yuichiro K./B-5051-2008	Johnston-Halperin, Ezekiel/0000-0002-6240-3505; Kato, Yuichiro K./0000-0002-9942-1459; Salis, Gian/0000-0001-6263-4517				BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; BARNER K, 1977, PHYS STATUS SOLIDI B, V80, P451, DOI 10.1002/pssb.2220800206; Crooker SA, 1996, PHYS REV LETT, V77, P2814, DOI 10.1103/PhysRevLett.77.2814; DiVincenzo DP, 1999, J APPL PHYS, V85, P4785, DOI 10.1063/1.370481; EPSTEIN R, UNPUB; Gammon D, 2001, PHYS REV LETT, V86, P5176, DOI 10.1103/PhysRevLett.86.5176; Kalevich V. K., 1986, Soviet Physics - Solid State, V28, P1947; Kawakami RK, 2000, APPL PHYS LETT, V77, P2379, DOI 10.1063/1.1316775; Kikkawa JM, 1998, PHYS REV LETT, V80, P4313, DOI 10.1103/PhysRevLett.80.4313; Kikkawa JM, 2000, SCIENCE, V287, P473, DOI 10.1126/science.287.5452.473; LAMPEL G, 1968, PHYS REV LETT, V20, P491, DOI 10.1103/PhysRevLett.20.491; LIDE DR, 1993, CRC HDB CHEM PHYSICS; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Meier F., 1984, OPTICAL ORIENTATION; Ohno H, 2000, NATURE, V408, P944, DOI 10.1038/35050040; Ohno Y, 1999, NATURE, V402, P790, DOI 10.1038/45509; OVERHAUSER AW, 1953, PHYS REV, V92, P411, DOI 10.1103/PhysRev.92.411; PAGET D, 1977, PHYS REV B, V15, P5780, DOI 10.1103/PhysRevB.15.5780; Salis G, 2001, PHYS REV LETT, V86, P2677, DOI 10.1103/PhysRevLett.86.2677; TANAKA M, 1994, APPL PHYS LETT, V65, P1964, DOI 10.1063/1.112831; TANOBE H, 1992, JPN J APPL PHYS 1, V31, P1597, DOI 10.1143/JJAP.31.1597	21	112	111	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					131	134		10.1126/science.1063186	http://dx.doi.org/10.1126/science.1063186			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588255				2022-12-28	WOS:000171448800043
J	Tekin, M; Arnos, KS; Pandya, A				Tekin, M; Arnos, KS; Pandya, A			Advances in hereditary deafness	LANCET			English	Review							SYNDROMIC HEARING-LOSS; AUTOSOMAL-DOMINANT DEAFNESS; HUMAN NONSYNDROMIC DEAFNESS; MYOSIN VIIA GENE; SENSORINEURAL DEAFNESS; RECESSIVE DEAFNESS; PENDRED-SYNDROME; CONNEXIN-26 MUTATIONS; WAARDENBURG-SYNDROME; INHERITED DEAFNESS	Progress in the Human Genome Project, availability of cochlea-specific cDNA libraries, and development of murine models of deafness have resulted in rapid discovery of many loci and corresponding genes for deafness. Up to now, the chromosomal locations of about 70 genes for non-syndromic deafness have been mapped, and the genes of more than 20 loci have been identified and characterised. Mutations in one gene, connexin 26 (CX26GJB2), are responsible for most cases of recessive non-syndromic deafness, accounting for 30-40% of all childhood genetic deafness in some populations (eg, white people of western European descent). We summarise advances In identification of genes for deafness and provide a guide to the clinical approach to diagnosis of patients with hearing loss.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Human Genet, Richmond, VA 23298 USA; Gallaudet Univ, Dept Biol, Washington, DC 20002 USA	Virginia Commonwealth University	Pandya, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Human Genet, 1101 E Marshall St,POB 980033, Richmond, VA 23298 USA.	apandya@hsc.vcu.edu	Tekin, Mustafa/ABG-7627-2020	Tekin, Mustafa/0000-0002-3525-7960				Abe S, 2000, J MED GENET, V37, P41, DOI 10.1136/jmg.37.1.41; ARNOS KS, 1992, AM J MED GENET, V44, P345, DOI 10.1002/ajmg.1320440315; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Bykhovskaya Y, 2000, AM J HUM GENET, V66, P1905, DOI 10.1086/302914; Coucke PJ, 1999, HUM MOL GENET, V8, P1321, DOI 10.1093/hmg/8.7.1321; Denoyelle F, 1999, LANCET, V353, P1298, DOI 10.1016/S0140-6736(98)11071-1; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; DeStefano AL, 1998, HUM GENET, V102, P499, DOI 10.1007/s004390050732; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; Estivill X, 1998, AM J HUM GENET, V62, P27, DOI 10.1086/301676; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Gasparini P, 2000, EUR J HUM GENET, V8, P19, DOI 10.1038/sj.ejhg.5200406; Grandori F, 1999, Am J Audiol, V8, P19, DOI 10.1044/1059-0889(1999/004); Green GE, 1999, JAMA-J AM MED ASSOC, V281, P2211, DOI 10.1001/jama.281.23.2211; Grifa A, 1999, NAT GENET, V23, P16, DOI 10.1038/12612; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kimberling WJ, 1999, AM J MED GENET, V89, P121, DOI 10.1002/(SICI)1096-8628(19990924)89:3<121::AID-AJMG1>3.0.CO;2-U; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Kudo T, 2000, AM J MED GENET, V90, P141, DOI 10.1002/(SICI)1096-8628(20000117)90:2<141::AID-AJMG10>3.0.CO;2-G; Lim DJ, 1998, KIDNEY INT, pS104; Liu XZ, 2000, HUM MOL GENET, V9, P63, DOI 10.1093/hmg/9.1.63; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; MARAZITA ML, 1993, AM J MED GENET, V46, P486, DOI 10.1002/ajmg.1320460504; McGuirt WT, 1999, NAT GENET, V23, P413, DOI 10.1038/70516; Middleton A, 1998, AM J HUM GENET, V63, P1175, DOI 10.1086/302060; Middleton A, 2001, J Genet Couns, V10, P121, DOI 10.1023/A:1009439630457; Morell RJ, 1998, NEW ENGL J MED, V339, P1500, DOI 10.1056/NEJM199811193392103; Mustapha M, 1999, HUM MOL GENET, V8, P409, DOI 10.1093/hmg/8.3.409; NANCE W E, 1971, Birth Defects Original Article Series, V7, P70; Nance WE, 2000, LANCET, V356, P500, DOI 10.1016/S0140-6736(00)02565-4; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; *OMIM NAT LIB MED, 2000, ONL MEN INH MAN; Pandya A, 1999, AM J HUM GENET, V65, P1803, DOI 10.1086/302658; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; Reardon W, 1997, QJM-MON J ASSOC PHYS, V90, P443, DOI 10.1093/qjmed/90.7.443; Reardon W, 1999, J MED GENET, V36, P595; Riazuddin S, 2000, NAT GENET, V26, P431, DOI 10.1038/82558; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Robertson NG, 1998, NAT GENET, V20, P299, DOI 10.1038/3118; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; Scott DA, 2000, HUM MOL GENET, V9, P1709, DOI 10.1093/hmg/9.11.1709; Stern S. J., 2000, American Journal of Human Genetics, V67, P32; Tekin M, 2001, CLIN GENET, V59, P269, DOI 10.1034/j.1399-0004.2001.590409.x; TEKIN M, IN PRESS HUM GENET; Van Camp G, 2000, CLIN GENET, V57, P409, DOI 10.1034/j.1399-0004.2000.570601.x; VANCAMP G, 2001, HEREDITARY HEARING L; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wilcox ER, 2001, CELL, V104, P165, DOI 10.1016/S0092-8674(01)00200-8; Xia JH, 1998, NAT GENET, V20, P370, DOI 10.1038/3845; Yoshinaga-Itano C, 1999, OTOLARYNG CLIN N AM, V32, P1089, DOI 10.1016/S0030-6665(05)70196-1; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	57	101	116	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	2001	358	9287					1082	1090		10.1016/S0140-6736(01)06186-4	http://dx.doi.org/10.1016/S0140-6736(01)06186-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589958				2022-12-28	WOS:000171393100030
J	Thompson, WT; Cupples, ME; Sibbett, CH; Skan, DI; Bradley, T				Thompson, WT; Cupples, ME; Sibbett, CH; Skan, DI; Bradley, T			Challenge of culture, conscience, and contract to general practitioners' care of their own health: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							DOCTORS; ILLNESS; SICKNESS; STRESS; JOB	Objective To explore general practitioners' perceptions of the effects of their profession and training on their attitudes to illness in themselves and colleagues. Design Qualitative study using focus groups and indepth interviews. Setting Primary care in Northern Ireland. Participants 27 general practitioners, including six recently appointed principals and six who also practised occupational medicine part time. Main outcome measures Participants' views about their own and colleagues' health. Results Participants were concerned about the current level of illness within the profession. They described their need to portray a healthy image to both patients and colleagues. This hindered acknowledgement of personal illness and engaging in health screening. Embarrassment in adopting the role of a patient and concerns about confidentiality also influenced their reactions to personal illness. Doctors' attitudes can impede their access to appropriate health care for themselves, their families, and their colleagues. A sense of conscience towards patients and colleagues and the working arrangements of the practice were cited as reasons for working through illness and expecting colleagues to do likewise. Conclusions General practitioners perceive that their professional position and training adversely influence their attitudes to illness in themselves and their colleagues. Organisational changes within general practice, including revalidation, must take account of barriers experienced by general practitioners in accessing health care. Medical education and culture should strive to promote appropriate self care among doctors.	Queens Univ Belfast, Sch Med, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland; Queens Univ Belfast, Grad Sch Educ, Belfast BT7 1HL, Antrim, North Ireland; Hlth & Safety Execut No Ireland, Employment Med Advisory Serv, Belfast BT6 9FR, Antrim, North Ireland; No Ireland Council Postgrad Med & Dent Educ, Belfast BT7 3JH, Antrim, North Ireland	Queens University Belfast; Queens University Belfast	Cupples, ME (corresponding author), Queens Univ Belfast, Sch Med, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland.			Cupples, Margaret/0000-0002-4248-9700				Appleton K, 1998, BRIT J GEN PRACT, V48, P1059; *BMA BOARD SCI ED, 1993, MORB MORT MED PROF; BRANDON S, 1997, BRIT MED J, V314, P2; Chambers R, 1996, BRIT MED J, V312, P722; CHAMBERS R, 1992, BRIT J GEN PRACT, V42, P153; Clarke J, 1998, IRISH MED J, V91, P175; Forsythe M, 1999, BRIT MED J, V319, P605, DOI 10.1136/bmj.319.7210.605; *GEN MED COUNC, 1998, GOOD MED PRACT; *GEN MED COUNC, 2000, REV DOCT ENS STAND; Gilliland AEV, 1998, BRIT J GEN PRACT, V48, P1663; Glaser B.G., 1965, AWARENESS DYING; *HLTH POL EC RES U, 2000, WORK REL STRESS SEN; KING MB, 1992, J ROY SOC MED, V85, P605; McKevitt C, 1997, J PUBLIC HEALTH MED, V19, P295, DOI 10.1093/oxfordjournals.pubmed.a024633; McKevitt C, 1997, SOCIOL HEALTH ILL, V19, P644, DOI 10.1111/1467-9566.ep10935530; McKevitt C, 1996, DOCTORS HLTH NEEDS S; MILLAR RL, 2000, RES LIFE STORIES FAM; MORTONWILLIAMS J, 1988, APPL QUALITATIVE RES, P27; PILOWSKI L, 1989, BRIT MED J, V298, P269, DOI 10.1136/bmj.298.6669.269; Schneck SA, 1998, JAMA-J AM MED ASSOC, V280, P2039, DOI 10.1001/jama.280.23.2039; Waldron HA, 1996, ANN OCCUP HYG, V40, P391, DOI 10.1093/annhyg/40.4.391; Wall TD, 1997, BRIT J PSYCHIAT, V171, P519, DOI 10.1192/bjp.171.6.519; Williams S, 1998, IMPROVING HLTH NHS W; 1994, LANCET, V344, P1583	24	107	109	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					728	731		10.1136/bmj.323.7315.728	http://dx.doi.org/10.1136/bmj.323.7315.728			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	478HJ	11576981	Green Published			2022-12-28	WOS:000171340700021
J	Nash, MS; Young, KW; Challiss, RAJ; Nahorski, SR				Nash, MS; Young, KW; Challiss, RAJ; Nahorski, SR			Intracellular signalling - Receptor-specific messenger oscillations	NATURE			English	Article							CALCIUM OSCILLATIONS; FEEDBACK		Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Nash, MS (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.		Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Petersen OH, 1999, TRENDS NEUROSCI, V22, P488, DOI 10.1016/S0166-2236(99)01456-3; Taylor CW, 2001, CURR BIOL, V11, pR352, DOI 10.1016/S0960-9822(01)00192-0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200	12	114	115	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					381	382		10.1038/35096643	http://dx.doi.org/10.1038/35096643			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574876				2022-12-28	WOS:000171188700042
J	Katz, JN				Katz, JN			Patient preferences and health disparities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INVASIVE CARDIAC PROCEDURES; SHARED DECISION-MAKING; TOTAL HIP; SOCIOECONOMIC-STATUS; RACIAL-DIFFERENCES; INTERACTIVE VIDEO; RACE; PHYSICIANS; ACCESS; REPLACEMENT		Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Katz, JN (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, 75 Francis St,B-3, Boston, MA 02115 USA.	jnkatz@partners.org			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308, K24AR002123] Funding Source: NIH RePORTER; AHRQ HHS [1R01 HS09775-01] Funding Source: Medline; NIAMS NIH HHS [P01 AR36308, K24 AR 02123] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAIDOLANZA AF, 1997, J GENDER CULTURE HLT, V2, P143; Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P656, DOI 10.1056/NEJM199308263290912; BAILEY EJ, 1987, J NATL MED ASSOC, V79, P389; Baron JA, 1996, AM J PUBLIC HEALTH, V86, P70, DOI 10.2105/AJPH.86.1.70; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BARRY MJ, 1995, MED CARE, V33, P771, DOI 10.1097/00005650-199508000-00003; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; Coyte PC, 1996, J RHEUMATOL, V23, P730; Deyo RA, 2000, MED CARE, V38, P959, DOI 10.1097/00005650-200009000-00009; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; Escalante A, 2000, ARTHRITIS RHEUM, V43, pS106; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; GRIFFIN N, 1986, JAMA-J AM MED ASSOC, V256, P1032; Hannan EL, 1999, MED CARE, V37, P68, DOI 10.1097/00005650-199901000-00010; HARRIS WH, 1990, NEW ENGL J MED, V323, P801, DOI 10.1056/NEJM199009203231206; Hawker GA, 2000, NEW ENGL J MED, V342, P1016, DOI 10.1056/NEJM200004063421405; Hine D. C., 1989, BLACK WOMEN WHITE RA; *HJ KAIS FAM FDN, 1999, RAC ETHN MED CAR SUR; Ibrahim SA, 2000, J CLIN EPIDEMIOL, V53, P441; Iezzoni LI, 1997, MED CARE, V35, P158, DOI 10.1097/00005650-199702000-00006; Kaplan RM, 1999, ANN BEHAV MED, V21, P3, DOI 10.1007/BF02895027; Karlson EW, 1997, AM J MED, V102, P524; Katz JN, 2001, MED CARE, V39, P203, DOI 10.1097/00005650-200103000-00001; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; Larkey LK, 2001, HEALTH EDUC BEHAV, V28, P65, DOI 10.1177/109019810102800107; Liao L, 1996, J GEN INTERN MED, V11, P373, DOI 10.1007/BF02600051; Mandelblatt JS, 2000, CANCER, V89, P561, DOI 10.1002/1097-0142(20000801)89:3<561::AID-CNCR11>3.0.CO;2-A; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; Montano D.E., 1997, HLTH BEHAV HLTH ED T; ODDONE EZ, 1993, ARCH INTERN MED, V153, P2781, DOI 10.1001/archinte.153.24.2781; Oddone EZ, 1998, J NATL MED ASSOC, V90, P25; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; Rankin EA, 1996, J NATL MED ASSOC, V88, P506; Saha S, 2000, HEALTH AFFAIR, V19, P76, DOI 10.1377/hlthaff.19.4.76; Schneider EC, 2001, JAMA-J AM MED ASSOC, V286, P1455, DOI 10.1001/jama.286.12.1455; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; *US DEP HHS, 2001, HLTH PEOPL 2010; WAGNER EH, 1995, MED CARE, V33, P765, DOI 10.1097/00005650-199508000-00002; WEINSTEIN J, 2000, DARTMOUTH ATLAS MUSC; Weinstein JN, 2000, SPINE, V25, P1; Whittle J, 1997, J GEN INTERN MED, V12, P267, DOI 10.1046/j.1525-1497.1997.012005267.x; Williams DR, 1999, ANN NY ACAD SCI, V896, P173, DOI 10.1111/j.1749-6632.1999.tb08114.x; Wilson Marcus Garvey, 1994, Ethnicity and Disease, V4, P57	48	134	135	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1506	1509		10.1001/jama.286.12.1506	http://dx.doi.org/10.1001/jama.286.12.1506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	475UX	11572745				2022-12-28	WOS:000171188600030
J	Ridker, PM				Ridker, PM			Role of inflammatory biomarkers in prediction of coronary heart disease	LANCET			English	Editorial Material							CELL-ADHESION MOLECULES; C-REACTIVE PROTEIN; ATHEROSCLEROSIS; SELECTIN; MICE		Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ridker, PM (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA.							Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Frenette PS, 1996, NEW ENGL J MED, V334, P1526, DOI 10.1056/NEJM199606063342308; Hackman A, 1996, CIRCULATION, V93, P1334, DOI 10.1161/01.CIR.93.7.1334; Hwang SJ, 1997, CIRCULATION, V96, P4219; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; Nageh MF, 1997, ARTERIOSCL THROM VAS, V17, P1517, DOI 10.1161/01.ATV.17.8.1517; Pasceri V, 2000, CIRCULATION, V102, P2165; Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Ridker PM, 2001, CIRCULATION, V103, P491, DOI 10.1161/01.CIR.103.4.491; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207	12	103	108	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					946	948		10.1016/S0140-6736(01)06112-8	http://dx.doi.org/10.1016/S0140-6736(01)06112-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583743				2022-12-28	WOS:000171135300010
J	von Reyn, CF; Waddell, R; Pallanygo, K				von Reyn, CF; Waddell, R; Pallanygo, K			Extrapulmonary tuberculosis	LANCET			English	Letter									Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA; Muhimbili Univ, Coll Hlth Sci, Dar Es Salaam, Tanzania	Dartmouth College	von Reyn, CF (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.							Archibald LK, 1998, CLIN INFECT DIS, V26, P290, DOI 10.1086/516297; GILKS CF, 1995, J ACQ IMMUN DEF SYND, V8, P195; Harries AD, 2001, LANCET, V357, P1519, DOI 10.1016/S0140-6736(00)04639-0; McDonald LC, 1999, LANCET, V354, P1159, DOI 10.1016/S0140-6736(98)12325-5; Waddell RD, 2001, AIDS, V15, P55, DOI 10.1097/00002030-200101050-00009	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					1010	1011		10.1016/S0140-6736(01)06132-3	http://dx.doi.org/10.1016/S0140-6736(01)06132-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11586981				2022-12-28	WOS:000171135300041
J	Wilson, T; Holt, T				Wilson, T; Holt, T			Complexity science - Complexity and clinical care	BRITISH MEDICAL JOURNAL			English	Article							BEHAVIOR; SMOKING; GLUCOSE; CHAOS		Royal Coll Gen Practitioners, St Paul RCGP Qual Unit, London SW7 1PU, England; Danby Practice, Dale End Surg, Danby YO21 2JE, Whitby, England		Wilson, T (corresponding author), Royal Coll Gen Practitioners, St Paul RCGP Qual Unit, London SW7 1PU, England.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				BALINT M, 1955, LANCET, V1, P683; BAXT WG, 1994, CANCER LETT, V77, P85, DOI 10.1016/0304-3835(94)90090-6; Benson H, 1996, ANNU REV MED, V47, P193; Chantelau E, 1997, BRIT MED J, V315, P185; Cox K, 1995, AUST NZ J SURG, V65, P553, DOI 10.1111/j.1445-2197.1995.tb01693.x; DICLEMENTE CC, 1982, ADDICT BEHAV, V7, P133, DOI 10.1016/0306-4603(82)90038-7; Goldberger AL, 1996, LANCET, V347, P1312, DOI 10.1016/S0140-6736(96)90948-4; Goldstein J., 1994, UNSHACKLED ORG; Greenhalgh T, 1999, BMJ-BRIT MED J, V318, P323, DOI 10.1136/bmj.318.7179.323; GREENHALGH T, IN PRESS BR J GEN PR; Gustafson D. H., 1992, SYSTEMS SUPPORT HLTH; Jack D, 2001, LANCET, V357, P1185, DOI 10.1016/S0140-6736(00)04391-9; Kroll MH, 1999, BIOSYSTEMS, V50, P189, DOI 10.1016/S0303-2647(99)00007-6; Lancaster T, 2000, BRIT MED J, V321, P355, DOI 10.1136/bmj.321.7257.355; Langley Gj., 1996, IMPROVEMENT GUIDE PR; Liszka-Hackzell JJ, 1999, COMPUT BIOMED RES, V32, P132, DOI 10.1006/cbmr.1998.1506; Mullen PD, 1997, BRIT MED J, V314, P691, DOI 10.1136/bmj.314.7082.691; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; Plsek P, 2001, BMJ, P323; Queale WS, 1997, ARCH INTERN MED, V157, P545, DOI 10.1001/archinte.157.5.545; Rogers E., 2003, DIFFUSION INNOVATION, VFifth; Ross A, 1998, BRIT MED J, V317, P1525, DOI 10.1136/bmj.317.7171.1525a; Rosser WW, 1996, J FAM PRACTICE, V42, P139; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Stacey RD., 1999, STRATEGIC MANAGEMENT; Zimmerman B., 1998, EDGEWARE INSIGHTS CO	26	259	264	1	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					685	688		10.1136/bmj.323.7314.685	http://dx.doi.org/10.1136/bmj.323.7314.685			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	476LP	11566836	Green Published			2022-12-28	WOS:000171228800029
J	Strohmaier, H; Spruck, CH; Kaiser, P; Won, KA; Sangfelt, O; Reed, SI				Strohmaier, H; Spruck, CH; Kaiser, P; Won, KA; Sangfelt, O; Reed, SI			Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line	NATURE			English	Article								Cyclin E, one of the activators of the cyclin-dependent kinase Cdk2, is expressed near the G(1)-S phase transition and is thought to be critical for the initiation of DNA replication and other S-phase functions(1-3). Accumulation of cyclin E at the G(1)-S boundary is achieved by periodic transcription coupled with regulated proteolysis linked to autophosphorylation of cyclin E-4. The proper timing and amplitude of cyclin E expression seem to be important, because elevated levels of cyclin E have been associated with a variety of malignancies(5,6) and constitutive expression of cyclin E leads to genomic instability(7). Here we show that turnover of phosphorylated cyclin E depends on an SCF-type protein-ubiquitin ligase that contains the human homologue of yeast Cdc4, which is an F-box protein containing repeated sequences of WD40 (a unit containing about 40 residues with tryptophan (W) and aspartic acid (D) at defined positions). The gene encoding hCdc4 was found to be mutated in a cell line derived from breast cancer that expressed extremely high levels of cyclin E.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Karolinska Hosp, Dept Oncol Pathol, S-17176 Stockholm, Sweden	Scripps Research Institute; Karolinska Institutet; Karolinska University Hospital	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB-7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	sreed@scripps.edu						BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Reed SI, 1996, BBA-REV CANCER, V1287, P151, DOI 10.1016/0304-419X(96)00006-6; Reed SI, 1997, CANCER SURV, V29, P7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sandhu C, 2000, CANCER DETECT PREV, V24, P107; Sauer K, 1995, Prog Cell Cycle Res, V1, P125; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442	26	499	513	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 20	2001	413	6853					316	322		10.1038/35095076	http://dx.doi.org/10.1038/35095076			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565034				2022-12-28	WOS:000171040500041
J	Melling, AC; Ali, B; Scott, EM; Leaper, DJ				Melling, AC; Ali, B; Scott, EM; Leaper, DJ			Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomised controlled trial	LANCET			English	Article							ANTIBIOTIC-PROPHYLAXIS; GENERAL-SURGERY; BREAST SURGERY; OXYGEN-TENSION; RISK-FACTORS; SURVEILLANCE; HOSPITALIZATION; COSTS	Background Wound infection after clean surgery is an expensive and often underestimated cause of patient morbidity, and the benefits of using prophylactic antibiotics have not been proven. Warming patients during colorectal surgery has been shown to reduce infection rates. We aimed to assess whether warming patients before short duration, clean surgery would have the same effect. Methods 421 patients having clean (breast, varicose vein, or hernia) surgery were randomly assigned to either a non-warmed (standard) group or one of two warmed groups (local and systemic). We applied warming for at least 30 min before surgery. Patients were followed up and masked outcome assessments made at 2 and 6 weeks. Findings Analysis was done on an intention-to-treat basis. We identified 19 wound infections in 139 non-warmed patients (14%) but only 13 in 277 who received warming (5%; p=0.001). Wound scores were also significantly lower (p=0.007) in warmed patients. There was no significant difference in the development of haematomas or seromas after surgery but the non-warmed group were prescribed significantly more postoperative antibiotics (p=0.002) Interpretation Warming patients before clean surgery seems to aid the prevention of postoperative wound infection. If applied according to the manufacturers guidelines these therapies have no known side-effects and might, with the support of further studies, provide an alternative to prophylactic antibiotics in this type of surgery.	Univ Hosp N Tees, N Tees & Hartlepool NHS Trust, Professorial Surg Unit, Stockton On Tees TS19 8PE, England	University Hospital of North Tees	Melling, AC (corresponding author), Univ Hosp N Tees, N Tees & Hartlepool NHS Trust, Professorial Surg Unit, Stockton On Tees TS19 8PE, England.	andymelling@pop.compuserve.com						BAILEY IS, 1992, BRIT MED J, V304, P469, DOI 10.1136/bmj.304.6825.469; BARBER GR, 1995, ARCH SURG-CHICAGO, V130, P1042; BREMMELGAARD A, 1989, J HOSP INFECT, V13, P1, DOI 10.1016/0195-6701(89)90090-X; BYRNE DJ, 1994, J HOSP INFECT, V26, P37, DOI 10.1016/0195-6701(94)90077-9; CRUSE PJE, 1980, SURG CLIN N AM, V60, P27; Gupta R, 2000, EUR J SURG ONCOL, V26, P363, DOI 10.1053/ejso.1999.0899; Hopf HW, 1997, ARCH SURG-CHICAGO, V132, P997; Ikeda T, 1998, AM J SURG, V175, P33, DOI 10.1016/S0002-9610(97)00237-7; KEELING NJ, 1995, ANN ROY COLL SURG, V77, P245; Kirkland KB, 1999, INFECT CONT HOSP EP, V20, P725, DOI 10.1086/501572; Kleinert JM, 1997, J BONE JOINT SURG AM, V79A, P503, DOI 10.2106/00004623-199704000-00005; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LAW DJW, 1990, ANN ROY COLL SURG, V72, P207; LizanGarcia M, 1997, INFECT CONT HOSP EP, V18, P310; Lynch W, 1992, Pharmacoeconomics, V2, P163, DOI 10.2165/00019053-199202020-00008; MILES AA, 1957, BRIT J EXP PATHOL, V38, P79; Moro M L, 1996, Ann Ital Chir, V67, P13; *NAT RES COUNC AD, 1964, ANN SURG S2, V160, P33; PLATT R, 1990, NEW ENGL J MED, V322, P153, DOI 10.1056/NEJM199001183220303; Sackett D. L., 1997, EVIDENCE BASED MED P; SEROPIAN R, 1971, AM J SURG, V121, P251, DOI 10.1016/0002-9610(71)90199-1; Sheffield C W, 1994, Wound Repair Regen, V2, P48, DOI 10.1046/j.1524-475X.1994.20108.x; SHEFFIELD CW, 1994, ACTA ANAESTH SCAND, V38, P201, DOI 10.1111/j.1399-6576.1994.tb03873.x; Taylor EW, 1997, WORLD J SURG, V21, P811, DOI 10.1007/s002689900311; WILSON APR, 1986, LANCET, V1, P311; WILSON APR, 1995, J HOSP INFECT, V29, P81, DOI 10.1016/0195-6701(95)90190-6; Zoutman D, 1998, INFECT CONT HOSP EP, V19, P254	27	408	430	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 15	2001	358	9285					876	880		10.1016/S0140-6736(01)06071-8	http://dx.doi.org/10.1016/S0140-6736(01)06071-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567703				2022-12-28	WOS:000171087000009
J	Pradillon, F; Shillito, B; Young, CM; Gaill, F				Pradillon, F; Shillito, B; Young, CM; Gaill, F			Deep-seaecology - Developmental arrest in vent worm embryos	NATURE			English	Article							LARVAL DISPERSAL; HOT		Univ Paris 06, Unite Mixte Rech, F-75252 Paris 05, France; Harbor Branch Oceanog Inst Inc, Div Marine Sci, Ft Pierce, FL 34946 USA	UDICE-French Research Universities; Sorbonne Universite; Harbor Branch Oceanographic Institute Foundation	Pradillon, F (corresponding author), Univ Paris 06, Unite Mixte Rech, 7 Quai St Bernard, F-75252 Paris 05, France.	francoise.gaill@snv.jussieu.fr	Pradillon, Florence/AAM-2992-2020	Pradillon, Florence/0000-0002-6473-6290				Cary SC, 1998, NATURE, V391, P545, DOI 10.1038/35286; CHEVALDONNE P, 1992, NATURE, V359, P593, DOI 10.1038/359593b0; EDMOND JM, 1982, NATURE, V297, P187, DOI 10.1038/297187a0; LUTZ RA, 1980, MAR BIOL, V57, P127, DOI 10.1007/BF00387378; Marsh AG, 2001, NATURE, V411, P77, DOI 10.1038/35075063; MULLINEAUX LS, 1995, SEAFLOOR HYDROTHERMA, P408; YOUNG CM, 1989, OLSEN INT S, P225; YOUNG CM, 1993, LIMNOL OCEANOGR, V38, P178; ZOTTOLI R, 1983, Proceedings of the Biological Society of Washington, V96, P379	9	80	88	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 18	2001	413	6857					698	699		10.1038/35099674	http://dx.doi.org/10.1038/35099674			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482ZK	11607020				2022-12-28	WOS:000171608000032
J	Aeppli, G; Soh, YA				Aeppli, G; Soh, YA			Physics - Quantum criticality in a clean metal	SCIENCE			English	Editorial Material							INSTABILITY; BEHAVIOR; SR3RU2O7; STATE		NEC Res Inst, Princeton, NJ 08540 USA	NEC Corporation	Aeppli, G (corresponding author), NEC Res Inst, 4 Independence Way, Princeton, NJ 08540 USA.	gabe@research.nj.nec.com						Aeppli G, 1997, SCIENCE, V278, P1432, DOI 10.1126/science.278.5342.1432; Aoki Y, 1998, J MAGN MAGN MATER, V177, P271, DOI 10.1016/S0304-8853(97)00484-8; Bitko D, 1996, PHYS REV LETT, V77, P940, DOI 10.1103/PhysRevLett.77.940; CAVA RJ, 1995, J SOLID STATE CHEM, V116, P141, DOI 10.1006/jssc.1995.1195; Grigera SA, 2001, SCIENCE, V294, P329, DOI 10.1126/science.1063539; HERTZ JA, 1976, PHYS REV B, V14, P1165, DOI 10.1103/PhysRevB.14.1165; Ikeda S, 2000, PHYS REV B, V62, pR6089, DOI 10.1103/PhysRevB.62.R6089; Kima JS, 2000, SOLID STATE COMMUN, V114, P413, DOI 10.1016/S0038-1098(00)00084-3; KIVELSON S, IN PRESS P NATL ACAD; OSHEROFF DD, 1980, PHYS LETT A, V77, P458, DOI 10.1016/0375-9601(80)90539-3; Perry RS, 2001, PHYS REV LETT, V86, P2661, DOI 10.1103/PhysRevLett.86.2661; Sachdev S., 1999, QUANTUM PHASE TRANSI; Schroder A, 2000, NATURE, V407, P351, DOI 10.1038/35030039; Sondhi SL, 1997, REV MOD PHYS, V69, P315, DOI 10.1103/RevModPhys.69.315; Stanley HE., 1971, PHASE TRANSITIONS CR; TAKAGI H, 1992, PHYS REV LETT, V69, P2975, DOI 10.1103/PhysRevLett.69.2975; VONLOHNEYSEN H, 1994, PHYS REV LETT, V72, P3262, DOI 10.1103/PhysRevLett.72.3262	17	10	10	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 12	2001	294	5541					315	316		10.1126/science.1065115	http://dx.doi.org/10.1126/science.1065115			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598287				2022-12-28	WOS:000171601400027
J	Deuss, A; Woodhouse, J				Deuss, A; Woodhouse, J			Seismic observations of splitting of the mid-transition zone discontinuity in Earth's mantle	SCIENCE			English	Article							TRANSITION ZONE; HYDROUS RINGWOODITE; TOPOGRAPHY; PHASE	The transition zone of Earth's mantle is delineated by globally observed discontinuities in seismic properties at depths of about 410 and 660 kilometers. Here, we investigate the detailed structure between 410 and 660 kilometers depth, by making use of regional stacks of precursors to the SS phase. The previously observed discontinuity at about 520 kilometers depth is confirmed in many regions, but is found to be absent in others. There are a number of regions in which we find two discontinuities at about 500 and 560 kilometers depth, an effect which can be interpreted as a "splitting" of the 520 kilometer discontinuity. These observations provide seismic constraints on the sharpness and observability of mineralogical phase transitions in the mantle transition zone.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	University of Oxford	Deuss, A (corresponding author), Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England.	arwen.deuss@earth.ox.ac.uk	Deuss, Arwen/F-6254-2012	Deuss, Arwen/0000-0003-3193-5987				BENZ HM, 1993, NATURE, V365, P147, DOI 10.1038/365147a0; CANIL D, 1994, PHYS EARTH PLANET IN, V86, P25, DOI 10.1016/0031-9201(94)05059-7; CHAPMAN CH, 1976, GEOPHYS RES LETT, V3, P153, DOI 10.1029/GL003i003p00153; CUMMINS PR, 1992, B SEISMOL SOC AM, V82, P323; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; FEI Y, 1999, GEOCHEM SOC SPEC PUB, V6, P189; Flanagan MP, 1998, J GEOPHYS RES-SOL EA, V103, P2673, DOI 10.1029/97JB03212; Gossler J, 1996, EARTH PLANET SC LETT, V138, P1, DOI 10.1016/0012-821X(95)00215-X; Gu Y, 1998, EARTH PLANET SC LETT, V157, P57, DOI 10.1016/S0012-821X(98)00027-2; Inoue T, 1998, EARTH PLANET SC LETT, V160, P107, DOI 10.1016/S0012-821X(98)00077-6; ITA J, 1992, J GEOPHYS RES-SOL EA, V97, P6849, DOI 10.1029/92JB00068; JONES LE, 1992, J GEOPHYS RES-SOL EA, V97, P8765, DOI 10.1029/92JB00887; Koito S, 2000, PHYS EARTH PLANET IN, V120, P1, DOI 10.1016/S0031-9201(99)00171-5; MOONEY WD, 1995, EOS T AGU S, V76, pF421; REVENAUGH J, 1991, J GEOPHYS RES, V96, P19736; RIGDEN SM, 1991, NATURE, V354, P143, DOI 10.1038/354143a0; Ringwood A.E, 1975, COMPOSITION PETROLOG; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; Ryberg T, 1997, J GEOPHYS RES-SOL EA, V102, P5413, DOI 10.1029/96JB03179; SHEARER PM, 1990, NATURE, V344, P121, DOI 10.1038/344121a0; SHEARER PM, 1992, NATURE, V355, P791, DOI 10.1038/355791a0; Shearer PM, 1996, J GEOPHYS RES-SOL EA, V101, P3053, DOI 10.1029/95JB02812; Simmons NA, 2000, NATURE, V405, P559, DOI 10.1038/35014589; Weidner DJ., 2000, EARTHS DEEP INTERIOR, P215, DOI [10.1029/gm117p0215, DOI 10.1029/GM117P0215]; Yusa H, 2000, GEOPHYS RES LETT, V27, P413, DOI 10.1029/1999GL011032	26	122	129	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 12	2001	294	5541					354	357		10.1126/science.1063524	http://dx.doi.org/10.1126/science.1063524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598296				2022-12-28	WOS:000171601400038
J	Etterson, JR; Shaw, RG				Etterson, JR; Shaw, RG			Constraint to adaptive evolution in response to global warming	SCIENCE			English	Article							CHAMAECRISTA-FASCICULATA; QUANTITATIVE GENETICS; NATURAL-SELECTION; SIZE	We characterized the genetic architecture of three populations of a native North American prairie plant in field conditions that simulate the warmer and more and climates predicted by global climate models. Despite genetic variance for traits under selection, among-trait genetic correlations that are antagonistic to the direction of selection limit adaptive evolution within these populations. Predicted rates of evolutionary response are much slower than the predicted rate of climate change.	Univ Minnesota, Dept Ecol Evolut & Behav, Minnesota Ctr Community Genet, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Etterson, JR (corresponding author), Univ Virginia, Dept Biol, Gilmer Hall, Charlottesville, VA 22903 USA.			Etterson, Julie/0000-0001-6657-0610				ANTONOVICS J, 1976, ANN MO BOT GARD, V63, P224, DOI 10.2307/2395303; BARTON NH, 1989, ANNU REV GENET, V23, P337, DOI 10.1146/annurev.ge.23.120189.002005; Davis MB, 2001, SCIENCE, V292, P673, DOI 10.1126/science.292.5517.673; ETTERSON JR, 2000, THESIS U MINNESOTA S; FENSTER CB, 1991, EVOLUTION, V45, P398, DOI 10.1111/j.1558-5646.1991.tb04413.x; GROOM MJ, 1993, BIOTIC INTERACTIONS; HUNTLY B, 1997, PAST FUTURE RAPID EN; KALISZ S, 1986, EVOLUTION, V40, P470; KELLY CA, 1992, EVOLUTION, V46, P1658, DOI 10.2307/2410022; LANDE R, 1979, EVOLUTION, V33, P402, DOI 10.2307/2407630; LANDE R, 1983, EVOLUTION, V37, P1210, DOI 10.2307/2408842; MITCHELLOLDS T, 1987, EVOLUTION, V41, P1149, DOI [10.2307/2409084, 10.1111/j.1558-5646.1987.tb02457.x]; PRICE GR, 1970, NATURE, V227, P520, DOI 10.1038/227520a0; ROBERTSON A, 1966, ANIM PROD, V8, P95, DOI 10.1017/S0003356100037752; SHAW RG, 1987, EVOLUTION, V41, P812, DOI 10.1111/j.1558-5646.1987.tb05855.x; SHAW RG, 1994, QUERCUS PROGRAMS; Shigesada N., 1997, BIOL INVASIONS THEOR; THOMPSON RS, 2000, 1650 AB US GEOL SURV; WALKER KV, COMMUNICATION	19	611	622	7	332	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					151	154		10.1126/science.1063656	http://dx.doi.org/10.1126/science.1063656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588260				2022-12-28	WOS:000171448800049
J	Schwetz, BA				Schwetz, BA			Congestive heart failure treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drug, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner Food & Drug, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	4	4	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1569	1569		10.1001/jama.286.13.1569-b	http://dx.doi.org/10.1001/jama.286.13.1569-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585463				2022-12-28	WOS:000171340600006
J	Rahman, M; DaVanzo, J; Razzaque, A				Rahman, M; DaVanzo, J; Razzaque, A			Do better family planning services reduce abortion in Bangladesh?	LANCET			English	Article							MATERNAL MORTALITY; RURAL BANGLADESH; PROGRAMS; MATLAB; DECLINE; TRENDS; AREA	Background Fertility decline is often associated with an increase in contraception and abortion, but the causal relations are difficult to examine with non-experimental data. We aimed to assess the effects of family planning services on abortion rates in two similar areas. Methods We examined trends in overall abortion rates and rates for intended and unintended pregnancies in two similar areas typical of rural Bangladesh. We analysed Matlab Demographic Surveillance System (DSS) data on pregnancy outcomes between 1979 and 1998 in these areas, matching them to survey data on fertility preferences, which enabled us to identify pregnancies as intended or unintended. Findings Abortion rates were significantly lower in the area with better family planning services compared with the comparison area (1984-86, 2.2 vs 5.2; 1996-98, 2.3 vs 6.8). Abortion of unintended pregnancies is similar in both areas, but the higher levels of contraceptive use in the treatment area have led to lower levels of unintended pregnancy and abortion. The likelihood that an unintended pregnancy will be aborted has increased in both areas but the decrease in unintended pregnancies was sufficiently large in the treatment area to offset this increase. Interpretations Abortion may increase during the fertility transition in less-developed countries as the desire to limit family size increases unless there is widespread availability of quality family planning services.	Pathfinder Int, Watertown, MA 02472 USA; RAND Corp, Santa Monica, CA 90401 USA; Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res B, Dhaka 1000, Bangladesh	RAND Corporation; International Centre for Diarrhoeal Disease Research (ICDDR)	Rahman, M (corresponding author), Pathfinder Int, 9 Galen St,Ste 217, Watertown, MA 02472 USA.	MRahman@pathfind.org						Ahmed K., 1996, DEMOGRAPHY INDIA, V25, P105; Ahmed MK, 1998, INT FAM PLAN PERSPEC, V24, P128, DOI 10.2307/3038209; ALAUDDIN M, 1986, STUD FAMILY PLANN, V17, P13, DOI 10.2307/1966951; BAIRAGI R, 2000, MCH FP PROGRAM BRING; BHATIA S, 1980, J BIOSOC SCI, V12, P31, DOI 10.1017/S0021932000012669; Bulatao R., 1998, VALUE FAMILY PLANNIN; Caldwell B, 2000, STUD FAMILY PLANN, V31, P239, DOI 10.1111/j.1728-4465.2000.00239.x; CHEN LC, 1974, STUD FAMILY PLANN, V5, P334, DOI 10.2307/1965185; DIXONMUELLER R, 1988, STUD FAMILY PLANN, V19, P129, DOI 10.2307/1966749; FAUVEAU V, 1989, SOC SCI MED, V29, P1121, DOI 10.1016/0277-9536(89)90025-7; Henshaw SK, 1999, INT FAM PLAN PERSPEC, V25, pS30, DOI 10.2307/2991869; *ICDDR B CTR HLTH, 2000, 87 ICDDR B CTR HLTH; KHAN AR, 1986, STUD FAMILY PLANN, V17, P95, DOI 10.2307/1967069; KOENIG MA, 1992, STUD FAMILY PLANN, V23, P352, DOI 10.2307/1966893; KOENIG MA, 1988, STUD FAMILY PLANN, V19, P69, DOI 10.2307/1966492; Maine D, 1996, STUD FAMILY PLANN, V27, P179, DOI 10.2307/2137952; MITRA S, 1997, BANGLADESH DEMOGRAPH; MITRA SNA, 1994, BANGLADESH DEMOGRAPH; *NAT I POP RES TRA, 2000, BANGL DEM HLTH SURV; POTTS M, 1977, ABORTION; REQUENA MB, 1968, MILBANK FUND Q, V46, P191; ROSS J, 1999, PROFILES FAMILY PLAN; SIMMONS GB, 1991, STUD FAMILY PLANN, V22, P83, DOI 10.2307/1966779; VANDERTAK J, 1974, ABORTION FERTILITY C; *WHO DIV REPR HLTH, 1998, UNS AB GLOB REG EST	25	40	40	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	2001	358	9287					1051	1056		10.1016/S0140-6736(01)06182-7	http://dx.doi.org/10.1016/S0140-6736(01)06182-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	479EY	11589936				2022-12-28	WOS:000171393100011
J	Jackson, JBC; Johnson, KG				Jackson, JBC; Johnson, KG			Paleoecology - Measuring past biodiversity	SCIENCE			English	Editorial Material							EXTINCTION; PATTERNS; DIVERSITY		Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Smithsonian Trop Res Inst, Balboa, Panama; Nat Hist Museum Los Agneles Cty, Los Angeles, CA 90007 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; Smithsonian Institution; Smithsonian Tropical Research Institute	Jackson, JBC (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.							Adrain JM, 2000, PALEOBIOLOGY, V26, P625, DOI 10.1666/0094-8373(2000)026<0625:STADAT>2.0.CO;2; ALLISON PA, 1993, GEOLOGY, V21, P65, DOI 10.1130/0091-7613(1993)021<0065:PSBPSD>2.3.CO;2; Alroy J, 2001, P NATL ACAD SCI USA, V98, P6261, DOI 10.1073/pnas.111144698; Behrensmeyer AK, 2000, PALEOBIOLOGY, V26, P103, DOI 10.1666/0094-8373(2000)26[103:TAP]2.0.CO;2; BUDD AF, 1994, J PALEONTOL, V68, P951, DOI 10.1017/S0022336000026585; Cheetham Alan H., 1999, Bulletins of American Paleontology, V357, P159; Collins Laurel S., 1999, Bulletins of American Paleontology, V357, P1; Conway Morris S., 1998, CRUCIBLE CREATION BU; Foote M, 1996, EVOLUTION, V50, P1, DOI 10.1111/j.1558-5646.1996.tb04467.x; FOOTE M, COMMUNICATION; Jackson J.B.C., 1996, EVOLUTION ENV TROPIC; JACKSON JBC, 1994, PALEOBIOLOGY, V20, P407, DOI 10.1017/S0094837300012902; Jackson JBC, 2000, PALEOBIOLOGY, V26, P221, DOI 10.1666/0094-8373(2000)26[221:LITLFM]2.0.CO;2; Jackson Jeremy B.C., 1999, Bulletins of American Paleontology, V357, P193; Jin YG, 2000, SCIENCE, V289, P432, DOI 10.1126/science.289.5478.432; Kestenbaum D, 1998, SCIENCE, V279, P798, DOI 10.1126/science.279.5352.798; Khain V.Y., 1981, INT GEOL REV, V23, P426, DOI [DOI 10.1080/00206818109455078, 10.1080/00206818109455078]; MAY RM, 1994, PHILOS T R SOC B, V343, P105, DOI 10.1098/rstb.1994.0014; MAY RM, 1990, PHILOS T R SOC B, V330, P171; Newman M, 2001, P NATL ACAD SCI USA, V98, P5955, DOI 10.1073/pnas.121190498; Pennisi E, 2000, SCIENCE, V289, P2306, DOI 10.1126/science.289.5488.2306; RAUP D M, 1976, Paleobiology, V2, P289; RAUP DM, 1994, P NATL ACAD SCI USA, V91, P6758, DOI 10.1073/pnas.91.15.6758; RAUP DM, 1991, PALEOBIOLOGY, V17, P37, DOI 10.1017/S0094837300010332; Roy K, 1996, PHILOS T R SOC B, V351, P1605, DOI 10.1098/rstb.1996.0144; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; Smith AB, 2001, PHILOS T R SOC B, V356, P351, DOI 10.1098/rstb.2000.0768; Stokstad E, 2001, SCIENCE, V291, P232, DOI 10.1126/science.291.5502.232; VALENTINE J W, 1970, Journal of Paleontology, V44, P410; VALENTINE JW, 1973, SCIENCE, V180, P1078, DOI 10.1126/science.180.4090.1078; Vermeij G.J., 1987, EVOLUTION ESCALATION; Wilson Moyra E. J., 1998, P165	32	92	98	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2401	+		10.1126/science.1063789	http://dx.doi.org/10.1126/science.1063789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577222				2022-12-28	WOS:000171237200031
J	Greengold, NL				Greengold, NL			Futility	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1420	1421		10.1001/jama.286.12.1420	http://dx.doi.org/10.1001/jama.286.12.1420			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572715				2022-12-28	WOS:000171188600001
J	Ludwig, DS; Ebbeling, CB				Ludwig, DS; Ebbeling, CB			Type 2 diabetes mellitus in children - Primary care and public health considerations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							POSTPRANDIAL STATE; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; GLYCEMIC INDEX; BIRTH-WEIGHT; RISK-FACTOR; SYNDROME-X; CHILDHOOD; ADOLESCENTS; OBESITY		Childrens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@tch.harvard.edu		Ludwig, David/0000-0003-3307-8544	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007699, K08DK002440] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07699-18, 1K08DK02440] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2000, Pediatrics, V105, P671; Arslanian S, 1996, J CLIN ENDOCR METAB, V81, P1058, DOI 10.1210/jc.81.3.1058; Bar-Or O, 1998, MED SCI SPORT EXER, V30, P2, DOI 10.1097/00005768-199801000-00002; BECKNIELSEN H, 1994, J CLIN INVEST, V94, P1714, DOI 10.1172/JCI117518; Blair SN, 1999, MED SCI SPORT EXER, V31, pS646, DOI 10.1097/00005768-199911001-00025; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Ceriello A, 2000, DIABETES-METAB RES, V16, P125, DOI 10.1002/(SICI)1520-7560(200003/04)16:2<125::AID-DMRR90>3.0.CO;2-4; Dabelea D, 1999, DIABETES CARE, V22, P944, DOI 10.2337/diacare.22.6.944; Dabelea D, 2000, J Matern Fetal Med, V9, P83, DOI 10.1002/(SICI)1520-6661(200001/02)9:1<83::AID-MFM17>3.0.CO;2-O; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Eckel RH, 1998, CIRCULATION, V97, P2099, DOI 10.1161/01.CIR.97.21.2099; Epstein LH, 2000, ARCH PEDIAT ADOL MED, V154, P220, DOI 10.1001/archpedi.154.3.220; Fagot-Campagna A, 2000, J PEDIATR-US, V136, P664, DOI 10.1067/mpd.2000.105141; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; Forsen T, 2000, ANN INTERN MED, V133, P176, DOI 10.7326/0003-4819-133-3-200008010-00008; Freemark M, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.4.e55; Glaser NS, 1998, WESTERN J MED, V168, P11; Glaser NS, 1997, PEDIATR CLIN N AM, V44, P307, DOI 10.1016/S0031-3955(05)70479-X; Gortmaker SL, 1996, ARCH PEDIAT ADOL MED, V150, P356, DOI 10.1001/archpedi.1996.02170290022003; Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433; Lefebvre P, 1998, DIABETIC MED, V15, pS63, DOI 10.1002/(SICI)1096-9136(1998120)15:4+<S63::AID-DIA737>3.3.CO;2-Z; Ludwig DS, 2000, J NUTR, V130, p280S, DOI 10.1093/jn/130.2.280S; MILLER JCB, 1994, AM J CLIN NUTR, V59, p747S, DOI 10.1093/ajcn/59.3.747S; Phillips DIW, 1998, DIABETES CARE, V21, pB150; PinhasHamiel O, 1996, J PEDIATR-US, V128, P608, DOI 10.1016/S0022-3476(96)80124-7; PiSunyer FX, 1996, CLIN THER, V18, P1006, DOI 10.1016/S0149-2918(96)80057-9; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Reaven GM, 1997, CURR OPIN LIPIDOL, V8, P23, DOI 10.1097/00041433-199702000-00006; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 2001, AM J CLIN NUTR, V73, P1019; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Trent Maria E., 1999, Current Opinion in Pediatrics, V11, P297, DOI 10.1097/00008480-199908000-00005; Troiano RP, 1998, PEDIATRICS, V101, P497; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Whitaker RC, 1998, J PEDIATR-US, V132, P768, DOI 10.1016/S0022-3476(98)70302-6; Willi SM, 1998, DIABETES, V47, pA306; WING RR, 1995, J AM DIET ASSOC, V95, P569, DOI 10.1016/S0002-8223(95)00155-7	37	121	125	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1427	1430		10.1001/jama.286.12.1427	http://dx.doi.org/10.1001/jama.286.12.1427			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572718				2022-12-28	WOS:000171188600002
J	Wise, LA; Zierler, S; Krieger, N; Harlow, BL				Wise, LA; Zierler, S; Krieger, N; Harlow, BL			Adult onset of major depressive disorder in relation to early life violent victimisation: a case-control study	LANCET			English	Article							CHILD SEXUAL ABUSE; PHYSICAL ABUSE; RISK-FACTORS; WOMEN; PREVALENCE; HEALTH; ADJUSTMENT; SYMPTOMS; HISTORY; IMPACT	Background Major depressive disorder is a significant cause of morbidity among women in the USA. Women are twice as likely as men to be diagnosed with major depressive disorder, yet no known risk factors can account for this sex difference. We aimed to assess violent victimisation as a risk factor for depression in women. Methods We undertook a case-control study to assess the association between violent victimisation early in life and major depressive disorder in women. We randomly selected a population-based sample of women, aged 36-45 years, from the greater Boston area. In 1999, 236 cases and 496 controls (n=732) completed a self-administered questionnaire designed to ascertain a lifetime history of exposure to violent victimisation. Our main outcome measure was major depressive disorder, assessed by structured clinical interview for Diagnostic Statistical Manual IV (DSM-IV) criteria. Findings 363 (50%) of 732 respondents reported experience or fear of abuse as a child or adolescent. 68 were excluded because they reported violence as an adult only. Compared with women who reported no abuse, risk of depression was increased in women who reported any abuse as a child or adolescent (relative risk 2.5, 95% CI 1.9-3.0), physical abuse only (2.4, 1.8-3.0), sexual abuse only (1.8, 1.2-2.8), and both physical and sexual abuse (3.3, 2.5-4.1). Severity of abuse had a linear dose-response relation with depression. Interpretation Our results suggest a positive association between violent victimisation early in life and major depressive disorder in women.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Brown Univ, Sch Med, Dept Community Hlth, Providence, RI 02912 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Brown University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Wise, LA (corresponding author), Slone Epidemiol Unit, 1371 Beacon St, Brookline, MA 02446 USA.			Harlow, Bernard/0000-0002-6735-8862; Wise, Lauren/0000-0003-2138-3752	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050013] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH577351, R01-MH50013] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Acierno R, 1997, BEHAV MED, V23, P53, DOI 10.1080/08964289709596729; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BEITCHMAN JH, 1992, CHILD ABUSE NEGLECT, V16, P101, DOI 10.1016/0145-2134(92)90011-F; BIFULCO A, 1991, BRIT J PSYCHIAT, V159, P115, DOI 10.1192/bjp.159.1.115; Breslow NE., 1980, IARC SCI PUBL, V32, P122; *BUR JUST STAT, 1993, PUBL US DEP JUST; Cheasty M, 1998, BRIT MED J, V316, P198; DEBELLIS MD, 1994, J AM ACAD CHILD PSY, V33, P320, DOI 10.1097/00004583-199403000-00004; FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7; FROMUTH ME, 1986, CHILD ABUSE NEGLECT, V10, P5, DOI 10.1016/0145-2134(86)90026-8; Gorey KM, 1997, CHILD ABUSE NEGLECT, V21, P391, DOI 10.1016/S0145-2134(96)00180-9; Hall L A, 1993, Image J Nurs Sch, V25, P317; Harlow BL, 1999, ARCH GEN PSYCHIAT, V56, P418, DOI 10.1001/archpsyc.56.5.418; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; HERMAN J, 1986, AM J PSYCHIAT, V143, P1293; Horwath Ewald, 1995, P317; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; MACLURE M, 1992, AM J EPIDEMIOL, V135, P96; MacMillan HL, 1997, JAMA-J AM MED ASSOC, V278, P131, DOI 10.1001/jama.278.2.131; McCauley J, 1997, JAMA-J AM MED ASSOC, V277, P1362, DOI 10.1001/jama.277.17.1362; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MULLEN PE, 1988, LANCET, V1, P841; POLUSNY MA, 1995, APPL PREV PSYCHOL, V4, P143, DOI 10.1016/S0962-1849(05)80055-1; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SINGER MI, 1995, JAMA-J AM MED ASSOC, V273, P477, DOI 10.1001/jama.273.6.477; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Straus M. A., 1980, CLOSED DOORS SURVEY; Weiss EL, 1999, AM J PSYCHIAT, V156, P816, DOI 10.1176/ajp.156.6.816; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; 1999, POPULATION REPOR L11, V27	30	129	130	1	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 15	2001	358	9285					881	887		10.1016/S0140-6736(01)06072-X	http://dx.doi.org/10.1016/S0140-6736(01)06072-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	474CP	11567704				2022-12-28	WOS:000171087000010
J	Bruick, RK; McKnight, SL				Bruick, RK; McKnight, SL			A conserved family of prolyl-4-hydroxylases that modify HIF	SCIENCE			English	Article							INDUCIBLE FACTOR 1-ALPHA; TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; DROSOPHILA-MELANOGASTER; TRANSGENIC MICE; O-2 HOMEOSTASIS; HYPOXIA; HIF-1-ALPHA; EXPRESSION; BINDING	Mammalian cells respond to changes in oxygen availability through a conserved pathway that is regulated by the hypoxia-inducible factor (HIF). The alpha subunit of HIF is targeted for degradation under normoxic conditions by a ubiquitin-ligase complex that recognizes a hydroxylated proline residue in HIF. We identified a conserved family of HIF prolyl hydoxylase (HPH) enzymes that appear to be responsible for this posttranslational modification. In cultured mammalian cells, inappropriate accumulation of HIF caused by forced expression of the HIF-1 alpha subunit under normoxic conditions was attenuated by coexpression of HPH. Suppression of HPH in cultured Drosophila melanogaster cells by RNA interference resulted in elevated expression of a hypoxia-inducible gene (LDH, encoding lactate dehydrogenase) under normoxic conditions. These findings indicate that HPH is an essential component of the pathway through which cells sense oxygen.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	McKnight, SL (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd L3-124, Dallas, TX 75390 USA.							Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Bacon NCM, 1998, BIOCHEM BIOPH RES CO, V249, P811, DOI 10.1006/bbrc.1998.9234; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bruick RK, 2001, GENE DEV, V15, P2497, DOI 10.1101/gad.931601; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Ma E, 1999, MOL BRAIN RES, V73, P11, DOI 10.1016/S0169-328X(99)00224-7; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	29	2017	2113	4	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1337	1340		10.1126/science.1066373	http://dx.doi.org/10.1126/science.1066373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11598268				2022-12-28	WOS:000172130200048
J	Ren, DJ; Navarro, B; Perez, G; Jackson, AC; Hsu, SF; Shi, Q; Tilly, JL; Clapham, DE				Ren, DJ; Navarro, B; Perez, G; Jackson, AC; Hsu, SF; Shi, Q; Tilly, JL; Clapham, DE			A sperm ion channel required for sperm motility and male fertility	NATURE			English	Article							MOUSE SPERM; ACROSOME REACTION; CALCIUM CHANNELS; ZONA-PELLUCIDA; CA2+ CHANNELS; ENTRY; SPERMATOZOA; EXPRESSION; INCREASE	Calcium and cyclic nucleotides have crucial roles in mammalian fertilization, but the molecules comprising the Ca2+-permeation pathway in sperm motility are poorly understood. Here we describe a putative sperm cation channel, CatSper, whose amino-acid sequence most closely resembles a single, six-transmembrane-spanning repeat of the voltage-dependent Ca2+-channel four-repeat structure. CatSper is located specifically in the principal piece of the sperm tail. Targeted disruption of the gene results in male sterility in otherwise normal mice. Sperm motility is decreased markedly in CatSper(-/-) mice, and CatSper(-/-) sperm are unable to fertilize intact eggs. In addition, the cyclic-AMP-induced Ca2+ influx is abolished in the sperm of mutant mice. CatSper is thus vital to cAMP-mediated Ca2+ influx in sperm, sperm motility and fertilization. CatSper represents an excellent target for non-hormonal contraceptives for both men and women.	Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Clapham, DE (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Enders 1309,320 Longwood Ave, Boston, MA 02115 USA.	dclapham@rascal.med.harvard.edu	Clapham, David/S-1123-2019; Oka, Yoshitaka/C-9670-2010; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; Oka, Yoshitaka/0000-0002-3482-3051; 	Howard Hughes Medical Institute Funding Source: Medline; NICHD NIH HHS [R01 HD045339] Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoki F, 1999, MOL REPROD DEV, V53, P77, DOI 10.1002/(SICI)1098-2795(199905)53:1&lt;77::AID-MRD9&gt;3.0.CO;2-C; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Arnoult C, 1997, EMBO J, V16, P1593, DOI 10.1093/emboj/16.7.1593; Bedford JM, 1998, BIOL REPROD, V59, P1275, DOI 10.1095/biolreprod59.6.1275; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Espinosa F, 1998, FEBS LETT, V426, P47, DOI 10.1016/S0014-5793(98)00305-6; HYNE RV, 1979, P NATL ACAD SCI USA, V76, P5699, DOI 10.1073/pnas.76.11.5699; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kobori H, 2000, BIOL REPROD, V63, P113, DOI 10.1095/biolreprod63.1.113; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Santi CM, 1996, AM J PHYSIOL-CELL PH, V271, pC1583, DOI 10.1152/ajpcell.1996.271.5.C1583; Serrano CJ, 1999, FEBS LETT, V462, P171, DOI 10.1016/S0014-5793(99)01518-5; Tash J.S., 1990, P229; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Wennemuth G, 2000, J BIOL CHEM, V275, P21210, DOI 10.1074/jbc.M002068200; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; Yanagimachi R., 1994, P189	21	667	698	0	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 11	2001	413	6856					603	609		10.1038/35098027	http://dx.doi.org/10.1038/35098027			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480WE	11595941	Green Accepted			2022-12-28	WOS:000171485700041
J	Bodenheimer, TS				Bodenheimer, TS			Affordable prescriptions for the elderly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DRUG		Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bodenheimer, TS (corresponding author), Bay W Family Hlth Care, 1580 Valencia St,Suite 201, San Francisco, CA 94110 USA.							Blustein J, 2000, HEALTH AFFAIR, V19, P219, DOI 10.1377/hlthaff.19.2.219; BOWEAN L, 2000, WALL STREET J   0801, pB8; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; BROWN AB, 2001, PATIENT CARE    0330, P22; Davidoff F, 2001, ANN INTERN MED, V134, P1068, DOI 10.7326/0003-4819-134-11-200106050-00014; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; HALL S, 2001, NY TIMES MAGAZI 0311, P91; HALL SS, 2001, NY TIMES MAGAZI 0311, P100; HALL SS, 2001, NY TIMES MAGAZI 0311, P40; Hall Stephen, 2001, NY TIMES MAGAZI 0311, P59; Heffler S, 2001, HEALTH AFFAIR, V20, P193, DOI 10.1377/hlthaff.20.2.193; Huang AJ, 2000, JAMA-J AM MED ASSOC, V284, P2240, DOI 10.1001/jama.284.17.2240; Iglehart JK, 2001, NEW ENGL J MED, V344, P1010, DOI 10.1056/NEJM200103293441311; *KAIS FAM FDN, 2001, MED PRESCR DRUGS; KESSLER DA, 1994, NEW ENGL J MED, V331, P1350, DOI 10.1056/NEJM199411173312007; KRELING DH, 2000, PRESCRIPTION DRUG TR; MOON M, 2001, TARGETING MEDICARE D; PAGE L, 2000, AM MED NEWS     0301, P1; Pear R., 2001, NY TIMES B      1025, P1; Phillips DP, 1998, LANCET, V351, P643, DOI 10.1016/S0140-6736(98)24009-8; Rothschild JM, 2000, ARCH INTERN MED, V160, P2717, DOI 10.1001/archinte.160.18.2717; SHULMAN NB, 1986, AM J PUBLIC HEALTH, V76, P1105, DOI 10.2105/AJPH.76.9.1105; Stolberg S G, 2000, N Y Times Web, pA15; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; *US ADM AG, 2000, PROF OLD AM; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	27	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1762	1763		10.1001/jama.286.14.1762	http://dx.doi.org/10.1001/jama.286.14.1762			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480NC	11594903				2022-12-28	WOS:000171466800028
J	Gilbert, DM				Gilbert, DM			Making sense of eukaryotic DNA replication origins	SCIENCE			English	Review							CEREVISIAE CHROMOSOME-VI; BETA-GLOBIN LOCUS; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; AUTONOMOUS REPLICATION; HUMAN-CELLS; SCHIZOSACCHAROMYCES-POMBE; DROSOPHILA-MELANOGASTER; GENE AMPLIFICATION; MAMMALIAN-CELLS	DNA replication is the process by which cells make one complete copy of their genetic information before cell division. In bacteria, readily identifiable DNA sequences constitute the start sites or origins of DNA replication. In eukaryotes, replication origins have been difficult to identify. In some systems, any DNA sequence can promote replication, but other systems require specific DNA sequences. Despite these disparities, the proteins that regulate replication are highly conserved from yeast to humans. The resolution may lie in a current model for once-per-cell-cycle regulation of eukaryotic replication that does not require defined origin sequences. This model implies that the specification of precise origins is a response to selective pressures that transcend those of once-per-cell-cycle replication, such as the coordination of replication with other chromosomal functions. Viewed in this context, the locations of origins may be an integral part of the functional organization of eukaryotic chromosomes.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Gilbert, DM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	gilbertd@mail.upstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057233] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057233, GM-57233-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdurashidova G, 2000, SCIENCE, V287, P2023, DOI 10.1126/science.287.5460.2023; Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; Altman AL, 2001, MOL CELL BIOL, V21, P1098, DOI 10.1128/MCB.21.4.1098-1110.2001; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; BEALL EL, COMMUNICATION; Bielinsky AK, 1999, MOL CELL, V3, P477, DOI 10.1016/S1097-2765(00)80475-X; BIELINSKY AK, IN PRESS CURR BIOL; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; BREWER BJ, 1994, P NATL ACAD SCI USA, V91, P3418, DOI 10.1073/pnas.91.8.3418; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1994, CURR OPIN GENET DEV, V4, P196, DOI 10.1016/S0959-437X(05)80045-0; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CARMINATI JL, 1992, MOL CELL BIOL, V12, P2444, DOI 10.1128/MCB.12.5.2444; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; CHESNOKOV I, IN PRESS P NATL ACAD; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; Cook P, 1998, SCIENCE, V281, P1466, DOI 10.1126/science.281.5382.1466; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DECICCO DV, 1984, CELL, V38, P45, DOI 10.1016/0092-8674(84)90525-7; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Dijkwel PA, 2000, EXP CELL RES, V256, P150, DOI 10.1006/excr.2000.4809; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; Ermakova OV, 1999, MOL CELL, V3, P321, DOI 10.1016/S1097-2765(00)80459-1; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; Gerber JK, 1997, CELL, V90, P559, DOI 10.1016/S0092-8674(00)80515-2; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; HAASE SB, 1994, MOL CELL BIOL, V14, P2516, DOI 10.1128/MCB.14.4.2516; HECK MMS, 1990, J CELL BIOL, V110, P903, DOI 10.1083/jcb.110.4.903; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; Ina S, 2001, CHROMOSOMA, V109, P551, DOI 10.1007/s004120000112; Kalejta RF, 1998, MOL CELL, V2, P797, DOI 10.1016/S1097-2765(00)80294-4; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KIM CS, 1992, DEV GENET, V13, P97; Klemm RD, 2001, P NATL ACAD SCI USA, V98, P8361, DOI 10.1073/pnas.131006898; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; KRYSAN PJ, 1993, MOL CELL BIOL, V13, P2688, DOI 10.1128/MCB.13.5.2688; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; Loupart ML, 2000, CURR BIOL, V10, P1547, DOI 10.1016/S0960-9822(00)00844-7; Lu L, 2001, GENE DEV, V15, P134, DOI 10.1101/gad.822101; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MASUKATA H, 1993, MOL BIOL CELL, V4, P1121, DOI 10.1091/mbc.4.11.1121; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Ogawa Y, 1999, MOL CELL BIOL, V19, P7228; Okuno Y, 1999, MOL CELL BIOL, V19, P6699; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pelizon C, 1996, MOL CELL BIOL, V16, P5358; Pflumm MF, 2001, DEVELOPMENT, V128, P1697; POLOUMIENKOL A, IN PRESS MOL BIOL CE; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Santocanale C, 1999, GENE DEV, V13, P2360, DOI 10.1101/gad.13.18.2360; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Sasaki T, 1999, MOL CELL BIOL, V19, P547; Schepers A, 2001, EMBO J, V20, P4588, DOI 10.1093/emboj/20.16.4588; SMITH JG, 1995, CHROMOSOMA, V103, P597; Spradling AC, 1999, GENE DEV, V13, P2619, DOI 10.1101/gad.13.20.2619; Stevenson JB, 1999, GENE DEV, V13, P146, DOI 10.1101/gad.13.2.146; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tillier ERM, 2000, NAT GENET, V26, P195, DOI 10.1038/79918; Toledo F, 1998, NUCLEIC ACIDS RES, V26, P2313, DOI 10.1093/nar/26.10.2313; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Wang YZ, 2001, MOL CELL BIOL, V21, P4938, DOI 10.1128/MCB.21.15.4938-4948.2001; WOHLGEMUTH JG, 1994, MOL BIOL CELL, V5, P839, DOI 10.1091/mbc.5.8.839; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x	77	224	228	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 5	2001	294	5540					96	100		10.1126/science.1061724	http://dx.doi.org/10.1126/science.1061724			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588251	Green Accepted			2022-12-28	WOS:000171448800039
J	Ibba, M				Ibba, M			Protein synthesis - Discriminating right from wrong	SCIENCE			English	Editorial Material							ELONGATION-FACTOR-TU; TRANSFER-RNA; COMPLEX; GTP		Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Ibba, M (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.							Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; Ibba M, 1999, SCIENCE, V286, P1893, DOI 10.1126/science.286.5446.1893; JANIAK F, 1990, BIOCHEMISTRY-US, V29, P4268, DOI 10.1021/bi00470a002; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; Nissen P, 1999, STRUCTURE, V7, P143, DOI 10.1016/S0969-2126(99)80021-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Rudinger J, 1996, EMBO J, V15, P650, DOI 10.1002/j.1460-2075.1996.tb00397.x; STANZEL M, 1994, EUR J BIOCHEM, V219, P435, DOI 10.1111/j.1432-1033.1994.tb19956.x	10	4	5	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					70	71		10.1126/science.1066106	http://dx.doi.org/10.1126/science.1066106			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588242				2022-12-28	WOS:000171448800030
J	Stevenson, DJ				Stevenson, DJ			Planetary science - Jupiter and its moons	SCIENCE			English	Editorial Material									CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology	Stevenson, DJ (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.							Anderson JD, 1998, SCIENCE, V280, P1573, DOI 10.1126/science.280.5369.1573; CANUP RM, 2000, ORIGIN EARTH MOON; Showman AP, 1999, SCIENCE, V286, P77, DOI 10.1126/science.286.5437.77; Wuchterl G., 2000, Protostars and planets 4, P1081	4	15	15	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					71	72		10.1126/science.1065306	http://dx.doi.org/10.1126/science.1065306			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588243				2022-12-28	WOS:000171448800031
J	McDevitt, H				McDevitt, H			Clinical implications of basic research - Closing in on type 1 diabetes.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	McDevitt, H (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.							Corper AL, 2000, SCIENCE, V288, P505, DOI 10.1126/science.288.5465.505; Lee KH, 2001, NAT IMMUNOL, V2, P501, DOI 10.1038/88694; Martin S, 2001, NEW ENGL J MED, V345, P1036, DOI 10.1056/NEJMoa010465; Yang M, 1997, J AUTOIMMUN, V10, P257, DOI 10.1006/jaut.1997.0128	4	27	27	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1060	1061		10.1056/NEJM200110043451411	http://dx.doi.org/10.1056/NEJM200110043451411			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586961				2022-12-28	WOS:000171340400011
J	Panikashvili, D; Simeonidou, C; Ben-Shabat, S; Hanus, L; Breuer, A; Mechoulam, R; Shohami, E				Panikashvili, D; Simeonidou, C; Ben-Shabat, S; Hanus, L; Breuer, A; Mechoulam, R; Shohami, E			An endogenous cannabinoid (2-AG) is neuroprotective after brain injury	NATURE			English	Article							CLOSED-HEAD-INJURY; NECROSIS-FACTOR-ALPHA; RECEPTOR-LIGAND; RAT-BRAIN; ANANDAMIDE; MICE; SYSTEM; 2-ARACHIDONOYLGLYCEROL; ENDOCANNABINOIDS; AMIDOHYDROLASE	Traumatic brain injury triggers the accumulation of harmful mediators that may lead to secondary damage(1,2). Protective mechanisms to attenuate damage are also set in motion(2). 2-Arachidonoyl glycerol (2-AG) is an endogenous cannabinoid, identified both in the periphery(3) and in the brain(4), but its physiological roles have been only partially clarified(5-7). Here we show that, after injury to the mouse brain, 2-AG may have a neuroprotective role in which the cannabinoid system is involved. After closed head injury (CHI) in mice, the level of endogenous 2-AG was significantly elevated. We administered synthetic 2-AG to mice after CHI and found significant reduction of brain oedema, better clinical recovery, reduced infarct volume and reduced hippocampal cell death compared with controls. When 2-AG was administered together with additional inactive 2-acyl-glycerols that are normally present in the brain, functional recovery was significantly enhanced. The beneficial effect of 2-AG was dose-dependently attenuated by SR-141761A, an antagonist of the CB1 cannabinoid receptor.	Hebrew Univ Jerusalem, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel.							Adams IB, 1998, J PHARMACOL EXP THER, V284, P1209; Axelrod J, 1998, NEUROCHEM RES, V23, P575, DOI 10.1023/A:1022418217479; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHEN DS, 1987, J GASTROEN HEPATOL, V2, P1, DOI 10.1111/j.1440-1746.1987.tb00142.x; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Klein TW, 2000, P SOC EXP BIOL MED, V225, P1, DOI 10.1046/j.1525-1373.2000.22501.x; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Mathews KS, 2000, J NEUROSCI METH, V102, P43, DOI 10.1016/S0165-0270(00)00277-6; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nagayama T, 1999, J NEUROSCI, V19, P2987; OVADIA H, 1995, NEUROPHARMACOLOGY, V34, P175, DOI 10.1016/0028-3908(94)00133-D; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Reggio PH, 2000, CHEM PHYS LIPIDS, V108, P15, DOI 10.1016/S0009-3084(00)00185-7; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 2000, DRUG DEVELOP RES, V50, P211, DOI 10.1002/1098-2299(200007/08)50:3/4<211::AID-DDR3>3.0.CO;2-G; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Smith SR, 2000, J PHARMACOL EXP THER, V293, P136; Sugiura T, 2000, BIOCHEM BIOPH RES CO, V271, P654, DOI 10.1006/bbrc.2000.2686; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; van der Stelt M, 2001, J NEUROSCI, V21, P6475, DOI 10.1523/JNEUROSCI.21-17-06475.2001	31	574	603	1	30	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					527	531		10.1038/35097089	http://dx.doi.org/10.1038/35097089			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586361				2022-12-28	WOS:000171340500048
J	Takayama, S; Shimosato, H; Shiba, H; Funato, M; Che, FS; Watanabe, M; Iwano, M; Isogai, A				Takayama, S; Shimosato, H; Shiba, H; Funato, M; Che, FS; Watanabe, M; Iwano, M; Isogai, A			Direct ligand-receptor complex interaction controls Brassica self-incompatibility	NATURE			English	Article							S-LOCUS GLYCOPROTEIN; CAMPESTRIS SYN. RAPA; TRANSGENIC TOBACCO; MALE DETERMINANT; KINASE; GENE; OLERACEA; STIGMA; EXPRESSION; HAPLOTYPES	Many higher plants have evolved self-incompatibility mechanisms to prevent self-fertilization(1). In Brassica self-incompatibility, recognition between pollen and the stigma is controlled by the S locus, which contains three highly polymorphic genes: S-receptor kinase (SRK)(2), S-locus protein 11 (SP11)(3) (also called S-locus cysteine-rich protein; SCR)(4) and S-locus glycoprotein (SLG)(5). SRK encodes a membrane-spanning serine/threonine kinase that determines the S-haplotype specificity of the stigma(6), and SP11 encodes a small cysteine-rich protein that determines the S-haplotype specificity of pollen(4,7,8). SP11 is localized in the pollen coat(8). It is thought that, during self-pollination, SP11 is secreted from the pollen coat and interacts with its cognate SRK in the papilla cell of the stigma to elicit the self-incompatibility response. SLG is a secreted stigma protein(9) that is highly homologous to the SRK extracellular domain. Although it is not required for S-haplotype specificity of the stigma, SLG enhances the self-incompatibility response(6); however, how this is accomplished remains controversial(10-12). Here we show that a single form of SP11 of the S-8 haplotype (S-8-SP11) stabilized with four intramolecular disulphide bonds specifically binds the stigma membrane of the S-8 haplotype to induce autophosphorylation of SRK8, and that SRK8 and SLG(8) together form a high-affinity receptor complex for S-8-SP11 on the stigma membrane.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan; Iwate Univ, Fac Agr, Morioka, Iwate 0208550, Japan	Nara Institute of Science & Technology; Iwate University	Isogai, A (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Ikoma 6300101, Japan.	isogai@bs.aist-nara.ac.jp	Isogai, Akira/O-8897-2017; Watanabe, Masao/N-1465-2019; Watanabe, Masao/E-6300-2011	Isogai, Akira/0000-0001-8095-0441; Watanabe, Masao/0000-0002-9419-5149; Watanabe, Masao/0000-0002-9419-5149				BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; Brugiere N, 2000, TRENDS PLANT SCI, V5, P432, DOI 10.1016/S1360-1385(00)01759-3; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; Cabrillac D, 2001, NATURE, V410, P220, DOI 10.1038/35065626; Dickinson HG, 2000, TRENDS GENET, V16, P373, DOI 10.1016/S0168-9525(00)02083-7; Dixit R, 2000, PLANT PHYSIOL, V124, P297, DOI 10.1104/pp.124.1.297; Doughty J, 1998, PLANT CELL, V10, P1333, DOI 10.1105/tpc.10.8.1333; Giranton JL, 1995, PLANT J, V8, P827, DOI 10.1046/j.1365-313X.1995.8060827.x; Giranton JL, 2000, P NATL ACAD SCI USA, V97, P3759, DOI 10.1073/pnas.070025097; Gomez-Gomez L, 2001, PLANT CELL, V13, P1155, DOI 10.1105/tpc.13.5.1155; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; LARSSON C, 1987, METHOD ENZYMOL, V148, P558; McCubbin AG, 2000, ANNU REV CELL DEV BI, V16, P333, DOI 10.1146/annurev.cellbio.16.1.333; NASRALLAH JB, 1987, NATURE, V326, P617, DOI 10.1038/326617a0; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; Shiba H, 2000, BIOSCI BIOTECH BIOCH, V64, P1016, DOI 10.1271/bbb.64.1016; Shiba H, 2001, PLANT PHYSIOL, V125, P2095, DOI 10.1104/pp.125.4.2095; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Stephenson AG, 1997, PLANT J, V12, P1351, DOI 10.1046/j.1365-313x.1997.12061351.x; Suzuki G, 1996, PLANT CELL PHYSIOL, V37, P866, DOI 10.1093/oxfordjournals.pcp.a029024; Suzuki G, 1999, GENETICS, V153, P391; Suzuki T, 2000, FEBS LETT, V482, P102, DOI 10.1016/S0014-5793(00)02048-2; Takasaki T, 2000, NATURE, V403, P913, DOI 10.1038/35002628; Takayama S, 2000, P NATL ACAD SCI USA, V97, P3765, DOI 10.1073/pnas.040580797; TAKAYAMA S, 1987, NATURE, V326, P102, DOI 10.1038/326102a0; Takayama S, 2000, P NATL ACAD SCI USA, V97, P1920, DOI 10.1073/pnas.040556397; Torii KU, 2000, CURR OPIN PLANT BIOL, V3, P361, DOI 10.1016/S1369-5266(00)00097-2; Trotochaud AE, 2000, SCIENCE, V289, P613, DOI 10.1126/science.289.5479.613; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Watanabe M, 2000, FEBS LETT, V473, P139, DOI 10.1016/S0014-5793(00)01514-3	30	319	361	2	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 4	2001	413	6855					534	538		10.1038/35097104	http://dx.doi.org/10.1038/35097104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586363				2022-12-28	WOS:000171340500050
J	Schwetz, BA				Schwetz, BA			Reprocessing of single-use devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	4	4	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1569	1569		10.1001/jama.286.13.1569-b	http://dx.doi.org/10.1001/jama.286.13.1569-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585463				2022-12-28	WOS:000171340600007
J	Mondal, N; Parvin, JD				Mondal, N; Parvin, JD			DNA topoisomerase IIa is required for RNA polymerase II transcription on chromatin templates	NATURE			English	Article							IN-VITRO; RIBOSOMAL-RNA; HOLOENZYME; PURIFICATION; ACTIVATION; YEAST; BRCA1; INVITRO; ELUTION; COMPLEX	In the nucleus of the cell, core RNA polymerase II (pol II) is associated with a large complex called the pol II holoenzyme (holo-pol)(1,2). Transcription by core pol II in vitro on nucleosomal templates is repressed compared with that on templates of histone-free naked DNA(3-5). We found that the transcriptional activity of holo-pol, in contrast to that of core pol II, is not markedly repressed on chromatin templates. We refer to this property of holo-pol as chromatin-dependent coactivation (CDC). Here we show that DNA topoisomerase II alpha is associated with the holo-pol and is a required component of CDC. Etoposide and ICRF-193, specific inhibitors of topoisomerase II, blocked transcription on chromatin templates, but did not affect transcription on naked templates. Addition of purified topoisomerase IIa reconstituted CDC activity in reactions with core pol II. These findings suggest that transcription on chromatin templates results in the accumulation of superhelical tension, making the relaxation activity of topoisomerase II essential for productive RNA synthesis on nucleosomal DNA.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Parvin, JD (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.	jparvin@rics.bwh.harvard.edu	Parvin, Jeffrey D/C-8955-2009					BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Cho H, 1997, J BIOL CHEM, V272, P11495; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; ISHIDA R, 1995, CANCER RES, V55, P2299; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; Sandbrink R, 1994, Neurobiol Dis, V1, P13, DOI 10.1006/nbdi.1994.0003; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; SCHULTZ MC, 1992, GENE DEV, V6, P1332, DOI 10.1101/gad.6.7.1332; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; WANG JC, 1993, CURR OPIN GENET DEV, V3, P764, DOI 10.1016/S0959-437X(05)80096-6; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419	25	100	100	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 27	2001	413	6854					435	438		10.1038/35096590	http://dx.doi.org/10.1038/35096590			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574892				2022-12-28	WOS:000171188700058
J	Smith, MR; McGovern, FJ; Zietman, AL; Fallon, MA; Hayden, DL; Schoenfeld, DA; Kantoff, PW; Finkelstein, JS				Smith, MR; McGovern, FJ; Zietman, AL; Fallon, MA; Hayden, DL; Schoenfeld, DA; Kantoff, PW; Finkelstein, JS			Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINERAL DENSITY; INTRAVENOUS PAMIDRONATE; HORMONE AGONISTS; INDUCED OSTEOPOROSIS; MEN; FRACTURES; ORCHIECTOMY; ALENDRONATE; INCREASES; WOMEN	Background: Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostate cancer. We conducted a controlled study of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone agonist. Methods: In a 48-week, open-label study, we randomly assigned 47 men with advanced or recurrent prostate cancer and no bone metastases to receive either leuprolide alone or leuprolide and pamidronate (60 mg intravenously every 12 weeks). Bone mineral density of the lumbar spine and the proximal femur was measured by dual-energy x-ray absorptiometry. Trabecular bone mineral density of the lumbar spine was measured by quantitative computed tomography. Forty-one men completed the study. Results: In men treated with leuprolide alone, the mean (+/-SE) bone mineral density decreased by 3.3+/-0.7 percent in the lumbar spine, 2.1+/-0.6 percent in the trochanter, and 1.8+/-0.4 percent in the total hip, and the mean trabecular bone mineral density of the lumbar spine decreased by 8.5+/-1.8 percent (P<0.001 for each comparison with the base-line value). In contrast, the mean bone mineral density did not change significantly at any skeletal site in men treated with both leuprolide and pamidronate. There were significant differences between the two groups in the mean changes in bone mineral density at 48 weeks in the lumbar spine (P<0.001), trochanter (P=0.003), total hip (P=0.005), and trabecular bone of the lumbar spine (P=0.02). Conclusions: Pamidronate prevents bone loss in the hip and lumbar spine in men receiving treatment for prostate cancer with a gonadotropin-releasing hormone agonist. (N Engl J Med 2001;345:948-55.) Copyright (C) 2001 Massachusetts Medical Society.	Massachusetts Gen Hosp, Boston, MA 02114 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute	Smith, MR (corresponding author), Massachusetts Gen Hosp, Cox 640,100 Blossom St, Boston, MA 02114 USA.	smith.matthew@mgh.harvard.edu	Finkelstein, Joel/M-6463-2019	Kantoff, Philip/0000-0001-7275-0597	NCRR NIH HHS [RR-1066] Funding Source: Medline; NIDDK NIH HHS [K24 DK02759] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002759] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1997, Br J Urol, V79, P235; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Boutsen Y, 2001, J BONE MINER RES, V16, P104, DOI 10.1359/jbmr.2001.16.1.104; Boutsen Y, 1997, CALCIFIED TISSUE INT, V61, P266, DOI 10.1007/s002239900334; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022-5347(05)68000-7; Daniell HW, 1997, J UROLOGY, V157, P439, DOI 10.1016/S0022-5347(01)65165-6; Diamond T, 1998, CANCER, V83, P1561, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.3.CO;2-Q; ERIKSSON S, 1995, CALCIFIED TISSUE INT, V57, P97, DOI 10.1007/BF00298427; FINKELSTEIN JS, 1989, J CLIN ENDOCR METAB, V69, P776, DOI 10.1210/jcem-69-4-776; FINKELSTEIN JS, 1998, TESTOSTERONE ACTION, P187; GRAMPP S, 1993, RADIOL CLIN N AM, V31, P1133; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Hatano T, 2000, BJU INT, V86, P449, DOI 10.1046/j.1464-410X.2000.00774.x; Katznelson L, 1996, J CLIN ENDOCR METAB, V81, P4358, DOI 10.1210/jc.81.12.4358; Littell R. C, 1996, SAS SYSTEM MIXED MOD; Maillefert JF, 1999, J UROLOGY, V161, P1219, DOI 10.1016/S0022-5347(01)61639-2; Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401; Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902; ORWOLL ES, 1990, J CLIN ENDOCR METAB, V70, P1202, DOI 10.1210/jcem-70-4-1202; Rosner B., 2010, FUNDAMENTALS BIOSTAT; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P1966, DOI 10.1210/jc.84.6.1966; Thiebaud D, 1997, AM J MED, V103, P298, DOI 10.1016/S0002-9343(97)00249-0; THIEBAUD D, 1994, OSTEOPOROSIS INT, V4, P76, DOI 10.1007/BF01623227; Townsend MF, 1997, CANCER, V79, P545, DOI 10.1002/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3; Wang C, 1996, J CLIN ENDOCR METAB, V81, P3654, DOI 10.1210/jc.81.10.3654; Zmuda JM, 2000, J BONE MINER RES, V15, P1417, DOI 10.1359/jbmr.2000.15.7.1417	29	523	536	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2001	345	13					948	955		10.1056/NEJMoa010845	http://dx.doi.org/10.1056/NEJMoa010845			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475NF	11575286				2022-12-28	WOS:000171170000003
J	Thomas, PC; Veverka, J; Robinson, MS; Murchie, S				Thomas, PC; Veverka, J; Robinson, MS; Murchie, S			Shoemaker crater as the source of most ejecta blocks on the asteroid 433 Eros	NATURE			English	Article							PHOBOS; 243-IDA; MOON	The loose material-regolith-on the surfaces of asteroids is thought to represent ballistically emplaced ejecta from impacts(1,2) but the identification of source craters and the detailed study of the regolith modification have been hampered by the limited spatial resolution and area coverage of the few asteroids imaged by spacecraft. Here we report the results of global mapping of the asteroid 433 Eros from high-resolution images obtained by the NEAR-Shoemaker spacecraft. Based on the images and ejecta-emplacement models, we suggest that most large ejecta blocks on Eros originate from a relatively young 7.6-km-diameter crater. A large fraction of the ejecta from impacts pre-dating that crater has apparently been buried or eroded. The images also show evidence for the action of a variety of sorting environments for regolith particles after they are deposited on the surface.	Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA; Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA	Cornell University; Northwestern University; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Thomas, PC (corresponding author), Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA.		Robinson, Mark/ABI-6841-2020; Murchie, Scott L/E-8030-2015	Murchie, Scott L/0000-0002-1616-8751				[Anonymous], [No title captured]; ARVIDSON R, 1975, MOON PLANETS, V13, P67, DOI 10.1007/BF00567508; ASPHAUG E, 1993, ICARUS, V101, P144, DOI 10.1006/icar.1993.1012; CINTALA MJ, 1982, P LUN PLAN SCI C, V13, P100; DUENNEBIER F, 1974, J GEOPHYS RES, V79, P4351, DOI 10.1029/JB079i029p04351; Geissler P, 1996, ICARUS, V120, P140, DOI 10.1006/icar.1996.0042; GREENBERG R, 1994, ICARUS, V107, P84, DOI 10.1006/icar.1994.1008; HARTMANN WK, 1969, ICARUS, V10, P201, DOI 10.1016/0019-1035(69)90022-0; HORSTMAN KC, 1989, J GEOPHYS RES-SOLID, V94, P12433, DOI 10.1029/JB094iB09p12433; HORZ F, 1975, MOON PLANETS, V13, P235, DOI 10.1007/BF00567517; HOUSEN KR, 1979, ICARUS, V39, P317, DOI 10.1016/0019-1035(79)90145-3; HOUSTON WN, 1973, P 4 LUN SCI C, V3, P2361; Lee P, 1996, ICARUS, V124, P181, DOI 10.1006/icar.1996.0197; Lee P, 1996, ICARUS, V120, P87, DOI 10.1006/icar.1996.0039; LEE SW, 1986, ICARUS, V68, P77, DOI 10.1016/0019-1035(86)90075-8; MELOY T, 1968, J GEOPHYS RES, V73, P2299, DOI 10.1029/JB073i006p02299; MOORE HH, 1971, NASA SPEC PUBL, P26; REEDY RC, 1983, ANNU REV NUCL PART S, V33, P505, DOI 10.1146/annurev.ns.33.120183.002445; Robinson MS, 2001, NATURE, V413, P396, DOI 10.1038/35096518; SHOEMAKER EM, 1967, 321246 JPLNASA; Thomas PC, 2000, J GEOPHYS RES-PLANET, V105, P15091, DOI 10.1029/1999JE001204; Thomas PC, 1998, ICARUS, V131, P78, DOI 10.1006/icar.1997.5858; THOMAS PC, 2000, B AM ASTRON SOC, V32, P994; Veverka J, 2001, NATURE, V413, P390, DOI 10.1038/35096507	24	92	94	1	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					394	396		10.1038/35096513	http://dx.doi.org/10.1038/35096513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574880				2022-12-28	WOS:000171188700046
J	Ghali, WA; Quan, HD; Brant, R; van Melle, G; Norris, CM; Faris, PD; Galbraith, PD; Knudtson, ML				Ghali, WA; Quan, HD; Brant, R; van Melle, G; Norris, CM; Faris, PD; Galbraith, PD; Knudtson, ML		APPROACH Investigators	Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MORTALITY; MEN	Context Adjusted survival curves are often presented in medical research articles. The most commonly used method for calculating such curves is the mean of covariates method, in which average values of covariates are entered into a proportional hazards regression equation. Use of this method is widespread despite published concerns regarding the validity of resulting curves. Objective To compare the mean of covariates method to the less widely used corrected group prognosis method in an analysis evaluating survival in patients with and without diabetes. In the latter method, a survival curve is calculated for each level of covariates, after which an average survival curve is calculated as a weighted average of the survival curves for each level of covariates. Design, Setting, and Patients Analysis of cohort study data from 11468 Alberta residents undergoing cardiac catheterization between January 1, 1995, and December 31, 1996. Main Outcome Measures Crude and risk-adjusted survival for up to 3 years after cardiac catheterization in patients with vs without diabetes, analyzed by the mean of covariates method vs the corrected group prognosis method. Results According to the mean of covariates method, adjusted survival at 1044 days was 94.1% and 94.9% for patients with and without diabetes, respectively, with misleading adjusted survival curves that fell above the unadjusted curves. With the corrected group prognosis method, the corresponding survival values were 91.3% and 92.4%, with curves that fell more appropriately between the unadjusted curves. Conclusions Misleading adjusted survival curves resulted from using the mean of covariates method of analysis for our data. We recommend using the corrected group prognosis method for calculating risk-adjusted curves.	Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB, Canada; Univ Lausanne, Inst Social & Prevent Med, Lausanne, Switzerland	University of Calgary; University of Calgary; University of Alberta; University of Lausanne	Ghali, WA (corresponding author), 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Faris, Peter/AAJ-3436-2020	Faris, Peter/0000-0001-5208-817X; Brant, Rollin/0000-0002-8026-2451; Norris, Colleen/0000-0002-6793-9333				ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; Carson JL, 1998, JAMA-J AM MED ASSOC, V279, P199, DOI 10.1001/jama.279.3.199; CHANG IM, 1982, J CHRON DIS, V35, P668; Ghali WA, 2000, AM J MED, V109, P543, DOI 10.1016/S0002-9343(00)00543-X; Ghali WA, 2000, CAN J CARDIOL, V16, P1225; LEE J, 1992, COMPUT APPL BIOSCI, V8, P23; MAKUCH RW, 1982, J CHRON DIS, V35, P437, DOI 10.1016/0021-9681(82)90058-3; Mesler DE, 1999, AM J MED, V106, P300, DOI 10.1016/S0002-9343(99)00020-0; Mesler DE, 1999, HEALTH SERV RES, V34, P365; NEUBERGER J, 1986, TRANSPLANTATION, V41, P713, DOI 10.1097/00007890-198606000-00009; Nieto FJ, 1996, AM J EPIDEMIOL, V143, P1059; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131	13	223	227	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1494	1497		10.1001/jama.286.12.1494	http://dx.doi.org/10.1001/jama.286.12.1494			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572743				2022-12-28	WOS:000171188600028
J	Groeneveld, PW; Kwong, JL; Liu, YY; Rodriguez, AJ; Jones, MP; Sanders, GD; Garber, AM				Groeneveld, PW; Kwong, JL; Liu, YY; Rodriguez, AJ; Jones, MP; Sanders, GD; Garber, AM			Cost-effectiveness of automated external defibrillators on airlines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY MEDICAL-SERVICES; HOSPITAL CARDIAC-ARREST; RAPID DEFIBRILLATION; SURVIVORS; QUALITY; LIFE; ANTIARRHYTHMICS; OUTCOMES; VICTIMS; STATES	Context Installation of automated external defibrillators (AEDs) on passenger aircraft has been shown to improve survival of cardiac arrest in that setting, but the cost-effectiveness of such measures has not been proven. Objective To examine the costs and effectiveness of several different options for AED deployment in the US commercial air transportation system. Design, Setting, and Subjects Decision and cost-effectiveness analysis of a strategy of full deployment on all aircraft as well as several strategies of partial deployment only on larger aircraft, compared with a baseline strategy of no AEDs on aircraft (but training flight attendants in basic life support) for a hypothetical cohort of persons experiencing cardiac arrest aboard US commercial aircraft. Estimates for costs and outcomes were obtained from the medical literature, the Federal Aviation Administration, the Air Transport Association of America, a population-based cohort of Medicare patients, AED manufacturers, and the Bureau of Labor Statistics. Main Outcome Measures Quality-adjusted survival after cardiac arrest; costs of AED deployment on aircraft and of medical care for cardiac arrest survivors. Results Adding AEDs on passenger aircraft with more than 200 passengers would cost $35300 per quality-adjusted life-year (QALY) gained. Additional AEDs on aircraft with capacities between 100 and 200 persons would cost an additional $40800 per added QALY compared with deployment on large-capacity aircraft only, and full deployment on all passenger aircraft would cost an additional $94700 per QALY gained compared with limited deployment on aircraft with capacity greater than 100. Sensitivity analyses indicated that the quality of life, annual mortality rate, and the effectiveness of AEDs in improving survival were the most influential factors in the model. In 85% of Monte Carlo simulations, AED placement on large-capacity aircraft produced cost-effectiveness ratios of less than $50000 per QALY. Conclusion The cost-effectiveness of placing AEDs on commercial aircraft compares favorably with the cost-effectiveness of widely accepted medical interventions and health policy regulations, but is critically dependent on the passenger capacity of the aircraft. Placing AEDs on most US commercial aircraft would meet conventional standards of cost-effectiveness.	Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Stanford Univ, Grad Sch Business, Stanford, CA 94305 USA; Stanford Univ, Stanford Biomed Informat, Stanford, CA 94305 USA; Front Line Strateg Management Consulting, Foster City, CA USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Groeneveld, PW (corresponding author), Stanford Univ, Ctr Primary Care & Outcomes Res, 179 Encina Commons,MC 6019, Stanford, CA 94305 USA.	petegro@healthpolicy.stanford.edu	Garber, Alan M/F-1476-2010	Groeneveld, Peter/0000-0002-7374-4292	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [F32HS000028, T32HS000028] Funding Source: NIH RePORTER; AHRQ HHS [HS00028-15] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AIR TRANSP ASS AM, 2000, IND ANN REP 2000; AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BANTA HD, 1990, JAMA-J AM MED ASSOC, V264, P235, DOI 10.1001/jama.264.2.235; Berek K, 1997, J NEUROL, V244, P556, DOI 10.1007/s004150050143; *BUR LAB STAT, 2000, OCC OUTL HDB; CREWDSON J, 1996, CHICAGO TRIBUNE 0630, P1; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1984, AM J EMERG MED, V2, P189, DOI 10.1016/0735-6757(84)90001-9; EVERY N, 1994, DEFIBRILLATION HEART, P182; Ewy GA, 2000, J AM COLL CARDIOL, V35, P830; Federal Aviation Administration, 2001, FED REGISTER, V66, P19028; FLINT P, 1998, INT AIR TRANSP ASS A; Foutz R A, 2000, Prehosp Emerg Care, V4, P314, DOI 10.1080/10903120090941010; FREEMAN KD, 2001, ACAD EMERG MED, V8, P431; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; Gold MR, 1996, COST EFFECTIVENESS H; Graham JD, 1997, JAMA-J AM MED ASSOC, V278, P1418, DOI 10.1001/jama.278.17.1418; Gratton M, 1999, Prehosp Emerg Care, V3, P303, DOI 10.1080/10903129908958958; Graves JR, 1997, RESUSCITATION, V35, P117; HOFER S, 1998, PUBLICATION FEDERAL; *INT AIR TRANSP AS, 2000, CORP AIR TRAV SURV 1; Jermyn B D, 2000, Prehosp Emerg Care, V4, P43, DOI 10.1080/10903120090941632; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; Kim SG, 1997, AM J CARDIOL, V80, P454, DOI 10.1016/S0002-9149(97)00394-9; Marenco JP, 2001, JAMA-J AM MED ASSOC, V285, P1193, DOI 10.1001/jama.285.9.1193; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; *NAT HEART LUNG BL, 2001, STUD LAUNCH TEST PUB; National Center for Health Statistics, 2000, HLTH US 2000; Nichol G, 1999, ANN EMERG MED, V34, P517, DOI 10.1016/S0196-0644(99)80054-7; Nichol G, 1999, ACAD EMERG MED, V6, P95, DOI 10.1111/j.1553-2712.1999.tb01044.x; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; Nichol G, 1996, ANN EMERG MED, V27, P711, DOI 10.1016/S0196-0644(96)70188-9; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; Page RL, 1998, CIRCULATION, V97, P1429; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Pasta DJ, 1999, MED DECIS MAKING, V19, P353, DOI 10.1177/0272989X9901900314; Pinski SL, 2000, AM HEART J, V139, P804, DOI 10.1016/S0002-8703(00)90011-5; RAYMAN RB, 1994, JAMA-J AM MED ASSOC, V271, P1657, DOI 10.1001/jama.271.21.1657; Riegel B, 1998, Am J Crit Care, V7, P402; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; SAPP F, 2001, PUBLICATION FEDERAL; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; Skogvoll E, 1999, ANN EMERG MED, V33, P409, DOI 10.1016/S0196-0644(99)70305-7; SoRelle R, 1999, CIRCULATION, V99, P2606, DOI 10.1161/01.CIR.99.20.2606; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; Thompson RJ, 1998, AM J CARDIOL, V81, P17, DOI 10.1016/S0002-9149(97)00798-4; TORRANCE GW, 1995, PHARMACOECONOMICS, V7, P503, DOI 10.2165/00019053-199507060-00005; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Valenzuela TD, 1997, CIRCULATION, V96, P3308; Varon J, 1999, RESUSCITATION, V41, P219, DOI 10.1016/S0300-9572(99)00064-7; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; Weiss JP, 2000, CIRCULATION, V102, P395; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	59	71	72	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1482	1489		10.1001/jama.286.12.1482	http://dx.doi.org/10.1001/jama.286.12.1482			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572741	Bronze			2022-12-28	WOS:000171188600026
J	Nakajima, K; Sena, G; Nawy, T; Benfey, PN				Nakajima, K; Sena, G; Nawy, T; Benfey, PN			Intercellular movement of the putative transcription factor SHR in root patterning	NATURE			English	Article							ARABIDOPSIS ROOT; CELL-DIFFERENTIATION; THALIANA; ORGANIZATION; MERISTEM; MORPHOGENESIS; TRAFFICKING; EXPRESSION; POSITION; PROTEINS	Positional information is pivotal for establishing developmental patterning in plants(1-3), but little is known about the underlying signalling mechanisms. The Arabidopsis root radial pattern is generated through stereotyped division of initial cells and the subsequent acquisition of cell fate(4). short-root (shr) mutants do not undergo the longitudinal cell division of the cortex/endodermis initial daughter cell, resulting in a single cell layer with only cortex attributes(5,6). Thus, SHR is necessary for both cell division and endodermis specification(5,6). SHR messenger RNA is found exclusively in the stele cells internal to the endodermis and cortex, indicating that it has a non-cell-autonomous mode of action(6). Here we show that the SHR protein, a putative transcription factor, moves from the stele to a single layer of adjacent cells, where it enters the nucleus. Ectopic expression of SHR driven by the promoter of the downstream gene SCARECROW(SCR) results in autocatalytic reinforcement of SHR signalling, producing altered cell fates and multiplication of cell layers. These results support a model in which SHR protein acts both as a signal from the stele and as an activator of endodermal cell fate and SCR-mediated cell division.	NYU, Dept Biol, New York, NY 10003 USA	New York University	Benfey, PN (corresponding author), NYU, Dept Biol, 1009 Main Bldg,100 Washington Sq E, New York, NY 10003 USA.		Sena, Giovanni/C-3297-2012	Sena, Giovanni/0000-0003-3626-5038; Nakajima, Keiji/0000-0002-1580-3354; Nawy, Tal/0000-0003-3720-3699				BENFEY PN, 1993, DEVELOPMENT, V119, P57; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; DOLAN L, 1993, DEVELOPMENT, V119, P71; Esau K., 1977, ANATOMY SEED PLANTS, V2nd Edn., P215; Freshour G, 1996, PLANT PHYSIOL, V110, P1413, DOI 10.1104/pp.110.4.1413; Helariutta Y, 2000, CELL, V101, P555, DOI 10.1016/S0092-8674(00)80865-X; JACKSON D, 1994, DEVELOPMENT, V120, P405; Kidner C, 2000, PLANTA, V211, P191, DOI 10.1007/s004250000284; KNOX JP, 1990, PLANTA, V181, P512, DOI 10.1007/BF00193004; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; Malamy JE, 1997, DEVELOPMENT, V124, P33; Masucci JD, 1996, DEVELOPMENT, V122, P1253; Perbal MC, 1996, DEVELOPMENT, V122, P3433; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; SESSIONS A, 2000, SCIENCE, V287, P419; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; von Arnim AG, 1998, GENE, V221, P35, DOI 10.1016/S0378-1119(98)00433-8; Wysocka-Diller JW, 2000, DEVELOPMENT, V127, P595	20	588	627	3	104	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 20	2001	413	6853					307	311		10.1038/35095061	http://dx.doi.org/10.1038/35095061			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565032	Green Submitted			2022-12-28	WOS:000171040500039
J	Allen, GE				Allen, GE			Is a new eugenics afoot?	SCIENCE			English	Editorial Material									Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Allen, GE (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.								0	33	34	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					59	+		10.1126/science.1066325	http://dx.doi.org/10.1126/science.1066325			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588239				2022-12-28	WOS:000171448800024
J	Bayes-Genis, A; Conover, CA; Overgaard, MT; Bailey, KR; Christiansen, M; Holmes, DR; Virmani, R; Oxvig, C; Schwartz, RS				Bayes-Genis, A; Conover, CA; Overgaard, MT; Bailey, KR; Christiansen, M; Holmes, DR; Virmani, R; Oxvig, C; Schwartz, RS			Pregnancy-associated plasma protein a as a marker of acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAJOR BASIC-PROTEIN; GROWTH-FACTOR-I; ACUTE MYOCARDIAL-INFARCTION; CARDIAC TROPONIN-T; EMERGENCY ROOM; CHEST PAIN; ATHEROSCLEROSIS; SERUM; RISK; EXPRESSION	Background: Circulating markers indicating the instability of atherosclerotic plaques could have diagnostic value in unstable angina or acute myocardial infarction. We evaluated pregnancy-associated plasma protein A (PAPP-A), a potentially proatherosclerotic metalloproteinase, as a marker of acute coronary syndromes. Methods: We examined the level of expression of PAPP-A in eight culprit unstable coronary plaques and four stable plaques from eight patients who had died suddenly of cardiac causes. We also measured circulating levels of PAPP-A, C-reactive protein, and insulin-like growth factor I (IGF-I) in 17 patients with acute myocardial infarction, 20 with unstable angina, 19 with stable angina, and 13 controls without atherosclerosis. Results: PAPP-A was abundantly expressed in plaque cells and extracellular matrix of ruptured and eroded unstable plaques, but not in stable plaques. Circulating PAPP-A levels were significantly higher in patients with unstable angina or acute myocardial infarction than in patients with stable angina and controls (P<0.001). A PAPP-A threshold value of 10 mIU per liter identified patients who had acute coronary syndromes with a sensitivity of 89.2 percent and a specificity of 81.3 percent. PAPP-A levels correlated with levels of C-reactive protein and free IGF-I, but not with markers of myocardial injury (troponin I and the MB isoform of creatine kinase). Conclusions: PAPP-A is present in unstable plaques, and circulating levels are elevated in acute coronary syndromes; these increased levels may reflect the instability of atherosclerotic plaques. PAPP-A is a new candidate marker of unstable angina and acute myocardial infarction. (N Engl J Med 2001;345:1022-9.) Copyright (C) 2001 Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Stat, Rochester, MN 55905 USA; Univ Aarhus, Dept Biol Mol & Struct, Aarhus, Denmark; Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen, Denmark; Armed Forces Inst Pathol, Dept Cardiovasc Pathol, Washington, DC 20306 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Aarhus University; Statens Serum Institut; United States Department of Defense	Schwartz, RS (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.		Bayes-Genis, Antoni/C-4002-2015; Bayes-Genis, Antonio/AAV-9422-2021; Christiansen, Michael/B-4588-2009; Overgaard, Michael Toft/E-1354-2011	Bayes-Genis, Antoni/0000-0002-3044-197X; Bayes-Genis, Antonio/0000-0002-3044-197X; Christiansen, Michael/0000-0003-4713-755X; Overgaard, Michael Toft/0000-0002-1423-2481; Oxvig, Claus/0000-0002-4715-9719				Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Bayes-Genis A, 2001, ARTERIOSCL THROM VAS, V21, P335, DOI 10.1161/01.ATV.21.3.335; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; Christiansen M, 2000, CLIN CHEM, V46, P1099; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; DEWINTER RJ, 1995, CIRCULATION, V92, P3401, DOI 10.1161/01.CIR.92.12.3401; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; JENKINS PJ, 1978, BMJ-BRIT MED J, V2, P388, DOI 10.1136/bmj.2.6134.388; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Kontos MC, 1997, J AM COLL CARDIOL, V30, P976, DOI 10.1016/S0735-1097(97)00264-7; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; LIN TM, 1974, AM J OBSTET GYNECOL, V118, P223, DOI 10.1016/0002-9378(74)90553-5; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Newby LK, 2000, AM HEART J, V140, P351, DOI 10.1067/mhj.2000.108824; Nichols TC, 1999, CIRC RES, V85, P1040; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; OXVIG C, 1995, J BIOL CHEM, V270, P13645, DOI 10.1074/jbc.270.23.13645; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; Qin QP, 1997, CLIN CHEM, V43, P2323; Renier G, 1996, ENDOCRINOLOGY, V137, P4611, DOI 10.1210/en.137.11.4611; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SABIA P, 1991, CIRCULATION, V84, pI85; Wald NJ, 1999, NEW ENGL J MED, V341, P461, DOI 10.1056/NEJM199908123410701	32	463	561	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1022	1029		10.1056/NEJMoa003147	http://dx.doi.org/10.1056/NEJMoa003147			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586954	Bronze			2022-12-28	WOS:000171340400003
J	Valladas, H; Clottes, J; Geneste, JM; Garcia, MA; Arnold, M; Cachier, H; Tisnerat-Laborde, N				Valladas, H; Clottes, J; Geneste, JM; Garcia, MA; Arnold, M; Cachier, H; Tisnerat-Laborde, N			Palaeolithic paintings - Evolution of prehistoric cave art	NATURE			English	Article							RADIOCARBON		Lab Sci Climat & Environm, UMR CEA CNRS 1572, F-91198 Gif Sur Yvette, France; DR AC Aquitaine, Serv Reg Archeol Aquitaine, F-33074 Bordeaux, France; Maison Archeol & Ethnol, F-92023 Nanterre, France; CEA, CNRS, UMS 2004, F-91198 Gif Sur Yvette, France	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Valladas, H (corresponding author), Lab Sci Climat & Environm, UMR CEA CNRS 1572, F-91198 Gif Sur Yvette, France.							Baffier D., 2001, INT NEWSLETT ROCK AR, V28, P1; CLOTTES J, 1995, CR ACAD SCI II, V320, P1133; Clottes J., 1992, B SOC PREHISTORIQUE, V89, P270; Clottes J., 1992, BULL SOC PREHIST FR, V89, P230, DOI [10.3406/bspf.1992.9527, DOI 10.3406/BSPF.1992.9527]; CLOTTES J, 1994, GROTTE COSQUER; Clottes J, 2001, GROTTE CHAUVET ART O; Girard M., 1996, CAHIERS ARCHEOLOGIQU, V6, P17; Lorblanchet M., 1995, GROTTES ORNEES PREHI; VALLADAS H, 1992, NATURE, V357, P68, DOI 10.1038/357068a0; VALLADAS H, 1990, ROCK ART RES, V7, P18; VALLADAS H, IN PRESS RADIOCARBON	11	99	101	2	50	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					479	479		10.1038/35097160	http://dx.doi.org/10.1038/35097160			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586348				2022-12-28	WOS:000171340500035
J	Foss, RD; Feaganes, JR; Rodgman, EA				Foss, RD; Feaganes, JR; Rodgman, EA			Initial effects of graduated driver licensing on 16-year-old driver crashes in North Carolina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTEM; RISK	Context Since 1997, 32 states have enacted graduated driver licensing (GDL) systems to reduce crash rates among young novice drivers. Objective To determine the initial effect of the North Carolina GDL system on crashes among 16-year-old drivers. Design, Setting, and Subjects Comparison of population-based North Carolina motor vehicle crash rates before (1996-1997) and after (1999) 16-year-old drivers were licensed under the GDL system. To control for other factors that might have influenced crashes, changes for 16-year-old drivers were compared with those of drivers 25 to 54 years of age. Crashes per licensed driver were also examined. Intervention The North Carolina GDL system, enacted December 1, 1997, requires beginning drivers 15 to 17 years of age to hold level 1 licenses, allowing driving only while supervised by a designated adult for a full year; followed by level 2 licensure, allowing unsupervised driving from 5 AM to 9 PM and supervised driving at any time for at least 6 months; and, finally, level 3-a full, unrestricted license. Main Outcome Measures Rates of motor vehicle crashes among 16-year-old drivers in 1996-1997 vs 1999, overall and by crash severity (fatal, injury, and noninjury), time (night vs day), type (single vs multiple vehicle), driver alcohol use, and driving environment (more vs less rural counties). Results Crash rates declined sharply for all levels of severity among 16-year-old drivers after the GDL program was implemented. Following GDL, 16-year-old driver crashes were substantially less likely. Comparing 1996 with 1999, fatal crashes declined 57%, from 5 to 2 per 10000 population (rate ratio [RR], 0.43; 95% confidence interval [CI] 0.27-0.70); crashes with no or minor injuries decreased 23%, from 1068 to 826 per 10000 (RR, 0.77; 95% CI, 0.75-0.80). Nighttime crashes were 43% less likely (156 vs 88 per 10000; RR, 0.57; 95% CI, 0.52-0.61) and daytime crashes decreased by 20% (951 vs 764 per 10000; RR, 0.80; 95% CI, 0.78-0.83). Single-vehicle crashes (245 vs 175; RR, 0.71; 95% CI, 0.67-0.76) declined somewhat more than multiple-vehicle crashes (866 vs 681; RR, 0.79; 95% CI, 0.76-0.81). Conclusion In its initial years, the North Carolina GDL system produced substantial declines in 16-year-old driver crashes.	Univ N Carolina, Highway Safety Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Foss, RD (corresponding author), Univ N Carolina, Highway Safety Res Ctr, 730 Airport Rd, Chapel Hill, NC 27599 USA.		Foss, Robert/W-1750-2019	Foss, Robert/0000-0002-1150-5763				AGRESTI A, 1990, CATEGORICAL DATA ANA, P81; [Anonymous], 1990, NEW ROAD YOUNG DRIVE; Chen LH, 2000, JAMA-J AM MED ASSOC, V283, P1578, DOI 10.1001/jama.283.12.1578; Foss RD, 1999, AM J PREV MED, V16, P47, DOI 10.1016/S0749-3797(98)00112-3; Foss RD, 2000, JAMA-J AM MED ASSOC, V283, P1617, DOI 10.1001/jama.283.12.1617; FRITH WJ, 1992, SEMINAR PAPERS NATL, V2, P256; *INS I HIGHW SAF, 1998, STATUS REPORT, V33, P1; *INS I HIGHW SAF, 2001, US LIC SYST YOUNG DR; *INS I HIGHW SAF T, 1999, GRAD LIC BLUEPR N AM; Langley JD, 1996, ACCIDENT ANAL PREV, V28, P139, DOI 10.1016/0001-4575(95)00040-2; MAYHEW DR, 1999, IMPACT GRADUATED DRI; MAYHEW DR, 2000, CHANGES COLLISION RA; MCCULLAGH P, 1989, GEN LINEAR MODELS, P204; *NAT COMM UN TRAFF, 2001, GRAD DRIV LIC MOD LA; *NAT CTR INJ PREV, 2001, WEB BAS INJ STAT QUE; National Highway Traffic Safety Administration, 1998, SAV TEEN LIV CAS GRA; *SAS I INC, 1999, SAS ONL VERS 8 GENM; SHOPE JT, 2001, ANN M TRANSP RES BOA; Ulmer RG, 2000, ACCIDENT ANAL PREV, V32, P527, DOI 10.1016/S0001-4575(99)00074-3; WILLIAMS AF, 1997, PUBLIC HLTH REP, V112, P453	20	100	101	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1588	1592		10.1001/jama.286.13.1588	http://dx.doi.org/10.1001/jama.286.13.1588			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585481	Bronze			2022-12-28	WOS:000171340600025
J	Wendler, D; Prasad, K				Wendler, D; Prasad, K			Core safeguards for clinical research with adults who are unable to consent	ANNALS OF INTERNAL MEDICINE			English	Article							SUBSTITUTED JUDGMENT; DECISION-MAKING	safeguards for clinical research with adults who are unable to consent. Three other major U.S. groups have also proposed additional safeguards for this population, and existing Canadian and European guidelines already include such safeguards. While these six guidelines agree on some safeguards, they disagree on others. To allow Important research to proceed while protecting adults who are unable to consent, it will be crucial to resolve these differences. This paper uses a side-by-side comparison of these six guidelines to highlight their major points of consensus, analyze their significant differences, and distill six core safeguards.	NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Wendler, D (corresponding author), NIH, Dept Clin Bioeth, Room 1C118,Bldg 10, Bethesda, MD 20892 USA.							[Anonymous], 1997, CONV PROT HUM RIGHTS; Beauchamp T, 1996, PRINCIPLES BIOMEDICA; Buchanan AE, 1990, DECIDING OTHERS ETHI; Cahill M, 2000, ALZ DIS ASSOC DIS, V14, P20, DOI 10.1097/00002093-200001000-00003; Dresser R, 1996, JAMA-J AM MED ASSOC, V276, P67, DOI 10.1001/jama.276.1.67; Dworkin Gerald, 1988, THEORY PRACTICE AUTO; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; Levine R J, 1988, Law Med Health Care, V16, P174; National Bioethics Advisory Commission, 1998, RES INV PERS MENT DI; *OFF MAR ATT GEN A, 1998, FIN REP RES INV DEC; *OFF PROT RES RISK, 1994, EV HUM SUBJ PROT SCH; Oldham J M, 1998, J Health Care Law Policy, V1, P154; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; Shore D, 1999, BIOL PSYCHIAT, V46, P1013; *STAT NEW YORK DEP, 1998, REC OV HUM SUBJ RES; SUHL J, 1994, ARCH INTERN MED, V154, P90, DOI 10.1001/archinte.154.1.90; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; 1998, RES INVOLVING INDIVI	18	56	56	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					514	523		10.7326/0003-4819-135-7-200110020-00011	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	477EF	11578155				2022-12-28	WOS:000171269600006
J	Cordner, SM				Cordner, SM			Contemplating the forensic medical implications of the attack	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					944	944		10.1016/S0140-6736(01)06122-0	http://dx.doi.org/10.1016/S0140-6736(01)06122-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11584821				2022-12-28	WOS:000171135300007
J	Uplekar, M; Pathania, V; Raviglione, M				Uplekar, M; Pathania, V; Raviglione, M			Private practitioners and public health: weak links in tuberculosis control	LANCET			English	Editorial Material							GENERAL-PRACTITIONERS; INDIA; CLINICS		WHO, Stop TB Dept, CH-1211 Geneva, Switzerland	World Health Organization	Uplekar, M (corresponding author), WHO, Stop TB Dept, CH-1211 Geneva, Switzerland.			RAVIGLIONE, Mario/0000-0002-9331-2067				FUJIWARA PI, 1996, TUBERCLE LUNG DIS S2, V77, P72; GRIFFIN C, 1989, 4 IFC WORLD BANK; Hong YP, 1999, INT J TUBERC LUNG D, V3, P695; Kamat V. R., 1997, PRIVATE HLTH PROVIDE, P124; LONROTH K, 2000, PUBLIC HLTH PRIVATE; LONROTH K, IN PRESS HLTH POL PL; *NAT COUNC APPL EC, 1995, 53 NCAER; Pathania V, 1997, WHOTB972231997; Reich MR, 2000, NAT MED, V6, P617, DOI 10.1038/76176; Singla N, 1998, INT J TUBERC LUNG D, V2, P384; TAYLOR E, 1999, TUBERCULOSIS AN INTE; Uplekar M, 1998, INT J TUBERC LUNG D, V2, P324; UPLEKAR M, 1996, SEARCH SOLUTIONS; UPLEKAR MW, 1991, TUBERCLE, V72, P284, DOI 10.1016/0041-3879(91)90055-W; Weil DEC, 2000, INT J TUBERC LUNG D, V4, P597; *WHO, 1995, WHOTB96202; *WHO, 2000, WHOCDSTB2000282; *WHO, 2000, WHOCDSTB2000	18	197	198	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 15	2001	358	9285					912	916		10.1016/S0140-6736(01)06076-7	http://dx.doi.org/10.1016/S0140-6736(01)06076-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567729				2022-12-28	WOS:000171087000030
J	Fukuchi-Shimogori, T; Grove, EA				Fukuchi-Shimogori, T; Grove, EA			Neocortex patterning by the secreted signaling molecule FGF8	SCIENCE			English	Article							CEREBRAL-CORTEX; SOMATOSENSORY CORTEX; REGIONAL DIFFERENCES; AREA IDENTITY; SPECIFICATION; EXPRESSION; MIDBRAIN; DIFFERENTIATION; HIPPOCAMPUS; FOREBRAIN	A classic model proposes that the mammalian neocortex is divided into areas early in neurogenesis, but the molecular mechanisms that generate the area map have been elusive. Here we provide evidence that FGF8 regulates development of the map from a source in the anterior telencephalon. Using electroporation-mediated gene transfer in mouse embryos, we show that augmenting the endogenous anterior FGF8 signal shifts area boundaries posteriorly, reducing the signal shifts them anteriorly, and introducing a posterior source of FGF8 elicits partial area duplications, revealed by ectopic somatosensory barrel fields. These findings support a rote for FGF signaling in specifying positional identity in the neocortex.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Grove, EA (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA.		Shimogori, Tomomi/L-2893-2013	Shimogori, Tomomi/0000-0002-6931-5401				Agarwala S, 2001, SCIENCE, V291, P2147, DOI 10.1126/science.1058624; BARBE MF, 1991, J NEUROSCI, V11, P519; Bishop KM, 2000, SCIENCE, V288, P344, DOI 10.1126/science.288.5464.344; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FERRI RT, 1995, DEVELOPMENT, V121, P1151; FUKUCHISHIMOGOR.T, UNPUB; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Galceran J, 2000, DEVELOPMENT, V127, P469; Gitton Y, 1999, J NEUROSCI, V19, P4889; Grove EA, 1998, DEVELOPMENT, V125, P2315; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Huffman KJ, 1999, J NEUROSCI, V19, P9939; JENSEN KF, 1987, J NEUROSCI, V7, P3529; Lee SMK, 2000, DEVELOPMENT, V127, P457; Lee SMK, 1997, DEVELOPMENT, V124, P959; Levitt P, 1997, ANNU REV NEUROSCI, V20, P1, DOI 10.1146/annurev.neuro.20.1.1; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; Mackarehtschian K, 1999, CEREB CORTEX, V9, P601, DOI 10.1093/cercor/9.6.601; Minowada G, 1999, DEVELOPMENT, V126, P4465; Miyashita-Lin EM, 1999, SCIENCE, V285, P906, DOI 10.1126/science.285.5429.906; Nauta W., 1986, FUNDAMENTAL NEUROANA; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Ragsdale CW, 2001, CURR OPIN NEUROBIOL, V11, P50, DOI 10.1016/S0959-4388(00)00173-2; RAGSDALE CW, UNPUB; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; Rubenstein JLR, 1999, CEREB CORTEX, V9, P524, DOI 10.1093/cercor/9.6.524; Shamim H, 1999, DEVELOPMENT, V126, P945; Shimamura K, 1997, DEVELOPMENT, V124, P2709; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Tucker AS, 1999, DEVELOPMENT, V126, P51; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; WONGRILEY MTT, 1980, P NATL ACAD SCI-BIOL, V77, P2333, DOI 10.1073/pnas.77.4.2333; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; Xu JS, 2000, DEVELOPMENT, V127, P1833; Yasuda K, 2000, DEV GROWTH DIFFER, V42, P203; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3	39	506	520	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 2	2001	294	5544					1071	1074		10.1126/science.1064252	http://dx.doi.org/10.1126/science.1064252			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489VU	11567107				2022-12-28	WOS:000172013800041
J	Owen, W				Owen, W			ABC of the upper gastrointestinal tract - Dysphagia	BRITISH MEDICAL JOURNAL			English	Article									Guys & St Thomass Hosp Trust, London, England		Owen, W (corresponding author), Guys & St Thomass Hosp Trust, London, England.								0	5	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 13	2001	323	7317					850	853		10.1136/bmj.323.7317.850	http://dx.doi.org/10.1136/bmj.323.7317.850			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597971	Green Published			2022-12-28	WOS:000171650500032
J	Lobanov, AP; Zensus, JA				Lobanov, AP; Zensus, JA			A cosmic double helix in the archetypical quasar 3C273	SCIENCE			English	Article							SHOCKED RELATIVISTIC JETS; ADIABATICALLY EXPANDING JET; SYNCHROTRON EMISSION; 3C 273	Finding direct evidence for plasma instability in extragalactic jets is crucial for understanding the nature of relativistic outflows from active galactic nuclei. our radio interferometric observations of the quasar 3CZ73 made with the orbiting radio telescope, HALCA, and an array of ground telescopes have yielded an image in which the emission across the jet is resolved, revealing two threadlike patterns that form a double helix inside the jet. This double helical structure is consistent with a Kelvin-Helmholtz instability, and at least five different instability modes can be identified and modeled by a light jet with a Lorentz factor of 2 and Mach number of 3.5. The model reproduces in detail the internal structure of the jet on scales of up to 30 milli-arc seconds (similar to 300 parsecs) and is consistent with the general morphology of the jet on scales of up to 1 kiloparsec.	Max Planck Inst Radioastron, D-53121 Bonn, Germany; Natl Radio Astron Observ, Charlottesville, VA 22903 USA	Max Planck Society; National Radio Astronomy Observatory (NRAO)	Lobanov, AP (corresponding author), Max Planck Inst Radioastron, Hugel 69, D-53121 Bonn, Germany.	alobanov@mpifr-bonn.mpg.de	Lobanov, Andrei P./G-5891-2014	Lobanov, Andrei/0000-0003-1622-1484; Zensus, J. Anton/0000-0001-7470-3321				Abraham Z, 1996, ASTRON ASTROPHYS SUP, V115, P543; Abraham Z, 1999, ASTRON ASTROPHYS, V344, P61; BABADZHANYANTS MK, 1993, ASTRON ZH+, V70, P241; BEGELMAN MC, 1984, REV MOD PHYS, V56, P255, DOI 10.1103/RevModPhys.56.255; CONWAY RG, 1993, ASTRON ASTROPHYS, V267, P347; Courvoisier TJL, 1998, ASTRON ASTROPHYS REV, V9, P1, DOI 10.1007/s001590050013; DAVIS RJ, 1991, NATURE, V354, P374, DOI 10.1038/354374a0; GOMEZ JL, 1994, ASTRON ASTROPHYS, V292, P33; GOMEZ JL, 1993, ASTRON ASTROPHYS, V274, P55; GOMEZ JL, 1994, ASTRON ASTROPHYS, V284, P51; HARDEE PE, 1986, ASTROPHYS J, V303, P111, DOI 10.1086/164057; Hardee PE, 1997, ASTROPHYS J, V485, P533, DOI 10.1086/304450; HARDEE PE, 1987, ASTROPHYS J, V313, P607, DOI 10.1086/165000; Hardee PE, 2000, ASTROPHYS J, V533, P176, DOI 10.1086/308656; HARDEE PE, 1984, ASTROPHYS J, V287, P523, DOI 10.1086/162710; Hirabayashi H, 1998, SCIENCE, V281, P1825, DOI 10.1126/science.281.5384.1825; Hirabayashi H, 2000, PUBL ASTRON SOC JPN, V52, P955, DOI 10.1093/pasj/52.6.955; Lobanov A. P., 1999, New Astronomy Reviews, V43, P741, DOI 10.1016/S1387-6473(99)00090-1; Lobanov AP, 2000, ADV SPACE RES, V26, P669, DOI 10.1016/S0273-1177(99)01187-4; MARSCHER AP, 1980, ASTROPHYS J, V235, P386, DOI 10.1086/157642; Marshall HL, 2001, ASTROPHYS J, V549, pL167, DOI 10.1086/319161; Mioduszewski AJ, 1997, ASTROPHYS J, V476, P649, DOI 10.1086/303652; PEARSON TJ, 1981, NATURE, V290, P365, DOI 10.1038/290365a0; Sambruna RM, 2001, ASTROPHYS J, V549, pL161, DOI 10.1086/319157; SCHMIDT M, 1963, NATURE, V197, P1040, DOI 10.1038/1971040a0; STRAUSS MA, 1992, ASTROPHYS J SUPPL S, V83, P29, DOI 10.1086/191730; THOMSON RC, 1993, NATURE, V365, P133, DOI 10.1038/365133a0; Turler M, 1999, ASTRON ASTROPHYS, V349, P45; UNWIN SC, 1985, ASTROPHYS J, V289, P109, DOI 10.1086/162868; ZENSUS JA, 1988, NATURE, V334, P410, DOI 10.1038/334410a0; ZENSUS JA, 1995, ASP C SERIES, V82	31	135	141	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 5	2001	294	5540					128	131		10.1126/science.1063239	http://dx.doi.org/10.1126/science.1063239			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588254				2022-12-28	WOS:000171448800042
J	Staessen, JA; Wang, JG				Staessen, JA; Wang, JG			Blood-pressure lowering for the secondary prevention of stroke	LANCET			English	Editorial Material							HYPERTENSION		Univ Louvain, Dept Mol & Cardiovasc Res, Lab Hypertens, Study Coordinating Ctr, B-3000 Louvain, Belgium	KU Leuven	Staessen, JA (corresponding author), Univ Louvain, Dept Mol & Cardiovasc Res, Lab Hypertens, Study Coordinating Ctr, B-3000 Louvain, Belgium.	jan.staessen@med.kuleuven.ac.be	Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				[Anonymous], 1997, ARCH INTERN MED, V157, P2413; Chalmers J, 1999, J HYPERTENS, V17, P151; Chalmers J, 1996, J HYPERTENS, V14, pS41; Dickinson CJ, 2001, J HYPERTENS, V19, P1515, DOI 10.1097/00004872-200109000-00001; Gueyffier F, 1997, STROKE, V28, P2557, DOI 10.1161/01.STR.28.12.2557; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; LIU LS, 1995, CHINESE MED J-PEKING, V108, P710; O'Brien E, 2000, Expert Opin Pharmacother, V1, P675, DOI 10.1517/14656566.1.4.675; STAESSEN JA, IN PRESS LANCET	10	43	45	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	2001	358	9287					1026	1027		10.1016/S0140-6736(01)06226-2	http://dx.doi.org/10.1016/S0140-6736(01)06226-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589927				2022-12-28	WOS:000171393100002
J	Blakely, RD				Blakely, RD			Neurobiology - Dopamine's reversal of fortune	SCIENCE			English	Editorial Material							DENDRO-DENDRITIC SYNAPSES; SUBSTANTIA-NIGRA; RELEASE; TRANSPORTER; TRAFFICKING; ACTIVATION		Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Ctr Mol Neurosci, 221 Kirkland Hall, Nashville, TN 37232 USA.	randy.blakely@mcmail.vanderbilt.edu						ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Bauman AL, 2000, J NEUROSCI, V20, P7571; CHERAMY A, 1981, NATURE, V289, P537, DOI 10.1038/289537a0; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; GROVES PM, 1983, EXP BRAIN RES, V49, P209; Kantor L, 1998, J PHARMACOL EXP THER, V284, P592; KUHAR MJ, 1997, NEUROTRANSMITTER TRA, P297; Levy M, 1998, J BIOL CHEM, V273, P6495, DOI 10.1074/jbc.273.11.6495; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; Melikian HE, 1999, J NEUROSCI, V19, P7699; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; Nirenberg MJ, 1997, J NEUROSCI, V17, P4037; Offen D, 1999, Adv Neurol, V80, P265; PUCAK ML, 1995, CRIT REV NEUROBIOL, V9, P67; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; SCHOMIG A, 1991, EUR HEART J, V12, P38, DOI 10.1093/eurheartj/12.suppl_F.38; SCHWARTZ EA, 1987, SCIENCE, V238, P350, DOI 10.1126/science.2443977; Skeberdis VA, 2001, NEUROPHARMACOLOGY, V40, P856, DOI 10.1016/S0028-3908(01)00005-3; WILSON CJ, 1977, EXP BRAIN RES, V30, P161	22	20	20	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2407	2409		10.1126/science.1065931	http://dx.doi.org/10.1126/science.1065931			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577225				2022-12-28	WOS:000171237200034
J	Parton, RG				Parton, RG			Cell biology - Life without caveolae	SCIENCE			English	Editorial Material							TRANSFORMATION		Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland	Parton, RG (corresponding author), Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, St Lucia, Qld 4072, Australia.		Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248				Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; Razani B, 2000, J CELL SCI, V113, P2103; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052	10	47	52	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2404	2405		10.1126/science.1065677	http://dx.doi.org/10.1126/science.1065677			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577223				2022-12-28	WOS:000171237200032
J	Adam, D				Adam, D			British archaeology boost may uncover old enthusiasm	NATURE			English	News Item																		ROBERTS MB, 1994, NATURE, V369, P311, DOI 10.1038/369311a0	1	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					338	338		10.1038/35096716	http://dx.doi.org/10.1038/35096716			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574840	Bronze			2022-12-28	WOS:000171188700008
J	Dexter, PR; Perkins, S; Overhage, JM; Maharry, K; Kohler, RB; McDonald, CJ				Dexter, PR; Perkins, S; Overhage, JM; Maharry, K; Kohler, RB; McDonald, CJ			A computerized reminder system to increase the use of preventive care for hospitalized patients.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCOCCAL VACCINATION; ANTITHROMBOTIC THERAPY; INFLUENZA VACCINATION; ELDERLY PERSONS; IMMUNIZATION; METAANALYSIS	Background: Although they are effective in outpatient settings, computerized reminders have not been proved to increase preventive care in inpatient settings. Methods: We conducted a randomized, controlled trial to determine the effects of computerized reminders on the rates at which four preventive therapies were ordered for inpatients. During an 18-month study period, a computerized system processed on-line information for all 6371 patients admitted to a general-medicine service (for a total of 10,065 hospitalizations), generating preventive care reminders as appropriate. Physicians who were in the intervention group viewed these reminders when they were using a computerized order-entry system for inpatients. Results: The reminder system identified 3416 patients (53.6 percent) as eligible for preventive measures that had not been ordered by the admitting physician. For patients with at least one indication, computerized reminders resulted in higher adjusted ordering rates for pneumococcal vaccination (35.8 percent of the patients in the intervention group vs. 0.8 percent of those in the control group, P<0.001), influenza vaccination (51.4 percent vs. 1.0 percent, P< 0.001), prophylactic heparin (32.2 percent vs. 18.9 percent, P<0.001), and prophylactic aspirin at discharge (36.4 percent vs. 27.6 percent, P<0.001). Conclusions: A majority of hospitalized patients in this study were eligible for preventive measures, and computerized reminders significantly increased the rate of delivery of such therapies. (N Engl J Med 2001;345:965-70.) Copyright (C) 2001 Massachusetts Medical Society.	Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Univ Indianapolis, Sch Med, Dept Med, Indianapolis, IN USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	McDonald, CJ (corresponding author), Regenstrief Inst Hlth Care, 1050 Wishard Blvd, Indianapolis, IN 46202 USA.			Overhage, Joseph/0000-0003-0223-0195	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007719] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [N01LM063546] Funding Source: NIH RePORTER; AHRQ HHS [HS07719] Funding Source: Medline; NLM NIH HHS [N01-LM-6-3546] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON FA, 1991, ANN INTERN MED, V115, P591, DOI 10.7326/0003-4819-591; [Anonymous], 1997, MMWR MORB MORT WKLY, V46, P1; CAIRNS JA, 1995, CHEST, V108, pS380, DOI 10.1378/chest.108.4_Supplement.380S; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; CLAGETT GP, 1995, CHEST, V108, pS431, DOI 10.1378/chest.108.4_Supplement.431S; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; Fedson DS, 1999, VACCINE, V17, pS85, DOI 10.1016/S0264-410X(99)00113-9; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V272, P1133, DOI 10.1001/jama.272.14.1133; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Jacobson TA, 1999, JAMA-J AM MED ASSOC, V282, P646, DOI 10.1001/jama.282.7.646; KEANE MG, 1994, CHEST, V106, P13, DOI 10.1378/chest.106.1.13; LeBaron CW, 1997, JAMA-J AM MED ASSOC, V277, P631, DOI 10.1001/jama.277.8.631; LIPSKY BA, 1986, ARCH INTERN MED, V146, P2179, DOI 10.1001/archinte.146.11.2179; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; McDonald CJ, 1999, INT J MED INFORM, V54, P225, DOI 10.1016/S1386-5056(99)00009-X; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDONALD CJ, 1986, WESTERN J MED, V145, P823; Morrow R W, 1995, Arch Fam Med, V4, P165, DOI 10.1001/archfami.4.2.165; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; Overhage J M, 1995, Proc Annu Symp Comput Appl Med Care, P178; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Overhage JM, 1996, ARCH INTERN MED, V156, P1551, DOI 10.1001/archinte.156.14.1551; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; SHERMAN DG, 1995, CHEST, V108, pS444, DOI 10.1378/chest.108.4_Supplement.444S; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Smith DM, 1999, J AM GERIATR SOC, V47, P1; SPITZER WO, 1989, ANN INTERN MED, V111, P939, DOI 10.7326/0003-4819-111-11-939; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1998, MMWR MORB MORTAL WKL, V47, P797	35	371	376	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2001	345	13					965	970		10.1056/NEJMsa010181	http://dx.doi.org/10.1056/NEJMsa010181			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475NF	11575289	Bronze			2022-12-28	WOS:000171170000006
J	Obeso, JA; Guridi, J; Rodriguez-Oroz, MC; Agid, Y; Bejjani, P; Bonnet, AM; Lang, AE; Lozano, AM; Kumar, R; Benabid, A; Pollack, P; Krack, P; Rehncrona, S; Ekberg, R; Grabowski, M; Albanese, A; Scerrati, M; Moro, E; Koller, W; Wilkinson, SB; Pahwa, R; Volkmann, J; Allert, N; Freund, HJ; Kulisevsky, J; Gironell, A; Molet, J; Tronnier, V; Fogel, W; Krause, M; Funk, T; Kern, C; Kestenbach, U; Iansek, R; Rosenfeld, J; Churchyard, A; O'Sullivan, D; Pell, M; Markus, R; Bayes, A; Blesa, R; Oliver, B; Olanow, CW; Germano, IM; Brin, M; Jankovic, J; Grossman, RG; Ondo, WG; Vitek, JL; Bakay, RAE; DeLong, MR; Tolosa, E; Rumia, J; Valldeoriola, F; Benabid, A; Albanese, A; DeLong, MR; Lang, AM; Lozano, A; Obeso, JA; Olanow, CW; Pollack, P; Koller, WC; Vitek, J; Wilkinson, S				Obeso, JA; Guridi, J; Rodriguez-Oroz, MC; Agid, Y; Bejjani, P; Bonnet, AM; Lang, AE; Lozano, AM; Kumar, R; Benabid, A; Pollack, P; Krack, P; Rehncrona, S; Ekberg, R; Grabowski, M; Albanese, A; Scerrati, M; Moro, E; Koller, W; Wilkinson, SB; Pahwa, R; Volkmann, J; Allert, N; Freund, HJ; Kulisevsky, J; Gironell, A; Molet, J; Tronnier, V; Fogel, W; Krause, M; Funk, T; Kern, C; Kestenbach, U; Iansek, R; Rosenfeld, J; Churchyard, A; O'Sullivan, D; Pell, M; Markus, R; Bayes, A; Blesa, R; Oliver, B; Olanow, CW; Germano, IM; Brin, M; Jankovic, J; Grossman, RG; Ondo, WG; Vitek, JL; Bakay, RAE; DeLong, MR; Tolosa, E; Rumia, J; Valldeoriola, F; Benabid, A; Albanese, A; DeLong, MR; Lang, AM; Lozano, A; Obeso, JA; Olanow, CW; Pollack, P; Koller, WC; Vitek, J; Wilkinson, S		Deep-Brain Stimulation Parkinsons	Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL NIGRAL TRANSPLANTATION; HIGH-FREQUENCY STIMULATION; FOLLOW-UP; ELECTRICAL-STIMULATION; MOVEMENT-DISORDERS; MEDIAL PALLIDOTOMY; 2 PARTS; MODEL	Background: Increased neuronal activity in the subthalamic nucleus and the pars interna of the globus pallidus is thought to account for motor dysfunction in patients with Parkinson's disease. Although creating lesions in these structures improves motor function in monkeys with induced parkinsonism and patients with Parkinson's disease, such lesions are associated with neurologic deficits, particularly when they are created bilaterally. Deep-brain stimulation simulates the effects of a lesion without destroying brain tissue. Methods: We performed a prospective, double-blind, crossover study in patients with advanced Parkinson's disease, in whom electrodes were implanted in the subthalamic nucleus or pars interna of the globus pallidus and who then underwent bilateral high-frequency deep-brain stimulation. We compared scores on the motor portion of the Unified Parkinson's Disease Rating Scale when the stimulation was randomly assigned to be turned on or off. We performed unblinded evaluations of motor function preoperatively and one, three, and six months postoperatively. Results: Electrodes were implanted bilaterally in 96 patients in the subthalamic-nucleus group and 38 patients in the globus-pallidus group. Three months after the procedures were performed, double-blind, crossover evaluations demonstrated that stimulation of the subthalamic nucleus was associated with a median improvement in the motor score (as compared with no stimulation) of 49 percent, and stimulation of the pars interna of the globus pallidus with a median improvement of 37 percent (P<0.001 for both comparisons). Between the preoperative and six-month visits, the percentage of time during the day that patients had good mobility without involuntary movements increased from 27 percent to 74 percent (P<0.001) with subthalamic stimulation and from 28 percent to 64 percent (P<0.001) with pallidal stimulation. Adverse events included intracranial hemorrhage in seven patients and infection necessitating removal of the leads in two. Conclusions: Bilateral stimulation of the subthalamic nucleus or pars interna of the globus pallidus is associated with significant improvement in motor function in patients with Parkinson's disease whose condition cannot be further improved with medical therapy. (N Engl J Med 2001;345:956-63.) Copyright (C) 2001 Massachusetts Medical Society.			Obeso, JA (corresponding author), Clin Univ, Ave Pio XII 36, Pamplona 31008, Spain.	jobeso@unav.es; warren.olanow@mssm.edu	Guridi, Jorge/G-2288-2018; Volkmann, Jens/AAK-7570-2020; germano, isabelle m/J-8327-2017; Rodriguez-Oroz, Maria Cruz/D-1490-2018; Lozano, Andres M/A-5058-2012; ARBOIX, JORDI RUMIÀ/AAA-3408-2019; Lang, Anthony/ABF-8114-2021; Moro, Elena/AAC-3136-2019	Guridi, Jorge/0000-0001-5714-5145; germano, isabelle m/0000-0002-3992-373X; Rodriguez-Oroz, Maria Cruz/0000-0001-5962-772X; ARBOIX, JORDI RUMIÀ/0000-0002-8755-8124; Lang, Anthony/0000-0003-1229-3667; Krack, Paul/0000-0002-3508-7295; Lozano, Andres M./0000-0001-8257-3694				ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Alvarez L, 2001, MOVEMENT DISORD, V16, P72, DOI 10.1002/1531-8257(200101)16:1<72::AID-MDS1019>3.0.CO;2-6; Ashby P, 2000, PROG NEUROL SURG, V15, P236; Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Fahn S., 1987, RECENT DEV PARKINSON, P153; Fine J, 2000, NEW ENGL J MED, V342, P1708, DOI 10.1056/NEJM200006083422304; Ghika J, 1998, J NEUROSURG, V89, P713, DOI 10.3171/jns.1998.89.5.0713; GOETZ CG, 1994, MOVEMENT DISORD, V9, P390, DOI 10.1002/mds.870090403; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; Hariz MI, 1999, J NEUROSURG, V90, P175; Hariz MI, 2000, PROG NEUROL SURG, V15, P246; Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179; Kishore A, 1997, BRAIN, V120, P729, DOI 10.1093/brain/120.5.729; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Obeso JA, 2000, ANN NEUROL, V47, pS22; Obeso JA, 2000, TRENDS NEUROSCI, V23, pS8, DOI 10.1016/S1471-1931(00)00028-8; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Olanow CW, 2001, ADV NEUROL, V86, P421; Olanow CW, 2001, NEUROLOGY, V56, pS1, DOI 10.1212/WNL.56.suppl_5.S1; Pahwa R, 1997, NEUROLOGY, V49, P249, DOI 10.1212/WNL.49.1.249; Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Snedecor G.W., 1989, AMES IOWA STATE U PR; Tasker R R, 1990, Neurosurg Clin N Am, V1, P841; Tasker RR, 1998, TXB STEREOTACTIC FUN, P1179; VIDAKOVIC A, 1994, J NEUROL NEUROSUR PS, V57, P945, DOI 10.1136/jnnp.57.8.945; Vitek JL, 1998, J NEUROSURG, V88, P1027, DOI 10.3171/jns.1998.88.6.1027; Volkmann J, 1998, ANN NEUROL, V44, P953, DOI 10.1002/ana.410440615; WICHMANN T, 1994, J NEUROPHYSIOL, V72, P521, DOI 10.1152/jn.1994.72.2.521	38	1154	1222	6	203	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2001	345	13					956	963		10.1056/nejmoa000827	http://dx.doi.org/10.1056/nejmoa000827			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475NF	11575287	Green Published, Bronze			2022-12-28	WOS:000171170000004
J	Brundtland, GH				Brundtland, GH			Health professionals must confront HIV/AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									WHO, CH-1211 Geneva, Switzerland	World Health Organization	Brundtland, GH (corresponding author), WHO, CH-1211 Geneva, Switzerland.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1444	1444		10.1001/jama.286.12.1444	http://dx.doi.org/10.1001/jama.286.12.1444			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572726				2022-12-28	WOS:000171188600010
J	Patak, MA; Froehlich, JM; von Weymarn, C; Ritz, MA; Zollikofer, CL; Wentz, KU				Patak, MA; Froehlich, JM; von Weymarn, C; Ritz, MA; Zollikofer, CL; Wentz, KU			Non-invasive distension of the small bowel for magnetic-resonance imaging	LANCET			English	Article							ENTEROCLYSIS; DISEASE; MRI	Magnetic resonance enteroclysis is a promising technique that allows assessment of the small bowel but needs Invasive nasoduodenal intubation. We propose a noninvasive distension method for magnetic-resonance imaging (MRI) in which ispaghula, dissolved in an aqueous solution with meglumine gadoterate taken orally over 4 h forms a viscous hydrogel within the intestinal lumen. MRI results from ten volunteers showed good luminal distension, constant signal homogeneity, optimum demarcation of the bowel content from surrounding tissues, and a low rate of artefacts. Our method permits non-Invasive high quality MRI of the small bowel.	Cantonal Hosp, Inst Diagnost Radiol, Magnet Resonance Res Grp, CH-8401 Winterthur, Switzerland; Cantonal Hosp, Dept Internal Med, Gastrointestinal Unit, CH-8401 Winterthur, Switzerland; Stadtspital Waid, Dept Radiol, Zurich, Switzerland; Stadtspital Waid, Dept Microtherapy, Zurich, Switzerland; Stadtspital Waid, Inst Diagnost Radiol, Zurich, Switzerland; Univ Witten Herdecke, Witten, Germany	Witten Herdecke University	Wentz, KU (corresponding author), Cantonal Hosp, Inst Diagnost Radiol, Magnet Resonance Res Grp, CH-8401 Winterthur, Switzerland.							Debatin JF, 1999, EUR RADIOL, V9, P1523, DOI 10.1007/s003300050878; DIXON PM, 1993, CLIN RADIOL, V47, P46, DOI 10.1016/S0009-9260(05)81213-9; Rieber A, 2000, EUR RADIOL, V10, P1377, DOI 10.1007/s003300000354; Singer AJ, 1999, ANN EMERG MED, V33, P652, DOI 10.1016/S0196-0644(99)70194-0; Umschaden HW, 2000, RADIOLOGY, V215, P717, DOI 10.1148/radiology.215.3.r00jn12717	5	67	68	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					987	988		10.1016/S0140-6736(01)06127-X	http://dx.doi.org/10.1016/S0140-6736(01)06127-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583757				2022-12-28	WOS:000171135300024
J	Favier, F; Walter, EC; Zach, MP; Benter, T; Penner, RM				Favier, F; Walter, EC; Zach, MP; Benter, T; Penner, RM			Hydrogen sensors and switches from electrodeposited palladium mesowire arrays	SCIENCE			English	Article							CONDUCTANCE QUANTIZATION; NANOWIRES	Hydrogen sensors and hydrogen-activated switches were fabricated from arrays of mesoscopic palladium wires. These palladium "mesowire" arrays were prepared by electrodeposition onto graphite surfaces and were transferred onto a cyanoacrylate film. Exposure to hydrogen gas caused a rapid (less than 75 milliseconds) reversible decrease in the resistance of the array that correlated with the hydrogen concentration over a range from 2 to 10%. The sensor response appears to involve the closing of nanoscopic gaps or "break junctions" in wires caused by the dilation of palladium grains undergoing hydrogen absorption. Wire arrays in which all wires possessed nanoscopic gaps reverted to open circuits in the absences of hydrogen gas.	Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Montpellier 2, CNRS, UMR 5072, F-34095 Montpellier, France	University of California System; University of California Irvine; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Penner, RM (corresponding author), Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.		Penner, Reginald/AAR-1772-2021; Benter, Thorsten/B-5765-2008; Penner, Reginald M/D-1521-2009; Zach, Michael/D-4160-2009; Favier, Frédéric/E-8938-2016	Penner, Reginald M/0000-0003-2831-3028; Zach, Michael/0000-0002-4409-3419; Favier, Frédéric/0000-0002-1515-7807				Bogozi A, 2001, J AM CHEM SOC, V123, P4585, DOI 10.1021/ja004335s; Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Lewis F. A., 1967, PALLADIUM HYDROGEN S; Li CZ, 1998, PHYS REV B, V58, P6775, DOI 10.1103/PhysRevB.58.6775; Li CZ, 2000, APPL PHYS LETT, V76, P1333, DOI 10.1063/1.126025; Zach MP, 2000, SCIENCE, V290, P2120, DOI 10.1126/science.290.5499.2120; Zahab A, 2000, PHYS REV B, V62, P10000, DOI 10.1103/PhysRevB.62.10000	8	1224	1283	19	532	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2227	2231		10.1126/science.1063189	http://dx.doi.org/10.1126/science.1063189			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567132				2022-12-28	WOS:000171139400035
J	Malek, NP; Sundberg, H; McGrew, S; Nakayama, K; Kyriakidis, TR; Roberts, JM				Malek, NP; Sundberg, H; McGrew, S; Nakayama, K; Kyriakidis, TR; Roberts, JM			A mouse knock-in model exposes sequential proteolytic pathways that regulate p27(Kip1) in G1 and S phase	NATURE			English	Article							KINASE INHIBITOR P27(KIP1); CELL-CYCLE; F-BOX; P27; MYC; ACCUMULATION; DEGRADATION; COMPLEX; UBIQUITINATION; PROGRESSION	The protein p27(Kip1) is an inhibitor of cell division(1). An increase in p27 causes proliferating cells to exit from the cell cycle, and a decrease in p27 is necessary for quiescent cells to resume division(2,3). Abnormally low amounts of p27 are associated with pathological states of excessive cell proliferation, especially cancers(4-8). In normal and tumour cells, p27 is regulated primarily at the level of translation(9-11) and protein turnover. Phosphorylation of p27 on threonine 187 (T187) by cyclin-dependent kinase 2 (Cdk2) is thought to initiate the major pathway for p27 proteolysis(12-15). To critically test the importance of this pathway in vivo, we replaced the murine p27 gene with one that encoded alanine instead of threonine at position 187 (p27(T187A)). Here we show that cells expressing p27(T187A) were unable to downregulate p27 during the S and G2 phases of the cell cycle, but that this had a surprisingly modest effect on cell proliferation both in vitro and in vivo. Our efforts to explain this unexpected result led to the discovery of a second proteolytic pathway for controlling p27, one that is activated by mitogens and degrades p27 exclusively during G1.	Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98104 USA; Kyushu Univ, Med Inst Bioregulat, Lab Embryon & Genet Engn, Fukuoka 8128582, Japan; Univ Washington, Dept Biochem, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center; Kyushu University; University of Washington; University of Washington Seattle	Roberts, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98104 USA.		高, 雨莉/HGU-8187-2022					Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HATAKEYAMA M, 1994, COLD SPRING HARB SYM, V59, P1; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kyriakides TR, 1999, J INVEST DERMATOL, V113, P782, DOI 10.1046/j.1523-1747.1999.00755.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nagy A, 1998, CURR BIOL, V8, P661, DOI 10.1016/S0960-9822(98)70254-4; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PORTENOY RK, 1997, T PALLIAT CARE, V1, P3; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan P, 1997, CANCER RES, V57, P1259; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x	30	222	232	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 20	2001	413	6853					323	327		10.1038/35095083	http://dx.doi.org/10.1038/35095083			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565035				2022-12-28	WOS:000171040500042
J	Alscher, DM; Mettang, T; Kuhlmann, U				Alscher, DM; Mettang, T; Kuhlmann, U			Cure of lifelong fatigue by calcium supplementation	LANCET			English	Editorial Material							RENAL DYSPLASIA; SENSORINEURAL DEAFNESS; HDR SYNDROME; HYPOPARATHYROIDISM		Robert Bosch Krankenhaus, Div Internal Med, Dept Gen Internal Med & Nephrol, Stuttgart, Germany	Bosch; Robert Bosch Krankenhaus	Alscher, DM (corresponding author), Robert Bosch Krankenhaus, Div Internal Med, Dept Gen Internal Med & Nephrol, Auerbachstr 110, Stuttgart, Germany.			Alscher, Mark Dominik/0000-0002-9658-1211				BILOUS RW, 1992, NEW ENGL J MED, V327, P1069, DOI 10.1056/NEJM199210083271506; Hasegawa T, 1997, AM J MED GENET, V73, P416, DOI 10.1002/(SICI)1096-8628(19971231)73:4<416::AID-AJMG9>3.0.CO;2-L; Lichtner P, 2000, J MED GENET, V37, P33, DOI 10.1136/jmg.37.1.33; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088	5	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 15	2001	358	9285					888	888		10.1016/S0140-6736(01)06074-3	http://dx.doi.org/10.1016/S0140-6736(01)06074-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567706				2022-12-28	WOS:000171087000011
J	Girardi, M; Oppenheim, DE; Steele, CR; Lewis, JM; Glusac, E; Filler, R; Hobby, P; Sutton, B; Tigelaar, RE; Hayday, AC				Girardi, M; Oppenheim, DE; Steele, CR; Lewis, JM; Glusac, E; Filler, R; Hobby, P; Sutton, B; Tigelaar, RE; Hayday, AC			Regulation of cutaneous malignancy by gamma delta T cells	SCIENCE			English	Article							EPIDERMAL-CELLS; NATURAL-KILLER; EXPRESSION; RECEPTOR; ANTIGEN; LIGAND; FAMILY; GENES; NKG2D; MICE	The localization of gamma delta T cells within epithelia suggests that these cells may contribute to the down-regulation of epithelial malignancies. We report that mice lacking gamma delta cells are highly susceptible to multiple regimens of cutaneous carcinogenesis. After exposure to carcinogens, skin cells expressed Rae-1 and H60, major histocompatibility complex-related molecules structurally resembling human MICA. Each of these is a ligand for NKG2d, a receptor expressed by cytolytic T cells and natural killer(NK) cells. In vitro, skin-associated NKG2d(+) gamma delta cells killed skin carcinoma cells by a mechanism that was sensitive to blocking NKG2d engagement. Thus, local T cells may use evolutionarily conserved proteins to negatively regulate malignancy.	Guys Kings St Thomas Med Sch, Peter Gorer Dept Immunobiol, London SE1 9RT, England; Guys Kings St Thomas Med Sch, Dept Dermatol, London SE1 9RT, England; Guys Kings St Thomas Med Sch, Yale Skin Dis Res Core Ctr, London SE1 9RT, England; Kings Coll London, Guys Hosp, Randall Ctr Mol Med, London SE1 9RT, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Hayday, AC (corresponding author), Guys Kings St Thomas Med Sch, Peter Gorer Dept Immunobiol, London SE1 9RT, England.	adrian.hayday@kcl.ac.uk		Girardi, Michael/0000-0003-1887-9343; HAYDAY, ADRIAN/0000-0002-9495-5793	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027855] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27855] Funding Source: Medline; PHS HHS [KO8] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; FUSENIG NE, 1978, B CANCER, V65, P271; Girardi M., UNPUB; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ho EL, 1998, P NATL ACAD SCI USA, V95, P6320, DOI 10.1073/pnas.95.11.6320; Holtmeier V, 2001, J INVEST DERMATOL, V116, P275, DOI 10.1046/j.1523-1747.2001.01250.x; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Lewis J M, UNPUB; Li PW, 2001, NAT IMMUNOL, V2, P443, DOI 10.1038/87757; Malarkannan S, 1998, J IMMUNOL, V161, P3501; MARSHALL V, 1974, TRANSPLANTATION, V17, P272, DOI 10.1097/00007890-197403000-00006; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; Nomura M, 1996, J BIOCHEM-TOKYO, V120, P987; Owens DM, 1999, CARCINOGENESIS, V20, P1837, DOI 10.1093/carcin/20.9.1837; Sanchez LM, 1999, SCIENCE, V283, P1914, DOI 10.1126/science.283.5409.1914; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Wolan DW, 2001, NAT IMMUNOL, V2, P248, DOI 10.1038/85311	27	748	777	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 19	2001	294	5542					605	609		10.1126/science.1063916	http://dx.doi.org/10.1126/science.1063916			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	484NC	11567106				2022-12-28	WOS:000171695600050
J	Tenopir, C; King, DW				Tenopir, C; King, DW			Lessons for the future of journals - Science journals can continue to thrive because they provide major benefits.	NATURE			English	Editorial Material									Univ Tennessee, Sch Informat Sci, Knoxville, TN 37996 USA; Univ Pittsburgh, Sch Informat Sci, Pittsburgh, PA 15260 USA	University of Tennessee System; University of Tennessee Knoxville; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tenopir, C (corresponding author), Univ Tennessee, Sch Informat Sci, Knoxville, TN 37996 USA.			Tenopir, Carol/0000-0002-9056-8251				AITCHISON J, 1974, ALTERNATIVES SCI PER; [Anonymous], 2001, NATURE, V413, P1; HILLS JA, 1972, REV LIT PRIMARY COMM; KING DW, 1978, SYSTEMS ANAL SCI TEC, P281; King DW, 1981, SCI J US THEIR PRODU; KING DW, IN PRESS BITS BUCKS; KING DW, 1977, LIB PHOTOCOPYING US; MCCABE MJ, 1998, IMPACT PUBLISHER MER; MCDONALD DD, 1982, LIB PUBLISHERS PHOTO; TENOPIR C, 2001, NATL ONLINE 2001 P; Tenopir C., 2000, ELECT J REALITIES SC	11	21	21	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 18	2001	413	6857					672	674		10.1038/35099602	http://dx.doi.org/10.1038/35099602			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482ZK	11606996				2022-12-28	WOS:000171608000020
J	Chodosh, J; Ferrell, BA; Shekelle, PG; Wenger, NS				Chodosh, J; Ferrell, BA; Shekelle, PG; Wenger, NS			Quality indicators for pain management in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC MUSCULOSKELETAL PAIN; PLACEBO-CONTROLLED TRIAL; GENERAL-POPULATION; NUTRITION EXAMINATION; DEPRESSIVE SYMPTOMS; DIABETIC NEUROPATHY; RANDOMIZED TRIAL; NATIONAL-HEALTH; PEPTIC-ULCER; DRUG-USE		Univ Calif Los Angeles, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA; RAND Corp, Hlth, Santa Monica, CA 90406 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA	University of California System; University of California Los Angeles; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Chodosh, J (corresponding author), Univ Calif Los Angeles, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA.	jchodosh@mednet.ucla.edu		Chodosh, Joshua/0000-0001-7784-4306				ANDERSEN S, 1987, PAIN S, V4, P332; [Anonymous], [No title captured]; Becker N, 1997, PAIN, V73, P393, DOI 10.1016/S0304-3959(97)00126-7; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; BRATTBERG G, 1989, PAIN, V37, P215, DOI 10.1016/0304-3959(89)90133-4; Brochet B, 1998, AGE AGEING, V27, P279, DOI 10.1093/ageing/27.3.279; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COONER E, 1997, 628200 NATL COUNC AG; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; Davis M A, 1988, Clin Geriatr Med, V4, P241; DIETRICH AJ, 1982, J FAM PRACTICE, V15, P929; Ellison Neil M., 1993, P185; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Ferrell BA, 1997, AGING-CLIN EXP RES, V9, P99, DOI 10.1007/BF03340134; Ferrell BA, 1998, J AM GERIATR SOC, V46, P635, DOI 10.1111/j.1532-5415.1998.tb01084.x; FERRELL BA, 1990, J AM GERIATR SOC, V38, P409, DOI 10.1111/j.1532-5415.1990.tb03538.x; Foley K, 1994, PRINCIPLES GERIATRIC, P317; GLARE P, 1992, J PAIN SYMPTOM MANAG, V7, P369, DOI 10.1016/0885-3924(92)90092-V; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; HAMEROFF SR, 1984, J CLIN PSYCHIAT, V45, P47; LAVSKYSHULAN M, 1985, J AM GERIATR SOC, V33, P23, DOI 10.1111/j.1532-5415.1985.tb02855.x; MAGNI G, 1993, PAIN, V53, P163, DOI 10.1016/0304-3959(93)90076-2; MAGNI G, 1990, PAIN, V43, P299, DOI 10.1016/0304-3959(90)90027-B; MAX MB, 1991, PAIN, V45, P3, DOI 10.1016/0304-3959(91)90157-S; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; Mobily P., 1994, J AGING HEALTH, V6, P139, DOI DOI 10.1177/089826439400600201; PANERAI AE, 1990, ACTA NEUROL SCAND, V82, P34; PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15; PFEIFER MA, 1993, DIABETES CARE, V16, P1103, DOI 10.2337/diacare.16.8.1103; POPP B, 1996, PAIN ELDERLY, P21; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; ROGERS M, 1989, J CLIN GASTROENTEROL, V11, P132; ROY R, 1986, CAN FAM PHYSICIAN, V32, P513; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; *US AG HLTH CAR PO, 1994, AHCPR PUBL; Wilson PR, 1997, ANESTHESIOLOGY, V86, P995	38	26	26	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				731	735		10.7326/0003-4819-135-8_Part_2-200110161-00012	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601956				2022-12-28	WOS:000171542400012
J	Grigera, SA; Perry, RS; Schofield, AJ; Chiao, M; Julian, SR; Lonzarich, GG; Ikeda, SI; Maeno, Y; Millis, AJ; Mackenzie, AP				Grigera, SA; Perry, RS; Schofield, AJ; Chiao, M; Julian, SR; Lonzarich, GG; Ikeda, SI; Maeno, Y; Millis, AJ; Mackenzie, AP			Magnetic field-tuned quantum criticality in the metallic ruthenate Sr3Ru2O7	SCIENCE			English	Article							HEAVY-FERMION COMPOUNDS; SUPERCONDUCTIVITY; METAMAGNETISM; INSTABILITY; BEHAVIOR; SYSTEMS; URU2SI2; STATE	The concept of quantum criticality is proving to be central to attempts to understand the physics of strongly correlated electrons. Here, we argue that observations on the itinerant metamagnet Sr3Ru2O7 represent good evidence for a new class of quantum critical point, arising when the critical end point terminating a tine of first-order transitions is depressed toward zero temperature. This is of interest both in its own right and because of the convenience of having a quantum critical point for which the tuning parameter is the magnetic field. The relationship between the resultant critical fluctuations and novel behavior very near the critical field is discussed.	Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland; Univ Birmingham, Sch Phys & Astron, Birmingham B15 2TT, W Midlands, England; Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; Tsukuba Cent 2, AIST, Nanoelect Res Inst, Tsukuba, Ibaraki 3058568, Japan; Kyoto Univ, Dept Phys, Kyoto 6068502, Japan; Rutgers State Univ, Dept Phys & Astron, Ctr Mat Theory, Piscataway, NJ 08854 USA	University of St Andrews; University of Birmingham; University of Cambridge; National Institute of Advanced Industrial Science & Technology (AIST); Kyoto University; Rutgers State University New Brunswick	Grigera, SA (corresponding author), Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland.	s.grigera@bham.ac.uk; apm9@st-and.ac.uk	grigera, santiago a/A-4932-2010; Mackenzie, Andrew P/K-6742-2015; Ikeda, Shinichi/I-5829-2012; Schofield, Andy J/C-5004-2009; Schofield, Andy/AAL-7382-2020	Mackenzie, Andrew P/0000-0001-8000-4949; Ikeda, Shinichi/0000-0003-2134-7786; Schofield, Andy J/0000-0002-1218-8560; Schofield, Andy/0000-0002-1218-8560; Grigera, Santiago/0000-0002-1343-5885				Allen PB, 1996, PHYS REV B, V53, P4393, DOI 10.1103/PhysRevB.53.4393; Aoki Y, 1999, PHYSICA B, V259-61, P28, DOI 10.1016/S0921-4526(98)01165-X; Bitko D, 1996, PHYS REV LETT, V77, P940, DOI 10.1103/PhysRevLett.77.940; CAPOGNA L, UNPUB; FRINGS PH, 1985, PHYS REV B, V31, P4355, DOI 10.1103/PhysRevB.31.4355; HERTZ JA, 1976, PHYS REV B, V14, P1165, DOI 10.1103/PhysRevB.14.1165; Ikeda S, 2000, PHYS REV B, V62, pR6089, DOI 10.1103/PhysRevB.62.R6089; Ikeda SI, 1999, PHYSICA B, V259-61, P947, DOI 10.1016/S0921-4526(98)01012-6; Ishida K, 1998, NATURE, V396, P658, DOI 10.1038/25315; KAMBE S, 1995, SOLID STATE COMMUN, V96, P175; KAMBE S, 1995, SOLID STATE COMMUN, V95, P449, DOI 10.1016/0038-1098(95)00243-X; Kima JS, 2000, SOLID STATE COMMUN, V114, P413, DOI 10.1016/S0038-1098(00)00084-3; Kirkpatrick TR, 1997, J STAT PHYS, V87, P1307, DOI 10.1007/BF02181286; Kolomiets AV, 1998, J APPL PHYS, V83, P6435, DOI 10.1063/1.367776; Laughlin RB, 2000, P NATL ACAD SCI USA, V97, P28, DOI 10.1073/pnas.97.1.28; Liu Y, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.174435; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; MILLIS AJ, 1993, PHYS REV B, V48, P7183, DOI 10.1103/PhysRevB.48.7183; Osborne IS, 2000, SCIENCE, V288, P461, DOI 10.1126/science.288.5465.461; Perry RS, 2001, PHYS REV LETT, V86, P2661, DOI 10.1103/PhysRevLett.86.2661; Sachdev S., 1999, QUANTUM PHASE TRANSI; Saxena SS, 2000, NATURE, V406, P587, DOI 10.1038/35020500; STRYJEWSKI E, 1977, ADV PHYS, V26, P487, DOI 10.1080/00018737700101433; Sugawara H, 1999, J PHYS SOC JPN, V68, P1094, DOI 10.1143/JPSJ.68.1094; Sugiyama K, 2000, PHYSICA B, V281, P244, DOI 10.1016/S0921-4526(99)00926-6; SUGIYAMA K, 1990, J PHYS SOC JPN, V59, P3331, DOI 10.1143/JPSJ.59.3331; von Lohneysen H, 2001, PHYS REV B, V63; VONLOHNEYSEN H, 1994, PHYS REV LETT, V72, P3262, DOI 10.1103/PhysRevLett.72.3262	28	468	469	9	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 12	2001	294	5541					329	332		10.1126/science.1063539	http://dx.doi.org/10.1126/science.1063539			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598292				2022-12-28	WOS:000171601400032
J	Bay-Nielsen, M; Kehlet, H; Strand, L; Malmstrom, J; Andersen, FH; Wara, P; Juul, P; Callesen, T				Bay-Nielsen, M; Kehlet, H; Strand, L; Malmstrom, J; Andersen, FH; Wara, P; Juul, P; Callesen, T		Danish Hernia Database Collaborat	Quality assessment of 26,304 herniorrhaphies in Denmark: a prospective nationwide study	LANCET			English	Article							INGUINAL HERNIORRHAPHY; HERNIA SURGERY	Background Groin hernia repair is one of the most frequent operations, but there is no consensus about surgical or anaesthetic technique. Furthermore, no nationwide studies have been done. Our aim was to investigate outcome results of groin hernia surgery to improve quality of treatment. Methods We prospectively recorded 26 304 groin hernia repairs done in Denmark from Jan 1, 1998, to June 30, 2000, in a nationwide Danish hernia database. Findings 93% of all groin herniorrhaphies done in Denmark in the 30 months of the study were recorded in the database. Kaplan-Meier estimates of reoperation rates 30 months after anterior mesh repair and laparoscopic repair were significantly lower than after sutured posterior wall repairs in primary inguinal hernia (2.2% and 2.6% vs 4.4%; p < 0.0001). Reoperation rates were also lower with anterior mesh repair (6.1%; p < 0.0001) and laparoscopic repair (3.4%; p < 0.0001) than with sutured posterior wall repair (10.6%) after recurrent hernia. Use of Lichtenstein mesh repair increased from 33% in January, 1998, to 62% in June, 2000, whereas use of laparoscopic repair remained constant at about 5%. Kaplan-Meier estimates of reoperation rates were 2.8% in the first 15 months and 1.6% in the second (p = 0.03). For elective repairs, only 59% of patients were treated on an outpatient basis, and only 18% had local anaesthesia. Interpretation Mesh repairs have a lower reoperation rate than conventional open repairs. Systematic prospective recording of treatment and outcome variables in a national clinical database improved the overall quality of surgical care. However, there is a large potential for cost savings and more efficient patient care with extended use of mesh techniques, outpatient surgery, and local anaesthesia.	Hvidovre Univ Hosp, Dept Surg Gastroenterol 435, DK-2650 Hvidovre, Denmark	University of Copenhagen	Bay-Nielsen, M (corresponding author), Hvidovre Univ Hosp, Dept Surg Gastroenterol 435, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.	morten.bay.nielsen@hh.hosp.dk						Amid PK, 1998, HERNIA, V22, P89, DOI [DOI 10.1007/BF01207492, 10.1007/BF01207492]; [Anonymous], 1926, REP PUBLIC HLTH MED; Bay-Nielsen M, 2001, ANN SURG, V233, P1, DOI 10.1097/00000658-200101000-00001; Bay-Nielsen M, 1999, HERNIA, V3, P81; Black N, 1999, LANCET, V353, P1205, DOI 10.1016/S0140-6736(99)00108-7; Callesen T, 1997, ANESTHESIOLOGY, V87, P1219, DOI 10.1097/00000542-199711000-00027; Callesen T, 1998, ANAESTHESIA, V53, P31, DOI 10.1111/j.1365-2044.1998.00244.x; Callesen T, 1999, EUR J SURG, V165, P236; DEYSINE M, 1991, ARCH SURG-CHICAGO, V126, P628; Grant A, 2000, BRIT J SURG, V87, P854, DOI 10.1046/j.1365-2168.2000.01539.x; Grant A, 2000, BRIT J SURG, V87, P860, DOI 10.1046/j.1365-2168.2000.01540.x; Kald A, 1998, EUR J SURG, V164, P45; Kark AE, 1998, J AM COLL SURGEONS, V186, P447, DOI 10.1016/S1072-7515(98)00057-X; Kingsnorth AN, 2000, HERNIA, V4, P1; MAJEED AW, 1995, BRIT MED J, V311, P296, DOI 10.1136/bmj.311.7000.296; Nilsson E, 1998, SURG CLIN N AM, V78, P1141, DOI 10.1016/S0039-6109(05)70375-3; Nilsson E, 1997, EUR J SURG, V163, P823; O'Riordan DC, 1998, SURG CLIN N AM, V78, P1129, DOI 10.1016/S0039-6109(05)70374-1; WELSH DRJ, 1993, SURG CLIN N AM, V73, P451	19	311	327	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	2001	358	9288					1124	1128		10.1016/S0140-6736(01)06251-1	http://dx.doi.org/10.1016/S0140-6736(01)06251-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597665				2022-12-28	WOS:000171399000008
J	Bosch, X				Bosch, X			Female genital mutilation in developed countries	LANCET			English	Article									Hosp Clin Barcelona, Dept Internal Med, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona	Bosch, X (corresponding author), Hosp Clin Barcelona, Dept Internal Med, Villarroel 170, E-08036 Barcelona, Spain.							Andersson C, 2001, Lakartidningen, V98, P2463; Bosch X, 2001, LANCET, V357, P1510, DOI 10.1016/S0140-6736(00)04713-9; Richards D, 2000, Med Ref Serv Q, V19, P79, DOI 10.1300/J115v19n04_07	3	16	18	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1177	1179		10.1016/S0140-6736(01)06262-6	http://dx.doi.org/10.1016/S0140-6736(01)06262-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597696				2022-12-28	WOS:000171399000038
J	Morrison, P				Morrison, P			Tales behind the tags	NATURE			English	Article									MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Morrison, P (corresponding author), MIT, Dept Phys, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							FRENCH AP, 1985, NIELS BOHR CENTENARY, V301, P305; GALILEI G, 1967, DIALOGUE CONCERNING, P171	2	1	1	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					461	461		10.1038/35097170	http://dx.doi.org/10.1038/35097170			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586334				2022-12-28	WOS:000171340500023
J	Ziegelstein, RC				Ziegelstein, RC			Depression in patients recovering from a myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-RATE-VARIABILITY; MAJOR DEPRESSION; CARDIAC REHABILITATION; HOSPITAL ANXIETY; MORTALITY; RISK; ADHERENCE; SAFETY; RECOMMENDATIONS; PAROXETINE	Depression is common among patients recovering from a myocardial infarction (MI). Approximately 1 in 6 patients with MI experience major depression and at least twice as many as that have significant symptoms of depression soon after the event. Post-MI depression is an independent risk factor for increased mortality. Although the mechanism responsible for this association has not yet been defined, depression is clearly associated with poor compliance with risk-reducing recommendations, with abnormalities in autonomic tone that may make patients more susceptible to ventricular arrhythmias, and with increased platelet activation. Coronary revascularization procedures also appear to be used less often in those with post-MI depression than in comparable patients without mood disorder. Ongoing research will address whether treating depression improves prognosis. Until this question is answered, efforts should focus on enhancing adherence to treatment regimens in this group of patients, who are clearly at risk for noncompliance. Cardiac rehabilitation programs and increasing levels of social support may help improve symptoms and should be recommended to all patients. Treatment of depression itself should be individualized until safety and efficacy are determined for antidepressant therapy in patients who recently have had an MI.	Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med,Div Cardiol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Ziegelstein, RC (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med,Div Cardiol, 4940 Eastern Ave, Baltimore, MD 21224 USA.	rziegel@jhmi.edu						*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P317; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Berkman LF, 2000, AM HEART J, V139, P1; BIGGER JT, 1993, J AM COLL CARDIOL, V21, P729, DOI 10.1016/0735-1097(93)90106-B; BLUMENTHAL JA, 1982, PSYCHOSOM MED, V44, P519, DOI 10.1097/00006842-198212000-00003; Bush DE, 2001, AM J CARDIOL, V88, P337, DOI 10.1016/S0002-9149(01)01675-7; CARNEY RM, 1995, HEALTH PSYCHOL, V14, P88, DOI 10.1037/0278-6133.14.1.88; Carney RM, 2000, PSYCHOSOM MED, V62, P639, DOI 10.1097/00006842-200009000-00007; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Delisi SM, 1998, BIOL PSYCHIAT, V43, P327, DOI 10.1016/S0006-3223(97)00377-6; DENOLLET J, 1995, PSYCHOSOM MED, V57, P582, DOI 10.1097/00006842-199511000-00011; DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101; Druss BG, 2000, JAMA-J AM MED ASSOC, V283, P506, DOI 10.1001/jama.283.4.506; Fox R, 1998, CIRCULATION, V97, P127, DOI 10.1161/01.CIR.97.2.127; Frasure-Smith N, 2000, CIRCULATION, V101, P1919, DOI 10.1161/01.CIR.101.16.1919; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; GLASSMAN AH, 1993, JAMA-J AM MED ASSOC, V269, P2673, DOI 10.1001/jama.269.20.2673; GUIRY E, 1987, CLIN CARDIOL, V10, P256, DOI 10.1002/clc.4960100409; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Irvine J, 1999, PSYCHOSOM MED, V61, P729, DOI 10.1097/00006842-199911000-00001; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Karege F, 1996, BIOL PSYCHIAT, V39, P697, DOI 10.1016/0006-3223(95)00187-5; Kaufmann MW, 1999, AM HEART J, V138, P549, DOI 10.1016/S0002-8703(99)70159-6; KELLNER R, 1987, J CLIN PSYCHIAT, V48, P268; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LADWIG KH, 1991, EUR HEART J, V12, P959; Lane D, 2000, QJM-MON J ASSOC PHYS, V93, P739, DOI 10.1093/qjmed/93.11.739; Lane D, 2001, PSYCHOSOM MED, V63, P221, DOI 10.1097/00006842-200103000-00005; Lane D, 2000, J PSYCHOSOM RES, V49, P229, DOI 10.1016/S0022-3999(00)00170-7; Markovitz JH, 2000, AM J PSYCHIAT, V157, P1006, DOI 10.1176/appi.ajp.157.6.1006; Mayou RA, 2000, PSYCHOSOM MED, V62, P212, DOI 10.1097/00006842-200003000-00011; McDermott MM, 1997, ARCH INTERN MED, V157, P1921, DOI 10.1001/archinte.157.17.1921; Milani RV, 1996, AM HEART J, V132, P726, DOI 10.1016/S0002-8703(96)90304-X; Milani RV, 1998, AM J CARDIOL, V81, P1233, DOI 10.1016/S0002-9149(98)00121-0; Miller NH, 1997, CIRCULATION, V95, P1085; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; Musselman DL, 2000, ARCH GEN PSYCHIAT, V57, P875, DOI 10.1001/archpsyc.57.9.875; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROOSE SP, 1989, J CLIN PSYCHIAT, V50, P12; Roose SP, 1998, JAMA-J AM MED ASSOC, V279, P287, DOI 10.1001/jama.279.4.287; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; Shapiro PA, 1999, AM HEART J, V137, P1100, DOI 10.1016/S0002-8703(99)70369-8; Stein PK, 2000, J PSYCHOSOM RES, V48, P493, DOI 10.1016/S0022-3999(99)00085-9; Strik JTMH, 2000, PSYCHOSOM MED, V62, P783, DOI 10.1097/00006842-200011000-00007; Welin C, 2000, J INTERN MED, V247, P629, DOI 10.1046/j.1365-2796.2000.00694.x; Ziegelstein R C, 2001, Cardiol Rev, V9, P45, DOI 10.1097/00045415-200101000-00009; Ziegelstein RC, 2000, ARCH INTERN MED, V160, P1818, DOI 10.1001/archinte.160.12.1818; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	49	127	131	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1621	1627		10.1001/jama.286.13.1621	http://dx.doi.org/10.1001/jama.286.13.1621			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	478HH	11585486				2022-12-28	WOS:000171340600030
J	Anglaret, X				Anglaret, X			Trimethoprim-sulfamethoxazole prophylaxis in sub-Saharan Africa	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; STREPTOCOCCUS-PNEUMONIAE; COTE-DIVOIRE; RESISTANCE; ABIDJAN; ADULTS; TRIAL		Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Anglaret, X (corresponding author), Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France.		Anglaret, Xavier/F-7333-2013; Anglaret, Xavier/T-2757-2019	Anglaret, Xavier/0000-0003-3319-8423				Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Badri M, 2001, AIDS, V15, P1143, DOI 10.1097/00002030-200106150-00009; BLOLAND PB, 1991, LANCET, V337, P518, DOI 10.1016/0140-6736(91)91299-A; Boeree MJ, 1999, LANCET, V354, P334, DOI 10.1016/S0140-6736(05)75236-3; COLEBUNDERS R, 1987, ANN INTERN MED, V107, P599, DOI 10.7326/0003-4819-107-4-599_2; Huovinen P, 2001, CLIN INFECT DIS, V32, P1608, DOI 10.1086/320532; Martin JN, 1999, J INFECT DIS, V180, P1809, DOI 10.1086/315132; Maynart M, 2001, J ACQ IMMUN DEF SYND, V26, P130, DOI 10.1097/00126334-200102010-00004; Meynard JL, 1996, CLIN INFECT DIS, V22, P437, DOI 10.1093/clinids/22.3.437; RodriguezBarradas MC, 1997, J INFECT DIS, V175, P590, DOI 10.1093/infdis/175.3.590; *UNAIDS WHO, 2001, PROV WHO UNAIDS SECR; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0	12	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 29	2001	358	9287					1027	1028		10.1016/S0140-6736(01)06227-4	http://dx.doi.org/10.1016/S0140-6736(01)06227-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589928				2022-12-28	WOS:000171393100003
J	Hammarstrom, P; Schneider, F; Kelly, JW				Hammarstrom, P; Schneider, F; Kelly, JW			Trans-suppression of misfolding in an amyloid disease	SCIENCE			English	Article							POLYNEUROPATHY; STABILITY; HOMOZYGOSITY; TRANSTHYRETIN-MET30-GENE; PROTEIN	The transthyretin (TTR) amyloid diseases, representative of numerous misfolding disorders, are of considerable interest because there are mutations that cause or suppress disease. The Val(30) --> Met(30) (V30M) TTR mutation is the most prevalent cause of familial amyloid polyneuropathy in heterozygotes, whereas a Thr(119) ---> Met(119) (T119M) mutation on the second TTR allele protects V30M carriers from disease. Here, we show that the incorporation of one or more T119M TTR subunits into a predominantly V30M tetramer strongly stabilized the! mixed tetramer against dissociation. Dissociation is required for amyloid formation, so these findings provide a molecular explanation for intragenic trans-suppression of amyloidosis. The data also suggest a potential therapeutic strategy, provide insight into tissue-specific deposition and amyloid composition, and support the validity of the amyloid hypothesis in human disease.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Kelly, JW (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd BCC265, La Jolla, CA 92037 USA.	jkelly@scripps.edu		Hammarstrom, Per/0000-0001-5827-3587	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK046335, R01DK046335, R29DK046335] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46335-09] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alves IL, 1997, EUR J BIOCHEM, V249, P662, DOI 10.1111/j.1432-1033.1997.00662.x; Ando Y, 1999, AMYLOID, V6, P119, DOI 10.3109/13506129909007312; Coehlo T., 1996, NEUROMUSCUL DISORD, V6, P27; Coelho Teresa, 1993, Journal of Rheumatology, V20, P179; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; DWULET FE, 1984, P NATL ACAD SCI-BIOL, V81, P694, DOI 10.1073/pnas.81.3.694; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Hammarstrom P, 2001, BIOCHEMISTRY-US, V40, P11453, DOI 10.1021/bi010673+; HOLMGREN G, 1992, CLIN GENET, V41, P39; HOLMGREN G, 1988, CLIN GENET, V34, P333; IKEDA S, 1992, EUR NEUROL, V32, P308, DOI 10.1159/000116850; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; SANDGREN O, 1990, ARCH OPHTHALMOL-CHIC, V108, P1584, DOI 10.1001/archopht.1990.01070130086036; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; Schneider F, 2001, PROTEIN SCI, V10, P1606, DOI 10.1110/ps.8901; Schuler B, 1998, J MOL BIOL, V281, P227, DOI 10.1006/jmbi.1998.1944; Sebastiao MP, 2001, J MOL BIOL, V306, P733, DOI 10.1006/jmbi.2000.4415; SUHR OB, 1995, TRANSPLANTATION, V60, P933, DOI 10.1097/00007890-199511150-00009; Yazaki M, 2000, BIOCHEM BIOPH RES CO, V274, P702, DOI 10.1006/bbrc.2000.3203	22	233	240	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2459	2462		10.1126/science.1062245	http://dx.doi.org/10.1126/science.1062245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577236				2022-12-28	WOS:000171237200049
J	Fajans, SS; Bell, GI; Polonsky, KS				Fajans, SS; Bell, GI; Polonsky, KS			Mechanisms of disease: Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NUCLEAR FACTOR-1-ALPHA GENE; INSULIN SECRETORY RESPONSES; BETA-CELL; GLUCOKINASE MUTATIONS; JAPANESE SUBJECTS; NONDIABETIC SUBJECTS; RENAL DYSFUNCTION; HEPATOCYTE; MELLITUS; GLUCOSE		Univ Michigan Hlth Syst, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago; Washington University (WUSTL); Washington University (WUSTL)	Fajans, SS (corresponding author), Univ Michigan Hosp, Taubman Ctr 3920, Box 0354, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, P60DK020595] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00042] Funding Source: Medline; NIDDK NIH HHS [DK-20572, DK-20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, IN PRESS ENCY MOL ME; Bingham C, 2001, AM J HUM GENET, V68, P219, DOI 10.1086/316945; Byrne MM, 1996, DIABETES, V45, P1503, DOI 10.2337/diabetes.45.11.1503; BYRNE MM, 1995, DIABETES, V44, P699, DOI 10.2337/diabetes.44.6.699; BYRNE MM, 1994, J CLIN INVEST, V93, P1120, DOI 10.1172/JCI117064; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Ellard S, 2000, DIABETOLOGIA, V43, P250, DOI 10.1007/s001250050038; FAJANS SS, 1993, DIABETES CARE, V16, P1254, DOI 10.2337/diacare.16.9.1254; FAJANS SS, 1994, LIFE SCI, V55, P413, DOI 10.1016/0024-3205(94)90052-3; FAJANS SS, 1987, HORM METAB RES, V19, P591, DOI 10.1055/s-2007-1011888; FAJANS SS, 1992, J LAB CLIN MED, V119, P206; Fajans SS, 2000, FRONT DIABETES, V15, P1; FAJANS SS, 1990, DIABETES CARE, V13, P910; FAJANS SS, 2000, DIABETES MELLITUS FU, P691; Frayling TM, 1997, DIABETES, V46, P720, DOI 10.2337/diabetes.46.4.720; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; FUJANS, 1990, DIABETES CARE, V13, P49; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hathout EH, 1999, DIABETES CARE, V22, P867, DOI 10.2337/diacare.22.5.867; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; Hegele RA, 1999, J CLIN ENDOCR METAB, V84, P1077, DOI 10.1210/jc.84.3.1077; Herman WH, 1997, DIABETES, V46, P1749, DOI 10.2337/diabetes.46.11.1749; HERMAN WH, 1994, DIABETES, V43, P1171; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Ilag LL, 2000, DIABETES, V49, P961, DOI 10.2337/diabetes.49.6.961; Isomaa B, 1998, DIABETOLOGIA, V41, P467, DOI 10.1007/s001250050931; Iwasaki N, 1998, DIABETES CARE, V21, P2144, DOI 10.2337/diacare.21.12.2144; Iwasaki N, 1997, DIABETES, V46, P1504, DOI 10.2337/diabetes.46.9.1504; Iwasaki N, 2001, DIABETOLOGIA, V44, P387; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEDERMANN HM, 1995, DIABETOLOGIA, V38, P1482, DOI 10.1007/BF00400611; Lehto M, 1999, DIABETES, V48, P423, DOI 10.2337/diabetes.48.2.423; Lehto M, 1997, J CLIN INVEST, V99, P582, DOI 10.1172/JCI119199; Lindner TH, 1999, HUM MOL GENET, V8, P2001, DOI 10.1093/hmg/8.11.2001; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Menzel R, 1998, DIABETIC MED, V15, P816, DOI 10.1002/(SICI)1096-9136(199810)15:10<816::AID-DIA714>3.0.CO;2-P; Moller AM, 1998, DIABETOLOGIA, V41, P1528, DOI 10.1007/s001250051101; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Nishigori H, 1998, DIABETES, V47, P1354, DOI 10.2337/diabetes.47.8.1354; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Pearson ER, 2000, DIABETIC MED, V17, P543, DOI 10.1046/j.1464-5491.2000.00305.x; Pearson ER, 2001, DIABETES, V50, pS101, DOI 10.2337/diabetes.50.2007.S101; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; Pontoglio M, 2000, EMBO REP, V1, P359, DOI 10.1093/embo-reports/kvd071; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Prisco F, 2000, DIABETOLOGIA, V43, P1331; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Shimomura H, 2000, DIABETES, V49, P1597, DOI 10.2337/diabetes.49.9.1597; Sovik O, 1998, DIABETOLOGIA, V41, P607, DOI 10.1007/s001250050956; Sreenan SK, 1998, DIABETES, V47, P1881, DOI 10.2337/diabetes.47.12.1881; St-Onge L, 1999, CURR OPIN GENET DEV, V9, P295, DOI 10.1016/S0959-437X(99)80044-6; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; STURIS J, 1994, DIABETES, V43, P718, DOI 10.2337/diabetes.43.5.718; Velho G, 1996, DIABETES CARE, V19, P915, DOI 10.2337/diacare.19.9.915; Velho G, 1996, J CLIN INVEST, V98, P1755, DOI 10.1172/JCI118974; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; WRIGHT NM, 1993, AM J DIS CHILD, V147, P607; YAGAMATA K, 1996, NATURE, V384, P458; Yamada S, 1997, DIABETES, V46, P1643, DOI 10.2337/diabetes.46.10.1643; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yoshiuchi I, 1999, DIABETOLOGIA, V42, P621, DOI 10.1007/s001250051204	69	700	751	0	53	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2001	345	13					971	980		10.1056/NEJMra002168	http://dx.doi.org/10.1056/NEJMra002168			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475NF	11575290				2022-12-28	WOS:000171170000007
J	Hwang, I; Sheen, J				Hwang, I; Sheen, J			Two-component circuitry in Arabidopsis cytokinin signal transduction	NATURE			English	Article							2-COMPONENT RESPONSE REGULATOR; MAP KINASE CASCADE; HISTIDINE KINASE; ASP PHOSPHORELAY; LEAF SENESCENCE; PROTEIN-KINASES; PLANTS; THALIANA; YEAST; TRANSFORMATION	Cytokinins are essential plant hormones that are involved in shoot meristem and leaf formation, cell division, chloroplast biogenesis and senescence. Although hybrid histidine protein kinases have been implicated in cytokinin perception in Arabidopsis, the action of histidine protein kinase receptors and the downstream signalling pathway has not been elucidated to date. Here we identify a eukaryotic two-component signalling circuit that initiates cytokinin signalling through distinct hybrid histidine protein kinase activities at the plasma membrane. Histidine phosphotransmitters act as signalling shuttles between the cytoplasm and nucleus in a cytokinin-dependent manner. The short signalling circuit reaches the nuclear target genes by enabling nuclear response regulators ARR1, ARR2 and ARR10 as transcription activators. The cytokinin-inducible ARR4, ARR5, ARR6 and ARR7 genes encode transcription repressors that mediate a negative feedback loop in cytokinin signalling. Ectopic expression in transgenic Arabidopsis of ARR2, the rate-limiting factor in the response to cytokinin, is sufficient to mimic cytokinin in promoting shoot meristem proliferation and leaf differentiation, and in delaying leaf senescence.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Sheen, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.		Ding, Cheng-Qiang/B-6287-2011					[Anonymous], 1995, PLANT HORMONES PHYSL, DOI DOI 10.1007/978-94-011-0473-9; Bleecker AB, 2000, ANNU REV CELL DEV BI, V16, P1, DOI 10.1146/annurev.cellbio.16.1.1; CLARKE FH, 1995, J DYN CONTROL SYST, V1, P1, DOI DOI 10.1007/BF02254655; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; D'Agostino IB, 2000, PLANT PHYSIOL, V124, P1706, DOI 10.1104/pp.124.4.1706; D'Agostino IB, 1999, TRENDS BIOCHEM SCI, V24, P452, DOI 10.1016/S0968-0004(99)01465-6; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; Frank M, 2000, PLANT PHYSIOL, V122, P721, DOI 10.1104/pp.122.3.721; Gamble RL, 1998, P NATL ACAD SCI USA, V95, P7825, DOI 10.1073/pnas.95.13.7825; GAN SS, 1995, SCIENCE, V270, P1986, DOI 10.1126/science.270.5244.1986; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Imamura A, 1999, PLANT CELL PHYSIOL, V40, P733, DOI 10.1093/oxfordjournals.pcp.a029600; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; Kiba T, 1999, PLANT CELL PHYSIOL, V40, P767, DOI 10.1093/oxfordjournals.pcp.a029604; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Lohrmann J, 2001, MOL GENET GENOMICS, V265, P2, DOI 10.1007/s004380000400; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Mahonen AP, 2000, GENE DEV, V14, P2938, DOI 10.1101/gad.189200; Meijer M, 2001, CURR OPIN PLANT BIOL, V4, P44, DOI 10.1016/S1369-5266(00)00134-5; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Nakamura A, 1999, BIOSCI BIOTECH BIOCH, V63, P1627, DOI 10.1271/bbb.63.1627; Ori N, 1999, PLANT CELL, V11, P1073, DOI 10.1105/tpc.11.6.1073; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Quirino BF, 2000, TRENDS PLANT SCI, V5, P278, DOI 10.1016/S1360-1385(00)01655-1; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Sakai H, 1998, PLANT CELL PHYSIOL, V39, P1232, DOI 10.1093/oxfordjournals.pcp.a029325; Sakai H, 2000, PLANT J, V24, P703, DOI 10.1046/j.1365-313x.2000.00909.x; Sakakibara H, 2000, PLANT MOL BIOL, V42, P273, DOI 10.1023/A:1006334926388; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Suzuki T, 2001, PLANT CELL PHYSIOL, V42, P107, DOI 10.1093/pcp/pce037; Suzuki T, 1998, PLANT CELL PHYSIOL, V39, P1258, DOI 10.1093/oxfordjournals.pcp.a029329; Suzuki T, 2001, PLANT CELL PHYSIOL, V42, P37, DOI 10.1093/pcp/pce011; Suzuki T, 2000, BIOSCI BIOTECH BIOCH, V64, P2486, DOI 10.1271/bbb.64.2486; Thomason P, 2000, J CELL SCI, V113, P3141; Tsiantis M, 2001, PLANT CELL, V13, P733, DOI 10.1105/tpc.13.4.733; Ueguchi C, 2001, PLANT CELL PHYSIOL, V42, P231, DOI 10.1093/pcp/pce015; Urao T, 2000, TRENDS PLANT SCI, V5, P67, DOI 10.1016/S1360-1385(99)01542-3; Urao T, 2000, FEBS LETT, V478, P227, DOI 10.1016/S0014-5793(00)01860-3; Urao T, 1998, FEBS LETT, V427, P175, DOI 10.1016/S0014-5793(98)00418-9; Urao T, 1999, PLANT CELL, V11, P1743, DOI 10.1105/tpc.11.9.1743; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593; Yanagisawa S, 1998, PLANT CELL, V10, P75, DOI 10.1105/tpc.10.1.75; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	48	683	750	4	111	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					383	389		10.1038/35096500	http://dx.doi.org/10.1038/35096500			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574878				2022-12-28	WOS:000171188700044
J	Moberg, KH; Bell, DW; Wahrer, DCR; Haber, DA; Hariharan, IK				Moberg, KH; Bell, DW; Wahrer, DCR; Haber, DA; Hariharan, IK			Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines	NATURE			English	Article							EYE IMAGINAL DISC; CONTROLS S-PHASE; F-BOX; PROLIFERATION; EXPRESSION; PROTEINS; ELEGANS; BREAST; ARREST; FAMILY	During Drosophila development and mammalian embryogenesis, exit from the cell cycle is contingent on tightly controlled downregulation of the activity of Cyclin E-Cdk2 complexes that normally promote the transition from G1 to S phase(1,2). Although protein degradation has a crucial role in downregulating levels of Cyclin E, many of the proteins that function in degradation of Cyclin E have not been identified. In a screen for Drosophila mutants that display increased cell proliferation, we identified archipelago, a gene encoding a protein with an F-box and seven tandem WD (tryptophan-aspartic acid) repeats. Here we show that archipelago mutant cells have persistently elevated levels of Cyclin E protein without increased levels of cyclin E RNA. They are under-represented in G1 fractions and continue to proliferate when their wild-type neighbours become quiescent. The Archipelago protein binds directly to Cyclin E and probably targets it for ubiquitin-mediated degradation. A highly conserved human homologue is present and is mutated in four cancer cell lines including three of ten derived from ovarian carcinomas. These findings implicate archipelago in developmentally regulated degradation of Cyclin E and potentially in the pathogenesis of human cancers.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Hariharan, IK (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.		Moberg, Ken/J-4849-2017	Moberg, Ken/0000-0002-9820-5543				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Courjal F, 1996, INT J CANCER, V69, P247; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; HAY BA, 1994, DEVELOPMENT, V120, P2121; Horsfield J, 1998, DEVELOPMENT, V125, P5069; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Kipreos ET, 2000, DEVELOPMENT, V127, P5071; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kiyokawa H, 1998, CURR TOP MICROBIOL, V227, P105; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PERRY MM, 1968, J MORPHOL, V124, P249, DOI 10.1002/jmor.1051240209; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; Secombe J, 1998, GENETICS, V149, P1867; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X	22	375	390	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 20	2001	413	6853					311	316		10.1038/35095068	http://dx.doi.org/10.1038/35095068			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565033				2022-12-28	WOS:000171040500040
J	Rioual, P; Andrieu-Ponel, V; Rietti-Shati, M; Battarbee, RW; de Beaulieu, JL; Cheddadi, R; Reille, M; Svobodova, H; Shemesh, A				Rioual, P; Andrieu-Ponel, V; Rietti-Shati, M; Battarbee, RW; de Beaulieu, JL; Cheddadi, R; Reille, M; Svobodova, H; Shemesh, A			High-resolution record of climate stability in France during the last interglacial period	NATURE			English	Article							EUROPEAN POLLEN RECORDS; LAKE DEVELOPMENT; OXYGEN ISOTOPES; BIOGENIC SILICA; NORTH-ATLANTIC; OCEAN; RECONSTRUCTION; VARIABILITY; TEMPERATURE; REGION	The last interglacial period (127-110 kyr ago) has been considered to be an analogue to the present interglacial period, the Holocene, which may help us to understand present climate evolution. But whereas Holocene climate has been essentially stable in Europe, variability in climate during the last interglacial period has remained unresolved, because climate reconstructions from ice cores(1,2), continental records(3,4) and marine sediment cores(5,6) give conflicting results for this period(7). Here we present a high-resolution multi-proxy lacustrine record of climate change during the last interglacial period, based on oxygen isotopes in diatom silica, diatom assemblages and pollen-climate transfer functions from the Ribains maar in France. Contrary to a previous study(8), our data do not show a cold event interrupting the warm interglacial climate. Instead, we rnd an early temperature maximum with a transition to a colder climate about halfway through the sequence. The end of the interglacial period is clearly marked by an abrupt change in all proxy records. Our study confirms that in southwestern Europe the last interglacial period was a time of climatic stability and is therefore still likely to represent a useful analogue for the present climate.	UCL, Environm Change Res Ctr, London WC1H 0AP, England; Fac Sci & Tech St Jerome, UDESAM, Inst Mediterraneen Ecol & Paleoecol, CNRS,UMR 6116, F-13397 Marseille 20, France; Weizmann Inst Sci, Dept Environm Sci & Energy Res, IL-76100 Rehovot, Israel; Inst Bot, CZ-25243 Prague, Czech Republic	University of London; University College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Weizmann Institute of Science; Czech Academy of Sciences; Institute of Botany of the Czech Academy of Sciences	Rioual, P (corresponding author), UCL, Environm Change Res Ctr, 26 Bedford Way, London WC1H 0AP, England.	prioual@geog.ucl.ac.uk	Svitavska, Helena Svobodova/D-4161-2013; Rioual, Patrick/H-5140-2018; ANDRIEU-PONEL, Valerie/J-2818-2014	Rioual, Patrick/0000-0001-9491-9197; ANDRIEU-PONEL, Valerie/0000-0001-7044-967X; Svitavska Svobodova, Helena/0000-0001-6092-4588				Aalbersberg G, 1998, J QUATERNARY SCI, V13, P367, DOI 10.1002/(SICI)1099-1417(1998090)13:5<367::AID-JQS400>3.3.CO;2-9; ANKLIN M, 1993, NATURE, V364, P203, DOI 10.1038/364203a0; BATTARBEE RW, 1982, LIMNOL OCEANOGR, V27, P184, DOI 10.4319/lo.1982.27.1.0184; Beyerle U, 1998, SCIENCE, V282, P731, DOI 10.1126/science.282.5389.731; Bjorck S, 2000, QUATERNARY SCI REV, V19, P509, DOI 10.1016/S0277-3791(99)00025-6; Cheddadi R, 1998, PALAEOGEOGR PALAEOCL, V143, P73, DOI 10.1016/S0031-0182(98)00067-4; Cortijo E, 2000, QUATERNARY SCI REV, V19, P227, DOI 10.1016/S0277-3791(99)00063-3; de Beaulieu J.L., 1992, VEG HIST ARCHAEOBOT, V1, P233, DOI DOI 10.1007/BF00189500; Frogley MR, 1999, SCIENCE, V285, P1886, DOI 10.1126/science.285.5435.1886; Fronval T, 1996, NATURE, V383, P806, DOI 10.1038/383806a0; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; GUIOT J, 1989, NATURE, V338, P309, DOI 10.1038/338309a0; JUILLETLECLERC A, 1987, EARTH PLANET SCI NEW, V84, P69, DOI DOI 10.1016/0012-821X(87)90177-4; Kukla G, 1997, QUATERNARY SCI REV, V16, P605, DOI 10.1016/S0277-3791(96)00114-X; Kukla GJ, 2000, SCIENCE, V287, P987, DOI 10.1126/science.287.5455.987; Litt T, 1996, VEG HIST ARCHAEOBOT, V5, P247, DOI 10.1007/BF00217502; MABERLY SC, 1994, FRESHWATER BIOL, V31, P19, DOI 10.1111/j.1365-2427.1994.tb00835.x; McManus JF, 1999, SCIENCE, V283, P971, DOI 10.1126/science.283.5404.971; Reille M, 2000, J QUATERNARY SCI, V15, P665, DOI 10.1002/1099-1417(200010)15:7<665::AID-JQS560>3.0.CO;2-G; Rosqvist GC, 1999, GEOLOGY, V27, P967, DOI 10.1130/0091-7613(1999)027<0967:LGTMHC>2.3.CO;2; Rozanski K., 1993, CLIMATE CHANGE CONTI, V78, P1, DOI DOI 10.1029/GM078P0001; SHEMESH A, 1992, SCIENCE, V256, P1434, DOI 10.1126/science.256.5062.1434; Shemesh A, 2001, GEOPHYS RES LETT, V28, P2305, DOI 10.1029/2000GL012720; SMOL JP, 1985, HYDROBIOLOGIA, V123, P199, DOI 10.1007/BF00034378; Stockhausen H, 1999, EARTH PLANET SC LETT, V173, P299, DOI 10.1016/S0012-821X(99)00237-X; Stoermer Eugene F., 1993, Journal of Paleolimnology, V8, P71; THOUVENY N, 1994, NATURE, V371, P503, DOI 10.1038/371503a0; Weckstrom J, 1997, ARCTIC ALPINE RES, V29, P75, DOI 10.2307/1551838; WOILLARD G, 1979, NATURE, V281, P558, DOI 10.1038/281558a0; Wolin JA, 1996, J PALEOLIMNOL, V15, P19; Zagwijn WH, 1996, QUATERNARY SCI REV, V15, P451, DOI 10.1016/0277-3791(96)00011-X	31	92	97	4	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 20	2001	413	6853					293	296		10.1038/35095037	http://dx.doi.org/10.1038/35095037			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565028				2022-12-28	WOS:000171040500035
J	Bachtold, A; Hadley, P; Nakanishi, T; Dekker, C				Bachtold, A; Hadley, P; Nakanishi, T; Dekker, C			Logic circuits with carbon nanotube transistors	SCIENCE			English	Article							SINGLE-WALL; TRANSPORT; JUNCTIONS	We demonstrate logic circuits with field-effect transistors based on single carbon nanotubes. Our device layout features local gates that provide excellent capacitive coupling between the gate and nanotube, enabling strong electrostatic doping of the nanotube from p-doping to n-doping and the study of the nonconventional long-range screening of charge along the one-dimensional, nanotubes. The transistors show favorable device characteristics such as high gain (>10), a large on-off ratio (>10(5)), and room-temperature operation. importantly, the local-gate layout allows for integration of multiple, devices on a single chip. Indeed, we demonstrate one-, two-, and three-transistor circuits that exhibit a range of digital logic operations, such: as an inverter, a logic NOR, a static random-access memory cell, and an ac ring oscillator.	Delft Univ Technol, Dept Appl Phys, NL-2628 CJ Delft, Netherlands	Delft University of Technology	Dekker, C (corresponding author), Delft Univ Technol, Dept Appl Phys, Lorentzweg 1, NL-2628 CJ Delft, Netherlands.		Dee, Chang Fu/G-4842-2010; Nakanishi, Takeshi/W-5652-2019; Hadley, Peter/C-3057-2015; Bachtold, Adrian/C-1389-2014	Dee, Chang Fu/0000-0003-1015-9181; Nakanishi, Takeshi/0000-0002-2855-9880; Hadley, Peter/0000-0002-7443-7980; Bachtold, Adrian/0000-0002-6145-2479; Dekker, Cees/0000-0001-6273-071X				Bachtold A, 2000, PHYS REV LETT, V84, P6082, DOI 10.1103/PhysRevLett.84.6082; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Collins PC, 2001, SCIENCE, V292, P706, DOI 10.1126/science.1058782; DERYCKE V, 2001, NANO LETT       0826; Fuhrer MS, 2000, SCIENCE, V288, P494, DOI 10.1126/science.288.5465.494; Horowitz P., 1980, ART ELECT; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; Kruger M, 2001, APPL PHYS LETT, V78, P1291, DOI 10.1063/1.1350427; KRUGER M, 2000, THESIS U BASEL BASEL; Lefebvre J, 1999, APPL PHYS LETT, V75, P3014, DOI 10.1063/1.125218; Leonard F, 2000, PHYS REV LETT, V84, P4693, DOI 10.1103/PhysRevLett.84.4693; Liu J, 1999, CHEM PHYS LETT, V303, P125, DOI 10.1016/S0009-2614(99)00209-2; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; Odintsov AA, 2000, PHYS REV LETT, V85, P150, DOI 10.1103/PhysRevLett.85.150; Persson SHM, 1999, APPL PHYS LETT, V74, P2546, DOI 10.1063/1.123893; Postma HWC, 2001, SCIENCE, V293, P76, DOI 10.1126/science.1061797; Schlittler RR, 2001, SCIENCE, V292, P1136, DOI 10.1126/science.1057823; Tans SJ, 2000, NATURE, V404, P834, DOI 10.1038/35009026; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Tombler TW, 2000, APPL PHYS LETT, V76, P2412, DOI 10.1063/1.125611; Venema LC, 2000, PHYS REV B, V62, P5238, DOI 10.1103/PhysRevB.62.5238; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241; Zhou CW, 2000, APPL PHYS LETT, V76, P1597, DOI 10.1063/1.126107	27	2218	2407	12	611	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1317	1320		10.1126/science.1065824	http://dx.doi.org/10.1126/science.1065824			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11588220				2022-12-28	WOS:000172130200041
J	Weiss, HB; Songer, TJ; Fabio, A				Weiss, HB; Songer, TJ; Fabio, A			Fetal deaths related to maternal injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMA; PREGNANCY; MORTALITY; HOMICIDE; ACCIDENTS; WOMEN	Context Maternal and fetal trauma is an important cause of adverse fetal outcomes. However, systematic exclusion from US injury surveillance programs of even the most severe outcome, fetal/neonatal death, has led to a lack of understanding about frequency, causes, and prevention. Objective To determine the rate of traumatic fetal deaths reported instate fetal death registries and the types of trauma and physiologic diagnoses associated with these deaths. Design and Setting Retrospective descriptive study of fetal death certificates from 1995 through 1997 obtained from 16 states, which accounted for 55% of US live births and approximately 15000 fetal death registrations per year. Main Outcome Measure Rate of fetal injury deaths, based on fetal death certificates coded with an underlying cause of death due to maternal injury at 20 weeks' gestation or later, by cause. Results During the 3-year study period, 240 traumatic fetal injury deaths were identified (3.7 fetal deaths per 100000 live births). Motor vehicle crashes were the leading trauma mechanism (82% of cases; 2.3 fetal deaths per 100000 live births), followed by firearm injuries (6% of cases) and falls (3% of cases). In 3 states, reported crash-related fetal deaths exceeded that of crash-related infant deaths. Placental injury was mentioned in 100 cases (42%) and maternal death was noted in 27 cases (11%). A peak rate of 9.3 fetal deaths per 100000 live births was observed among 15- to 19-year-old women. Conclusions Motor vehicle crashes are the leading cause of fetal deaths related to maternal trauma. improved tracking of traumatic fetal injury deaths is important to stimulate and guide research and efforts to reduce the risks to women and fetuses from injury during pregnancy.	Univ Pittsburgh, Ctr Injury Res & Control, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weiss, HB (corresponding author), Univ Pittsburgh, Ctr Injury Res & Control, Dept Neurosurg, 200 Lothrop St,Suite B400, Pittsburgh, PA 15213 USA.		Weiss, Hank/D-1052-2010	Fabio, Anthony/0000-0002-6808-4939; Songer, Thomas/0000-0002-5253-2514				AGRAN PF, 1987, ANN EMERG MED, V16, P1355, DOI 10.1016/S0196-0644(87)80418-3; *AM AC PED AM COLL, 1988, STAND TERM REP REPR, P308; Bausch L C, 1996, Nebr Med J, V81, P120; Brinton JH, 1884, T AM SURG ASS, V2, P425; Buchsbaum H J, 1976, Med Times, V104, P134; BUCHSBAUM HJ, 1968, AM J OBSTET GYNECOL, V102, P752, DOI 10.1016/0002-9378(68)90390-6; CROSBY WM, 1971, NEW ENGL J MED, V284, P632, DOI 10.1056/NEJM197103252841203; DANNENBERG AL, 1995, AM J OBSTET GYNECOL, V172, P1557, DOI 10.1016/0002-9378(95)90496-4; Dietz PM, 1998, AM J PUBLIC HEALTH, V88, P641, DOI 10.2105/AJPH.88.4.641; Elliott M, 1966, Aust N Z J Obstet Gynaecol, V6, P279, DOI 10.1111/j.1479-828X.1966.tb00389.x; ESPOSITO TJ, 1989, J TRAUMA, V29, P1628, DOI 10.1097/00005373-198912000-00006; FILDES J, 1992, J TRAUMA, V32, P643, DOI 10.1097/00005373-199205000-00017; Gaudino JA, 1997, AM J PUBLIC HEALTH, V87, P1323, DOI 10.2105/AJPH.87.8.1323; GREB AE, 1987, AM J PUBLIC HEALTH, V77, P1202, DOI 10.2105/AJPH.77.9.1202; HANSEN G, 1990, J MED SOC N J, V87, P995; Harper M, 1997, OBSTET GYNECOL, V90, P920, DOI 10.1016/S0029-7844(97)00485-7; HERSCHEL M, 1995, AM J PREV MED, V11, P185, DOI 10.1016/S0749-3797(18)30471-9; Horon IL, 2001, JAMA-J AM MED ASSOC, V285, P1455, DOI 10.1001/jama.285.11.1455; Jacob S, 1998, OBSTET GYNECOL, V91, P187, DOI 10.1016/S0029-7844(97)00664-9; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; KIRBY RS, 1993, AM J PUBLIC HEALTH, V83, P1088, DOI 10.2105/AJPH.83.8.1088; KISSINGER DP, 1991, ARCH SURG-CHICAGO, V126, P1079; KLINICH KD, 1998, ANN C ASS ADV AUT ME; KOWALSKI J, 1997, STATE DEFINITIONS RE, P3; Krulewitch CJ, 2001, J MIDWIFERY WOM HEAL, V46, P4, DOI 10.1016/S1526-9523(00)00096-9; LANE P L, 1989, Journal of Emergency Medicine, V7, P433, DOI 10.1016/0736-4679(89)90135-2; *MOD STAT VIT STAT, 1992, DHHS PUBL; *NAT CTR HLTH STAT, 1998, 1995 PER MORT DAT FI; *NAT CTR INF PREV, 2001, LEAD CAUS DEATH REP; ONI OOA, 1984, INJURY, V15, P376, DOI 10.1016/0020-1383(84)90199-2; PEARLMAN MD, 1990, AM J OBSTET GYNECOL, V162, P1502, DOI 10.1016/0002-9378(90)90913-R; PEARLMAN MD, 1990, NEW ENGL J MED, V323, P1609; PEPPERELL RJ, 1977, MED J AUSTRALIA, V1, P203, DOI 10.5694/j.1326-5377.1977.tb130630.x; Rasmussen S, 1996, ACTA OBSTET GYN SCAN, V75, P229, DOI 10.3109/00016349609047092; ROSE PG, 1985, AM J OBSTET GYNECOL, V153, P844, DOI 10.1016/0002-9378(85)90687-8; Rosner B, 1994, FUNDAMENTALS BIOSTAT, V4th; ROTHENBERGER D, 1978, J TRAUMA, V18, P173, DOI 10.1097/00005373-197803000-00004; Rumbolz W L, 1991, Nebr Med J, V76, P31; Schiff M, 1997, WESTERN J MED, V167, P19; SEEAR T, 1953, AM J OBSTET GYNECOL, V65, P450, DOI 10.1016/0002-9378(53)90459-1; Theodorou DA, 2000, AM SURGEON, V66, P809; TIMBERLAKE GA, 1989, AM SURGEON, V55, P151; VENTURA S, 1998, REPORT FINAL NATALIT, P32; VFAMER MW, 1987, SURG GYNECOL OBSTET, V168, P555; Weiss H, 2001, JAMA-J AM MED ASSOC, V285, P2854, DOI 10.1001/jama.285.22.2854; WEISS H, 1999, EPIDEMIOLOGY PERINAT, P32; Weiss HB, 2001, ACCIDENT ANAL PREV, V33, P449, DOI 10.1016/S0001-4575(00)00058-0; Woodhull RB, 1942, SURGERY, V12, P615	48	135	137	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2001	286	15					1863	1868		10.1001/jama.286.15.1863	http://dx.doi.org/10.1001/jama.286.15.1863			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	482UH	11597288				2022-12-28	WOS:000171595300027
J	Katz, MH; Cunningham, WE; Fleishman, JA; Andersen, RM; Kellogg, T; Bozzette, SA; Shapiro, MF				Katz, MH; Cunningham, WE; Fleishman, JA; Andersen, RM; Kellogg, T; Bozzette, SA; Shapiro, MF			Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons	ANNALS OF INTERNAL MEDICINE			English	Article							NATIONAL PROBABILITY SAMPLES; LOW-PREVALENCE DISEASES; ANTIRETROVIRAL THERAPY; SERVICES UTILIZATION; PROTEASE INHIBITORS; AIDS; COST; PREDICTORS; SURVIVAL; FAILURE	Background: Although case management has been advocated as a method for improving the care of chronically ill persons, its effectiveness is poorly understood. Objective: To assess the effect of case managers on unmet need for supportive services and utilization of medical care and medications among HIV-Infected persons. Design: Baseline and follow-up interview of a national probability sample. Setting: Inpatient and outpatient medical facilities in the United States. Participants: 2437 HIV-infected adults representing 217 081 patients receiving medical care. Measurements: Outcomes measured at follow-up were unmet need for supportive services, medical care utilization (ambulatory visits, emergency department visits, and hospitalizations), and use of HIV medication (receipt of antiretroviral therapy and prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis). Results: At baseline, 56.5% of the sample had contact with a case manager in the previous 6 months. In multiple logistic regression analyses that adjusted for potential confounders, contact with a case manager at baseline was associated with decreased unmet need for income assistance (odds ratio [OR], 0.57 [95% Cl, 0.36 to 0.91]), health insurance (OR, 0.54 [CI, 0.33 to 0.89]), home health care (OR, 0.29 [Cl, 0.15 to 0.56]), and emotional counseling (OR, 0.62 [CI, 0.41 to 0.94]) at follow-up. Contact with case managers was not significantly associated with utilization of ambulatory care (OR, 0.77 [Cl, 0.57 to 1.04]), hospitalization (OR, 1.13 [CI, 0.84 to 1.54]), or emergency department visits (OR, 1.30 [Cl, 0.97 to 1.73]) but was associated with higher utilization of two-drug (OR, 1.58 (Cl, 1.23 to 2.03]) and three-drug (OR, 1.34 [Cl, 1.00 to 1.80]) antiretroviral regimens and of treatment with protease inhibitors or non-nucleoside reverse transcriptase inhibitors (OR, 1.29 [CI, 1.02 to 1.64]) at follow-up. Conclusions: case management appears to be associated with fewer unmet needs and higher use of HIV medications in patients receiving HIV treatment.	Dept Publ Hlth, San Francisco, CA 94102 USA		Katz, MH (corresponding author), Dept Publ Hlth, 101 Grove St,Rom 308, San Francisco, CA 94102 USA.	mitch_katz@dph.sf.ca.us			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS008578] Funding Source: NIH RePORTER; AHRQ HHS [HS08578] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AMSEL JL, 1998, EVALUATING HIV CASE, P101; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114; BERRY SH, 1998, MR1090AHCPR; Bing EG, 1999, J ACQ IMMUN DEF SYND, V20, P474, DOI 10.1097/00042560-199904150-00010; Cunningham WE, 1997, J CLIN EPIDEMIOL, V50, P829, DOI 10.1016/S0895-4356(97)00061-9; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; DUAN M, 1998, MR1060AHCPR; FLEISHMAN JA, 1991, HEALTH SERV RES, V26, P447; Frankel MR, 1999, HEALTH SERV RES, V34, P969; GANT LL, 1998, EVALUATING HIV CASE, P8; JELLINEK PS, 1988, ISSUES SCI TECHNOL, V4, P59; KALTON G, 1983, COMPENSATING MISSING; Katz MH, 2000, MED CARE, V38, P58, DOI 10.1097/00005650-200001000-00007; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; London AS, 1998, AIDS CARE, V10, P481, DOI 10.1080/09540129850124019; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Markson LE, 1998, J ACQ IMMUN DEF SYND, V17, P35, DOI 10.1097/00042560-199801010-00005; McNaghten AD, 1999, AIDS, V13, P1687, DOI 10.1097/00002030-199909100-00012; MESSERI P, 1996, 11 CHAIN COL U SCH P; MOR V, 1989, HEALTH AFFAIR, V8, P139, DOI 10.1377/hlthaff.8.4.139; MOR V, 1994, NETWORKING AIDS SERV, P173; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Riley T A, 1992, Clin Nurse Spec, V6, P136, DOI 10.1097/00002800-199200630-00004; Schwarcz SK, 2000, AM J EPIDEMIOL, V152, P178, DOI 10.1093/aje/152.2.178; Shapiro MF, 1999, HEALTH SERV RES, V34, P951; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; Sonsel G E, 1989, QRB Qual Rev Bull, V15, P31; Thompson AS, 1998, J COMMUN HEALTH, V23, P419, DOI 10.1023/A:1018706107776; Valdez H, 1999, ARCH INTERN MED, V159, P1771, DOI 10.1001/archinte.159.15.1771; WIGHT RG, 1995, AIDS CARE, V7, P509, DOI 10.1080/09540129550126452	32	134	141	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	1				557	565		10.7326/0003-4819-135-8_Part_1-200110160-00006	http://dx.doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481VY	11601927				2022-12-28	WOS:000171542200001
J	[Anonymous]				[Anonymous]			ACOVE quality indicators	ANNALS OF INTERNAL MEDICINE			English	Article																			0	119	121	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				653	667		10.7326/0003-4819-135-8_Part_2-200110161-00004	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00004			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481WA	11601948				2022-12-28	WOS:000171542400004
J	Dinkevich, E; Hupert, J; Moyer, VA				Dinkevich, E; Hupert, J; Moyer, VA			Evidence based paediatrics - Evidence based well child care	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Texas, Dept Pediat, Ctr Populat Hlth & Evidence Based Med, Houston, TX 77030 USA; Univ Illinois, Div Gen Pediat, Chicago, IL 60612 USA; SUNY Hlth Sci Ctr, Dept Pediat, Brooklyn, NY 11203 USA	University of Texas System; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Moyer, VA (corresponding author), Univ Texas, Dept Pediat, Ctr Populat Hlth & Evidence Based Med, Houston, TX 77030 USA.	Virginia.A.Moyer@uth.tmc.edu						Canadian Task Force on the Periodic Health Examination, 1994, CAN GUID CLIN PREV H; *COMM PSYCH ASP CH, 1997, AM AC PED 1997 GUID; Cote P, 1998, SPINE, V23, P796, DOI 10.1097/00007632-199804010-00011; GILBERT JR, 1984, CAN MED ASSOC J, V130, P857; GOLDBERG C, 1983, IRISH MED J, V76, P247; GOLDBERG CJ, 1995, SPINE, V20, P1368, DOI 10.1097/00007632-199506000-00007; HINKSON GB, 1983, PEDIATRICS, V72, P619; HOEKELMAN R A, 1989, Current Opinion in Pediatrics, V1, P146; HOEKELMAN RA, 1975, PEDIATRICS, V55, P313; HOEKELMAN RA, 1983, AM J DIS CHILD, V137, P1057, DOI 10.1001/archpedi.1983.02140370019007; LOGAN S, 2000, EVIDENCE BASED PEDIA; Panagiotou L, 1998, CAN FAM PHYSICIAN, V44, P558; Rice RL, 1997, CLIN PEDIATR, V36, P685, DOI 10.1177/000992289703601203; TAYLOR DRF, 1997, P 18 INT CART C STOC, V1, P1; Taylor JA, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e9; Taylor JA, 1998, ARCH PEDIAT ADOL MED, V152, P579; *US C, 1988, PUBL US C OFF TECHN, P121; VANDOORNINCK WJ, 1981, CHILD DEV, V52, P1080, DOI 10.2307/1129116; WOOLF SH, 1993, JAMA-J AM MED ASSOC, V269, P2667; 1990, PEDIATRICS S, V86, P1025	20	8	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 13	2001	323	7317					846	849		10.1136/bmj.323.7317.846	http://dx.doi.org/10.1136/bmj.323.7317.846			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597970	Green Published			2022-12-28	WOS:000171650500031
J	Bobrov, K; Mayne, AJ; Dujardin, G				Bobrov, K; Mayne, AJ; Dujardin, G			Atomic-scale imaging of insulating diamond through resonant electron injection	NATURE			English	Article							SURFACE-STATES; PHOTOELECTRON-SPECTROSCOPY; CRYSTAL-SURFACES; INTERFEROMETRY; STM	The electronic properties of insulators such as diamond are of interest not only for their passive dielectric capabilities for use in electronic devices(1), but also for their strong electron confinement(2) on atomic scales. However, the inherent lack of electrical conductivity in insulators usually prevents the investigation of their surfaces by atomic-scale characterization techniques such as scanning tunnelling microscopy (STM). And although atomic force microscopy could in principle be used, imaging diamond surfaces has not yet been possible. Here, we demonstrate that STM can be used in an unconventional resonant electron injection mode to image insulating diamond surfaces and to probe their electronic properties at the atomic scale. Our results reveal striking electronic features in high-purity diamond single crystals, such as the existence of one-dimensional fully delocalized electronic states and a very long diffusion length for conduction-band electrons. We expect that our method can be applied to investigate the electronic properties of other insulating materials and so help in the design of atomic-scale electronic devices.	Univ Paris Sud, Photophys Mol Lab, F-91405 Orsay, France	UDICE-French Research Universities; Universite Paris Saclay	Dujardin, G (corresponding author), Univ Paris Sud, Photophys Mol Lab, Bat 210, F-91405 Orsay, France.	gerald.dujardin@ppm.u-psud.fr						BECKER RS, 1985, PHYS REV LETT, V55, P987, DOI 10.1103/PhysRevLett.55.987; BINNIG G, 1985, PHYS REV LETT, V55, P991, DOI 10.1103/PhysRevLett.55.991; Bobrov K, 1998, DIAM RELAT MATER, V7, P170, DOI 10.1016/S0925-9635(97)00211-2; Caamano AJ, 1999, SURF SCI, V426, pL420, DOI 10.1016/S0039-6028(99)00346-5; Diederich L, 1998, SURF SCI, V418, P219, DOI 10.1016/S0039-6028(98)00718-3; Furthmuller J, 1996, PHYS REV B, V53, P7334, DOI 10.1103/PhysRevB.53.7334; Graupner R, 1997, PHYS REV B, V55, P10841, DOI 10.1103/PhysRevB.55.10841; Hofer U, 1997, SCIENCE, V277, P1480, DOI 10.1126/science.277.5331.1480; Kohn W., 1965, PHYS REV A, V133, P171; KUBBY JA, 1991, PHYS REV B, V43, P9346, DOI 10.1103/PhysRevB.43.9346; LIBUDA J, 1994, SURF SCI, V318, P61, DOI 10.1016/0039-6028(94)90341-7; Maier F, 2000, PHYS REV LETT, V85, P3472, DOI 10.1103/PhysRevLett.85.3472; Nutzenadel C, 1996, SURF SCI, V369, pL111, DOI 10.1016/S0039-6028(96)01120-X; RADNY M, 1991, J PHYS-CONDENS MAT, V3, P5525, DOI 10.1088/0953-8984/3/29/007; Ristein J, 1997, PHYS REV LETT, V78, P1803, DOI 10.1103/PhysRevLett.78.1803; Silkin VM, 1999, PHYS REV B, V60, P7820, DOI 10.1103/PhysRevB.60.7820; Strahberger C, 2000, PHYS REV B, V62, P7289, DOI 10.1103/PhysRevB.62.7289; THOMS BD, 1994, APPL PHYS LETT, V65, P2957, DOI 10.1063/1.112503; Viernow J, 1999, PHYS REV B, V59, P10356, DOI 10.1103/PhysRevB.59.10356	19	97	100	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 11	2001	413	6856					616	619		10.1038/35098053	http://dx.doi.org/10.1038/35098053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480WE	11595944				2022-12-28	WOS:000171485700044
J	Fishman, A; Fessler, H; Martinez, F; McKenna, RJ; Naunheim, K; Piantadosi, S; Weinmann, G; Wise, R				Fishman, A; Fessler, H; Martinez, F; McKenna, RJ; Naunheim, K; Piantadosi, S; Weinmann, G; Wise, R		National Emphysema Treatment Trial	Patients at high risk of death after lung-volume-reduction surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY-EMPHYSEMA; MORTALITY; PREDICTORS; MORBIDITY; VALUES; REHABILITATION; SELECTION; TERM; CT	Background: Lung-volume-reduction surgery is a proposed treatment for emphysema, but optimal selection criteria have not been defined. The National Emphysema Treatment Trial is a randomized, multicenter clinical trial comparing lung-volume-reduction surgery with medical treatment. Methods: After evaluation and pulmonary rehabilitation, we randomly assigned patients to undergo lung-volume-reduction surgery or receive medical treatment. Outcomes were monitored by an independent data and safety monitoring board. Results: A total of 1033 patients had been randomized by June 2001. For 69 patients who had a forced expiratory volume in one second (FEV(sub 1)) that was no more than 20 percent of their predicted value and either a homogeneous distribution of emphysema on computed tomography or a carbon monoxide diffusing capacity that was no more than 20 percent of their predicted value, the 30-day mortality rate after surgery was 16 percent (95 percent confidence interval, 8.2 to 26.7 percent), as compared with a rate of 0 percent among 70 medically treated patients (P<0.001). Among these high-risk patients, the overall mortality rate was higher in surgical patients than medical patients (0.43 deaths per person-year vs. 0.11 deaths per person-year; relative risk, 3.9; 95 percent confidence interval, 1.9 to 9.0). As compared with medically treated patients, survivors of surgery had small improvements at six months in the maximal workload (P=0.06), the distance walked in six minutes (P=0.03), and FEV(sub 1) (P<0.001), but a similar health-related quality of life. The results of the analysis of functional outcomes for all patients, which accounted for deaths and missing data, did not favor either treatment. Conclusions: Caution is warranted in the use of lung-volume-reduction surgery in patients with emphysema who have a low FEV(sub 1) and either homogeneous emphysema or a very low carbon monoxide diffusing capacity. These patients are at high risk for death after surgery and also are unlikely to benefit from the surgery. (N Engl J Med 2001;345:1075-83.) Copyright (C) 2001 Massachusetts Medical Society.	Baylor Coll Med, Houston, TX 77030 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Columbia Univ, New York, NY USA; Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA; Duke Univ, Med Ctr, Durham, NC USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Ohio State Univ, Columbus, OH 43210 USA; St Louis Univ, St Louis, MO 63103 USA; Temple Univ, Philadelphia, PA 19122 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Maryland, College Pk, MD 20742 USA; Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA; Univ Washington, Seattle, WA 98195 USA; Agcy Healthcare Res & Qual, Rockville, MD USA; Johns Hopkins Univ, Coordinating Ctr, Baltimore, MD USA; Fred Hutchinson Canc Res Ctr, Cost Effectivness Data Ctr, Seattle, WA 98104 USA; Univ Iowa, CT Scan Image Storage & Anal Ctr, Iowa City, IA USA; Ctr Medicare & Medicaid Serv, Baltimore, MD USA; Temple Univ, Mkt Ctr, Philadelphia, PA 19122 USA; Univ Penn, Off Chair Steering Comm, Philadelphia, PA 19104 USA; NHLBI, Project Off, Bethesda, MD 20892 USA	Baylor College of Medicine; Harvard University; Brigham & Women's Hospital; Cedars Sinai Medical Center; Cleveland Clinic Foundation; Columbia University; Northwell Health; Duke University; Mayo Clinic; National Jewish Health; University System of Ohio; Ohio State University; Saint Louis University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California San Diego; University System of Maryland; University of Maryland College Park; Johns Hopkins University; Johns Hopkins Medicine; University of Michigan System; University of Michigan; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; Agency for Healthcare Research & Quality; Johns Hopkins University; Fred Hutchinson Cancer Center; University of Iowa; Centers for Medicare & Medicaid Services; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Piantadosi, S (corresponding author), NETT, Coordinating Ctr, 615 N Wolfe St,Rm 5010, Baltimore, MD 21205 USA.			Wise, Robert/0000-0002-8353-2349	NHLBI NIH HHS [N01HR76115, N01HR76108, N01HR76114, N01HR76109, N01HR76113, N01HR76112, N01HR76110, N01HR76107, N01HR76106, N01HR76116, N01HR76105, N01HR76104, N01HR76103, N01HR76118, N01HR76119, N01HR76102, N01HR76101, N01HR76111] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR076102, N01HR076105, N01HR076111, N01HR076101, N01HR076106, N01HR076115, N01HR076109, N01HR076112, N01HR076107, N01HR076114, N01HR076113, N01HR076116, N01HR076119, N01HR076118, N01HR076110, N01HR076104, N01HR076103, N01HR076108] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185; Argenziano M, 1996, ANN THORAC SURG, V62, P1588, DOI 10.1016/S0003-4975(96)00886-7; Bankier AA, 1999, RADIOLOGY, V211, P851, DOI 10.1148/radiology.211.3.r99jn05851; BERGIN C, 1986, AM REV RESPIR DIS, V133, P541; Brenner M, 1996, CHEST, V110, P205, DOI 10.1378/chest.110.1.205; Butler CW, 2001, CHEST, V119, P1056, DOI 10.1378/chest.119.4.1056; Chatila W, 2000, AM J RESP CRIT CARE, V162, P1292, DOI 10.1164/ajrccm.162.4.9912074; Chen JC, 1999, J THORAC CARDIOV SUR, V117, P728, DOI 10.1016/S0022-5223(99)70293-X; Cooper JD, 1996, J THORAC CARDIOV SUR, V112, P1319, DOI 10.1016/S0022-5223(96)70147-2; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P419; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P185; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Criner GJ, 1999, AM J RESP CRIT CARE, V160, P2018, DOI 10.1164/ajrccm.160.6.9902117; Eugene J, 1997, ANN THORAC SURG, V63, P186; Flaherty KR, 2001, CHEST, V119, P1337, DOI 10.1378/chest.119.5.1337; Fujita RA, 1996, ANN THORAC SURG, V62, P251, DOI 10.1016/0003-4975(96)00227-5; Geddes D, 2000, NEW ENGL J MED, V343, P239, DOI 10.1056/NEJM200007273430402; Gelb AF, 2001, CHEST, V119, P1300, DOI 10.1378/chest.119.5.1300; Gelb AF, 1999, CHEST, V116, P1608, DOI 10.1378/chest.116.6.1608; Gierada DS, 1997, RADIOLOGY, V205, P235, DOI 10.1148/radiology.205.1.9314991; Glaspole IN, 2000, ANN THORAC SURG, V69, P1711, DOI 10.1016/S0003-4975(00)01270-4; GODDARD PR, 1982, CLIN RADIOL, V33, P379, DOI 10.1016/S0009-9260(82)80301-2; Hamacher J, 1999, ANN THORAC SURG, V68, P1792, DOI 10.1016/S0003-4975(99)00990-X; Hazelrigg S, 1996, J THORAC CARDIOV SUR, V112, P319, DOI 10.1016/S0022-5223(96)70257-X; Health Care Financing Administration, 1998, REP C LUNG VOL RED S; Howard G, 1997, JAMA-J AM MED ASSOC, V278, P1432; HOWARD G, 1998, JAMA-J AM MED ASSOC, V279, P580; Ingenito EP, 2001, AM J RESP CRIT CARE, V163, P1068, DOI 10.1164/ajrccm.163.5.9911013; KAPLAN RM, 1984, J CHRON DIS, V37, P85, DOI 10.1016/0021-9681(84)90050-X; Keenan RJ, 1996, J THORAC CARDIOV SUR, V111, P308, DOI 10.1016/S0022-5223(96)70439-7; Maki DD, 1999, RADIOLOGY, V212, P49, DOI 10.1148/radiology.212.1.r99jl4849; MANTEL N, 1959, J NATL CANCER I, V22, P719; McKenna RJ, 1997, J THORAC CARDIOV SUR, V114, P957, DOI 10.1016/S0022-5223(97)70010-2; Naunheim KS, 2000, EUR J CARDIO-THORAC, V17, P673, DOI 10.1016/S1010-7940(00)00450-4; Pompeo E, 2000, ANN THORAC SURG, V70, P948, DOI 10.1016/S0003-4975(00)01646-5; Pompeo E, 2000, EUR J CARDIO-THORAC, V17, P680, DOI 10.1016/S1010-7940(00)00441-3; Redelmeier DA, 1997, AM J RESP CRIT CARE, V155, P1278, DOI 10.1164/ajrccm.155.4.9105067; Rodarte J, 1999, J THORAC CARDIOV SUR, V118, P518; Sciurba FC, 1996, NEW ENGL J MED, V334, P1095, DOI 10.1056/NEJM199604253341704; Slone RM, 1997, RADIOLOGY, V204, P685, DOI 10.1148/radiology.204.3.9280244; Statacorp, 2001, STAT STAT SOFTW REL; Steele B, 1996, J Cardiopulm Rehabil, V16, P25; Sugi K, 1999, Jpn J Thorac Cardiovasc Surg, V47, P489; Szekely LA, 1997, CHEST, V111, P550, DOI 10.1378/chest.111.3.550; Weder W, 1997, ANN THORAC SURG, V64, P313, DOI 10.1016/S0003-4975(97)00564-X; Weg IL, 1999, AM J RESP CRIT CARE, V159, P552, DOI 10.1164/ajrccm.159.2.9802056; Wisser W, 2000, EUR J CARDIO-THORAC, V17, P666, DOI 10.1016/S1010-7940(00)00446-2	50	413	420	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2001	345	15					1075	1083						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480QH	11596586				2022-12-28	WOS:000171473100001
J	Scheffer, M; Carpenter, S; Foley, JA; Folke, C; Walker, B				Scheffer, M; Carpenter, S; Foley, JA; Folke, C; Walker, B			Catastrophic shifts in ecosystems	NATURE			English	Review							MULTIPLE STABLE STATES; ARABIAN PENINSULA; GRAZING SYSTEMS; SHALLOW LAKES; PHASE-SHIFTS; VEGETATION; DYNAMICS; CLIMATE; SAHEL; MANAGEMENT	All ecosystems are exposed to gradual changes in climate, nutrient loading, habitat fragmentation or biotic exploitation. Nature is usually assumed to respond to gradual change in a smooth way. However, studies on lakes, coral reefs, oceans, forests and arid lands have shown that smooth change can be interrupted by sudden drastic switches to a contrasting state. Although diverse events can trigger such shifts, recent studies show that a loss of resilience usually paves the way for a switch to an alternative state. This suggests that strategies for sustainable management of such ecosystems should focus on maintaining resilience.	Wageningen Univ, Dept Aquat Ecol & Water Qual Management, NL-6700 DD Wageningen, Netherlands; Univ Wisconsin, Ctr Limnol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Sustainabil & Global Environm, Inst Environm Studies, Madison, WI 53706 USA; Stockholm Univ, Dept Syst Ecol, S-10691 Stockholm, Sweden; Stockholm Univ, Ctr Res Nat Resources & Environm CNM, S-10691 Stockholm, Sweden; CSIRO Sustainable Ecosyst, Canberra, ACT 2601, Australia	Wageningen University & Research; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Stockholm University; Stockholm University; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Scheffer, M (corresponding author), Wageningen Univ, Dept Aquat Ecol & Water Qual Management, POB 8080, NL-6700 DD Wageningen, Netherlands.	marten.scheffer@aqec.wkao.wau.nl	Scheffer, Marten/C-1852-2012; Folke, Carl/Z-1545-2019; Carpenter, Stephen/AAQ-6404-2020; Foley, Jonathan A/GRS-5522-2022; Walker, Brian H/F-2386-2011	Folke, Carl/0000-0002-4050-3281; Carpenter, Stephen/0000-0001-8097-8700				[Anonymous], LANDSCAPE ECOLOGY FU; Brovkin V, 1998, J GEOPHYS RES-ATMOS, V103, P31613, DOI 10.1029/1998JD200006; Carpenter SR, 1999, ECOL APPL, V9, P751, DOI 10.1890/1051-0761(1999)009[0751:MOEFLS]2.0.CO;2; Carpenter SR, 1997, OIKOS, V78, P3, DOI 10.2307/3545794; CARPENTER SR, 2001, ECOLOGY ACHIEVEMENT; CHARNEY JG, 1975, Q J ROY METEOR SOC, V101, P193, DOI 10.1002/qj.49710142802; Claussen M, 1999, GEOPHYS RES LETT, V26, P2037, DOI 10.1029/1999GL900494; CONNELL JH, 1983, AM NAT, V121, P789, DOI 10.1086/284105; Cury P, 2000, ICES J MAR SCI, V57, P603, DOI 10.1006/jmsc.2000.0712; deMenocal P, 2000, QUATERNARY SCI REV, V19, P347, DOI 10.1016/S0277-3791(99)00081-5; DONE TJ, 1992, HYDROBIOLOGIA, V247, P121, DOI 10.1007/BF00008211; DUBLIN HT, 1990, J ANIM ECOL, V59, P1147, DOI 10.2307/5037; ELLNER S, 1995, AM NAT, V145, P343, DOI 10.1086/285744; HALL CAS, 1992, OIKOS, V65, P377, DOI 10.2307/3545553; Hare SR, 2000, PROG OCEANOGR, V47, P103, DOI 10.1016/S0079-6611(00)00033-1; Hoelzmann P, 1998, GLOBAL BIOGEOCHEM CY, V12, P35, DOI 10.1029/97GB02733; Holling C.S., 1973, Annual Rev Ecol Syst, V4, P1, DOI 10.1146/annurev.es.04.110173.000245; Holling CS, 1996, CONSERV BIOL, V10, P328, DOI 10.1046/j.1523-1739.1996.10020328.x; Holmgren M, 2001, ECOSYSTEMS, V4, P151, DOI 10.1007/s100210000065; Ives AR, 1998, ECOLOGY, V79, P1039, DOI 10.2307/176599; Jeppesen E, 1999, HYDROBIOLOGIA, V395, P419, DOI 10.1023/A:1017071602549; Jolly D, 1998, J BIOGEOGR, V25, P1007, DOI 10.1046/j.1365-2699.1998.00238.x; KASSAS M, 1995, J ARID ENVIRON, V30, P115, DOI 10.1016/S0140-1963(05)80063-1; KNOWLTON N, 1992, AM ZOOL, V32, P674; Kuznetsov Y.A., 1997, ELEMENTS APPL BIFURC; LEVIN SA, 1992, ECOLOGY, V73, P1943, DOI 10.2307/1941447; LUDWIG D, 1997, CONSERV ECOL    0801; Maler KG, 2000, EUR ECON REV, V44, P645, DOI 10.1016/S0014-2921(00)00043-X; MAY RM, 1977, NATURE, V269, P471, DOI 10.1038/269471a0; McCook LJ, 1999, CORAL REEFS, V18, P357, DOI 10.1007/s003380050213; Meijer M.-L., 2000, BIOMANIPULATION NETH, P1, DOI [10.1109/48.820749, DOI 10.1109/48.820749]; MEIJER ML, 1994, HYDROBIOLOGIA, V276, P457; Nicholson S, 2000, REV GEOPHYS, V38, P117, DOI 10.1029/1999RG900014; Nystrom M, 2000, TRENDS ECOL EVOL, V15, P413, DOI 10.1016/S0169-5347(00)01948-0; Paine RT, 1998, ECOSYSTEMS, V1, P535, DOI 10.1007/s100219900049; RAHMSTORF S, 1995, NATURE, V378, P145, DOI 10.1038/378145a0; Reid PC, 1998, NATURE, V391, P546, DOI 10.1038/35290; Reid PC, 2000, ICES J MAR SCI, V57, P495, DOI 10.1006/jmsc.2000.0740; Rietkerk M, 1997, OIKOS, V80, P241, DOI 10.2307/3546592; Rinaldi S, 2000, ECOSYSTEMS, V3, P507, DOI 10.1007/s100210000045; SCHEFFER M, 1990, HYDROBIOLOGIA, V200, P475, DOI 10.1007/BF02530365; SCHEFFER M, 1993, TRENDS ECOL EVOL, V8, P275, DOI 10.1016/0169-5347(93)90254-M; Scheffer M, 1997, ECOLOGY, V78, P272; Scheffer M, 2000, ECOSYSTEMS, V3, P451, DOI 10.1007/s100210000040; Scheffer M., 1998, ECOLOGY SHALLOW LAKE; Schelske Claire L., 1999, P367; Schelske Claire L., 1992, P393; Shiomoto A, 1997, MAR ECOL PROG SER, V150, P75, DOI 10.3354/meps150075; Taylor K, 1999, AM SCI, V87, P320, DOI 10.1511/1999.4.320; Tilman D, 2001, SCIENCE, V292, P281, DOI 10.1126/science.1057544; Tucker CJ, 1999, AMBIO, V28, P587; vandeKoppel J, 1997, TRENDS ECOL EVOL, V12, P352, DOI 10.1016/S0169-5347(97)01133-6; Vandermeer J, 1999, ECOLOGY, V80, P1817, DOI 10.1890/0012-9658(1999)080[1817:BBCAAM]2.0.CO;2; Verity PG, 1996, MAR ECOL PROG SER, V130, P277, DOI 10.3354/meps130277; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Walker B., 1989, P121; WALKER BH, 1993, AMBIO, V22, P2; Wang GL, 2000, GEOPHYS RES LETT, V27, P795, DOI 10.1029/1999GL011089; Wang GL, 2000, WATER RESOUR RES, V36, P1013, DOI 10.1029/1999WR900361; WILSON JB, 1992, ADV ECOL RES, V23, P263, DOI 10.1016/S0065-2504(08)60149-X; Zeng N, 1999, SCIENCE, V286, P1537, DOI 10.1126/science.286.5444.1537	61	4466	4701	118	3071	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 11	2001	413	6856					591	596		10.1038/35098000	http://dx.doi.org/10.1038/35098000			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480WE	11595939				2022-12-28	WOS:000171485700039
J	Grigg, ME; Bonnefoy, S; Hehl, AB; Suzuki, Y; Boothroyd, JC				Grigg, ME; Bonnefoy, S; Hehl, AB; Suzuki, Y; Boothroyd, JC			Success and virulence in toxoplasma as the result of sexual recombination between two distinct ancestries	SCIENCE			English	Article							GONDII STRAINS; INTRAGENIC RECOMBINATION; GENE; PLASMODIUM; ANTIGEN; POLYMORPHISM; MICE; PATHOGENICITY; TRYPANOSOMA; ALLELES	Toxoplasma gondii is a common human pathogen causing serious, even fatal, disease in the developing fetus and in immunocompromised patients. Despite its ability to reproduce sexually and its broad geographic and host range, Toxoplasma has a clonal population structure comprised principally of three lines. We have analyzed 15 polymorphic loci in the archetypal type I, II, and III strains and found that polymorphism was limited to, at most, two rather than three allelic classes and no polymorphism was detected between alleles in strains of a given type. Multilocus analysis of 10 nonarchetypal isolates likewise clustered the vast majority of alleles into the same two distinct ancestries. These data strongly suggest that the currently predominant genotypes exist as a pandemic outbreak from a genetic mixing of two discrete ancestral lines. To determine if such mixing could lead to the extreme virulence observed for some strains, we examined the F-1 progeny of a cross between a type II and III strain, both of which are relatively avirulent in mice. Among the progeny were recombinants that were at least 3 logs more virulent than either parent. Thus, sexual recombination, by combining polymorphisms in two distinct and competing clonal lines, can be a powerful force driving the natural evolution of virulence in this highly successful pathogen.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Palo Alto Med Fdn, Res Inst, Dept Immunol & Infect Dis, Palo Alto, CA 94301 USA; Stanford Univ, Sch Med, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA	Stanford University; Palo Alto Medical Foundation Research Institute; Stanford University	Suzuki, Y (corresponding author), Virginia Polytech Inst & State Univ, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA.	ysuzuki@vt.edu; John.Boothroyd@stanford.edu	Bonnefoy, Serge/B-2466-2014	Bonnefoy, Serge/0000-0001-9148-0123; Boothroyd, John C./0000-0001-9719-745X; Hehl, Adrian/0000-0002-2110-4445	NIAID NIH HHS [AI04717, AI41014, AI21423] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI004717, R01AI021423, R01AI041014, R37AI004717, R37AI021423] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P3346, DOI 10.1073/pnas.95.7.3346; Binas M, 1998, INT J PARASITOL, V28, P1033, DOI 10.1016/S0020-7519(98)00052-6; BOOTHROYD JC, 1993, INFECT AGENT DIS, V2, P100; BOOTHROYD JC, 1993, TOXIPLASMOSIS, P63; BULOW R, 1991, J IMMUNOL, V147, P3496; CONWAY DJ, 1991, EXP PARASITOL, V73, P469, DOI 10.1016/0014-4894(91)90071-4; COUVREUR G, 1988, PARASITOLOGY, V97, P1, DOI 10.1017/S0031182000066695; Darde ML, 1998, J CLIN MICROBIOL, V36, P324; Darde ML, 1996, CURR TOP MICROBIOL, V219, P27; Fazaeli A, 2000, J PARASITOL, V86, P716, DOI 10.1645/0022-3395(2000)086[0716:ISIPAN]2.0.CO;2; Fazaeli A, 2000, INT J PARASITOL, V30, P637, DOI 10.1016/S0020-7519(00)00036-9; Grigg ME, 2001, J INFECT DIS, V184, P633, DOI 10.1086/322800; Homan WL, 1997, PARASITOL RES, V83, P285, DOI 10.1007/s004360050248; HOWE DK, 1995, J INFECT DIS, V172, P1561, DOI 10.1093/infdis/172.6.1561; Howe DK, 1997, J CLIN MICROBIOL, V35, P1411, DOI 10.1128/JCM.35.6.1411-1414.1997; HOWE DK, 1994, EXP PARASITOL, V78, P242, DOI 10.1006/expr.1994.1024; Howe DK, 1996, INFECT IMMUN, V64, P5193, DOI 10.1128/IAI.64.12.5193-5198.1996; KERR PJ, 1994, MOL BIOCHEM PARASIT, V66, P241, DOI 10.1016/0166-6851(94)90151-1; Lehmann T, 2000, J PARASITOL, V86, P960, DOI 10.1645/0022-3395(2000)086[0960:STOTGC]2.0.CO;2; LUTON K, 1995, PARASITOL RES, V81, P310, DOI 10.1007/BF00931536; MacLeod A, 2000, P NATL ACAD SCI USA, V97, P13442, DOI 10.1073/pnas.230434097; Meisel R, 1996, MOL BIOCHEM PARASIT, V81, P259, DOI 10.1016/0166-6851(96)02719-3; PARMLEY SF, 1994, J PARASITOL, V80, P293, DOI 10.2307/3283761; PFEFFERKORN LC, 1980, EXP PARASITOL, V50, P305, DOI 10.1016/0014-4894(80)90034-X; RINDER H, 1995, MOL BIOCHEM PARASIT, V69, P123, DOI 10.1016/0166-6851(94)00211-5; SCHOLTISSEK C, 1979, VIROLOGY, V95, P492, DOI 10.1016/0042-6822(79)90503-8; SIBLEY LD, 1992, GENETICS, V132, P1003; SIBLEY LD, 1992, NATURE, V359, P82, DOI 10.1038/359082a0; Sibley LD, 1996, CURR TOP MICROBIOL, V219, P3; SMITH JM, 1993, P NATL ACAD SCI USA, V90, P4384, DOI 10.1073/pnas.90.10.4384; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; TOMAVO S, 1991, INFECT IMMUN, V59, P3750, DOI 10.1128/IAI.59.10.3750-3753.1991	34	231	243	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 5	2001	294	5540					161	165		10.1126/science.1061888	http://dx.doi.org/10.1126/science.1061888			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588262				2022-12-28	WOS:000171448800052
J	Pennacchio, LA; Olivier, M; Hubacek, JA; Cohen, JC; Cox, DR; Fruchart, JC; Krauss, RM; Rubin, EM				Pennacchio, LA; Olivier, M; Hubacek, JA; Cohen, JC; Cox, DR; Fruchart, JC; Krauss, RM; Rubin, EM			An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing	SCIENCE			English	Article							FAMILIAL COMBINED HYPERLIPIDEMIA; C-III GENE; TRANSGENIC MICE; CAUSES HYPERTRIGLYCERIDEMIA; A-II; OVEREXPRESSION; ATHEROSCLEROSIS; IDENTIFICATION; POLYMORPHISMS; ATHEROGENESIS	Comparison of genomic DNA sequences from human and mouse revealed a new apolipoprotein (APO) gene (APOAV) located proximal to the well-characterized APOAI/CIII/AIV gene cluster on human 11q23. Mice expressing a human APOAV transgene showed a decrease in plasma triglyceride concentrations to one-third of those in control mice; conversely, knockout mice lacking Apoav had four times as much plasma triglycerides as controls. In humans, single nucleotide polymorphisms (SNPs) across the APOAV locus were found to be significantly associated with plasma triglyceride levels in two independent studies. These findings indicate that APOAV is an important determinant of plasma triglyceride levels, a major risk factor for coronary artery disease.	Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA; Stanford Univ, Sch Med, Dept Genet, Stanford Human Genome Ctr, Palo Alto, CA 94304 USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Inst Pasteur, Dept Atherosclerosis, INSERM, U545, F-59019 Lille, France; Univ Lille, Fac Pharm, F-59006 Lille, France	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Rubin, EM (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA.		Hubacek, Jaroslav Alois/AAN-6134-2021	Hubacek, Jaroslav Alois/0000-0001-6537-1353; Pennacchio, Len/0000-0002-8748-3732	NHLBI NIH HHS [HL-53917, HL66681, HL-18574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574, U01HL066681, R01HL053917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; Allan CM, 1996, J LIPID RES, V37, P1510; Allayee H, 1998, AM J HUM GENET, V63, P577, DOI 10.1086/301983; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEASLEY EM, 1999, PCR APPL; Boisfer E, 1999, J BIOL CHEM, V274, P11564, DOI 10.1074/jbc.274.17.11564; BRUNS GAP, 1984, ARTERIOSCLEROSIS, V4, P97, DOI 10.1161/01.ATV.4.2.97; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dreon DM, 1997, ARTERIOSCL THROM VAS, V17, P707, DOI 10.1161/01.ATV.17.4.707; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; Gong EL, 1996, J BIOL CHEM, V271, P5984, DOI 10.1074/jbc.271.11.5984; HAYDEN MR, 1987, AM J HUM GENET, V40, P421; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; KRAUSS R, UNPUB; KRAUSS RM, 1998, AM J MED, V105, P585; KRAUSS RM, 1995, AM J CLIN NUTR, V62, P478; LEWONTIN RC, 1988, GENETICS, V120, P849; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MasucciMagoulas L, 1997, SCIENCE, V275, P391, DOI 10.1126/science.275.5298.391; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Mein CA, 2000, GENOME RES, V10, P330, DOI 10.1101/gr.10.3.330; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OLIVIER M, UNPUB; Osoegawa K, 2000, GENOME RES, V10, P116; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; PENNACCHIO LA, UNPUB; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rubin EM, 2000, NATURE, V407, P265, DOI 10.1038/35025236; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SHACHTER NS, 1994, J CLIN INVEST, V93, P1683, DOI 10.1172/JCI117151; Shachter NS, 1996, J CLIN INVEST, V98, P846, DOI 10.1172/JCI118857; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0	43	740	853	3	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					169	173		10.1126/science.1064852	http://dx.doi.org/10.1126/science.1064852			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588264	Green Submitted			2022-12-28	WOS:000171448800054
J	Lohse, D; Schmitz, B; Versluis, M				Lohse, D; Schmitz, B; Versluis, M			Snapping shrimp make flashing bubbles	NATURE			English	Article							SONOLUMINESCENCE		Univ Twente, Res Ctr Fluid Dynam, NL-7500 AE Enschede, Netherlands; Tech Univ Munich, Lehrstuhl Zool, D-85747 Garching, Germany	University of Twente; Technical University of Munich	Lohse, D (corresponding author), Univ Twente, Res Ctr Fluid Dynam, POB 217, NL-7500 AE Enschede, Netherlands.		Lohse, Detlef/B-4915-2013; Versluis, Michel/F-3541-2011	Lohse, Detlef/0000-0003-4138-2255; Versluis, Michel/0000-0002-2296-1860				Baghdassarian O, 1999, PHYS REV LETT, V83, P2437, DOI 10.1103/PhysRevLett.83.2437; Brennen C.E., 1995, CAVITATION BUBBLE DY; CRUM LA, 1994, PHYS TODAY, V47, P22, DOI 10.1063/1.881402; EVEREST FA, 1948, J ACOUST SOC AM, V20, P137, DOI 10.1121/1.1906355; McNamara WB, 1999, NATURE, V401, P772, DOI 10.1038/44536; OHL CD, 1999, THESIS G AUGUST U GO; SCHMITZ B, 2001, PHYSL CRUSTACEAN NER, P521; Versluis M, 2000, SCIENCE, V289, P2114, DOI 10.1126/science.289.5487.2114	8	67	72	5	110	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					477	478		10.1038/35097152	http://dx.doi.org/10.1038/35097152			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586346				2022-12-28	WOS:000171340500033
J	Plsek, PE; Wilson, T				Plsek, PE; Wilson, T			Complexity science - Complexity, leadership, and management in healthcare organisations	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRIALS		Paul E Plsek & Associates, Roswell, GA 30075 USA; Royal Coll Gen Practitioners, St Paul RCGP Qual Unit, London SW7 1P, England		Plsek, PE (corresponding author), Paul E Plsek & Associates, 1005 Allenbrook Lane, Roswell, GA 30075 USA.	paulplsek@directedcreativity.com	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				COULTER A, 1988, SOC SCI MED, V27, P987, DOI 10.1016/0277-9536(88)90289-4; *DEP HLTH, 2000, NAT SERV FRAM COR H; *DEP HLTH, 2000, NHS PLAN; EGGER E, 2000, HLTH CARE STRATEG MA, V18, P18; FOOTE C, 2001, HLTH SERV J, V111, P32; Goldstein J., 1994, UNSHACKLED ORG FACIN; Greenhalgh PM, 1997, DIABETIC MED, V14, P10; Gustafson D. H., 1992, SYSTEMS SUPPORT HLTH; Institute of Medicine, 2001, CROSSING QUALITY CHA; Kelley MA, 2001, BMJ-BRIT MED J, V323, P61, DOI 10.1136/bmj.323.7304.61; Lane D, 1996, LONG RANGE PLANN, V29, P215, DOI 10.1016/0024-6301(96)00011-8; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; McCormack J, 2000, BMJ-BRIT MED J, V320, P1720, DOI 10.1136/bmj.320.7251.1720; Miller WL, 1998, J FAM PRACTICE, V46, P369; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; Morgan G, 1997, IMAGES ORG; PETZINGER T, 1999, NEW PIONEERS MEN WO; Plsek PE, 2001, BRIT MED J, V323, P625, DOI 10.1136/bmj.323.7313.625; Roper NA, 2001, BRIT MED J, V322, P1389, DOI 10.1136/bmj.322.7299.1389; Ruston A, 1998, BRIT MED J, V316, P1060; Taylor FrederickWinslow., 1911, PRINCIPLES SCI MANAG; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Zimmerman B., 1998, EDGEWARE INSIGHTS CO	23	517	527	2	72	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 29	2001	323	7315					746	749		10.1136/bmj.323.7315.746	http://dx.doi.org/10.1136/bmj.323.7315.746			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HJ	11576986	Green Published			2022-12-28	WOS:000171340700026
J	Schon, JH; Dorget, M; Beuran, FC; Xu, XZ; Arushanov, E; Lagues, M; Cavellin, CD				Schon, JH; Dorget, M; Beuran, FC; Xu, XZ; Arushanov, E; Lagues, M; Cavellin, CD			Field-induced superconductivity in a spin-ladder cuprate	SCIENCE			English	Article							RETRACTED ARTICLE. SEE; TRANSPORT-PROPERTIES; PRESSURE; SYSTEM; GAP	We report on the modulation of the transport properties of thin films, grown by molecular beam epitaxy, of the spin-ladder compound [CaCu2O3](4), using the field effect in a gated structure. At high hole-doping levels, superconductivity is induced in the nominally insulating [adder material without the use of high-pressure or chemical substitution. The observation of superconductivity is in agreement with the theoretical prediction that holes doped into spin ladders could pair and possibly superconduct.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Univ Konstanz, Dept Phys, D-78457 Constance, Germany; Univ Paris 12, Grp Phys Milieux Denses, F-94010 Creteil, France; Ecole Super Phys & Chim Ind Ville Paris, CNRS, UPR 5, F-75005 Paris, France; Moldavian Acad Sci, Inst Appl Phys, Kishinev 277028, Moldova	Alcatel-Lucent; Lucent Technologies; AT&T; University of Konstanz; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Academy of Sciences of Moldova; Institute of Applied Physics - Moldova	Schon, JH (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	j.hendrix@ratskrone.de	Arushanov, Ernest/L-6045-2017; Arushanov, Ernest/O-7372-2019	Arushanov, Ernest/0000-0002-5859-4943; Arushanov, Ernest/0000-0002-5859-4943				Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152; AZUMA M, 1994, PHYS REV LETT, V73, P3463, DOI 10.1103/PhysRevLett.73.3463; Cavellin CD, 1997, PHYSICA C, V282, P929, DOI 10.1016/S0921-4534(97)00566-2; DAGOTTO E, 1992, PHYS REV B, V45, P5744, DOI 10.1103/PhysRevB.45.5744; Dagotto E, 1996, SCIENCE, V271, P618, DOI 10.1126/science.271.5249.618; Dorget M, 2000, PHYSICA C, V341, P477, DOI 10.1016/S0921-4534(00)00551-7; Eccleston RS, 1996, PHYS REV B, V53, P14721, DOI 10.1103/PhysRevB.53.R14721; Furubayashi Y, 1999, PHYS REV B, V60, pR3720, DOI 10.1103/PhysRevB.60.R3720; Isobe M, 1998, PHYS REV B, V57, P613, DOI 10.1103/PhysRevB.57.613; Kazakov SM, 2001, PHYSICA C, V351, P301, DOI 10.1016/S0921-4534(00)01631-2; Kiryukhin V, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.144418; Maple MB, 1998, J MAGN MAGN MATER, V177, P18, DOI 10.1016/S0304-8853(97)00999-2; Mayaffre H, 1998, SCIENCE, V279, P345, DOI 10.1126/science.279.5349.345; MCCARRON EM, 1988, MATER RES BULL, V23, P1355, DOI 10.1016/0025-5408(88)90124-9; Nagata T, 1998, PHYS REV LETT, V81, P1090, DOI 10.1103/PhysRevLett.81.1090; Nakanishi T, 2000, PHYSICA B, V281, P957, DOI 10.1016/S0921-4526(99)00966-7; Osafune T, 1997, PHYS REV LETT, V78, P1980, DOI 10.1103/PhysRevLett.78.1980; Partiot C, 2000, PHYSICA C, V341, P475, DOI 10.1016/S0921-4534(00)00550-5; Revcolevschi A, 1997, PHYSICA C, V282, P493, DOI 10.1016/S0921-4534(97)00356-0; REVCOLEVSCHI A, 1996, COHERENCE HIGH TEMPE; Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008; Schon JH, 2000, NATURE, V406, P702, DOI 10.1038/35021011; Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656; Schon JH, 2001, NATURE, V410, P189, DOI 10.1038/35065565; Uehara M, 1996, J PHYS SOC JPN, V65, P2764, DOI 10.1143/JPSJ.65.2764	27	29	29	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2430	2432		10.1126/science.1064204	http://dx.doi.org/10.1126/science.1064204			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577230				2022-12-28	WOS:000171237200039
J	Dalton, R				Dalton, R			Transgenic corn found growing in Mexico	NATURE			English	News Item																			0	17	26	1	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					337	337		10.1038/35096714	http://dx.doi.org/10.1038/35096714			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574839	Bronze			2022-12-28	WOS:000171188700007
J	van Walraven, C; Mamdani, MM; Wells, PS; Williams, JI				van Walraven, C; Mamdani, MM; Wells, PS; Williams, JI			Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FLUOXETINE; HEMORRHAGE; RISK; ASSOCIATION; DRUGS; TIME	Objectives To determine the association between inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding. Design Retrospective cohort study from population based databases. Setting Ontario, Canada. Participants 317 824 elderly people observed for more than 130 000 person years. The patients started taking an antidepressant between 1992 and 1998 and were grouped by how much the drug inhibited serotonin reuptake. Patients were observed until they stopped the drug, had an upper gastrointestinal bleed, or died or the study ended. Main outcome measure Admission to hospital for acute upper gastrointestinal bleeding. Results Overall, 974 bleeds were observed, with an overall bleeding rate of 7.3 per 1000 person years. After controlling for age or previous gastrointestinal bleeding, the risk of bleeding significantly increased by 10.7% and 9.8%, respectively, with increasing inhibition of serotonin reuptake. Absolute differences in bleeding between antidepressant groups were greatest for octogenarians (low inhibition of serotonin reuptake, 10.6 bleeds/1000 person years v high inhibition of serotonin reuptake, 14.7 bleeds/1000 person years; number needed to harm 244) and those with previous upper gastrointestinal bleeding (low, 28.6 bleeds/1000 person years v high, 40.3 bleeds/1000 person years; number needed to harm 85). Conclusions After age or previous upper gastrointestinal bleeding were controlled for, antidepressants with high inhibition of serotonin reuptake increased the risk of upper gastrointestinal bleeding. These increases are clinically important for elderly patients and those with previous gastrointestinal bleeding.	Ottawa Hosp, Ottawa Hlth Res Inst, Clin Epidemiol Unit, Ottawa, ON K1Y 4E9, Canada; Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute	van Walraven, C (corresponding author), Ottawa Hosp, Ottawa Hlth Res Inst, Clin Epidemiol Unit, Civ Campus, Ottawa, ON K1Y 4E9, Canada.	carlv@ohri.ca						ALDERMAN CP, 1992, ANN PHARMACOTHER, V26, P1517, DOI 10.1177/106002809202601205; ARANTH J, 1992, AM J PSYCHIAT, V149, P412; Blatchford O, 1997, BMJ-BRIT MED J, V315, P510, DOI 10.1136/bmj.315.7107.510; Calhoun JW, 1996, AM J PSYCHIAT, V153, P443; de Abajo FJ, 1999, BRIT MED J, V319, P1106, DOI 10.1136/bmj.319.7217.1106; Dickinson T, 2000, BRIT MED J, V320, P1406; Dunn NR, 2000, BRIT MED J, V320, P1405; Grymonpre RE, 1998, ANN PHARMACOTHER, V32, P749, DOI 10.1345/aph.17423; GUNZBERGER DW, 1992, AM J PSYCHIAT, V149, P1751; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P153; HUMPHRIES JE, 1990, ARCH PATHOL LAB MED, V114, P727; Leung M, 1996, CAN J PSYCHIAT, V41, P604, DOI 10.1177/070674379604100919; Li N, 1997, BLOOD COAGUL FIBRIN, V8, P517, DOI 10.1097/00001721-199711000-00006; OTTERVANGER JD, 1994, AM J PSYCHIAT, V151, P781; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PAHOR M, 1994, JAMA-J AM MED ASSOC, V272, P595, DOI 10.1001/jama.272.8.595; Po ALW, 1999, BMJ-BRIT MED J, V319, P1081, DOI 10.1136/bmj.319.7217.1081; Raiford DS, 1996, EPIDEMIOLOGY, V7, P101, DOI 10.1097/00001648-199601000-00018; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; ROSS SB, 1980, PSYCHOPHARMACOLOGY, V67, P1, DOI 10.1007/BF00427588; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; Weil J, 2000, GUT, V46, P27, DOI 10.1136/gut.46.1.27; Williams D, 2000, BRIT MED J, V320, P1405, DOI 10.1136/bmj.320.7246.1405; Wilmshurst PT, 1996, EYE, V10, P141, DOI 10.1038/eye.1996.26	24	167	167	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 22	2001	323	7314					655	658		10.1136/bmj.323.7314.655	http://dx.doi.org/10.1136/bmj.323.7314.655			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	476LP	11566827	Bronze, Green Published			2022-12-28	WOS:000171228800014
J	Guest, JR; Stievater, TH; Chen, G; Tabak, EA; Orr, BG; Steel, DG; Gammon, D; Katzer, DS				Guest, JR; Stievater, TH; Chen, G; Tabak, EA; Orr, BG; Steel, DG; Gammon, D; Katzer, DS			Near-field coherent spectroscopy and microscopy of a quantum dot system	SCIENCE			English	Article							OPTICAL SPECTROSCOPY; EXCITONS; WELL; REPULSION; SPECTRA	We combined coherent nonlinear optical spectroscopy with nano-electron volt energy resolution and low-temperature near-field microscopy with subwavelength resolution (<<lambda>/2) to provide direct and local access to the excitonic dipole in a semiconductor nanostructure quantum system. Our technique allows the ability to address, excite, and probe single eigenstates of solid-state quantum systems with spectral. and spatial selectivity while simultaneously providing a measurement of all the various time scales of the excitation including state relaxation and decoherence rates. In analogy to scanning tunneling microscopy measurements, we can now map the optical local density of states of a disordered nanostructure. These measurements lay the groundwork for studying and exploiting spatial and temporal coherence in the nanoscopic regime of solid-state systems.	Univ Michigan, Harrison M Randall Lab Phys, Ann Arbor, MI 48109 USA; USN, Res Lab, Washington, DC 20375 USA	University of Michigan System; University of Michigan; United States Department of Defense; United States Navy; Naval Research Laboratory	Steel, DG (corresponding author), Univ Michigan, Harrison M Randall Lab Phys, Ann Arbor, MI 48109 USA.	dst@umich.edu	/AAE-2493-2020; Katzer, D. Scott/N-7841-2013; Guest, Jeffrey R/B-2715-2009	Guest, Jeffrey R/0000-0002-9756-8801				Barenz J, 1996, REV SCI INSTRUM, V67, P1912, DOI 10.1063/1.1146995; Bonadeo NH, 1998, PHYS REV LETT, V81, P2759, DOI 10.1103/PhysRevLett.81.2759; Bryant GW, 1998, APPL PHYS LETT, V72, P768, DOI 10.1063/1.120868; Chen G, 2000, SCIENCE, V289, P1906, DOI 10.1126/science.289.5486.1906; Chen G., UNPUB; CROMMIE MF, 1993, NATURE, V363, P524, DOI 10.1038/363524a0; Erland J, 1999, PHYS REV B, V60, pR8497, DOI 10.1103/PhysRevB.60.R8497; FAFARD S, 1994, PHYS REV B, V50, P8086, DOI 10.1103/PhysRevB.50.8086; Gammon D, 1996, PHYS REV LETT, V76, P3005, DOI 10.1103/PhysRevLett.76.3005; GUEST JR, 2000, NONL NEAR FIELD SPEC; Hanewinkel B, 1997, PHYS REV B, V55, P13715, DOI 10.1103/PhysRevB.55.13715; HESS HF, 1994, SCIENCE, V264, P1740, DOI 10.1126/science.264.5166.1740; Imamoglu A, 1999, PHYS REV LETT, V83, P4204, DOI 10.1103/PhysRevLett.83.4204; Intonti F, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.076801; Jahn U, 1997, PHYS REV B, V56, pR4387, DOI 10.1103/PhysRevB.56.R4387; Levy J, 1996, PHYS REV LETT, V76, P1948, DOI 10.1103/PhysRevLett.76.1948; Lewis MK, 1998, OPT LETT, V23, P1111, DOI 10.1364/OL.23.001111; Mauritz O, 1999, PHYS REV LETT, V82, P847, DOI 10.1103/PhysRevLett.82.847; Meystre P, 1991, ELEMENTS QUANTUM OPT; REMILLARD JT, 1989, PHYS REV LETT, V62, P2861, DOI 10.1103/PhysRevLett.62.2861; Runge E, 1998, PHYS STATUS SOLIDI B, V206, P167, DOI 10.1002/(SICI)1521-3951(199803)206:1<167::AID-PSSB167>3.0.CO;2-L; Savasta S, 2000, PHYS REV B, V61, P13852, DOI 10.1103/PhysRevB.61.13852; TAKAGAHARA T, 1989, PHYS REV B, V39, P10206, DOI 10.1103/PhysRevB.39.10206; Vollmer M, 1999, APPL PHYS LETT, V74, P1791, DOI 10.1063/1.123087; WANG H, 1990, PHYS REV LETT, V65, P1255, DOI 10.1103/PhysRevLett.65.1255; Wu Q, 1999, PHYS REV LETT, V83, P2652, DOI 10.1103/PhysRevLett.83.2652; YABLONOVITCH E, 1987, APPL PHYS LETT, V51, P2222, DOI 10.1063/1.98946	27	99	101	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2224	2227		10.1126/science.1063696	http://dx.doi.org/10.1126/science.1063696			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567131				2022-12-28	WOS:000171139400034
J	Lee, DM; Weinblatt, ME				Lee, DM; Weinblatt, ME			Rheumatoid arthritis	LANCET			English	Review							TUMOR-NECROSIS-FACTOR; CARTILAGE-PANNUS JUNCTION; ALPHA MONOCLONAL-ANTIBODY; COLLAGENASE MESSENGER-RNA; IL-1 RECEPTOR ANTAGONIST; IN-SITU HYBRIDIZATION; LONG-TERM; COMBINATION THERAPY; DISEASE-ACTIVITY; SYNOVIAL-FLUID	Rheumatoid arthritis is a systemic inflammatory disorder that mainly affects the diarthrodial joint. It is the most common form of inflammatory arthritis, and has a substantial societal effect in terms of cost, disability, and lost productivity. Although the pathogenesis of rheumatoid arthritis remains incompletely understood, much insight into the cellular and molecular mechanisms involved has been gained in the past decade. On the basis of these insights, new therapies have been developed, and clinical trials have shown the efficacy of aggressive treatment of patients with active disease. In this review, we discuss improvements in our understanding of the pathophysiology of inflammatory synovitis in rheumatoid arthritis, and improvements in therapy for patients with the disorder. The past decade has seen substantial advances in these areas. Future studies will be directed at improving methods for early diagnosis and identification of patients with progressive disease, and at Improving methods to Identify candidates for subclasses of disease-modifying antirheumatic drugs (DMARDs). Long-term safety and efficacy data for the new DMARD agents and combination regimens will also further delineate efficacy and toxicity and thus the appropriate clinical context for use of these therapeutic approaches. The continuing elucidation of pathophysiological pathways relevant in rheumatoid arthritis, coupled with continuing advances In biotechnology and rational drug design, offer substantial hope for the continued development of increasingly potent and specific pharmacotherapy for treatment of rheumatoid arthritis.	Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Weinblatt, ME (corresponding author), Brigham & Womens Hosp, Dept Med, Div Rheumatol, 75 Francis St, Boston, MA 02115 USA.	mweinblatt@partners.org						AHO K, 1986, J RHEUMATOL, V13, P899; AREND WP, 1994, J IMMUNOL, V153, P4766; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; CHERWINSKI HM, 1995, J PHARMACOL EXP THER, V275, P1043; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; Cohen S, 1999, ARTHRITIS RHEUM, V42, pS271; Cooper NJ, 2000, RHEUMATOLOGY, V39, P28, DOI 10.1093/rheumatology/39.1.28; COPE AP, 1992, ARTHRITIS RHEUM, V35, P1160, DOI 10.1002/art.1780351008; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; Drossaers-Bakker KW, 1999, ARTHRITIS RHEUM, V42, P1854, DOI 10.1002/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO;2-F; EGSMOSE C, 1995, J RHEUMATOL, V22, P2208; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; Elder RT, 1997, J IMMUNOL, V159, P22; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FELSON DT, 1992, ARTHRITIS RHEUM, V35, P1117, DOI 10.1002/art.1780351003; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FIRESTEIN GS, 1992, J IMMUNOL, V149, P1054; FITZGERALD O, 1991, ANN RHEUM DIS, V50, P792, DOI 10.1136/ard.50.11.792; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GRAVALLESE EM, 1991, ARTHRITIS RHEUM-US, V34, P1076, DOI 10.1002/art.1780340903; HALE LP, 1989, ARTHRITIS RHEUM, V32, P22, DOI 10.1002/anr.1780320105; JENKINS RN, 1993, J CLIN INVEST, V92, P2688, DOI 10.1172/JCI116886; JOHNSON BA, 1993, ARTHRITIS RHEUM, V36, P137, DOI 10.1002/art.1780360203; Joosten LAB, 1996, ARTHRITIS RHEUM, V39, P797, DOI 10.1002/art.1780390513; Kavanaugh A, 2000, J RHEUMATOL, V27, P841; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KOBAYASHI I, 1975, ARTHRITIS RHEUM-US, V18, P475, DOI 10.1002/art.1780180507; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; KOCH AE, 1990, J CLIN IMMUNOL, V10, P192, DOI 10.1007/BF00918651; Kohem CL, 1996, ARTHRITIS RHEUM, V39, P844, DOI 10.1002/art.1780390518; Kremer JM, 2000, ARTHRITIS RHEUM, V43, pS224; Kremer JM, 1997, ARTHRITIS RHEUM, V40, P984, DOI 10.1002/art.1780400533; LAFYATIS R, 1989, J CLIN INVEST, V83, P1267, DOI 10.1172/JCI114011; LARSEN A, 1975, Scandinavian Journal of Rheumatology, V4, P225; Lipsky P, 1999, ARTHRITIS RHEUM, V42, pS401; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B; MACGREGOR AJ, 1995, BRIT J RHEUMATOL, V34, P215; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; MARTELPELLETIER J, 1994, LAB INVEST, V70, P807; MCCACHREN SS, 1990, J CLIN IMMUNOL, V10, P19, DOI 10.1007/BF00917494; McGonagle D, 1999, ARTHRITIS RHEUM, V42, P1706, DOI 10.1002/1529-0131(199908)42:8<1706::AID-ANR20>3.0.CO;2-Z; McQueen FM, 1998, ANN RHEUM DIS, V57, P350, DOI 10.1136/ard.57.6.350; MLADENOVIC V, 1995, ARTHRITIS RHEUM-US, V38, P1595, DOI 10.1002/art.1780381111; MORAND EF, 1992, J RHEUMATOL, V19, P704; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Moreland LW, 1996, J RHEUMATOL, V23, P1849; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4; Mulherin D, 1996, BRIT J RHEUMATOL, V35, P1263; NYKANEN P, 1986, RHEUMATOL INT, V6, P269, DOI 10.1007/BF00541318; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; OLLIER WER, 1995, BRIT MED BULL, V51, P267, DOI 10.1093/oxfordjournals.bmb.a072960; PINCUS T, 1992, J RHEUMATOL, V19, P1885; REILLY PA, 1990, ANN RHEUM DIS, V49, P363, DOI 10.1136/ard.49.6.363; RENNINGEN KS, 1990, TISSUE ANTIGENS, V36, P235, DOI 10.1111/j.1399-0039.1990.tb01834.x; ROONEY M, 1989, J RHEUMATOL, V16, P459; SANY J, 1991, J RHEUMATOL, V18, P1323; SCOTT DL, 1987, LANCET, V1, P1108; Seldin MF, 1999, ARTHRITIS RHEUM, V42, P1071, DOI 10.1002/1529-0131(199906)42:6<1071::AID-ANR1>3.0.CO;2-8; Sharp JT, 2000, ARTHRITIS RHEUM-US, V43, P495, DOI 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U; SHARP JT, 1989, ARTHRITIS RHEUM-US, V32, P221, DOI 10.1002/anr.1780320218; SHIOZAWA S, 1983, ARTHRITIS RHEUM-US, V26, P472, DOI 10.1002/art.1780260404; SILMAN AJ, 1993, BRIT J RHEUMATOL, V32, P903; Simms RW, 1996, ARTHRITIS RHEUM-US, V39, P723; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; SODEN M, 1989, BRIT J RHEUMATOL, V28, P287; Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TRABANDT A, 1991, ARTHRITIS RHEUM, V34, P1444; Tugwell P, 2000, ARTHRITIS RHEUM, V43, P506, DOI 10.1002/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; UEMATSU Y, 1991, P NATL ACAD SCI USA, V88, P8534, DOI 10.1073/pnas.88.19.8534; vanderHeide A, 1996, ANN INTERN MED, V124, P699, DOI 10.7326/0003-4819-124-8-199604150-00001; VANDERHEIJDE DMFM, 1993, J RHEUMATOL, V20, P579; Wagner UG, 1998, P NATL ACAD SCI USA, V95, P14447, DOI 10.1073/pnas.95.24.14447; Weinblatt ME, 1999, ARTHRITIS RHEUM, V42, pS401; WEINBLATT ME, 1993, ARTHRITIS RHEUM-US, V36, P613, DOI 10.1002/art.1780360507; WEINBLATT ME, 1994, ARTHRITIS RHEUM, V37, P1492, DOI 10.1002/art.1780371013; Weinblatt ME, 1999, ARTHRITIS RHEUM-US, V42, P1322, DOI 10.1002/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P; Weinblatt ME, 1998, J RHEUMATOL, V25, P238; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; WILLIAMS HJ, 1992, ARTHRITIS RHEUM, V35, P259, DOI 10.1002/art.1780350304; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; WILLKENS RF, 1992, ARTHRITIS RHEUM-US, V35, P849, DOI 10.1002/art.1780350802; Wolfe F, 1998, ARTHRITIS RHEUM, V41, P1571, DOI 10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R; WOOD NC, 1992, CLIN IMMUNOL IMMUNOP, V62, P295, DOI 10.1016/0090-1229(92)90106-X; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049	93	1033	1137	8	151	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 15	2001	358	9285					903	911		10.1016/S0140-6736(01)06075-5	http://dx.doi.org/10.1016/S0140-6736(01)06075-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567728				2022-12-28	WOS:000171087000029
J	Parle, JV; Maisonneuve, P; Sheppard, MC; Boyle, P; Franklyn, JA				Parle, JV; Maisonneuve, P; Sheppard, MC; Boyle, P; Franklyn, JA			Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study	LANCET			English	Article							SUPPRESSIVE THERAPY; FOLLOW-UP; THYROTOXICOSIS; LEVOTHYROXINE; ASSAY; TSH; HYPERTHYROIDISM; THYROXINE; HEART	Background Low serum thyrotropin, in combination with normal concentrations of circulating thyroid hormones, is common, especially in elderly people and in individuals with a history of thyroid disease. We aimed to assess the long-term effects of subclinical hyperthyroidism on mortality. Methods We did a population-based study of mortality in a cohort of 1191 individuals not on thyroxine or antithyroid medication. All participants were aged 60 years or older. We measured concentration of thyrotropin in serum at baseline in 1988-89. We recorded vital status on June 1, 1999, and ascertained causes of death for those who had died. We compared data for causes of death with age-specific, sex-specific, and year-specific data for England and Wales. We also compared mortality within the cohort according to initial thyrotropin measurement. Results During 9733 person-years of follow-up, 509 of 1191 people died, the expected number of deaths being 496 (standardised mortality ratio [SMR] 1.0, 95% CI 0.9-1.1). Mortality from all causes was significantly increased at 2 (SMR 2.1), 3 (2.1), 4 (1.7), and 5 (1.8) years after first measurement in those with low serum thyrotropin (n=71). These increases were largely accounted for by significant increases in mortality due to circulatory diseases (SMR 2.1, 2.2, 1.9, 2.0, at years 2, 3, 4, and 5 respectively). Increases in mortality from all causes in years 2-5 were higher in patients with low serum thyrotropin than in the rest of the cohort (hazard ratios for years 2, 3, 4, and 5 were 2.1, 2.2, 1.8, and 1.8, respectively). This result reflects an increase in mortality from circulatory diseases (hazard ratios at years 2, 3, 4, and 5 were 2.3, 2.6, 2.3, 2.3), and specifically from cardiovascular diseases (hazard ratios at years 2, 3, 4, and 5 were 3.3, 3.0, 2.3, 2.2). Interpretation A single measurement of low serum thyrotropin in individuals aged 60 years or older is associated with increased mortality from all causes, and in particular mortality due to circulatory and cardiovascular diseases.	Univ Birmingham, Div Primary Care Publ & Occupat Hlth, Birmingham, W Midlands, England; Univ Birmingham, Div Med Sci, Birmingham, W Midlands, England; European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy	University of Birmingham; University of Birmingham; IRCCS European Institute of Oncology (IEO)	Franklyn, JA (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England.		Maisonneuve, Patrick/U-9789-2018; Boyle, Peter/A-4380-2014	Maisonneuve, Patrick/0000-0002-5309-4704; Boyle, Peter/0000-0001-6251-0610				Biondi B, 1996, J CLIN ENDOCR METAB, V81, P4224, DOI 10.1210/jc.81.12.4224; BIONDI B, 1994, J CLIN ENDOCR METAB, V78, P1028, DOI 10.1210/jc.78.5.1028; BIONDI B, 1993, J CLIN ENDOCR METAB, V77, P334, DOI 10.1210/jc.77.2.334; Ching GW, 1996, HEART, V75, P363, DOI 10.1136/hrt.75.4.363; DAVIES PH, 1992, J CLIN ENDOCR METAB, V74, P1189, DOI 10.1210/jc.74.5.1189; EGGERTSEN R, 1988, BRIT MED J, V297, P1586, DOI 10.1136/bmj.297.6663.1586; Franklyn JA, 1998, NEW ENGL J MED, V338, P712, DOI 10.1056/NEJM199803123381103; LADENSON PW, 1993, J CLIN ENDOCR METAB, V77, P332, DOI 10.1210/jc.77.2.332; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PRESTI CF, 1989, AM HEART J, V117, P967; SANDLER G, 1958, Q J MED, V111, P347; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SPENCER CA, 1990, J CLIN ENDOCR METAB, V70, P453, DOI 10.1210/jcem-70-2-453; UTIGER RD, 1994, NEW ENGL J MED, V331, P1302, DOI 10.1056/NEJM199411103311909; Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278; WOEBER KA, 1992, NEW ENGL J MED, V327, P94	17	499	522	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 15	2001	358	9285					861	865		10.1016/S0140-6736(01)06067-6	http://dx.doi.org/10.1016/S0140-6736(01)06067-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567699				2022-12-28	WOS:000171087000006
J	Shenoy, SK; McDonald, PH; Kohout, TA; Lefkowitz, RJ				Shenoy, SK; McDonald, PH; Kohout, TA; Lefkowitz, RJ			Regulation of receptor fate by ubiquitination of activated beta(2)-adrenergic receptor and beta-arrestin	SCIENCE			English	Article							ADRENERGIC-RECEPTOR; CLATHRIN ADAPTER; PROTEIN LIGASE; ENDOCYTOSIS; P53; SYSTEM; MDM2; COMPLEX	Although trafficking and degradation of several membrane proteins are regulated by ubiquitination catalyzed by E3 ubiquitin ligases, there has been little evidence connecting ubiquitination with regulation of mammalian G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR) function. Agonist stimulation of endogenous or transfected beta (2)-adrenergic receptors (beta (2)ARs) led to rapid ubiquitination of both the receptors and the receptor regulatory protein, beta -arrestin. Moreover, proteasome inhibitors reduced receptor internalization and degradation, thus implicating a role for the ubiquitination machinery in the trafficking of the beta (2)AR. Receptor ubiquitination required beta -arrestin, which bound to the E3 ubiquitin ligase Mdm2. Abrogation of beta -arrestin ubiquitination, either by expression in Mdm2-null cells or by dominant-negative forms of Mdm2 lacking E3 ligase activity, inhibited receptor internalization with marginal effects on receptor degradation. However, a beta (2)AR mutant tacking lysine residues, which was not ubiquitinated, was internalized normally but was degraded ineffectively. These findings delineate an adapter role of beta -arrestin in mediating the ubiquitination of the beta (2)AR and indicate that ubiquitination of the receptor and of beta -arrestin have distinct and obligatory roles in the trafficking and degradation of this prototypic GPCR.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Mori S, 1997, EUR J BIOCHEM, V247, P1190, DOI 10.1111/j.1432-1033.1997.01190.x; Nakamura K, 1999, MOL ENDOCRINOL, V13, P1295, DOI 10.1210/me.13.8.1295; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; Parola AL, 1997, ANAL BIOCHEM, V254, P88, DOI 10.1006/abio.1997.2361; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; SHENOY SR, UNPUB; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; van Kerkhof P, 2001, J BIOL CHEM, V276, P3778, DOI 10.1074/jbc.M007326200; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200	25	669	689	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2001	294	5545					1307	1313		10.1126/science.1063866	http://dx.doi.org/10.1126/science.1063866			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491VF	11588219				2022-12-28	WOS:000172130200039
J	Bates-Jensen, BM				Bates-Jensen, BM			Quality indicators for prevention and management of pressure ulcers in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							PREDICTIVE-VALIDITY; COST-EFFECTIVENESS; RANDOMIZED TRIAL; WOUND CLEANSERS; BRADEN-SCALE; SORE RISK; INTERVENTIONS; DEBRIDEMENT; MULTISITE; DRESSINGS		Univ Calif Los Angeles, Borun Ctr Gerontol Res, Reseda, CA 91335 USA	University of California System; University of California Los Angeles	Bates-Jensen, BM (corresponding author), Univ Calif Los Angeles, Borun Ctr Gerontol Res, 7150 Tampa Ave, Reseda, CA 91335 USA.		Bates-Jensen, Barbara/ABA-3726-2020					ALLMAN RM, 1987, ANN INTERN MED, V107, P641, DOI 10.7326/0003-4819-107-5-641; ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; *AM MED DIR ASS, 1996, PRESS ULC CLIN PRACT; AMLUNG S, 2000, 14 ANN CLIN S WOUND, P234; Bale S, 1998, J Wound Care, V7, P65; Bates-Jensen B M, 1992, Decubitus, V5, P20; Bates-Jensen B M, 1997, Adv Wound Care, V10, P65; BATESJENSEN BM, 1999, WOUND CARE COLLABORA, P139; BATESJENSEN BM, 1999, THESIS LOS ANGELES U, V59; BATESJENSEN BM, 1998, WOUND CARE COLLABORA, P235; Bergstrom N, 1996, J AM GERIATR SOC, V44, P22, DOI 10.1111/j.1532-5415.1996.tb05633.x; Bergstrom N, 1998, NURS RES, V47, P261, DOI 10.1097/00006199-199809000-00005; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; BERLOWITZ DR, 1990, J AM GERIATR SOC, V38, P748, DOI 10.1111/j.1532-5415.1990.tb01464.x; BRADEN BJ, 1994, RES NURS HEALTH, V17, P459, DOI 10.1002/nur.4770170609; BRANDEIS GH, 1990, JAMA-J AM MED ASSOC, V264, P2905, DOI 10.1001/jama.264.22.2905; BRENNAN SS, 1988, ANN EMERG MED, V17, P1274; Colin D, 1996, J Wound Care, V5, P444; *DESCR NPUAP, 1995, ADV WOUND CAR S, V8, P93; FERRELL BA, 1993, JAMA-J AM MED ASSOC, V269, P494, DOI 10.1001/jama.269.4.494; Flanagan M, 1995, J Wound Care, V4, P264; FORESMAN PA, 1993, WOUNDS, V5, P226; GORSE GJ, 1987, ARCH DERMATOL, V123, P766, DOI 10.1001/archderm.123.6.766; Hellewell TB, 1997, WOUNDS, V9, P15; LAZARUS GS, 1994, ARCH DERMATOL, V130, P489, DOI 10.1001/archderm.130.4.489; LEVINE NS, 1976, J TRAUMA, V16, P89, DOI 10.1097/00005373-197602000-00002; LINEAWEAVER W, 1985, ARCH SURG-CHICAGO, V120, P267; Martin S J, 1996, J Wound Care, V5, P310; MOOLTEN SE, 1972, ARCH PHYS MED REHAB, V53, P430; Mulder G D, 1995, Ostomy Wound Manage, V41, P62; MULDER GD, 1993, WOUNDS, V5, P112; *NAT PRESS ULC ADV, 2001, STAT PRESS ULC PREV; *NPUAP STAT REV ST, 1995, NPUAP REP NEWSL NAT, V4, P1; PINCHCOFSKYDEVIN GD, 1986, J AM GERIATR SOC, V34, P435, DOI 10.1111/j.1532-5415.1986.tb03411.x; *PRESS ULC AD PREV, 1992, AHCPR PUBL; ROBSON MC, 1988, ANN EMERG MED, V17, P1274, DOI 10.1016/S0196-0644(88)80352-4; ROBSON MC, 1990, CLIN PLAST SURG, V17, P485; ROUSSEAU P, 1989, WOUNDS, V1, P135; SAPICO FL, 1986, DIAGN MICR INFEC DIS, V5, P31, DOI 10.1016/0732-8893(86)90089-1; Saydak S J, 1990, J Enterostomal Ther, V17, P139; SEBERN MD, 1986, ARCH PHYS MED REHAB, V67, P726, DOI 10.1016/0003-9993(86)90004-3; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Steed DL, 1996, J AM COLL SURGEONS, V183, P61; Stotts N A, 1995, Adv Wound Care, V8, P46; Thomas D R, 1997, Adv Wound Care, V10, P96; Thomas DR, 1997, CLIN GERIATR MED, V13, P497; THOMAS DR, 1997, GERIATRIC MED, P767; *TREATM PRESS ULC, 1994, AHCPR PUBL; *US DEP HHS, 2000, HLTH PEOP 2010; van Rijswijk L, 1993, Decubitus, V6, P16; van Rijswijk L, 1994, Ostomy Wound Manage, V40, P40; van Rijswijk L, 1999, Ostomy Wound Manage, V45, p56S; VANRIJSWIJK L, 1997, CHRONIC WOUND CARE C; Whittington K, 2000, J Wound Ostomy Continence Nurs, V27, P209, DOI 10.1067/mjw.2000.107879; XAKELLIS GC, 1992, J AM GERIATR SOC, V40, P1250, DOI 10.1111/j.1532-5415.1992.tb03651.x; XAKELLIS GC, 1992, ARCH PHYS MED REHAB, V73, P463	57	40	42	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				744	751		10.7326/0003-4819-135-8_Part_2-200110161-00014	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00014			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601958				2022-12-28	WOS:000171542400014
J	MacLean, CH				MacLean, CH			Quality indicators for the management of osteoarthritis in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ARTHRITIS SELF-MANAGEMENT; SERIOUS GASTROINTESTINAL COMPLICATIONS; TOTAL HIP-ARTHROPLASTY; RHEUMATOID-ARTHRITIS; PATIENT EDUCATION; DOUBLE-BLIND; KNEE OSTEOARTHRITIS; MEDICAL-MANAGEMENT; FUNCTIONAL STATUS		RAND Corp, RAND Hlth, Santa Monica, CA 90407 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA	RAND Corporation; University of California System; University of California Los Angeles	MacLean, CH (corresponding author), RAND Corp, RAND Hlth, 1700 Main St,M-23C, Santa Monica, CA 90407 USA.							*AM AC ORTH SURG, 1991, OST HIP CLIN POL; [Anonymous], 1994, NIH Consens Statement, V12, P1; Bautch JC, 1997, ARTHRIT CARE RES, V10, P48, DOI 10.1002/art.1790100108; BECKENBAUGH RD, 1978, J BONE JOINT SURG AM, V60, P306, DOI 10.2106/00004623-197860030-00005; Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095; BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Borjesson M, 1996, Physiother Res Int, V1, P89; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; *CADM J SERV, 1998, 18 AM BOARD FAM PRAC; CALLAGHAN MJ, 1995, CLIN REHABIL, V9, P213, DOI DOI 10.1177/026921559500900306; CALLAHAN CM, 1994, JAMA-J AM MED ASSOC, V271, P1349, DOI 10.1001/jama.271.17.1349; Chamberlain M A, 1982, Int Rehabil Med, V4, P101; COVENTRY MB, 1974, J BONE JOINT SURG AM, VA 56, P273, DOI 10.2106/00004623-197456020-00005; DALTROY LH, 1993, HEALTH EDUC QUART, V20, P3, DOI 10.1177/109019819302000103; Deyle GD, 2000, ANN INTERN MED, V132, P173, DOI 10.7326/0003-4819-132-3-200002010-00002; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FELSON DT, 1990, SEMIN ARTHRITIS RHEU, V20, P42, DOI 10.1016/0049-0172(90)90046-I; FREUND D, 1995, ASSESSING IMPROVING; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GOEPPINGER J, 1989, ARTHRITIS RHEUM, V32, P706, DOI 10.1002/anr.1780320608; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; HIRANO PC, 1994, PATIENT EDUC COUNS, V24, P9, DOI 10.1016/0738-3991(94)90024-8; Hochberg M C, 1996, Arthritis Care Res, V9, P170, DOI 10.1002/1529-0131(199606)9:3<170::AID-ANR1790090304>3.0.CO;2-K; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; Holman HR, 1997, WESTERN J MED, V167, P265; Hughes SL, 1995, ARTHRIT CARE RES, V8, P257, DOI 10.1002/art.1790080409; HUGHES SL, 1991, ARTHRITIS RHEUM-US, V34, P856, DOI 10.1002/art.1780340711; Jan M H, 1991, J Formos Med Assoc, V90, P1008; Katz BP, 1996, HEALTH SERV RES, V31, P125; KAVANAGH BF, 1989, J BONE JOINT SURG AM, V71A, P1496, DOI 10.2106/00004623-198971100-00007; KEEFE FJ, 1990, BEHAV THER, V21, P435, DOI 10.1016/S0005-7894(05)80357-0; KJAERSGAARDANDERSEN P, 1990, PAIN, V43, P309, DOI 10.1016/0304-3959(90)90028-C; KNETTNER KE, 1995, OSTEOARTHRITIC DISOR, pR21; Koch M, 1996, ARCH INTERN MED, V156, P2321, DOI 10.1001/archinte.156.20.2321; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; LABORDE JM, 1989, MULTIPLE LINEAR REGR, V12, P12; Langman MJ, 1999, JAMA-J AM MED ASSOC, V282, P1929, DOI 10.1001/jama.282.20.1929; Lanza FL, 1998, AM J GASTROENTEROL, V93, P2037; LORIG K, 1992, HEALTH EDUC QUART, V19, P355, DOI 10.1177/109019819201900307; LORIG K, 1989, ARTHRITIS RHEUM, V32, P91, DOI 10.1002/anr.1780320116; LORIG K, 1986, J RHEUMATOL, V13, P763; LORIG K, 1989, SOC SCI MED, V29, P221, DOI 10.1016/0277-9536(89)90170-6; LORIG K, 1987, PATIENT EDUC COUNS, V10, P207, DOI 10.1016/0738-3991(87)90126-1; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; LORIG K, 1985, ARTHRITIS RHEUM, V28, P680, DOI 10.1002/art.1780280612; MCCUNE WJ, 1997, TXB RHEUMATOLOGY, P378; MINOR MA, 1989, ARTHRITIS RHEUM, V32, P1396, DOI 10.1002/anr.1780321108; MULLEN PD, 1987, J RHEUMATOL, V14, P33; *OST ARTHR KNEE DE, 1996, CLIN POL AM AC ORTH; Pincus T, 2001, ARTHRITIS RHEUM-US, V44, P1587, DOI 10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X; Schilke JM, 1996, NURS RES, V45, P68, DOI 10.1097/00006199-199603000-00002; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Shmerling RH, 1996, ARTHRITIS RHEUM, V39, P1; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; SuperioCabuslay E, 1996, ARTHRIT CARE RES, V9, P292, DOI 10.1002/1529-0131(199608)9:4<292::AID-ANR1790090414>3.0.CO;2-4; Taal E, 1997, SEMIN ARTHRITIS RHEU, V26, P805, DOI 10.1016/S0049-0172(97)80024-8; Taal E, 1996, ARTHRIT CARE RES, V9, P229, DOI 10.1002/1529-0131(199606)9:3<229::AID-ANR1790090312>3.0.CO;2-U; TOWHEED T, 2001, OSTEOARTHRITIS SYSTE, P2; Towheed TE, 1996, SEMIN ARTHRITIS RHEU, V26, P483, DOI 10.1016/S0049-0172(96)80029-1; Van Baar ME, 1998, J RHEUMATOL, V25, P2432; Van Baar ME, 1999, ARTHRITIS RHEUM-US, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9; VERBRUGGE LM, 1991, J GERONTOL, V46, pS71, DOI 10.1093/geronj/46.2.S71; WATSON MC, 2001, OSTEOARTHRITIS COMP, P2; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; WHITE RH, 1990, J GEN INTERN MED, V5, P304, DOI 10.1007/BF02600396; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904; YELIN EH, 1990, ARTHRITIS RHEUM, V33, P1205; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104; Zicat B, 1993, J Arthroplasty, V8, P395, DOI 10.1016/S0883-5403(06)80038-0	74	49	51	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				711	721		10.7326/0003-4819-135-8_Part_2-200110161-00010	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00010			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601954				2022-12-28	WOS:000171542400010
J	Schnelle, JF; Smith, RL				Schnelle, JF; Smith, RL			Quality indicators for the management of urinary incontinence in vulnerable community-dwelling elders	ANNALS OF INTERNAL MEDICINE			English	Article							INTRINSIC SPHINCTERIC DEFICIENCY; GENUINE STRESS-INCONTINENCE; RANDOMIZED CONTROLLED TRIAL; MUSCLE EXERCISE TREATMENT; DETRUSOR INSTABILITY; OLDER WOMEN; OXYBUTYNIN CHLORIDE; SURGICAL-TREATMENT; FOLLOW-UP; FEMALE		Anna & Harry Borun Ctr Gerontol Res, Reseda, CA 91335 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Los Angeles Jewish Home Aging, Los Angeles, CA USA; Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA; Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda, CA USA	University of California System; University of California Los Angeles; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Schnelle, JF (corresponding author), Anna & Harry Borun Ctr Gerontol Res, 7150 Tampa Ave, Reseda, CA 91335 USA.	lcarmona@ucla.edu						BENT AE, 1983, AM J OBSTET GYNECOL, V145, P218, DOI 10.1016/0002-9378(83)90495-7; Berghmans LCM, 1996, NEUROUROL URODYNAM, V15, P37, DOI 10.1002/(SICI)1520-6777(1996)15:1<37::AID-NAU4>3.0.CO;2-G; Blowman C, 1991, PHYSIOTHERAPY, V77, P661; Brown JS, 2000, J AM GERIATR SOC, V48, P721, DOI 10.1111/j.1532-5415.2000.tb04744.x; Burgio KL, 2000, J AM GERIATR SOC, V48, P370, DOI 10.1111/j.1532-5415.2000.tb04692.x; BURGIO KL, 1986, AM J OBSTET GYNECOL, V154, P58; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; BURNS PA, 1993, J GERONTOL, V48, pM167; Chang PL, 1998, J UROLOGY, V160, P402, DOI 10.1016/S0022-5347(01)62908-2; Cohen SJ, 1999, J GERONTOL A-BIOL, V54, pM34, DOI 10.1093/gerona/54.1.M34; COUILLARD DR, 1994, UROLOGY, V43, P203, DOI 10.1016/0090-4295(94)90045-0; Demarco Eileen, 1994, Journal of Urology, V151, p420A; DIOKNO A, 1995, J UROLOGY, V154, P1727, DOI 10.1016/S0022-5347(01)66768-5; DIOKNO AC, 1988, J UROLOGY, V140, P567, DOI 10.1016/S0022-5347(17)41720-4; Dugan E, 2000, J AM GERIATR SOC, V48, P413, DOI 10.1111/j.1532-5415.2000.tb04699.x; EASTWOOD HDH, 1984, AGE AGEING, V13, P230, DOI 10.1093/ageing/13.4.230; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; Galloway NTM, 1997, AM J MED SCI, V314, P268, DOI 10.1097/00000441-199710000-00011; Haab F, 1997, J UROLOGY, V158, P1738, DOI 10.1016/S0022-5347(01)64114-4; HILTON P, 1981, BRIT MED J, V282, P940, DOI 10.1136/bmj.282.6268.940; HOLMES DM, 1989, BRIT J OBSTET GYNAEC, V96, P607, DOI 10.1111/j.1471-0528.1989.tb03263.x; JENSEN JK, 1994, OBSTET GYNECOL, V83, P904; Johnson TM, 1997, AM J MED SCI, V314, P250, DOI 10.1097/00000441-199710000-00008; JUMA S, 1992, UROLOGY, V39, P424, DOI 10.1016/0090-4295(92)90238-R; Kaplan SA, 1996, UROLOGY, V47, P885, DOI 10.1016/S0090-4295(96)00062-3; Kinn AC, 1995, SCAND J UROL NEPHROL, V29, P449, DOI 10.3109/00365599509180026; Kondo A, 1998, J UROLOGY, V160, P756, DOI 10.1016/S0022-5347(01)62778-2; KOONINGS PP, 1990, UROLOGY, V36, P245, DOI 10.1016/0090-4295(90)80265-O; Leach GE, 1997, J UROLOGY, V158, P875, DOI 10.1016/S0022-5347(01)64346-5; Litwiller SE, 1997, J UROLOGY, V157, P1279, DOI 10.1016/S0022-5347(01)64950-4; Mason RC, 1996, J UROLOGY, V156, P1991, DOI 10.1016/S0022-5347(01)65412-0; MCGUIRE EJ, 1995, UROL CLIN N AM, V22, P657; Miller JM, 1998, J AM GERIATR SOC, V46, P870, DOI 10.1111/j.1532-5415.1998.tb02721.x; Mostwin JL, 1996, J ENDOUROL, V10, P207, DOI 10.1089/end.1996.10.207; NORTON PA, 1994, OBSTET GYNECOL, V84, P770; OUSLANDER J, 1988, J UROLOGY, V140, P1482, DOI 10.1016/S0022-5347(17)42080-5; OUSLANDER J, 1989, J AM GERIATR SOC, V37, P715, DOI 10.1111/j.1532-5415.1989.tb02232.x; OUSLANDER JG, 1986, J AM GERIATR SOC, V34, P507, DOI 10.1111/j.1532-5415.1986.tb04242.x; PANNILL FC, 1988, J AM GERIATR SOC, V36, P902, DOI 10.1111/j.1532-5415.1988.tb05783.x; Pfister S M, 1994, J Community Health Nurs, V11, P155, DOI 10.1207/s15327655jchn1103_4; RESNICK NM, 1987, JAMA-J AM MED ASSOC, V257, P3076, DOI 10.1001/jama.257.22.3076; RESNICK NM, 1995, LANCET, V346, P94, DOI 10.1016/S0140-6736(95)92117-6; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; Resnick NM, 1995, NEUROUROL URODYNAM, V14, P577; SAND PK, 1995, AM J OBSTET GYNECOL, V173, P72, DOI 10.1016/0002-9378(95)90172-8; SAND PK, 1987, OBSTET GYNECOL, V69, P399; SCHNELLE JF, 1990, J AM GERIATR SOC, V38, P356, DOI 10.1111/j.1532-5415.1990.tb03521.x; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Smith JJ, 1996, J UROLOGY, V155, P127, DOI 10.1016/S0022-5347(01)66567-4; SUMMITT RL, 1990, J REPROD MED, V35, P877; Swierzewski Stanley J. Iii, 1994, Journal of Urology, V151, p419A; SWIFT SE, 1996, UROGYNECOLOGY URODYN; SZONYI G, 1995, AGE AGEING, V24, P287, DOI 10.1093/ageing/24.4.287; TAPP AJS, 1990, BRIT J OBSTET GYNAEC, V97, P521, DOI 10.1111/j.1471-0528.1990.tb02523.x; *UR INC AD AC CHRO, 1996, 2 CLIN PRACT GUID UR; WELLS TJ, 1991, J AM GERIATR SOC, V39, P785, DOI 10.1111/j.1532-5415.1991.tb02701.x; WISKIND AK, 1994, OBSTET GYNECOL, V83, P108; Wright EJ, 1998, J UROLOGY, V160, P759, DOI 10.1016/S0022-5347(01)62779-4; Wyman JF, 1998, AM J OBSTET GYNECOL, V179, P999, DOI 10.1016/S0002-9378(98)70206-6; Yamada T, 1998, J UROLOGY, V160, P746, DOI 10.1016/S0022-5347(01)62774-5; ZORZITTO ML, 1989, AGE AGEING, V18, P195, DOI 10.1093/ageing/18.3.195	61	26	26	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				752	758		10.7326/0003-4819-135-8_Part_2-200110161-00015	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00015			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601959				2022-12-28	WOS:000171542400015
J	Warkentin, TE				Warkentin, TE			Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							HEPARIN-INDUCED THROMBOCYTOPENIA; TISSUE FACTOR; FACTOR-VIIA; PROCOAGULANT; THERAPY	Background: The cause of cancer-associated venous limb gangrene is unknown but could paradoxically be due to warfarin. Objective: To determine the pathogenesis of venous gangrene in a patient with cancer. Design: case report. Setting: University hospital in Ontario, Canada. Patient: 66-year-old woman with metastatic lung cancer and deep venous thrombosis. Measurements: Levels of vitamin K-dependent factors, additional coagulation factors, and thrombin-antithrombin complexes (marker of thrombin generation). Results: During warfarin use, venous limb gangrene developed when the international normalized ratio (INR) reached 6.0 (therapeutic range, 2.0 to 3.0); at this time, the level of protein C (a vitamin K-dependent natural anticoagulant) was severely reduced, but thrombin-antithrombin complexes remained markedly elevated. The supratherapeutic INR was explained by the greatly reduced levels of factor VII, which correlated closely with protein C levels; therefore, the high INR was a surrogate marker for severely reduced protein C activity. Conclusion: Warfarin may contribute to the pathogenesis of cancer-associated venous limb gangrene by leading to severe depletion of protein C while at the same time failing to reduce thrombin generation.	McMaster Univ, Hamilton, ON L8S 4L8, Canada; Hamilton Hlth Sci, Hamilton, ON, Canada	McMaster University; McMaster University	Warkentin, TE (corresponding author), Hamilton Gen Hosp, Hamilton Hlth Sci, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.							ADAMSON DJA, 1993, BRIT J CLIN PRACT, V47, P190; BAHADIR I, 1977, SURG GYNECOL OBSTET, V145, P497; BELL WR, 1985, AM J MED, V79, P423, DOI 10.1016/0002-9343(85)90028-2; CINES DB, 1987, NEW ENGL J MED, V316, P581, DOI 10.1056/NEJM198703053161004; Draper NR, 1998, APPL REGRESSION ANAL, P179; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Greinacher A, 2000, BLOOD, V96, P846, DOI 10.1182/blood.V96.3.846.015k09_846_851; Harrison L, 1997, ANN INTERN MED, V126, P133, DOI 10.7326/0003-4819-126-2-199701150-00006; Heinmoller E, 1996, J CANCER RES CLIN, V122, P735, DOI 10.1007/BF01209121; KAKKAR AK, 1995, LANCET, V346, P1004, DOI 10.1016/S0140-6736(95)91690-3; Lind SE, 1997, BLOOD COAGUL FIBRIN, V8, P48, DOI 10.1097/00001721-199701000-00008; Rance A, 1997, LANCET, V350, P1448, DOI 10.1016/S0140-6736(05)64210-9; RAO LVM, 1993, BLOOD, V81, P2600; ROSS JV, 1961, CIRCULATION, V24, P549, DOI 10.1161/01.CIR.24.3.549; STIRLING Y, 1995, BLOOD COAGUL FIBRIN, V6, P361, DOI 10.1097/00001721-199507000-00001; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Warkentin TE, 1999, AM J HEMATOL, V62, P44, DOI 10.1002/(SICI)1096-8652(199909)62:1<44::AID-AJH7>3.0.CO;2-F; Warkentin TE, 2000, J THROMB THROMBOLYS, V10, pS35, DOI 10.1023/A:1027381103184; Warkentin TE, 1999, PLATELETS, V10, P319	19	57	58	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	1				589	593		10.7326/0003-4819-135-8_Part_1-200110160-00009	http://dx.doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481VY	11601930				2022-12-28	WOS:000171542200004
J	Chisholm, SW; Falkowski, PG; Cullen, JJ				Chisholm, SW; Falkowski, PG; Cullen, JJ			Oceans - Dis-crediting ocean fertilization	SCIENCE			English	Editorial Material							PHYTOPLANKTON BLOOM; CARBON-CYCLE; CO2		MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; Rutgers State Univ, Dept Geol, New Brunswick, NJ 08901 USA; Dalhousie Univ, Dept Oceanog, Halifax, NS B3H 4J1, Canada	Massachusetts Institute of Technology (MIT); Rutgers State University New Brunswick; Dalhousie University	Chisholm, SW (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	chisholm@mit.edu	Cuillen, John/AAE-1371-2019; Cullen, John J/B-6105-2008	Cuillen, John/0000-0002-7740-0999; Cullen, John J/0000-0002-7740-0999; Chisholm, Sallie/0000-0003-1480-2445				BERNER RA, 1990, SCIENCE, V249, P1382, DOI 10.1126/science.249.4975.1382; Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; Carson Rachel, 1951, SEA US; CHISHOLM SW, 1991, LIMNOL OCEANOGR, V36, pU1507; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Falkowski P, 2000, SCIENCE, V290, P291, DOI 10.1126/science.290.5490.291; FUHRMAN JA, 1991, LIMNOL OCEANOGR, V36, P1951, DOI 10.4319/lo.1991.36.8.1951; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Jones RR, 1997, ADV ATOM MOL OPT PHY, V38, P1; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; MARTIN JH, 1992, ENVIR SCI R, V43, P123; Ney RA, 2000, ENVIRON SCI TECHNOL, V34, p176A, DOI 10.1021/es003230m; PEARCE F, 2000, NEW SCI         0408, P18; RAWLS R, 2000, CHEM ENG NEWS   0918, P66; SARMIENTO JL, 1991, LIMNOL OCEANOGR, V36, P1928, DOI 10.4319/lo.1991.36.8.1928; Seibel BA, 2001, SCIENCE, V294, P319, DOI 10.1126/science.1065301; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; Smetacek V., 2001, US JGOFS NEWS, V11, P11; 5965117; 5992089; 5535701; 6200530; 20010002983; 5967087; 55433173; 6056919	28	121	124	3	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 12	2001	294	5541					309	310		10.1126/science.1065349	http://dx.doi.org/10.1126/science.1065349			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598285				2022-12-28	WOS:000171601400023
J	Channick, RN; Simonneau, G; Sitbon, O; Robbins, IM; Frost, A; Tapson, VF; Badesch, DB; Roux, S; Rainisio, M; Bodin, F; Rubin, LJ				Channick, RN; Simonneau, G; Sitbon, O; Robbins, IM; Frost, A; Tapson, VF; Badesch, DB; Roux, S; Rainisio, M; Bodin, F; Rubin, LJ			Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study	LANCET			English	Article							CONTINUOUS INTRAVENOUS EPOPROSTENOL; PROSTACYCLIN ANALOG; SYSTEMIC-SCLEROSIS; 6-MINUTE WALK; HEART-FAILURE; SURVIVAL; DISEASE	Background Endothelin 1, a powerful endogenous vasoconstrictor and mitogen, might be a cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual endothelin-receptor antagonist that can be taken orally, in patients with severe pulmonary hypertension. Methods In this double-blind, placebo-controlled study, 32 patients with pulmonary hypertension (primary or associated with scleroderma) were randomly assigned to bosentan (62.5 mg taken twice daily for 4 weeks then 125 mg twice daily) or placebo for a minimum of 12 weeks. The primary endpoint was change in exercise capacity. Secondary endpoints included changes in cardiopulmonary haemodynamics, Borg dyspnoea index, WHO functional class, and withdrawal due to clinical worsening. Analysis was by intention to treat. Findings In patients given bosentan, the distance walked in 6 min improved by 70 m at 12 weeks compared with baseline, whereas it worsened by 6 m in those on placebo (difference 76 m [95% Cl 12-139], p = 0.021). The improvement was maintained for at least 20 weeks. The cardiac index was 1.0 L min(-1) m(-2) (95% Cl 0.6-1.4, p < 0.0001) greater in patients given bosentan than in those given placebo. Pulmonary vascular resistance decreased by 223 dyn s cm(-5) with bosentan, but increased by 191 dyn s cm(-5) with placebo (difference -415 [-608 to -221], p = 0.0002). Patients given bosentan had a reduced Borg dyspnoea index and an improved WHO functional class. All three withdrawals from clinical worsening were in the placebo group (p = 0.033). The number and nature of adverse events did not differ between the two groups. Interpretation Bosentan increases exercise capacity and improves haemodynamics in patients with pulmonary hypertension, suggesting that endothelin has an important role in pulmonary hypertension.	Univ Calif San Diego, Div Pulm & Crit Care Med, La Jolla, CA 92037 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Baylor Coll Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; Hop Antoine Beclere, Clamart, France; Duke Univ, Med Ctr, Durham, NC USA; Actelion Ltd, Allschwil, Switzerland; Stat Res Ltd, Basel, Switzerland	University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Vanderbilt University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Duke University; Actelion Pharmaceuticals Ltd	Channick, RN (corresponding author), Univ Calif San Diego, Div Pulm & Crit Care Med, 9300 Campus Point Dr,7381 7372, La Jolla, CA 92037 USA.		Simonneau, Gerald/ABE-6614-2020; Sitbon, Olivier/I-3623-2019	Sitbon, Olivier/0000-0002-1942-1951; Rainisio, Maurizio/0000-0002-4450-5751				Badesch DB, 2000, ANN INTERN MED, V132, P425, DOI 10.7326/0003-4819-132-6-200003210-00002; BARST RJ, 1986, CHEST, V89, P497, DOI 10.1378/chest.89.4.497; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Cardillo C, 1999, HYPERTENSION, V33, P753, DOI 10.1161/01.HYP.33.2.753; Carratu P, 1997, AM J PHYSIOL-LUNG C, V272, pL1021, DOI 10.1152/ajplung.1997.272.5.L1021; Chen SJ, 1995, J APPL PHYSIOL, V79, P2122, DOI 10.1152/jappl.1995.79.6.2122; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; FILEP JG, 1995, BRIT J PHARMACOL, V115, P227, DOI 10.1111/j.1476-5381.1995.tb15868.x; GALIE N, 1996, EUR J CLIN INVEST S1, V26, P48; Gater PR, 1996, EUR J PHARMACOL, V304, P123, DOI 10.1016/0014-2999(96)00125-2; GIAID A, 1993, J VASC RES, V30, P333, DOI 10.1159/000159015; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Hoeper MM, 2000, NEW ENGL J MED, V342, P1866, DOI 10.1056/NEJM200006223422503; KATWA LC, 1993, CARDIOVASC RES, V27, P2125, DOI 10.1093/cvr/27.12.2125; Krum H, 1999, CIRCULATION, V100, P646; MacLean MR, 1998, PULM PHARMACOL THER, V11, P125, DOI 10.1006/pupt.1998.0126; McCulloch KM, 1996, BRIT J PHARMACOL, V119, P1125, DOI 10.1111/j.1476-5381.1996.tb16013.x; Miyamoto S, 2000, AM J RESP CRIT CARE, V161, P487, DOI 10.1164/ajrccm.161.2.9906015; Mylona P, 1999, EUR J HEART FAIL, V1, P197, DOI 10.1016/S1388-9842(99)00022-7; Okano Y, 1997, LANCET, V349, P1365, DOI 10.1016/S0140-6736(97)24019-5; Park SH, 1997, AM J RESP CRIT CARE, V156, P600, DOI 10.1164/ajrccm.156.2.9607123; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RICH S, 1999, WORLD S PRIM PULM HY; Roux S, 1999, J MOL MED-JMM, V77, P364, DOI 10.1007/s001090050363; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; Saleh D, 1997, AM J RESP CELL MOL, V16, P187, DOI 10.1165/ajrcmb.16.2.9032126; STUPI AM, 1986, ARTHRITIS RHEUM, V29, P515, DOI 10.1002/art.1780290409; Williamson DJ, 2000, CIRCULATION, V102, P411; YAMANE K, 1994, INTERNAL MED, V33, P579, DOI 10.2169/internalmedicine.33.579	31	1147	1222	0	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1119	1123		10.1016/S0140-6736(01)06250-X	http://dx.doi.org/10.1016/S0140-6736(01)06250-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597664				2022-12-28	WOS:000171399000007
J	Epstein, ACR; Gleadle, JM; McNeill, LA; Hewitson, KS; O'Rourke, J; Mole, DR; Mukherji, M; Metzen, E; Wilson, MI; Dhanda, A; Tian, YM; Masson, N; Hamilton, DL; Jaakkola, P; Barstead, R; Hodgkin, J; Maxwell, PH; Pugh, CW; Schofield, CJ; Ratcliffe, PJ				Epstein, ACR; Gleadle, JM; McNeill, LA; Hewitson, KS; O'Rourke, J; Mole, DR; Mukherji, M; Metzen, E; Wilson, MI; Dhanda, A; Tian, YM; Masson, N; Hamilton, DL; Jaakkola, P; Barstead, R; Hodgkin, J; Maxwell, PH; Pugh, CW; Schofield, CJ; Ratcliffe, PJ			C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation	CELL			English	Article							INDUCIBLE FACTOR 1-ALPHA; CAENORHABDITIS-ELEGANS; FACTOR-I; ALPHA; PROTEIN; GENE; UBIQUITINATION; EXPRESSION; MECHANISM; BINDING	HIF is a transcriptional complex that plays a central role in mammalian oxygen homeostasis. Recent studies have defined posttranslational modification by prolyl hydroxylation as a key regulatory event that targets HIF-alpha. subunits for proteasomal destruction via the von Hippel-Lindau ubiquitylation complex. Here, we define a conserved HIF-VHL-prolyl hydroxylase pathway in C. elegans, and use a genetic approach to identify EGL-9 as a dioxygenase that regulates HIF by prolyl hydroxylation. In mammalian cells, we show that the HIF-prolyl hydroxylases are represented by a series of isoforms bearing a conserved 2-histidine-1-carboxylate iron coordination motif at the catalytic site. Direct modulation of recombinant enzyme activity by graded hypoxia, iron chelation, and cobaltous ions mirrors the characteristics of HIF induction in vivo, fulfilling requirements for these enzymes being oxygen sensors that regulate HIF.	Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Dyson Perrins Lab, Oxford OX1 3QY, England; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England	University of Oxford; University of Oxford; Oklahoma Medical Research Foundation; University of Oxford	Ratcliffe, PJ (corresponding author), Henry Wellcome Bldg Genom Med,Roosevelt Dr, Oxford OX3 7BN, England.	peter.ratcliffe@imm.ox.ac.uk	Jaakkola, Panu M/B-4355-2012; Maxwell, Patrick H/C-5557-2008; Knowles, Helen/F-3857-2018; Gleadle, Jonathan M/K-4188-2012	Maxwell, Patrick H/0000-0002-0338-2679; Knowles, Helen/0000-0002-9575-6067; Gleadle, Jonathan M/0000-0002-5215-7208; Ratcliffe, Peter/0000-0002-2853-806X; Mole, David/0000-0002-0984-300X; Jaakkola, Panu/0000-0002-2365-4985; Schofield, Christopher/0000-0002-0290-6565; Pugh, Chris/0000-0002-5170-1662				BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Darby C, 1999, P NATL ACAD SCI USA, V96, P15202, DOI 10.1073/pnas.96.26.15202; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Lloyd MD, 1999, J MOL BIOL, V287, P943, DOI 10.1006/jmbi.1999.2594; Madden SL, 1996, CANCER RES, V56, P5384; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mukherji M, 2001, CHEM COMMUN, P972, DOI 10.1039/b101039p; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; TRENT C, 1983, GENETICS, V104, P619; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wenger RH, 2000, J EXP BIOL, V203, P1253; Woodward ER, 2000, GENOMICS, V65, P253, DOI 10.1006/geno.2000.6144; Wu M, 1999, J AM CHEM SOC, V121, P587, DOI 10.1021/ja981193h; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127; Zhou J, 1998, J AM CHEM SOC, V120, P13539, DOI 10.1021/ja983534x; Zhu H, 2001, SCIENCE, V292, P449, DOI 10.1126/science.1060849	40	2610	2729	3	162	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 5	2001	107	1					43	54		10.1016/S0092-8674(01)00507-4	http://dx.doi.org/10.1016/S0092-8674(01)00507-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595184	Bronze			2022-12-28	WOS:000171453100008
J	Ritz, D; Lim, J; Reynolds, CM; Poole, LB; Beckwith, J				Ritz, D; Lim, J; Reynolds, CM; Poole, LB; Beckwith, J			Conversion of a peroxiredoxin into a disulfide reductase by a triplet repeat expansion	SCIENCE			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; ESCHERICHIA-COLI CYTOPLASM; OXIDATIVE STRESS; SALMONELLA-TYPHIMURIUM; FRAMESHIFT MUTATION; PEROXIDE REDUCTION; PHASE VARIATION; HYDROGEN DONOR; BOND FORMATION; THIOREDOXIN	Pathways for the reduction of protein disulfide bonds are found in all organisms and are required for the reductive recycling of certain enzymes including the essential protein ribonucleotide reductase. An Escherichia coli strain that lacks both thioredoxin reductase and glutathione reductase grows extremely poorly. Here, we show that a mutation occurring at high frequencies in the gene ahpC, encoding a peroxiredoxin, restores normal growth to this strain. This mutation is the result of a reversible expansion of a triplet nucleotide repeat sequence, leading to the addition of one amino acid that converts the AhpC protein from a peroxidase to a disulfide reductase. The ready mutational interconversion between the two activities could provide an evolutionary advantage to E. coli.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Harvard University; Harvard Medical School; Wake Forest University; Wake Forest Baptist Medical Center	Beckwith, J (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.			Poole, Leslie/0000-0003-0334-7328	NIGMS NIH HHS [R01 GM050389, R001 GM55090, R01 GM50389] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055090, R01GM050389] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Bessette PH, 1999, P NATL ACAD SCI USA, V96, P13703, DOI 10.1073/pnas.96.24.13703; Calzi ML, 1997, BIOCHEMISTRY-US, V36, P13357, DOI 10.1021/bi9713660; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Carroll PA, 1997, MOL MICROBIOL, V25, P1099, DOI 10.1046/j.1365-2958.1997.5371901.x; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Harvey SC, 1997, BIOCHEMISTRY-US, V36, P3047, DOI 10.1021/bi962771e; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Park SF, 2000, J BACTERIOL, V182, P207, DOI 10.1128/JB.182.1.207-210.2000; Poole LB, 2000, BIOCHEMISTRY-US, V39, P6602, DOI 10.1021/bi000405w; Poole LB, 2000, FREE RADICAL BIO MED, V28, P108, DOI 10.1016/S0891-5849(99)00218-X; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; REYNOLDS AE, 1981, NATURE, V293, P625, DOI 10.1038/293625a0; Ritz D, 2000, J BIOL CHEM, V275, P2505, DOI 10.1074/jbc.275.4.2505; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; Theiss P, 1997, J BACTERIOL, V179, P4013, DOI 10.1128/jb.179.12.4013-4022.1997; Warren ST, 1996, SCIENCE, V271, P1374, DOI 10.1126/science.271.5254.1374; Wood ZA, 2001, BIOCHEMISTRY-US, V40, P3900, DOI 10.1021/bi002765p	26	98	101	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					158	160		10.1126/science.1063143	http://dx.doi.org/10.1126/science.1063143			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588261				2022-12-28	WOS:000171448800051
J	Warkentin, TE; Kelton, JG				Warkentin, TE; Kelton, JG			Delayed-onset heparin-induced thrombocytopenia and thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							PLATELET-DERIVED MICROPARTICLES; PROCOAGULANT ACTIVITY; COMPLICATIONS; GENERATION; ANTIBODIES; EPITOPE	Background: Heparin-Induced thrombocytopenia is a prothrombotic drug reaction caused by platelet-activating antibodies that recognize complexes of platelet factor 4 and heparin. Objective: To describe a syndrome termed delayed-onset heparin-induced thrombocytopenia, in which thrombocytopenia and thrombotic events begin 5 or more days after withdrawal of heparin. Design: Case series. Setting: Secondary and tertiary care hospitals. Patients: 12 patients who presented with serologically confirmed, delayed-onset heparin-induced thrombocytopenia, including 6 outpatients presenting after hospital discharge. Measurements: The platelet serotonin-release assay was used to measure IgG-Induced heparin-dependent and heparin-independent platelet activation; an enzyme immunoassay that detects IgG against platelet factor 4-heparin complexes was also used. Results: Patients with delayed-onset heparin-induced thrombocytopenia presented with thrombocytopenia and associated thrombosis a mean of 9.2 days (range, 5 to 19 days) after stopping heparin therapy. Nine patients received additional heparin, with further decrease in platelet counts. Compared with controls, patients with delayed-onset heparin-Induced thrombocytopenia had higher titers of IgG antibodies to platelet factor 4-heparin and greater IgG-Induced heparin-dependent and heparin-independent platelet activation. Conclusions: Delayed-onset heparin-induced thrombocytopenia should be suspected when patients present with thrombocytopenia and thrombosis up to 3 weeks after exposure to heparin. This syndrome could be caused by high titers of platelet-activating IgG induced by heparin.	Hamilton Reg Lab, Program Med, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON, Canada	McMaster University	Warkentin, TE (corresponding author), Hamilton Gen Hosp, Hamilton Reg Lab Med Program, Hamilton Hlth Sci, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.							AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95; DEMERS C, 1991, BLOOD, V78, P2194; Greinacher A, 2000, BLOOD, V96, P846, DOI 10.1182/blood.V96.3.846.015k09_846_851; GREINACHER A, 1994, THROMB HAEMOSTASIS, V71, P247; Hirsh J, 1998, CHEST, V114, p489S, DOI 10.1378/chest.114.5_Supplement.489S; Horsewood P, 1996, BRIT J HAEMATOL, V95, P161, DOI 10.1046/j.1365-2141.1996.d01-1876.x; Hughes M, 2000, BLOOD, V96, P188, DOI 10.1182/blood.V96.1.188.013k12_188_194; MOHIUDDIN SM, 1992, AM HEART J, V123, P729, DOI 10.1016/0002-8703(92)90513-U; VISENTIN GP, 1994, J CLIN INVEST, V93, P81, DOI 10.1172/JCI116987; Warkentin TE, 2000, BLOOD, V96, P1703, DOI 10.1182/blood.V96.5.1703.h8001703_1703_1708; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; WARKENTIN TE, 1994, BLOOD, V84, P3691, DOI 10.1182/blood.V84.11.3691.bloodjournal84113691; WARKENTIN TE, 1992, J LAB CLIN MED, V120, P371; Warkentin TE, 1997, ANN INTERN MED, V127, P804, DOI 10.7326/0003-4819-127-9-199711010-00005; Warkentin TE, 1998, SEMIN HEMATOL, V35, P17; Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1; Warkentin TE, 1999, PLATELETS, V10, P319; WARKENTIN TE, 2001, HEPARIN INDUCED THRO, P43; ZALCBERG JR, 1983, BRIT J HAEMATOL, V54, P655, DOI 10.1111/j.1365-2141.1983.tb02146.x; Ziporen L, 1998, BLOOD, V92, P3250, DOI 10.1182/blood.V92.9.3250.421k23_3250_3259	20	306	315	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					502	506		10.7326/0003-4819-135-7-200110020-00009	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	477EF	11578153				2022-12-28	WOS:000171269600004
J	Cookson, R; McDaid, D; Maynard, A				Cookson, R; McDaid, D; Maynard, A			Wrong SIGN, NICE mess: is national guidance distorting allocation of resources?	BRITISH MEDICAL JOURNAL			English	Article									Univ York, Dept Hlth Studies, York Hlth Policy Grp, York YO10 5DQ, N Yorkshire, England; Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London WC2A 2AE, England; Univ E Anglia, Sch Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England	University of York - UK; University of London; London School Economics & Political Science; University of East Anglia	Maynard, A (corresponding author), Univ York, Dept Hlth Studies, York Hlth Policy Grp, York YO10 5DQ, N Yorkshire, England.		McDaid, David/E-5959-2014	McDaid, David/0000-0003-0744-2664				Jefferson T, 2000, ELEMENTARY EC EVALUA; KNIETOWICZ Z, 2001, BRIT MED J, V322, P382; *NAT I CLIN EXC, 2001, CLIN GUID D IND LAB; *NAT I CLIN EXC, 2001, FRAM DOC; *NAT I CLIN EXC, 2001, NICE COMM FURTH RES; *NAT I CLIN EXC, 2001, GUID US TAX BREAST C; *NAT I CLIN EXC, 2001, CORP PLAN 2000 2003; National Institute for Clinical Excellence, 2001, TECHN GUID MAN SPONS; *NIH EX, 1999, FAST ACC MOD TREATM; Rawlins MD, 2001, BRIT MED J, V322, P489, DOI 10.1136/bmj.322.7284.489; *SCOTT EX, 2001, SCOTT HLTH TECHN ASS; *SCOTT INT GUID NE, 2001, ANT PROPH SURG NAT C; *SCOTT INT GUID NE, 2001, INTRO SIGN; Scottish Intercollegiate Guidelines Network, 2001, SIGN 50 GUID DEV HDB; Smith R, 2000, BRIT MED J, V321, P1363, DOI 10.1136/bmj.321.7273.1363; SCRIP 2000      1215, P4	16	68	69	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					743	745		10.1136/bmj.323.7315.743	http://dx.doi.org/10.1136/bmj.323.7315.743			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HJ	11576985	Green Accepted, Green Published			2022-12-28	WOS:000171340700025
J	Beaufort, L; de Garidel-Thoron, T; Mix, AC; Pisias, NG				Beaufort, L; de Garidel-Thoron, T; Mix, AC; Pisias, NG			ENSO-like forcing on oceanic primary production during the Late Pleistocene	SCIENCE			English	Article							INDIAN-OCEAN; EQUATORIAL PACIFIC; TROPICAL CLIMATE; VARIABILITY; DYNAMICS; ATLANTIC; MONSOON; AGE	Late Pleistocene changes in oceanic primary productivity along the equator in the Indian and Pacific oceans are revealed by quantitative changes in nanoplankton communities preserved in nine deep-sea cores. We show that variations in equatorial productivity are primarily caused by glacial-interglacial variability and by precession-controlled changes in the east-west thermodine slope of the Indo-Pacific. The precession-controlled variations in productivity are linked to processes similar to the Southern Oscillation phenomenon, and they precede changes in the oxygen isotopic ratio, which indicates that they are not the result of ice sheet fluctuations. The 30,000-year spectral peak in the tropical Indo-Pacific Ocean productivity records is also present in the Antarctica atmospheric CO2 record, suggesting an important rote for equatorial biological productivity in modifying atmospheric CO2.	CNRS, CEREGE, F-13545 Aix En Provence 04, France; Oregon State Univ, Coll Oceanog & Atmospher Sci, Corvallis, OR 97331 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Oregon State University	Beaufort, L (corresponding author), CNRS, CEREGE, BP 80, F-13545 Aix En Provence 04, France.		Beaufort, Luc/ABG-2289-2021; de Garidel-Thoron, Thibault/B-1204-2008; Beaufort, Luc/AAH-5305-2021	Beaufort, Luc/0000-0001-6055-9373; de Garidel-Thoron, Thibault/0000-0001-8983-9571; 				Bard E, 1997, NATURE, V385, P707, DOI 10.1038/385707a0; BASSINOT FC, 1994, EARTH PLANET SC LETT, V126, P91, DOI 10.1016/0012-821X(94)90244-5; Beaufort L, 1997, SCIENCE, V278, P1451, DOI 10.1126/science.278.5342.1451; Charles CD, 1997, SCIENCE, V277, P925, DOI 10.1126/science.277.5328.925; CLEMENS S, 1991, NATURE, V353, P720, DOI 10.1038/353720a0; Clement AC, 1999, PALEOCEANOGRAPHY, V14, P441, DOI 10.1029/1999PA900013; Cole JE, 2000, SCIENCE, V287, P617, DOI 10.1126/science.287.5453.617; Dollfus D, 1999, NEURAL NETWORKS, V12, P553, DOI 10.1016/S0893-6080(99)00011-8; EDWARDS RL, 1987, SCIENCE, V236, P1547, DOI 10.1126/science.236.4808.1547; Fedorov AV, 2000, SCIENCE, V288, P1997, DOI 10.1126/science.288.5473.1997; Flenley JR, 1998, CLIMATIC CHANGE, V39, P177, DOI 10.1023/A:1005367822750; GALLUP CD, 1994, SCIENCE, V263, P796, DOI 10.1126/science.263.5148.796; Harris SE, 1999, QUATERNARY RES, V51, P14, DOI 10.1006/qres.1998.2008; Henderson GM, 2000, NATURE, V404, P61, DOI 10.1038/35003541; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; LEWIS MR, 1986, SCIENCE, V234, P870, DOI 10.1126/science.234.4778.870; MEEHL GA, 1993, J CLIMATE, V6, P31, DOI 10.1175/1520-0442(1993)006<0031:ACASBM>2.0.CO;2; Mix AC, 1999, PALEOCEANOGRAPHY, V14, P350, DOI 10.1029/1999PA900012; Mix AC, 1986, PALEOCEANOGRAPHY, V1, P43, DOI 10.1029/PA001i001p00043; MOLFINO B, 1990, SCIENCE, V249, P766, DOI 10.1126/science.249.4970.766; OKADA H, 1973, DEEP-SEA RES, V20, P355, DOI 10.1016/0011-7471(73)90059-4; Paillard D., 1996, EOS T AM GEOPHYS UN, V77, P379, DOI 10.1029/96EO00259; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Pisias NG, 1997, PALEOCEANOGRAPHY, V12, P381, DOI 10.1029/97PA00583; POKRAS EM, 1987, NATURE, V326, P486, DOI 10.1038/326486a0; PRELL WL, 1984, MILANKOVITCH CLIMATE, V1, P349; Reichart GJ, 1998, PALEOCEANOGRAPHY, V13, P607, DOI 10.1029/98PA02203; Rich JJ, 1999, GLOBAL BIOGEOCHEM CY, V13, P531, DOI 10.1029/1998GB900023; Saji NH, 1999, NATURE, V401, P360, DOI 10.1038/43854; Tudhope AW, 2001, SCIENCE, V291, P1511, DOI 10.1126/science.1057969; Turk D, 2001, SCIENCE, V293, P471, DOI 10.1126/science.1056449; Villanueva J, 1998, PALEOCEANOGRAPHY, V13, P561, DOI 10.1029/98PA02318; Webster PJ, 1999, NATURE, V401, P356, DOI 10.1038/43848; [No title captured]	34	228	269	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2440	2444		10.1126/science.293.5539.2440	http://dx.doi.org/10.1126/science.293.5539.2440			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577233				2022-12-28	WOS:000171237200043
J	Pullum, GK; Scholz, BC				Pullum, GK; Scholz, BC			More than words	NATURE			English	Article									Univ Calif Santa Cruz, Dept Linguist, Santa Cruz, CA 95064 USA; San Jose State Univ, Dept Philosophy, San Jose, CA 95192 USA	University of California System; University of California Santa Cruz; California State University System; San Jose State University	Pullum, GK (corresponding author), Univ Calif Santa Cruz, Dept Linguist, Santa Cruz, CA 95064 USA.							KARMILOFF K, 2001, PATHWAYS LANGUAGE; Pullum G. K., 2001, Logical Aspects of Computational Linguistics. 4th International Conference, LACL 2001. Proceedings (Lecture Notes in Computer Science Vol.2099), P17; Wallman J, 1992, APING LANGUAGE	3	6	6	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					367	367		10.1038/35096656	http://dx.doi.org/10.1038/35096656			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574865	Bronze			2022-12-28	WOS:000171188700033
J	Zhang, PC; Keleshian, AM; Sachs, F				Zhang, PC; Keleshian, AM; Sachs, F			Voltage-induced membrane movement	NATURE			English	Article							OUTER HAIR CELL; ATOMIC-FORCE MICROSCOPY; LIPID BILAYER; ION CHANNELS; SALICYLATE; MOTILITY; MODEL; ELECTROMOTILITY; CAPACITANCE; POTENTIALS	Thermodynamics predicts that transmembrane voltage modulates membrane tension(1) and that this will cause movement. The magnitude and polarity of movement is governed by cell stiffness and surface potentials. Here we confirm these predictions using the atomic force microscope to dynamically follow the movement of voltage-clamped HEK293 cells(2) in different ionic-strength solutions. In normal saline, depolarization caused an outward movement, and at low ionic strength an inward movement. The amplitude was proportional to voltage (about 1 nm per 100 mV) and increased with indentation depth. A simple physical model of the membrane and tip provided an estimate of the external and internal surface charge densities (-5 x10(-3) C m(-2) and -18x10(-3) C m(-2), respectively). Salicylate (a negative amphiphile(3)) inhibited electromotility by increasing the external charge density by -15x10(-3) C m(-2). As salicylate blocks electromotility in cochlear outer hair cells at the same concentration(4,5), the role of prestin as a motor protein(6) may need to be reassessed.	SUNY Buffalo, HHMI Ctr Single Mol Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Sachs, F (corresponding author), SUNY Buffalo, HHMI Ctr Single Mol Biophys, Buffalo, NY 14214 USA.		Zhang, Ping-Cheng/G-7862-2011					Akinlaja J, 1998, BIOPHYS J, V75, P247, DOI 10.1016/S0006-3495(98)77511-3; Bockris J. O. M., 1973, MODERN ELECTROCHEMIS, V2; CARNIE S, 1983, BIOPHYS J, V44, P325, DOI 10.1016/S0006-3495(83)84306-9; Carslaw H.S., 1986, CONDUCTION HEAT SOLI; Chou T, 1997, BIOPHYS J, V72, P2042, DOI 10.1016/S0006-3495(97)78848-9; GUTKNECHT J, 1973, SCIENCE, V182, P1258, DOI 10.1126/science.182.4118.1258; Hille B., 1992, IONIC CHANNELS EXCIT; Hwang WC, 1997, BIOPHYS J, V72, P2669, DOI 10.1016/S0006-3495(97)78910-0; IWASA K, 1980, SCIENCE, V210, P338, DOI 10.1126/science.7423196; Iwasa KH, 1997, BIOPHYS J, V73, P546, DOI 10.1016/S0006-3495(97)78092-5; Kakehata S, 1996, J NEUROSCI, V16, P4881; KRAAYENHOF R, 1993, BIOCHEMISTRY-US, V32, P10057, DOI 10.1021/bi00089a022; Lue AJC, 1999, HEARING RES, V135, P163, DOI 10.1016/S0378-5955(99)00102-1; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; MARKIN VS, 1991, BIOPHYS J, V60, P1120, DOI 10.1016/S0006-3495(91)82147-6; MCLAUGHLIN S, 1973, NATURE, V203, P234; Mosbacher J, 1998, J GEN PHYSIOL, V111, P65, DOI 10.1085/jgp.111.1.65; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; PETROV AG, 1993, EUR BIOPHYS J BIOPHY, V22, P289, DOI 10.1007/BF00180263; Raphael RM, 2000, BIOPHYS J, V78, P2844, DOI 10.1016/S0006-3495(00)76827-5; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; SHEHATA WE, 1991, ACTA OTO-LARYNGOL, V111, P707, DOI 10.3109/00016489109138403; SHIH CW, 1992, J MATER RES, V7, P1011, DOI 10.1557/JMR.1992.1011; SINGH AK, 1992, BIOCHIM BIOPHYS ACTA, V1120, P337, DOI 10.1016/0167-4838(92)90257-E; TODOROV AT, 1994, LANGMUIR, V10, P2344, DOI 10.1021/la00019a053; WINISKI AP, 1986, BIOCHEMISTRY-US, V25, P8206, DOI 10.1021/bi00373a013; Wu HW, 1998, SCANNING, V20, P389; Wu M, 1998, J MEMBRANE BIOL, V166, P111, DOI 10.1007/s002329900453; Yamaguchi T, 1997, COLLOID SURFACE B, V9, P275, DOI 10.1016/S0927-7765(97)00033-7; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	30	172	177	3	48	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					428	432		10.1038/35096578	http://dx.doi.org/10.1038/35096578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574890				2022-12-28	WOS:000171188700056
J	Gingerich, PD; ul Haq, M; Zalmout, IS; Khan, IH; Malkani, MS				Gingerich, PD; ul Haq, M; Zalmout, IS; Khan, IH; Malkani, MS			Origin of whales from early artiodactyls: Hands and feet of eocene Protocetidae from Pakistan	SCIENCE			English	Article							PHYLOGENETIC-RELATIONSHIPS; EARLIEST CETACEANS; MOLECULAR EVIDENCE; PRINCIPLES; DIACODEXIS; INCLUSION; RELATIVES; EVOLUTION	Partial skeletons of two new fossil whales, Artiocetus clavis and Rodhocetus balochistanensis, are among the oldest known protocetid archaeocetes. These came from early Lutetian age (47 million years ago) strata in eastern Balochistan Province, Pakistan. Both have an astragalus and cuboid in the ankle with characteristics diagnostic of artiodactyls; R. balochistanensis has virtually complete fore- and hind limbs. The new skeletons are important in augmenting the diversity of early Protocetidae, clarifying that Cetacea evolved from early Artiodactyla rather than Mesonychia and showing how early protocetids swam.	Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Museum Paleontol, Ann Arbor, MI 48109 USA; Geol Survey Pakistan, Quetta, Pakistan; Univ New Hampshire, Dept Earth Sci, Durham, NH 03824 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System Of New Hampshire; University of New Hampshire	Gingerich, PD (corresponding author), Univ Michigan, Dept Geol Sci, 1006 CC Little Bldg, Ann Arbor, MI 48109 USA.	girigeric@umich.edu	Gingerich, Philip D/A-6903-2008	Gingerich, Philip D/0000-0002-1550-2674				Arnason U, 2000, J MOL EVOL, V50, P569, DOI 10.1007/s002390010060; Bajpai S, 1998, P NATL ACAD SCI USA, V95, P15464, DOI 10.1073/pnas.95.26.15464; Berggren W. A., 1995, GEOCHRONOLOGY TIME S, P129, DOI DOI 10.2110/PEC.95.04.0129; BOYDEN ALAN, 1950, ZOOL [NEW YORK], V35, P145; Colbert E.H., 1935, AM MUS NOVIT, V799, P1; FORDYCE RE, 1994, ANNU REV EARTH PL SC, V22, P419, DOI 10.1146/annurev.ea.22.050194.002223; Gatesy J, 1996, MOL BIOL EVOL, V13, P954, DOI 10.1093/oxfordjournals.molbev.a025663; Gatesy J, 1999, SYST BIOL, V48, P6, DOI 10.1080/106351599260409; GINGERICH PD, 1990, SCIENCE, V249, P154, DOI 10.1126/science.249.4965.154; Gingerich PD, 1998, ADV VERT PALEOBIOL, P423; GINGERICH PD, 1983, SCIENCE, V220, P403, DOI 10.1126/science.220.4595.403; GINGERICH PD, 1994, NATURE, V368, P844, DOI 10.1038/368844a0; Gingerich Philip D., 1995, Contributions from the Museum of Paleontology University of Michigan, V29, P291; GRAUR D, 1994, MOL BIOL EVOL, V11, P357; Hardenbol J., 1998, SEPM SPEC PUBL, V60, P3, DOI DOI 10.2110/PEC.98.02.0003; Irwin David M., 1994, Journal of Mammalian Evolution, V2, P37, DOI 10.1007/BF01464349; Kleineidam RG, 1999, J MOL EVOL, V48, P360, DOI 10.1007/PL00006480; Kowalevsky W., 1873, PHILOS T ROY SOC LON, V163, P19; Liu FGR, 1999, SYST BIOL, V48, P54, DOI 10.1080/106351599260436; Luckett W. Patrick, 1998, Journal of Mammalian Evolution, V5, P127, DOI 10.1023/A:1020501622015; Lum JK, 2000, MOL BIOL EVOL, V17, P1417, DOI 10.1093/oxfordjournals.molbev.a026242; Luo Z., 1999, U MICHIGAN PAPERS PA, V31, P1; MCKENNA MC, 1997, CLASSIFICATION MAMMA, P366; Montgelard C, 1997, MOL BIOL EVOL, V14, P550, DOI 10.1093/oxfordjournals.molbev.a025792; Naylor GJP, 2001, SYST BIOL, V50, P444, DOI 10.1080/106351501300318030; Nikaido M, 1999, P NATL ACAD SCI USA, V96, P10261, DOI 10.1073/pnas.96.18.10261; O'Leary MA, 1999, SYST BIOL, V48, P455, DOI 10.1080/106351599260102; ROSE KD, 1982, SCIENCE, V216, P621, DOI 10.1126/science.216.4546.621; Rose KD, 1996, P NATL ACAD SCI USA, V93, P1705, DOI 10.1073/pnas.93.4.1705; SARICH VM, 1993, MAMMAL PHYLOGENY : PLACENTALS, P103; Schaeffer Bobb, 1947, AMER MUS NOVITATES, V1356, P1; Scott W. B., 1940, Transactions of the American Philosophical Society Philadelphia, V28, P363, DOI 10.2307/1005504; SCOTT WB, 1894, J ACAD NAT SCI-PHILA, V9, P461; Shimamura M, 1997, NATURE, V388, P666, DOI 10.1038/41759; SIMPSON GG, 1945, B AM MUS NAT HIST, V85, P1; SZALAY FS, 1969, EVOLUTION, V23, P703, DOI 10.1111/j.1558-5646.1969.tb03552.x; Thewissen J.G.M., 1996, Courier Forschungsinstitut Senckenberg, V191, P1; Thewissen J. G. M., 1994, Journal of Mammalian Evolution, V2, P157, DOI 10.1007/BF01473527; Thewissen JGM, 1997, PALEOBIOLOGY, V23, P482, DOI 10.1017/S0094837300019850; THEWISSEN JGM, 1994, SCIENCE, V263, P210, DOI 10.1126/science.263.5144.210; THEWISSEN JGM, 1990, ANAT HISTOL EMBRYOL, V19, P37, DOI 10.1111/j.1439-0264.1990.tb00876.x; Thewissen JGM, 1998, NATURE, V395, P452, DOI 10.1038/26656; Thewissen JGM, 1999, SYST BIOL, V48, P21, DOI 10.1080/106351599260418; Ursing BM, 1998, P ROY SOC B-BIOL SCI, V265, P2251, DOI 10.1098/rspb.1998.0567; VAN VALEN LEIGH, 1966, BULL AMER MUS NATUR HIST, V132, P1; WEBB PW, 1988, AM ZOOL, V28, P709	46	229	247	5	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2239	2242		10.1126/science.1063902	http://dx.doi.org/10.1126/science.1063902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567134				2022-12-28	WOS:000171139400039
J	Griffiths, EK; Krawczyk, C; Kong, YY; Raab, M; Hyduk, SJ; Bouchard, D; Chan, VS; Kozieradzki, I; Oliveira-Dos-Santos, AJ; Wakeham, A; Ohashi, PS; Cybulsky, MI; Rudd, CE; Penninger, JM				Griffiths, EK; Krawczyk, C; Kong, YY; Raab, M; Hyduk, SJ; Bouchard, D; Chan, VS; Kozieradzki, I; Oliveira-Dos-Santos, AJ; Wakeham, A; Ohashi, PS; Cybulsky, MI; Rudd, CE; Penninger, JM			Positive regulation of T cell activation and integrin adhesion by the adapter Fyb/Slap	SCIENCE			English	Article							INTERLEUKIN-2 PRODUCTION; ENA/VASP PROTEINS; TYROSINE KINASES; IMMUNE-SYSTEM; DRIVING-FORCE; RECEPTOR; SLP-76; FYN; SLAP-130; CLONING	The molecular adapter Fyb/Slap regulates signaling downstream of the T cell receptor (TCR), but whether it plays a positive or negative role is controversial. We demonstrate that Fyb/Slap-deficient T cells exhibit defective proliferation and cytokine production in response to TCR stimulation. Fyb/Slap is also required in vivo for T cell-dependent immune responses. Functionally, Fyb/Slap has no apparent role in the activation of known TCR signaling pathways, F-actin polymerization, or TCR clustering. Rather, Fyb/Slap regulates TCR-induced integrin clustering and adhesion. Thus, Fyb/Slap is the first molecular adapter to be identified that couples TCR stimulation to the avidity modulation of integrins governing T cell adhesion.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada; Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Toronto, Toronto Gen Hosp, Res Inst, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Penninger, JM (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Rudd, Christopher E/ABF-7259-2021; Cybulsky, Myron I./AAD-6539-2019; Penninger, Josef M/I-6860-2013; Rudd, Christopher E/GOH-2021-2022; Chan, Vera Sau Fong/B-3419-2011	Penninger, Josef M/0000-0002-8194-3777; Rudd, Christopher E/0000-0001-5295-9019; Hyduk, Sharon J./0000-0003-2862-0300; Cybulsky, Myron/0000-0002-1696-2867; Ohashi, Pamela S./0000-0003-2915-9317				Bachmann MF, 1999, J IMMUNOL, V163, P137; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Boerth NJ, 2000, J BIOL CHEM, V275, P5143, DOI 10.1074/jbc.275.7.5143; Chan JR, 2000, J IMMUNOL, V164, P746, DOI 10.4049/jimmunol.164.2.746; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; GENG L, IN PRESS P NATL ACAD; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Machesky LM, 2000, CELL, V101, P685, DOI 10.1016/S0092-8674(00)80879-X; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Raab M, 1999, J BIOL CHEM, V274, P21170, DOI 10.1074/jbc.274.30.21170; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; VAN SG, 1990, J IMMUNOL, V144, P4579; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Veale M, 1999, J BIOL CHEM, V274, P28427, DOI 10.1074/jbc.274.40.28427; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413	26	240	246	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2260	2263		10.1126/science.1063397	http://dx.doi.org/10.1126/science.1063397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567140				2022-12-28	WOS:000171139400045
J	Charon, R				Charon, R			Narrative medicine - A model for empathy, reflection, profession, and trust	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN; CARE	The effective practice of medicine requires narrative competence, that is, the ability to acknowledge, absorb, interpret, and act on the stories and plights of others. Medicine practiced with narrative competence, called narrative medicine, is proposed as a model for humane and effective medical practice. Adopting methods such as close reading of literature and reflective writing allows narrative medicine to examine and illuminate 4 of medicine's central narrative situations: physician and patient, physician and self, physician and colleagues, and physicians and society. With narrative competence, physicians can reach and join their patients in illness, recognize their own personal journeys through medicine, acknowledge kinship with and duties toward other health care professionals, and inaugurate consequential discourse with the public about health care. By bridging the divides that separate physicians from patients, themselves, colleagues, and society, narrative medicine offers fresh opportunities for respectful, empathic, and nourishing medical care.	Columbia Univ, Coll Phys & Surg, Div Gen Med, New York, NY 10032 USA	Columbia University	Charon, R (corresponding author), Columbia Univ, Coll Phys & Surg, Div Gen Med, PH 9-E,Room 105,630 W 168th St, New York, NY 10032 USA.	rac5@columbia.edu						AMTES S, 1994, GOOD DOCTOR; ANDERS G, 1996, HLTH WELATH HMOS BRE; Anderson C. M., 2000, WRITING HEALING INFO; Anderson CM, 1998, LIT MED, V17, P280, DOI 10.1353/lm.1998.0013; Anderson SJ, 2000, ZOO BIOL, V19, P1, DOI 10.1002/(SICI)1098-2361(2000)19:1&lt;1::AID-ZOO1&gt;3.0.CO;2-F; [Anonymous], 1983, RHETORIC FICTION; Balint M., 1957, DOCTOR; Barthes Roland, 1974, SZ ESSAY; Bauby J.-D, 1998, DIVING BELL BUTTERFL; Berger John, 1967, 7 UOMO; Bolton Gillie., 1999, THERAPEUTIC POTENTIA; BOSK C, 1979, FORGIVE REMEMBER  MA; BRANCH W, 1993, NEW ENGL J MED, V329, P1130, DOI 10.1056/NEJM199310073291518; Brody H., 1987, STORIES SICKNESS; Brooks Peter, 1985, READING PLOT DESIGN; Bruner JS, 1986, ACTUAL MINDS POSSIBL, DOI DOI 10.4159/9780674029019; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CHAMBARS T, 1999, FICTION BIOETHICS CA; CHARON R, 1986, LIT MED, V5, P58; Charon R, 2000, AM J MED SCI, V319, P285, DOI 10.1097/00000441-200005000-00004; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; Charon R, 2000, ACAD MED, V75, P23, DOI 10.1097/00001888-200001000-00008; Charon R, 2000, ANN INTERN MED, V132, P63, DOI 10.7326/0003-4819-132-1-200001040-00011; Charon R, 2001, ANN INTERN MED, V134, P83, DOI 10.7326/0003-4819-134-1-200101020-00024; Charon R., 1993, EMPATHY PRACTICE MED, P147; Charon R., 1993, J NARRAT LIFE HIST, V3, P79, DOI [https://doi.org/10.1075/jnlh.3.1.03med, DOI 10.1075/JNLH.3.1.03MED]; CHARON R, IN PRESS PRACTICE NA; COHEN JJ, 1995, ACAD MED, V70, P755, DOI 10.1097/00001888-199509000-00009; Coles R, 1989, CALL STORIES TEACHIN; Connelly J, 1999, ACAD MED, V74, P420, DOI 10.1097/00001888-199904000-00039; Cruess RL, 1997, ACAD MED, V72, P941, DOI 10.1097/00001888-199711000-00009; Desalvo Louise, 1999, WRITING WAY HEALING; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Feinstein AR., 1967, CLIN JUDGMENT; Feldman DS, 1998, ARCH INTERN MED, V158, P1626, DOI 10.1001/archinte.158.15.1626; GENETTE G, 1980, NARRATIVE SISCOURSE; GROOPMAN J, 1998, MEASURE OUR DAYS SPI; Halpern J, 2001, DETACHED CONCERN EMP; Harden J, 2000, J ADV NURS, V31, P506, DOI 10.1046/j.1365-2648.2000.01303.x; Hawkins A., 1999, RECONSTRUCTING ILLNE, V2nd; HAWKINS AH, 2000, TEACHING LIT MED; Hazard G.C., 1996, CONFLICTS INTEREST C, P85; Heliker D, 1999, Issues Ment Health Nurs, V20, P513, DOI 10.1080/016128499248330; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; Hurwitz B, 2000, LANCET, V356, P2086, DOI 10.1016/S0140-6736(00)03412-7; Iser Wolfgang, 1978, ACT READING THEORY A; James H., 1934, REV ART NOVEL, P84; JAMES H, 1866, NOVELS G ELLIOT; Jones AH, 1997, LANCET, V349, P1243, DOI 10.1016/S0140-6736(97)03395-3; Kermode Frank., 1983, ART TELLING ESSAYS F; Kleinman A., 1988, ILLNESS NARRATIVES; Konner M., 1993, MED CROSSROADS CRISI; KREISWIRTH M, 1992, NEW LITERARY HIST, V23, P629, DOI 10.2307/469223; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LEWIS RWB, 1955, AM ADAM INNOCENCE TR, P3; Lief H. I., 1963, PSYCHOL BASIS MED PR, P12; Lipkin MJ, 1995, MED INTERVIEW CLIN C; Ludmerer K., 1999, TIME HEAL AM MED ED; Mairs Nancy, 1996, WAIST HIGH WORLD LIF; Martin Wallace, 1986, RECENT THEORIES NARR; Miller SZ, 1999, ACAD MED, V74, P800, DOI 10.1097/00001888-199907000-00014; MISHLER E. G., 1986, RES INTERVIEWING CON; Montgomery Hunter Kathryn, 1993, DOCTORS STORIES NARR; Morreim E. Haavi, 1995, BALANCING ACT NEW ME; MORRIUS DM, 1998, ILLNESS CULTURE POST; Nelson Hilde Lindemann, 1997, STORIES THEIR LIMITS; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; PAULOS JA, 1998, ONCE UPON NUMBER HID; Pennebaker JW, 2000, LIT MED, V19, P3, DOI 10.1353/lm.2000.0011; Polkinghome D.E., 1988, NARRATIVE KNOWING HU; REENHALGH T, 1998, NARRATIVE BASED MED; Reifler DR, 1996, LIT MED, V15, P183, DOI 10.1353/lm.1996.0024; REYNOLDS PP, 1994, ANN INTERN MED, V120, P609, DOI 10.7326/0003-4819-120-7-199404010-00013; Risdon C, 1999, ACAD MED, V74, P896, DOI 10.1097/00001888-199908000-00013; Rodwin M. A., 1993, MED MONEY MORALS PHY; Rothman DJ, 2000, NEW ENGL J MED, V342, P1284, DOI 10.1056/NEJM200004273421711; Sacks O., 1985, MAN WHO MISTOOK HIS; SELZER R, 1982, COMMUNICATION; Skelton JR, 2000, LANCET, V356, P2001, DOI 10.1016/S0140-6736(00)03318-3; SMITH BH, 1981, NARRATIVE, P228; Smyth JM, 1999, JAMA-J AM MED ASSOC, V281, P1304, DOI 10.1001/jama.281.14.1304; Spiro HM, 1993, EMPATHY PRACTICE MED; Stolorow R., 1987, PSYCHOANALYTIC TREAT, DOI [10.4324/9781315803487, DOI 10.4324/9781315803487]; Swenson MM, 2000, J NURS EDUC, V39, P109; Tompkins Jane P., 1980, READER RESPONSE CRIT; Toombs SK, 1993, MEANING ILLNESS PHEN; TOULMIN S, 1983, POLITICS INTERPRETAT, P99; Verghese Abraham, 1994, MY OWN COUNTRY DOCTO; Weine SM, 1996, LIT MED, V15, P167, DOI 10.1353/lm.1996.0029; WILLIAMS WC, 1985, DOCTOR STORIES; WINCKLER M, 2000, CASE SACHS; WINKLER MG, 1995, ACAD MED, V70, P822, DOI 10.1097/00001888-199509000-00019; Wynia MK, 1999, NEW ENGL J MED, V341, P1612, DOI 10.1056/NEJM199911183412112; ZABERANKO RN, 1978, DOCTOR TREE DEV STAG	94	1004	1068	18	200	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2001	286	15					1897	1902		10.1001/jama.286.15.1897	http://dx.doi.org/10.1001/jama.286.15.1897			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	482UH	11597295				2022-12-28	WOS:000171595300034
J	Ramsey, SD; Clarke, L; Etzioni, R; Higashi, M; Berry, K; Urban, N				Ramsey, SD; Clarke, L; Etzioni, R; Higashi, M; Berry, K; Urban, N			Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer	ANNALS OF INTERNAL MEDICINE			English	Article							INSTITUTE WORKSHOP; FAMILIES; COLON; PREDISPOSITION; RISK; SUSCEPTIBILITY; SURVEILLANCE; COLONOSCOPY; MANAGEMENT; CARCINOMA	Background: The National Cancer Institute has published consensus guidelines for universal screening for hereditary nonpolyposis colorectal cancer (HNPCC) in patients with newly diagnosed colorectal cancer. Objective: To determine the cost-effectiveness of screening compared with standard care in eligible patients with colorectal cancer and their siblings and children. Design: Cost-effectiveness analysis. Data Sources: National colorectal cancer registry data, the Creighton International Hereditary Colorectal Cancer Registry, Medicare claims records, and published literature. Target Population: Patients with newly diagnosed colorectal cancer and their siblings and children. Time Horizon: Lifetime (varies depending on age at screening). Perspective: societal. Interventions: initial office-based screening to determine eligibility (based on personal and family cancer history), followed by tumor testing for microsatellite instability, Those with microsatellite instability were offered genetic testing for HNPCC. Siblings and children of patients with cancer and the HNPCC mutation were offered genetic testing, and those who were found to carry the mutation received lifelong colorectal cancer screening. Measurements: Life-years gained. Results of Base-Case Analysis: When only the patients with cancer were considered, cost-effectiveness of screening was $42 210 per life-year gained. When patients with cancer and their siblings and children were considered together, cost-effectiveness increased to $7556 per life-year gained. Results of Sensitivity Analysis: The model was most sensitive to the estimated survival gain from screening siblings and children, to the prevalence of HNPCC mutations among patients with newly diagnosed cancer, and to the discount rate. In probabilistic analysis, the 90% CI for the cost-effectiveness of screening patients with cancer plus their relatives was $4874 to $21 576 per life-year gained. Conclusion: Screening patients with newly diagnosed colorectal cancer for HNPCC is cost-effective, especially if the benefits to their immediate relatives are considered.				sramsey@fhcrc.org			NATIONAL CANCER INSTITUTE [U01CA074794] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA074794] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1994, CANCER DETECT PREV, V18, P57; Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C; Aarnio M, 1995, INT J CANCER, V64, P430, DOI 10.1002/ijc.2910640613; American Cancer Society, 1999, CANC FACTS FIG 1999; Benson AB, 2000, J CLIN ONCOL, V18, P3586, DOI 10.1200/JCO.2000.18.20.3586; Bernhardt B A, 1998, J Genet Couns, V7, P317, DOI 10.1023/A:1022067916528; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; Boland CR, 1998, CANCER RES, V58, P5248; BOLAND CR, 1998, GENETIC BASIS HUMAN; BROWN ML, 1995, J NATL CANCER I, V87, P1131, DOI 10.1093/jnci/87.15.1131; Bubb VJ, 1996, ONCOGENE, V12, P2641; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; CORAN AG, 1990, ANN SURG, V212, P242, DOI 10.1097/00000658-199009000-00002; CROYLE RT, 1993, PREV MED, V22, P284, DOI 10.1006/pmed.1993.1023; Deftos L J, 1998, Spec Law Dig Health Care Law, P9; deLeon MP, 1996, TUMORI, V82, P102, DOI 10.1177/030089169608200202; Etzioni R, 1996, J CLIN EPIDEMIOL, V49, P95, DOI 10.1016/0895-4356(96)89259-6; Freyer G, 1999, ANN ONCOL, V10, P87, DOI 10.1023/A:1008349318728; GOLD MR, 1996, COST EFFECTIVENESS H, P214; Gonzalez-Garcia I, 2000, JNCI-J NATL CANCER I, V92, P544, DOI 10.1093/jnci/92.7.544; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; *HLTH CAR FIN ADM, 2001, MED PROV AN REV MEDP; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5; JENTSCHURA D, 1994, SURG ENDOSC, V8, P472; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Kinney AY, 2000, AM J PREV MED, V18, P249, DOI 10.1016/S0749-3797(99)00162-2; KOLATA G, 1998, NY TIMES        0327; LERMAN C, 1994, ARCH INTERN MED, V154, P609, DOI 10.1001/archinte.154.6.609; Lerman C, 1999, JAMA-J AM MED ASSOC, V281, P1618, DOI 10.1001/jama.281.17.1618; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; LO AY, 1994, J AM COLL SURGEONS, V179, P333; LOTHE RA, 1993, CANCER RES, V53, P5849; Lynch HT, 1999, CANCER, V86, P2449, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2449::AID-CNCR1>3.0.CO;2-M; Lynch HT, 1999, SEMIN ONCOL, V26, P478; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; Marta M R, 1999, J Healthc Risk Manag, V19, P26; Myrhoj T, 1997, SCAND J GASTROENTERO, V32, P572, DOI 10.3109/00365529709025102; Nakahara M, 1997, CANCER EPIDEM BIOMAR, V6, P1057; *NAT CANC I DIV CA, 2000, SURV EP END RES SEER; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Olick R S, 2000, N J Med, V97, P43; PEDERSEN T, 1990, ACTA ANAESTH SCAND, V34, P176, DOI 10.1111/j.1399-6576.1990.tb03066.x; Peltomaki P, 1999, ADV EXP MED BIOL, V470, P95; Percesepe A, 1997, INT J CANCER, V71, P373, DOI 10.1002/(SICI)1097-0215(19970502)71:3<373::AID-IJC12>3.0.CO;2-H; POTOSKY AL, 1993, MED CARE, V31, P732; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; ROUFFET F, 1994, DIS COLON RECTUM, V37, P651, DOI 10.1007/BF02054407; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; STELZNER M, 1989, SURG GYNECOL OBSTET, V169, P187; STEVENSON G, 1989, COLON CANC DIAGNOSIS; SUTER SM, 1993, MICH LAW REV, V91, P1854, DOI 10.2307/1289655; Syngal S, 1999, JAMA-J AM MED ASSOC, V282, P247, DOI 10.1001/jama.282.3.247; *US C OFF TECHN AS, 1992, GEN TESTS HLTH INS R; *US CENS BUR, 2000, STAT ABSTR US 1999; *US CENS BUR, 2000, STAT ABSTR US; VASEN HF, 1993, DIS COLON RECTUM, V36, P1, DOI 10.1007/BF02050292; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804; 2000, FERTILITY AM WOMEN	60	99	100	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	1				577	588		10.7326/0003-4819-135-8_Part_1-200110160-00008	http://dx.doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481VY	11601929				2022-12-28	WOS:000171542200003
J	Heller, T				Heller, T			How safe is MMR vaccine?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Open Univ, Sch Hlth & Social Welf, Milton Keynes MK7 6AA, Bucks, England	Open University - UK	Heller, T (corresponding author), Open Univ, Sch Hlth & Social Welf, Milton Keynes MK7 6AA, Bucks, England.							*DEP HLTH, 2000, CM4818L; Elliman D, 2001, BMJ-BRIT MED J, V322, P183, DOI 10.1136/bmj.322.7280.183; Goldberg D, 2000, BRIT MED J, V320, P389, DOI 10.1136/bmj.320.7231.389; Hunt G, 1995, WHISTLEBLOWING HLTH, P3; Kaye JA, 2001, BRIT MED J, V322, P460, DOI 10.1136/bmj.322.7284.460; Petrovic M, 2001, BRIT MED J, V322, P82, DOI 10.1136/bmj.322.7278.82	6	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 13	2001	323	7317					838	839		10.1136/bmj.323.7317.838	http://dx.doi.org/10.1136/bmj.323.7317.838			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597968	Bronze, Green Published			2022-12-28	WOS:000171650500026
J	Wiechert, U; Halliday, AN; Lee, DC; Snyder, GA; Taylor, LA; Rumble, D				Wiechert, U; Halliday, AN; Lee, DC; Snyder, GA; Taylor, LA; Rumble, D			Oxygen isotopes and the moon-forming giant impact	SCIENCE			English	Article							ORIGIN; RATIOS; EARTH; GAS	We have determined the abundances of O-16, O-17, and O-18 in 31 lunar samples from Apollo missions 11, 12, 15, 16, and 17 using a high-precision laser fluorination technique. All oxygen isotope compositions plot within +/-0.016 per mit (2 standard deviations) on a single mass-dependent fractionation line that is identical to the terrestrial fractionation tine within uncertainties. This observation is consistent with the Giant Impact model, provided that the proto-Earth and the smaller impactor planet (named Theia) formed from an identical mix of components. The similarity between the proto-Earth and Theia is consistent with formation at about the same heliocentric distance. The three oxygen isotopes (Delta O-17) provide no evidence that isotopic heterogeneity on the Moon was created by lunar impacts.	ETH Zentrum, Dept Earth Sci, Inst Isotope Geol & Mineral Resources, CH-8092 Zurich, Switzerland; Univ Tennessee, Dept Geol Sci, Planetary Geosci Inst, Knoxville, TN 37996 USA; Carnegie Inst Sci, Geophys Lab, Washington, DC 20015 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Tennessee System; University of Tennessee Knoxville; Carnegie Institution for Science	Wiechert, U (corresponding author), ETH Zentrum, Dept Earth Sci, Inst Isotope Geol & Mineral Resources, Sonneggstr 5, CH-8092 Zurich, Switzerland.	wiechert@erdw.ethz.ch	Rumble, Douglas/AAU-3930-2020; Lee, Der-Chuen/N-9225-2013	Rumble, Douglas/0000-0002-7440-9189; Lee, Der-Chuen/0000-0001-8855-9594				BENZ W, COMMUNICATION; CAMERON AGW, 1991, ICARUS, V92, P204, DOI 10.1016/0019-1035(91)90046-V; Cameron AGW, 2001, METEORIT PLANET SCI, V36, P9, DOI 10.1111/j.1945-5100.2001.tb01806.x; CAMERON AGW, 1998, LUNAR PLANET SCI, V29, P1062; Canup RM, 2001, NATURE, V412, P708, DOI 10.1038/35089010; CLAYTON RN, 1977, EARTH PLANET SC LETT, V34, P209, DOI 10.1016/0012-821X(77)90005-X; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; CLAYTON RN, 1984, P LUNAR PLANET SCI C, V15, pC245; CLAYTON RN, 1975, P LUNAR PLANET SCI C, V11, P1761; Eiler JM, 2000, NATURE, V403, P530, DOI 10.1038/35000553; Halliday AN, 2000, EARTH PLANET SC LETT, V176, P17, DOI 10.1016/S0012-821X(99)00317-9; HALLIDAY AN, IN PRESS EARTH PLANE; Lugmair GW, 1998, GEOCHIM COSMOCHIM AC, V62, P2863, DOI 10.1016/S0016-7037(98)00189-6; Newton J, 2000, METEORIT PLANET SCI, V35, P689, DOI 10.1111/j.1945-5100.2000.tb01452.x; Rumble D, 1997, GEOCHIM COSMOCHIM AC, V61, P4229, DOI 10.1016/S0016-7037(97)00232-9; SHARP ZD, 1990, GEOCHIM COSMOCHIM AC, V54, P1353, DOI 10.1016/0016-7037(90)90160-M; Valley JW, 1995, GEOCHIM COSMOCHIM AC, V59, P5223, DOI 10.1016/0016-7037(95)00386-X; WETHERILL GW, 1994, GEOCHIM COSMOCHIM AC, V58, P4513, DOI 10.1016/0016-7037(94)90352-2; Yi W, 2000, J GEOPHYS RES-SOL EA, V105, P18927, DOI 10.1029/2000JB900152; Young ED, 1999, SCIENCE, V286, P1331, DOI 10.1126/science.286.5443.1331	23	265	268	1	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 12	2001	294	5541					345	348		10.1126/science.1063037	http://dx.doi.org/10.1126/science.1063037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598294				2022-12-28	WOS:000171601400035
J	Benavente, O; Eliasziw, M; Streifler, JY; Fox, AJ; Barnett, HJM; Meldrum, H				Benavente, O; Eliasziw, M; Streifler, JY; Fox, AJ; Barnett, HJM; Meldrum, H		No Amer Symptomatic Carotid Endart	Prognosis after transient monocular blindness associated with carotid-artery stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMAUROSIS FUGAX; ENDARTERECTOMY; STROKE; RISK	Background: Transient monocular blindness associated with internal-carotid-artery stenosis is a risk factor for stroke. The effect of carotid endarterectomy in patients who present with transient monocular blindness has not been determined. Methods: We compared the risk of stroke among patients presenting with transient monocular blindness with the risk among patients presenting with hemispheric transient ischemic attack. The effect of endarterectomy was assessed in patients with transient monocular blindness. The analyses were based on data from the North American Symptomatic Carotid Endarterectomy Trial. Results: A total of 198 medically treated patients with transient monocular blindness had a three-year risk of ipsilateral stroke that was approximately half of that among 417 medically treated patients with hemispheric transient ischemic attack (adjusted hazard ratio, 0.53; 95 percent confidence interval, 0.30 to 0.94). Six factors were associated with a higher risk of stroke in patients with monocular blindness -- an age of 75 years or more, male sex, a history of hemispheric transient ischemic attack or stroke, a history of intermittent claudication, stenosis of 80 to 94 percent of the luminal diameter, and the absence of collateral circulation. The three-year risk of stroke with medical treatment for patients with zero or one risk factor was 1.8 percent, with two risk factors 12.3 percent, and with three or more risk factors 24.2 percent (P=0.003). The three-year absolute reduction in the risk of stroke associated with endarterectomy was -2.2 percent (i.e., a 2.2 percent increase in risk) among patients with zero or one risk factor, 4.9 percent among those with two risk factors, and 14.3 percent among those with three or more risk factors (P=0.23 by a test for interaction). Conclusions: Among patients with internal-carotid-artery stenosis, the prognosis was better for those presenting with transient monocular blindness than for those presenting with hemispheric transient ischemic attack. Among patients with transient monocular blindness, carotid endarterectomy may be beneficial when other risk factors for stroke are also present. (N Engl J Med 2001;345:1084-90.) Copyright (C) Massachusetts Medical Society.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, San Antonio, TX 78229 USA; John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; Univ Western Ontario, Dept Diagnost Radiol, London, ON, Canada; Rabin Med Ctr, Petah Tiqwa, Israel	University of Texas System; University of Texas Health San Antonio; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Rabin Medical Center	Benavente, O (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, Mail Code 7883,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	benavente@uthscsa.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024456] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS-24456] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSENCU, 1988, STROKE, V19, P196, DOI 10.1161/01.STR.19.2.196; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711; Boiten J, 1997, CEREBROVASC DIS, V7, P138, DOI 10.1159/000108179; Brown RD, 1998, STROKE, V29, P2109, DOI 10.1161/01.STR.29.10.2109; EISENBERG RL, 1978, STROKE, V9, P254, DOI 10.1161/01.STR.9.3.254; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FISHER M, 1952, AMA ARCH OPHTHALMOL, V47, P167; FOX AJ, 1993, RADIOLOGY, V186, P316, DOI 10.1148/radiology.186.2.8421726; GACS G, 1982, STROKE, V13, P39, DOI 10.1161/01.STR.13.1.39; Henderson RD, 2000, STROKE, V31, P128, DOI 10.1161/01.STR.31.1.128; HURWITZ BJ, 1985, ANN NEUROL, V18, P698, DOI 10.1002/ana.410180612; MARSHALL J, 1968, BRAIN, V91, P419, DOI 10.1093/brain/91.3.419; Morgenstern LB, 1997, NEUROLOGY, V48, P911, DOI 10.1212/WNL.48.4.911; POOLE CJM, 1985, J NEUROL NEUROSUR PS, V48, P902, DOI 10.1136/jnnp.48.9.902; RANKIN J, 1957, Scott Med J, V2, P200; RUSSELL RW, 1963, LANCET, V2, P1354; SANDOK BA, 1974, AM J OPHTHALMOL, V78, P137, DOI 10.1016/0002-9394(74)90022-1; SLEPYAN DH, 1975, STROKE, V6, P493, DOI 10.1161/01.STR.6.5.493; STREIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P246, DOI 10.1001/archneur.1995.00540270034016; Taylor DW, 1999, LANCET, V353, P2179, DOI 10.1016/S0140-6736(99)05388-X; VISONA A, 1987, Heart and Vessels, V3, P91, DOI 10.1007/BF02058525; WHISNANT JP, 1982, STROKE, V13, P720, DOI 10.1161/01.STR.13.5.720; WILTERDINK JL, 1992, ARCH NEUROL-CHICAGO, V49, P857, DOI 10.1001/archneur.1992.00530320089016	24	138	142	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2001	345	15					1084	1090		10.1056/NEJMoa002994	http://dx.doi.org/10.1056/NEJMoa002994			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480QH	11596587				2022-12-28	WOS:000171473100002
J	Bartek, J; Lukas, J				Bartek, J; Lukas, J			Cell cycle - Order from destruction	SCIENCE			English	Editorial Material							TRANSITION; ROLES		Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; MOBERG KH, IN PRESS NATURE; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; STROHMAIER H, IN PRESS NATURE; Winston JT, 1999, GENE DEV, V13, P2751, DOI 10.1101/gad.13.21.2751	11	30	34	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					66	67		10.1126/science.1066237	http://dx.doi.org/10.1126/science.1066237			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588240				2022-12-28	WOS:000171448800028
J	Gumienny, TL; Brugnera, E; Tosello-Trampont, AC; Kinchen, JM; Haney, LB; Nishiwaki, K; Walk, SF; Nemergut, ME; Macara, IG; Francis, R; Schedl, T; Qin, Y; Van Aelst, L; Hengartner, MO; Ravichandran, KS				Gumienny, TL; Brugnera, E; Tosello-Trampont, AC; Kinchen, JM; Haney, LB; Nishiwaki, K; Walk, SF; Nemergut, ME; Macara, IG; Francis, R; Schedl, T; Qin, Y; Van Aelst, L; Hengartner, MO; Ravichandran, KS			CED-12/ELMO, a novel member of the crkII/dock180/rac pathway, is required for phagocytosis and cell migration	CELL			English	Article							CORPSE ENGULFMENT; BINDING PROTEIN; MYOBLAST CITY; RHO GTPASES; NEMATODE; ENCODES; GENES; DEATH; MECHANISMS; EXPRESSION	The C. elegans genes ced-2, ced-5, and ced-10, and their mammalian homologs crkII, dock180, and rac1, mediate cytoskeletal rearrangements during phagocytosis of apoptotic cells and cell motility. Here, we describe an additional member of this signaling pathway, ced-12, and its mammalian homologs, elmo1 and elmo2. In C. elegans, CED-12 is required for engulfment of dying cells and for cell migrations. In mammalian cells, ELMO1 functionally cooperates with CrkII and Dock180 to promote phagocytosis and cell shape changes. CED-12/ELMO-1 binds directly to CED-5/ Dock180; this evolutionarily conserved complex stimulates a Rac-GEF, leading to Rac1 activation and cytoskeletal rearrangements. These studies identify CED-12/ELMO as an upstream regulator of Rac1 that affects engulfment and cell migration from C. elegans to mammals.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11743 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Japan Sci & Technol Corp, PRESTO, Tsukuba, Ibaraki 3058501, Japan; NEC Corp Ltd, Fundamental Res Labs, Tsukuba, Ibaraki 3058501, Japan; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Virginia; University of Virginia; Japan Science & Technology Agency (JST); NEC Corporation; University of Virginia; Washington University (WUSTL)	Hengartner, MO (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11743 USA.	michael.hengartner@molbio.unizh.ch; ravi@virginia.edu	Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008; Kinchen, Jason/ABC-5663-2021; Gumienny, Tina/AAJ-5273-2020	Nemergut, Michael/0000-0002-6803-1765; Gumienny, Tina/0000-0002-3932-7815; Kinchen, Jason/0000-0001-8430-2265; Hengartner, Michael/0000-0002-7584-596X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052540, R01GM063310] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063310, GM63310, GM52540] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Chung SB, 2000, NAT CELL BIOL, V2, P931, DOI 10.1038/35046585; ELLIS RE, 1991, GENETICS, V129, P79; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; Hengartner MO, 1999, RECENT PROG HORM RES, V54, P213; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hengartner MO, 2001, CELL, V104, P325, DOI 10.1016/S0092-8674(01)00219-7; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; HODGKIN J, 1988, NEMATODE CAENORHABDI, P502; Hubbard EJA, 2000, DEV DYNAM, V218, P2, DOI 10.1002/(SICI)1097-0177(200005)218:1<2::AID-DVDY2>3.0.CO;2-W; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KLASS M, 1976, DEV BIOL, V52, P1, DOI 10.1016/0012-1606(76)90002-6; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mello C, 1995, METHOD CELL BIOL, V48, P451; Montell DJ, 1999, DEVELOPMENT, V126, P3035; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; Nishiwaki K, 1999, GENETICS, V152, P985; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TOSELLOTRAMPONT A, 2001, IN PRESS J BIOL CHEM; VAN AL, 1997, GENE DEV, V11, P2295; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	46	430	458	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 5	2001	107	1					27	41		10.1016/S0092-8674(01)00520-7	http://dx.doi.org/10.1016/S0092-8674(01)00520-7			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595183	Green Accepted, Bronze			2022-12-28	WOS:000171453100007
J	Singer, PA; Daar, AS				Singer, PA; Daar, AS			Harnessing genomics and biotechnology to improve global health equity	SCIENCE			English	Editorial Material								With decisive and timely action, genome-related biotechnology can be harnessed to improve global health equity. In June 2002 in Kananaskis, Canada, leaders of the G8 industrial nations will develop an action plan to support implementation of the New African Initiative. By extending their discussion of health issues raised in the New African Initiative to include genomics, G8 leaders could signal their intention to increase global health equity by preventing a health genomics divide from developing. There are already some early and growing examples of genome-related biotechnology being applied successfully to health problems in developing countries. But how can genomics be systematically harnessed to benefit health in developing countries? We propose a five-point strategy, including research, capacity strengthening, consensus building, public engagement, and an investment fund.	Univ Toronto, Joint Ctr Bioeth, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto	Singer, PA (corresponding author), 88 Coll St, Toronto, ON M5G 1L4, Canada.							Bloom BR, 2001, BRIT MED J, V322, P1006, DOI 10.1136/bmj.322.7293.1006; Carr K, 1999, NATURE, V398, pA22; CHEN LC, 2000, C HLTH RES DEV BANGK; DAAR A, 1999, WHOEIPGPE001; Harris E, 1996, BIOCHEM EDUC, V24, P3, DOI 10.1016/0307-4412(95)00154-9; Harris E., 1998, LOW COST APPROACH PC; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; JUMA C, 1999, I NATURAL RESOURCES; Richter LJ, 2000, NAT BIOTECHNOL, V18, P1167, DOI 10.1038/81153; Schaeffeler E, 2001, LANCET, V358, P383, DOI 10.1016/S0140-6736(01)05579-9; Singer PA, 2000, NAT BIOTECHNOL, V18, P1225, DOI 10.1038/82256; Singer PA, 2001, BRIT MED J, V322, P747, DOI 10.1136/bmj.322.7289.747; World Bank, 1998, WORLD DEV REP 1998 9	13	82	88	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					87	89		10.1126/science.1062633	http://dx.doi.org/10.1126/science.1062633			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588248				2022-12-28	WOS:000171448800036
J	Steinberg, KK; Gwinn, M; Khoury, MJ				Steinberg, KK; Gwinn, M; Khoury, MJ			The role of genomics in public health and disease prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGY		Ctr Dis Control & Prevent, Chamblee, GA 30341 USA	Centers for Disease Control & Prevention - USA	Steinberg, KK (corresponding author), Ctr Dis Control & Prevent, Chamblee, GA 30341 USA.							Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Jacobson Terry A., 2001, American Journal of Medicine, V110, p3S; Khoury MJ, 1997, EPIDEMIOL REV, V19, P175, DOI 10.1093/oxfordjournals.epirev.a017940; Myerowitz R, 1997, HUM MUTAT, V9, P195, DOI 10.1002/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.0.CO;2-7; Yang QH, 2000, GENET MED, V2, P186, DOI 10.1097/00125817-200005000-00005	6	11	12	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1635	1635		10.1001/jama.286.13.1635	http://dx.doi.org/10.1001/jama.286.13.1635			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585491	hybrid			2022-12-28	WOS:000171340600034
J	Simon, JA; Hunninghake, DB; Agarwal, SK; Lin, F; Cauley, JA; Ireland, CC; Pickar, JH				Simon, JA; Hunninghake, DB; Agarwal, SK; Lin, F; Cauley, JA; Ireland, CC; Pickar, JH		Heart Estrogen Progestin Replaceme	Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease - The heart and estrogen/progestin replacement study	ANNALS OF INTERNAL MEDICINE			English	Article							HMG-COA REDUCTASE; GALLBLADDER-DISEASE; GALLSTONE DISEASE; CHOLESTEROL SATURATION; SYMPTOMATIC GALLSTONES; SECONDARY PREVENTION; ORAL-CONTRACEPTIVES; ASCORBIC-ACID; THERAPY; CHOLECYSTECTOMY	Background: Animal and observational epidemiologic studies have reported that estrogens may increase the risk for gallstones. No major clinical trials have examined the effect of estrogen plus progestin therapy in postmenopausal women on the risk for biliary tract surgery. Objective: To determine the effect of estrogen plus progestin on the risk for biliary tract surgery in postmenopausal women with known coronary artery disease. Design: Randomized, double-blind placebo-controlled trial of postmenopausal hormone therapy for coronary heart disease. Setting: 20 U.S. clinical centers. Participants: 2253 postmenopausal women with a gallbladder, 44 to 79 years of age at baseline, in the Heart and Estrogen/progestin Replacement Study (HERS). Intervention: conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, daily in one tablet or identical placebo. Measurements: Documented biliary tract surgery. Results: A total of 147 women (7%) were hospitalized for biliary tract surgery in HERS. Treatment with estrogen plus progestin resulted in a marginally significant 38% increase in the relative risk for biliary tract surgery (P = 0.05). A small absolute difference in risk suggested that for every 185 women treated with estrogen plus progestin, one additional woman had biliary tract surgery per year. After adjustment for baseline and in-study statin use, the association was attenuated further (P = 0.09). After adjustment for treatment assignment and other variables, increased body mass index, fibric acid use, and a history of nonsurgical gallbladder disease were associated with an increased risk for biliary tract surgery, whereas statin use was associated with a decreased risk (for each comparison, P < 0.05). Conclusion: Estrogen plus progestin therapy among postmenopausal women with known coronary disease resulted in a marginally significant increase In the risk for biliary tract surgery.	Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA; Wyeth Ayerst Res, Pittsburgh, PA 19101 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Cedars Sinai Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pfizer	Simon, JA (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	jasimon@itsa.ucsf.edu	Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Chapman BA, 1998, DIGEST DIS SCI, V43, P349, DOI 10.1023/A:1018862507469; DIEHL AK, 1991, GASTROENTEROL CLIN N, V20, P1; DUANE WC, 1988, HEPATOLOGY, V8, P1147, DOI 10.1002/hep.1840080531; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; EVERSON GT, 1991, J CLIN INVEST, V87, P237, DOI 10.1172/JCI114977; FRICK MH, 1992, NIH CONSENSUS STATE, V10, P1; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; Gilloteaux J, 1997, MICROSC RES TECHNIQ, V39, P56, DOI 10.1002/(SICI)1097-0029(19971001)39:1<56::AID-JEMT5>3.0.CO;2-Y; GRODSTEIN F, 1994, OBSTET GYNECOL, V84, P207; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; HENRIKSSON P, 1989, J CLIN INVEST, V84, P811, DOI 10.1172/JCI114240; HONORE LH, 1980, J REPROD MED, V25, P187; HOOGERBRUGGE VD, 1990, GUT, V31, P348; Hulley S, 1999, JAMA-J AM MED ASSOC, V281, P796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JOHNSTON DE, 1993, NEW ENGL J MED, V328, P412, DOI 10.1056/NEJM199302113280608; JORGENSEN T, 1988, GUT, V29, P433, DOI 10.1136/gut.29.4.433; KAKAR F, 1988, AM J PUBLIC HEALTH, V78, P564, DOI 10.2105/AJPH.78.5.564; LAVECCHIA C, 1992, J EPIDEMIOL COMMUN H, V46, P234, DOI 10.1136/jech.46.3.234; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; LOGAN GM, 1990, GASTROENTEROLOGY, V98, P1572, DOI 10.1016/0016-5085(90)91092-K; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MESSA C, 1990, DIGESTION, V46, P214, DOI 10.1159/000200348; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; OCONNELL MB, 1995, J CLIN PHARMACOL, V35, pS18, DOI 10.1002/j.1552-4604.1995.tb04143.x; PAUMGARTNER G, 1991, LANCET, V338, P1117, DOI 10.1016/0140-6736(91)91972-W; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; PETITTI DB, 1981, NEW ENGL J MED, V304, P1396, DOI 10.1056/NEJM198106043042305; *SAS I INC, 1997, SAS; Simon JA, 1998, J CLIN EPIDEMIOL, V51, P257, DOI 10.1016/S0895-4356(97)80280-6; Simon JA, 2000, ARCH INTERN MED, V160, P931, DOI 10.1001/archinte.160.7.931; THORNTON J, 1983, LANCET, V2, P819; Uhler ML, 2000, MENOPAUSE, V7, P162, DOI 10.1097/00042192-200007030-00006; VANERPECUM KJ, 1991, GASTROENTEROLOGY, V100, P482, DOI 10.1016/0016-5085(91)90220-F; 1977, N ENGL J MED, V296, P1185; 1974, N ENGL J MED, V290, P15; 1999, STATA STAT SOFTWARE	39	71	72	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					493	501		10.7326/0003-4819-135-7-200110020-00008	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	477EF	11578152				2022-12-28	WOS:000171269600003
J	Greenberg, DS				Greenberg, DS			Presidential and Congressional responses as a nation reels after the attacks	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					942	942		10.1016/S0140-6736(01)06120-7	http://dx.doi.org/10.1016/S0140-6736(01)06120-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11584819	Bronze			2022-12-28	WOS:000171135300005
J	Hippisley-Cox, J; Pringle, M; Hammersley, V; Crown, N; Wynn, A; Meal, A; Coupland, C				Hippisley-Cox, J; Pringle, M; Hammersley, V; Crown, N; Wynn, A; Meal, A; Coupland, C			Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; TRICYCLIC ANTIDEPRESSANTS; PSYCHOTROPIC-DRUGS; DEPRESSION	Objectives To determine whether antidepressants are a risk factor for ischaemic heart disease and tp compare the risk for different subgroups of antidepressants and individual antidepressants. Design Case-control study. Setting Nine general practices recruited from the Trent Focus Collaborative Research Network, Participants 933 men and women with ischaemic heart disease matched by age, sex, and practice to 5516 controls. Main outcome measure Adjusted odds ratio for ischaemic heart disease calculated by logistic regression. Results Odds ratios for ischaemic heart disease were significantly raised for patients who had ever received a prescription for tricyclic antidepressants even after diabetes, hypertension, smoking, body mass index, and use of selective serotonin reuptake inhibitors had been adjusted for (1.56; 95% confidence interval 1.18 to 2.05). Patients who had ever taken dosulepin (dothiepin) had a significantly raised odds ratio for ischaemic heart disease after adjustment for confounding factors and use of other antidepressants (1.67, 1.17 to 2.36), There was no significant increase in the odds ratios for amitriptyline, lofepramine, and selective serotonin reuptake inhibitors in multivariate analysis. Increasing maximum doses of dosulepin were associated with increasing odds ratios for ischaemic heart disease. Similarly, there was a significant positive trend associated with increasing numbers of prescriptions of dosulepin (adjusted odds ratio 1.52 for 1 prescription, 1.39 for 2-3, and 1.96 for greater than or equal to4,P<0.002). Conclusion There is good evidence for an association between dosulepin and subsequent ischaemic heart disease and for a dose-response relation.	Univ Nottingham, Div Gen Practice, Nottingham NG7 2RD, England; Collingham Med Ctr, Collingham NG23 7LB, Notts, England; Queens Med Ctr, Sch Med, Sch Nursing, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Hippisley-Cox, J (corresponding author), Univ Nottingham, Div Gen Practice, Nottingham NG7 2RD, England.		Hippisley-Cox, Julia/AAY-2788-2020; Meal, Andy/B-9083-2008	Hippisley-Cox, Julia/0000-0002-2479-7283; Coupland, Carol/0000-0002-2327-3306				*AG HLTH CAR POL R, 1999, TREATM DEPR NEW PHAR; Breslow NE, 1987, STAT METHODS CANC RE; BUCKLEY NA, 1994, LANCET, V343, P159, DOI 10.1016/S0140-6736(94)90940-7; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; Cohen HW, 2000, AM J MED, V108, P2, DOI 10.1016/S0002-9343(99)00301-0; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; GLASSMAN AH, 1994, GERONTOLOGY, V40, P15, DOI 10.1159/000213616; Glassman AH, 1998, J CLIN PSYCHIAT, V59, P13; HAMMERSLEY V, 1998, J INF PRIMARY CARE, V1, P3; HARRIS M, 1992, CLASSIFICATION DIABE; Hippisley-Cox J, 1998, BMJ-BRIT MED J, V316, P1714, DOI 10.1136/bmj.316.7146.1714; LADWIG KH, 1994, LANCET, V343, P20, DOI 10.1016/S0140-6736(94)90877-X; LAPANE KL, 1995, EPIDEMIOLOGY, V6, P376, DOI 10.1097/00001648-199507000-00008; Penttinen J, 1996, INT J EPIDEMIOL, V25, P760, DOI 10.1093/ije/25.4.760; PRATT L, 1996, CIRCULATION, V94, P123; ROOSE SP, 1994, J CLIN PSYCHIAT, V55, P83; Royal College of General Practitioners Office of Population Consensus & Survey. Department of Health, 1995, MORB STAT GEN PRACT; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; Sheline YI, 1997, AM J MED, V102, P54, DOI 10.1016/S0002-9343(96)00374-9	20	76	76	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					666	669		10.1136/bmj.323.7314.666	http://dx.doi.org/10.1136/bmj.323.7314.666			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	476LP	11566831	Bronze, Green Published			2022-12-28	WOS:000171228800019
J	Kapp, C				Kapp, C			International gatherings of health leaders added to the casualties	LANCET			English	Article																			0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					944	944		10.1016/S0140-6736(01)06123-2	http://dx.doi.org/10.1016/S0140-6736(01)06123-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11584822				2022-12-28	WOS:000171135300008
J	Gillooly, JF; Brown, JH; West, GB; Savage, VM; Charnov, EL				Gillooly, JF; Brown, JH; West, GB; Savage, VM; Charnov, EL			Effects of size and temperature on metabolic rate	SCIENCE			English	Article								We derive a general model, based on principles of biochemical kinetics and allometry, that characterizes the effects of temperature and body mass on metabolic rate. The model fits metabolic rates of microbes, ectotherms, endotherms; (including those in hibernation), and plants in temperatures ranging from 0 degrees to 40 degreesC. Mass- and temperature-compensated resting metabolic rates of all organisms are similar: The lowest (for unicellular organisms and plants) is separated from the highest (for endothermic vertebrates) by a factor of about 20. Temperature and body size are primary determinants of biological time and ecological roles.	Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	University of New Mexico; The Santa Fe Institute; United States Department of Energy (DOE); Los Alamos National Laboratory	Gillooly, JF (corresponding author), Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA.	gillooly@unm.edu	Langerhans, R. Brian/A-7205-2009					Enquist BJ, 1999, NATURE, V398, P573, DOI 10.1038/19219; GEISER F, 1988, J COMP PHYSIOL B, V158, P25, DOI 10.1007/BF00692726; Hemmingsen AM, 1960, REPORTS STENO MEMORI, V9, P1; Hulbert AJ, 2000, ANNU REV PHYSIOL, V62, P207, DOI 10.1146/annurev.physiol.62.1.207; KLEIBER MAX, 1932, HILGARDIA, V6, P315; NAGY KA, 1987, ECOL MONOGR, V57, P111, DOI 10.2307/1942620; Niklas KJ, 2001, P NATL ACAD SCI USA, V98, P2922, DOI 10.1073/pnas.041590298; RAVEN JA, 1988, NEW PHYTOL, V110, P441, DOI 10.1111/j.1469-8137.1988.tb00282.x; Rivkin RB, 2001, SCIENCE, V291, P2398, DOI 10.1126/science.291.5512.2398; Valentini R, 2000, NATURE, V404, P861, DOI 10.1038/35009084; VETTER RAH, 1995, J COMP PHYSIOL B, V165, P46, DOI 10.1007/BF00264685; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122	12	2427	2495	31	1431	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2248	2251		10.1126/science.1061967	http://dx.doi.org/10.1126/science.1061967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567137	Green Submitted			2022-12-28	WOS:000171139400042
J	Lomvardas, S; Thanos, D				Lomvardas, S; Thanos, D			Nucleosome sliding via TBP DNA binding in vivo	CELL			English	Article							REMODELING COMPLEX; TRANSCRIPTION FACTORS; CHROMATIN STRUCTURE; HISTONE OCTAMER; ARCHITECTURAL SPECIFICITY; POSITIONED NUCLEOSOMES; ORDERED RECRUITMENT; CRYSTAL-STRUCTURE; GENE-EXPRESSION; HMG I(Y)	Here, we show that a nucleosome obstructing transcription from the IFN-beta promoter slides in vivo in response to virus infection, thus exposing the previously masked TATA box and the initiation site, a requirement for transcriptional activation. Our experiments also revealed that this mode of chromatin remodeling is a two-step reaction. First, the enhanceosome recruits the SWI/SNF chromatin-remodeling complex that modifies the nucleosome to allow binding of TBP. Second, DNA bending is induced by TBP binding, and the nucleosome slides to a new position. Experiments with other DNA binding proteins demonstrated a strong correlation between the ability to bend DNA and nucleosome sliding, suggesting that the sliding is induced by the bend.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University	Thanos, D (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.		Thanos, Dimitris/AAE-5720-2019	Lomvardas, Stavros/0000-0002-7668-3026	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; HONG L, 1993, J BIOL CHEM, V268, P305; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li GF, 1998, P NATL ACAD SCI USA, V95, P4772, DOI 10.1073/pnas.95.8.4772; Lohr D, 1997, J BIOL CHEM, V272, P26795, DOI 10.1074/jbc.272.43.26795; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; Lorch Y, 2001, MOL CELL, V7, P89, DOI 10.1016/S1097-2765(01)00157-5; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Munshi N, 1999, COLD SPRING HARB SYM, V64, P149, DOI 10.1101/sqb.1999.64.149; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; Peterson CL, 2000, FEBS LETT, V476, P68, DOI 10.1016/S0014-5793(00)01673-2; Reeves R, 2000, MOL CELL BIOL, V20, P4666, DOI 10.1128/MCB.20.13.4666-4679.2000; Reinke H, 2001, MOL CELL, V7, P529, DOI 10.1016/S1097-2765(01)00200-3; Roychoudhury M, 2000, P NATL ACAD SCI USA, V97, P13608, DOI 10.1073/pnas.250476297; Rubbi L, 1997, BIOCHEM J, V328, P401, DOI 10.1042/bj3280401; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Shen CH, 2001, MOL CELL BIOL, V21, P534, DOI 10.1128/MCB.21.2.534-547.2001; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; Verdone L, 1996, MOL CELL BIOL, V16, P1978; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Wolffe A., 1995, CHROMATIN STRUCTURE; XIAO H, 2001, IN PRESS MOL CELL	61	161	164	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 21	2001	106	6					685	696		10.1016/S0092-8674(01)00490-1	http://dx.doi.org/10.1016/S0092-8674(01)00490-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572775	Bronze			2022-12-28	WOS:000171213000006
J	Simon, I; Barnett, J; Hannett, N; Harbison, CT; Rinaldi, NJ; Volkert, TL; Wyrick, JJ; Zeitlinger, J; Gifford, DK; Jaakkola, TS; Young, RA				Simon, I; Barnett, J; Hannett, N; Harbison, CT; Rinaldi, NJ; Volkert, TL; Wyrick, JJ; Zeitlinger, J; Gifford, DK; Jaakkola, TS; Young, RA			Serial regulation of transcriptional regulators in the yeast cell cycle	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; S-PHASE; SWI5 TRANSCRIPTION; GENE-EXPRESSION; DNA-REPLICATION; FORKHEAD GENES; G1 CYCLINS; PROTEIN; IDENTIFICATION	Genome-wide location analysis was used to determine how the yeast cell cycle gene expression program is regulated by each of the nine known cell cycle transcriptional activators. We found that cell cycle transcriptional activators that function during one stage of the cell cycle regulate transcriptional activators that function during the next stage. This serial regulation of transcriptional activators forms a connected regulatory network that is itself a cycle. Our results also reveal how the nine transcriptional regulators coordinately regulate global gene expression and diverse stage-specific functions to produce a continuous cycle of cellular events. This information forms the foundation for a complete map of the transcriptional regulatory network that controls the cell cycle.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Artificial Intelligence Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Rinaldi, Nicola J/J-5858-2017; Young, Richard A/F-6495-2012	Rinaldi, Nicola J/0000-0002-0358-0747; Young, Richard A/0000-0001-8855-8647; Simon, Itamar/0000-0002-8517-1903				ALTHOEFER H, 1995, MOL CELL BIOL, V15, P5917; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Breeden LL, 2000, CURR BIOL, V10, pR586, DOI 10.1016/S0960-9822(00)00634-5; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; FOSTER R, 1993, MOL CELL BIOL, V13, P3792, DOI 10.1128/MCB.13.6.3792; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; Grether ME, 1999, MOL BIOL CELL, V10, P3689, DOI 10.1091/mbc.10.11.3689; Hollenhorst PC, 2000, GENETICS, V154, P1533; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Knapp D, 1996, MOL CELL BIOL, V16, P5701; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Koch C, 1996, GENE DEV, V10, P129, DOI 10.1101/gad.10.2.129; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Kumar R, 2000, CURR BIOL, V10, P896, DOI 10.1016/S0960-9822(00)00618-7; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; Loy CJ, 1999, MOL CELL BIOL, V19, P3312; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MacKay VL, 2001, MOL CELL BIOL, V21, P4140, DOI 10.1128/MCB.21.13.4140-4148.2001; McBride HJ, 1999, J BIOL CHEM, V274, P21029, DOI 10.1074/jbc.274.30.21029; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; Partridge JF, 1997, J BIOL CHEM, V272, P9071; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; TOONE WM, 1995, EMBO J, V14, P5824, DOI 10.1002/j.1460-2075.1995.tb00270.x; Toyn JH, 1997, GENETICS, V145, P85; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VERMA R, 1991, P NATL ACAD SCI USA, V88, P7155, DOI 10.1073/pnas.88.16.7155; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	53	482	498	0	18	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 21	2001	106	6					697	708		10.1016/S0092-8674(01)00494-9	http://dx.doi.org/10.1016/S0092-8674(01)00494-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572776	Bronze			2022-12-28	WOS:000171213000007
J	Stamler, JS; Lamas, S; Fang, FC				Stamler, JS; Lamas, S; Fang, FC			Nitrosylation: The prototypic redox-based signaling mechanism	CELL			English	Review							NITRIC-OXIDE SYNTHASE; NADPH PHAGOCYTE OXIDASE; DNA-REPAIR RESPONSE; NITROSATIVE STRESS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TRANSCRIPTION ACTIVATOR; ANTIMICROBIAL ACTIONS; LATENT LEISHMANIASIS; S-NITROSYLATION		Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; CSIC, Ctr Invest Biol, Inst Reina Sofia Invest Nefrol, Madrid, Spain; Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.		Lamas, Santiago/G-7308-2015	Lamas, Santiago/0000-0001-5166-4155; Stamler, Jonathan/0000-0002-6866-1572; Fang, Ferric/0000-0002-3243-110X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI039557, R01AI039557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009206] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39557] Funding Source: Medline; NIEHS NIH HHS [R01-ES-09206] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328; Bogdan C, 2000, J EXP MED, V191, P2121, DOI 10.1084/jem.191.12.2121; Broillet MC, 1997, NEURON, V18, P951, DOI 10.1016/S0896-6273(00)80334-7; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; COX JH, 1989, INFECT IMMUN, V57, P1719, DOI 10.1128/IAI.57.6.1719-1724.1989; Crawford MJ, 1998, J BIOL CHEM, V273, P34028, DOI 10.1074/jbc.273.51.34028; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Degroote M.A., 2002, NITRIC OXIDE INFECT, V12, P231, DOI [10.1007/0-306-46816-6_12, DOI 10.1007/0-306-46816-6_12]; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; Fang FC, 1999, P NATL ACAD SCI USA, V96, P7502, DOI 10.1073/pnas.96.13.7502; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Flynn JL, 1998, J IMMUNOL, V160, P1796; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GRANGER DL, 1993, MONONUCLEAR PHAGOCYT, P8; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Lai TS, 2001, BIOCHEMISTRY-US, V40, P4904, DOI 10.1021/bi002321t; LANE P, 2001, SCI STKE, P1; Lee YS, 2001, J BIOL CHEM, V276, P9917, DOI 10.1074/jbc.M008629200; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Lobysheva II, 1999, FEBS LETT, V454, P177, DOI 10.1016/S0014-5793(99)00777-2; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MORRIS SL, 1984, J BIOL CHEM, V259, P3590; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; Nojiri M, 1999, J BIOCHEM-TOKYO, V125, P696, DOI 10.1093/oxfordjournals.jbchem.a022339; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469; Pan H, 2000, STRUCTURE, V8, P231, DOI 10.1016/S0969-2126(00)00101-5; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Persichini T, 1998, BIOCHEM BIOPH RES CO, V250, P575, DOI 10.1006/bbrc.1998.9350; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; SAHN SA, 1976, BRIT J DIS CHEST, V70, P195, DOI 10.1016/0007-0971(76)90029-2; Salvati L, 2001, BBA-PROTEIN STRUCT M, V1545, P357, DOI 10.1016/S0167-4838(00)00297-1; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Scanga CA, 1999, INFECT IMMUN, V67, P4531, DOI 10.1128/IAI.67.9.4531-4538.1999; Shiloh MU, 1999, IMMUNITY, V10, P29, DOI 10.1016/S1074-7613(00)80004-7; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; St John G, 2001, P NATL ACAD SCI USA, V98, P9901; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Stenger S, 1996, J EXP MED, V183, P1501, DOI 10.1084/jem.183.4.1501; Stupakova MV, 2000, BIOCHEMISTRY-MOSCOW+, V65, P690; SUN J, 2001, IN PRESS P NATL ACAD; Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227; VazquezTorres A, 1996, INFECT IMMUN, V64, P3127, DOI 10.1128/IAI.64.8.3127-3133.1996; Venturini G, 2000, BIOCHEM BIOPH RES CO, V270, P437, DOI 10.1006/bbrc.2000.2447; Venturini G, 2000, BIOCHEM BIOPH RES CO, V267, P190, DOI 10.1006/bbrc.1999.1922; WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491; Yu K., 1999, Tubercle and Lung Disease, V79, P191, DOI 10.1054/tuld.1998.0203; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773; Zaman K, 2001, BIOCHEM BIOPH RES CO, V284, P65, DOI 10.1006/bbrc.2001.4935; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	81	1033	1071	2	65	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 21	2001	106	6					675	683		10.1016/S0092-8674(01)00495-0	http://dx.doi.org/10.1016/S0092-8674(01)00495-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572774	Bronze			2022-12-28	WOS:000171213000005
J	Gerrish, P				Gerrish, P			The rhythm of microbial adaptation	NATURE			English	Article							DIMINISHING RETURNS; EVOLUTION; POPULATION; LIMITS; INTERFERENCE; MUTATIONS; LINKAGE	The evolutionary biologist "studies the steps by which the miraculous adaptations so characteristic of every aspect of the organic world have evolved''(1). But the general nature of such adaptive steps is still unclear. Evolution is often thought to be random and dependent on unpredictable events(2). In this light, one might expect the steps taken by adaptation to be completely random, both biologically and temporally. Here I present a mathematical derivation to show that, on the contrary, adaptive steps can have fairly strong rhythm. I find that the strength of the adaptive rhythm, that is its relative temporal regularity, is equal to a constant that is the same for all microbial populations. As a consequence, numbers of accumulated adaptations are predicted to have a universal variance/mean ratio. The theory derived here is potentially applicable to the study of molecular evolution.	Los Alamos Natl Lab, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Gerrish, P (corresponding author), Los Alamos Natl Lab, T-10,Mailstop K710, Los Alamos, NM 87545 USA.	gerrish@lanl.gov	Gerrish, Philip/AAE-7346-2019	Gerrish, Philip/0000-0001-6393-0553				BARTON NH, 1995, GENETICS, V140, P821; BARTON NH, 1994, GENET RES, V64, P199, DOI 10.1017/S0016672300032857; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; FELLER W, 1968, INTRO PROBABILITY TH, V2, P346; FELSENSTEIN J, 1974, GENETICS, V78, P737; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fisher R., 1930, GENETICAL THEORY NAT, P102; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; GILLESPIE JH, 1998, POPULATION GENETICS, P77; Gould S. J., 1989, WONDERFUL LIFE BURGE; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; Haldane JBS, 1927, P CAMB PHILOS SOC, V23, P838, DOI 10.1017/S0305004100015644; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; HOGG RV, 1995, INTRO MATH STAT, P59; KORBER BT, 1998, SNAP SYNONYMOUS NONS; MAYR E, 1988, NEW PHILOS BIOL, P26; McVean GAT, 2000, GENETICS, V155, P929; Miralles R, 1999, SCIENCE, V285, P1745, DOI 10.1126/science.285.5434.1745; Miralles R, 2000, J VIROL, V74, P3566, DOI 10.1128/JVI.74.8.3566-3571.2000; Morgan T.H., 1913, HEREDITY SEX; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Orr HA, 2000, GENETICS, V155, P961; Orr HA, 1998, EVOLUTION, V52, P935, DOI [10.2307/2411226, 10.1111/j.1558-5646.1998.tb01823.x]; OSMANOV S, 1994, AIDS RES HUM RETROV, V10, P1327, DOI 10.1089/aid.1994.10.1327; Ota T, 1971, J Mol Evol, V1, P18, DOI 10.1007/BF01659391; Otto SP, 1997, GENETICS, V147, P879; ROBERTSON A, 1970, MATH TOPICS POPULATI, P246; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wahl LM, 2000, GENETICS, V156, P1437	29	57	58	1	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 20	2001	413	6853					299	302		10.1038/35095046	http://dx.doi.org/10.1038/35095046			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565030				2022-12-28	WOS:000171040500037
J	Stiell, IG; Wells, GA; Vandemheen, KL; Clement, CM; Lesiuk, H; De Maio, VJ; Laupacis, A; Schull, M; McKnight, RD; Verbeek, R; Brison, R; Cass, D; Dreyer, J; Eisenhauer, MA; Greenberg, GH; MacPhail, I; Morrison, L; Reardon, M; Worthington, J				Stiell, IG; Wells, GA; Vandemheen, KL; Clement, CM; Lesiuk, H; De Maio, VJ; Laupacis, A; Schull, M; McKnight, RD; Verbeek, R; Brison, R; Cass, D; Dreyer, J; Eisenhauer, MA; Greenberg, GH; MacPhail, I; Morrison, L; Reardon, M; Worthington, J			The Canadian C-spine rule for radiography in alert and stable trauma patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PREDICTION RULES; CERVICAL-SPINE; BLUNT TRAUMA; DECISION RULES; HEAD; INJURY; IMPLEMENTATION; METHODOLOGY; ETIOLOGY; CRITERIA	Context High levels of variation and inefficiency exist in current clinical practice regarding use of cervical spine (C-spine) radiography in alert and stable trauma patients. Objective To derive a clinical decision rule that is highly sensitive for detecting acute C-spine injury and will allow emergency department (ED) physicians to be more selective in use of radiography in alert and stable trauma patients. Design Prospective cohort study conducted from October 1996 to April 1999, in which physicians evaluated patients for 20 standardized clinical findings prior to radiography. In some cases, a second physician performed independent interobserver assessments. Setting Ten EDs in large Canadian community and university hospitals. Patients Convenience sample of 8924 adults (mean age, 37 years) who presented to the ED with blunt trauma to the head/neck, stable vital signs, and a Glasgow Coma Scale score of 15. Main Outcome Measure Clinically important C-spine injury, evaluated by plain radiography, computed tomography, and a structured follow-up telephone interview. The clinical decision rule was derived using the kappa coefficient, logistic regression analysis, and chi (2) recursive partitioning techniques. Results Among the study sample, 151 (1.7%) had important C-spine injury. The resultant model and final Canadian C-Spine Rule comprises 3 main questions: (1) is there any high-risk factor present that mandates radiography (ie, age greater than or equal to 65 years, dangerous mechanism, or paresthesias in extremities)? (2) is there any low-risk factor present that allows safe assessment of range of motion (ie, simple rear-end motor vehicle collision, sitting position in ED, ambulatory at any time since injury, delayed onset of neck pain, or absence of midline C-spine tenderness)? and (3) is the patient able to actively rotate neck 45 degrees to the left and right? By cross-validation, this rule had 100% sensitivity (95% confidence interval [CI], 98%-100%) and 42.5% specificity (95% CI, 40%-44%) for identifying 151 clinically important C-spine injuries. The potential radiography ordering rate would be 58.2%. Conclusion We have derived the Canadian C-Spine Rule, a highly sensitive decision rule for use of C-spine radiography in alert and stable trauma patients. If prospectively validated in other cohorts, this rule has the potential to significantly reduce practice variation and inefficiency in ED use of C-spine radiography.	Univ Ottawa, Div Emergency Med, Ottawa, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; Univ Ottawa, Div Neurosurg, Ottawa, ON, Canada; Univ Ottawa, Clin Epidemiol Unit, Ottawa, ON, Canada; Queens Univ, Dept Emergency Med, Kingston, ON, Canada; Univ Toronto, Div Emergency Med, Toronto, ON, Canada; Univ Western Ontario, Div Emergency Med, London, ON, Canada; Univ British Columbia, Div Emergency Med, Vancouver, BC V5Z 1M9, Canada	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Queens University - Canada; University of Toronto; Western University (University of Western Ontario); University of British Columbia	Stiell, IG (corresponding author), Ottawa Hlth Res Inst, Clin Epidemiol Unit, F6,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	istiell@ohri.ca	Schull, Michael J/A-7955-2013; Morrison, Laurie Jean/A-6325-2012; Reardon, Michael/ABF-8880-2021	Schull, Michael J/0000-0002-1318-6364; Morrison, Laurie Jean/0000-0001-8369-9774; Stiell, Ian/0000-0002-2583-6408				*AM COLL SURG, 1993, ADV TRAUM LIF SUPP I; ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; [Anonymous], 1982, JACKKNIFE BOOTSTRAP; BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; BAYLESS P, 1989, AM J EMERG MED, V7, P139, DOI 10.1016/0735-6757(89)90125-3; CHANGARIS DG, 1987, AM J SURG, V153, P478, DOI 10.1016/0002-9610(87)90797-5; CIAMPI A, 1988, COMPUT METH PROG BIO, V26, P239, DOI 10.1016/0169-2607(88)90004-1; Daffner Richard H., 1993, Journal of Emergency Medicine, V11, P619, DOI 10.1016/0736-4679(93)90318-2; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; DILIBERTI T, 1992, ORTHOPEDICS, V15, P179; DOMEIER RM, 1995, ACAD EMERG MED, V2, P355; Efron B., 1994, MONOGRAPHS STAT APPL; Feinstein AR, 1987, CLINIMETRICS; FISCHER RP, 1984, ANN EMERG MED, V13, P905, DOI 10.1016/S0196-0644(84)80667-8; FRIEDMAN JH, 1977, IEEE T COMPUT, V26, P404, DOI 10.1109/TC.1977.1674849; FRYE G, 1994, ANN EMERG MED, V23, P797, DOI 10.1016/S0196-0644(94)70316-7; GBAANADOR GBM, 1986, AM J SURG, V152, P643, DOI 10.1016/0002-9610(86)90441-1; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; GRAHAM ID, 1998, P 14 ANN M INT SOC T; HILLS MW, 1993, J TRAUMA, V34, P549, DOI 10.1097/00005373-199304000-00011; Hoffman JR, 1998, ANN EMERG MED, V32, P461, DOI 10.1016/S0196-0644(98)70176-3; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; HOFFMAN JR, 1992, ANN EMERG MED, V21, P1454, DOI 10.1016/S0196-0644(05)80059-9; JACOBS LM, 1986, ANN EMERG MED, V15, P44, DOI 10.1016/S0196-0644(86)80485-1; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; McCaig L F, 1994, Adv Data, P1; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; MCKEE TR, 1990, J TRAUMA, V30, P623, DOI 10.1097/00005373-199005000-00018; MCNAMARA R M, 1990, Journal of Emergency Medicine, V8, P177, DOI 10.1016/0736-4679(90)90229-O; MCNAMARA RM, 1988, ANN EMERG MED, V17, P906, DOI 10.1016/S0196-0644(88)80669-3; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; NEIFELD G L, 1988, Journal of Emergency Medicine, V6, P203, DOI 10.1016/0736-4679(88)90327-7; Nichol G, 1999, ACAD EMERG MED, V6, P95, DOI 10.1111/j.1553-2712.1999.tb01044.x; REID DC, 1987, J TRAUMA, V27, P980, DOI 10.1097/00005373-198709000-00005; ROBERGE R J, 1991, Emergency Medicine Clinics of North America, V9, P733; ROBERGE R J, 1992, Journal of Emergency Medicine, V10, P539, DOI 10.1016/0736-4679(92)90133-E; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; ROSEN P, 1998, EMERGENCY MED CONCEP; ROTH BJ, 1994, ARCH SURG-CHICAGO, V129, P643; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Stiell IG, 1997, CAN MED ASSOC J, V156, P1537; Stiell IG, 1997, JAMA-J AM MED ASSOC, V278, P2075, DOI 10.1001/jama.278.23.2075; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P611, DOI 10.1001/jama.275.8.611; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; Stiell IG, 2000, ACAD EMERG MED, V7, P566; TINTINALLI JE, 2000, EMERGENCY MED COMPRE; VANDEMARK RM, 1990, AM J ROENTGENOL, V155, P465, DOI 10.2214/ajr.155.3.2117342; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WILLIAMS J, 1992, ANN EMERG MED, V21, P719, DOI 10.1016/S0196-0644(05)82786-6; WOODRING JH, 1993, J TRAUMA, V34, P32, DOI 10.1097/00005373-199301000-00006	53	717	723	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2001	286	15					1841	1848		10.1001/jama.286.15.1841	http://dx.doi.org/10.1001/jama.286.15.1841			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	482UH	11597285	Bronze			2022-12-28	WOS:000171595300024
J	Chow, TW; MacLean, CH				Chow, TW; MacLean, CH			Quality indicators for dementia in vulnerable community-dwelling and hospitalized elders	ANNALS OF INTERNAL MEDICINE			English	Article							NURSING-HOME PLACEMENT; MENTAL-STATE-EXAMINATION; ALZHEIMERS-DISEASE; CONTROLLED TRIAL; DOUBLE-BLIND; PHYSICAL RESTRAINTS; REVERSIBLE DEMENTIA; COGNITIVE DECLINE; AMERICAN-ACADEMY; SENILE DEMENTIA		Univ So Calif, Rancho Los Amigos Natl Rehabil Ctr, Alzheimers Dis Ctr, Downey, CA 90242 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; RAND Corp, Hlth, Santa Monica, CA 90406 USA	University of Southern California; University of California System; University of California Los Angeles; RAND Corporation	Chow, TW (corresponding author), Univ So Calif, Rancho Los Amigos Natl Rehabil Ctr, Alzheimers Dis Ctr, 7601 E Imperial Highway,800,W Annex, Downey, CA 90242 USA.	tchow@usc.edu						Aevarsson O, 1998, ARCH NEUROL-CHICAGO, V55, P1226, DOI 10.1001/archneur.55.9.1226; ALEXANDER EM, 1995, J AM GERIATR SOC, V43, P138, DOI 10.1111/j.1532-5415.1995.tb06378.x; *AM MED DIR ASS, 1998, CLIN PRACT GIUD 1998; American Psychiatric Association, 1997, PRACT GUID TREATM PA; Bellini M, 1998, ARCH GERONTOL GERIAT, P33; Bowen JD, 1996, NEUROLOGY, V47, P433, DOI 10.1212/WNL.47.2.433; BRADSHAW JR, 1983, BRIT MED J, V286, P277, DOI 10.1136/bmj.286.6361.277; Brodaty H, 1991, Int Psychogeriatr, V3, P11, DOI 10.1017/S1041610291000479; BURDZ MP, 1988, PSYCHOL AGING, V3, P38; BURTON LC, 1992, J AM GERIATR SOC, V40, P811, DOI 10.1111/j.1532-5415.1992.tb01854.x; CAIN ED, 2000, KAPLAN SADOCKS COMPR, P892; CAINE E, 1996, AM J GERIAT PSYCHI S, V4, pS56; Castle NG, 1998, MED CARE RES REV, V55, P139, DOI 10.1177/107755879805500201; CHIVERTON P, 1989, J AM GERIATR SOC, V37, P593, DOI 10.1111/j.1532-5415.1989.tb01248.x; Chow TW, 2000, INT J GERIATR PSYCH, V15, P838, DOI 10.1002/1099-1166(200009)15:9<838::AID-GPS209>3.0.CO;2-U; Chui H, 1997, NEUROLOGY, V49, P925, DOI 10.1212/WNL.49.4.925; CLARFIELD AM, 1988, ANN INTERN MED, V109, P476, DOI 10.7326/0003-4819-109-6-476; COREYBLOOM J, 1995, NEUROLOGY, V45, P211, DOI 10.1212/WNL.45.2.211; COSTA PT, 1996, AHCPR PUBL; COYNE AC, 1995, AM J ALZHEIMER DIS, P27; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; CUMMINGS J, 1983, DEMENTIA CLIN APPROA; DIETCH JT, 1983, WESTERN J MED, V138, P835; DRACHMAN DA, 1993, NEUROLOGY, V43, P2448, DOI 10.1212/WNL.43.12.2448; Draper B, 1998, AGE AGEING, V27, P503, DOI 10.1093/ageing/27.4.503; Dubinsky RM, 2000, NEUROLOGY, V54, P2205, DOI 10.1212/WNL.54.12.2205; Eccles M, 1998, BMJ-BRIT MED J, V317, P802, DOI 10.1136/bmj.317.7161.802; Fillenbaum GG, 1996, AGING-CLIN EXP RES, V8, P379, DOI 10.1007/BF03339599; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; GRAFSTROM M, 1993, SCAND J SOC MED, V21, P247, DOI 10.1177/140349489302100404; Grasel E, 1997, Int Psychogeriatr, V9, P437; Gurian B, 1997, J GERIATR PSYCHIAT, V30, P211; HALL GR, 1996, RES BASES PROTOCOL A; Hendrie HC, 1998, AM J GERIAT PSYCHIAT, V6, pS3, DOI 10.1097/00019442-199821001-00002; HUNT L, 1993, J AM GERIATR SOC, V41, P747, DOI 10.1111/j.1532-5415.1993.tb07465.x; Innes E M, 1983, QRB Qual Rev Bull, V9, P30; JARVIK LF, 1991, GERIATRICS, V46, P31; Johansson K, 1996, J AM GERIATR SOC, V44, P1198, DOI 10.1111/j.1532-5415.1996.tb01369.x; Kapust L R, 1992, J Geriatr Psychiatry Neurol, V5, P210; Kaufer DI, 1996, J GERIATR PSYCH NEUR, V9, P1, DOI 10.1177/089198879600900101; Keady J, 1995, J Psychiatr Ment Health Nurs, V2, P33, DOI 10.1111/j.1365-2850.1995.tb00163.x; KENT DL, 1994, ANN INTERN MED, V120, P872; KITANO H, 1969, CROSS CULTURAL COUNS, P228; KNIGHT BG, 1993, GERONTOLOGIST, V33, P240, DOI 10.1093/geront/33.2.240; Knopman D, 1996, NEUROLOGY, V47, P166, DOI 10.1212/WNL.47.1.166; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; KOENIG HG, 1989, J AM GERIATR SOC, V37, P599, DOI 10.1111/j.1532-5415.1989.tb01249.x; Kunik ME, 1998, J NERV MENT DIS, V186, P299, DOI 10.1097/00005053-199805000-00006; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; LEDFORD L, 1996, RES BASES PROTOCOL; LIN KM, 1997, DSM IV 4 SOURCE BOOK, V3, P885; MAHLER ME, 1987, WESTERN J MED, V146, P705; MARAE TD, 1999, REICHELS CARE ELDERL, P200; MARTIN DC, 1987, ARCH INTERN MED, V147, P77, DOI 10.1001/archinte.147.1.77; McCurry SM, 1999, INT J GERIATR PSYCH, V14, P882, DOI 10.1002/(SICI)1099-1166(199910)14:10<882::AID-GPS42>3.0.CO;2-D; McHutchion E, 1989, J Gerontol Nurs, V15, P16; MILES SH, 1992, GERONTOLOGIST, V32, P762, DOI 10.1093/geront/32.6.762; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MOHIDE EA, 1990, J AM GERIATR SOC, V38, P446, DOI 10.1111/j.1532-5415.1990.tb03544.x; MOSCA LJ, 1992, CLIN RES, V40, pA561; Mungas D, 1996, NEUROLOGY, V46, P700, DOI 10.1212/WNL.46.3.700; *OFF GER EXT CAR D, 1989, DEM GUID DIAGN TREAT; OKAGAKI JF, 1994, NEUROLOGY, V44, P2203; Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720; Perryman KM, 1996, J GERIATR PSYCH NEUR, V9, P136, DOI 10.1177/089198879600900306; Rao R, 1997, INT J GERIATR PSYCH, V12, P337, DOI 10.1002/(SICI)1099-1166(199703)12:3<337::AID-GPS498>3.0.CO;2-T; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Ross GW, 1997, JAMA-J AM MED ASSOC, V277, P800, DOI 10.1001/jama.277.10.800; SCHNELLE JF, 1992, GERONTOLOGIST, V32, P767, DOI 10.1093/geront/32.6.767; SCHULZ B M, 1991, Clinical Gerontologist, V11, P80; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; SMALL G, 1995, COMPREHENSIVE TXB PS, V2, P2562; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; Small GW, 1998, CLIN THER, V20, P838, DOI 10.1016/S0149-2918(98)80145-8; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Swan GE, 1998, NEUROLOGY, V51, P986, DOI 10.1212/WNL.51.4.986; Teunisse S, 1996, J NEUROL, V243, P522, DOI 10.1007/BF00886874; Thal LJ, 1997, NEUROLOGY, V49, P897, DOI 10.1212/WNL.49.3.897-b; THOMPSON P, 1987, BRIT J PSYCHIAT, V151, P206, DOI 10.1192/bjp.151.2.206; *UCLA MED CTR STAN, 1998, INV PHYS RESTR POL 0; *US BUR CENS, 1996, US BUR CENS PUBL; *VET HLTH ADM US D, 1997, DEM ID ASS GUID PRIM, P1; Walstra GJM, 1997, J NEUROL, V244, P17; WEYTINGH MD, 1995, J NEUROL, V242, P466, DOI 10.1007/BF00873551; 1986, JAMA, V256, P2234	88	23	23	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				668	676		10.7326/0003-4819-135-8_Part_2-200110161-00005	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601949				2022-12-28	WOS:000171542400005
J	Kampe, KKW; Frith, CD; Dolan, RJ; Frith, U				Kampe, KKW; Frith, CD; Dolan, RJ; Frith, U			Reward value of attractiveness and gaze - Making eye contact enhances the appeal of a pleasing face, irrespective of gender.	NATURE			English	Article									UCL, Inst Cognit Neurosci, London WC1N 3AR, England; Wellcome Dept Cognit Neurol, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Kampe, KKW (corresponding author), UCL, Inst Cognit Neurosci, 17 Queen Sq, London WC1N 3AR, England.	k.kampe@ucl.ac.uk	Frith, Chris D/A-2171-2009; Frith, Uta/C-1757-2008	Frith, Chris D/0000-0002-8665-0690; Frith, Uta/0000-0002-9063-4466; Dolan, Ray/0000-0001-9356-761X				Berridge KC, 1996, NEUROSCI BIOBEHAV R, V20, P1, DOI 10.1016/0149-7634(95)00033-B; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; Emery NJ, 2000, NEUROSCI BIOBEHAV R, V24, P581, DOI 10.1016/S0149-7634(00)00025-7; KLEINKE CL, 1986, PSYCHOL BULL, V100, P78, DOI 10.1037/0033-2909.100.1.78; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1	6	329	335	2	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 11	2001	413	6856					589	589		10.1038/35098149	http://dx.doi.org/10.1038/35098149			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	480WE	11595937	Green Published, Bronze			2022-12-28	WOS:000171485700037
J	De Leo, GA; Rizzi, L; Caizzi, A; Gatto, M				De Leo, GA; Rizzi, L; Caizzi, A; Gatto, M			Carbon emissions - The economic benefits of the Kyoto Protocol	NATURE			English	Article									Univ Parma, Dipartimento Sci Ambientali, I-43100 Parma, Italy; Ctr Elettrotecn Sperimentale Italiano, Business Unit Ambiente, I-20092 Segrate, Italy; Politecn Milan, Consiglio Nazl Ric, Ctr Ingn Biomed, I-20133 Milan, Italy	University of Parma; Consiglio Nazionale delle Ricerche (CNR); Polytechnic University of Milan	De Leo, GA (corresponding author), Univ Parma, Dipartimento Sci Ambientali, Parco Area Sci, I-43100 Parma, Italy.		De Leo, Giulio/AAC-5098-2019; Gatto, Marino/D-9531-2012	De Leo, Giulio/0000-0002-4186-3369; Gatto, Marino/0000-0001-8063-9178				Callan S. J., 2009, S W CENGAGE LEARNING, VFifth, P64; DELEO GA, 2000, P 29 INT C AUT DEC M, P247; DEPAOLI L, 1999, EC POLITICA FONTI RI; *EUR COMM, 1995, EXT EXT EN, V1; Gatto M, 2000, BIOSCIENCE, V50, P347, DOI 10.1641/0006-3568(2000)050[0347:PBAEST]2.3.CO;2; *INT WORK GROUP, OPRNLCON476 INT WORK; *INT WORK GROUP, LBNL44029 INT WORK G; ROWE RD, 1995, NEW YORK STATE ENV E, V1; RUSSELL L, 1994, EXTERNAL COSTS BENEF	9	25	26	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					478	479		10.1038/35097156	http://dx.doi.org/10.1038/35097156			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586347				2022-12-28	WOS:000171340500034
J	Manges, AR; Johnson, JR; Foxman, B; O'Bryan, TT; Fullerton, KE; Riley, LW				Manges, AR; Johnson, JR; Foxman, B; O'Bryan, TT; Fullerton, KE; Riley, LW			Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; SEROTYPE O-15-K52-H1; STRAINS; SEQUENCES; WOMEN; PYELONEPHRITIS; UROPATHOGENS; BACTEREMIA; PREVALENCE; UROSEPSIS	Background: The management of urinary tract infections is complicated by the increasing prevalence of antibiotic-resistant strains of Escherichia coli. We studied the clonal composition of E. coli isolates that were resistant to trimethoprim-sulfamethoxazole from women with community-acquired urinary tract infections. Methods: Prospectively collected E. coli isolates from women with urinary tract infections in a university community in California were evaluated for antibiotic susceptibility, O:H serotype, DNA fingerprinting, pulsed-field gel electrophoretic pattern, and virulence factors. The prevalence and characteristics of an antibiotic-resistant clone were evaluated in this group of isolates and in those from comparison cohorts in Michigan and Minnesota. Results: Fifty-five of the 255 E. coli isolates (22 percent) from the California cohort were resistant to trimethoprim-sulfamethoxazole as well as other antibiotics. There was a common pattern of DNA fingerprinting, suggesting that the isolates belonged to the same clonal group (clonal group A), in 28 of 55 isolates with trimethoprim-sulfamethoxazole resistance (51 percent) and in 2 of 50 randomly selected isolates that were susceptible to trimethoprim-sulfamethoxazole (4 percent, P<0.001). In addition, 11 of 29 resistant isolates (38 percent) from the Michigan cohort and 7 of 18 (39 percent) from the Minnesota cohort belonged to clonal group A. Most of the clonal group A isolates were serotype O11:H(nt) or O77:H(nt), with similar patterns of virulence factors, antibiotic susceptibility, and electrophoretic features. Conclusions: In three geographically diverse communities, a single clonal group accounted for nearly half of community-acquired urinary tract infections in women that were caused by E. coli strains with resistance to trimethoprim-sulfamethoxazole. The widespread distribution and high prevalence of E. coli clonal group A have major public health implications. (N Engl J Med 2001;345:1007-13.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol & Publ Hlth Biol, Berkeley, CA 94720 USA; Minneapolis Vet Affairs Med Ctr, Med Serv, Minneapolis, MN USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	University of California System; University of California Berkeley; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan	Riley, LW (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol & Publ Hlth Biol, 140 Warren Hall, Berkeley, CA 94720 USA.			Foxman, Betsy/0000-0001-6682-238X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK035368, R01DK047504, R01DK035368] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35368, DK-47504] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender JB, 1997, NEW ENGL J MED, V337, P388, DOI 10.1056/NEJM199708073370604; Bettelheim K. A., 1997, P85; Cooke EM, 1974, ESCHERICHIA COLI MAN, P31; Dalmau D, 1996, J HOSP INFECT, V34, P233, DOI 10.1016/S0195-6701(96)90073-0; Donnenberg Michael S., 1996, P135; DORN CR, 1993, J AM VET MED ASSOC, V203, P1583; Foxman B, 1997, J INFECT DIS, V175, P989, DOI 10.1086/514007; Foxman B, 2000, AM J EPIDEMIOL, V151, P1194, DOI 10.1093/oxfordjournals.aje.a010170; Foxman B, 2000, ANN EPIDEMIOL, V10, P509, DOI 10.1016/S1047-2797(00)00072-7; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; HARDY K, 1983, BACTERIAL PLASMIDS; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; HULTON CSJ, 1991, MOL MICROBIOL, V5, P825, DOI 10.1111/j.1365-2958.1991.tb00755.x; Johnson JR, 2000, J INFECT DIS, V181, P2122; Johnson JR, 1998, J INFECT DIS, V177, P1120, DOI 10.1086/517409; Johnson JR, 2000, CLIN DIAGN LAB IMMUN, V7, P265, DOI 10.1128/CDLI.7.2.265-273.2000; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; JOHNSON JR, 1988, INFECT IMMUN, V56, P405, DOI 10.1128/IAI.56.2.405-412.1988; Johnson JR, 2000, INFECT IMMUN, V68, P1587, DOI 10.1128/IAI.68.3.1587-1599.2000; Johnson JR, 2000, J INFECT DIS, V181, P261, DOI 10.1086/315217; Johnson JR, 2000, INFECT IMMUN, V68, P3327, DOI 10.1128/IAI.68.6.3327-3336.2000; JOHNSON JR, 1999, 99 GEN M AM SOC MICR, P31; Kahlmeter G, 2000, J ANTIMICROB CHEMOTH, V46, P15, DOI 10.1093/jac/46.suppl_1.15; MANIATIS T, 1991, CLIN MICROBIOL REV, V4, P80; MOBLEY HLT, 1990, INFECT IMMUN, V58, P1281, DOI 10.1128/IAI.58.5.1281-1289.1990; *NAT COMM CLIN LAB, 2000, M100S10 NCCLS, V14, P8; National Archives, 2000, M7A5 NCCLS, P1; Olesen B, 1995, J HOSP INFECT, V31, P295, DOI 10.1016/0195-6701(95)90208-2; PHILLIPS I, 1988, LANCET, V1, P1038; Prats G, 2000, J CLIN MICROBIOL, V38, P201; SHARPLES GJ, 1990, NUCLEIC ACIDS RES, V18, P6503, DOI 10.1093/nar/18.22.6503; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; TULLUS K, 1984, J INFECT DIS, V150, P728, DOI 10.1093/infdis/150.5.728; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; Versalovic James, 1994, Methods in Molecular and Cellular Biology, V5, P25; WOODS CR, 1993, J CLIN MICROBIOL, V31, P1927, DOI 10.1128/JCM.31.7.1927-1931.1993; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	360	370	0	29	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1007	1013		10.1056/NEJMoa011265	http://dx.doi.org/10.1056/NEJMoa011265			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586952				2022-12-28	WOS:000171340400001
J	Nott, J; Hayne, M				Nott, J; Hayne, M			High frequency of 'super-cyclones' along the Great Barrier Reef over the past 5,000 years	NATURE			English	Article							CORAL-REEFS; RECRUITMENT; DISTURBANCE; COMMUNITY; DIVERSITY; ATOLL; BEBE	Understanding long-term variability in the occurrence of tropical cyclones that are of extreme intensity is important for determining their role in ecological disturbances(1-5), for predicting present and future community vulnerability and economic loss(6) and for assessing whether changes in the variability of such cyclones are induced by climate change(7). Our ability to accurately make these assessments has been limited by the short (less than 100 years) instrumented record of cyclone intensity. Here we determine the intensity of prehistoric tropical cyclones over the past 5,000 years from ridges of detrital coral and shell deposited above highest tide and terraces that have been eroded into coarse-grained alluvial fan deposits. These features occur along 1,500 km of the Great Barrier Reef and also the Gulf of Carpentaria, Australia. We infer that the deposits were formed by storms with recurrence intervals of two to three centuries(8-11), and we show that the cyclones responsible must have been of extreme intensity (central pressures less than 920 hPa). Our estimate of the frequency of such 'super-cyclones' is an order of magnitude higher than that previously estimated (which was once every several millennia(12-14)), and is sufficiently high to suggest that the character of rainforests and coral reef communities were probably shaped by these events.	James Cook Univ N Queensland, Sch Trop Environm Studies & Geog, Cairns, Qld 4870, Australia; Australial Geol Survey Org, Canberra, ACT 2601, Australia	James Cook University	Nott, J (corresponding author), James Cook Univ N Queensland, Sch Trop Environm Studies & Geog, POB 6811, Cairns, Qld 4870, Australia.	Jonathan.Nott@jcu.edu.au	Nott, Jonathan/H-5156-2011	Nott, Jonathan/0000-0001-7258-017X				BLUMENSTOCK DI, 1958, NATURE, V182, P1267, DOI 10.1038/1821267a0; Bryant E. A., 1991, NATURAL HAZARDS; CHAPPELL J, 1983, BMR J AUST GEOL GEOP, V8, P223; CHAPPELL J, 1984, COASTAL GEOMORPHOLOG, P197; CHIVAS A, 1986, MAR GEOL, V69, P273, DOI 10.1016/0025-3227(86)90043-5; Connell JH, 1997, ECOL MONOGR, V67, P461, DOI 10.1890/0012-9615(1997)067[0461:AYSOCA]2.0.CO;2; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; Everham EM, 1996, BOT REV, V62, P113, DOI 10.1007/BF02857920; Fitchett K, 1987, AUST GEOGR, V18, P1, DOI 10.1080/00049188708702920; HARPER B, 1998, 10 QUEENSL DEP ENV H; Hayne M, 2001, PALAEOGEOGR PALAEOCL, V168, P207, DOI 10.1016/S0031-0182(00)00217-0; HAYNE M, IN PRESS PALAEOGEOGR; Henderson-Sellers A, 1998, B AM METEOROL SOC, V79, P19, DOI 10.1175/1520-0477(1998)079<0019:TCAGCC>2.0.CO;2; Hubbell SP, 1999, SCIENCE, V283, P554, DOI 10.1126/science.283.5401.554; Hubbert GD, 1999, J COASTAL RES, V15, P168; HUGHES TP, 1989, ECOLOGY, V70, P275, DOI 10.2307/1938434; Hughes TP, 1999, LIMNOL OCEANOGR, V44, P932, DOI 10.4319/lo.1999.44.3_part_2.0932; LIRMAN D, 1997, P 8 INT COR REEF S P, V1, P561; LOURENSZ H, 1981, TROPICAL CYCLONES AU; MARAGOS JE, 1973, SCIENCE, V181, P1161, DOI 10.1126/science.181.4105.1161; MCINNES K, 2000, CYCLONES IMPACTS TOU; OLIVER J, 1989, NATURAL HAZARDS REIN; POTTS DC, 1985, MAR ECOL PROG SER, V23, P79, DOI 10.3354/meps023079; SANDERSON B, 1995, 9528 MON U DEP MATH; SCOFFIN TP, 1993, CORAL REEFS, V12, P203, DOI 10.1007/BF00334480; SOUSA WP, 1984, ANNU REV ECOL SYST, V15, P353, DOI 10.1146/annurev.es.15.110184.002033; Tanner JE, 1996, ECOLOGY, V77, P108, DOI 10.2307/2265660; *USA CORPS ENG, 1986, SHOR PROT MAN; Walsh K., 2001, CLIMATE CHANGE QUEEN	29	155	162	3	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 4	2001	413	6855					508	512		10.1038/35097055	http://dx.doi.org/10.1038/35097055			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586356				2022-12-28	WOS:000171340500043
J	Brazier, JE; Johnson, AG				Brazier, JE; Johnson, AG			Economics of surgery	LANCET			English	Article							LAPAROSCOPIC CHOLECYSTECTOMY; GALLSTONE DISEASE; MINI-CHOLECYSTECTOMY; COST-EFFECTIVENESS; RANDOMIZED TRIAL	The time has come to subject surgery to the same rigours of economic assessment that other health-care sectors are already receiving-namely, the comparative assessment of costs and benefits. The surgical management of gallstones provides a good example of the role of economics in surgery. Gallstone disease is common and patients are usually referred to a surgeon, but the threshold for intervention is not agreed and varies widely, with considerable implications for resources. Gallstone removal has been subject to much innovation over the past 1.0 years, yet economic assessment of laparoscopic and "mini" cholecystectomy and of gallstone lithotripsy Is rare, despite the fact that operation rates have Increased by up to 50% In some countries. For surgery to compete with other interventions, economic assessment of new surgical techniques will be increasingly important. This assessment should be based on well-conducted clinical trials In which interventions are provided in a routine service setting, and in which benefits are assessed among other things on the basis of the patient's perceived quality of life. Economic assessment often needs data beyond those collected In a clinical trial, however pragmatic the trial design, so modelling will often be required, incorporating a range of sources of evidence. Finally, evidence alone will not be enough to promote cost-effective practices. The take-up of surgical techniques will always be affected by the way hospitals and surgeons are remunerated. Affecting practice requires a realistic system of reimbursement that reflects evidence on cost effectiveness.	Univ Sheffield, Sch Hlth & Related Res, Sheffield Hlth Econ Grp, Sheffield S1 4DE, S Yorkshire, England; Royal Hallamshire Hosp, Sect Surg & Anaesthet Sci, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield	Brazier, JE (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield Hlth Econ Grp, Sheffield S1 4DE, S Yorkshire, England.		brazier, john e/B-1936-2008	Brazier, John/0000-0001-8645-4780				Ahmed R, 2000, EUR J SURG, V166, P447; BARKUN JS, 1995, SURG ENDOSC-ULTRAS, V9, P1221; BASS EB, 1994, MED DECIS MAKING, V14, P307, DOI 10.1177/0272989X9401400401; Berggren U, 1996, AM J SURG, V172, P305, DOI 10.1016/S0002-9610(96)00197-3; Brazier J, 1999, HEALTH TECHNOL ASSES, V3, P9; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Calvert NW, 2000, EUR J SURG, V166, P782, DOI 10.1080/110241500447416; CAPOCACCIA L, 1984, AM J EPIDEMIOL, V119, P796; COOK J, 1994, HEALTH ECON, V3, P157, DOI 10.1002/hec.4730030305; DONALDSON C, 1997, SOC SCI MED, V44, P285; Drummond MF, 2015, METHODS EC EVALUATIO; FLETCHER DR, 1995, MJA, V163, P553; FURLONG W, 1998, 9811 WP U MCM CTR HL; GOUMA DJ, 1994, J AM COLL SURGEONS, V178, P229; JORGENSEN T, 1989, HEPATOLOGY, V9, P856, DOI 10.1002/hep.1840090611; Jorgensen T., 2000, TREATMENT GALLSTONE; Kesteloot K, 1993, Health Econ, V2, P303, DOI 10.1002/hec.4730020403; Lam CM, 1996, GUT, V38, P282, DOI 10.1136/gut.38.2.282; Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; Meltzer MI, 2001, LANCET, V358, P993, DOI 10.1016/S0140-6736(01)06107-4; NICHOLL JP, 1992, LANCET, V340, P801, DOI 10.1016/0140-6736(92)92682-6; ROSS A, IN PRESS ANN SURG; SAUERBRUCH T, 1986, NEW ENGL J MED, V314, P818, DOI 10.1056/NEJM198603273141304; Savader SJ, 1997, ANN SURG, V225, P268, DOI 10.1097/00000658-199703000-00005; SCOTT EA, 1992, ANN ROY COLL SURG, V74, P97; Seale AK, 1999, ARCH SURG-CHICAGO, V134, P308, DOI 10.1001/archsurg.134.3.308	27	19	21	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 29	2001	358	9287					1077	1081		10.1016/S0140-6736(01)06185-2	http://dx.doi.org/10.1016/S0140-6736(01)06185-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	479EY	11594315				2022-12-28	WOS:000171393100029
J	Bell, G				Bell, G			Ecology - Neutral macroecology	SCIENCE			English	Review							GEOGRAPHIC RANGE SIZE; SPECIES ABUNDANCE; COMMUNITY STRUCTURE; DIVERSITY; PATTERNS; NUMBER	The central themes of community ecology-distribution, abundance, and diversity-display strongly marked and very general patterns. These include the log-normal distribution of abundance, the relation between range and abundance, the species-area law, and the turnover of species composition. Each pattern is the subject of a large literature that interprets it in terms of ecological processes, typically involving the sorting of differently specialized species onto heterogeneous landscapes. Alt of these patterns can be shown to arise, however, from neutral community models in which all individuals have identical properties, as the consequence of local dispersal alone. This implies, at the least, that functional interpretations of these patterns must be reevaluated. More fundamentally, neutral community models provide a general theory for biodiversity and conservation biology capable of predicting the fundamental processes and patterns of community ecology.	McGill Univ, Redpath Museum, Montreal, PQ H3A 2K6, Canada	McGill University	Bell, G (corresponding author), McGill Univ, Redpath Museum, 859 Sherbrooke St W, Montreal, PQ H3A 2K6, Canada.	gbell2@po-box.mcgill.ca	Ebersole, Joseph L/A-8371-2009					[Anonymous], 1975, COMMUNITIES ECOSYSTE; ANTONOVICS J, 1976, ANN MO BOT GARD, V63, P224, DOI 10.2307/2395303; Bell G, 2000, J ECOL, V88, P67, DOI 10.1046/j.1365-2745.2000.00427.x; Bell G, 2000, AM NAT, V155, P606, DOI 10.1086/303345; BELL G, IN PRESS PLANTS STAN; Blackburn TM, 1996, PHILOS T R SOC B, V351, P897, DOI 10.1098/rstb.1996.0083; Blackburn TM, 1997, PHILOS T ROY SOC B, V352, P419, DOI 10.1098/rstb.1997.0030; Brown J.H., 1995, MACROECOLOGY; Brown JH, 1996, ANNU REV ECOL SYST, V27, P597, DOI 10.1146/annurev.ecolsys.27.1.597; BROWN JH, 1984, AM NAT, V124, P255, DOI 10.1086/284267; CASWELL H, 1976, ECOL MONOGR, V46, P327, DOI 10.2307/1942257; CHEPLICK GP, 1988, AM J BOT, V75, P1048, DOI 10.2307/2443772; CONNOR EF, 1979, AM NAT, V113, P791, DOI 10.1086/283438; Fisher RA, 1943, J ANIM ECOL, V12, P42, DOI 10.2307/1411; Gaston K.J., 1994, RARITY, P1; Gaston KJ, 1996, TRENDS ECOL EVOL, V11, P197, DOI 10.1016/0169-5347(96)10027-6; Gaston KJ, 1996, OIKOS, V76, P211, DOI 10.2307/3546192; Gaston KJ, 1997, J ANIM ECOL, V66, P579, DOI 10.2307/5951; Gaston KJ, 1996, J ANIM ECOL, V65, P701, DOI 10.2307/5669; Gotelli N.J., 1996, NULL MODELS ECOLOGY; HARRISON S, 1992, J ANIM ECOL, V61, P151, DOI 10.2307/5518; He FL, 2000, AM NAT, V156, P553, DOI 10.1086/303403; HENGEVELD R, 1982, J BIOGEOGR, V9, P303, DOI 10.2307/2844717; HUBBELL SP, 1979, SCIENCE, V203, P1299, DOI 10.1126/science.203.4387.1299; HUBBELL SP, 1995, PROG BIOMET, V9, P171; HUBBELL SP, IN PRESS NIFIED NEUT; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; Lawton JH, 1996, BIRD STUDY, V43, P3, DOI 10.1080/00063659609460991; LEWONTIN RC, 1978, GENETIC BASIS EVOLUT; Lovett-Doust L., 1981, J ECOL, V69, P757, DOI DOI 10.2307/2259634; MACARTHUR RH, 1957, P NATL ACAD SCI USA, V43, P293, DOI 10.1073/pnas.43.3.293; May R.M., 1975, P81; NEE S, 1991, P ROY SOC B-BIOL SCI, V243, P161, DOI 10.1098/rspb.1991.0026; PAGEL MD, 1991, AM NAT, V137, P791, DOI 10.1086/285194; PRESTON FW, 1948, ECOLOGY, V29, P254, DOI 10.2307/1930989; REED T, 1981, J ANIM ECOL, V50, P613, DOI 10.2307/4078; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SCHOENER TW, 1987, OECOLOGIA, V74, P161, DOI 10.1007/BF00379356; SUGIHARA G, 1980, AM NAT, V116, P770, DOI 10.1086/283669; TOKESHI M, 1990, J ANIM ECOL, V59, P1129, DOI 10.2307/5036; VANTIENDEREN PH, 1991, J ECOL, V79, P43, DOI 10.2307/2260783	41	585	627	12	369	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2001	293	5539					2413	2418		10.1126/science.293.5539.2413	http://dx.doi.org/10.1126/science.293.5539.2413			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	476PD	11577228				2022-12-28	WOS:000171237200037
J	Braveman, P; Starfield, B; Geiger, HJ				Braveman, P; Starfield, B; Geiger, HJ			World Health Report 2000: how it removes equity from the agenda for public health monitoring and policy	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL INEQUALITIES		Univ Calif San Francisco, San Francisco, CA 94143 USA; Johns Hopkins Med Inst, Baltimore, MD 21205 USA; CUNY, Sch Med, Dept Community Hlth & Social Med, New York, NY 10031 USA	University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Medicine; City University of New York (CUNY) System	Braveman, P (corresponding author), Univ Calif San Francisco, Box 0900,500 Parnassus Ave,MU3E, San Francisco, CA 94143 USA.							Braveman P, 2000, B WORLD HEALTH ORGAN, V78, P232; Gakidou EE, 2000, B WORLD HEALTH ORGAN, V78, P42; Kawachi I, 1997, BMJ-BRIT MED J, V314, P1037, DOI 10.1136/bmj.314.7086.1037; MacIntyre S, 1997, SOC SCI MED, V44, P723, DOI 10.1016/S0277-9536(96)00183-9; Murray CJL, 1999, B WORLD HEALTH ORGAN, V77, P537; Murray CJL, 2000, B WORLD HEALTH ORGAN, V78, P234; VICTORA CG, 1992, INT J EPIDEMIOL, V21, P911, DOI 10.1093/ije/21.5.911; *WHO, 2000, WHO200044; World Health Organization, 2000, WORLD HLTH REP 2000	9	75	83	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					678	680		10.1136/bmj.323.7314.678	http://dx.doi.org/10.1136/bmj.323.7314.678			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	476LP	11566834	Green Published			2022-12-28	WOS:000171228800023
J	Hollander, E; Evers, M				Hollander, E; Evers, M			New developments in impulsivity	LANCET			English	Editorial Material							VENTROMEDIAL PREFRONTAL CORTEX; DECISION-MAKING; DEFICIT; BLIND		Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Hollander, E (corresponding author), Mt Sinai Sch Med, Dept Psychiat, Box 1230, New York, NY 10029 USA.	eric.hollander@mssm.edu						Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Bechara A, 1999, J NEUROSCI, V19, P5473; Brunner D, 1997, ANN NY ACAD SCI, V836, P81, DOI 10.1111/j.1749-6632.1997.tb52356.x; Cardinal RN, 2001, SCIENCE, V292, P2499, DOI 10.1126/science.1060818; Ernst M, 1998, J NEUROSCI, V18, P5901; Hollander E, 1998, AM J PSYCHIAT, V155, P1781, DOI 10.1176/ajp.155.12.1781; Hollander E, 1998, BRIT J PSYCHIAT, V173, P7, DOI 10.1192/S0007125000297845; Hollander E, 2001, J CLIN PSYCHIAT, V62, P199, DOI 10.4088/JCP.v62n0311; Hollander E, 2000, PSYCHIAT CLIN N AM, V23, P629, DOI 10.1016/S0193-953X(05)70185-4; HOLLANDER E, IN PRESS AM PSYCHIAT; Luria A. R., 2012, HIGHER CORTICAL FUNC; New AS, 1998, AM J MED GENET, V81, P13, DOI 10.1002/(SICI)1096-8628(19980207)81:1<13::AID-AJMG3>3.0.CO;2-O; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; Siever LJ, 1999, NEUROPSYCHOPHARMACOL, V20, P413, DOI 10.1016/S0893-133X(98)00111-0	15	41	44	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 22	2001	358	9286					949	950		10.1016/S0140-6736(01)06114-1	http://dx.doi.org/10.1016/S0140-6736(01)06114-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583745				2022-12-28	WOS:000171135300012
J	Ellison, V; Stillman, B				Ellison, V; Stillman, B			Opening of the clamp: An intimate view of an ATP-driven biological machine	CELL			English	Review							EUKARYOTIC DNA-REPLICATION; CRYSTAL-STRUCTURE; POLYMERASE; COMPLEX; PROTEINS	DNA polymerases require tethering to an accessory factor, typically a ring-shaped clamp, to remain bound to DNA during replication. Three recent structural studies provide unique insight into how these clamps are loaded onto DNA by the clamp loader machinery.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091				ALLEY S, 2001, IN PRESS J BIOL CHEM; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; Mayanagi K, 2001, J STRUCT BIOL, V134, P35, DOI 10.1006/jsbi.2001.4357; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Neuwald AF, 1999, GENOME RES, V9, P27; Oyama T, 2001, MOL CELL, V8, P455, DOI 10.1016/S1097-2765(01)00328-8; Pietroni P, 2001, J MOL BIOL, V309, P869, DOI 10.1006/jmbi.2001.4687; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	22	70	73	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 21	2001	106	6					655	660		10.1016/S0092-8674(01)00498-6	http://dx.doi.org/10.1016/S0092-8674(01)00498-6			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572772	Bronze			2022-12-28	WOS:000171213000003
J	Hale, ML; Lurz, PWW; Shirley, MDF; Rushton, S; Fuller, RM; Wolff, K				Hale, ML; Lurz, PWW; Shirley, MDF; Rushton, S; Fuller, RM; Wolff, K			Impact of landscape management on the genetic structure of red squirrel populations	SCIENCE			English	Article							MICROSATELLITE DATA; DISPERSAL; DISTANCE; FOREST; MAP	Landscape management practices that alter the degree of habitat fragmentation can significantly affect the genetic structure of animal populations. British red squirrels use "stepping stone" patches of habitat to move considerable distances through a fragmented habitat. Over the past few decades, the planting of a large conifer forest has connected groups of forest fragments in the north of England with those in southern Scotland. This "defragmentation" of the landscape has resulted in substantial genetic mixing of Scottish and Cumbrian genes in squirrel populations up to 100 kilometers from the site of the new forest. These results have implications for the conservation management of animal and plant species in fragmented landscapes such as those found in Britain.	Univ Newcastle Upon Tyne, Dept Agr & Environm Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Newcastle Upon Tyne, Ctr Life Sci Modelling, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Ctr Ecol & Hydrol, Huntingdon PE28 2LS, England	Newcastle University - UK; Newcastle University - UK; UK Centre for Ecology & Hydrology (UKCEH)	Hale, ML (corresponding author), Univ Newcastle Upon Tyne, Dept Agr & Environm Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.		Lurz, Peter/O-5108-2019; Wolff, Kirsten/E-7961-2012	Wolff, Kirsten/0000-0002-6050-8493; Shirley, Mark/0000-0002-6220-2578				[Anonymous], 1997, ECOL SOC, DOI DOI 10.5751/ES-00015-010104; Beier P, 1998, CONSERV BIOL, V12, P1241, DOI 10.1046/j.1523-1739.1998.98036.x; Bevers M, 1999, THEOR POPUL BIOL, V55, P61, DOI 10.1006/tpbi.1998.1392; CARO TM, 1994, SCIENCE, V263, P485, DOI 10.1126/science.8290956; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FULLER RM, 1994, PHOTOGRAMM ENG REM S, V60, P553; Gaggiotti OE, 1999, MOL ECOL, V8, P1513, DOI 10.1046/j.1365-294x.1999.00730.x; Gurnell J, 1997, CONSERVATION RED SQU; Haddad N, 2000, CONSERV BIOL, V14, P738, DOI 10.1046/j.1523-1739.2000.99041.x; Hale ML, 2001, MOL ECOL NOTES, V1, P47, DOI 10.1046/j.1471-8278 .2000.00020.x; Lande R, 1996, EVOLUTION, V50, P434, DOI 10.2307/2410812; Lurz, 1997, CONSERVATION RED SQU, P5; Lurz P.W.W., 1995, THESIS U NEWCASTLE N; Lurz PWW, 1995, FOREST ECOL MANAG, V79, P79, DOI 10.1016/0378-1127(95)03617-2; Matthews J. D., 1955, Report on forest research by the Forestry Commission for the year ending March, 1954., P64; McIntosh R, 1995, FOREST ECOL MANAG, V79, P1, DOI 10.1016/0378-1127(95)03628-8; NEI M, 1972, AM NAT, V106, P283, DOI 10.1086/282771; Paetkau D, 1997, GENETICS, V147, P1943; PAETKAU D, 1995, MOL ECOL, V4, P347, DOI 10.1111/j.1365-294X.1995.tb00227.x; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; REYNOLDS JC, 1985, J ANIM ECOL, V54, P149, DOI 10.2307/4627; Schneider S. D., 2000, ARLEQUIN VERSION 200; Shorten M, 1954, SQUIRRELS; TONKIN JM, 1983, THESIS U BRADFORD BR; Waser PM, 1998, TRENDS ECOL EVOL, V13, P43, DOI 10.1016/S0169-5347(97)01255-X; WAUTERS L, 1994, OIKOS, V69, P140, DOI 10.2307/3545294	26	98	110	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2246	2248		10.1126/science.1062574	http://dx.doi.org/10.1126/science.1062574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567136				2022-12-28	WOS:000171139400041
J	Ji, YD; Zhang, B; Van Horn, SF; Warren, P; Woodnutt, G; Burnham, MKR; Rosenberg, M				Ji, YD; Zhang, B; Van Horn, SF; Warren, P; Woodnutt, G; Burnham, MKR; Rosenberg, M			Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA	SCIENCE			English	Article							IN-VITRO; REGULATED EXPRESSION; BACILLUS-SUBTILIS; AUREUS; VIRULENCE; OLIGONUCLEOTIDES; INACTIVATION; MUTAGENESIS; PLASMIDS; SYSTEM	Comprehensive genomic analysis of the important human pathogen Staphylococcus aureus was achieved by a strategy involving antisense technology in a regulatable gene expression system. In addition to known essential genes, many genes of unknown or poorly defined biological function were identified. This methodology allowed gene function to be characterized in a comprehensive, defined set of conditionally growth-defective/lethal isogenic strains. Quantitative titration of the conditional growth effect was performed either in bacterial culture or in an animal model of infection. This genomic strategy offers an approach to the identification of staphylococcal gene products that could serve as targets for antibiotic discovery.	GlaxoSmithKline Pharmaceut Res & Dev, Dept Microbiol, Collegeville, PA 19426 USA; GlaxoSmithKline Pharmaceut Res & Dev, Genet Res, Collegeville, PA 19426 USA	GlaxoSmithKline; GlaxoSmithKline	Ji, YD (corresponding author), 1250 S Collegeville Rd,UP1345, Collegeville, PA 19426 USA.							Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Akerley BJ, 1998, P NATL ACAD SCI USA, V95, P8927, DOI 10.1073/pnas.95.15.8927; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851; Brantl S, 2000, MOL MICROBIOL, V35, P1469, DOI 10.1046/j.1365-2958.2000.01813.x; CHEUNG AL, 1995, J BACTERIOL, V177, P3220, DOI 10.1128/jb.177.11.3220-3226.1995; De Backer MD, 2001, NAT BIOTECHNOL, V19, P235, DOI 10.1038/85677; DEBEAUREGARD MAC, 1995, EMBO J, V14, P409, DOI 10.1002/j.1460-2075.1995.tb07017.x; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GEISSENDORFER M, 1990, APPL MICROBIOL BIOT, V33, P657, DOI 10.1007/BF00604933; Good L, 1998, NAT BIOTECHNOL, V16, P355, DOI 10.1038/nbt0498-355; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Ji YD, 1999, J BACTERIOL, V181, P6585, DOI 10.1128/JB.181.21.6585-6590.1999; Martin PK, 1999, J BACTERIOL, V181, P3666, DOI 10.1128/JB.181.12.3666-3673.1999; Mizuta T, 1999, NAT BIOTECHNOL, V17, P583, DOI 10.1038/9893; Parish T, 1997, FEMS MICROBIOL LETT, V154, P151, DOI 10.1016/S0378-1097(97)00317-0; Rappleye CA, 1997, J BACTERIOL, V179, P5827, DOI 10.1128/jb.179.18.5827-5834.1997; SCHMID MB, 1989, GENETICS, V123, P625; Stieger M, 1999, GENE, V226, P243, DOI 10.1016/S0378-1119(98)00561-7; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P717; Zhang L, 2000, GENE, V255, P297, DOI 10.1016/S0378-1119(00)00325-5	24	328	2946	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2266	2269		10.1126/science.1063566	http://dx.doi.org/10.1126/science.1063566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567142				2022-12-28	WOS:000171139400047
J	Hodge, A; Campbell, CD; Fitter, AH				Hodge, A; Campbell, CD; Fitter, AH			An arbuscular mycorrhizal fungus accelerates decomposition and acquires nitrogen directly from organic material	NATURE			English	Article							ROOT PROLIFERATION; SOIL; BIODIVERSITY; ACQUISITION; ASSOCIATION; DIVERSITY; HYPHAE; INFLOW	Arbuscular mycorrhizal fungi (order Glomales), which form mycorrhizal symbioses with two out of three of all plant species(1), are believed to be obligate biotrophs that are wholly dependent on the plant partner for their carbon supply(2). It is thought that they possess no degradative capability and that they are unable to decompose complex organic molecules, the form in which most soil nutrients occur. Earlier suggestions that they could exist saprotrophically were based on observation of hyphal proliferation on organic materials(3,4). In contrast, other mycorrhizal types have been shown to acquire nitrogen directly from organic sources(5-7). Here we show that the arbuscular mycorrhizal symbiosis can both enhance decomposition of and increase nitrogen capture from complex organic material (grass leaves) in soil. Hyphal growth of the fungal partner was increased in the presence of the organic material, independently of the host plant.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Macaulay Land Use Res Inst, Aberdeen AB15 8QH, Scotland	University of York - UK; James Hutton Institute	Hodge, A (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.		Campbell, Colin D/B-3944-2010	Campbell, Colin D/0000-0002-5163-7656	Biotechnology and Biological Sciences Research Council [JF13140] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ABUZINADAH RA, 1989, NEW PHYTOL, V112, P55, DOI 10.1111/j.1469-8137.1989.tb00308.x; [Anonymous], 1982, METHODS PRINCIPLES M; Bever JD, 1999, ECOL LETT, V2, P52, DOI 10.1046/j.1461-0248.1999.21050.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHAPIN FS, 1993, NATURE, V361, P150, DOI 10.1038/361150a0; Fransen B, 1998, OECOLOGIA, V115, P351, DOI 10.1007/s004420050527; Frostegard A, 1996, SOIL BIOL BIOCHEM, V28, P55, DOI 10.1016/0038-0717(95)00100-X; Hodge A, 1998, NEW PHYTOL, V139, P479, DOI 10.1046/j.1469-8137.1998.00216.x; HODGE A, 1995, MYCOL RES, V99, P935, DOI 10.1016/S0953-7562(09)80752-1; JONES DL, 1992, PLANT SOIL, V143, P259, DOI 10.1007/BF00007881; KOIDE RT, 1989, NEW PHYTOL, V111, P35, DOI 10.1111/j.1469-8137.1989.tb04215.x; LEAKE JR, 1990, NEW PHYTOL, V116, P123, DOI 10.1111/j.1469-8137.1990.tb00517.x; Mader P, 2000, NEW PHYTOL, V146, P155, DOI 10.1046/j.1469-8137.2000.00615.x; MOSSE BARBARA, 1959, TRANS BRIT MYOL SOC, V42, P439; NEWSHAM KK, 1995, TRENDS ECOL EVOL, V10, P407, DOI 10.1016/S0169-5347(00)89157-0; READ DJ, 1991, EXPERIENTIA, V47, P376, DOI 10.1007/BF01972080; SANDERS FE, 1971, NATURE, V233, P278, DOI 10.1038/233278c0; Smith SE., 1996, MYCORRHIZAL SYMBIOSI; Staddon PL, 1999, GLOBAL CHANGE BIOL, V5, P347, DOI 10.1046/j.1365-2486.1999.00230.x; Stark JM, 1994, EXPLOITATION ENV HET, P255; STJOHN TV, 1983, ECOLOGY, V64, P957, DOI 10.2307/1937216; Tinker PBH., 2000, SOLUTE TRANSPORT RHI; TOBAR RM, 1994, MYCORRHIZA, V4, P105, DOI 10.1007/BF00203769; Trappe JM, 1987, ECOPHYSIOLOGY VA MYC, P5; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; vanVuuren MMI, 1996, PLANT SOIL, V178, P185, DOI 10.1007/BF00011582; VITOUSEK PM, 1991, BIOGEOCHEMISTRY, V13, P87	27	675	775	28	547	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 20	2001	413	6853					297	299		10.1038/35095041	http://dx.doi.org/10.1038/35095041			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565029	Green Accepted			2022-12-28	WOS:000171040500036
J	Glynn, I				Glynn, I			An intriguing door	NATURE			English	Editorial Material									Univ Cambridge, Trinity Coll, Cambridge CB2 1QT, England	University of Cambridge	Glynn, I (corresponding author), Univ Cambridge, Trinity Coll, Cambridge CB2 1QT, England.							Glynn I., 1999, ANATOMY THOUGHT ORIG; LOGOTHETIS NK, 1999, SCI AM           NOV, P44; ORICK F, 1994, ASTONISHING HYPOTHES; Richards Robert J., 2016, DEBATING DARWIN	4	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 18	2001	413	6857					683	683		10.1038/35099639	http://dx.doi.org/10.1038/35099639			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482ZK	11607008	Bronze			2022-12-28	WOS:000171608000022
J	Moss, J; DeCastro, R; Patronas, NJ; Taveira-DeSilva, A				Moss, J; DeCastro, R; Patronas, NJ; Taveira-DeSilva, A			Meningiomas in lymphangioleiomyomatosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUBEROUS SCLEROSIS COMPLEX; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; PROGESTERONE-RECEPTORS; TSC2; MUTATIONS; WOMEN; LYMPHANGIOMYOMATOSIS; EPIDEMIOLOGY; GROWTH; GENES	Context Lymphangioleiomyomatosis (LAM), a cystic lung disease associated with progressive respiratory failure, is found predominantly in women of childbearing age and therefore has been treated with progesterone and other hormonal agents. However, meningiomas have progesterone receptors, and progesterone is believed to be a mitogen for meningioma cells in culture. Since 30% to 40% of patients with tuberous sclerosis complex (TSC) have LAM, we routinely screen patients with LAM for brain lesions found in TSC. Objective To determine the prevalence of meningiomas in women with LAM. Design and Setting Analysis of results from ongoing routine screening protocols initiated in December 1995 at the National Heart, Lung, and Blood Institute. Patients Two hundred fifty women with sporadic LAM who were referred for screening by magnetic resonance imaging (MRI) and/or computed tomography (CT) of the brain. Main Outcome Measures Presence of meningiomas on MRI and/or CT scans. Results Eight women with LAM (3 with and 5 without a diagnosis of TSC) had lesions on MRI scans compatible with meningiomas. Five of the patients had been treated with progesterone. Multiple meningiomas were observed in 2 patients. Conclusions Women with LAM appear to have a high prevalence of meningiomas. We recommend that patients with LAM be screened for meningiomas regardless of diagnosis of TSC. In view of the lack of a documented effect of progesterone on progression of lung disease in LAM and the reported mitogenic response of meningiomas to progesterone, we recommend that the drug not be given to LAM patients with an MRI result consistent with diagnosis of meningioma.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NIH, Dept Diagnost Radiol, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Moss, J (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Room 6D05,Bldg 10,MSC 1590, Bethesda, MD 20892 USA.	mossj@nhlbi.nih.gov						Avila NA, 2000, RADIOLOGY, V214, P441, DOI 10.1148/radiology.214.2.r00fe41441; Blankenstein MA, 2000, STEROIDS, V65, P795, DOI 10.1016/S0039-128X(00)00193-8; Boehler A, 1996, NEW ENGL J MED, V335, P1275, DOI 10.1056/NEJM199610243351704; Bondy M, 1996, J NEURO-ONCOL, V29, P197, DOI 10.1007/BF00165649; BONETTI F, 1993, AM J SURG PATHOL, V17, P1092, DOI 10.1097/00000478-199311000-00002; CARROLL RS, 1993, CANCER RES, V53, P1312; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Chu SC, 1999, CHEST, V115, P1041, DOI 10.1378/chest.115.4.1041; Cordier JF, 1999, LUNG BIOL HEALTH DIS, V131, P9; Costello LC, 2000, MAYO CLIN PROC, V75, P591, DOI 10.4065/75.6.591; Gomez MR, 1988, TUBEROUS SCLEROSIS, P9; GRUNBERG SM, 1994, HUM REPROD, V9, P202, DOI 10.1093/humrep/9.suppl_1.202; Hewitt S, 1999, AM J RESP CRIT CARE, V159, pA531; Izumi T, 1999, LUNG BIOL HEALTH DIS, V131, P1; JAY JR, 1985, J NEUROSURG, V62, P757, DOI 10.3171/jns.1985.62.5.0757; KALASSIAN GK, 1999, LAM OTHER DIS CHARAC, P45; Kalassian KG, 1997, AM J RESP CRIT CARE, V155, P1183, DOI 10.1164/ajrccm.155.4.9105053; Lie J. T., 1999, TUBEROUS SCLEROSIS C, P207; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; Moss J, 2001, AM J RESP CRIT CARE, V164, P669, DOI 10.1164/ajrccm.164.4.2101154; NELLIST M, 1993, CELL, V75, P1305; Roach ES, 1999, J CHILD NEUROL, V14, P401, DOI 10.1177/088307389901400610; Short MP, 1999, LUNG BIOL HEALTH DIS, V131, P387; Smolarek TA, 1998, AM J HUM GENET, V62, P810, DOI 10.1086/301804; Strizheva GD, 2001, AM J RESP CRIT CARE, V163, P253, DOI 10.1164/ajrccm.163.1.2005004; SUTHERLAND GR, 1987, CAN J NEUROL SCI, V14, P586; TAYLOR JR, 1990, NEW ENGL J MED, V323, P1254, DOI 10.1056/NEJM199011013231807; TONN JC, 1994, ANTICANCER RES, V14, P2453; Trulock EP, 1999, LUNG BIOL HEALTH DIS, V131, P65; VALENCIA JC, 2000, AM J RESP CRIT CARE, V161, pA15; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Weiner DM, 1998, J AM COLL SURGEONS, V187, P548, DOI 10.1016/S1072-7515(98)00239-7; Zhang H, 1999, J HUM GENET, V44, P391, DOI 10.1007/s100380050185	33	36	37	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2001	286	15					1879	1881		10.1001/jama.286.15.1879	http://dx.doi.org/10.1001/jama.286.15.1879			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	482UH	11597290	Bronze			2022-12-28	WOS:000171595300029
J	Venkatasubramanian, R; Siivola, E; Colpitts, T; O'Quinn, B				Venkatasubramanian, R; Siivola, E; Colpitts, T; O'Quinn, B			Thin-film thermoelectric devices with high room-temperature figures of merit	NATURE			English	Article							FILLED SKUTTERUDITE ANTIMONIDES; THERMAL-CONDUCTIVITY; LOCALIZATION; LATTICE	Thermoelectric materials are of interest for applications as heat pumps and power generators. The performance of thermoelectric devices is quantified by a figure of merit, ZT, where Z is a measure of a material's thermoelectric properties and T is the absolute temperature. A material with a figure of merit of around unity was first reported over four decades ago, but since then-despite investigation of various approaches-there has been only modest progress in finding materials with enhanced ZT values at room temperature. Here we report thin-film thermoelectric materials that demonstrate a significant enhancement in ZT at 300 K, compared to state-of-the-art bulk Bi2Te3 alloys. This amounts to a maximum observed factor of similar to2.4 for our p-type Bi2Te3/Sb2Te3 superlattice devices. The enhancement is achieved by controlling the transport of phonons and electrons in the superlattices. Preliminary devices exhibit significant cooling (32 K at around room temperature) and the potential to pump a heat flux of up to 700 W cm(-2); the localized cooling and heating occurs some 23,000 times faster than in bulk devices. We anticipate that the combination of performance, power density and speed achieved in these materials will lead to diverse technological applications: for example, in thermochemistry-on-a-chip, DNA microarrays, fibre-optic switches and microelectrothermal systems.	Res Triangle Inst, Res Triangle Pk, NC 27709 USA	Research Triangle Institute	Venkatasubramanian, R (corresponding author), Res Triangle Inst, POB 12194, Res Triangle Pk, NC 27709 USA.	rama@rti.org						[Anonymous], 1979, SOLID STATE PHYS, DOI 10.1016/S0081-1947(08)60359-8; BERGER HH, 1972, SOLID STATE ELECTRON, V15, P145, DOI 10.1016/0038-1101(72)90048-2; CADOFF IB, 1960, THERMOELECTRIC MAT D; CAHILL DG, 1992, PHYS REV B, V46, P6131, DOI 10.1103/PhysRevB.46.6131; CAPASSO F, 1986, IEEE J QUANTUM ELECT, V22, P1853, DOI 10.1109/JQE.1986.1073171; Chung DY, 2000, SCIENCE, V287, P1024, DOI 10.1126/science.287.5455.1024; DRABBLE JR, 1958, P PHYS SOC LOND, V71, P430, DOI 10.1088/0370-1328/71/3/317; Ettenberg MH, 1996, PROCEEDINGS ICT '96 - FIFTEENTH INTERNATIONAL CONFERENCE ON THERMOELECTRICS, P52, DOI 10.1109/ICT.1996.553255; Fan XF, 2001, APPL PHYS LETT, V78, P1580, DOI 10.1063/1.1356455; Fleurial JP, 1996, PROCEEDINGS ICT '96 - FIFTEENTH INTERNATIONAL CONFERENCE ON THERMOELECTRICS, P91, DOI 10.1109/ICT.1996.553263; GOLDSMID HJ, 1999, P 18 INT C THERM, P531; Harman T. C., 1999, Eighteenth International Conference on Thermoelectrics. Proceedings, ICT'99 (Cat. No.99TH8407), P280, DOI 10.1109/ICT.1999.843386; HARMAN TC, 1959, J APPL PHYS, V30, P1351, DOI 10.1063/1.1735334; HICKS LD, 1993, PHYS REV B, V47, P12727, DOI 10.1103/PhysRevB.47.12727; Ioffe A., 1957, SEMICONDUCTOR THERMO; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; Kittel C, 2007, INTRO SOLID STATE PH, V7th; Lee SM, 1997, APPL PHYS LETT, V70, P2957, DOI 10.1063/1.118755; Mahan GD, 1998, PHYS REV LETT, V80, P4016, DOI 10.1103/PhysRevLett.80.4016; Mandrus D, 1997, MATER RES SOC SYMP P, V478, P199, DOI 10.1557/PROC-478-199; NARAYANAMURTI V, 1979, PHYS REV LETT, V43, P2012, DOI 10.1103/PhysRevLett.43.2012; PALMIER JF, 1986, HETEROJUNCTIONS SEMI, P127; Polvani DA, 2001, CHEM MATER, V13, P2068, DOI 10.1021/cm000888q; Sales BC, 1996, SCIENCE, V272, P1325, DOI 10.1126/science.272.5266.1325; Scherrer H., 1995, CRC HDB THERMOELECTR, P211; Shakouri A, 1997, APPL PHYS LETT, V71, P1234, DOI 10.1063/1.119861; Sheng P., 1995, INTRO WAVE SCATTERIN, Vsecond; Simkin MV, 2000, PHYS REV LETT, V84, P927, DOI 10.1103/PhysRevLett.84.927; SLACK GA, 1994, J APPL PHYS, V76, P1665, DOI 10.1063/1.357750; Tritt TM, 1997, MATER RES SOC SYMP P, V478, P25, DOI 10.1557/PROC-478-25; VENKATASUBRAMAN.R, 1996, NAV RES REV, V48, P31; VENKATASUBRAMAN.R, 1992, P 1 NATL THERM COOL, P196; VENKATASUBRAMAN.R, 2001, RECENT TRENDS THERMO, V3, pCH4; Venkatasubramanian R, 1999, APPL PHYS LETT, V75, P1104, DOI 10.1063/1.124610; Venkatasubramanian R, 2000, PHYS REV B, V61, P3091, DOI 10.1103/PhysRevB.61.3091; VENKATASUBRAMANIAN R, 2001, Patent No. 60282185; VENKATASUBRAMANIAN R, 2001, Patent No. 6300150; VENKATASUBRAMANIAN R, 2000, Patent No. 6071351; VINING CB, 1992, P 11 INT C THERM ARL, P276; Wiersma DS, 1997, NATURE, V390, P671, DOI 10.1038/37757; WRIGHT DA, 1958, NATURE, V181, P834, DOI 10.1038/181834a0; YIM WM, 1972, SOLID STATE ELECTRON, V15, P1141, DOI 10.1016/0038-1101(72)90173-6	42	4308	4491	67	2949	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 11	2001	413	6856					597	602		10.1038/35098012	http://dx.doi.org/10.1038/35098012			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480WE	11595940				2022-12-28	WOS:000171485700040
J	Fraser, SW; Greenhalgh, T				Fraser, SW; Greenhalgh, T			Complexity science - Coping with complexity: educating for capability	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; WORK		UCL, London N19 3UA, England	University of London; University College London	Fraser, SW (corresponding author), 5 Cuddington Rd, Aylesbury HP18 0AB, Bucks, England.	sfraser881@aol.com	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				BLIGH J, 1995, BRIT MED J, V311, P342, DOI 10.1136/bmj.311.7001.342; Challis M, 2000, MED TEACH, V22, P225, DOI 10.1080/01421590050006160; Cox K, 2001, MED EDUC, V35, P862, DOI 10.1046/j.1365-2923.2001.01016.x; Crossley ML, 2001, SOC SCI MED, V52, P1477, DOI 10.1016/S0277-9536(00)00257-4; Daniel JS, 1996, MEGAUNIVERSITIES KNO, P101; *DEP HLTH, 1996, PAT INT MULT WORK OR; *DEP HLTH, 1999, WELC NHS LEARN NETW; *DEP HLTH, 2001, CONT PROF DEV QUAL N; *DEP HLTH, 1996, PROM CLIN EFF FRAM A; Department of Health, 2001, NHS PLAN; Dreyfus H.L., 1986, MIND MACHINE POWER H; ELWYN G, 2000, GROUPS HANDS ON GUID; *ENGL NAT BOARD NU, 2001, PREP MENT TEACH NEW; Greenhalgh T, 1999, BRIT MED J, V318, P48; GREENHALGH T, IN PRESS BR J GEN PR; Herxheimer A, 2000, LANCET, V355, P1540, DOI 10.1016/S0140-6736(00)02174-7; HITE JH, 1999, LEARNING CHAOS; Hull C., 1943, PRINCIPLES BEHAV; Knowles M. S, 1984, ADULT LEARNER NEGLEC; Langley P., 1987, SCI DISCOVERY COMPUT; LAVE J, 1990, SITUATED LEARNING LE; Plsek PE, 2001, BRIT MED J, V323, P625, DOI 10.1136/bmj.323.7313.625; PRINCLE M, 1995, 70 RCGP; ROWLEY DJ, 1998, STRATEGIC CHOICES AC; *SECR STAT HLTH, 1999, WORK TOG HLTH INF; Secretary of State for Health, 1998, 1 CLASS SERV QUAL NE; Senge PM, 2006, 5 DISCIPLINE ART PRA; Skultans V, 1998, NARRATIVE BASED MED; SLAWSON DC, 1994, J FAM PRACTICE, V38, P505; Smith R, 1998, BMJ-BRIT MED J, V316, P1917, DOI 10.1136/bmj.316.7149.1917; STACEY RD, 1996, STRATEGIC MANAGEMENT; STEPHENSON J, 1995, CAPABILITY QUALITY H; THOMSON A, 2001, TIMES HIGHER ED 0518, P1; Thorndike E.L., 1932, FUNDAMENTALS LEARNIN; VERNON DTA, 1993, ACAD MED, V68, P550, DOI 10.1097/00001888-199307000-00015; Wyatt JC, 2000, J ROY SOC MED, V93, P423, DOI 10.1177/014107680009300809	36	451	462	0	33	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 6	2001	323	7316					799	803		10.1136/bmj.323.7316.799	http://dx.doi.org/10.1136/bmj.323.7316.799			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481LK	11588088	Green Published			2022-12-28	WOS:000171520600036
J	Avise, JC				Avise, JC			Evolving genomic metaphors: A new look at the language of DNA	SCIENCE			English	Editorial Material								Recent genome-sequencing efforts have confirmed that traditional "good-citizen" genes (those that encode functional RNA and protein molecules of obvious benefit to the organism) constitute only a small fraction of the genomic populace in humans and other multicellular creatures. The rest of the DNA sequence includes an astonishing collection of noncoding regions, regulatory modules, deadbeat pseudogenes, legions of repetitive elements, and hosts of oft-shifty, self-interested nomads, renegades, and immigrants. To help visualize functional operations in such intracellular genomic societies and to better encapsulate the evolutionary origins of complex genomes, new and evocative metaphors may be both entertaining and research-stimulating.	Univ Georgia, Dept Genet, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Avise, JC (corresponding author), Univ Georgia, Dept Genet, Athens, GA 30602 USA.	avise@arches.uga.edu						AVISE J, 1998, GENETIC GODS EVOLUTI; CONDIT CM, 1999, MEANING GENE; Dawkins Richard, 1976, SELFISH GENE; Kidwell MG, 2001, EVOLUTION, V55, P1, DOI 10.1111/j.0014-3820.2001.tb01268.x; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	6	52	53	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					86	87		10.1126/science.294.5540.86	http://dx.doi.org/10.1126/science.294.5540.86			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588247	Green Submitted			2022-12-28	WOS:000171448800035
J	Hemann, MT; Strong, MA; Hao, LY; Greider, CW				Hemann, MT; Strong, MA; Hao, LY; Greider, CW			The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability	CELL			English	Article							MINOR SATELLITE DNA; REPLICATIVE SENESCENCE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; HUMAN FIBROBLASTS; PROTEIN; REPAIR; RNA; IDENTIFICATION; RECOMBINATION	Loss of telomere function can induce cell cycle arrest and apoptosis. To investigate the processes that trigger cellular responses to telomere dysfunction, we crossed mTR-/- G6 mice that have short telomeres with mice heterozygous for telomerase (mTR+/-) that have long telomeres. The phenotype of the telomerase null offspring was similar to that of the late generation parent, although only half of the chromosomes were short. Strikingly, spectra[ karyotyping (SKY) analysis revealed that loss of telomere function occurred preferentially on chromosomes with critically short telomeres. Our data indicate that, while average telomere length is measured in most studies, it is not the average but rather the shortest telomeres that constitute telomere dysfunction and limit cellular survival in the absence of telomerase.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Grad Training Program Human Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Greider, CW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.			Strong, Margaret/0000-0002-0055-6573; Greider, Carol/0000-0002-5494-8126	NCI NIH HHS [P01 CA16519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Blackburn E, 1999, MT SINAI J MED, V66, P292; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; GARAGNA S, 1995, CHROMOSOMA, V103, P685, DOI 10.1007/BF00344229; Garagna S, 2001, P NATL ACAD SCI USA, V98, P171, DOI 10.1073/pnas.98.1.171; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Hemann MT, 2001, MOL BIOL CELL, V12, P2023, DOI 10.1091/mbc.12.7.2023; HEMANN MT, 2001, COLD SPRING HARB S Q; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIPLING D, 1991, GENOMICS, V11, P235, DOI 10.1016/0888-7543(91)90128-2; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; Lansdorp PM, 2000, MECH AGEING DEV, V118, P23, DOI 10.1016/S0047-6374(00)00151-2; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Martens UM, 2000, EXP CELL RES, V256, P291, DOI 10.1006/excr.2000.4823; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; McClintock B, 1941, GENETICS, V26, P234; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Muller H.J., 1938, COLLECTING NET, V13, P181; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; PIETRAS DF, 1983, NUCLEIC ACIDS RES, V11, P6965, DOI 10.1093/nar/11.20.6965; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; Slijepcevic P, 1998, CHROMOSOMA, V107, P136, DOI 10.1007/s004120050289; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	50	861	889	3	53	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 5	2001	107	1					67	77		10.1016/S0092-8674(01)00504-9	http://dx.doi.org/10.1016/S0092-8674(01)00504-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595186	Bronze			2022-12-28	WOS:000171453100010
J	Hochstrasser, M				Hochstrasser, M			SP-RING for SUMO: New functions bloom for a ubiquitin-like protein	CELL			English	Review							YEAST	SUMO is covalently linked to a variety of cellular proteins. Three groups now describe related E3-like factors that enhance transfer of SUMO to specific proteins. This family of factors includes proteins important for chromosome condensation, signal transduction, and ion channel biogenesis.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Hochstrasser, M (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.			Hochstrasser, Mark/0000-0002-1131-5484				Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; BRZOVIC PS, 2001, J BIOL CHEM; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Greenhalgh CJ, 2001, J LEUKOCYTE BIOL, V70, P348; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Strunnikov AV, 2001, GENETICS, V158, P95; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; TAKAHASHI Y, 1999, BIOCHEM BIOPH RES CO, V275, P223; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642	19	229	239	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 5	2001	107	1					5	8		10.1016/S0092-8674(01)00519-0	http://dx.doi.org/10.1016/S0092-8674(01)00519-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595179	Bronze			2022-12-28	WOS:000171453100003
J	Ling, H; Boudsocq, F; Woodgate, R; Yang, W				Ling, H; Boudsocq, F; Woodgate, R; Yang, W			Crystal structure of a Y-family DNA polymerase in action: A mechanism for error-prone and lesion-bypass replication	CELL			English	Article							REPAIR PROTEIN MUTS; ESCHERICHIA-COLI; MISMATCH REPAIR; GENE ENCODES; LARGE FRAGMENT; THYMINE DIMER; FIDELITY; COMPLEX; IOTA; ETA	Sulfolobus solfataricus P2 DNA polymerase IV [Dpo4) is a DinB homolog that belongs to the recently described Y-family of DNA polymerases, which are best characterized by their low-fidelity synthesis on undamaged DNA templates and propensity to traverse normally replication-blocking lesions. Crystal structures of Dpo4 in ternary complexes with DNA and an incoming nucleotide, either correct or incorrect, have been solved at 1.7 Angstrom and 2.1 Angstrom resolution, respectively. Despite a conserved active site and a hand-like configuration similar to all known polymerases, Dpo4 makes limited and nonspecific contacts with the replicating base pair, thus relaxing base selection. Dpo4 is also captured in the crystal translocating two template bases to the active site at once, suggesting a possible mechanism for bypassing thymine dimers.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NICHHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Yang, W (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.		Yang, Wei/D-4926-2011; Yang, Wei/ABB-4785-2020; Ling, Hong/E-3729-2010	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195; Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036119, ZIADK036119] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOUDSOCQ F, 2001, IN PRESS NUCL ACIDS; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Ishikawa T, 2001, J BIOL CHEM, V276, P15155, DOI 10.1074/jbc.M009822200; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kondratick CM, 2001, MOL CELL BIOL, V21, P2018, DOI 10.1128/MCB.21.6.2018-2025.2001; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Muchmore CRA, 1998, PROTEIN SCI, V7, P39, DOI 10.1002/pro.5560070104; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Strauss BS, 2000, J BACTERIOL, V182, P6742, DOI 10.1128/JB.182.23.6742-6750.2000; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tissier A, 2000, GENE DEV, V14, P1642; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	56	533	541	2	29	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 5	2001	107	1					91	102		10.1016/S0092-8674(01)00515-3	http://dx.doi.org/10.1016/S0092-8674(01)00515-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595188	Bronze			2022-12-28	WOS:000171453100012
J	Ada, G				Ada, G			Advances in immunology - Vaccines and vaccination	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CELLULAR IMMUNE-RESPONSES; CYTOTOXIC T-LYMPHOCYTES; IMMUNODEFICIENCY-VIRUS; PROTECTIVE EFFICACY; DENDRITIC CELLS; ENHANCED IMMUNOGENICITY; ALZHEIMERS-DISEASE; CONJUGATE VACCINE; PERIPHERAL-BLOOD; DNA VACCINATION		Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Ada, G (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Box 334, Canberra, ACT 2601, Australia.							Ada G, 2000, VIROLOGY, V268, P227, DOI 10.1006/viro.2000.0207; ADA G, 1997, VACCINES VACCINATION; ADA GL, 1986, CURR TOP MICROBIOL, V128, P1; ALESSANDRO UD, 1995, LANCET, V346, P462; Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Amin J, 1999, Commun Dis Intell, V23, P222; BACHMANN MF, 1994, EUR J IMMUNOL, V24, P2228, DOI 10.1002/eji.1830240944; Backskai BJ, 2001, NAT MED, V7, P369, DOI 10.1038/85525; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; BEGG N, 1995, VFACCINATION WORLD H, P123; Berard F, 2000, J EXP MED, V192, P1535, DOI 10.1084/jem.192.11.1535; Biasin M, 2000, J INFECT DIS, V182, P1365, DOI 10.1086/315873; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Brandt ER, 2000, NAT MED, V6, P455, DOI 10.1038/74719; BROWN F, 1994, DEV BIOL STANDARDICI, V82; Butcher J, 2000, LANCET, V356, P2161, DOI 10.1016/S0140-6736(00)03504-2; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; Cohen J, 2001, SCIENCE, V292, P24, DOI 10.1126/science.292.5514.24; Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107; *DIV MICR INF DIS, 2000, ACC DEV VACC JORD RE; EGEA E, 1991, J EXP MED, V173, P531, DOI 10.1084/jem.173.3.531; Elliman D, 2001, BMJ-BRIT MED J, V322, P183, DOI 10.1136/bmj.322.7280.183; Enserink M, 1999, SCIENCE, V284, P883; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; FLEXNER C, 1987, NATURE, V330, P259, DOI 10.1038/330259a0; GAYDOS CA, 1999, VACCINES, P609; Gerbase AC, 1998, LANCET, V351, P2, DOI 10.1016/S0140-6736(98)90001-0; GLASS RI, 1994, SCIENCE, V265, P1389, DOI 10.1126/science.8073280; Glenn G M, 1999, Expert Opin Investig Drugs, V8, P797, DOI 10.1517/13543784.8.6.797; *GLOB ALL VACC IMM, 2000, IMM FOC, P1; Hammond J, 1999, CURR TOP MICROBIOL, V240, P1; Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Helmuth L, 2000, SCIENCE, V289, P375; Imaoka K, 1998, J IMMUNOL, V161, P5952; Jackson RJ, 2001, J VIROL, V75, P1205, DOI 10.1128/JVI.75.3.1205-1210.2001; Jezek Z, 1988, HUMAN MONKEYPOX; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; JONES PD, 1988, SCAND J IMMUNOL, V27, P645, DOI 10.1111/j.1365-3083.1988.tb02397.x; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kent SJ, 1998, J VIROL, V72, P10180, DOI 10.1128/JVI.72.12.10180-10188.1998; Knutson KL, 2001, J CLIN INVEST, V107, P477, DOI 10.1172/JCI11752; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; Krieg AM, 2000, IMMUNOL TODAY, V21, P521, DOI 10.1016/S0167-5699(00)01719-9; Kwiatkowski D, 2000, BMJ-BRIT MED J, V321, P1061, DOI 10.1136/bmj.321.7268.1061; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LEONG KH, 1995, VACCINES, P327; Levin A, 2000, ANN INTERN MED, V133, P661, DOI 10.7326/0003-4819-133-8-200010170-00102; Lin FYC, 2001, NEW ENGL J MED, V344, P1263, DOI 10.1056/NEJM200104263441701; Lucas AH, 2001, PEDIATR INFECT DIS J, V20, P235, DOI 10.1097/00006454-200103000-00002; Ma JKC, 1998, NAT MED, V4, P601, DOI 10.1038/nm0598-601; MACKETT M, 1982, P NATL ACAD SCI-BIOL, V79, P7415, DOI 10.1073/pnas.79.23.7415; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001; Modlin RL, 2000, NATURE, V408, P659, DOI 10.1038/35047207; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Moxon ER, 1997, LANCET, V350, P1240, DOI 10.1016/S0140-6736(97)03259-5; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Musey L, 1997, J EXP MED, V185, P293, DOI 10.1084/jem.185.2.293; Nabel GJ, 2001, NATURE, V410, P1002, DOI 10.1038/35073500; Nardin EH, 2001, J IMMUNOL, V166, P481, DOI 10.4049/jimmunol.166.1.481; Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; PANICALI D, 1982, P NATL ACAD SCI-BIOL, V79, P4927, DOI 10.1073/pnas.79.16.4927; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; Podda A, 2001, VACCINE, V19, P2673, DOI 10.1016/S0264-410X(00)00499-0; Ramsay ME, 2001, LANCET, V357, P195, DOI 10.1016/S0140-6736(00)03594-7; RAMSHAW IA, 1987, NATURE, V329, P545, DOI 10.1038/329545a0; Robinson HL, 1999, NAT MED, V5, P526, DOI 10.1038/8406; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; Timmerman JM, 1999, ANNU REV MED, V50, P507; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Walker BD, 2000, NAT MED, V6, P1094, DOI 10.1038/80415; Webster R. G, 1994, ENCY VIROLOGY, V2, P709; Weibel RE, 1998, PEDIATRICS, V101, P383, DOI 10.1542/peds.101.3.383; Weiner HL, 2000, ANN NEUROL, V48, P567, DOI 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.3.CO;2-N; WHO (World Health Organization), 1998, WORLD HLTH REP 1998; Yusibov V, 1999, CURR TOP MICROBIOL, V240, P81; Zhang LF, 2000, VACCINE, V18, P1051, DOI 10.1016/S0264-410X(99)00351-5; ZHOU F, 1992, J IMMUNOL, V149, P1599; 2000, WKLY EPIDEMIOL REC, V75, P371; 1998, MMWR MORB MORTAL S S, V47, P1	93	177	190	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1042	1053		10.1056/NEJMra011223	http://dx.doi.org/10.1056/NEJMra011223			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586958				2022-12-28	WOS:000171340400008
J	Johnson, ME; Viggiano, L; Bailey, JA; Abdul-Rauf, M; Goodwin, G; Rocchi, M; Eichler, EE				Johnson, ME; Viggiano, L; Bailey, JA; Abdul-Rauf, M; Goodwin, G; Rocchi, M; Eichler, EE			Positive selection of a gene family during the emergence of humans and African apes	NATURE			English	Article							DARWINIAN SELECTION; RAPID EVOLUTION; HUMAN-GENOME; DNA; DUPLICATIONS	Gene duplication followed by adaptive evolution is one of the primary forces for the emergence of new gene function(1). Here we describe the recent proliferation, transposition and selection of a 20-kilobase (kb) duplicated segment throughout 15 Mb of the short arm of human chromosome 16. The dispersal of this segment was accompanied by considerable variation in chromosomal-map location and copy number among hominoid species. In humans, we identified a gene family (morpheus) within the duplicated segment. Comparison of putative protein-encoding exons revealed the most extreme case of positive selection among hominoids. The major episode of enhanced amino-acid replacement occurred after the separation of human and great-ape lineages from the orangutan. Positive selection continued to alter amino-acid composition after the divergence of human and chimpanzee lineages. The rapidity and bias for amino-acid-altering nucleotide changes suggest adaptive evolution of the morpheus gene family during the emergence of humans and African apes. Moreover, some genes emerge and evolve very rapidly, generating copies that bear little similarity to their ancestral precursors. Consequently, a small fraction of human genes may not possess discernible orthologues within the genomes of model organisms.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; DAPEG, Sez Genet, I-70126 Bari, Italy; Inst Canc Res, Sect Mol Carcinogenesis, Haddow Labs, Surrey MS2 5NG, England	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University of London; Institute of Cancer Research - UK	Eichler, EE (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.	eee@po.cwru.edu	Rocchi, Mariano/B-8451-2011	Viggiano, Luigi/0000-0002-2067-5166	Telethon [C.50] Funding Source: Medline	Telethon(Fondazione Telethon)		Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; Duda TF, 1999, P NATL ACAD SCI USA, V96, P6820, DOI 10.1073/pnas.96.12.6820; Goodman M, 1999, AM J HUM GENET, V64, P31, DOI 10.1086/302218; Horvath JE, 2000, GENOME RES, V10, P839, DOI 10.1101/gr.10.6.839; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; JUKES T H, 1969, P21; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li W. H, 1997, MOL EVOLUTION; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Loftus BJ, 1999, GENOMICS, V60, P295, DOI 10.1006/geno.1999.5927; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; NEI M, 1986, MOL BIOL EVOL, V3, P418; Nei M., 2000, MOL EVOLUTION PHYLOG, P352; Nurminsky DI, 1998, NATURE, V396, P572, DOI 10.1038/25126; Ohno S., 1970, EVOLUTION GENE DUPLI; STALLINGS RL, 1993, CYTOGENET CELL GENET, V63, P97, DOI 10.1159/000133509; TAJIMA F, 1993, GENETICS, V135, P599; Ting CT, 1998, SCIENCE, V282, P1501, DOI 10.1126/science.282.5393.1501; Vacquier VD, 1997, J MOL EVOL, V44, pS15, DOI 10.1007/PL00000049; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708	22	233	241	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					514	519		10.1038/35097067	http://dx.doi.org/10.1038/35097067			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586358				2022-12-28	WOS:000171340500045
J	Jones, JK; Fife, D; Curkendall, S; Goehring, E; Guo, JJF; Shannon, M				Jones, JK; Fife, D; Curkendall, S; Goehring, E; Guo, JJF; Shannon, M			Coprescribing and codispensing of cisapride and contraindicated drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPACT	Context Cisapride, an oral prokinetic drug indicated for the symptomatic treatment of nocturnal heartburn due to gastroesophageal reflux disease, was approved by the US Food and Drug Administration in July 1993. After reports of serious cardiac arrhythmias and deaths during administration of cisapride, most involving concomitant exposure to another drug, a series of label changes and warnings were issued in February 1995, October 1995, June 1998, and June 1999. Cisapride was removed from general distribution in July 2000. Objective To determine the frequency of contraindicted coprescribing and codispensings, in which cisapride and a contraindicated drug were prescribed or dispensed to the same patient for overlapping periods, and the proportion of contraindicated coprescribing by the same physicians and codispensing by the same pharmacies. Design and Setting Retrospective study of prescription claims from a managed care organization database for all patients with cisapride prescriptions between July 1993 and December 1998. Participants A total of 38757 adult and pediatric patients who had a cisapride prescription immediately preceded by at least 60 days of insurance eligibility. Main Outcome Measure Proportion of cisapride prescriptions or dispensing occurring during the same treatment period as a drug contraindicated at that time prescribed by the same physicians or dispensed by the same pharmacies. Results Of 131485 cisapride prescriptions dispensed after the warnings began, 4414 (3.4%) overlapped with at least 1 drug contraindicated in the labeling at the time of the prescription. Of all overlapping prescription pairs, 2190 (50%) were by the same physicians, 3908 (89%) were by the same pharmacies, and 765 (17%) were dispensed on the same day. Conclusion Prescriptions dispensed by the same pharmacies accounted for afar higher proportion of contraindicated medication pairs than prescriptions from the same physicians. The pharmacy may be an important and underutilized intervention point to prevent contraindicated drugs from being used together.	Degge Grp Ltd, Res, Arlington, VA 22209 USA; Janssen Res Inst, Dept Epidemiol Drug Safety & Surveillance, Titusville, NJ USA; Univ Cincinnati, Med Ctr, Coll Pharm, Cincinnati, OH 45267 USA; Jorie Kent Associates Inc, Milton, DE USA	Johnson & Johnson; Johnson & Johnson USA; University System of Ohio; University of Cincinnati	Curkendall, S (corresponding author), Degge Grp Ltd, Res, 1616 N Ft Myer Dr,1430, Arlington, VA 22209 USA.							Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; McMullin ST, 1999, ARCH INTERN MED, V159, P2077, DOI 10.1001/archinte.159.17.2077; *MED EC CO, 2000, PHYS DESK REF, P1451; Piquette RK, 1999, ANN PHARMACOTHER, V33, P22, DOI 10.1345/aph.18107; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518; Thompson D, 1996, JAMA-J AM MED ASSOC, V275, P1339, DOI 10.1001/jama.275.17.1339; *US FOOD DRUG ADM, 2000, JAMA-J AM MED ASSOC, V283, P2228; Wysowski DK, 1996, NEW ENGL J MED, V335, P290, DOI 10.1056/NEJM199607253350416	10	42	43	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1607	1609		10.1001/jama.286.13.1607	http://dx.doi.org/10.1001/jama.286.13.1607			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585484	Bronze			2022-12-28	WOS:000171340600028
J	Jutel, M; Watanabe, T; Klunker, S; Akdis, M; Thomet, OAR; Malolepszy, J; Zak-Nejmark, T; Koga, R; Kobayashi, T; Blaser, K; Akdis, CA				Jutel, M; Watanabe, T; Klunker, S; Akdis, M; Thomet, OAR; Malolepszy, J; Zak-Nejmark, T; Koga, R; Kobayashi, T; Blaser, K; Akdis, CA			Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors	NATURE			English	Article							BEE VENOM IMMUNOTHERAPY; MOLECULAR-BASIS; LYMPHOCYTES; MICE; INDUCTION; IMMUNITY	Many pathological processes, including those causing allergies and autoimmune diseases, are associated with the presence of specialized subsets of T helper cells (T(H)1 and T(H)2) at the site of inflammation(1-4). The diversity of T(H)1 and T(H)2 function is not predetermined but depends on signals that drive the cells towards either subset(1-4). Histamine, released from effector cells (mast cells and basophils) during inflammatory reactions can influence immune response(5-8). Here we report that histamine enhances T(H)1-type responses by triggering the histamine receptor type 1 (H1R), whereas both T(H)1- and T(H)2-type responses are negatively regulated by H2R through the activation of different biochemical intracellular signals. In mice, deletion of H1R results in suppression of interferon (IFN)-gamma and dominant secretion of T(H)2 cytokines (interleukin (IL)-4 and IL-13). Mutant mice lacking H2R showed upregulation of both T(H)1 and T(H)2 cytokines. Relevant to T-cell cytokine profiles, mice lacking H1R displayed increased specific antibody response with increased immunoglobulin-e (IgE) and IgG1, IgG2b and IgG3 compared with mice lacking H2R. These findings account for an important regulatory mechanism in the control of inflammatory functions through effector-cell-derived histamine.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Wroclaw Med Univ, Dept Internal Med & Allergol, PL-50417 Wroclaw, Poland	Swiss Institute of Allergy & Asthma Research; Kyushu University; Wroclaw Medical University	Jutel, M (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.		Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; BEER DJ, 1987, CRC CR REV IMMUNOL, V7, P55; Bodor J, 1996, P NATL ACAD SCI USA, V93, P3536, DOI 10.1073/pnas.93.8.3536; Boss V, 1996, J BIOL CHEM, V271, P10429, DOI 10.1074/jbc.271.18.10429; Chen Q, 2000, NATURE, V407, P916, DOI 10.1038/35038103; Corry DB, 1999, NATURE, V402, pB18; DELPRETE GF, 1991, J CLIN INVEST, V88, P344; Faith A, 1997, J IMMUNOL, V159, P53; GANTZ I, 1992, J BIOL CHEM, V267, P20840; Inoue I, 1996, P NATL ACAD SCI USA, V93, P13316, DOI 10.1073/pnas.93.23.13316; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1111/j.1365-2222.1996.tb00496.x; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kobayashi T, 2000, J CLIN INVEST, V105, P1741, DOI 10.1172/JCI9441; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; Mobarakeh JI, 2000, EUR J PHARMACOL, V391, P81, DOI 10.1016/S0014-2999(00)00060-1; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; PLAUT M, 1983, J IMMUNOL, V131, P2945; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROSZKOWSKI W, 1977, SCIENCE, V195, P683, DOI 10.1126/science.190677; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; VANNIER E, 1993, J CLIN INVEST, V92, P281, DOI 10.1172/JCI116562; WATANABE N, 1988, P NATL ACAD SCI USA, V85, P4460, DOI 10.1073/pnas.85.12.4460; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	29	437	463	2	33	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					420	425		10.1038/35096564	http://dx.doi.org/10.1038/35096564			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574888				2022-12-28	WOS:000171188700054
J	Robinson, MS; Thomas, PC; Veverka, J; Murchie, S; Carcich, B				Robinson, MS; Thomas, PC; Veverka, J; Murchie, S; Carcich, B			The nature of ponded deposits on Eros	NATURE			English	Article								One of the surprises of the NEAR-Shoemaker mission was that Eros's surface exhibits a wide variety of landforms, which are indicative of a global covering of loose fragmental debris(1). At one extreme in roughness is the Shoemaker Regio area, which is characterized by a high density of boulders up to 100 m across, slumps, slides, and finer blanketing material. At the other extreme are distinctive, flat deposits that appear smooth down to a resolution of 1.2 cm per pixel. Here we report the results of global mapping and colour analysis of these smooth deposits. They have formed most efficiently in restricted areas, and appear to be the result of deposition of finer material sorted from the upper portion of the asteroid's regolith. The smooth deposits constitute a family of features with a range of morphologies, but all appear to be the result of sedimentation. The geography of the deposits is consistent with some predicted aspects of photoelectric sorting, but these exotic transport and depositional mechanisms are not well understood. Deposits with the properties seen on Eros have no obvious analogues in previous lunar or asteroid data.	Northwestern Univ, Dept Geol Sci, Evanston, IL 60201 USA; Cornell Univ, Ithaca, NY 14853 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA	Northwestern University; Cornell University; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Robinson, MS (corresponding author), Northwestern Univ, Dept Geol Sci, 1847 Sheridan Rd, Evanston, IL 60201 USA.		Robinson, Mark/ABI-6841-2020; Murchie, Scott L/E-8030-2015	Murchie, Scott L/0000-0002-1616-8751				ADAMS JB, 1967, J GEOPHYS RES, V72, P5705, DOI 10.1029/JZ072i022p05705; BELL JF, IN PRESS ICARUS; Cheng AF, 2001, SCIENCE, V292, P488, DOI 10.1126/science.1058330; CLARK BE, IN PRESS ICARUS; Criswell D R, 1973, PHOTON PARTICLE INTE, P545, DOI 10.1007/978-94-010-2647-5_36; DUENNEBIER F, 1974, J GEOPHYS RES, V79, P4351, DOI 10.1029/JB079i029p04351; Hapke B, 2001, J GEOPHYS RES-PLANET, V106, P10039, DOI 10.1029/2000JE001338; Lee P, 1996, ICARUS, V124, P181, DOI 10.1006/icar.1996.0197; LEE PC, 1977, THESIS CORNELL U; Matson D.L., 1977, P 8 LUNAR SCI C, P1001; McCord T. B., 1973, Moon, V7, P453, DOI 10.1007/BF00564646; MCCORD TB, 1970, SCIENCE, V169, P855, DOI 10.1126/science.169.3948.855; MURCHIE S, IN PRESS ICARUS; Pieters CM, 2000, METEORIT PLANET SCI, V35, P1101, DOI 10.1111/j.1945-5100.2000.tb01496.x; Thomas PC, 2001, NATURE, V413, P394, DOI 10.1038/35096513; THOMAS PC, IN PRESS ICARUS; Veverka J, 2001, SCIENCE, V292, P484, DOI 10.1126/science.1058651; Veverka J, 2001, NATURE, V413, P390, DOI 10.1038/35096507	18	142	143	1	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					396	400		10.1038/35096518	http://dx.doi.org/10.1038/35096518			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574881				2022-12-28	WOS:000171188700047
J	Klotz, L				Klotz, L			Back to nephrectomy for patients with metastatic renal cancer	LANCET			English	Editorial Material							CELL-CARCINOMA; INTERFERON GAMMA-1B; PLACEBO		Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Urol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Klotz, L (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Urol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							BELLDEGRUN A, 1990, EUR UROL, V18, P42; Elhilali MM, 2000, BJU INT, V86, P613, DOI 10.1046/j.1464-410x.2000.00880.x; Flanigan Robert C., 2000, Journal of Urology, V163, P154; Gleave ME, 1998, NEW ENGL J MED, V338, P1265, DOI 10.1056/NEJM199804303381804; MINASIAN LM, 1993, J CLIN ONCOL, V11, P1368, DOI 10.1200/JCO.1993.11.7.1368; MONTIE JE, 1977, J UROLOGY, V117, P272, DOI 10.1016/S0022-5347(17)58429-3; MYERS GH, 1968, J UROLOGY, V100, P420, DOI 10.1016/S0022-5347(17)62543-6; Oliver R T, 1989, Semin Urol, V7, P149; UMEDA T, 1986, CANCER, V58, P1231, DOI 10.1002/1097-0142(19860915)58:6<1231::AID-CNCR2820580610>3.0.CO;2-#	9	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					948	949		10.1016/S0140-6736(01)06113-X	http://dx.doi.org/10.1016/S0140-6736(01)06113-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583744				2022-12-28	WOS:000171135300011
J	Malik, I; Danesh, J; Whincup, P; Bhatia, V; Papacosta, O; Walker, M; Lennon, L; Thomson, A; Haskard, D				Malik, I; Danesh, J; Whincup, P; Bhatia, V; Papacosta, O; Walker, M; Lennon, L; Thomson, A; Haskard, D			Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis	LANCET			English	Article							C-REACTIVE PROTEIN; MIDDLE-AGED MEN; CARDIOVASCULAR RISK-FACTORS; APPARENTLY HEALTHY-MEN; UNSTABLE ANGINA; E-SELECTIN; MYOCARDIAL-INFARCTION; P-SELECTIN; PLASMA-CONCENTRATION; HELICOBACTER-PYLORI	Background Previous studies have suggested that circulating concentrations of soluble adhesion molecules are useful predictors of risk of coronary heart disease (CHD). Larger studies are needed, however, to test this hypothesis. Methods We measured serum concentrations of four soluble cell adhesion molecules (intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1], E-selectin, and P-selectin) in the stored baseline serum samples of 643 men with coronary heart disease and 1278 controls nested in a prospective study of 5661 men who were monitored for 16 years. We also did a meta-analysis of previous relevant studies to place our findings in context. Results Concentrations of soluble adhesion molecules were significantly associated with one another, with other markers of inflammation, and with some classic coronary risk factors. For ICAM-1, the odds ratio for CHD was 1.68 (95% Cl 1.32-2.14) in a comparison of men in the top third with those in the bottom third of baseline measurements after adjustments for age and town. This decreased to 1.11 (0.75-1.64) after adjustment for some classic coronary risk factors and indicators of socioeconomic status. For the three other cell adhesion molecules, the odds ratios for CHD, first adjusted for age and town only, and then additionally adjusted for other risk factors, were: VCAM-1:1.26 (0.99-1.61) and 0.96 (0.66-1.40); E-selectin: 1.27 (1.00-1.61) and 1.13 (0.78-1.62); and P-selectin: 1.23 (0.96-1.56) and 1.20 (0.81-.1.76). Interpretation The measurement of these adhesion molecules is unlikely to add much predictive information to that provided by more established risk factors.	Hammersmith Hosp, Imperial Coll Sch Med, BHF Cardiovasc Med Unit, Natl Heart & Lung Inst, London W12 0NN, England; Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge CB2 1TN, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, London, England	Imperial College London; University of Cambridge; St Georges University London; University of London; University College London	Haskard, D (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, BHF Cardiovasc Med Unit, Natl Heart & Lung Inst, London W12 0NN, England.	d.haskard@ic.ac.uk	Lennon, Lucy/ABB-9433-2020; Lennon, Lucy/AFT-1973-2022	Lennon, Lucy/0000-0002-1738-1351; Papacosta, Olia/0000-0001-8781-6747; Whincup, Peter/0000-0002-5589-4107				Blann AD, 1997, ATHEROSCLEROSIS, V132, P151, DOI 10.1016/S0021-9150(97)00081-6; Clarke R, 1999, AM J EPIDEMIOL, V150, P341; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; Danesh J, 2000, BRIT MED J, V321, P208, DOI 10.1136/bmj.321.7255.208; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; DAVIES MJ, 1993, J PATHOL, V171, P223, DOI 10.1002/path.1711710311; de Lemos JA, 2000, J AM COLL CARDIOL, V36, P423, DOI 10.1016/S0735-1097(00)00742-7; Dong ZM, 1998, J CLIN INVEST, V102, P145, DOI 10.1172/JCI3001; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Ghaisas NK, 1997, AM J CARDIOL, V80, P617, DOI 10.1016/S0002-9149(97)00432-3; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Hwang SJ, 1997, CIRCULATION, V96, P4219; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; Kaikita K, 1997, JPN CIRC J, V61, P741, DOI 10.1253/jcj.61.741; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Nageh MF, 1997, ARTERIOSCL THROM VAS, V17, P1517, DOI 10.1161/01.ATV.17.8.1517; POSTON RN, 1992, AM J PATHOL, V140, P665; Rebuzzi AG, 1998, AM J CARDIOL, V82, P715, DOI 10.1016/S0002-9149(98)00458-5; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Ridker PM, 2001, CIRCULATION, V103, P491, DOI 10.1161/01.CIR.103.4.491; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rohde LEP, 1999, ARTERIOSCL THROM VAS, V19, P1595, DOI 10.1161/01.ATV.19.7.1595; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; Shyu KG, 1996, CHEST, V109, P1627, DOI 10.1378/chest.109.6.1627; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Walker M, 2000, J PUBLIC HEALTH MED, V22, P479, DOI 10.1093/pubmed/22.4.479; Wallen NH, 1999, EUR HEART J, V20, P1039; Whincup P, 2000, CIRCULATION, V101, P1647; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568	32	311	328	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					971	975		10.1016/S0140-6736(01)06104-9	http://dx.doi.org/10.1016/S0140-6736(01)06104-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583751				2022-12-28	WOS:000171135300018
J	Manns, MP; McHutchison, JG; Gordon, SC; Rustgi, VK; Shiffman, M; Reindollar, R; Goodman, ZD; Koury, K; Ling, MH; Albrecht, JK				Manns, MP; McHutchison, JG; Gordon, SC; Rustgi, VK; Shiffman, M; Reindollar, R; Goodman, ZD; Koury, K; Ling, MH; Albrecht, JK		Int Hepatitis Interventional Thera	Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial	LANCET			English	Article							PEGYLATED INTERFERON-ALPHA-2B; VIRUS-INFECTION; MORTALITY; THERAPY; RNA	Background A sustained virological response (SVR) rate of 41% has been achieved with interferon alfa-2b plus ribavirin therapy of chronic hepatitis C. In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin. Methods 1530 patients with chronic hepatitis C were assigned interferon alfa-2b (3 MU subcutaneously three times per week) plus ribavirin 1000-1200 mg/day orally, peginterferon alfa-2b 1.5 mug/kg each week plus 800 mg/day ribavirin, or peginterferon alfa-2b 1.5 mug/kg per week for 4 weeks then 0.5 mug/kg per week plus ribavirin 1000-1200 mg/day for 48 weeks. The primary endpoint was the SVR rate (undetectable hepatitis C virus [HCV] RNA in serum at 24-week follow-up). Analyses were based on patients who received at least one dose of study medication. Findings The SVR rate was significantly higher (p=0.01 for both comparisons) in the higher-dose peginterferon group (274/511 [54%]) than in the lower-dose peginterferon (244/514 [47%]) or interferon (235/505 [47%]) groups. Among patients with HCV genotype I infection, the corresponding SVR rates were 42% (J-45/348), 34% (118/349), and 33% (114/343). The rate for patients with genotype 2 and 3 infections was about 80% for all treatment groups. Secondary analyses identified bodyweight as an important predictor of SVR, prompting comparison of the interferon regimens after adjusting ribavirin for bodyweight (mg/kg). Side-effect profiles were similar between the treatment groups. Interpretation In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 mug/kg per week plus ribavirin. The benefit is mostly achieved in patients with HCV genotype 1 infections.	Hannover Med Sch, Div Gastroenterol & Hepatol, D-3000 Hannover, Germany; Scripps Res Inst, La Jolla, CA 92037 USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Georgetown Univ, Washington, DC USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Charlotte Clin Gastrointestinal & Liver Dis, Charlotte, NC USA; Armed Forces Inst Pathol, Bethesda, MD USA; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA	Hannover Medical School; Scripps Research Institute; Beaumont Health; Georgetown University; Virginia Commonwealth University; United States Department of Defense; Merck & Company; Schering Plough Corporation	Manns, MP (corresponding author), Hannover Med Sch, Div Gastroenterol & Hepatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	manns.michael@mh-hannover.de			NCRR NIH HHS [MO1-RR00833, MO1-RR01066, 5MO1-RR00082] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066, M01RR000833, M01RR000082] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Blatt LM, 1998, J INTERF CYTOK RES, V18, P75, DOI 10.1089/jir.1998.18.75; Buti M, 2000, DIGEST DIS SCI, V45, P685, DOI 10.1023/A:1005479207106; Carithers RL, 2000, HEPATOLOGY, V32, p317A; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; DETRE KM, 1996, VIRAL HEPATITIS REV, V2, P219; Glue P, 2000, CLIN PHARMACOL THER, V68, P556, DOI 10.1067/mcp.2000.110973; Glue P, 2000, HEPATOLOGY, V32, P647, DOI 10.1053/jhep.2000.16661; GOODMAN ZD, 1995, SEMIN LIVER DIS, V15, P70, DOI 10.1055/s-2007-1007264; He XH, 1999, LIFE SCI, V65, P355, DOI 10.1016/S0024-3205(99)00257-X; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; National Institutes of Health Consensus Development Conference Panel statement, 1997, HEPATOLOGY S1, V26, P2; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Shiffman ML, 1999, GASTROENTEROLOGY, V117, P1164, DOI 10.1016/S0016-5085(99)70402-6; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; Tong MJ, 1997, HEPATOLOGY, V26, P1640, DOI 10.1002/hep.510260637; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	21	5049	5313	3	265	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 22	2001	358	9286					958	965		10.1016/S0140-6736(01)06102-5	http://dx.doi.org/10.1016/S0140-6736(01)06102-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583749				2022-12-28	WOS:000171135300016
J	Koch, SW; Knorr, A				Koch, SW; Knorr, A			Applied physics - Optics in the nano-world	SCIENCE			English	Editorial Material									Univ Marburg, Dept Phys, D-35032 Marburg, Germany; Tech Univ Berlin, Inst Theoret Phys, D-10623 Berlin, Germany	Philipps University Marburg; Technical University of Berlin	Koch, SW (corresponding author), Univ Marburg, Dept Phys, D-35032 Marburg, Germany.							Banyai L., 1993, SEMICONDUCTOR QUANTU; BONNELL D, 2000, SCANNING PROBE MICRO; Guest JR, 2001, SCIENCE, V293, P2224, DOI 10.1126/science.1063696; PAESLER MA, 1996, NEAR FIELD OPTICS TH; Rayleigh L., 1879, LONDON EDINBURGH DUB, V8, P261, DOI [10.1080/14786447908639684, DOI 10.1080/14786447908639684]	5	24	25	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2217	2218		10.1126/science.1065119	http://dx.doi.org/10.1126/science.1065119			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567128				2022-12-28	WOS:000171139400031
J	Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Snapinn, SM; Zhang, ZX; Shahinfar, S				Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Snapinn, SM; Zhang, ZX; Shahinfar, S		RENAAL Study Investigators	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONVERTING ENZYME-INHIBITION; HYPERTENSIVE NIDDM; PROGRESSION; ENALAPRIL; RAMIPRIL; IRBESARTAN; AMLODIPINE; CREATININE	Background Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available for patients with type 2, the most common form of diabetes. We assessed the role of the angiotensin-II receptor antagonist losartan in patients with type 2 diabetes and nephropathy. Methods A total of 1513 patients were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once daily) with placebo, both taken in addition to conventional antihypertensive treatment (calcium-channel antagonists, diuretics, alpha-blockers, beta-blockers, and centrally acting agents), for a mean of 3.4 years. The primary outcome was the composite of a doubling of the base-line serum creatinine concentration, end-stage renal disease, or death. Secondary end points included a composite of morbidity and mortality from cardiovascular causes, proteinuria, and the rate of progression of renal disease. Results A total of 327 patients in the losartan group reached the primary end point, as compared with 359 in the placebo group (risk reduction, 16 percent; P=0.02). Losartan reduced the incidence of a doubling of the serum creatinine concentration ( risk reduction, 25 percent; P=0.006) and end-stage renal disease ( risk reduction, 28 percent; P=0.002) but had no effect on the rate of death. The benefit exceeded that attributable to changes in blood pressure. The composite of morbidity and mortality from cardiovascular causes was similar in the two groups, although the rate of first hospitalization for heart failure was significantly lower with losartan ( risk reduction, 32 percent; P=0.005). The level of proteinuria declined by 35 percent with losartan ( P<0.001 for the comparison with placebo). Conclusions Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated. (N Engl J Med 2001; 345: 861-9.) Copyright (C) 2001 Massachusetts Medical Society.	Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Univ Melbourne, Dept Med, Melbourne, Vic, Australia; Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, Groningen, Netherlands; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA; Emory Univ, Div Renal, Atlanta, GA 30322 USA; Steno Diabet Ctr, DK-2820 Gentofte, Denmark; Ist Ric Farmacol Mario Negri, Lab Negri Bergamo, Bergamo, Italy; Merck Res Labs, Blue Bell, PA USA	Harvard University; Brigham & Women's Hospital; University of Melbourne; University of Groningen; Hennepin County Medical Center; Emory University; Steno Diabetes Center; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Merck & Company	Brenner, BM (corresponding author), Brigham & Womens Hosp, Div Renal, 75 Francis St, Boston, MA 02115 USA.	bbrenner@partners.org	Boehm, Bernhard Otto/F-8750-2015; Cooper, Mark E/E-8680-2010; de Zeeuw, Dick/E-9080-2014; Cooper, Mark/AAC-5326-2020; Remuzzi, Giuseppe/V-9766-2017	Cooper, Mark E/0000-0002-5953-642X; de Zeeuw, Dick/0000-0003-3434-7777; Remuzzi, Giuseppe/0000-0002-6194-3446				Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Ahmad J, 1997, DIABETES CARE, V20, P1576, DOI 10.2337/diacare.20.10.1576; Bakris GL, 1996, KIDNEY INT, V50, P1641, DOI 10.1038/ki.1996.480; Bauer JH, 2000, KIDNEY, P2253; Black HR, 1999, J HYPERTENS, V17, pS3; Brenner B M, 2000, J Renin Angiotensin Aldosterone Syst, V1, P328, DOI 10.3317/jraas.2000.062; COX DR, 1972, J R STAT SOC B, V34, P187; Estacio RO, 2000, DIABETES CARE, V23, pB54; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Fogari R, 1999, J HUM HYPERTENS, V13, P47, DOI 10.1038/sj.jhh.1000732; Gerstein HC, 2000, LANCET, V355, P253; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEBOVITZ HE, 1994, KIDNEY INT, V45, pS150; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MITCH WE, 1976, LANCET, V2, P1326; National Institutes of Health, 2000, AM J KIDNEY DIS S, V36, pS37; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Nielsen FS, 1997, DIABETES, V46, P1182, DOI 10.2337/diabetes.46.7.1182; *NIH, 2000, AM J KIDNEY DIS S, V36, pS163; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 2000, AM J KIDNEY DIS, V35, P1155, DOI 10.1016/S0272-6386(00)70054-0; *SAS I, 1977, SAS STAT SOFTW CHANG, P573; Stearne MR, 1998, BRIT MED J, V317, P713; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; WALKER W G, 1992, Journal of the American Society of Nephrology, V3, P339; Yusuf S, 2000, NEW ENGL J MED, V342, P145	34	5149	5389	5	303	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2001	345	12					861	869		10.1056/NEJMoa011161	http://dx.doi.org/10.1056/NEJMoa011161			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	473JW	11565518	Green Submitted, Green Published			2022-12-28	WOS:000171039600002
J	Bahary, N; Zon, LI				Bahary, N; Zon, LI			Development - Endothelium - Chicken soup for the endoderm	SCIENCE			English	Editorial Material							GROWTH-FACTOR; DIFFERENTIATION; ANGIOGENESIS; CELLS		Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Dept Hematol Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Bahary, N (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.	zon@genetics.med.harvard.edu						Boyer AS, 1999, DEV BIOL, V208, P530, DOI 10.1006/dbio.1999.9211; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Drummond IA, 1998, DEVELOPMENT, V125, P4655; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Jiang WG, 1999, CLIN CANCER RES, V5, P3695; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Majumdar A, 1999, DEV GENET, V24, P220, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<220::AID-DVG5>3.3.CO;2-T; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Nakajima Y, 2000, ANAT RECORD, V258, P119, DOI 10.1002/(SICI)1097-0185(20000201)258:2<119::AID-AR1>3.0.CO;2-U; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Stewart RJ, 2001, J UROLOGY, V165, P688, DOI 10.1097/00005392-200102000-00095	13	26	29	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 19	2001	294	5542					530	531		10.1126/science.1066282	http://dx.doi.org/10.1126/science.1066282			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	484NC	11577202				2022-12-28	WOS:000171695600030
J	Piccirillo, JF; Mager, DE; Frisse, ME; Brophy, RH; Goggin, A				Piccirillo, JF; Mager, DE; Frisse, ME; Brophy, RH; Goggin, A			Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; ANTIMICROBIAL TREATMENT; AMOXICILLIN; ADULTS; RHINOSINUSITIS; THERAPY; INFECTIONS; PRINCIPLES; CURE	Context Studies suggest little benefit in relief of acute sinusitis symptoms from the use of newer and more expensive (second-line) antibiotics instead of older and less expensive (first-line) antibiotics. However, researchers have failed to include development of complications and cost of care in their analyses. Objective To compare the effectiveness and cost of first-line with second-line antibiotics for the treatment of acute uncomplicated sinusitis in adults. Design, Setting, and Patients Retrospective cohort study using a pharmaceutical database containing demographic, clinical (International Classification of Diseases, Ninth Revision), treatment, and charge information for 29102 adults with a diagnosis of acute sinusitis receiving initial antibiotic treatment between July 1, 1996, and June 30, 1997. Main Outcome Measures Absence of additional claim for an antibiotic in the 28 days after the initial antibiotic, presence of a claim for a second antibiotic, serious complications of sinusitis, and direct charges and use for the acute sinusitis treatment. Results There were 17 different antibiotics prescribed in this study. The majority (59.5%) of patients received 1 of the first-line antibiotics. The overall success rate was 90.4% (95% confidence interval [CI], 90.0%-90.8%). The success rate for the 17 329 patients who received a first-line antibiotic was 90.1% and for the 11773 patients who received a second-line antibiotic was 90.8%, a difference of 0.7% (95% CI, 0.01%-1.40%; P<.05). There were 2 cases of periorbital cellulitis, one in each treatment group. The average total direct charge for patients receiving a first-line antibiotic was $68.98 and a second-line antibiotic was $135.17, a difference of $66.19 (95% Cl, $64.95-$67.43; P<.001). This difference was due entirely to the difference in charge of antibiotics and not other charges, such as professional fees, laboratory tests, or emergency department visits. Conclusions Patients treated with a first-line antibiotic for acute uncomplicated sinusitis did not have clinically significant differences in outcomes vs those treated with a second-line antibiotic. However, cost of care was significantly higher for patients treated with a second-line antibiotic.	Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Clin Outcomes Res, St Louis, MO 63110 USA; Express Scripts Inc, Maryland Hts, MO USA	Washington University (WUSTL); Express Scripts Holding Company	Piccirillo, JF (corresponding author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Clin Outcomes Res, Campus Box 8115,660 S Euclid Ave, St Louis, MO 63110 USA.	piccirij@msnotes.wustl.edu	Frisse, Mark E/B-3824-2016; Brophy, Robert H/AAX-8562-2021	Frisse, Mark E/0000-0003-0382-6222; Brophy, Robert H/0000-0002-2912-8265				Adelglass J, 1999, OTOLARYNG HEAD NECK, V120, P320, DOI 10.1016/S0194-5998(99)70269-X; Adelglass J, 1998, CLIN THER, V20, P1115, DOI 10.1016/S0149-2918(98)80108-2; *AG HLTH CAR POL R, 1999, 999E015 AG HLTH CAR; Benninger MS, 1997, ARCH OTOLARYNGOL, V123, P1175; BERG O, 1986, Rhinology (Utrecht), V24, P223; Bro F, 1988, Scand J Prim Health Care, V6, P175, DOI 10.3109/02813438809009312; Burke T, 1999, CLIN THER, V21, P1664, DOI 10.1016/S0149-2918(99)80046-0; De Bock Geertruida H., 1994, Scandinavian Journal of Primary Health Care, V12, P9, DOI 10.3109/02813439408997050; de Bock GH, 2001, SCAND J PRIM HEALTH, V19, P58, DOI 10.1080/028134301300034729; de Ferranti SD, 1998, BMJ-BRIT MED J, V317, P632, DOI 10.1136/bmj.317.7159.632; deBock GH, 1997, J CLIN EPIDEMIOL, V50, P881, DOI 10.1016/S0895-4356(97)00117-0; DINGLE JH, 1964, ILLNESS HOME STUDY 2, P347; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; EDELSTEIN DR, 1993, LARYNGOSCOPE, V103, P33; Garbutt JM, 2001, PEDIATRICS, V107, P619, DOI 10.1542/peds.107.4.619; GEHANNO P, 1990, J ANTIMICROB CHEMOTH, V26, P87, DOI 10.1093/jac/26.suppl_E.87; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; Halpern M, 2000, AM J HEALTH-SYST PH, V57, P875, DOI 10.1093/ajhp/57.9.875; Hickner JM, 2001, ANN INTERN MED, V134, P498, DOI 10.7326/0003-4819-134-6-200103200-00017; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; KENNEDY DW, 1990, OTOLARYNG HEAD NECK, V103, P887, DOI 10.1177/01945998901030S510; Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9; Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46; Lindbaek M, 1996, BMJ-BRIT MED J, V313, P325, DOI 10.1136/bmj.313.7053.325; MANN W, 1981, HNO, V29, P92; Mansfield E L, 1994, J La State Med Soc, V146, P287; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCCOMBS JS, 1995, PHARMACOECONOMICS, V7, P543, DOI 10.2165/00019053-199507060-00008; Piccirillo JF, 1995, AM J RHINOL, V9, P297, DOI 10.2500/105065895781808711; POOLE MD, 1999, AM J MED, V106, P385; *RHIN TASK FORC CO, 1997, OTOLARYNGOL HEAD NEC, V117, pS1; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Schrag SJ, 2001, JAMA-J AM MED ASSOC, V286, P49, DOI 10.1001/jama.286.1.49; *SIN ALL HLTH PART, 2000, OTOLARYNGOL HEAD NEC, V123, pS1; Snow V, 2001, ANN INTERN MED, V134, P495, DOI 10.7326/0003-4819-134-6-200103200-00016; vanBuchem FL, 1997, LANCET, V349, P683, DOI 10.1016/S0140-6736(96)07585-X; WAGENMANN M, 1992, J ALLERGY CLIN IMMUN, V90, P552, DOI 10.1016/0091-6749(92)90184-4; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WILLIAMS JW, 1995, JAMA-J AM MED ASSOC, V273, P1015, DOI 10.1001/jama.273.13.1015; WILLIAMS JW, 2001, ANTIBIOTICS ACUTE MA	41	72	73	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2001	286	15					1849	1856		10.1001/jama.286.15.1849	http://dx.doi.org/10.1001/jama.286.15.1849			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	482UH	11597286	Bronze			2022-12-28	WOS:000171595300025
J	Rubenstein, LZ; Powers, CM; MacLean, CH				Rubenstein, LZ; Powers, CM; MacLean, CH			Quality indicators for the management and prevention of falls and mobility problems in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; LOWER-EXTREMITY STRENGTH; OLDER ADULTS; CLINICAL-TRIAL; POSTURAL STABILITY; NURSING-HOME; BALANCE; EXERCISE; COMMUNITY; WOMEN		Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA; Univ So Calif, Los Angeles, CA 90089 USA; RAND Corp, RAND Hlth, Santa Monica, CA 90406 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Southern California; RAND Corporation; University of California System; University of California Los Angeles	Rubenstein, LZ (corresponding author), Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Greater Los Angeles Healthcare Syst, 16 111 Plummer St, Sepulveda, CA 91343 USA.		Powers, Christopher M/J-2662-2014	Rubenstein, Laurence/0000-0001-5910-0266				Alexander NB, 1996, J AM GERIATR SOC, V44, P434, DOI 10.1111/j.1532-5415.1996.tb06417.x; AshtonMiller JA, 1996, ARCH PHYS MED REHAB, V77, P446, DOI 10.1016/S0003-9993(96)90032-5; Bohannon RW, 1996, J ORTHOP SPORT PHYS, V24, P86, DOI 10.2519/jospt.1996.24.2.86; Brown M, 1991, Aging (Milano), V3, P129; Buchner DM, 1997, AGING CLIN EXP RES, V9, P112, DOI 10.1007/BF03340136; Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Chandler JM, 1998, ARCH PHYS MED REHAB, V79, P24, DOI 10.1016/S0003-9993(98)90202-7; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; CRILLY RG, 1989, GERONTOLOGY, V35, P137, DOI 10.1159/000213012; Cumming Robert G., 1990, Annals of Epidemiology, V1, P49; DEAN E, 1993, PHYS THER, V73, P494, DOI 10.1093/ptj/73.8.494; ERA P, 1985, J GERONTOL, V40, P287, DOI 10.1093/geronj/40.3.287; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FIEBERT IM, 1979, PHYS THER, V59, P423, DOI 10.1093/ptj/59.4.423; HU MH, 1994, J GERONTOL, V49, pM52, DOI 10.1093/geronj/49.2.M52; JARRETT PG, 1995, ARCH INTERN MED, V155, P1060, DOI 10.1001/archinte.155.10.1060; JUDGE JO, 1993, PHYS THER, V73, P254, DOI 10.1093/ptj/73.4.254; King MB, 1996, CLIN GERIATR MED, V12, P745; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; LICHTENSTEIN MJ, 1989, ARCH PHYS MED REHAB, V70, P138; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; MacRae PG, 1994, J AGING PHYS ACTIV, V2, P127, DOI DOI 10.1123/JAPA.2.2.127; MASDEU JC, 1987, GAIT DISORDERS AGING; NANDAPALAN V, 1995, J LARYNGOL OTOL, V109, P836, DOI 10.1017/S0022215100131457; Nevitt MC, 1997, GAIT DISORDERS AGING; PERRY J, 1993, ARCH PHYS MED REHAB, V74, P165; Peterson M G, 1993, Arthritis Care Res, V6, P11, DOI 10.1002/art.1790060104; Powers CM, 1997, PHYS THER, V77, P1063, DOI 10.1093/ptj/77.10.1063; Powers CM, 1996, PHYS THER, V76, P369, DOI 10.1093/ptj/76.4.369; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Ray WA, 1997, JAMA-J AM MED ASSOC, V278, P557, DOI 10.1001/jama.278.7.557; REINSCH S, 1992, GERONTOLOGIST, V32, P450, DOI 10.1093/geront/32.4.450; ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.1989.00390070138022; ROBERTS BL, 1989, NURS RES, V38, P180; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; Rubenstein LZ, 2000, J GERONTOL A-BIOL, V55, pM317, DOI 10.1093/gerona/55.6.M317; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; RUBENSTEIN LZ, IN PRESS GER MED CLI; SAUVAGE LR, 1992, AM J PHYS MED REHAB, V71, P333, DOI 10.1097/00002060-199212000-00005; Schenkman M, 1996, J AM GERIATR SOC, V44, P1441, DOI 10.1111/j.1532-5415.1996.tb04068.x; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Shih JP, 1997, PERCEPT MOTOR SKILL, V84, P287, DOI 10.2466/pms.1997.84.1.287; ShumwayCook A, 1997, PHYS THER, V77, P46, DOI 10.1093/ptj/77.1.46; Sonn U, 1994, Disabil Rehabil, V16, P85; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; Taaffe DR, 1999, J AM GERIATR SOC, V47, P1208, DOI 10.1111/j.1532-5415.1999.tb05201.x; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; TOPP R, 1993, GERONTOLOGIST, V33, P501, DOI 10.1093/geront/33.4.501; TRUEBLOOD P R, 1991, Comprehensive Therapy, V17, P20; Wolf SL, 1997, PHYS THER, V77, P371, DOI 10.1093/ptj/77.4.371; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x	54	138	145	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				686	693		10.7326/0003-4819-135-8_Part_2-200110161-00007	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601951				2022-12-28	WOS:000171542400007
J	Duchek, P; Somogyi, K; Jekely, G; Beccari, S; Rorth, P				Duchek, P; Somogyi, K; Jekely, G; Beccari, S; Rorth, P			Guidance of cell migration by the Drosophila PDGF/VEGF receptor	CELL			English	Article							SH2/SH3 ADAPTER PROTEIN; TYROSINE KINASE; MYOBLAST CITY; EGF RECEPTOR; ACTIVATION; OOGENESIS; MORPHOGENESIS; PHAGOCYTOSIS; CHEMOTAXIS; MEMBRANE	Directed cell migrations are important for development, but the signaling pathways and mechanisms responsible for guiding cell migration in vivo are poorly understood. Migration of border cells during Drosophila oogenesis is a simple and attractive model system in which to address these questions. We demonstrate that PVR, a receptor tyrosine kinase related to mammalian PDGF and VEGF receptors, acts in border cells to guide them to the oocyte. The oocyte is the source of a ligand for PVR, PDGF/VEGF factor 1 (PVF1). Intriguingly, the guidance function of PVR is largely redundant with that of EGFR. We present evidence implicating Rac and the Rac activator Mbc/DOCK180/CED-5 as mediators of the guidance signal.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Rorth, P (corresponding author), European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany.		Jékely, Gáspár/I-8708-2012; Rørth, Pernille/H-3020-2011	Jékely, Gáspár/0000-0001-8496-9836; 				Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chen J, 2001, NAT CELL BIOL, V3, P204, DOI 10.1038/35055120; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Edwards KA, 1996, DEVELOPMENT, V122, P1499; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Galletta BJ, 1999, GENE, V228, P243, DOI 10.1016/S0378-1119(99)00010-4; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Holder N, 1999, DEVELOPMENT, V126, P2033; KING RC, 1970, OVARIAN DEV DROSOPHL; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; Liu YR, 2001, DEVELOPMENT, V128, P321; Luschnig S, 2000, MOL CELL, V5, P231, DOI 10.1016/S1097-2765(00)80419-0; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NeumanSilberberg FS, 1996, MECH DEVELOP, V59, P105, DOI 10.1016/0925-4773(96)00567-9; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; NOBES CD, 1995, J CELL SCI, V108, P225; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Queenan AM, 1997, DEVELOPMENT, V124, P3871; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Reich A, 1999, DEVELOPMENT, V126, P4139; RIDELY AJ, 1992, CELL, V70, P401; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Rorth P, 1998, DEVELOPMENT, V125, P1049; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; Tallquist MD, 2000, GENE DEV, V14, P3179, DOI 10.1101/gad.844700; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; XU T, 1993, DEVELOPMENT, V117, P1223	54	346	350	1	21	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 5	2001	107	1					17	26		10.1016/S0092-8674(01)00502-5	http://dx.doi.org/10.1016/S0092-8674(01)00502-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595182	Bronze			2022-12-28	WOS:000171453100006
J	Raghuraman, MK; Winzeler, EA; Collingwood, D; Hunt, S; Wodicka, L; Conway, A; Lockhart, DJ; Davis, RW; Brewer, BJ; Fangman, WL				Raghuraman, MK; Winzeler, EA; Collingwood, D; Hunt, S; Wodicka, L; Conway, A; Lockhart, DJ; Davis, RW; Brewer, BJ; Fangman, WL			Replication dynamics of the yeast genome	SCIENCE			English	Article							CEREVISIAE CHROMOSOME-VI; S-PHASE; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; ORIGIN ACTIVATION; MAMMALIAN-CELLS; ARS ELEMENTS; TIME; INITIATION; TELOMERES	Oligonucleotide microarrays were used to map the detailed topography of chromosome replication in the budding yeast Saccharomyces cerevisiae. The times of replication of thousands of sites across the genome were determined by hybridizing replicated and unreplicated DNAs, isolated at different times in S phase, to the microarrays. Origin activations take place continuously throughout S phase but with most firings near mid-S phase. Rates of replication fork movement vary greatly from region to region in the genome. The two ends of each of the 16 chromosomes are highly correlated in their times of replication. This microarray approach is readily applicable to other organisms, including humans.	Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Math, Seattle, WA 98195 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Affymetrix, Santa Clara, CA USA; Silicon Genet, San Carlos, CA 94070 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Novartis; Affymetrix; Stanford University	Raghuraman, MK (corresponding author), Univ Washington, Dept Genet, Seattle, WA 98195 USA.		Winzeler, Elizabeth/AAP-6752-2020	Winzeler, Elizabeth/0000-0002-4049-2113				APARICIO O, COMMUNICATION; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; HAND R, 1975, J CELL BIOL, V64, P89, DOI 10.1083/jcb.64.1.89; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; KEARSEY S, 1984, CELL, V37, P299, DOI 10.1016/0092-8674(84)90326-X; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P9419, DOI 10.1073/pnas.97.17.9419; KOLOR K, UNPUB; Lengronne A, 2001, NUCLEIC ACIDS RES, V29, P1433, DOI 10.1093/nar/29.7.1433; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; NEWLON CS, 1980, ICN UCLA S MOL CELL, V19, P399; Pasero P, 2000, CURR OPIN GENET DEV, V10, P178, DOI 10.1016/S0959-437X(00)00067-8; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108; Seoighe C, 1999, GENE, V238, P253, DOI 10.1016/S0378-1119(99)00319-4; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; Stevenson JB, 1999, GENE DEV, V13, P146, DOI 10.1101/gad.13.2.146; Toone WM, 1997, ANNU REV MICROBIOL, V51, P125, DOI 10.1146/annurev.micro.51.1.125; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x	35	597	608	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 5	2001	294	5540					115	121		10.1126/science.294.5540.115	http://dx.doi.org/10.1126/science.294.5540.115			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	480EJ	11588253				2022-12-28	WOS:000171448800041
J	Miyamoto, K; Miyake, S; Yamamura, T				Miyamoto, K; Miyake, S; Yamamura, T			A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing T(H)2 bias of natural killer T cells	NATURE			English	Article							ALTERED PEPTIDE LIGAND; ALPHA-GALACTOSYLCERAMIDE; SELECTIVE REDUCTION; MULTIPLE-SCLEROSIS; NKT CELLS; TCR; RECOGNITION; ACTIVATION; ANTIGENS; DISEASE	Experimental autoimmune encephalomyelitis (EAE) is a prototype autoimmune disease mediated by type 1 helper T (T(H)1) cells and under the control of regulatory cells(1-3). Here we report that a synthetic glycolipid ligand for CD1d-restricted natural killer T (NKT) cells expressing the semi-invariant T-cell receptor (V alpha 14(+)) is preventive against EAE. The ligand is an analogue of alpha -galactosylceramide (alpha -GC), a prototype NKT cell ligand, with a truncated sphingosine chain. alpha -GC causes NKT cells to produce both interferon (IFN)-gamma and interleukin (IL)-4 (refs 4, 5). However, this new ligand can induce a predominant production of IL-4 by the NKT cells. A single injection of this glycolipid, but not of alpha -GC, consistently induced T(H)2 bias of autoimmune T cells by causing NKT cells to produce IL-4, leading to suppression of EAE. The lack of polymorphism of CD1d and cross-reactive response of mouse and human NKT cells to the same ligand(6) indicates that targeting NKT cells with this ligand may be an attractive means for intervening in human autoimmune diseases such as multiple sclerosis.	NCNP, Natl Inst Neurosci, Dept Immunol, Tokyo 1878502, Japan	National Center for Neurology & Psychiatry - Japan	Yamamura, T (corresponding author), NCNP, Natl Inst Neurosci, Dept Immunol, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.							Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BIX M, 1995, J IMMUNOL, V155, P1020; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Illes Z, 2000, J IMMUNOL, V164, P4375, DOI 10.4049/jimmunol.164.8.4375; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KIRSTEN JL, 1998, J EXP MED, V187, P1047; Kumar V, 1997, J EXP MED, V185, P1725, DOI 10.1084/jem.185.10.1725; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Mieza MA, 1996, J IMMUNOL, V156, P4035; Moody DB, 1999, IMMUNOL REV, V172, P285, DOI 10.1111/j.1600-065X.1999.tb01373.x; MORITA M, 1995, BIOORG MED CHEM LETT, V5, P699, DOI 10.1016/0960-894X(95)00097-D; Nicholson LB, 1996, CURR OPIN IMMUNOL, V8, P837, DOI 10.1016/S0952-7915(96)80013-6; Pal E, 2001, J IMMUNOL, V166, P662, DOI 10.4049/jimmunol.166.1.662; Pedotti R, 2001, NAT IMMUNOL, V2, P216, DOI 10.1038/85266; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; SUMIDA T, 1995, J EXP MED, V182, P1163, DOI 10.1084/jem.182.4.1163; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; Zhang BN, 1997, J EXP MED, V186, P1677, DOI 10.1084/jem.186.10.1677	21	720	785	1	20	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					531	534		10.1038/35097097	http://dx.doi.org/10.1038/35097097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586362				2022-12-28	WOS:000171340500049
J	Solomon, DH; Simel, DL; Bates, DW; Katz, JN; Schaffer, JL				Solomon, DH; Simel, DL; Bates, DW; Katz, JN; Schaffer, JL			Does this patient have a torn meniscus or ligament of the knee? Value of the physical examination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTERIOR CRUCIATE LIGAMENT; CLINICAL EXAMINATION; MUSCULOSKELETAL EXAMINATION; DIAGNOSTIC-TESTS; LACHMAN TEST; DRAWER SIGN; ACCURACY; INJURIES; ARTHROSCOPY; TEARS	Context While most meniscal or ligamentous knee injuries heal with nonoperative treatments, a subset should be treated with arthroscopic or open surgery. Objective To analyze the accuracy of the clinical examination for meniscal or ligamentous knee injuries. Data Sources MEDLINE (1966-December 31, 2000) and HealthSTAR (1975-December 31, 2000) databases were searched for English-language articles describing the diagnostic accuracy of individual examination items for the knee and a combination of physical examination items (composite examination). Other data sources included reference lists from relevant articles. Study Selection Studies selected for data extraction were those that compared the performance of the physical examination of the knee with a reference standard, such as arthroscopy, arthrotomy, or magnetic resonance imaging. Eighty-eight articles were identified, of which 23 (26%) met inclusion criteria. Data Extraction A rheumatologist and an orthopedic surgeon independently reviewed each article using a standardized rating scale that scored the assembly of the study, the relevance of the patients enrolled, the appropriateness of the reference standard, and the blinding of the examiner. Data Synthesis Summary likelihood ratios (LRs) were estimated from random effects models. The summary LRs for physical examination for tears of the anterior cruciate ligament, using the anterior drawer test, were 3.8 (95% confidence interval [CI], 0.7-22.0) for a positive examination and 0.30 (95% CI, 0.05-1.50) for a negative examination; the Lachman test, 25.0 (95% CI, 2.7-651.0) and 0.1 (95% CI, 0.0-0.4); and the composite assessment, 25.0 (95% CI, 2.1-306.0) and 0.04 (95% CI, 0.01-0.48), respectively. The LRs could not be generated for any specific examination maneuver for a posterior cruciate ligament tear, but the composite assessment had an LR of 21.0 (95% CI, 2.1-205.0) for a positive examination and 0.05 (95% CI, 0.01-0.50) for a negative examination. Determination of meniscal lesions, using McMurray test, had an LR of 1.3 (95% CI, 0.9-1.7) for a positive examination and 0.8 (95% CI, 0.6-1.1) for a negative examination; joint line tenderness, 0.9 (95% CI, 0.8-1.0) and 1.1 (95% CI, 1.0-1.3); and the composite assessment, 2.7 (95% CI, 1.4-5.1) and 0.4 (95% CI, 0.2-0.7), respectively. Conclusion The composite examination for specific meniscal or ligamentous injuries of the knee performed much better than specific maneuvers, suggesting that synthesis of a group of examination maneuvers and historical items may be required for adequate diagnosis.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Div Rheumatol, Robert B Brigham Multipurpose Arthrit & Musculosk, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Gen Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA; Duke Univ, Med Ctr, Durham, NC USA; Durham Vet Affairs Med Ctr, Durham, NC USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Schaffer, JL (corresponding author), Cleveland Clin, Dept Orthoped Surg, 9500 Euclid Ave,Desk A41, Cleveland, OH 44195 USA.	schaffj@ccf.org		Schaffer, Jonathan/0000-0002-3131-3355	NIAMS NIH HHS [AR36308, K24 AR02123] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308, K24AR002123] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON AF, 1986, AM J SPORT MED, V14, P291, DOI 10.1177/036354658601400408; BAKER CL, 1984, AM J SPORT MED, V12, P204, DOI 10.1177/036354658401200307; BARRY OCD, 1983, IRISH J MED SCI, V152, P149, DOI 10.1007/BF02960058; Bjordal JM, 1997, AM J SPORT MED, V25, P341, DOI 10.1177/036354659702500312; BODEN SD, 1992, CLIN ORTHOP RELAT R, P177; Branch VK, 1999, ARTHRIT CARE RES, V12, P61, DOI 10.1002/1529-0131(199902)12:1<61::AID-ART10>3.0.CO;2-G; BRAUNSTEIN EM, 1982, AM J ROENTGENOL, V138, P423, DOI 10.2214/ajr.138.3.423; CRATON N, 1993, SPORTS MED, V15, P328, DOI 10.2165/00007256-199315050-00004; CUNNINGHAM LS, 1984, AM J PUBLIC HEALTH, V74, P574, DOI 10.2105/AJPH.74.6.574; Curl WW, 1997, ARTHROSCOPY, V13, P456, DOI 10.1016/S0749-8063(97)90124-9; DAHLSTEDT LJ, 1989, ACTA ORTHOP SCAND, V60, P181, DOI 10.3109/17453678909149249; DANIEL DM, 1991, AM J SPORT MED, V19, P139, DOI 10.1177/036354659101900209; DEHAVEN KE, 1980, AM J SPORT MED, V8, P9, DOI 10.1177/036354658000800102; DONALDSON WF, 1985, AM J SPORT MED, V13, P5, DOI 10.1177/036354658501300102; EDDY DM, 1992, METANALYSIS CONFIDEN, P92; FEAGIN JA, 1988, CRUCIAL LIGAMENTS, P1; FOWLER P J, 1989, Arthroscopy, V5, P184, DOI 10.1016/0749-8063(89)90168-0; Friden T, 1999, KNEE SURG SPORT TR A, V7, P226, DOI 10.1007/s001670050153; GILLIES H, 1979, J BONE JOINT SURG AM, V61, P343, DOI 10.2106/00004623-197961030-00004; GURTLER RA, 1987, CLIN ORTHOP RELAT R, P141; Gwinn DE, 2000, AM J SPORT MED, V28, P98, DOI 10.1177/03635465000280012901; HARDAKER WT, 1990, SOUTH MED J, V83, P640, DOI 10.1097/00007611-199006000-00011; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; HUGHSTON JC, 1976, J BONE JOINT SURG AM, V58, P159, DOI 10.2106/00004623-197658020-00001; IKE RW, 1995, ARTHRITIS RHEUM, V38, P917, DOI 10.1002/art.1780380707; JONSSON T, 1982, AM J SPORT MED, V10, P100, DOI 10.1177/036354658201000207; Katz JN, 2000, AM J MED, V108, P28, DOI 10.1016/S0002-9343(99)00313-7; Lawry GV, 1999, ACAD MED, V74, P199, DOI 10.1097/00001888-199902000-00020; LEE JK, 1988, RADIOLOGY, V166, P861, DOI 10.1148/radiology.166.3.3340785; LIU SH, 1995, J BONE JOINT SURG BR, V77B, P586; LOOS WC, 1981, AM J SPORT MED, V9, P86, DOI 10.1177/036354658100900203; LOSEE RE, 1983, CLIN ORTHOP RELAT R, V172, P45; Marchi AG, 1999, ARCH DIS CHILD, V81, P324, DOI 10.1136/adc.81.4.324; Miller GK, 1996, ARTHROSCOPY, V12, P406, DOI 10.1016/S0749-8063(96)90033-X; MITSOU A, 1988, INJURY, V19, P427, DOI 10.1016/0020-1383(88)90139-8; NOBLE J, 1980, J BONE JOINT SURG BR, V62, P7, DOI 10.1302/0301-620X.62B1.7351438; OShea KJ, 1996, AM J SPORT MED, V24, P164, DOI 10.1177/036354659602400208; Praemer A., 1992, MUSCULOSKELETAL COND, P143; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Rath E, 2000, BRIT J SPORT MED, V34, P252, DOI 10.1136/bjsm.34.4.252; Rose NE, 1996, ARTHROSCOPY, V12, P398, DOI 10.1016/S0749-8063(96)90032-8; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SHRIVE NG, 1978, CLIN ORTHOP RELAT R, P279; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SIMONSEN O, 1984, INJURY, V16, P96, DOI 10.1016/S0020-1383(84)80007-8; Stevenson H, 1998, Iowa Orthop J, V18, P64; Torg J S, 1976, Am J Sports Med, V4, P84, DOI 10.1177/036354657600400206; WRIGHT V, 1992, BRIT J RHEUMATOL, V31, P279	49	145	151	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1610	1620		10.1001/jama.286.13.1610	http://dx.doi.org/10.1001/jama.286.13.1610			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585485				2022-12-28	WOS:000171340600029
J	Seow, CS; Teo, NB; Wilson, CR; Oien, KA				Seow, CS; Teo, NB; Wilson, CR; Oien, KA			Attitudes and training of research fellows in surgery: national questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Surg, Glasgow G11 6NT, Lanark, Scotland; Univ Liverpool, Dept Surg, Liverpool L69 3GA, Merseyside, England	University of Glasgow; University of Glasgow; University of Liverpool	Seow, CS (corresponding author), Gartnavel Royal Hosp, Dept Vasc Surg, Glasgow G12 0YN, Lanark, Scotland.		Oien, Karin/AAH-3849-2019					*COLL VIC CHANC PR, 1997, CLIN AC CAR REP IND; Dawson J, 1996, ANN ROY COLL SURG, V78, P188; Smith R, 2000, LANCET, V355, P849, DOI 10.1016/S0140-6736(05)72468-5; Taylor I, 2000, ANN ROY COLL SURG, V82, P234; *WORK GROUP SPEC M, 1993, HOSP DOCT TRAIN FUT	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					725	726		10.1136/bmj.323.7315.725	http://dx.doi.org/10.1136/bmj.323.7315.725			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HJ	11576979	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000171340700019
J	D'Anna, G; Gremaud, G				D'Anna, G; Gremaud, G			The jamming route to the glasss tate in weakly perturbed granular media	NATURE			English	Article							DYNAMICS; LIQUIDS; GASES	It has been suggested that a common conceptual framework known as 'jamming' (refs 1 and 2) may be used to classify a wide variety of physical systems; these include granular media(3), colloidal suspensions(4) and glass-forming liquids(5), all of which display a critical slowdown in their dynamics before a sudden transition to an amorphous rigid state. Decreasing the relevant control parameter (such as temperature, drive or inverse density) may cause geometrical constraints to build up progressively and thus restrict the accessible part of the system's phase space. In glass-forming liquids (thermal molecular systems), jamming is provided by the classical vitrification process of supercooling, characterized by a rapidly increasing and apparently diverging viscosity at sufficiently low temperatures(6,7). In driven (athermal) macroscopic systems, a similar slowdown has been predicted to occur, notably in sheared foam or vibrated granular media(8,9). Here we report experimental evidence for dynamic behaviour, qualitatively analogous to supercooling, in a driven granular system of macroscopic millimetre-size particles. The granular medium is perturbed by isolated tapping or continuous vibration, with the perturbation intensity serving as a control parameter. We observe the random deflection of an immersed torsion oscillator that moves each time the grains rearrange, like a 'thermometer' sensing the granular noise(10,11). We caution that our granular analogy to supercooling is based on similarities in the dynamical behaviour, rather than quantitative theory.	Ecole Polytech Fed Lausanne, Inst Genie Atom, Dept Phys, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	D'Anna, G (corresponding author), Ecole Polytech Fed Lausanne, Inst Genie Atom, Dept Phys, CH-1015 Lausanne, Switzerland.							ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; Barrat A, 2000, PHYS REV LETT, V85, P5034, DOI 10.1103/PhysRevLett.85.5034; Berthier L, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.051302; Bocquet L, 1998, NATURE, V396, P735, DOI 10.1038/25492; D'Anna G, 2001, EUROPHYS LETT, V54, P599, DOI 10.1209/epl/i2001-00108-7; D'Anna G, 2000, EUROPHYS LETT, V51, P293, DOI 10.1209/epl/i2000-00351-x; Debenedetti PG, 2001, NATURE, V410, P259, DOI 10.1038/35065704; Jaeger HM, 1996, REV MOD PHYS, V68, P1259, DOI 10.1103/RevModPhys.68.1259; Kurchan J, 2000, J PHYS-CONDENS MAT, V12, P6611, DOI 10.1088/0953-8984/12/29/332; Langer SA, 2000, EUROPHYS LETT, V49, P68, DOI 10.1209/epl/i2000-00121-4; Liu A., 2001, JAMMING RHEOLOGY CON; Liu AJ, 1998, NATURE, V396, P21, DOI 10.1038/23819; Nowak ER, 1998, PHYS REV E, V57, P1971, DOI 10.1103/PhysRevE.57.1971; O'Hern CS, 2001, PHYS REV LETT, V86, P111, DOI 10.1103/PhysRevLett.86.111; PAK HK, 1995, PHYS REV LETT, V74, P4643, DOI 10.1103/PhysRevLett.74.4643; Risken H., 1989, FOKKER PLANCK EQUATI, DOI DOI 10.1007/978-3-642-61544-3; Speedy RJ, 1998, MOL PHYS, V95, P169, DOI 10.1080/00268979809483148; TARJUS G, 2001, JAMMING RHEOLOGY CON, P20; Trappe V, 2001, NATURE, V411, P772, DOI 10.1038/35081021	19	99	99	2	30	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					407	409		10.1038/35096540	http://dx.doi.org/10.1038/35096540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574884				2022-12-28	WOS:000171188700050
J	Bjorntorp, P				Bjorntorp, P			Thrifty genes and human obesity. Are we chasing ghosts?	LANCET			English	Editorial Material							WOMEN; FAT		Gothenburg Univ, Sahlgrens Hosp, Dept Heart & Lung Dis, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg	Bjorntorp, P (corresponding author), Gothenburg Univ, Sahlgrens Hosp, Dept Heart & Lung Dis, S-41345 Gothenburg, Sweden.							[Anonymous], 1998, WHONUTNCD981; BJORNTORP P, 1978, METABOLISM, V27, P1853, DOI 10.1016/S0026-0495(78)80004-3; Bjorntorp P, 1993, Obes Res, V1, P206; BJORNTORP P, 1999, DIABETIC MED, V16, P1; Bjorntorp PA, 1999, BEST PRACT RES CL EN, V13, P47, DOI 10.1053/beem.1999.0006; Chagnon YC, 2000, OBES RES, V8, P89, DOI 10.1038/oby.2000.12; Comings DE, 1998, MOL PSYCHIATR, V3, P21, DOI 10.1038/sj.mp.4000289; Elbers JMH, 1997, J CLIN ENDOCR METAB, V82, P2044, DOI 10.1210/jc.82.7.2044; FOLKOW B, 1987, CIRCULATION S1, V76, P1; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Jones MEE, 2000, P NATL ACAD SCI USA, V97, P12735, DOI 10.1073/pnas.97.23.12735; LINDSTEDT G, 1991, DIABETES, V40, P123, DOI 10.2337/diabetes.40.1.123; Lovejoy JC, 1996, J CLIN ENDOCR METAB, V81, P2198, DOI 10.1210/jc.81.6.2198; NEEL JV, 1962, AM J HUM GENET, V14, P353; Pond C.M., 1998, FATS LIFE; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rosmond R, 2000, J CLIN ENDOCR METAB, V85, P3126, DOI 10.1210/jc.85.9.3126; Rotimi C, 1996, HYPERTENSION, V27, P558, DOI 10.1161/01.HYP.27.3.558; Sharma AM, 1998, J MOL MED-JMM, V76, P568, DOI 10.1007/s001090050251; STUBBS RJ, 1995, AM J CLIN NUTR, V62, P316	20	31	32	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					1006	1008		10.1016/S0140-6736(01)06110-4	http://dx.doi.org/10.1016/S0140-6736(01)06110-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583771				2022-12-28	WOS:000171135300036
J	Rajaratnam, SM; Arendt, J				Rajaratnam, SM; Arendt, J			Health in a 24-h society	LANCET			English	Review							HUMAN CIRCADIAN PACEMAKER; NIGHT-SHIFT WORK; BRIGHT LIGHT; 6-SULPHATOXYMELATONIN RHYTHM; PERFORMANCE IMPAIRMENT; MELATONIN SECRETION; DIURNAL-VARIATIONS; SLEEP-DEPRIVATION; JET-LAG; ADAPTATION	With increasing economic and social demands, we are rapidly evolving into a 24-h society. In any urban economy, about 20% of the population are required to work outside the regular 0800-1700 h working day and this figure is likely to increase. Although the increase in shiftwork has led to greater flexibility in work schedules, the ability to provide goods and services throughout the day and night, and possibly greater employment opportunities, the negative effects of shiftwork and chronic sleep. loss on health and productivity are now being appreciated. For example, sleepiness surpasses alcohol and drugs as the greatest identifiable and preventable cause of accidents in all modes of transport. Industrial accidents associated with night work are common, perhaps the most famous being Chernobyl, Three Mile Island, and Bhopal.	Univ Surrey, Sch Biomed & Life Sci, Ctr Chronobiol, Guildford GU2 7XH, Surrey, England	University of Surrey	Arendt, J (corresponding author), Univ Surrey, Sch Biomed & Life Sci, Ctr Chronobiol, Guildford GU2 7XH, Surrey, England.	j.arendt@surrey.ac.uk	Rajaratnam, Shantha/D-8144-2012	Rajaratnam, Shantha/0000-0001-7527-8558				Akerstedt T, 1995, J SLEEP RES, V4, P15, DOI 10.1111/j.1365-2869.1995.tb00221.x; Arendt J, 1997, J BIOL RHYTHM, V12, P604, DOI 10.1177/074873049701200616; Arendt J., 2000, PRINCIPLES PRACTICE, Vthird, P591; Barnes R, 1998, NEUROSCI LETT, V252, P179, DOI 10.1016/S0304-3940(98)00585-0; Barnes RG, 1998, NEUROSCI LETT, V241, P9, DOI 10.1016/S0304-3940(97)00965-8; BARTON J, 1993, ERGONOMICS, V36, P59, DOI 10.1080/00140139308967855; Batejat DM, 1999, AVIAT SPACE ENVIR MD, V70, P493; Boggild H, 1999, SCAND J WORK ENV HEA, V25, P85, DOI 10.5271/sjweh.410; Bonn D, 1996, LANCET, V347, P184, DOI 10.1016/S0140-6736(96)90359-1; BROADWAY J, 1987, NEUROSCI LETT, V79, P185, DOI 10.1016/0304-3940(87)90694-X; Buxton OM, 1997, J BIOL RHYTHM, V12, P568, DOI 10.1177/074873049701200611; Cajochen C, 2000, BEHAV BRAIN RES, V115, P75, DOI 10.1016/S0166-4328(00)00236-9; Cho K, 2000, J NEUROSCI, V20, part. no.; *CONS STAT, 2000, J SLEEP RES, V9, P395; Costa G, 1996, APPL ERGON, V27, P9, DOI 10.1016/0003-6870(95)00047-X; Dawson D, 1997, NATURE, V388, P235, DOI 10.1038/40775; Dijk DJ, 1999, J PHYSIOL-LONDON, V516, P611, DOI 10.1111/j.1469-7793.1999.0611v.x; DIJK DJ, 1997, SLEEP SCI INTEGRATIN, P10; Dinges DF, 1991, SLEEP SLEEPINESS PER; Eastman CI, 1999, ANN MED, V31, P87, DOI 10.3109/07853899908998783; FOLKARD S, 1992, ERGONOMICS, V35, P1453, DOI 10.1080/00140139208967414; Hampton SM, 1996, J ENDOCRINOL, V151, P259, DOI 10.1677/joe.0.1510259; Horne J, 1999, OCCUP ENVIRON MED, V56, P289, DOI 10.1136/oem.56.5.289; Jewett ME, 1999, J SLEEP RES, V8, P1, DOI 10.1111/j.1365-2869.1999.00128.x; JEWETT ME, 1994, J BIOL RHYTHM, V9, P295, DOI 10.1177/074873049400900310; Johnson M P, 1992, J Sleep Res, V1, P24; Katzenberg D, 1998, SLEEP, V21, P569, DOI 10.1093/sleep/21.6.569; KENNAWAY DJ, 1991, AM J PHYSIOL, V260, pR1137, DOI 10.1152/ajpregu.1991.260.6.R1137; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Lamond N, 1999, J SLEEP RES, V8, P255, DOI 10.1046/j.1365-2869.1999.00167.x; Lockley SW, 2000, J ENDOCRINOL, V164, pR1, DOI 10.1677/joe.0.164R001; Lockley SW, 1997, J CLIN ENDOCR METAB, V82, P3763, DOI 10.1210/jc.82.11.3763; Monk TH, 2000, J BIOL RHYTHM, V15, P86, DOI 10.1177/074873040001500202; Moore-Ede M., 1993, 24 HOUR SOC UNDERSTA; Morgan L, 1998, J ENDOCRINOL, V157, P443, DOI 10.1677/joe.0.1570443; Morgan LM, 1999, ANN CLIN BIOCHEM, V36, P447, DOI 10.1177/000456329903600407; Owens DS, 2000, BRIT J PSYCHOL, V91, P41, DOI 10.1348/000712600161664; PARKES KR, 1996, 96530 OTH; Penev PD, 1998, AM J PHYSIOL-HEART C, V275, pH2334; Quera-Salva MA, 1997, SLEEP, V20, P1145; ROSS JK, 1995, PHYSIOL BEHAV, V57, P1169, DOI 10.1016/0031-9384(95)00018-E; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; SMITH L, 1994, LANCET, V344, P1137, DOI 10.1016/S0140-6736(94)90636-X; SMITH R, 2000, SLEEP, V23, pA110; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; VANCAUTER E, 1992, AM J PHYSIOL, V262, pE467, DOI 10.1152/ajpendo.1992.262.4.E467; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Williamson AM, 2000, OCCUP ENVIRON MED, V57, P649, DOI 10.1136/oem.57.10.649; Wright N, 2001, ERGONOMICS, V44, P82, DOI 10.1080/00140130150203893; Zeitzer JM, 2000, J PHYSIOL-LONDON, V526, P695, DOI 10.1111/j.1469-7793.2000.00695.x; 1999, J BIOL RHYTHMS, V14, P577	51	498	513	2	92	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 22	2001	358	9286					999	1005		10.1016/S0140-6736(01)06108-6	http://dx.doi.org/10.1016/S0140-6736(01)06108-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	474YR	11583769				2022-12-28	WOS:000171135300034
J	Hyde, TB; Gay, K; Stephens, DS; Vugia, DJ; Pass, M; Johnson, S; Barrett, NL; Schaffner, W; Cieslak, PR; Maupin, PS; Zell, ER; Jorgensen, JH; Facklam, RR; Whitney, CG				Hyde, TB; Gay, K; Stephens, DS; Vugia, DJ; Pass, M; Johnson, S; Barrett, NL; Schaffner, W; Cieslak, PR; Maupin, PS; Zell, ER; Jorgensen, JH; Facklam, RR; Whitney, CG		Active Bacterial Core Surveillance	Macrolide resistance among invasive Streptococcus pneumoniae isolates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; UNITED-STATES; ANTIBIOTICS; LINCOSAMIDE; PREVALENCE; MECHANISMS; EMERGENCE; COLONIZATION; AZITHROMYCIN; SURVEILLANCE	Context Macrolide antibiotics, including erythromycin, clarithromycin, and azithromycin, are the mainstays of empirical pneumonia therapy. Macrolide resistance among Streptococcus pneumoniae, the most common cause of community-acquired pneumonia, is increasing in the United States. Whether resistance is a significant problem or whether macrolides remain useful for treatment of most resistant strains is unknown. Objective To examine the epidemiology of macrolide-resistant pneumococci in the United States. Design and Setting Analysis of 15481 invasive isolates from 1995 to 1999 collected by the Centers for Disease Control and Prevention's Active Bacterial Core surveillance system in 8 states. Main Outcome Measures Trends in macrolide use (1993-1999) and resistance and factors associated with resistance, including examination of 2 subtypes, the M phenotype, associated with moderate minimum inhibitory concentrations (MICs), and the MLS8 phenotype, associated with high MICs and clindamycin resistance. Results From 1993 to 1999, macrolide use increased 13% macrolide use increased 320% among children younger than 5 years. Macrolide resistance increased from 10.6% in 1995 to 20.4% in 1999. M phenotype isolates increased from 7.4% to 16.5% (P<.001), while the proportion with the MLSB phenotype was stable (3%-4%). The median erythromycin MIC (MIC50) of M phenotype isolates increased from 4 <mu>g/mL to 8 mug/mL. In 1999, M phenotype strains were more often from children than persons 5 years or older (25.2% vs 12.6%; P<.001) and from whites than blacks (19.3% vs 11.2%; P<.001). Conclusions In the setting of increasing macrolide use, pneumococcal resistance has become common. Most resistant strains have MICs in the range in which treatment failures have been reported. Further study and surveillance are critical to understanding the clinical implications of our findings.	CDCP, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; CDCP, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Emory Univ, Sch Med, Dept Vet Affairs Med Ctr, Atlanta, GA USA; Calif Dept Hlth & Human Serv, Berkeley, CA USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA; Minnesota Dept Hlth, Sch Publ Hlth, Minneapolis, MN USA; Connecticut Dept Publ Hlth, Hartford, CT USA; Vanderbilt Univ Sch Med, Dept Prevent Med, Nashville, TN USA; Oregon Dept Human Serv, Hlth Div, Portland, OR USA; Monroe Cty Hlth Dept Human Serv, Rochester, NY USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; California Health & Human Services Agency; Johns Hopkins University; Minnesota Department of Health (MHD); Vanderbilt University; University of Texas System; University of Texas Health San Antonio	Whitney, CG (corresponding author), CDCP, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd NE,Mailstop C-23, Atlanta, GA 30333 USA.		Stephens, David S/A-8788-2012					Amsden GW, 1999, J ANTIMICROB CHEMOTH, V44, P1, DOI 10.1093/jac/44.1.1; ARTHUR M, 1987, J ANTIMICROB CHEMOTH, V20, P783, DOI 10.1093/jac/20.6.783; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; BOKEN DJ, 1995, PEDIATR INFECT DIS J, V14, P879, DOI 10.1097/00006454-199510000-00012; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; DOEM GV, 1996, ANTIMICROB AGENTS CH, V40, P1208; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; Gay K, 2000, J INFECT DIS, V182, P1417, DOI 10.1086/315853; GLADUE RP, 1989, ANTIMICROB AGENTS CH, V33, P277, DOI 10.1128/AAC.33.3.277; Heffelfinger JD, 2000, ARCH INTERN MED, V160, P1399, DOI 10.1001/archinte.160.10.1399; Johnston NJ, 1998, ANTIMICROB AGENTS CH, V42, P2425, DOI 10.1128/AAC.42.9.2425; Kelley MA, 2000, CLIN INFECT DIS, V31, P1008, DOI 10.1086/318157; Lagrou K, 2000, J ANTIMICROB CHEMOTH, V45, P119, DOI 10.1093/jac/45.1.119; Marchese A, 1999, J ANTIMICROB CHEMOTH, V44, P461, DOI 10.1093/jac/44.4.461; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; McCracken GH, 1997, PEDIATR INFECT DIS J, V16, P432, DOI 10.1097/00006454-199704000-00026; *NAT COMM CLIN LAB, 2001, M100S10 NCCLS; *NAT CTR HLTH STAT, 2001, NAT HOSP AMB MED CAR; *NAT CTR HLTH STAT, 2001, NAT AMB MED CAR SURV; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; Nishijima T, 1999, J ANTIMICROB CHEMOTH, V43, P637, DOI 10.1093/jac/43.5.637; Roberts MC, 1999, ANTIMICROB AGENTS CH, V43, P2823, DOI 10.1128/AAC.43.12.2823; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Shortridge VD, 1999, CLIN INFECT DIS, V29, P1186, DOI 10.1086/313452; Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P1817, DOI 10.1128/AAC.40.8.1817; Tait-Kamradt A, 2000, ANTIMICROB AGENTS CH, V44, P3395, DOI 10.1128/AAC.44.12.3395-3401.2000; Waites K, 2000, J CLIN MICROBIOL, V38, P1731, DOI 10.1128/JCM.38.5.1731-1734.2000; WEISBLUM B, 1985, J ANTIMICROB CHEMOTH, V16, P63, DOI 10.1093/jac/16.suppl_A.63; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; Widdowson CA, 1998, EMERG INFECT DIS, V4, P277, DOI 10.3201/eid0402.980216; ZENNI MK, 1995, J PEDIATR-US, V127, P533, DOI 10.1016/S0022-3476(95)70108-7	33	240	266	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2001	286	15					1857	1862		10.1001/jama.286.15.1857	http://dx.doi.org/10.1001/jama.286.15.1857			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	482UH	11597287				2022-12-28	WOS:000171595300026
J	Armstrong, RJE; Barker, RA				Armstrong, RJE; Barker, RA			Neurodegeneration: a failure of neuroregeneration?	LANCET			English	Article							NEURAL STEM-CELLS; DENTATE GYRUS; ADULT; NEUROGENESIS; DIFFERENTIATION; PROLIFERATION; PATHOGENESIS; INDUCTION; NEOCORTEX; NEURONS	Evidence suggests that the brain, like many other tissues, Is In a state of dynamic equilibrium. It has an endogenous population of stem cells that proliferate in response to environmental and pharmacological manipulations and that can replace cells lost In some experimental lesions. However, the fact remains that neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases are characterised by continuous loss of neurons that are not replaced. In this hypothesis, we postulate that a primary deficit In neural stem-cell proliferation; migration, or differentiation, or both, might contribute to net cell loss and neuronal circuit disruption In these disorders. Experimental validation of this hypothesis would not only substantially advance understanding of the pathogenesis of these diseases, but could also have profound implications for future treatment of these Incurable disorders.	Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England; Univ Cambridge, Dept Neurol, Cambridge, England	University of Cambridge; University of Cambridge	Barker, RA (corresponding author), Univ Cambridge, Cambridge Ctr Brain Repair, Forvie Site,Robinson Way, Cambridge CB2 2PY, England.	rab46@cus.cam.ac.uk		Barker, Roger Alistair/0000-0001-8843-7730				Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; BARKER RA, 1999, NEUROPSY REHABIL MOD, P1; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MOTT SH, 1995, ANN NEUROL, V37, P810, DOI 10.1002/ana.410370616; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Roy NS, 2000, NAT MED, V6, P271; Schulz JB, 1999, CURR OPIN NEUROL, V12, P433, DOI 10.1097/00019052-199908000-00010; Shastry BS, 1999, BRAIN RES BULL, V48, P121, DOI 10.1016/S0361-9230(98)00156-7; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Sinden JD, 2000, NOVART FDN SYMP, V231, P270, DOI 10.1002/0470870834.ch16; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Temple S, 1999, CURR BIOL, V9, pR397, DOI 10.1016/S0960-9822(99)80252-8; Trojanowski JQ, 2000, ANN NY ACAD SCI, V924, P62; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; ZHAO M, 2000, SOC NEUROSCI, V26, P302; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	31	95	103	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	2001	358	9288					1174	1176		10.1016/S0140-6736(01)06260-2	http://dx.doi.org/10.1016/S0140-6736(01)06260-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597694				2022-12-28	WOS:000171399000036
J	Hansel, W; Hommelhoff, P; Hansch, TW; Reichel, J				Hansel, W; Hommelhoff, P; Hansch, TW; Reichel, J			Bose-Einstein condensation on a microelectronic chip	NATURE			English	Article							GUIDING NEUTRAL ATOMS; BEAM SPLITTER; WAVE-GUIDE; TRAPS	Although Bose-Einstein condensates(1-3) of ultracold atoms have been experimentally realizable for several years, their formation and manipulation still impose considerable technical challenges. An all-optical technique(4) that enables faster production of Bose-Einstein condensates was recently reported. Here we demonstrate that the formation of a condensate can be greatly simplified using a microscopic magnetic trap on a chip(5). We achieve Bose-Einstein condensation inside the single vapour cell of a magneto-optical trap in as little as 700 ms-more than a factor of ten faster than typical experiments, and a factor of three faster than the all-optical technique(4). A coherent matter wave is emitted normal to the chip surface when the trapped atoms are released into free fall; alternatively, we couple the condensate into an 'atomic conveyor belt'(6), which is used to transport the condensed cloud nondestructively over a macroscopic distance parallel to the chip surface. The possibility of manipulating laser-like coherent matter waves with such an integrated atom-optical system holds promise for applications in interferometry, holography, microscopy, atom lithography and quantum information processing(7).	Univ Munich, Max Planck Inst Quantenopt, D-80799 Munich, Germany; Univ Munich, Sekt Phys, D-80799 Munich, Germany	Max Planck Society; University of Munich; University of Munich	Reichel, J (corresponding author), Univ Munich, Max Planck Inst Quantenopt, Schellingstr 4, D-80799 Munich, Germany.	jakob.reichel@physik.uni-muenchen.de	Reichel, Jakob/AAW-1107-2021; Hommelhoff, Peter/C-5121-2013	Reichel, Jakob/0000-0003-3420-4178; Hommelhoff, Peter/0000-0003-4757-5410				Anderson BP, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.023404; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Barrett MD, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.010404; Bradley CC, 1997, PHYS REV LETT, V78, P985, DOI 10.1103/PhysRevLett.78.985; Cassettari D, 2000, PHYS REV LETT, V85, P5483, DOI 10.1103/PhysRevLett.85.5483; Cornell EA, 1999, P INT SCH PHYS, V140, P15; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; Dekker NH, 2000, PHYS REV LETT, V84, P1124, DOI 10.1103/PhysRevLett.84.1124; DETTMER S, 2001, IN PRESS PHYS REV LE; Drndic M, 1998, APPL PHYS LETT, V72, P2906, DOI 10.1063/1.121455; Fortagh J, 2000, APPL PHYS B-LASERS O, V70, P701, DOI 10.1007/s003400050884; Hansel W, 2001, PHYS REV LETT, V86, P608, DOI 10.1103/PhysRevLett.86.608; HANSEL W, IN PRESS PHYS REV A; Hinds EA, 2001, PHYS REV LETT, V86, P1462, DOI 10.1103/PhysRevLett.86.1462; Ketterle W, 1996, ADV ATOM MOL OPT PHY, V37, P181; Muller D, 2000, OPT LETT, V25, P1382, DOI 10.1364/OL.25.001382; Muller D, 1999, PHYS REV LETT, V83, P5194, DOI 10.1103/PhysRevLett.83.5194; OTT H, IN PRESS PHYS REV LE; Petrov DS, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.050404; Reichel J, 1999, PHYS REV LETT, V83, P3398, DOI 10.1103/PhysRevLett.83.3398; Reichel J, 2001, APPL PHYS B-LASERS O, V72, P81, DOI 10.1007/s003400000460; WEINSTEIN JD, 1995, PHYS REV A, V52, P4004, DOI 10.1103/PhysRevA.52.4004	23	525	538	3	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 4	2001	413	6855					498	501		10.1038/35097032	http://dx.doi.org/10.1038/35097032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586353				2022-12-28	WOS:000171340500040
J	Knight, J				Knight, J			Senators call for biodefence boost	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					441	441		10.1038/35097219	http://dx.doi.org/10.1038/35097219			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586309	Bronze			2022-12-28	WOS:000171340500003
J	Levy, GG; Nichols, WC; Lian, EC; Foroud, T; McClintick, JN; McGee, BM; Yang, AY; Siemieniak, DR; Stark, KR; Gruppo, R; Sarode, R; Shurin, SB; Chandrasekaran, V; Stabler, SP; Sabio, H; Bouhassira, EE; Upshaw, JD; Ginsburg, D; Tsai, HM				Levy, GG; Nichols, WC; Lian, EC; Foroud, T; McClintick, JN; McGee, BM; Yang, AY; Siemieniak, DR; Stark, KR; Gruppo, R; Sarode, R; Shurin, SB; Chandrasekaran, V; Stabler, SP; Sabio, H; Bouhassira, EE; Upshaw, JD; Ginsburg, D; Tsai, HM			Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura	NATURE			English	Article							VON-WILLEBRAND-FACTOR; HEMOLYTIC-UREMIC SYNDROME; FACTOR-CLEAVING PROTEASE; PLASMA VONWILLEBRAND-FACTOR; ENDOTHELIAL-CELLS; LINKAGE ANALYSIS; METALLOPROTEINASE; CLEAVAGE; PURIFICATION; DERMATOSPARAXIS	Thrombotic thrombocytopenic purpura (TTP) is a life-threatening systemic illness of abrupt onset and unknown cause. Proteolysis of the blood-clotting protein von Willebrand factor (VWF) observed in normal plasma is decreased in TTP patients. However, the identity of the responsible protease and its role in the pathophysiology of TTP remain unknown. We performed genome-wide linkage analysis in four pedigrees of humans with congenital TTP and mapped the responsible genetic locus to chromosome 9q34. A predicted gene in the identifed interval corresponds to a segment of a much larger transcript, identifying a new member of the ADAMTS family of zinc metalloproteinase genes (ADAMTS13). Analysis of patients' genomic DNA identified 12 mutations in the ADAMTS13 gene, accounting for 14 of the 15 disease alleles studied. We show that deficiency of ADAMTS13 is the molecular mechanism responsible for TTP, and suggest that physiologic proteolysis of VWF and/or other ADAMTS13 substrates is required for normal vascular homeostasis.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; Univ Miami, Hemophilia & Thrombosis Ctr, Miami, FL 33136 USA; Univ Miami, Sylvester Canc Ctr, Miami, FL 33136 USA; Vet Affairs Med Ctr, Miami, FL 33136 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Childrens Hosp, Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA; Univ Texas, SW Med Sch, Blood Bank, Dallas, TX 75390 USA; Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; Long Isl Jewish Med Ctr, Blood Bank, New Hyde Pk, NY 11040 USA; Albert Einstein Coll Med, New Hyde Pk, NY 11040 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Med Coll Georgia, Augusta, GA 30912 USA; Albert Einstein Coll Med, Dept Med Hematol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Memphis Canc Ctr, Memphis, TN 38119 USA; Montefiore Med Ctr, Div Hematol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Cincinnati Children's Hospital Medical Center; University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); Indiana University System; Indiana University-Purdue University Indianapolis; Cincinnati Children's Hospital Medical Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Northwell Health; Yeshiva University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University System of Georgia; Augusta University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Ginsburg, D (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA.	ginsburg@umich.edu	Bouhassira, Eric/AAZ-4184-2021		NHLBI NIH HHS [R01 HL062136, R37 HL039693] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL039693, R01HL062136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett CL, 2000, NEW ENGL J MED, V342, P1773, DOI 10.1056/NEJM200006153422402; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; BURNS ER, 1982, BLOOD, V60, P1030; Cines DB, 2000, THROMB HAEMOSTASIS, V84, P528; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; George JN, 2000, BLOOD, V96, P1223, DOI 10.1182/blood.V96.4.1223.h8001223_1223_1229; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Kaushal GP, 2000, J CLIN INVEST, V105, P1335, DOI 10.1172/JCI10078; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LYONS SE, 1992, J BIOL CHEM, V267, P4424; MANNUCCI PM, 1989, BLOOD, V74, P978; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Mitra D, 1997, BLOOD, V89, P1224, DOI 10.1182/blood.V89.4.1224; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SIDDIQUI FA, 1985, J CLIN INVEST, V76, P1330, DOI 10.1172/JCI112107; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tsai H M, 2001, Clin Lab, V47, P387; Tsai HM, 1997, BLOOD, V89, P1954, DOI 10.1182/blood.V89.6.1954; Tsai HM, 2000, ANN INTERN MED, V132, P794, DOI 10.7326/0003-4819-132-10-200005160-00005; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; UPSHAW JD, 1978, NEW ENGL J MED, V298, P1350, DOI 10.1056/NEJM197806152982407; ZIMMERMAN TS, 1986, J CLIN INVEST, V77, P947, DOI 10.1172/JCI112394	40	1257	1348	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 4	2001	413	6855					488	494		10.1038/35097008	http://dx.doi.org/10.1038/35097008			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586351	Green Published			2022-12-28	WOS:000171340500038
J	Riipi, M; Alatalo, RV; Lindstrom, L; Mappes, J				Riipi, M; Alatalo, RV; Lindstrom, L; Mappes, J			Multiple benefits of gregariousness cover detectability costs in aposematic aggregations	NATURE			English	Article							KIN SELECTION; EVOLUTION; PREDATION; COLORATION; PROTECTION; LARVAE	Understanding the early evolution of aposematic (warning) coloration has been a challenge for scientists, as a new conspicuous morph in a population of cryptic insects would have a high predation risk and would probably die out before local predators learnt to avoid it(1-4). Fisher(5) presented the idea of aggregation benefit through the survival of related individuals; however, his theory has been strongly debated(6-8) as the mechanisms that favour grouping have never been explored experimentally with the incorporation of detectability costs. Here we create a comprehensive 'novel world' experiment with the great tit (Parus major) as a predator to explore simultaneously the predation-related benefits and costs for aposematic aggregated prey, manipulating both group size and signal strength. Our results show that grouping would have been highly beneficial for the first aposematic prey individuals surrounded by naive predators, because (1) detectability risk increased only asymptotically with group size; (2) additional detectability costs due to conspicuous signals were marginal in groups; (3) even naive predators deserted the group after detecting unpalatability (dilution effect); and (4) avoidance learning of signal was faster in groups. None of these mechanisms require kin selection.	Univ Jyvaskyla, Dept Biol & Environm Sci, Konnevesi Res Stn, FIN-40351 Jyvaskyla, Finland	University of Jyvaskyla	Riipi, M (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, Konnevesi Res Stn, POB 35, FIN-40351 Jyvaskyla, Finland.	marianna.riipi@utu.fi; mappes@cc.jyu.fi	Lindstrom, Leena/B-2326-2012; Mappes, Johanna/AAZ-3627-2021	Lindstrom, Leena/0000-0002-6452-4538; Mappes, Johanna/0000-0002-1117-5629				Alatalo RV, 1996, NATURE, V382, P708, DOI 10.1038/382708a0; ENDLER JA, 1988, PHILOS T R SOC B, V319, P505, DOI 10.1098/rstb.1988.0062; Fisher R.A., 1930, GENETICAL THEORY NAT; GAGLIARDO A, 1993, P ROY SOC B-BIOL SCI, V251, P69, DOI 10.1098/rspb.1993.0010; GUILFORD T, 1985, OIKOS, V45, P31, DOI 10.2307/3565219; Guilford T., 1990, P23; HAMILTON WD, 1971, J THEOR BIOL, V31, P295, DOI 10.1016/0022-5193(71)90189-5; JARVI T, 1981, OIKOS, V36, P267, DOI 10.2307/3544623; Lindstrom L, 1999, NATURE, V397, P249, DOI 10.1038/16692; LINDSTROM L, P R SOC LOND B, V268, P357; MALLET J, 1987, BIOL J LINN SOC, V32, P337, DOI 10.1111/j.1095-8312.1987.tb00435.x; Mallet J, 1999, ANNU REV ECOL SYST, V30, P201, DOI 10.1146/annurev.ecolsys.30.1.201; MARPLES NM, 1994, ANIM BEHAV, V48, P967, DOI 10.1006/anbe.1994.1322; Rivero A, 2000, ANIM BEHAV, V60, P187, DOI 10.1006/anbe.2000.1452; SCHULER W, 1992, ADV STUD BEHAV, V21, P111, DOI 10.1016/S0065-3454(08)60143-6; SILLENTULLBERG B, 1982, OIKOS, V39, P131, DOI 10.2307/3544476; SILLENTULLBERG B, 1988, AM NAT, V132, P723, DOI 10.1086/284884; TREISMAN M, 1975, ANIM BEHAV, V23, P779, DOI 10.1016/0003-3472(75)90106-2; Tullberg BS, 2000, ANIM BEHAV, V59, P281, DOI 10.1006/anbe.1999.1302; TURNER GF, 1986, AM NAT, V128, P228, DOI 10.1086/284556; Weismann A, 1882, STUDIES THEORY DESCE	21	155	156	0	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 4	2001	413	6855					512	514		10.1038/35097061	http://dx.doi.org/10.1038/35097061			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586357				2022-12-28	WOS:000171340500044
J	Korczyn, AD				Korczyn, AD			Hallucinations in Parkinson's disease	LANCET			English	Editorial Material							DREAM PHENOMENA; RISK-FACTORS; LEVODOPA; PREVALENCE; PSYCHOSIS; DEMENTIA; SLEEP		Tel Aviv Univ, Dept Neurol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Korczyn, AD (corresponding author), Tel Aviv Univ, Dept Neurol, IL-69978 Tel Aviv, Israel.	neuro13@post.tau.ac.il	Korczyn, Amos D/C-3461-2017	Korczyn, Amos D/0000-0003-0125-2579				Aarsland D, 1999, ARCH NEUROL-CHICAGO, V56, P595, DOI 10.1001/archneur.56.5.595; Arnulf I, 2000, NEUROLOGY, V55, P281, DOI 10.1212/WNL.55.2.281; Barnes J, 2001, J NEUROL NEUROSUR PS, V70, P727, DOI 10.1136/jnnp.70.6.727; BODISWOLLNER I, 1990, TRENDS NEUROSCI, V13, P296, DOI 10.1016/0166-2236(90)90113-O; Fenelon G, 2000, BRAIN, V123, P733, DOI 10.1093/brain/123.4.733; Fernandez HH, 1999, MOVEMENT DISORD, V14, P484, DOI 10.1002/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B; Giladi N, 2000, J NEURAL TRANSM, V107, P59, DOI 10.1007/s007020050005; Goetz CG, 1998, NEUROLOGY, V51, P811, DOI 10.1212/WNL.51.3.811; Goetz CG, 1998, NEUROLOGY, V50, P515, DOI 10.1212/WNL.50.2.515; Holroyd S, 2001, J NEUROL NEUROSUR PS, V70, P734, DOI 10.1136/jnnp.70.6.734; Inzelberg R, 1998, J NEUROL NEUROSUR PS, V64, P533, DOI 10.1136/jnnp.64.4.533; Korczyn AD, 1998, MOVEMENT DISORD, V13, P46, DOI 10.1002/mds.870130112; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; Pappert EJ, 1999, MOVEMENT DISORD, V14, P117, DOI 10.1002/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0; Parkinson J, 1817, ESSAY SHAKING PALSY, P7; RABEY JM, 1995, NEUROLOGY, V45, P432, DOI 10.1212/WNL.45.3.432; SHARF B, 1978, J NEURAL TRANSM, V43, P143, DOI 10.1007/BF01579073; WHITEHOUSE PJ, 1983, ANN NEUROL, V13, P243, DOI 10.1002/ana.410130304	18	24	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	2001	358	9287					1031	1032		10.1016/S0140-6736(01)06230-4	http://dx.doi.org/10.1016/S0140-6736(01)06230-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	479EY	11589931				2022-12-28	WOS:000171393100006
J	Marks, LJ; Michael, JW				Marks, LJ; Michael, JW			Science, medicine, and the future - Artificial limbs	BRITISH MEDICAL JOURNAL			English	Review							INTELLIGENT PROSTHESIS; AMPUTATIONS; INJURIES; WALKING; FOOT		Royal Natl Orthopaed Hosp, Stanmore DSC, Stanmore HA7 4LP, Middx, England; CPO Serv, Chanhassen, MN 55317 USA	University of London; University College London; Royal National Orthopaedic Hospital NHS Trust	Marks, LJ (corresponding author), Royal Natl Orthopaed Hosp, Stanmore DSC, Stanmore HA7 4LP, Middx, England.							Buckley JG, 1997, ARCH PHYS MED REHAB, V78, P330, DOI 10.1016/S0003-9993(97)90044-7; FISHER LD, 1986, PROSTHET ORTHOT INT, V10, P35; Heim M, 1997, J BONE JOINT SURG BR, V79B, P638, DOI 10.1302/0301-620X.79B4.7350; Hsu MJ, 1999, J ORTHOP SPORT PHYS, V29, P526, DOI 10.2519/jospt.1999.29.9.526; Islinger RB, 2000, MIL MED, V165, P463, DOI 10.1093/milmed/165.6.463; Jensen JS, 2000, PROSTHET ORTHOT INT, V24, P47, DOI 10.1080/03093640008726521; Kastner J., 1999, MED ORTHOP TECH, V119, P131; KRISTINSSON O, 1993, PROSTHET ORTHOT INT, V17, P49, DOI 10.3109/03093649309164354; LEHMANN JF, 1993, ARCH PHYS MED REHAB, V74, P1225; Lundborg G, 1996, J HAND SURG-AM, V21A, P216, DOI 10.1016/S0363-5023(96)80103-1; Meade P, 2000, J TRAUMA, V48, P735, DOI 10.1097/00005373-200004000-00024; Michael JW., 1994, J PROSTHET ORTHOT, V6, P10; MILLER LA, 1995, P 8 WORLD C INT SOC, P1; POWERS CM, 1994, ARCH PHYS MED REHAB, V75, P825; Taylor MB, 1996, PROSTHET ORTHOT INT, V20, P116; Verhoeff TT, 1999, PROSTHET ORTHOT INT, V23, P249; 2000, AMPUTEE STAT DATABAS; [No title captured]	18	61	64	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					732	735		10.1136/bmj.323.7315.732	http://dx.doi.org/10.1136/bmj.323.7315.732			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HJ	11576982	Green Published			2022-12-28	WOS:000171340700022
J	Geldner, N; Friml, J; Stierhof, YD; Jurgens, G; Palme, K				Geldner, N; Friml, J; Stierhof, YD; Jurgens, G; Palme, K			Auxin transport inhibitors block PIN1 cycling and vesicle traficking	NATURE			English	Article							BREFELDIN-A; ARABIDOPSIS-THALIANA; PLASMA-MEMBRANE; ACID-BINDING; CYTOSKELETON; PROTEIN; EFFLUX; CELLS; PLANT; ROOT	Polar transport of the phytohormone auxin mediates various processes in plant growth and development, such as apical dominance, tropisms, vascular patterning and axis formation(1,2). This view is based largely on the effects of polar auxin transport inhibitors. These compounds disrupt auxin efflux from the cell but their mode of action is unknown(3). It is thought that polar auxin flux is caused by the asymmetric distribution of efflux carriers acting at the plasma membrane(4). The polar localization of efflux carrier candidate PIN1 supports this model(4). Here we show that the seemingly static localization of PIN1 results from rapid actin-dependent cycling between the plasma membrane and endosomal compartments. Auxin transport inhibitors block PIN1 cycling and inhibit trafficking of membrane proteins that are unrelated to auxin transport. Our data suggest that PIN1 cycling is of central importance for auxin transport and that auxin transport inhibitors affect efflux by generally interfering with membrane-trafficking processes. In support of our conclusion, the vesicle-trafficking inhibitor brefeldin A mimics physiological effects of auxin transport inhibitors.	Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany; Max Planck Gesell, Max Delbruck Lab, D-50829 Cologne, Germany; Masaryk Univ, Fac Sci, Dept Biochem, CS-61137 Brno, Czech Republic	Eberhard Karls University of Tubingen; Max Planck Society; Masaryk University Brno	Jurgens, G (corresponding author), Univ Tubingen, Zentrum Mol Biol Pflanzen, Morgenstelle 3, D-72076 Tubingen, Germany.		Palme, Klaus/A-9524-2013; Friml, Jiri/D-9511-2012; Geldner, Niko/Y-2481-2019	Palme, Klaus/0000-0002-2728-3835; Friml, Jiri/0000-0002-8302-7596; Geldner, Niko/0000-0002-2300-9644				Berleth T, 2001, CURR OPIN PLANT BIOL, V4, P57, DOI 10.1016/S1369-5266(00)00136-9; Bernasconi P, 1996, PLANT PHYSIOL, V111, P427, DOI 10.1104/pp.111.2.427; COX DN, 1994, PLANT CELL, V6, P1941, DOI 10.1105/tpc.6.12.1941; Delbarre A, 1998, PLANT PHYSIOL, V116, P833, DOI 10.1104/pp.116.2.833; Estelle M, 1998, PLANT CELL, V10, P1775, DOI 10.1105/tpc.10.11.1775; Fujita H, 1996, PLANT CELL PHYSIOL, V37, P1094, DOI 10.1093/oxfordjournals.pcp.a029059; Fujita H, 1997, PLANT J, V12, P583, DOI 10.1046/j.1365-313X.1997.00583.x; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Garbers C, 1996, EMBO J, V15, P2115, DOI 10.1002/j.1460-2075.1996.tb00565.x; Hadfi K, 1998, DEVELOPMENT, V125, P879; HAGER A, 1991, PLANTA, V185, P527, DOI 10.1007/BF00202963; KATEKAR GF, 1977, PLANT PHYSIOL, V60, P826, DOI 10.1104/pp.60.6.826; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Mathur J, 1999, DEVELOPMENT, V126, P5559; Mattsson J, 1999, DEVELOPMENT, V126, P2979; MICHALKE W, 1992, PLANTA, V187, P254, DOI 10.1007/BF00201948; Morris DA, 1998, PLANTA, V205, P606, DOI 10.1007/s004250050363; Morris DA, 2000, PLANT GROWTH REGUL, V32, P161, DOI 10.1023/A:1010701527848; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Palme K, 1999, CURR OPIN PLANT BIOL, V2, P375, DOI 10.1016/S1369-5266(99)00008-4; Ruegger M, 1997, PLANT CELL, V9, P745, DOI 10.1105/tpc.9.5.745; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; SatiatJeunemaitre B, 1996, J MICROSC-OXFORD, V181, P162, DOI 10.1046/j.1365-2818.1996.112393.x; SatiatJeunemaitre B, 1996, PROTOPLASMA, V191, P21, DOI 10.1007/BF01280822; SATIATJEUNEMAITRE B, 1992, J CELL SCI, V103, P1153; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; VOLKER A, IN PRESS J CELL SCI; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	30	919	977	11	170	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					425	428		10.1038/35096571	http://dx.doi.org/10.1038/35096571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574889				2022-12-28	WOS:000171188700055
J	Israel, E; Banerjee, TR; Fitzmaurice, GM; Kotlov, TV; LaHive, K; LeBoff, MS				Israel, E; Banerjee, TR; Fitzmaurice, GM; Kotlov, TV; LaHive, K; LeBoff, MS			Effects of inhaled glucocorticoids on bone density in premenopausal women.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINERAL DENSITY; ASTHMATIC-PATIENTS; BECLOMETHASONE DIPROPIONATE; INDUCED OSTEOPOROSIS; CORTICOSTEROIDS; THERAPY; FLUTICASONE; BUDESONIDE; METABOLISM; STEROIDS	Background: Inhaled glucocorticoids are the most commonly used medications for the long-term treatment of patients with asthma. Whether long-term therapy with inhaled glucocorticoids reduces bone mass, as oral glucocorticoid therapy does, is controversial. In a three-year prospective study, we examined the relation between the dose of inhaled glucocorticoids and the rate of bone loss in premenopausal women with asthma. Methods: We studied 109 premenopausal women, 18 to 45 years of age, who had asthma and no known conditions that cause bone loss and who were treated with inhaled triamcinolone acetonide (100 mu-g per puff). We measured bone density by dual-photon absorptiometry at base line, at six months, and at one, two, and three years. Serum osteocalcin and parathyroid hormone and urinary N-telopeptide, cortisol, and calcium excretion were measured serially. We measured inhaled glucocorticoid use by means of monthly diaries, supported by the use of an automated actuator-monitoring device. Results: Inhaled glucocorticoid therapy was associated with a dose-related decline in bone density at both the total hip and the trochanter of 0.00044 g per square centimeter per puff per year of treatment (P=0.01 and P=0.005, respectively). No dose-related effect was noted at the femoral neck or the spine. Even after the exclusion of all women who received oral or parenteral glucocorticoids at any time during the study, there was still an association between the decline in bone density and the number of puffs per year of use. Serum and urinary markers of bone turnover or adrenal function did not predict the degree of bone loss. Conclusions: Inhaled glucocorticoids lead to a dose-related loss of bone at the hip in premenopausal women. (N Engl J Med 2001;345:941-7.) Copyright (C) 2001 Massachusetts Medical Society.	Brigham & Womens Hosp, Div Pulm & Crit Care Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Endocrine Hypertens, Skeletal Hlth & Osteoporosis Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Dept Internal Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard Pilgrim Health Care	Israel, E (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, Dept Med, 75 Francis St, Boston, MA 02115 USA.	eisrael@partners.org			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-02635] Funding Source: Medline; NHLBI NIH HHS [HL0843] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAYLINK DJ, 1983, NEW ENGL J MED, V309, P306, DOI 10.1056/NEJM198308043090509; Boulet LP, 1999, AM J RESP CRIT CARE, V159, P838, DOI 10.1164/ajrccm.159.3.9802096; Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283; Egan JJ, 1999, EUR RESPIR J, V13, P1267, DOI 10.1183/09031936.99.13612769; EL-HAJJ FULEIHAN G, 1995, J BONE MINER RES, V10, P1004; Hughes JA, 1999, THORAX, V54, P223, DOI 10.1136/thx.54.3.223; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; KRISKA AM, 1992, DIABETES METAB REV, V8, P355, DOI 10.1002/dmr.5610080404; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Luengo M, 1997, EUR RESPIR J, V10, P2110, DOI 10.1183/09031936.97.10092110; LUENGO M, 1990, AM REV RESPIR DIS, V142, P104, DOI 10.1164/ajrccm/142.1.104; LUKERT BP, 1992, J BONE MINER RES, V7, P1063; MELTON LJ, 1983, OSTEOPOROTIC SYNDROM, P45; *NAT ASTHM ED PREV, 1997, NIH PUBL; *NHLBI, 1995, NIH PUBL; Packe GE, 1996, J ROY COLL PHYS LOND, V30, P128; PACKE GE, 1992, THORAX, V47, P414, DOI 10.1136/thx.47.6.414; RICH GM, 1992, J HEART LUNG TRANSPL, V11, P950; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091-6749(95)70003-X; Wisniewski AF, 1997, THORAX, V52, P853, DOI 10.1136/thx.52.10.853; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3	25	218	227	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2001	345	13					941	947		10.1056/NEJMoa002304	http://dx.doi.org/10.1056/NEJMoa002304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475NF	11575285	Green Published			2022-12-28	WOS:000171170000002
J	Oktay, K; Economos, K; Kan, M; Rucinski, J; Veeck, L; Rosenwaks, Z				Oktay, K; Economos, K; Kan, M; Rucinski, J; Veeck, L; Rosenwaks, Z			Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE	Context In reproductive-age women, one of the common adverse effects of chemotherapy and radiotherapy is premature ovarian failure. In addition, a significant number of women experience early menopause due to oophorectomy performed for benign indications. Objective To develop an ovarian transplantation technique to preserve endocrine function in women undergoing sterilizing radiotherapy and/or chemotherapy, or oophorectomy. Design and Setting Case study of 2 patients in New York who received autologous ovarian transplantation (patient A, November 1999; patient B, April 2000) to the forearm prior to pelvic radiotherapy or after oophorectomy. Participants Patient A is a 35-year-old woman with stage IIIB squamous cell cervical carcinoma and patient B is a 37-year-old woman with recurrent benign ovarian serous cysts. Main Outcome Measures Follicular development evident by ultrasound examination; cyclical production of estradiol and progesterone; restoration of serum follicle-stimulating hormone, luteinizing hormone, and testosterone levels to nonmenopausal range; and disappearance of menopausal symptoms. Results Menopause was confirmed immediately after the transplantation in both patients by serum follicle-stimulating hormone measurements (patient A, 47 mIU/mL; patient B, 50.7 mIU/mL). In patient A, follicle development was noted by physical and ultrasound examinations approximately 10 weeks after the transplantation. The mean (SE) follicle-stimulating hormone and luteinizing hormone levels decreased to 8.6 (0.4) mIU/mL and 12.8 (0.8) mIU/mL, respectively. The peripheral estradiol levels showed cyclical variation (mean [SE], 115 [9.2] pg/mL [422 {33.8} pmol/L), and during the 18-month followup, a dominant follicle developed each month. The estradiol levels from the right cubital vein were consistent with ovarian vein measurements (mean [SE], 1069 [269] pg/mL [3924 {987.5} pmol/L]). Percutaneous oocyte aspirations yielded a mature oocyte. In patient B, ovarian function was demonstrated by ultrasound visualization of a 9-mm follicle by 6 months after transplantation. Thereafter, the patient had spontaneous menstruation every 25 to 28 days. Ovulation was further confirmed by midluteal progesterone measurements (range, 7-10.1 ng/mL; mean [SE], 8.5 [0.9] ng/mL). Patient B's ovarian graft was still functional 10 months after the transplantation. Conclusions Subcutaneous ovarian transplantation appears to be a relatively simple, novel technique to preserve endocrine function in women undergoing sterilizing cancer therapy or surgery.	Cornell Univ, Weill Med Coll, Ctr Reprod Med & Infertil, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Inst Reprod Med, New York, NY 10021 USA; New York Methodist Hosp, Dept Obstet & Gynecol, New York, NY USA; New York Methodist Hosp, Dept Surg, New York, NY USA	Cornell University; Cornell University; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital	Oktay, K (corresponding author), Cornell Univ, Weill Med Coll, Ctr Reprod Med & Infertil, 505 E 70th St,HT340, New York, NY 10021 USA.							Ala-Fossi SL, 1998, MATURITAS, V29, P239, DOI 10.1016/S0378-5122(98)00034-6; ANDERSON B, 1993, GYNECOL ONCOL, V49, P206, DOI 10.1006/gyno.1993.1109; APPERLEY JF, 1995, BLOOD REV, V9, P93, DOI 10.1016/S0268-960X(95)90030-6; Buekers TE, 2001, GYNECOL ONCOL, V80, P85, DOI 10.1006/gyno.2000.6039; LICCIARDI FL, 1995, FERTIL STERIL, V64, P991, DOI 10.1016/S0015-0282(16)57916-3; LIU JH, 1983, J CLIN ENDOCR METAB, V57, P797; Oktay K, 2000, NEW ENGL J MED, V342, P1919, DOI 10.1056/NEJM200006223422516; Oktay K, 2001, FERTIL STERIL, V75, P1212, DOI 10.1016/S0015-0282(01)01776-9; Oktay K, 1998, FERTIL STERIL, V69, P1, DOI 10.1016/S0015-0282(97)00207-0; OKTAY K, 2001, TXB ASSISTED REPROD, P2523; SCHNORR J, 2000, FERTIL STERIL S3, V74, P1; WAGNER PK, 1991, WORLD J SURG, V15, P751, DOI 10.1007/BF01665310; WELLS SA, 1976, NEW ENGL J MED, V295, P57, DOI 10.1056/NEJM197607082950201	13	237	253	3	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1490	1493		10.1001/jama.286.12.1490	http://dx.doi.org/10.1001/jama.286.12.1490			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572742	Bronze			2022-12-28	WOS:000171188600027
J	Richardson, DK				Richardson, DK			A woman with an extremely premature newborn	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT INFANTS; NEONATAL INTENSIVE-CARE; NATIONAL INSTITUTE; CHILD HEALTH; CONTROLLED-TRIAL; INTRAVENTRICULAR HEMORRHAGE; DEVELOPMENTAL-DISABILITY; FUNCTIONAL OUTCOMES; DUCTUS-ARTERIOSUS; MAGNESIUM-SULFATE		Beth Israel Deaconess Med Ctr, Dept Neonatol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Richardson, DK (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neonatol, 330 Brookline Ave, Boston, MA 02215 USA.	drichard@caregroup.harvard.edu						[Anonymous], 1984, PEDIATRICS, V74, P306; [Anonymous], 1997, Arch Dis Child Fetal Neonatal Ed, V77, pF91; Banks BA, 1999, AM J OBSTET GYNECOL, V181, P709, DOI 10.1016/S0002-9378(99)70517-X; BERNBAUM J, 1991, PRIMARY CARE PRETERM; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; Bregman J, 1998, PEDIATR CLIN N AM, V45, P673, DOI 10.1016/S0031-3955(05)70035-3; Brodie SB, 2000, PEDIATR INFECT DIS J, V19, P56, DOI 10.1097/00006454-200001000-00012; Campbell AGM, 1995, J MED ETHICS, V21, P339, DOI 10.1136/jme.21.6.339; CASSADY G, 1989, NEW ENGL J MED, V320, P1511, DOI 10.1056/NEJM198906083202302; Costeloe K, 2000, PEDIATRICS, V106, P659, DOI 10.1542/peds.106.4.659; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; *CRYOTH RET PREM C, 1988, PEDIATRICS, V81, P697; Davis J M, 2000, J Perinatol, V20, P213, DOI 10.1038/sj.jp.7200363; Doron MW, 1998, PEDIATRICS, V102, P574, DOI 10.1542/peds.102.3.574; Ehrenkranz R.A., 1992, EFFECTIVE CARE NEWBO; Ehrenkranz RA, 1999, PEDIATRICS, V104, P280, DOI 10.1542/peds.104.2.280; Eichenwald EC, 1997, PEDIATRICS, V100, P354, DOI 10.1542/peds.100.3.354; Evans MI, 1996, CLIN PERINATOL, V23, P437, DOI 10.1016/S0095-5108(18)30219-7; Frader JE, 2000, JAMA-J AM MED ASSOC, V284, P1143, DOI 10.1001/jama.284.9.1143; GERSONY WM, 1983, J PEDIATR-US, V102, P895, DOI 10.1016/S0022-3476(83)80022-5; Gerstmann DR, 1996, PEDIATRICS, V98, P1044; GILSTRAP LC, 1995, JAMA-J AM MED ASSOC, V273, P413, DOI 10.1001/jama.1995.03520290065031; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Graven S N, 1992, J Perinatol, V12, P164; Gray JE, 2000, PEDIATRICS, V106, P1318, DOI 10.1542/peds.106.6.1318; GROSS RT, 1990, JAMA-J AM MED ASSOC, V263, P3035; Guyer B, 1999, PEDIATRICS, V104, P1229, DOI 10.1542/peds.104.6.1229; HARRISON H, 1993, PEDIATRICS, V92, P643; HARRISON H, 1983, PREMATURE BABY BOOK; HORBAR JD, 1988, PEDIATRICS, V82, P554; Horbar JD, 2001, PEDIATRICS, V107, P14, DOI 10.1542/peds.107.1.14; Hussain N, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.3.e26; Ikegami M, 1997, AM J RESP CRIT CARE, V156, P178, DOI 10.1164/ajrccm.156.1.9612036; Inder T E, 2000, Semin Neonatol, V5, P3, DOI 10.1053/siny.1999.0112; JELLINEK MS, 1992, PEDIATRICS, V89, P119; JOBE AH, 1993, NEW ENGL J MED, V328, P861; Jobe AH, 1998, EARLY HUM DEV, V53, P81, DOI 10.1016/S0378-3782(98)00045-0; Joffe S, 1999, PEDIATRICS, V104, P419, DOI 10.1542/peds.104.3.419; Kuban K, 1999, J PEDIATR-US, V134, P539, DOI 10.1016/S0022-3476(99)70237-4; LAPINE TR, 1995, PEDIATRICS, V96, P479; Leach CL, 1996, NEW ENGL J MED, V335, P761, DOI 10.1056/NEJM199609123351101; Lee SK, 2000, PEDIATRICS, V106, P1070, DOI 10.1542/peds.106.5.1070; Lemons JA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.1.e1; Leviton A, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.4.e2; Leviton A, 1999, PEDIATR RES, V46, P566, DOI 10.1203/00006450-199911000-00013; LIGGINS GC, 1972, PEDIATRICS, V50, P515; LINDEN DW, 2000, PREEMIES ESSENTIAL G; Lorenz JM, 2000, CLIN PERINATOL, V27, P255, DOI 10.1016/S0095-5108(05)70020-8; Mariani G, 1999, PEDIATRICS, V104, P1082, DOI 10.1542/peds.104.5.1082; McCarton CM, 1997, JAMA-J AM MED ASSOC, V277, P126, DOI 10.1001/jama.277.2.126; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; MCCORMICK MC, 1992, JAMA-J AM MED ASSOC, V267, P2204, DOI 10.1001/jama.267.16.2204; MCCORMICK MC, 1980, PEDIATRICS, V66, P991; MCCORMICK MC, 1995, FUTURE CHILD, V5, P162, DOI 10.2307/1602513; MCCORMICK MC, 1993, J PEDIATR-US, V123, P527, DOI 10.1016/S0022-3476(05)80945-X; MCCORMICK MC, 1993, CLIN PERINATOL, V20, P263, DOI 10.1016/S0095-5108(18)30423-8; MEHREN E, 1991, BORN SOON STORY EMIL; Miura E, 2001, PEDIATRICS, V107, P30, DOI 10.1542/peds.107.1.30; Muraskas J, 1999, CAMB Q HEALTHC ETHIC, V8, P160, DOI 10.1017/S0963180199002054; Murphy BP, 2001, PEDIATRICS, V107, P217, DOI 10.1542/peds.107.2.217; *NAT CTR HLTH STAT, 2000, VIT STAT US 1997, V1; NELSON KB, 1995, PEDIATRICS, V95, P263; Neu J, 1996, PEDIATR CLIN N AM, V43, P409, DOI 10.1016/S0031-3955(05)70413-2; Norwitz ER, 1999, NEW ENGL J MED, V341, P660, DOI 10.1056/NEJM199908263410906; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; OH W, 1995, PEDIATRICS, V96, P974; OShea TM, 1997, PEDIATRICS, V100, P982, DOI 10.1542/peds.100.6.982; Paris J J, 1999, J Perinatol, V19, P383, DOI 10.1038/sj.jp.7200196; Peabody JL, 1996, CLIN PERINATOL, V23, P473; Perlman JM, 1998, EARLY HUM DEV, V53, P99, DOI 10.1016/S0378-3782(98)00037-1; Phelps D L, 1995, Pediatr Rev, V16, P50, DOI 10.1542/pir.16-2-50; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; Rawlings JS, 1996, ARCH PEDIAT ADOL MED, V150, P260, DOI 10.1001/archpedi.1996.02170280030005; Rogowski J, 1999, Pediatrics, V103, P329; ROTH J, 1995, ARCH PEDIAT ADOL MED, V149, P1311, DOI 10.1001/archpedi.1995.02170250017002; Schanler RJ, 1999, PEDIATRICS, V103, P434, DOI 10.1542/peds.103.2.434; SCHWARTZ RM, 1994, NEW ENGL J MED, V330, P1476, DOI 10.1056/NEJM199405263302102; SHENNAN AT, 1988, PEDIATRICS, V82, P527; SILVERMAN WA, 1992, PEDIATRICS, V90, P971; Stanley F, 2000, CLIN DEV MED; STOLL BJ, 1994, CLIN PERINATOL, V21, P205, DOI 10.1016/S0095-5108(18)30341-5; Stoll BJ, 1996, J PEDIATR-US, V129, P63, DOI 10.1016/S0022-3476(96)70191-9; Stoll BJ, 1996, J PEDIATR-US, V129, P72, DOI 10.1016/S0022-3476(96)70192-0; STOWE ZN, 1995, AM J OBSTET GYNECOL, V173, P639, DOI 10.1016/0002-9378(95)90296-1; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; Van Marter LJ, 2000, PEDIATRICS, V105, P1194, DOI 10.1542/peds.105.6.1194; Van Overmeire B, 2000, NEW ENGL J MED, V343, P674, DOI 10.1056/NEJM200009073431001; Vohr B, 1999, SEMIN PERINATOL, V23, P212, DOI 10.1016/S0146-0005(99)80065-2; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; Vohr BR, 1997, SEMIN PERINATOL, V21, P202, DOI 10.1016/S0146-0005(97)80064-X; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	92	11	12	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1498	1505		10.1001/jama.286.12.1498	http://dx.doi.org/10.1001/jama.286.12.1498			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	475UX	11572744				2022-12-28	WOS:000171188600029
J	Meltzer, MI				Meltzer, MI			Introduction to health economics for physicians	LANCET			English	Article							COST-EFFECTIVENESS ANALYSIS; MEDICAL LITERATURE; VACCINATION PROGRAM; CLINICAL-PRACTICE; UNITED-STATES; USERS GUIDES; QUALITY; TRANSMISSION; PREVENTION; CHILDREN	Since the 1960s, expenditure an health care in developed countries has risen faster than the general rate of inflation, thus making economic assessment of interventions an integral part of decision making in health services. This paper Is the first in a series whose goal is to provide some basic principles of health economics that will allow practising physicians to understand better the economic relations between their practice of medicine, the health-care sector, and the national economy. Some of the most important principles described in this paper include opportunity costs, identifying the appropriate perspective, correctly categorising costs, and discounting costs and non-monetary benefits (eg, lives saved) over time. Economic analyses of medical interventions must also take into consideration the difference between efficacy and effectiveness. Efficacy is the maximum possible benefit, often achieved with carefully controlled trials, and effectiveness is the actual decrease in disease achieved when the intervention is applied over a large, non-homogeneous population. This introduction ends with three methods of assessing the costs and benefits of an intervention-namely, cost-benefit, cost-effectiveness, and cost-utility analyses.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Meltzer, MI (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Mailstop D-59,1600 Clifton Rd, Atlanta, GA 30333 USA.		Meltzer, Martin/AAT-3235-2021	Meltzer, Martin/0000-0002-7250-0472				Brown AD, 1999, JAMA-J AM MED ASSOC, V281, P347, DOI 10.1001/jama.281.4.347; Centers for Disease Control and Prevention, 1992, MMWR, V41; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Drummond MF, 2015, METHODS EC EVALUATIO; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; Gold MR, 1996, COST EFFECTIVENESS H; Graham JD, 1998, ANNU REV PUBL HEALTH, V19, P125, DOI 10.1146/annurev.publhealth.19.1.125; HADDIX AC, 1996, PREVENTION EFFECTIVN; HATZIANDREU EJ, 1995, PUBLIC HEALTH REP, V110, P251; Kassler WJ, 1997, AIDS, V11, P1045, DOI 10.1097/00002030-199708000-00014; Krahn M, 1998, AM J PUBLIC HEALTH, V88, P1638, DOI 10.2105/AJPH.88.11.1638; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201; Marseille E, 1998, AIDS, V12, P939, DOI 10.1097/00002030-199808000-00017; Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507; Meltzer MI, 1999, EMERG INFECT DIS, V5, P321, DOI 10.3201/eid0503.990302; Meltzer MI, 1998, AM J TROP MED HYG, V59, P265, DOI 10.4269/ajtmh.1998.59.265; Meltzer MI, 1998, QUANTITATIVE SOLUTIO, P123; MI MELTZER, 2000, ENCY MICROBIOLOGY, P137; Neumann PJ, 2000, ANN INTERN MED, V132, P964, DOI 10.7326/0003-4819-132-12-200006200-00007; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; Patrick D. L., 1993, HLTH STATUS HLTH POL; Smith WJ, 1998, OBSTET GYNECOL, V92, P535, DOI 10.1016/S0029-7844(98)00221-X; STEWART KJ, 1996, FAM PRACTICE MAN JUL, P16; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304	30	103	110	1	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					993	998		10.1016/S0140-6736(01)06107-4	http://dx.doi.org/10.1016/S0140-6736(01)06107-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	474YR	11583768				2022-12-28	WOS:000171135300033
J	Emanuel, EJ; Miller, FG				Emanuel, EJ; Miller, FG			The ethics of placebo-controlled trials - A middle ground.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CISPLATIN-INDUCED NAUSEA; HIGH-DOSE METOCLOPRAMIDE; MAMMARY-ARTERY LIGATION; ACTIVE-CONTROL TRIALS; CLINICAL-RESEARCH; ONDANSETRON GR-38032F; SEROTONIN ANTAGONIST; DOUBLE-BLIND; EFFICACY; PREVENTION		NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Emanuel, EJ (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; BECK TM, 1993, ANN INTERN MED, V118, P407, DOI 10.7326/0003-4819-118-6-199303150-00002; Bienenfeld L, 1996, AM HEART J, V132, P1207, DOI 10.1016/S0002-8703(96)90465-2; Brody BA, 1997, CONTROL CLIN TRIALS, V18, P602, DOI 10.1016/S0197-2456(97)00006-8; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; DIMOND EG, 1958, CIRCULATION, V18, P712; Ellenberg SS, 2000, ANN INTERN MED, V133, P464, DOI 10.7326/0003-4819-133-6-200009190-00015; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Enserink M, 2000, SCIENCE, V290, P418, DOI 10.1126/science.290.5491.418; FEINSTEIN AR, 1980, EUR J CLIN PHARMACOL, V17, P1, DOI 10.1007/BF00561669; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; GANDARA DR, 1992, SEMIN ONCOL, V19, P67; GLASSER SP, 1991, JAMA-J AM MED ASSOC, V265, P1550, DOI 10.1001/jama.265.12.1550; GRALLA RJ, 1981, NEW ENGL J MED, V305, P905, DOI 10.1056/NEJM198110153051601; HAINSWORTH J, 1991, J CLIN ONCOL, V9, P721, DOI 10.1200/JCO.1991.9.5.721; HAIT WN, 1990, NEW ENGL J MED, V323, P1485; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Khan A, 2000, ARCH GEN PSYCHIAT, V57, P311, DOI 10.1001/archpsyc.57.4.311; Koski G, 2001, NEW ENGL J MED, V345, P136, DOI 10.1056/NEJM200107123450211; LASAGNA L, 1979, EUR J CLIN PHARMACOL, V15, P373, DOI 10.1007/BF00561733; LASAGNA L, 1954, AM J MED, V16, P770, DOI 10.1016/0002-9343(54)90441-6; Leon AC, 2000, ARCH GEN PSYCHIAT, V57, P329, DOI 10.1001/archpsyc.57.4.329; LILIENFELD AM, 1982, B HIST MED, V56, P1; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; Miller FG, 2000, BIOL PSYCHIAT, V47, P707, DOI 10.1016/S0006-3223(00)00833-7; Rothman KJ, 2000, BMJ-BRIT MED J, V321, P442, DOI 10.1136/bmj.321.7258.442; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; RUTSTEIN DD, 1970, EXPT HUMAN SUBJECTS, P383; SENN S, IN PRESS APPL CLIN T; SENN S, 1997, STAT ISSUES DRUG DEV, P207; Shapiro HT, 2001, NEW ENGL J MED, V345, P139, DOI 10.1056/NEJM200107123450212; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Temple R, 1982, DRUG INF J, V10-17, DOI DOI 10.1177/009286158201600102; Temple Robert, 1996, Account Res, V4, P267, DOI 10.1080/08989629608573887; VANRIJ AM, 1994, CIRCULATION, V90, P1194, DOI 10.1161/01.CIR.90.3.1194; Vastag B, 2000, JAMA-J AM MED ASSOC, V284, P2983, DOI 10.1001/jama.284.23.2983; WAY WL, 1984, NEW ENGL J MED, V311, P413; WINSLOW R, 2000, WALL STREET J   1019, pB14; *WORLD MED ASS DEC, 2001, ETH PRINC MED RES IN	42	232	241	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2001	345	12					915	919		10.1056/NEJM200109203451211	http://dx.doi.org/10.1056/NEJM200109203451211			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	473JW	11565527				2022-12-28	WOS:000171039600011
J	Moll, J; Barzaghi, P; Lin, S; Bezakova, G; Lochmuller, H; Engvall, E; Muller, U; Ruegg, MA				Moll, J; Barzaghi, P; Lin, S; Bezakova, G; Lochmuller, H; Engvall, E; Muller, U; Ruegg, MA			An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy	NATURE			English	Article							CREATINE-KINASE GENE; NEUROMUSCULAR-JUNCTION; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; SKELETAL-MUSCLE; LAMININ; MICE; EXPRESSION; DIFFERENTIATION; DYSTROGLYCAN	Congenital muscular dystrophy is a heterogeneous and severe, progressive muscle-wasting disease that frequently leads to death in early childhood(1,2). Most cases of congenital muscular dystrophy are caused by mutations in LAMA2, the gene encoding the alpha2 chain of the main laminin isoforms expressed by muscle fibres. Muscle fibre deterioration in this disease is thought to be caused by the failure to form the primary laminin scaffold, which is necessary for basement membrane structure(3), and the missing interaction between muscle basement membrane and the dystrophin-glycoprotein complex (DGC)(4) or the integrins(5). With the aim to restore muscle function in a mouse model for this disease, we have designed a minigene of agrin, a protein known for its role in the formation of the neuromuscular junction(6). Here we show that this mini-agrin-which binds to basement membrane(7) and to alpha -dystroglycan(8), a member of the DGC-amends muscle pathology by a mechanism that includes agrin-mediated stabilization of alpha -dystroglycan and the laminin alpha5 chain. Our data provides in vivo evidence that a non-homologous protein in combination with rational protein design can be used to devise therapeutic tools that may restore muscle function in human muscular dystrophies.	Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland; Univ Munich, Genzentrum Munich, D-81377 Munich, Germany; Burnham Inst, La Jolla, CA 92037 USA; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	University of Basel; University of Munich; Sanford Burnham Prebys Medical Discovery Institute; Friedrich Miescher Institute for Biomedical Research	Ruegg, MA (corresponding author), Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Ruegg, Markus/X-7256-2019	Ruegg, Markus/0000-0002-4974-9384; Lochmuller, Hanns/0000-0003-2324-8001; Lin, Shuo/0000-0003-2317-0339				Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Colognato H, 1999, CURR BIOL, V9, P1327, DOI 10.1016/S0960-9822(00)80056-1; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; Denzer AJ, 1998, EMBO J, V17, P335, DOI 10.1093/emboj/17.2.335; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Herrmann R, 2000, HUM MOL GENET, V9, P2335, DOI 10.1093/oxfordjournals.hmg.a018926; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; MACPIKE AD, 1976, P SOC EXP BIOL MED, V151, P670, DOI 10.3181/00379727-151-39283; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; Meier T, 1998, EUR J NEUROSCI, V10, P3141, DOI 10.1046/j.1460-9568.1998.00320.x; Miyagoe-Suzuki Y, 2000, MICROSC RES TECHNIQ, V48, P181, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<181::AID-JEMT6>3.0.CO;2-Q; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Ringelmann B, 1999, EXP CELL RES, V246, P165, DOI 10.1006/excr.1998.4244; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; Sorokin LM, 1997, DEV DYNAM, V210, P446, DOI 10.1002/(SICI)1097-0177(199712)210:4<446::AID-AJA8>3.0.CO;2-G; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; TOME FMS, 1998, NEUROMUSCULAR DISORD, P21; Turney SG, 1996, J NEUROSCI METH, V64, P199, DOI 10.1016/0165-0270(95)00135-2; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572	30	175	180	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 20	2001	413	6853					302	307		10.1038/35095054	http://dx.doi.org/10.1038/35095054			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	473KB	11565031				2022-12-28	WOS:000171040500038
J	Roose, SP; Glassman, AH; Seidman, SN				Roose, SP; Glassman, AH; Seidman, SN			Relationship between depression and other medical illnesses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; ASSOCIATION; EVENTS; MEN		Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute	Roose, SP (corresponding author), Columbia Univ Coll Phys & Surg, Dept Psychiat, 1051 Riverside Dr, New York, NY 10032 USA.	spr2@columbia.edu						AROMAA A, 1994, ACTA PSYCHIAT SCAND, V89, P77, DOI 10.1111/j.1600-0447.1994.tb05807.x; Berkman LF, 2000, AM HEART J, V139, P1; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; Carney RM, 2001, PSYCHOSOM MED, V63, P102; CONNERNEY I, 2000, P AM PSYCH SOC MARCH; FORD DE, 1994, CIRCULATION, V90, P614; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; GLASSMAN A, 2001, POST PRES AM PSYCH A; GLASSMAN AH, 1993, JAMA-J AM MED ASSOC, V269, P2673, DOI 10.1001/jama.269.20.2673; Glassman AH, 1998, AM J PSYCHIAT, V155, P4, DOI 10.1176/ajp.155.1.4; KEMPER JW, 1957, ANN INTERN MED, V46, P831, DOI 10.7326/0003-4819-46-5-831; Kessler RC, 1997, ANNU REV PSYCHOL, V48, P191, DOI 10.1146/annurev.psych.48.1.191; LaghrissiThode F, 1997, BIOL PSYCHIAT, V42, P290, DOI 10.1016/S0006-3223(96)00345-9; Lesperance F, 1998, J AM COLL CARDIOL, V31, p208A, DOI 10.1016/S0735-1097(97)84610-4; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; Musselman DL, 1998, ARCH GEN PSYCHIAT, V55, P580, DOI 10.1001/archpsyc.55.7.580; POLLOCK BG, 1995, 34 ANN M AM COLL NEU; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; Roose SP, 1998, JAMA-J AM MED ASSOC, V279, P287, DOI 10.1001/jama.279.4.287; Roose SP, 1998, AM J PSYCHIAT, V155, P660, DOI 10.1176/ajp.155.5.660; ROOSE SP, 1991, J CLIN PSYCHIAT, V52, P34; ROSS R, 1976, SCIENCE, V193, P1094, DOI 10.1126/science.822515; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SEIDMAN SN, IN PRESS AM J PSYCHI; Seidman SN, 1999, PSYCHIAT CLIN N AM, P21; Shabsigh R, 1998, UROLOGY, V52, P848, DOI 10.1016/S0090-4295(98)00292-1; Shapiro PA, 1999, AM HEART J, V137, P1100, DOI 10.1016/S0002-8703(99)70369-8; SIMONSICK EM, 1995, PSYCHOSOM MED, V57, P427, DOI 10.1097/00006842-199509000-00003; TROXLER RG, 1977, ATHEROSCLEROSIS, V26, P151, DOI 10.1016/0021-9150(77)90098-3	30	56	56	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1687	1690		10.1001/jama.286.14.1687	http://dx.doi.org/10.1001/jama.286.14.1687			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	480NC	11594878				2022-12-28	WOS:000171466800001
J	Wyatt, K; Dimmock, P; Jones, P; Obhrai, M; O'Brien, S				Wyatt, K; Dimmock, P; Jones, P; Obhrai, M; O'Brien, S			Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND CROSSOVER; VAGINAL SUPPOSITORIES; CONTROLLED-TRIAL; MENSTRUAL-CYCLE; CLINICAL-TRIALS; PLACEBO; TENSION; SYMPTOMS; DYDROGESTERONE; METAANALYSIS	Objective To evaluate the efficacy of progesterone and progestogens in the management of premenstrual syndrome. Design Systematic review of published randomised, placebo controlled trials. Studies reviewed 10 trials of progesterone therapy (531 women) and four trials of progestogen therapy (378 women). Main outcome measures Proportion of Women Whose symptoms showed improvement with progesterone preparations (suppositories and oral micronised). Proportion of women whose symptoms showed improvement with progestogens. Secondary analysis of efficacy of progesterone and progestogens in managing physical and behavioural symptoms. Results Overall standardised mean difference for all trials that assessed efficacy of progesterone (by both routes of administration) was -0.028 (95% confidence interval -0.017 to -0.040). The odds ratio was 1.05 (1.03 to 1.08) in favour of progesterone, indicating no clinically important difference between progesterone and placebo. For progestogens the overall standardised mean was -0.036 (-0.059 to -0.014), which corresponds to an odds ratio of 1.07 (1.03 to 1.11) showing a statistically, but not clinically, significant improvement for women taking progestogens. Conclusion The evidence from these metes-analyses does not support the use of progesterone or progestogens in the management of premenstrual syndrome.	Keele Univ, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England; N Staffordshire Hosp, Stoke On Trent ST4 6QG, Staffs, England; Keele Univ, Dept Math, Keele ST5 5BG, Staffs, England	Keele University; Keele University; University Hospital of North Staffordshire NHS Trust; Keele University	O'Brien, S (corresponding author), Keele Univ, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England.	pma06@keele.ac.uk						ANDERSCH B, 1985, J PSYCHOSOM RES, V29, P489, DOI 10.1016/0022-3999(85)90082-0; BACKSTROM T, 1983, PSYCHOSOM MED, V45, P503, DOI 10.1097/00006842-198312000-00004; BAKER ER, 1995, J ASSIST REPROD GEN, V12, P205, DOI 10.1007/BF02211800; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; COPPEN AJ, 1969, CLIN TRIALS J, V6, P33; CORNEY RH, 1990, J PSYCHOSOM OBST GYN, V11, P211, DOI 10.3109/01674829009084416; Dalton K., 1984, PREMENSTRUAL SYNDROM; DELIGNIERES B, 1995, MATURITAS, V21, P251, DOI 10.1016/0378-5122(94)00882-8; DENNERSTEIN L, 1985, BRIT MED J, V290, P1617, DOI 10.1136/bmj.290.6482.1617; DENNERSTEIN L, 1986, J AFFECT DISORDERS, V11, P199, DOI 10.1016/0165-0327(86)90070-4; Dimmock PW, 2000, LANCET, V356, P1131, DOI 10.1016/S0140-6736(00)02754-9; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FREEMAN E, 1990, JAMA-J AM MED ASSOC, V264, P349; FREEMAN EW, 1995, JAMA-J AM MED ASSOC, V274, P51, DOI 10.1001/jama.274.1.51; HAMMARBACK S, 1985, ACTA OBSTET GYN SCAN, V64, P393, DOI 10.3109/00016348509155154; HASPELS AA, 1980, PREMENSTRUAL SYNDROM, P81; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; HELLBERG D, 1991, INT J GYNECOL OBSTET, V34, P243, DOI 10.1016/0020-7292(91)90357-B; Hoffmann V, 1988, Scand J Prim Health Care, V6, P179, DOI 10.3109/02813438809009313; Hylan TR, 1999, J WOMEN HEALTH GEN-B, V8, P1043, DOI 10.1089/jwh.1.1999.8.1043; Israel SL, 1938, J AMER MED ASSOC, V110, P1721, DOI 10.1001/jama.1938.02790210001001; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JORDHEIM O, 1972, ACTA OBSTET GYN SCAN, V51, P77, DOI 10.3109/00016347209154971; KERR GD, 1980, PRACTITIONER, V224, P852; LEE JR, 1995, NATURAL PROGESTERONE; LYON KE, 1984, J REPROD MED, V29, P705; MADDOCKS S, 1986, AM J OBSTET GYNECOL, V154, P573, DOI 10.1016/0002-9378(86)90604-6; MAGILL PJ, 1995, BRIT J GEN PRACT, V45, P589; MAXSON WS, 1987, CLIN OBSTET GYNECOL, V30, P465, DOI 10.1097/00003081-198706000-00026; MORSE CA, 1991, J BEHAV MED, V14, P469, DOI 10.1007/BF00845105; RAPKIN A, 1987, J OBSTET GYNAECOL, V7, P217, DOI 10.3109/01443618709068522; Rapkin AJ, 1997, OBSTET GYNECOL, V90, P709, DOI 10.1016/S0029-7844(97)00417-1; REDEI E, 1995, PSYCHONEUROENDOCRINO, V20, P259, DOI 10.1016/0306-4530(94)00057-H; RICHTER MA, 1984, CURR THER RES, V36, P850; SAMPSON GA, 1979, BRIT J PSYCHIAT, V135, P209, DOI 10.1192/bjp.135.3.209; SAMPSON GA, 1988, BRIT J PSYCHIAT, V153, P232, DOI 10.1192/bjp.153.2.232; SAMPSON GA, 1982, P WORKSH PREM SYNDR, P66; Smith SL, 1975, TOPICS PSYCHOENDOCRI, P19; STEWART A, 1989, RATIONAL APPROACH TR; STRECKER JR, 1980, FORTSCHR MED, V98, P145; STRECKER JR, 1981, PREMENSTRUAL SYNDROM, P71; TAYLOR RW, 1977, CURR MED RES OPIN, V4, P35, DOI 10.1185/03007997709115299; VANDEGINSTE BGM, 1983, TRAC-TREND ANAL CHEM, V2, P220; Vanselow W, 1996, J PSYCHOSOM OBST GYN, V17, P29, DOI 10.3109/01674829609025661; WEST CP, 1990, EUR J OBSTET GYN R B, V34, P119, DOI 10.1016/0028-2243(90)90015-S; WILLIAMS JGC, 1983, BR J SEX MED, V10, P8	46	78	83	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 6	2001	323	7316					776	780B		10.1136/bmj.323.7316.776	http://dx.doi.org/10.1136/bmj.323.7316.776			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481LK	11588078	Bronze, Green Published			2022-12-28	WOS:000171520600025
J	Phillips, JA				Phillips, JA			Genomic medicine: Managing the complexity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	Vanderbilt University	Phillips, JA (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1639	1639		10.1001/jama.286.13.1639	http://dx.doi.org/10.1001/jama.286.13.1639			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585494	hybrid			2022-12-28	WOS:000171340600037
J	Veverka, J; Farquhar, B; Robinson, M; Thomas, P; Murchie, S; Harch, A; Antreasian, PG; Chesley, SR; Miller, JK; Owen, WM; Williams, BG; Yeomans, D; Dunham, D; Heyler, G; Holdridge, M; Nelson, RL; Whittenburg, KE; Ray, JC; Carcich, B; Cheng, A; Chapmank, C; Bell, JF; Bell, M; Bussey, B; Clark, B; Domingue, D; Gaffey, MJ; Hawkins, E; Izenberg, N; Joseph, J; Kirk, R; Lucey, P; Malin, M; McFadden, L; Merline, WJ; Peterson, C; Prockter, L; Warren, J; Wellnitz, D				Veverka, J; Farquhar, B; Robinson, M; Thomas, P; Murchie, S; Harch, A; Antreasian, PG; Chesley, SR; Miller, JK; Owen, WM; Williams, BG; Yeomans, D; Dunham, D; Heyler, G; Holdridge, M; Nelson, RL; Whittenburg, KE; Ray, JC; Carcich, B; Cheng, A; Chapmank, C; Bell, JF; Bell, M; Bussey, B; Clark, B; Domingue, D; Gaffey, MJ; Hawkins, E; Izenberg, N; Joseph, J; Kirk, R; Lucey, P; Malin, M; McFadden, L; Merline, WJ; Peterson, C; Prockter, L; Warren, J; Wellnitz, D			The landing of the NEAR-Shoemaker spacecraft on asteroid 433 Eros	NATURE			English	Article							EJECTA BLOCKS; 243-IDA	The NEAR-Shoemaker spacecraft was designed to provide a comprehensive characterization of the S-type asteroid 433 Eros (refs 1-3), an irregularly shaped body with approximate dimensions of 34x13x13 km. Following the completion of its yearlong investigation, the mission was terminated with a controlled descent to its surface, in order to provide extremely high resolution images. Here we report the results of the descent on 12 February 2001, during which 70 images were obtained. The landing area is marked by a paucity of small craters and an abundance of 'ejecta blocks'. The properties and distribution of ejecta blocks are discussed in a companion paper(4). The last sequence of images reveals a transition from the blocky surface to a smooth area, which we interpret as a 'pond'. Properties of the 'ponds' are discussed in a second companion paper(5). The closest image, from an altitude of 129 m, shows the interior of a 100-m-diameter crater at 1-cm resolution.	Cornell Univ, Ithaca, NY 14853 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; SW Res Inst, Boulder, CO 80302 USA; Rensselaer Polytech Inst, Ctr Sci, Dept Earth & Environm Sci, Troy, NY 12180 USA; US Geol Survey, Flagstaff, AZ 86001 USA; Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; Malin Space Sci Syst Inc, San Diego, CA 92191 USA; Univ Maryland, Dept Astron, College Pk, MD 20742 USA	Cornell University; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; Northwestern University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Rensselaer Polytechnic Institute; United States Department of the Interior; United States Geological Survey; University of Hawaii System; University System of Maryland; University of Maryland College Park	Veverka, J (corresponding author), Cornell Univ, Space Sci Bldg, Ithaca, NY 14853 USA.		Izenberg, Noam R/F-3952-2015; Dunham, David W/A-5214-2014; Murchie, Scott L/E-8030-2015; McFadden, Lucy-Ann/I-4902-2013; Wellnitz, Dennis/B-4080-2012	Izenberg, Noam R/0000-0003-1629-6478; Dunham, David W/0000-0001-7527-4207; Murchie, Scott L/0000-0002-1616-8751; McFadden, Lucy-Ann/0000-0002-0537-9975; Antreasian, Peter/0000-0001-9040-310X				CHAPMAN CR, IN PRESS ICARUS; Farquhar RW, 1995, J ASTRONAUT SCI, V43, P353; HAWKINS SE, 1997, SPACE SCI REV, V82, P30; Lee P, 1996, ICARUS, V120, P87, DOI 10.1006/icar.1996.0039; Robinson MS, 2001, NATURE, V413, P396, DOI 10.1038/35096518; Sullivan R, 1996, ICARUS, V120, P119, DOI 10.1006/icar.1996.0041; THOMAS P, 1980, ICARUS, V42, P234, DOI 10.1016/0019-1035(80)90073-1; Thomas PC, 2001, NATURE, V413, P394, DOI 10.1038/35096513; Thomas PC, 2000, J GEOPHYS RES-PLANET, V105, P15091, DOI 10.1029/1999JE001204; Veverka J, 2000, SCIENCE, V289, P2088, DOI 10.1126/science.289.5487.2088; Veverka J, 1997, J GEOPHYS RES-PLANET, V102, P23709, DOI 10.1029/97JE01742; Veverka J, 2001, SCIENCE, V292, P484, DOI 10.1126/science.1058651; WOLFE EM, 1972, P LUNAR PLANET SCI C, V3, P15; Zuber MT, 2000, SCIENCE, V289, P2097, DOI 10.1126/science.289.5487.2097	14	148	157	1	19	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2001	413	6854					390	393		10.1038/35096507	http://dx.doi.org/10.1038/35096507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475UY	11574879				2022-12-28	WOS:000171188700045
J	Larkin, M				Larkin, M			New York physicians respond to the terror, tragedy, and trauma	LANCET			English	Article																			0	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					940	940		10.1016/S0140-6736(01)06117-7	http://dx.doi.org/10.1016/S0140-6736(01)06117-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11584817				2022-12-28	WOS:000171135300003
J	Logan, R; Delaney, B				Logan, R; Delaney, B			ABC of the upper gastrointestinal tract - Implications of dyspepsia for the NHS	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Nottingham NG7 2UH, England; Univ Birmingham, Birmingham B15 2TT, W Midlands, England	University of Nottingham; University of Birmingham	Logan, R (corresponding author), Univ Nottingham Hosp, Nottingham NG7 2UH, England.		Delaney, Brendan C/C-5578-2008	Delaney, Brendan/0000-0002-3518-0131	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)			0	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					675	677		10.1136/bmj.323.7314.675	http://dx.doi.org/10.1136/bmj.323.7314.675			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	476LP	11566833	Green Published			2022-12-28	WOS:000171228800022
J	Bermingham, E; Dick, C				Bermingham, E; Dick, C			Ecology and evolution - The Inga - Newcomer of museum antiquity?	SCIENCE			English	Editorial Material									Smithsonian Trop Res Inst, Balboa, Panama	Smithsonian Institution; Smithsonian Tropical Research Institute	Bermingham, E (corresponding author), Smithsonian Trop Res Inst, Apartado 2072, Balboa, Panama.							Condit R, 1996, J TROP ECOL, V12, P231, DOI 10.1017/S0266467400009433; FJELDSA J, 1994, BIODIVERS CONSERV, V3, P207, DOI 10.1007/BF00055939; FOSTER RB, 1990, 4 NEOTROPICAL RAINFO, P85; Gentry A., 1989, TROPICAL FORESTS BOT, P113; GENTRY AH, 1987, ANN MO BOT GARD, V74, P205, DOI 10.2307/2399395; HAFFER J, 1969, SCIENCE, V165, P131, DOI 10.1126/science.165.3889.131; Latham Roger Earl, 1993, P294; Moritz C, 2000, ANNU REV ECOL SYST, V31, P533, DOI 10.1146/annurev.ecolsys.31.1.533; Morley R.J., 2000, ORIGIN EVOLUTION TRO; Richardson JE, 2001, SCIENCE, V293, P2242, DOI 10.1126/science.1061421; Ricklefs Robert E., 1993, P350; Romoleroux K., 1997, ESTUDIOS DIVERSIDAD, P189; STEBBINS GL, 1974, FLOWERING PLANTS; Van der Pijl L., 1966, ORCHID FLOWERS THEIR; WALLACE AR, 1978, TROPICAL NATURE OTHE; ZUCKERKANDL EMILE, 1965, P97	16	21	24	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 21	2001	293	5538					2214	2216		10.1126/science.1065310	http://dx.doi.org/10.1126/science.1065310			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567126	Green Submitted			2022-12-28	WOS:000171139400029
J	Kang, HJ; Sun, LD; Atkins, CM; Soderling, TR; Wilson, MA; Tonegawa, S				Kang, HJ; Sun, LD; Atkins, CM; Soderling, TR; Wilson, MA; Tonegawa, S			An important role of neural activity-dependent CaMKIV signaling in the consolidation of long-term memory	CELL			English	Article							ELEMENT-BINDING PROTEIN; LATE-PHASE; CREB PHOSPHORYLATION; RETROGRADE-AMNESIA; ADENYLYL-CYCLASE; CONTEXTUAL FEAR; DORSAL STRIATUM; KINASE-IV; CALCIUM; TRANSCRIPTION	Calcium/calmodulin-dependent protein kinase IV (CaMKIV) has been implicated in the regulation of CRE-dependent transcription. To investigate the role of this kinase in neuronal plasticity and memory, we generated transgenic mice in which the expression of a dominant-negative form of CaMKIV (dnCaMKIV) is restricted to the postnatal forebrain. In these transgenic mice, activity-induced CREB phosphorylation and c-Fos expression were significantly attenuated. Hippocampal late LTP (L-LTP) was also impaired, whereas basic synaptic function and early LTP (E-LTP) were unaffected. These deficits correlated with impairments in long-term memory, specifically in its consolidation/retention phase but not in the acquisition phase. These results indicate that neural activity-dependent CaMKIV signaling in the neuronal nucleus plays an important role in the consolidation/retention of hippocampus-dependent long-term memory.	MIT, RIKEN MIT Neurosci Res Ctr, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Ctr Learning & Memory, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN; Massachusetts Institute of Technology (MIT); Oregon Health & Science University	Tonegawa, S (corresponding author), MIT, RIKEN MIT Neurosci Res Ctr, Dept Biol, Howard Hughes Med Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tonegawa@mit.edu		Atkins, Coleen/0000-0003-4718-7493	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027037, R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS27037, R01-NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Anagnostaras SG, 1999, J NEUROSCI, V19, P1106; Anagnostaras SG, 2000, LEARN MEMORY, V7, P58, DOI 10.1101/lm.7.1.58; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Churchill L, 1998, J NEUROSCI, V18, P8074; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Devan BD, 1999, J NEUROSCI, V19, P2789; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Gringhuis SI, 1997, J BIOL CHEM, V272, P31809, DOI 10.1074/jbc.272.50.31809; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Kim JJ, 2001, J NEUROSCI, V21, P5222, DOI 10.1523/JNEUROSCI.21-14-05222.2001; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Kogan JH, 1997, CURR BIOL, V7, P1, DOI 10.1016/S0960-9822(06)00022-4; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; MIYAKAWA T, 2001, IN PRESS J NEUROSCI; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	52	226	236	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 21	2001	106	6					771	783		10.1016/S0092-8674(01)00497-4	http://dx.doi.org/10.1016/S0092-8674(01)00497-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572782	Bronze			2022-12-28	WOS:000171213000013
J	Pimm, SL; Ayres, M; Balmford, A; Branch, G; Brandon, K; Brooks, T; Bustamante, R; Costanza, R; Cowling, R; Curran, LM; Dobson, A; Farber, S; da Fonseca, GAB; Gascon, C; Kitching, R; McNeely, J; Lovejoy, T; Mittermeier, RA; Myers, N; Patz, JA; Raffle, B; Rapport, D; Raven, P; Roberts, C; Rodriguez, JP; Rylands, AB; Tucker, C; Safina, C; Samper, C; Stiassny, MLJ; Supriatna, J; Hall, DH; Wilcove, D				Pimm, SL; Ayres, M; Balmford, A; Branch, G; Brandon, K; Brooks, T; Bustamante, R; Costanza, R; Cowling, R; Curran, LM; Dobson, A; Farber, S; da Fonseca, GAB; Gascon, C; Kitching, R; McNeely, J; Lovejoy, T; Mittermeier, RA; Myers, N; Patz, JA; Raffle, B; Rapport, D; Raven, P; Roberts, C; Rodriguez, JP; Rylands, AB; Tucker, C; Safina, C; Samper, C; Stiassny, MLJ; Supriatna, J; Hall, DH; Wilcove, D			Environment - Can we defy nature's end?	SCIENCE			English	Editorial Material							CONSERVATION		Columbia Univ, Ctr Environm Res & Conservat, New York, NY 10027 USA	Columbia University	Pimm, SL (corresponding author), Columbia Univ, Ctr Environm Res & Conservat, MC 5556, New York, NY 10027 USA.	StuartPimm@aol.com	Wall, Diana H/F-5491-2011; Kitching, Roger/C-5102-2009; Rodriguez, Jon P/G-7224-2012; Ayres, Matthew/AAI-6873-2020; Rodriguez, Jon P/A-1491-2009; Costanza, Robert/AAJ-3546-2021; Costanza, Robert/A-4912-2008	Ayres, Matthew/0000-0001-6120-9068; Rodriguez, Jon P/0000-0001-5019-2870; Costanza, Robert/0000-0001-6348-8734; Wilcove, David S./0000-0002-1354-0503; Balmford, Andrew/0000-0002-0144-3589; Brooks, Thomas/0000-0001-8159-3116				Cincotta RP, 2000, NATURE, V404, P990, DOI 10.1038/35010105; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; DYNESIUS M, 1994, SCIENCE, V266, P753, DOI 10.1126/science.266.5186.753; GRAINGER A, 1988, International Tree Crops Journal, V5, P31; HARDNER JJ, 2000, MITIG ADAPT STRAT GL, V5, P61, DOI DOI 10.1023/A:1009685323704; James A, 2000, NATURE, V404, P120, DOI 10.1038/35004750; Kremen C, 2000, SCIENCE, V288, P1828, DOI 10.1126/science.288.5472.1828; Kress WJ, 2001, SCIENCE, V291, P828; LUDWIG D, 1993, SCIENCE, V260, P17, DOI 10.1126/science.260.5104.17; MICKLIN PP, 1988, SCIENCE, V241, P1170, DOI 10.1126/science.241.4870.1170; Milazzo M, 1998, WTP406; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Myers N, 1998, NATURE, V392, P327, DOI 10.1038/32761; Myers N, 2001, PERVERSE SUBSIDIES T; MYERS N, 1992, PRIMARY SOURCE TROPI; National Research Council, 1980, RES PRIOR TROP BIOL; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; Patz JA, 2000, ANNU REV PUBL HEALTH, V21, P271, DOI 10.1146/annurev.publhealth.21.1.271; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Pimm SL, 1998, SCIENCE, V279, P2068, DOI 10.1126/science.279.5359.2068; Pimm SL, 2001, WORLD ACCORDING PIMM; Rapport DJ, 1998, TRENDS ECOL EVOL, V13, P397, DOI 10.1016/S0169-5347(98)01449-9; Reisner M., 1986, CADILLAC DESERT AM W; Roberts CM, 1999, TRENDS ECOL EVOL, V14, P241, DOI 10.1016/S0169-5347(98)01584-5; SIZER N, 2001, INCREASED INVESTMENT; Smith AT, 2000, SCIENCE, V290, P2073; Stein BA, 2000, PRECIOUS HERITAGE ST; Sugden A, 2000, SCIENCE, V289, P2305; *UN ENV PROGR, 2000, STAT DES IMPL UN PLA; *UN FAO, 2000, STAT WORLD FISH AQ 2; Wilson EO, 2000, SCIENCE, V289, P2279	31	178	187	1	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2001	293	5538					2207	2208		10.1126/science.1061626	http://dx.doi.org/10.1126/science.1061626			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	475AL	11567124				2022-12-28	WOS:000171139400024
J	Ades, PA				Ades, PA			Medical progress: Cardiac rehabilitation and secondary prevention of coronary heart disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; RISK-FACTOR MODIFICATION; QUALITY-OF-LIFE; CONTROLLED-TRIAL; ARTERY-DISEASE; WEIGHT-LOSS; FUNCTIONAL-CAPACITY; SMOKING-CESSATION; EXERCISE THERAPY; OLDER		Fletcher Allen Hlth Care, Burlington, VT 05401 USA; Univ Vermont, Coll Med, Dept Med, Div Cardiol, Burlington, VT 05405 USA	University of Vermont Medical Center; University of Vermont	Ades, PA (corresponding author), Fletcher Allen Hlth Care, McClure 1,MCHV Campus, Burlington, VT 05401 USA.	philip.ades@vtmednet.org			NATIONAL INSTITUTE ON AGING [R01AG015114] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG15114-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ades P A, 1997, J Cardiopulm Rehabil, V17, P222, DOI 10.1097/00008483-199707000-00002; Ades P A, 1999, J Cardiopulm Rehabil, V19, P255, DOI 10.1097/00008483-199907000-00007; Ades PA, 1999, J AM GERIATR SOC, V47, P98, DOI 10.1111/j.1532-5415.1999.tb01909.x; ADES PA, 1992, AM J CARDIOL, V69, P1422, DOI 10.1016/0002-9149(92)90894-5; Ades PA, 1996, CIRCULATION, V94, P323, DOI 10.1161/01.CIR.94.3.323; ADES PA, 1992, ARCH INTERN MED, V152, P1033, DOI 10.1001/archinte.152.5.1033; Ades PA, 1999, ARCH INTERN MED, V159, P2357, DOI 10.1001/archinte.159.19.2357; Ades PA, 1996, ANN INTERN MED, V124, P568, DOI 10.7326/0003-4819-124-6-199603150-00005; Ades PA, 2000, AM HEART J, V139, P543, DOI 10.1016/S0002-8703(00)90100-5; ADES PA, 1989, AM J CARDIOL, V63, P1032, DOI 10.1016/0002-9149(89)90073-8; ADES PA, 1995, J GERONTOL A-BIOL, V50, pM7, DOI 10.1093/gerona/50A.1.M7; ADES PA, 1990, AM HEART J, V120, P585, DOI 10.1016/0002-8703(90)90015-P; *AM HEART ASS, 1999, HEART STROK FACTS; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Balady GJ, 2000, CIRCULATION, V102, P1069, DOI 10.1161/01.CIR.102.9.1069; Belardinelli R, 1999, CIRCULATION, V99, P1173, DOI 10.1161/01.CIR.99.9.1173; BLANKENHORN DH, 1988, JAMA-J AM MED ASSOC, V259, P2698; Bramlet DA, 1997, AM J CARDIOL, V80, pH39, DOI 10.1016/S0002-9149(97)00819-9; Brochu M, 2000, J Cardiopulm Rehabil, V20, P96, DOI 10.1097/00008483-200003000-00003; Brochu M, 2000, J Cardiopulm Rehabil, V20, P180, DOI 10.1097/00008483-200005000-00006; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; Burke LE, 1997, ANN BEHAV MED, V19, P239, DOI 10.1007/BF02892289; CallesEscandon J, 1996, AM J CLIN NUTR, V64, P7, DOI 10.1093/ajcn/64.1.7; CANNISTRA LB, 1995, AM J CARDIOL, V75, P890, DOI 10.1016/S0002-9149(99)80682-1; Carlson JJ, 2000, AM J CARDIOL, V86, P17, DOI 10.1016/S0002-9149(00)00822-5; CHIRIKOS TN, 1986, SOC SCI MED, V22, P1329, DOI 10.1016/0277-9536(86)90096-1; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; DENNIS C, 1988, JAMA-J AM MED ASSOC, V260, P214, DOI 10.1001/jama.260.2.214; DUNBAR-JACOB J, 1991, Annals of Behavioral Medicine, V13, P31; Dylewicz P, 2000, CHEST, V117, P47, DOI 10.1378/chest.117.1.47; EHSANI AA, 1986, CIRCULATION, V74, P938; Evenson K R, 1998, J Cardiopulm Rehabil, V18, P192, DOI 10.1097/00008483-199805000-00002; FOREYT JP, 1993, ANN INTERN MED, V119, P698, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00014; Fragnoli-Munn K, 1998, J Cardiopulm Rehabil, V18, P416, DOI 10.1097/00008483-199811000-00003; Franklin BA, 1998, CHEST, V114, P902, DOI 10.1378/chest.114.3.902; Frasure-Smith N, 2000, CIRCULATION, V101, P1919, DOI 10.1161/01.CIR.101.16.1919; Friedman DB, 1997, AM J CARDIOL, V79, P281, DOI 10.1016/S0002-9149(96)00748-5; Gordon NF, 1997, AM J CARDIOL, V80, pH69, DOI 10.1016/S0002-9149(97)00825-4; HAGBERG JM, 1991, MED SCI SPORT EXER, V23, P661; Hambrecht R, 2000, NEW ENGL J MED, V342, P454, DOI 10.1056/NEJM200002173420702; HAMBRECHT R, 1995, J AM COLL CARDIOL, V25, P1239, DOI 10.1016/0735-1097(94)00568-B; Harvey-Berino J, 1998, CORONARY ARTERY DIS, V9, P795, DOI 10.1097/00019501-199809120-00003; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HELLERSTEIN HK, 1968, B NEW YORK ACAD MED, V44, P1028; KATZEL LI, 1995, METABOLISM, V44, P307, DOI 10.1016/0026-0495(95)90159-0; Kaufmann P, 1997, EUR HEART J, V18, P1853; KAVANAGH T, 1973, MED SCI SPORT EXER, V5, P34; Keteyian SJ, 1996, ANN INTERN MED, V124, P1051, DOI 10.7326/0003-4819-124-12-199606150-00004; Kobashigawa JA, 1999, NEW ENGL J MED, V340, P976; Kokkinos PF, 2000, CORONARY ARTERY DIS, V11, P99, DOI 10.1097/00019501-200003000-00002; KONSTAM M, 1994, AHCPR PUBLICATION; KRUSE WHH, 1991, PATIENT COMPLIANCE M, P175; LAPLANTE MP, 1989, DATA DISABILITY NATL; LAVIE CJ, 1993, J AM COLL CARDIOL, V22, P678, DOI 10.1016/0735-1097(93)90176-2; Lavie CJ, 1996, CHEST, V109, P52, DOI 10.1378/chest.109.1.52; Lee JY, 1996, MED SCI SPORT EXER, V28, P47, DOI 10.1097/00005768-199601000-00013; LEVIN LA, 1991, J INTERN MED, V230, P427, DOI 10.1111/j.1365-2796.1991.tb00468.x; Linden W, 1996, ARCH INTERN MED, V156, P2302; Malfatto G, 1998, AM J CARDIOL, V81, P834, DOI 10.1016/S0002-9149(98)00021-6; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; MENDOZA SG, 1991, METABOLISM, V40, P368, DOI 10.1016/0026-0495(91)90147-O; Mertens DJ, 1998, J SPORT MED PHYS FIT, V38, P310; MILLER NH, 1984, CIRCULATION, V70, P645, DOI 10.1161/01.CIR.70.4.645; NEILL WA, 1985, ARCH INTERN MED, V145, P1642, DOI 10.1001/archinte.145.9.1642; Newby LK, 2000, NEW ENGL J MED, V342, P749, DOI 10.1056/NEJM200003163421101; Niebauer J, 1997, CIRCULATION, V96, P2534, DOI 10.1161/01.CIR.96.8.2534; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE N, 1993, AM J CARDIOL, V72, P154, DOI 10.1016/0002-9149(93)90152-3; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; Oldridge N. B., 1984, J CARDIAC REHABIL, V4, P166; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; Oldridge NB, 1983, J CARDIAC REHABIL, V3, P257; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Ornish D, 1999, JAMA-J AM MED ASSOC, V281, P1380; PASHKOW FJ, 1993, J AM COLL CARDIOL, V21, P822, DOI 10.1016/0735-1097(93)90116-I; PEDERSEN TR, 1994, LANCET, V344, P1383; PINSKY JL, 1990, AM J PUBLIC HEALTH, V80, P1363, DOI 10.2105/AJPH.80.11.1363; REDWOOD DR, 1972, NEW ENGL J MED, V286, P959, DOI 10.1056/NEJM197205042861801; ROSENMAN RH, 1975, JAMA-J AM MED ASSOC, V233, P872, DOI 10.1001/jama.233.8.872; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Ruderman N., 1995, HLTH PROFESSIONALS G; Ruzumna P, 1996, CURR OPIN CARDIOL, V11, P269, DOI 10.1097/00001573-199605000-00007; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Salomaa V, 2000, CIRCULATION, V101, P1913, DOI 10.1161/01.CIR.101.16.1913; Savage PD, 2000, AM HEART J, V140, P527, DOI 10.1067/mhj.2000.109219; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; Schairer J R, 1998, J Cardiopulm Rehabil, V18, P290, DOI 10.1097/00008483-199807000-00006; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SMITH SC, 1995, CIRCULATION, V92, P2; STEVENSON LW, 1995, J AM COLL CARDIOL, V25, P163, DOI 10.1016/0735-1097(94)00357-V; STRATTON JR, 1991, CIRCULATION, V83, P1692, DOI 10.1161/01.CIR.83.5.1692; Sueta, 1999, AM J CARDIOL, V84, P1143; Sueta CA, 1999, AM J CARDIOL, V83, P1303, DOI 10.1016/S0002-9149(99)00117-4; SUZUKI T, 1992, CLIN CARDIOL, V15, P358, DOI 10.1002/clc.4960150510; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; Thomas R J, 1996, J Cardiopulm Rehabil, V16, P402, DOI 10.1097/00008483-199611000-00010; Tremblay A, 1999, OBES RES, V7, P556, DOI 10.1002/j.1550-8528.1999.tb00714.x; VANCAMP SP, 1986, JAMA-J AM MED ASSOC, V256, P1160, DOI 10.1001/jama.256.9.1160; VONGVANICH P, 1996, J CARDIOPULM REHABIL, V16, P23; Wannamethee SG, 2000, CIRCULATION, V102, P1358, DOI 10.1161/01.CIR.102.12.1358; WARNER JG, 1995, CIRCULATION, V92, P773, DOI 10.1161/01.CIR.92.4.773; WENGER NK, 1973, JAMA-J AM MED ASSOC, V224, P511, DOI 10.1001/jama.224.4.511; Wenger NK, 1995, AHCPR PUBLICATION; WILHELMSSON C, 1975, LANCET, V1, P416; WILLIAMS MA, 1985, AM J CARDIOL, V55, P263, DOI 10.1016/0002-9149(85)90357-1; Wilson K, 2000, ARCH INTERN MED, V160, P939, DOI 10.1001/archinte.160.7.939	110	502	525	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2001	345	12					892	902		10.1056/NEJMra001529	http://dx.doi.org/10.1056/NEJMra001529			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	473JW	11565523				2022-12-28	WOS:000171039600007
J	Fatourechi, V				Fatourechi, V			Adverse effects of subclinical hyperthyroidism	LANCET			English	Editorial Material									Mayo Clin, Div Endocrinol Metab Nutr & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Fatourechi, V (corresponding author), Mayo Clin, Div Endocrinol Metab Nutr & Internal Med, Rochester, MN 55905 USA.							*AM ASS CLIN END, 1999, ENDOCR PRACT, V5, P220; Bauer DC, 2001, ANN INTERN MED, V134, P561, DOI 10.7326/0003-4819-134-7-200104030-00009; Biondi B, 2000, J CLIN ENDOCR METAB, V85, P4701, DOI 10.1210/jc.85.12.4701; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Charkes ND, 1996, THYROID, V6, P391, DOI 10.1089/thy.1996.6.391; Helfand M, 1998, ANN INTERN MED, V129, P141, DOI 10.7326/0003-4819-129-2-199807150-00020; Kalmijn S, 2000, CLIN ENDOCRINOL, V53, P733, DOI 10.1046/j.1365-2265.2000.01146.x; Marqusee E, 1998, ENDOCRIN METAB CLIN, V27, P37, DOI 10.1016/S0889-8529(05)70296-6; ROSS DS, 2000, WERNER INGBARS THYRO, P1007; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; Toft AD, 2001, NEW ENGL J MED, V345, P512, DOI 10.1056/NEJMcp010145	11	16	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 15	2001	358	9285					856	857		10.1016/S0140-6736(01)06036-6	http://dx.doi.org/10.1016/S0140-6736(01)06036-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567696				2022-12-28	WOS:000171087000003
J	Bernard, P; Maure, JF; Partridge, JF; Genier, S; Javerzat, JP; Allshire, RC				Bernard, P; Maure, JF; Partridge, JF; Genier, S; Javerzat, JP; Allshire, RC			Requirement of heterochromatin for cohesion at centromeres	SCIENCE			English	Article							FISSION YEAST CENTROMERES; MITOTIC SPINDLES; CHROMOSOME ARMS; ANAPHASE; SEPARATION; COMPONENT; DOMAINS	Centromeres are heterochromatic in many organisms, but the mitotic function of this silent chromatin remains unknown. During cell division, newly replicated sister chromatids must cohere until anaphase when Scc1/Rad21-mediated cohesion is destroyed. In metazoans, chromosome arm cohesins dissociate during prophase, leaving centromeres as the only linkage before anaphase. it is not known what distinguishes centromere cohesion from arm cohesion. Fission yeast Swi6 (a Heterochromatin protein 1 counterpart) is a component of si[ent heterochromatin. Here we show that this heterochromatin is specifically required for cohesion between sister centromeres. Swi6 is required for association of Rad21-cohesin with centromeres but not along chromosome arms and, thus, acts to distinguish centromere from arm cohesion. Therefore, one function of centromeric heterochromatin is to attract cohesin, thereby ensuring sister centromere cohesion and proper chromosome segregation.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Inst Biochim & Genet Cellulaires, CNRS, Unite Mixte Rech 5095, F-33077 Bordeaux, France	University of Edinburgh; Centre National de la Recherche Scientifique (CNRS)	Allshire, RC (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.		Bernard, Pascal/I-1859-2015; Partridge, Janet/M-9352-2018	Bernard, Pascal/0000-0003-2732-9685; Partridge, Janet/0000-0003-1102-6305; Allshire, Robin/0000-0002-8005-3625				ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Dej KJ, 2000, TRENDS CELL BIOL, V10, P392, DOI 10.1016/S0962-8924(00)01821-3; DING R, 1993, J CELL BIOL, V120, P141, DOI 10.1083/jcb.120.1.141; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Laloraya S, 2000, J CELL BIOL, V151, P1047, DOI 10.1083/jcb.151.5.1047; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; O'Toole ET, 1999, MOL BIOL CELL, V10, P2017, DOI 10.1091/mbc.10.6.2017; Partridge JF, 2000, GENE DEV, V14, P783; Pidoux AL, 2000, J CELL SCI, V113, P4177; PIDOUX AL, UNPUB; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Warren WD, 2000, CURR BIOL, V10, P1463, DOI 10.1016/S0960-9822(00)00806-X; Watanabe Y, 2001, NATURE, V409, P359, DOI 10.1038/35053103; WINES DR, 1992, GENETICS, V131, P683; Yamada H, 1997, J CELL SCI, V110, P1793	27	486	501	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2539	2542		10.1126/science.1064027	http://dx.doi.org/10.1126/science.1064027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11598266				2022-12-28	WOS:000172927700056
J	Rhew, DC				Rhew, DC			Quality indicators for the management of pneumonia in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; PROSPECTIVE PAYMENT SYSTEM; INFLUENZA VACCINATION; HOSPITALIZED-PATIENTS; PRACTICE GUIDELINE; EARLY SWITCH; LOW-RISK; IMMUNIZATION; EFFICACY		Zynx Hlth Inc, Beverly Hills, CA 90212 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Rhew, DC (corresponding author), Zynx Hlth Inc, 9100 Wilshire Blvd,Suite 655 E Tower, Beverly Hills, CA 90212 USA.	rhew@zynx.com						*ACP TASK FORC AD, 1994, GUID AD IMM, P107; ARNSTEN JH, 1995, J GEN INTERN MED S, V10, pA97; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; BLOOM HG, 1988, J AM GERIATR SOC, V36, P897, DOI 10.1111/j.1532-5415.1988.tb05782.x; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BUFFINGTON J, 1991, J GEN INTERN MED, V6, P204, DOI 10.1007/BF02598961; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; *CDCP NAT CTR HLTH, 1998, NAT VIT STAT REP; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CROUSE BJ, 1994, J FAM PRACTICE, V38, P258; *CTR DIS CONTR PRE, 1998, JAMA-J AM MED ASSOC, V280, P1818; DUNN WF, 1991, AM REV RESPIR DIS, V144, P526, DOI 10.1164/ajrccm/144.3_Pt_1.526; FARR BM, 1995, ARCH INTERN MED, V155, P2336, DOI 10.1001/archinte.155.21.2336; FEDSON DS, 1983, AM J PUBLIC HEALTH, V73, P442, DOI 10.2105/AJPH.73.4.442; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; FEDSON DS, 1985, J AM GERIATR SOC, V33, P142, DOI 10.1111/j.1532-5415.1985.tb02281.x; FEDSON KS, 1994, VACCINES, P517; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; FINE MJ, 1994, ARCH INTERN MED, V154, P2666, DOI 10.1001/archinte.1994.00420230051007; Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244; GAILLAT J, 1985, REV EPIDEMIOL SANTE, V33, P437; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS14; Halm EA, 1998, JAMA-J AM MED ASSOC, V279, P1452, DOI 10.1001/jama.279.18.1452; HERMAN CJ, 1994, J AM GERIATR SOC, V42, P1154, DOI 10.1111/j.1532-5415.1994.tb06981.x; Honkanen PO, 1997, VACCINE, V15, P317, DOI 10.1016/S0264-410X(96)00171-5; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; Lave JR, 1999, SEM RESP CRIT CARE M, V20, P189, DOI 10.1055/s-2007-1021315; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; MAGNUSSEN CR, 1984, ARCH INTERN MED, V144, P1755, DOI 10.1001/archinte.144.9.1755; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; McGarvey R N, 1993, QRB Qual Rev Bull, V19, P124; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; MUSHER DM, 1990, J INFECT DIS, V161, P728, DOI 10.1093/infdis/161.4.728; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nuorti JP, 1998, NEW ENGL J MED, V338, P1861, DOI 10.1056/NEJM199806253382601; Plans Rubio P, 1995, Rev Esp Salud Publica, V69, P409; Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1; *PREV PNEUM DIS, 1997, MMWR-MORBID MORTAL W, V46, P1; Ramirez JA, 1999, ARCH INTERN MED, V159, P2449, DOI 10.1001/archinte.159.20.2449; RAMIREZ JA, 1995, ARCH INTERN MED, V155, P1273, DOI 10.1001/archinte.155.12.1273; Rhew DC, 1998, CHEST, V114, P115, DOI 10.1378/chest.114.1.115; SAHN SA, 1993, AM REV RESPIR DIS, V148, P813, DOI 10.1164/ajrccm/148.3.813; SETIA U, 1985, J AM GERIATR SOC, V33, P856, DOI 10.1111/j.1532-5415.1985.tb05440.x; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; *US PUBL HLTH SERV, 2001, HEALTH PEOPL, V1; Wait MA, 1997, CHEST, V111, P1548, DOI 10.1378/chest.111.6.1548; WEINGARTEN SR, 1994, CHEST, V105, P1109, DOI 10.1378/chest.105.4.1109; Weingarten SR, 1996, AM J RESP CRIT CARE, V153, P1110, DOI 10.1164/ajrccm.153.3.8630553	53	18	20	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				736	743		10.7326/0003-4819-135-8_Part_2-200110161-00013	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601957				2022-12-28	WOS:000171542400013
J	Wenger, NS; Shekelle, PG				Wenger, NS; Shekelle, PG		ACOVE Investigators	Assessing Care of Vulnerable Elders: ACOVE project overview	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY		RAND Corp, Santa Monica, CA 90407 USA	RAND Corporation	Wenger, NS (corresponding author), RAND Corp, 1700 Main St,M-26, Santa Monica, CA 90407 USA.	nwenger@mednet.ucla.edu						Berlowitz DR, 1996, ANN INTERN MED, V124, P557, DOI 10.7326/0003-4819-124-6-199603150-00003; Casalino LP, 1999, NEW ENGL J MED, V341, P1147, DOI 10.1056/NEJM199910073411511; *JOINT COMM ACCR H, 1997, 1997 HOSP ACCR STAND; Mukamel DB, 1997, MED CARE, V35, P367, DOI 10.1097/00005650-199704000-00007; National Committee for Quality Assurance, 1996, HLTH PLAN EMPL DAT I; OUSLANDER JG, 1995, JAMA-J AM MED ASSOC, V273, P1366; SALIBA D, IN PRESS J AM GERIAT; Sloss EM, 2000, J AM GERIATR SOC, V48, P363, DOI 10.1111/j.1532-5415.2000.tb04691.x; Solomon DH, 2001, J AM GERIATR SOC, V49, pS34; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; 1996, J AM GERIATR SOC, V44, P1112; 1997, J AM GERIATR SOC, V45, P1273	12	185	186	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				642	646		10.7326/0003-4819-135-8_Part_2-200110161-00002	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601946				2022-12-28	WOS:000171542400002
J	Ewart, RM				Ewart, RM			The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									So Illinois Univ, Ctr Family Med, Sch Med, Dept Family & Community Med, Springfield, IL 62702 USA	Southern Illinois University System; Southern Illinois University	Ewart, RM (corresponding author), So Illinois Univ, Ctr Family Med, Sch Med, Dept Family & Community Med, 520 N 4th St, Springfield, IL 62702 USA.	rewart@siumed.edu						*AM DIAB ASS, 1999, DIABETES CARE S1, V17, P5; Amer Diabet Assoc, 1998, DIABETES CARE, V21, P2180; [Anonymous], 1995, Diabetes, V44, P1249; [Anonymous], 1983, Diabetologia, V24, P404; [Anonymous], 2000, DIABETES CARE S1, V23, pS20; DeMets DL, 1999, LANCET, V354, P1983, DOI 10.1016/S0140-6736(99)03464-9; Ewart R M, 2000, J Am Board Fam Pract, V13, P188; HOLMAN RR, 1977, LANCET, V1, P469; Levy J C, 1993, Journ Annu Diabetol Hotel Dieu, P123; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; Turner R, 1999, LANCET, V354, P600, DOI 10.1016/S0140-6736(05)77957-5; Turner RC, 1998, LANCET, V352, P1934, DOI 10.1016/S0140-6736(05)60426-6; Turner RC, 1998, DIABETES CARE, V21, pC35, DOI 10.2337/diacare.21.3.C35; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; TURNER RC, 1984, DIABETOLOGIA, V27, P419, DOI 10.1007/BF00304862; TURNER RC, 1990, DIABETES CARE, V13, P1011, DOI 10.2337/diacare.13.9.1011; *UK PROSP DIAB STU, 1988, LANCET, V352, P854; UK Prospective Diabetes Grp, 1998, LANCET, V352, P1558; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83	20	25	25	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 13	2001	323	7317					854	857		10.1136/bmj.323.7317.854	http://dx.doi.org/10.1136/bmj.323.7317.854			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	483RW	11597972	Green Published			2022-12-28	WOS:000171650500033
J	Dolmetsch, RE; Pajvani, U; Fife, K; Spotts, JM; Greenberg, ME				Dolmetsch, RE; Pajvani, U; Fife, K; Spotts, JM; Greenberg, ME			Signaling to the nucleus by an L-type calcium channel - Calmodulin complex through the MAP kinase pathway	SCIENCE			English	Article							GENE-EXPRESSION; CREB PHOSPHORYLATION; CA2+-DEPENDENT INACTIVATION; HIPPOCAMPAL-NEURONS; CA2+ CHANNELS; TRANSCRIPTION; MECHANISM; MOTIF; FACILITATION; SUPPORTS	Increases in the intracellutar concentration of calcium ([Ca2+](i)) activate various signaling pathways that lead to the expression of genes that are essential for dendritic development, neuronal. survival, and synaptic plasticity. The mode of Ca2+ entry into a neuron plays a key rote in determining which signaling pathways are activated and thus specifies the cellular response to Ca2+. Ca2+ influx through L-type voltage-activated channels (LTCs) is particularly effective at activating transcription factors such as CREB and MEF-2. We developed a functional knock-in technique to investigate the features of LTCs that specifically couple them to the signaling pathways that regulate gene expression. We found that an isoleucine-glutamine ("IQ") motif in the carboxyl terminus of the LTC that binds Ca2+-calmodutin (CaM) is critical for conveying the Ca2+ signal to the nucleus. Ca2+-CaM binding to the LTC was necessary for activation of the Ras/mitogen-activated protein kinase (MAPK) pathway, which conveys local Ca2+ signals from the mouth of the LTC to the nucleus. CaM functions as a local Ca2+ sensor at the mouth of the LTC that activates the MAPK pathway and leads to the stimulation of genes that are essential for neuronal survival and plasticity.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Enders Pediat Res Labs, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Greenberg, ME (corresponding author), Childrens Hosp, Div Neurosci, Boston, MA 02115 USA.		Oka, Yoshitaka/C-9670-2010; soler, martha maricel m gomez/L-6025-2014	Oka, Yoshitaka/0000-0002-3482-3051; soler, martha maricel m gomez/0000-0002-4412-8108	NICHD NIH HHS [P30-HD18655] Funding Source: Medline; NINDS NIH HHS [NS28829] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COWAN CE, UNPUB; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DOLMETSCH RE, UNPUB; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; RANDALL A, 1995, J NEUROSCI, V15, P2995; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Westenbroek RE, 1998, J NEUROSCI, V18, P6319; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	31	682	705	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 12	2001	294	5541					333	339		10.1126/science.1063395	http://dx.doi.org/10.1126/science.1063395			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	482WZ	11598293				2022-12-28	WOS:000171601400033
J	Weisner, C; Mertens, J; Parthasarathy, S; Moore, C; Lu, Y				Weisner, C; Mertens, J; Parthasarathy, S; Moore, C; Lu, Y			Integrating primary medical care with addiction treatment - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATION; SUBSTANCE-ABUSE TREATMENT; TREATMENT SERVICES; SEVERITY INDEX; ALCOHOL; COCAINE; CONSEQUENCES; DISORDERS; COST; COMPLICATIONS	Context The prevalence of medical disorders is high among substance abuse patients, yet medical services are seldom provided in coordination with substance abuse treatment. Objective To examine differences in treatment outcomes and costs between integrated and independent models of medical and substance abuse care as well as the effect of integrated care in a subgroup of patients with substance abuse-related medical conditions (SAMCs). Design Randomized controlled trial conducted between April 1997 and December 1998 Setting and Patients Adult men and women (n=592) who were admitted to a large health maintenance organization chemical dependency program in Sacramento, Calif. Interventions Patients were randomly assigned to receive treatment through an integrated model, in which primary health care was included within the addiction treatment program (n=285), or an independent treatment-as-usual model, in which primary care and substance abuse treatment were provided separately (n=307). Both programs were group based and lasted 8 weeks, with 10 months of aftercare available. Main Outcome Measures Abstinence outcomes, treatment utilization, and costs 6 months after randomization. Results Both groups showed improvement on all drug and alcohol measures. overall, there were no differences in total abstinence rates between the integrated care and independent care groups (68% vs 63%, P=.18). For patients without SAMCs, there were also no differences in abstinence rates (integrated care, 66% vs independent care, 73%; P=.23) and there was a slight but nonsignificant trend of higher costs for the integrated care group ($367.96 vs $324.09, P=.19). However, patients with SAMCs (n=341) were more likely to be abstinent in the integrated care group than the independent care group (69% vs 55%, P=.006; odds ratio [OR], 1.90; 95% confidence interval [CI], 1.22-2.97). This was true for both those with medical (OR, 3.38; 95% Cl, 1.68-6.80) and psychiatric (OR, 2.10; 95% Cl, 1.04-4.25) SAMCS. Patients with SAMCs had a slight but nonsignificant trend of higher costs in the integrated care group ($470.81 vs $427.95, P=.14). The incremental cost-effectiveness ratio per additional abstinent patient with an SAMC in,the integrated care group was $1581. Conclusions Individuals with SAMCs benefit from integrated medical and substance abuse treatment, and such an approach can be cost-effective. These findings are relevant given the high prevalence and cost of medical conditions among substance abuse patients, new developments in medications for addiction, and recent legislation on parity of substance abuse with other medical benefits.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Kaiser Permanente Chem Dependency Recovery Progra, Sacramento, CA USA	Kaiser Permanente; University of California System; University of California San Francisco; Kaiser Permanente	Weisner, C (corresponding author), Kaiser Permanente Med Care Program, Div Res, No Calif Reg,3505 Broadway,12th Floor, Oakland, CA 94611 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010572, R37DA010572] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA010572, R37 DA010572, R01-DA10572, R37 DA010572-06] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Alaja R, 1998, ALCOHOL CLIN EXP RES, V22, P1820, DOI 10.1111/j.1530-0277.1998.tb03987.x; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BENZER DG, 1991, COMPREHENSIVE HDB DR, P551; Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; Butterworth K. R., 1993, HLTH ISSUES RELATED, P1; Chou SP, 1996, ALCOHOL CLIN EXP RES, V20, P1423, DOI 10.1111/j.1530-0277.1996.tb01144.x; Committee on Treatment of Alcohol Problems, 1990, BROAD BAS TREATM ALC; Cooper R., 1992, ACCOUNT HORIZ, P12; EDMUNDS M, 1997, MANAGING MANAGED CAR; EDWARDS G, 1996, ALCOHOL MISUSE EUROP, P195; Efron B., 1994, MONOGRAPHS STAT APPL; Etheridge R M, 1995, J Subst Abuse, V7, P9, DOI 10.1016/0740-5472(95)90003-9; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; GERSTEIN DR, 1990, TREATING DRUG PROBLE, V1; GRAY JD, 1993, CAN FAM PHYSICIAN, V39, P1975; HEISCHOBER B, 1991, METHAMPHETAMINE ABUS, P60; Hubbard JR, 1999, AM FAM PHYSICIAN, V60, P2583; JENTZEN J, 1993, AM J CLIN PATHOL, V100, P475, DOI 10.1093/ajcp/100.5.475; Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151; Kunnes R, 1993, J Addict Dis, V12, P23, DOI 10.1300/J069v12n02_03; MANNING WG, 1996, HLTH MED, P236; MCLELLAN AT, 1994, J CONSULT CLIN PSYCH, V62, P1141, DOI 10.1037/0022-006X.62.6.1141; MCLELLAN AT, 1992, J NERV MENT DIS, V180, P101, DOI 10.1097/00005053-199202000-00007; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; MENDELSON JH, 1986, J STUD ALCOHOL, V47, P361, DOI 10.15288/jsa.1986.47.361; MOOS RH, 1994, ALCOHOL CLIN EXP RES, V18, P187, DOI 10.1111/j.1530-0277.1994.tb00902.x; MULLAHY J, 1994, VALUING HLTH CARE, P149; *NAT I ALC AB ALC, 1990, DHHS ADM PUBL; Parthasarathy S, 2001, J STUD ALCOHOL, V62, P89, DOI 10.15288/jsa.2001.62.89; Ray GT, 2000, MED CARE RES REV, V57, P92, DOI 10.1177/107755870005700106; RUBIN RB, 1992, J TOXICOL-CLIN TOXIC, V30, P1; Samet JH, 2001, ARCH INTERN MED, V161, P85, DOI 10.1001/archinte.161.1.85; Schmittdiel J, 1997, JAMA-J AM MED ASSOC, V278, P1596, DOI 10.1001/jama.278.19.1596; Selby JV, 1997, ANN INTERN MED, V127, P719, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00056; SELWYN PA, 1993, PUBLIC HEALTH REP, V108, P492; SIKKINK J, 1991, ADDICTIVE DISORDERS, P145; Stein MD, 1999, PSYCHIAT CLIN N AM, V22, P351, DOI 10.1016/S0193-953X(05)70081-2; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P925; Sturm R, 1998, J Health Care Finance, V24, P82; UMBRICHTSCHNEITER A, 1994, AM J PUBLIC HEALTH, V84, P207, DOI 10.2105/AJPH.84.2.207; Weisner C, 2000, HEALTH SERV RES, V35, P791; Weisner C, 2000, J SUBST ABUSE TREAT, V19, P103, DOI 10.1016/S0740-5472(99)00103-8; Weisner C, 1995, HEALTH SERV RES, V30, P707; Weisner C, 2000, J STUD ALCOHOL, V61, P121, DOI 10.15288/jsa.2000.61.121; WEISNER C, 1997, INDICATORS CHRONIC H, P260; WHEELER JRC, 1992, AM J PUBLIC HEALTH, V82, P711, DOI 10.2105/AJPH.82.5.711; Willenbring ML, 1999, ARCH INTERN MED, V159, P1946, DOI 10.1001/archinte.159.16.1946	47	297	298	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1715	1723		10.1001/jama.286.14.1715	http://dx.doi.org/10.1001/jama.286.14.1715			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	480NC	11594896	Bronze, Green Accepted			2022-12-28	WOS:000171466800021
J	Bennett, J				Bennett, J			ABC of the upper gastrointestinal tract - Oesophagus: Atypical chest pain and motility disorders	BRITISH MEDICAL JOURNAL			English	Article									Royal Coll Phys, London NW1 4LE, England	Royal College of Physicians	Bennett, J (corresponding author), Royal Coll Phys, London NW1 4LE, England.								0	15	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 6	2001	323	7316					791	794		10.1136/bmj.323.7316.791	http://dx.doi.org/10.1136/bmj.323.7316.791			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481LK	11588085	Green Published			2022-12-28	WOS:000171520600033
J	Wilkin, T; Devendra, D; Dequeker, J; Luyten, FP				Wilkin, T; Devendra, D; Dequeker, J; Luyten, FP			For and against - Bone densitometry is not a good predictor of hip fracture	BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; RISK; WOMEN; OSTEOPOROSIS; TRIAL	Bone densitometry is widely used in osteoporosis clinics to identify people at increased risk of fracture. Terence Wilkin and Devasenan Devendra. believe that evidence for the efficacy of bone densitometry is weak, but Jan Dequeker and Frank P Luyten argue that their interpretation of the evidence is too narrow and that screening high risk patients is cost effective.	Derriford Hosp, Postgrad Med Sch, Dept Med, Plymouth PL6 8DH, Devon, England	Derriford Hospital; University of Plymouth	Wilkin, T (corresponding author), Derriford Hosp, Postgrad Med Sch, Dept Med, Plymouth PL6 8DH, Devon, England.		Luyten, Frank/GPS-7793-2022					Burger H, 1999, BONE, V25, P369, DOI 10.1016/S8756-3282(99)00173-8; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DeLaet CEDH, 1997, BRIT MED J, V315, P221, DOI 10.1136/bmj.315.7102.221; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Faulkner KG, 2000, J BONE MINER RES, V15, P183, DOI 10.1359/jbmr.2000.15.2.183; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; Jonsson B, 1999, OSTEOPOROSIS INT, V10, P193, DOI 10.1007/s001980050215; Kanis JA, 2000, BONE, V26, P387, DOI 10.1016/S8756-3282(00)00238-6; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5; TOBIAS JH, 1994, CLIN SCI, V87, P587, DOI 10.1042/cs0870587; Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231; Wilkin TJ, 1999, BRIT MED J, V318, P862, DOI 10.1136/bmj.318.7187.862; World Health Organization, 1994, WHO TECHN REP SER, V843; Xiaoge D, 2000, CALCIFIED TISSUE INT, V67, P195, DOI 10.1007/s002230001139	17	38	41	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 6	2001	323	7316					795	797		10.1136/bmj.323.7316.795	http://dx.doi.org/10.1136/bmj.323.7316.795			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481LK	11588087	Green Published			2022-12-28	WOS:000171520600034
J	Semenza, GL				Semenza, GL			HIF-1, O-2, and the 3 PHDs: How animal cells signal hypoxia to the nucleus	CELL			English	Review							INDUCIBLE FACTOR 1-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; OXYGEN; PROTEIN; EXPRESSION	Hypoxia-inducible factor 1 (HIF-1) is a global regulator of cellular and systemic O-2 homeostasis in animals. A molecular basis for O-2-regulated expression of the HIF-1 alpha subunit has now been determined, providing a mechanism for changes in gene expression in response to changes in cellular oxygenation.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA	Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA.							Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gilles-Gonzalez MA, 2001, IUBMB LIFE, V51, P165, DOI 10.1080/152165401753544232; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Poyton RO, 1999, RESP PHYSIOL, V115, P119, DOI 10.1016/S0034-5687(99)00028-6; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2000, GENE DEV, V14, P1983; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253	15	729	769	2	65	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 5	2001	107	1					1	3		10.1016/S0092-8674(01)00518-9	http://dx.doi.org/10.1016/S0092-8674(01)00518-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	480GF	11595178	Bronze			2022-12-28	WOS:000171453100002
J	Cloeren, M; Craig, E				Cloeren, M; Craig, E			Porphyria cutana tarda	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Vet Affairs Maryland Hlth Care Syst, Perry Point, MD 21902 USA		Cloeren, M (corresponding author), Vet Affairs Maryland Hlth Care Syst, Perry Point, MD 21902 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					E3	E3		10.1056/ENEJMicm980855	http://dx.doi.org/10.1056/ENEJMicm980855			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586972				2022-12-28	WOS:000171340400007
J	Dalton, R				Dalton, R			Bilateral Vietnam study plans to assess war fallout of dioxin	NATURE			English	News Item																		2000, NATURE, V406, P818	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 4	2001	413	6855					442	442		10.1038/35097221	http://dx.doi.org/10.1038/35097221			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	478HG	11586310	Bronze			2022-12-28	WOS:000171340500004
J	Mann, K; Fox, SP; Abbs, SJ; Yau, SC; Scriven, PN; Docherty, Z; Ogilvie, CM				Mann, K; Fox, SP; Abbs, SJ; Yau, SC; Scriven, PN; Docherty, Z; Ogilvie, CM			Development and implementation of a new rapid aneuploidy diagnostic service within the UK National Health Service and implications for the future of prenatal diagnosis	LANCET			English	Article							POLYMERASE CHAIN-REACTION; IN-SITU HYBRIDIZATION; CHROMOSOME ANEUPLOIDIES; DOWNS-SYNDROME; PCR; POLYMORPHISMS; INTEGRATION; GENE; SEX	Background Prenatal diagnosis for chromosome abnormality is routinely undertaken by full karyotype analysis of chromosomes from cultured cells; pregnant women must wait on average 13-14 days for their results. Autosomal trisomies, which account for around 80% of significant abnormalities, can be detected by quantitative fluorescence (QF) PCR. We report on the development and implementation of this technique as the first such routine service within a diagnostic department of the UK National Health Service (NHS). Methods We designed a "one-tube test" comprising four primer pairs for polymorphic tetranucleotide repeat sequences on chromosome 21, four primer pairs for sequences on chromosome 18, three primer pairs for sequences on chromosome 13, and one primer pair to identify the sex chromosomes. All prenatal samples received by our NHS diagnostic department between April, 2000, and April, 2001, were tested. After DNA extraction, PCR amplification was done and the products separated on a capillary-based genetic analyser; the results were interpreted with dedicated software. Follow-up karyotype analysis was done on all samples. Findings 1148 amniotic fluid samples, 188 chorionic villus samples, and 37 fetal tissue samples were tested; the amplification failure rate was zero with our current protocol. QF-PCR results were obtained and reported on 1314 (98%) of the prenatal samples; the remaining 22 (2%) were uninformative because of maternal-cell contamination. One case of mosaicism in a chorionic villus sample, and two cases indicating somatic expansion of a tetranucleotide repeat were found. No false positive or false negative results were obtained. The mean reporting time for the last 4 months of data collection was 1.25 working days. Interpretation QF-PCR aneuploidy testing is an efficient and accurate technique for the detection of autosomal trisomies in prenatal samples. Implementation of this service has led to the rapid diagnosis of abnormalities and early reassurance for women with normal results.	Guys & St Thomas Hosp Trust, Genet Ctr, London, England	Guy's & St Thomas' NHS Foundation Trust	Ogilvie, CM (corresponding author), Dept Cytogenet, 5th Floor,Guys Tower,St Thomas St, London SE1 9RT, England.		Ogilve, Caroline/AAW-3793-2021	Scriven, Paul/0000-0002-0036-984X				Bosch A, 1996, EUR J HUM GENET, V4, P135; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; Cirigliano V, 1999, PRENATAL DIAG, V19, P1099, DOI 10.1002/(SICI)1097-0223(199912)19:12<1099::AID-PD709>3.0.CO;2-2; GERKEN S, 1994, GENOMICS, V24, P612, DOI 10.1006/geno.1994.1679; KLINGER K, 1992, AM J HUM GENET, V51, P55; Levett LJ, 2001, ULTRASOUND OBST GYN, V17, P115, DOI 10.1046/j.1469-0705.2001.00340.x; MANSFIELD ES, 1993, HUM MOL GENET, V2, P43, DOI 10.1093/hmg/2.1.43; MCINNIS MG, 1991, GENOMICS, V11, P573, DOI 10.1016/0888-7543(91)90064-L; Morris A, 1999, PRENATAL DIAG, V19, P546, DOI 10.1002/(SICI)1097-0223(199906)19:6<546::AID-PD589>3.0.CO;2-8; *NEQAS, 2000, NAT EXT QUAL ASS SCH; Pertl B, 1996, HUM GENET, V98, P55, DOI 10.1007/s004390050159; Pertl B, 1997, AM J OBSTET GYNECOL, V177, P899, DOI 10.1016/S0002-9378(97)70292-8; Pertl B, 1999, J MED GENET, V36, P300; PERTL B, 1994, LANCET, V343, P1197, DOI 10.1016/S0140-6736(94)92404-X; Schmidt W, 2000, MOL HUM REPROD, V6, P855, DOI 10.1093/molehr/6.9.855; SPATHAS DH, 1994, PRENATAL DIAG, V14, P1049, DOI 10.1002/pd.1970141107; SULLIVAN KM, 1993, BIOTECHNIQUES, V15, P636; Thilaganathan B, 2000, BRIT J OBSTET GYNAEC, V107, P262, DOI 10.1111/j.1471-0528.2000.tb11698.x; Verma L, 1998, LANCET, V352, P9, DOI 10.1016/S0140-6736(97)11090-X	19	165	206	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 29	2001	358	9287					1057	1061		10.1016/S0140-6736(01)06183-9	http://dx.doi.org/10.1016/S0140-6736(01)06183-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589937				2022-12-28	WOS:000171393100012
J	Haxby, JV; Gobbini, MI; Furey, ML; Ishai, A; Schouten, JL; Pietrini, P				Haxby, JV; Gobbini, MI; Furey, ML; Ishai, A; Schouten, JL; Pietrini, P			Distributed and overlapping representations of faces and objects in ventral temporal cortex	SCIENCE			English	Article							INFEROTEMPORAL CORTEX; PERCEPTION; AREA; RECOGNITION; COMPONENTS; EXPERTISE; STIMULI; SPACE	The functional architecture of the object vision pathway in the human brain was investigated using functional magnetic resonance imaging to measure patterns of response in ventral temporal cortex white subjects viewed faces, cats, five categories of man-made objects, and nonsense pictures. A distinct pattern of response was found for each stimulus category. The distinctiveness of the response to a given category was not due simply to the regions that responded maximally to that category, because the category being viewed also could be identified on the basis of the pattern of response when those regions were excluded from the analysis. Patterns of response that discriminated among A categories were found even within cortical regions that responded maximally to only one category. These results indicate that the representations of faces and objects in ventral temporal cortex are widely distributed and overlapping.	NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA; Univ Pisa, Dept Human & Environm Sci, I-56126 Pisa, Italy; Univ Pisa, Dept Expt Pathol, Lab Clin Biochem, I-56126 Pisa, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Pisa; University of Pisa	Haxby, JV (corresponding author), NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA.		Patanaik, Amiya/G-4336-2010; Pietrini, Pietro/Z-4202-2019; Furey, Maura/H-5273-2013	Pietrini, Pietro/0000-0002-6768-5556				Aguirre GK, 1998, NEURON, V21, P373, DOI 10.1016/S0896-6273(00)80546-2; Allison T, 1999, CEREB CORTEX, V9, P415, DOI 10.1093/cercor/9.5.415; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; Blanz V, 2000, PERCEPTION, V29, P885, DOI 10.1068/p2851; Chao LL, 1999, NAT NEUROSCI, V2, P913, DOI 10.1038/13217; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DEVALOIS RL, 1965, COLD SPRING HARB SYM, V30, P567, DOI 10.1101/SQB.1965.030.01.055; Edelman S, 1998, PSYCHOBIOLOGY, V26, P309; Edelman S, 1997, TRENDS COGN SCI, V1, P296, DOI 10.1016/S1364-6613(97)01090-5; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Gauthier I, 2000, NAT NEUROSCI, V3, P191, DOI 10.1038/72140; Gauthier I, 1999, NAT NEUROSCI, V2, P568, DOI 10.1038/9224; Gauthier I, 2000, J COGNITIVE NEUROSCI, V12, P495, DOI 10.1162/089892900562165; Gauthier I, 2000, TRENDS COGN SCI, V4, P1, DOI 10.1016/S1364-6613(99)01416-3; Grill-Spector K, 1999, NEURON, V24, P187, DOI 10.1016/S0896-6273(00)80832-6; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; Hancock PJB, 1996, MEM COGNITION, V24, P26, DOI 10.3758/BF03197270; Haxby JV, 2000, TRENDS COGN SCI, V4, P223, DOI 10.1016/S1364-6613(00)01482-0; Haxby JV, 1999, NEURON, V22, P189, DOI 10.1016/S0896-6273(00)80690-X; Haxby JV, 2000, TRENDS COGN SCI, V4, P3, DOI 10.1016/S1364-6613(99)01423-0; HAXBY JV, IN PRESS MAPPING MOD; Hecaen H., 1962, ARCH NEUROL-CHICAGO, V7, P24; Hering E., 1964, OUTLINES THEORY LIGH; HURVICH LM, 1957, PSYCHOL REV, V64, P384, DOI 10.1037/h0041403; Ishai A, 1999, P NATL ACAD SCI USA, V96, P9379, DOI 10.1073/pnas.96.16.9379; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Lanitis A, 1997, IEEE T PATTERN ANAL, V19, P743, DOI 10.1109/34.598231; Leopold DA, 2001, NAT NEUROSCI, V4, P89, DOI 10.1038/82947; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; MARTIN A, 1999, NEW COGNITIVE NEUROS, P1023; McCarthy G, 1997, J COGNITIVE NEUROSCI, V9, P605, DOI 10.1162/jocn.1997.9.5.605; OTOOLE AJ, 1993, J OPT SOC AM A, V10, P405, DOI 10.1364/JOSAA.10.000405; TALAIRACH J, 1988, COPLANAR STEREOTOXIC; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829	35	2480	2513	7	283	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2001	293	5539					2425	2430		10.1126/science.1063736	http://dx.doi.org/10.1126/science.1063736			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	476PD	11577229	Green Accepted			2022-12-28	WOS:000171237200038
J	Stern, MA; Chey, WD				Stern, MA; Chey, WD			Pneumatosis coli and colonic intussusception.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Dekalb Gastroenterol Associates, Atlanta, GA 30033 USA; Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Stern, MA (corresponding author), Dekalb Gastroenterol Associates, Atlanta, GA 30033 USA.		Chey, William/AAY-7766-2021						0	2	2	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2001	345	13					964	964		10.1056/NEJMicm980041	http://dx.doi.org/10.1056/NEJMicm980041			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475NF	11575288				2022-12-28	WOS:000171170000005
J	de la Vega, M; Rivero, JC; Ruiz, L; Suarez, S				de la Vega, M; Rivero, JC; Ruiz, L; Suarez, S			A fish bone in the liver	LANCET			English	Editorial Material							HEPATIC-ABSCESS; FOREIGN-BODY; PERFORATION		Hosp Dr Negrin, Dept Pathol, Las Palmas de Gran Canaria, Spain; Hosp Dr Negrin, Dept Internal Med, Las Palmas de Gran Canaria, Spain		de la Vega, M (corresponding author), Hosp Dr Negrin, Dept Pathol, Las Palmas de Gran Canaria, Spain.							BLOOM RR, 1986, AM SURGEON, V52, P618; Broome CJ, 2000, CLIN RADIOL, V55, P242, DOI 10.1053/crad.1999.0339; DUGGER K, 1990, AM J EMERG MED, V8, P323, DOI 10.1016/0735-6757(90)90086-F; Horii K, 1999, SURG TODAY, V29, P922, DOI 10.1007/BF02482788; LAMBERT A, 1898, NY MED J         FEB, P177	5	46	48	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					982	982		10.1016/S0140-6736(01)06106-2	http://dx.doi.org/10.1016/S0140-6736(01)06106-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583753				2022-12-28	WOS:000171135300020
J	Blackburn, EH				Blackburn, EH			Switching and signaling at the telomere	CELL			English	Review							IN-VIVO; YEAST TELOMERES; FISSION YEAST; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; REVERSE-TRANSCRIPTASE; ECTOPIC EXPRESSION; TERMINAL REGION; HUMAN-CELLS; LENGTH	This review describes the structure of telomeres, the protective DNA-protein complexes at eukaryotic chromosomal ends, and several molecular mechanisms involved in telomere functions. Also discussed are cellular responses to compromising the functions of telomeres and of telomerase, which synthesizes telomeric DNA.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	telomer@itsa.ucsf.edu	Wharton, Stephen B/B-5117-2009; Reddel, Roger R/A-6635-2014	Wharton, Stephen B/0000-0003-2785-333X; Reddel, Roger R/0000-0002-6302-6107				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Baumann P, 2000, MOL BIOL CELL, V11, P3265, DOI 10.1091/mbc.11.10.3265; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bertuch A, 1998, TRENDS CELL BIOL, V8, P339, DOI 10.1016/S0962-8924(98)01331-2; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; Blackburn EH, 1998, COLD SPRING HARBOR M, P669; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chan SWL, 2001, CURR BIOL, V11, P1240, DOI 10.1016/S0960-9822(01)00391-8; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Cohen P, 1998, J MOL BIOL, V280, P327, DOI 10.1006/jmbi.1998.1867; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Craven RJ, 1999, GENETICS, V152, P1531; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; DEMBURG AF, 1995, TELOMERES; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dorer DR, 1997, GENETICS, V147, P1181; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Evans SK, 2000, J CELL SCI, V113, P3357; Evans SK, 1999, TRENDS CELL BIOL, V9, P329, DOI 10.1016/S0962-8924(99)01596-2; Fulton TB, 1998, MOL CELL BIOL, V18, P4961, DOI 10.1128/MCB.18.9.4961; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hemann MT, 1999, NUCLEIC ACIDS RES, V27, P3964, DOI 10.1093/nar/27.20.3964; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM B, 2000, GENETICS, V155, P475; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Krauskopf A, 1998, P NATL ACAD SCI USA, V95, P12486, DOI 10.1073/pnas.95.21.12486; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Laroche T, 2000, J STRUCT BIOL, V129, P159, DOI 10.1006/jsbi.2000.4240; Le S, 1999, GENETICS, V152, P143; LEE MS, 1993, COLD SPRING HARB SYM, V58, P707, DOI 10.1101/SQB.1993.058.01.078; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Marcand S, 2000, CURR BIOL, V10, P487, DOI 10.1016/S0960-9822(00)00450-4; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; McEachern MJ, 2000, P NATL ACAD SCI USA, V97, P11409, DOI 10.1073/pnas.210388397; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McEachern MJ, 2001, MOL CELL, V7, P695, DOI 10.1016/S1097-2765(01)00215-5; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PARDUE M, 1995, TELOMERES; Pardue ML, 1999, GENETICA, V107, P189, DOI 10.1023/A:1003905210770; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Pryde FE, 1997, CURR OPIN GENET DEV, V7, P822, DOI 10.1016/S0959-437X(97)80046-9; Ray A, 1999, MOL CELL BIOL, V19, P31; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roy J, 1998, GENE DEV, V12, P3286, DOI 10.1101/gad.12.20.3286; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893; Strahl C, 1996, MOL CELL BIOL, V16, P53; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(00)00092-7; Teng SC, 1999, MOL CELL BIOL, V19, P8083; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VERMEESCH JR, 1993, NUCLEIC ACIDS RES, V21, P5366, DOI 10.1093/nar/21.23.5366; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; von Zglinicki T, 2000, LAB INVEST, V80, P1739, DOI 10.1038/labinvest.3780184; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhang D, 2001, MOL CELL, V7, P319, DOI 10.1016/S1097-2765(01)00180-0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	108	1668	1740	5	259	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 21	2001	106	6					661	673		10.1016/S0092-8674(01)00492-5	http://dx.doi.org/10.1016/S0092-8674(01)00492-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	476EJ	11572773	Bronze			2022-12-28	WOS:000171213000004
J	Proano, JV; Madrazo, I; Avelar, F; Lopez-Felix, B; Diaz, G; Grijalva, I				Proano, JV; Madrazo, I; Avelar, F; Lopez-Felix, B; Diaz, G; Grijalva, I			Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRAZIQUANTEL; ALBENDAZOLE	Background Infection with the larval form of the pork tapeworm, Taenia solium, can lead to the development of cysts in the brain. Surgical removal of cysts has been the accepted treatment for neurocysticercosis characterized by giant cysts when there is associated intracranial hypertension. Methods We describe 33 patients whom we treated medically for malignant forms of neurocysticercosis. All patients had evidence of intracranial hypertension and subarachnoid cysts at least 50 mm in diameter. All patients received 15 mg of albendazole per kilogram of body weight per day for four weeks. Ten patients were also treated with 100 mg of praziquantel per kilogram per day for four weeks. Seventeen patients received a second course of albendazole, three received a third course, and one received a fourth course. During the first cycle of treatment, all patients also received dexamethasone. Five patients had previously undergone neurosurgery for giant cysts. Results After a median of 59 months of follow-up (range, 7 to 102), the condition of all 33 patients had improved, and the cysts had disappeared or become calcified. Of the 22 patients with a history of seizures, only 11 continued to receive antiseizure medications. The median quality-of-life score on the Karnofsky scale improved from 40 to 100. Fifteen patients received a ventriculoperitoneal shunt because of hydrocephalus. Four patients had persistent sequelae ( bilateral partial optic atrophy, stroke, or diplopia) of the cysts. Conclusions Intensive medical treatment can be effective in patients with neurocysticercosis characterized by giant cysts. Neurosurgery may be required only when there is an imminent risk of death. (N Engl J Med 2001; 345: 879-85.) Copyright (C) 2001 Massachusetts Medical Society.	Mexican Inst Social Secur, Ctr Med Nacl Siglo 21, Hosp Especialidades, Med Res Unit Neurol Dis, Mexico City, DF, Mexico; Mexican Inst Social Secur, Ctr Med Nacl Siglo 21, Hosp Especialidades, Dept Imaging, Mexico City, DF, Mexico; Mexican Inst Social Secur, Ctr Med Nacl Siglo 21, Hosp Especialidades, Dept Neurosurg, Mexico City, DF, Mexico	Instituto Mexicano del Seguro Social; Instituto Mexicano del Seguro Social; Instituto Mexicano del Seguro Social	Proano, JV (corresponding author), Santiago Valverde 68,Col Presidentes Ejidales, Mexico City 04470, DF, Mexico.	proanio_00@yahoo.com						Agapejev S, 1996, ARQ NEURO-PSIQUIAT, V54, P82, DOI 10.1590/S0004-282X1996000100014; BANDRES JC, 1992, CLIN INFECT DIS, V15, P799, DOI 10.1093/clind/15.5.799; BERMAN JD, 1981, AM J TROP MED HYG, V30, P616, DOI 10.4269/ajtmh.1981.30.616; BITTENCOURT PRM, 1992, NEUROLOGY, V42, P492, DOI 10.1212/WNL.42.3.492; BITTENCOURT PRM, 1990, EUR NEUROL, V30, P229, DOI 10.1159/000117352; Castellanos F, 2000, REV NEUROLOGIA, V30, P433, DOI 10.33588/rn.3005.99422; Colli B O, 1994, Arq Neuropsiquiatr, V52, P166; COLLI BO, 1986, J NEUROSURG, V65, P309, DOI 10.3171/jns.1986.65.3.0309; DELBRUTTO OH, 1992, ARCH NEUROL-CHICAGO, V49, P535, DOI 10.1001/archneur.1992.00530290123021; ESCOBEDO F, 1987, ARCH INTERN MED, V147, P738, DOI 10.1001/archinte.147.4.738; GREENBERG MS, 1997, HDB NEUROSURGERY, V2; JOUBERT J, 1990, S AFR MED J, V77, P154; JUNG H, 1990, CLIN NEUROPHARMACOL, V13, P559, DOI 10.1097/00002826-199012000-00008; MADRAZO I, 1997, NEUROCISTICERCOSIS, P299; MADRAZO I, 1993, BRAIN SURG COMPLICAT, P1419; NOBOA C, 1993, ARCH NEUROL-CHICAGO, V50, P347, DOI 10.1001/archneur.1993.00540040009006; PROANO J, 1993, GUIA INTERVENCION NO, P49; Proano JV, 1997, J NEUROSURG, V87, P29, DOI 10.3171/jns.1997.87.1.0029; RABIELA T, 1989, CISTICERCOSIS HUMANA, P47; Robles C, 1979, Salud Publica Mex, V21, P603; SHANDERA WX, 1994, MEDICINE, V73, P37, DOI 10.1097/00005792-199401000-00004; SotoHernandez JL, 1996, SURG NEUROL, V45, P57, DOI 10.1016/0090-3019(95)00259-6	22	107	109	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2001	345	12					879	885		10.1056/NEJMoa010212	http://dx.doi.org/10.1056/NEJMoa010212			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	473JW	11565520				2022-12-28	WOS:000171039600004
J	Wisse, BE; Schwartz, MW				Wisse, BE; Schwartz, MW			Role of melanocortins in control of obesity	LANCET			English	Editorial Material							FOOD-INTAKE; SYSTEM; BEHAVIOR; HORMONE		Univ Washington, Harborview Med Ctr, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Schwartz, MW (corresponding author), Univ Washington, Harborview Med Ctr, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98104 USA.		Schwartz, Michael W/H-9950-2012					Asakawa A, 1999, GASTROENTEROLOGY, V116, P1287, DOI 10.1016/S0016-5085(99)70491-9; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Fehm HL, 2001, J CLIN ENDOCR METAB, V86, P1144, DOI 10.1210/jc.86.3.1144; Hagan MM, 1999, J NEUROSCI, V19, P2362; Huang QH, 1999, AM J PHYSIOL-REG I, V276, pR864, DOI 10.1152/ajpregu.1999.276.3.R864; Hwa JJ, 2001, AM J PHYSIOL-REG I, V281, pR444, DOI 10.1152/ajpregu.2001.281.2.R444; Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Mantzoros CS, 2000, J CLIN ENDOCR METAB, V85, P4000, DOI 10.1210/jc.85.11.4000; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; SAFER DJ, 1991, SOUTHERN MED J, V84, P1470, DOI 10.1097/00007611-199112000-00015; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Tatro JB, 1996, NEUROIMMUNOMODULAT, V3, P259, DOI 10.1159/000097281; Thim L, 1998, INT J BIOCHEM CELL B, V30, P1281, DOI 10.1016/S1357-2725(98)00110-1; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Wessells H, 2000, UROLOGY, V56, P641, DOI 10.1016/S0090-4295(00)00680-4; Wisse BE, 2001, ENDOCRINOLOGY, V142, P3292, DOI 10.1210/en.142.8.3292; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	20	17	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 15	2001	358	9285					857	859		10.1016/S0140-6736(01)06037-8	http://dx.doi.org/10.1016/S0140-6736(01)06037-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CP	11567697				2022-12-28	WOS:000171087000004
